
<html lang="en"     class="pb-page"  data-request-id="27c339a2-bf0b-4725-804e-6ca99f31f9b7"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.6b00463;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2016.59.issue-19"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth" /></meta><meta name="dc.Creator" content="María-Jesús  Pérez-Pérez" /></meta><meta name="dc.Creator" content="Eva-María  Priego" /></meta><meta name="dc.Creator" content="Oskía  Bueno" /></meta><meta name="dc.Creator" content="Maria Solange  Martins" /></meta><meta name="dc.Creator" content="María-Dolores  Canela" /></meta><meta name="dc.Creator" content="Sandra  Liekens" /></meta><meta name="dc.Description" content="The unique characteristics of the tumor vasculature offer the possibility to selectively target tumor growth and vascularization using tubulin-destabilizing agents. Evidence accumulated with combre..." /></meta><meta name="Description" content="The unique characteristics of the tumor vasculature offer the possibility to selectively target tumor growth and vascularization using tubulin-destabilizing agents. Evidence accumulated with combre..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 27, 2016" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00463" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00463" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00463" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00463" /></link>
        
    
    

<title>Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00463" /></meta><meta property="og:title" content="Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0018.jpeg" /></meta><meta property="og:description" content="The unique characteristics of the tumor vasculature offer the possibility to selectively target tumor growth and vascularization using tubulin-destabilizing agents. Evidence accumulated with combretastatin A-4 (CA-4) and its prodrug CA-4P support the therapeutic value of compounds sharing this mechanism of action. However, the chemical instability and poor solubility of CA-4 demand alternative compounds that are able to surmount these limitations. This Perspective illustrates the different classes of compounds that behave similar to CA-4, analyzes their binding mode to αβ-tubulin according to recently available structural complexes, and includes described approaches to improve their delivery. In addition, dissecting the mechanism of action of CA-4 and analogues allows a closer insight into the advantages and drawbacks associated with these tubulin-destabilizing agents that behave as vascular disrupting agents (VDAs)." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00463"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00463">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00463&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00463&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00463&amp;href=/doi/10.1021/acs.jmedchem.6b00463" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 19</span><span class="cit-fg-pageRange">, 8685-8711</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/19" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b00150" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.6b00472" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mar%C3%ADa-Jes%C3%BAs++P%C3%A9rez-P%C3%A9rez">María-Jesús Pérez-Pérez</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eva-Mar%C3%ADa++Priego">Eva-María Priego</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Osk%C3%ADa++Bueno">Oskía Bueno</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Maria+Solange++Martins">Maria Solange Martins</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mar%C3%ADa-Dolores++Canela">María-Dolores Canela</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sandra++Liekens">Sandra Liekens</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">#</span> <span class="aff-text">Instituto de Química Médica (IQM-CSIC), Juan de la Cierva 3, E-28006 Madrid, Spain</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">†</span> <span class="aff-text">Rega Institute for Medical Research, KU Leuven, B-3000 Leuven, Belgium</span></div><div class="corresp-info"><strong>*</strong>Phone: 34 91 2587516. Fax: 34 91 5644853. E-mail: <a href="/cdn-cgi/l/email-protection#e4898e948196819ea48d9589ca87978d87ca8197"><span class="__cf_email__" data-cfemail="97fafde7f2e5f2edd7fee6fab9f4e4fef4b9f2e4">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00463&amp;href=/doi/10.1021%2Facs.jmedchem.6b00463" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 19</span><span class="cit-pageRange">, 8685–8711</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 27, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>29 March 2016</li><li><span class="item_label"><b>Published</b> online</span>27 June 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 October 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00463" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00463</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice_termsofuse.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00463"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4246</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">86</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00463" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;María-Jesús&quot;,&quot;last_name&quot;:&quot;Pérez-Pérez&quot;},{&quot;first_name&quot;:&quot;Eva-María&quot;,&quot;last_name&quot;:&quot;Priego&quot;},{&quot;first_name&quot;:&quot;Oskía&quot;,&quot;last_name&quot;:&quot;Bueno&quot;},{&quot;first_name&quot;:&quot;Maria&quot;,&quot;last_name&quot;:&quot;Solange Martins&quot;},{&quot;first_name&quot;:&quot;María-Dolores&quot;,&quot;last_name&quot;:&quot;Canela&quot;},{&quot;first_name&quot;:&quot;Sandra&quot;,&quot;last_name&quot;:&quot;Liekens&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;27&quot;,&quot;issue&quot;:&quot;19&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;8685-8711&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00463&quot;},&quot;abstract&quot;:&quot;The unique characteristics of the tumor vasculature offer the possibility to selectively target tumor growth and vascularization using tubulin-destabilizing agents. Evidence accumulated with combretastatin A-4 (CA-4) and its prodrug CA-4P support the therapeutic value of compounds sharing this mechanism of action. However, the chemical instability and poor solubility of CA-4 demand alternative compounds that are able to surmount these limitations. This Perspective illustrates the different classes of compounds that behave similar to CA-4, analyzes their binding mode to αβ-tubulin according to recently available structural complexes, and includes described approaches to improve their delivery. In addition, dissecting the mechanism of action of CA-4 and analogues allows a closer insight into the advantages and drawbacks associated with these tubulin-destabilizing agents that behave as vascular disrupting agents (VDAs).&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00463&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00463" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00463&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00463" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00463&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00463" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00463&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00463&amp;href=/doi/10.1021/acs.jmedchem.6b00463" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00463" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00463" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00463%26sid%3Dliteratum%253Aachs%26pmid%3D27348355%26genre%3Darticle%26aulast%3DP%25C3%25A9rez-P%25C3%25A9rez%26date%3D2016%26atitle%3DBlocking%2BBlood%2BFlow%2Bto%2BSolid%2BTumors%2Bby%2BDestabilizing%2BTubulin%253A%2BAn%2BApproach%2Bto%2BTargeting%2BTumor%2BGrowth%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D19%26spage%3D8685%26epage%3D8711%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/19" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/jmcmar.2016.59.issue-19/20161013/jmcmar.2016.59.issue-19.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The unique characteristics of the tumor vasculature offer the possibility to selectively target tumor growth and vascularization using tubulin-destabilizing agents. Evidence accumulated with combretastatin A-4 (CA-4) and its prodrug CA-4P support the therapeutic value of compounds sharing this mechanism of action. However, the chemical instability and poor solubility of CA-4 demand alternative compounds that are able to surmount these limitations. This Perspective illustrates the different classes of compounds that behave similar to CA-4, analyzes their binding mode to αβ-tubulin according to recently available structural complexes, and includes described approaches to improve their delivery. In addition, dissecting the mechanism of action of CA-4 and analogues allows a closer insight into the advantages and drawbacks associated with these tubulin-destabilizing agents that behave as vascular disrupting agents (VDAs).</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">1 Tumor Vascularization</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34282" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34282" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The requirement of vascularization for tumor growth and metastasis has become one of the greatest areas of research in recent years. It is widely accepted that a solid tumor cannot grow further than approximately 2 mm<sup>3</sup> without blood vessels that provide oxygen and nutrients. Two main approaches have been followed to target tumor vascularization: inhibition of angiogenesis, that is, the formation of new blood vessels, or targeting the already existing vasculature.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Both approaches are directed against endothelial cells, a cell type that is genetically more stable and less prone to mutations compared to tumor cells.<a onclick="showRef(event, 'ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4">(2-4)</a></div><div class="NLM_p">Angiogenesis has been extensively investigated promoting fundamental work on how this process occurs under physiological and pathological conditions.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> There are currently a number of approved drugs, both monoclonal antibodies and small molecules, that are able to affect this process.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> However, from an anticancer perspective, antiangiogenic agents have not accomplished their expectations. Clinical data indicate that treatment with these agents is accompanied by lack of efficacy, resistance development, and toxicity.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Still, antiangiogenic agents have proven useful in combination therapies, and applications outside cancer treatment continue to be explored.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><div class="NLM_p last">The second approach targeting the tumor vasculature relies on the so-called vascular-disrupting agents, commonly designated as VDAs.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> These agents target already existing vessels in the tumor environment, thereby provoking a rapid collapse of the tumor vasculature leading to necrosis at the tumor core. Although it is not always easy to dissect between an antiangiogenic and a VDA effect, antiangiogenic agents are considered to be cytostatic against endothelial cells and are particularly active at early stage (small) tumors. These compounds should ideally be administered for long periods, so almost chronically. On the other hand, VDAs are cytotoxic and exert an almost immediate effect on the existing tumor vessels leading to a rapid vascular collapse and subsequent tumor cell death. Therefore, they are particularly efficient against large tumors and should be administered acutely.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">2 Vascular Disrupting Agents (VDAS)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34426" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34426" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3">2.1 Characteristics of the Tumor Vasculature</h3><div class="NLM_p">Vascular endothelial cells are planar cells that cover the internal/luminal surface of blood vessels, thus ensuring laminar blood flow and providing a nonthrombogenic surface. Endothelial cells are highly heterogeneous and display different morphologies and functions depending on their location (e.g., liver versus lung, macro- versus microvasculature). Moreover, significant differences exist between physiological vessels and vessels in the tumor microenvironment.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> The normal vasculature is a well-organized network that is strictly controlled by a balance between proangiogenic and antiangiogenic factors and is arranged in a hierarchy of well-differentiated arteries, arterioles, capillaries, venules, and veins. In contrast, the overexpression of proangiogenic factors in the tumor environment results in an unevenly distributed and chaotic vasculature with irregular branches and the formation of arteriovenous shunts. Moreover, tumor blood vessels are structurally abnormal and often lack pericytes and a proper basement membrane, which makes these vessels more fragile and immature (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> These morphological abnormalities have a significant impact on vessel function, i.e., blood vessel permeability is increased in the tumor, leading to extravasation of macromolecules and increased interstitial pressure. Vascular resistance is equally increased in tumor vessels, and blood flow is reduced. Thus, any alteration of blood vessel perfusion that would not be relevant for a normal vessel may be catastrophic for the intratumoral vasculature,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> leading to ischemia and tumor cell death (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). Agents that may lead to such vascular destruction were designated as VDAs.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> It should be noted that imaging techniques provide evidence that the vascular damage after VDA treatment is confined to the tumor vessel network.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> It is also relevant to mention that cells at the outer rim of the tumor are not affected by the VDAs, probably due to nutritional support from the nearby blood vessels which are less responsive to VDAs.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic representation of the effects of VDA treatment on tumor vascularization. (a) In the normal vasculature, blood vessels are organized hierarchically and the basement membrane and pericytes provide structure and stability to the vessels. (b) Intratumoral vessels are chaotic and often lack pericytes and a proper basement membrane. Reduced blood flow renders the tumor center hypoxic, and tumor cells can invade the unstable and leaky vessels. VDA treatment results in disruption of the cytoskeleton and reduced cell–cell junctions, further increasing vascular leakage. This triggers a cascade of events, resulting in a reduction of blood flow, vessel occlusion, and necrosis in the tumor center. In the periphery, there is a rim of surviving tumor cells that receive nutritional support from nearby blood vessels, which are less responsive to VDAs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.2 Classification of VDAs</h3><div class="NLM_p">Early reviews on VDAs a decade ago proposed a classification of these agents in two main groups:<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> ligand-directed VDAs and small molecules (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>a). The ligand-directed VDAs make use of antibodies, peptides, or growth factors to target toxins or procoagulants to the tumor endothelium.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> The second class of VDAs contains small molecules and has been further classified into derivatives of 8-flavon acetic acid (<b>1</b>, FAA, <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>a), designated as flavonoids in previous reviews,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and tubulin-depolymerizing agents. According to IUPAC recommendations, the flavonoid designation, currently under evaluation, is too wide and includes among others, flavones, isoflavones, neoflavones, chalcones, dehydrochalcones, aurones, etc. As we will later describe, compounds belonging to these structural families (i.e., chalcones) are tubulin-depolymerizing agents, so the designation of flavone derivatives for this first group should be more accurate than flavonoids, and we propose such designation.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) Classification of VDAs. (b) Incorporation of αβ-tubulin dimers into protofilaments, sheet assembly, and microtubule formation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">FAA and its best studied derivative 5,6-dimethylxanthenone-4-acetic acid (<b>2</b>, DMXAA, ASA404, <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>a)<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> induce the activation of nuclear factor κB (NF-κB) which increases the production of various cytokines, including tumor necrosis factor-α (TNF-α). As a consequence endothelial cells enter apoptosis, leading to hemorrhagic necrosis of the tumor. Compound <b>2</b> was discontinued after phase III clinical trials against advanced NSCLC.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13, 14)</a> More details about the biological activity of FAA and DMXAA can be found in a very recent review.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><div class="NLM_p last">The second group of small molecules that behave as VDAs has been designated as tubulin-depolymerizing VDAs,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and they will be the subject of this Perspective. This group comprises a very large and structurally diverse group of compounds that bind at the colchicine site in tubulin.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">2.3 VDAs Acting at Tubulin</h3><div class="NLM_p">Microtubules are dynamic structures that, together with actin microfilaments and intermediate filaments, constitute the cellular cytoskeleton. Besides their well-known role in cell division, their functions involve maintenance of cell shape and morphology, cellular motility, and trafficking of organelles and vesicles.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Microtubules are formed by the polymerization of heterodimers of α and β tubulin. These heterodimers assemble head to tail into linear protofilaments, which further polymerize in a polar manner to form the microtubules that have a plus end where β-tubulin is exposed and a minus end where the α-subunit is present (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>b). Binding and hydrolysis of GTP at the microtubule ends is directly involved in microtubule dynamics.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><div class="NLM_p">Colchicine (<b>3</b>) (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>a) is a natural alkaloid present in different species particularly in <i>Colchicum autumnale</i>. In 1968, this alkaloid was used for the identification of tubulin, a protein unknown until then.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Colchicine was characterized as a potent cytotoxic agent that binds tubulin at the αβ-tubulin interface<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and causes microtubule depolymerization,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> probably by inhibiting assembly of the protofilaments. However, due to a very narrow therapeutic window, colchicine has been discarded as an antitumor drug, although at lower doses it is used for the treatment of gout, familiar Mediterranean fever, osteoarthritis, pericarditis, and atherosclerosis.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><div class="NLM_p">The prototype compound among VDAs acting at the colchicine site in tubulin is combretastatin A-4 (<b>4</b>, CA-4) (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>a), a natural product isolated from <i>Combretum caffum</i>.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Binding of CA-4 to the colchicine site was established early through a competitive-binding assay.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Additional studies demonstrated rapid binding of CA-4 to tubulin in contrast to the relatively slow and temperature-dependent binding of colchicine. Moreover, dissociation of CA-4 from tubulin in the presence of high concentrations of radiolabeled colchicine was quite rapid, indicating a different kinetic behavior in tubulin binding between CA-4 and colchicine.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> CA-4 was the first compound reported to show vascular disrupting properties at a tolerated dose.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Although identified more than two decades ago, the mechanism of action of CA-4 is still not fully elucidated. It is known that the binding of CA-4 to tubulin at the colchicine site inhibits tubulin polymerization, leading to the activation of RhoA, a protein that is crucial for coordinating the interactions of F-actin and microtubules in the cytoskeleton,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> as will later be discussed in <a class="ref internalNav" href="#sec5_1_1" aria-label="section 5.1.1">section 5.1.1</a>.</div><div class="NLM_p">In addition, CA-4, as a colchicine site binder, has antimitotic activity in rapidly proliferating cells by interfering with mitotic spindle formation and chromosome alignment (see <a class="ref internalNav" href="#sec5_2_1" aria-label="section 5.2.1">section 5.2.1</a>). Compared to microtubule targeting agents acting at other tubulin sites (i.e., taxol and vinca alkaloids) for which drug resistance is an important issue due to P-glycoprotein (P-gp) or βIII-tubulin overexpression, compounds binding at the colchicine site retain activity against cell lines that overexpress these factors.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><div class="NLM_p">The potential therapeutic value of vascular disrupting agents binding at the colchicine site has led to a plethora of original and review articles on this subject in recent years. We have made an effort to refer to these review articles throughout this Perspective, while it has not been our intention to cover exhaustively the information that can be found in such articles. Our review is centered on combretastatin A-4 and how medicinal chemistry approaches have tried to improve the limitations of this archetypical VDA (particularly instability and poor solubility). We have also included compounds whose structure differs from CA-4 but that have provided significant VDA properties, most of them reaching clinical trials. Because solubility and delivery have been a significant limitation for CA-4, a brief reference to prodrugs and other approaches meant to improve the delivery of CA-4 has also been included. Lately, an increasing number of structures of VDA–tubulin complexes have been solved. A section will be devoted to this structural information because it may inspire a new generation of VDAs. It is also very relevant for the future of this family of therapeutic agents to dissect the biological actions of CA-4 because this may pave the way for new interventions. Results obtained from preclinical and clinical studies have been recently reviewed by other authors, and the reader is referred to them.<a onclick="showRef(event, 'ref15 ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref15 ref26 ref27 ref28">(15, 26-28)</a></div><div class="NLM_p">As we will discuss later, the biological actions of CA-4 have been investigated in endothelial and tumor cells including effects on the cell cycle and on cell morphology as well as binding to tubulin. Various assays have been established to investigate these CA-4-mediated effects and to demonstrate the combretastatin-like behavior of most of the compounds included in this Perspective. We will briefly mention these assays here. For more detailed information, we refer to the review of Barbier  et al.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> on the molecular mechanisms of antitubulin plant-derived drugs.</div><div class="NLM_p">In general, VDAs and, in particular, CA-4-like compounds, are submitted to a proliferation assay using tumor (and endothelial) cell lines. CA-4 and analogues are antimitotic, blocking cell cycle progression during mitosis, which can be evidenced by flow cytometry as an increase of cells in G2/M phase. Additionally, mitotically arrested cells may undergo apoptosis, noticed by an increase in the subG1 population (see <a class="ref internalNav" href="#sec5_2" aria-label="section 5.2">section 5.2</a> for pathways involved). To visualize the tubulin-binding effects of the compounds, mitotic spindle organization is investigated by immunofluorescence staining of the cells with an antibody against tubulin. A direct interaction of the compound with tubulin may be shown by measuring tubulin polymerization or by biophysical assays to determine the stoichiometry and the association constant (<i>K</i><sub>a</sub>) including fluorescence spectroscopy using established ligands or radioligand displacement using [<sup>3</sup>H]colchicine. It is interesting to mention that the particularities of tubulin and its associated proteins (microtubule-associated proteins, MAPs) limit the employment of some standard techniques such as surface plasmon resonance (SPR) or ITC to determine kinetics or binding affinity for a small ligand. For example, the tendency of tubulin to self-aggregate makes a biophysical method such as SPR not ideal for these determinations. On the other hand, ITC has mostly been used to characterize the binding of tubulin to MAPs such as stathmin<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> with just a few examples for small ligands.</div><div class="NLM_p">An additional and convenient assay to show that the compound binds specifically at the colchicine binding site of tubulin is a recently described competition assay with <i>N</i>,<i>N</i>′-ethylene-bis(iodoacetamide) (EBI)<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> in human breast cancer MDA-MB-231 cells. EBI is an alkylating agent that specifically binds to two cysteine residues present in the colchicine-binding site of tubulin, Cys239 and Cys354. This β-tubulin adduct can be detected by Western blot as a second immunoreactive β-tubulin band that migrates faster than β-tubulin itself. A compound binding at this site will prevent the formation of the β-tubulin adduct.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32, 33)</a></div><div class="NLM_p">Finally, the capacity to destroy a preexisting vasculature network formed by endothelial cells on Matrigel, a solubilized basement membrane that promotes tube formation, provides evidence for the vascular-disrupting activity of the compound. This should however be confirmed in vivo by imaging of blood flow or vascular shutdown in tumor xenografts.</div><div class="NLM_p last">For most VDAs binding at the colchicine site in tubulin, including CA-4, inhibition of tubulin assembly was found at μM concentrations while cytoxicity in cell culture assays was detected at nM or even sub-nM concentrations. As recently discussed,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> the reason for this apparent inconsistency is not completely clear, but there are several factors that may contribute to explain this experimental fact. One factor could be that the stoichiometry (compound versus tubulin concentration) required in the tubulin (cell-free) assay to achieve an IC<sub>50</sub> value might be completely different from the stoichiometry that exists when inhibiting tubulin in cell culture. It is also possible that tubulin depolymerization in cells may release other factors involved in signal transduction so that the biological effect is amplified. In addition, there may be factors directly linked to the limitations and sensitivity of the protein assay.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">2.4 Classes of Compounds</h3><div class="NLM_p">A huge number of compounds mimicking combretastatin A-4 have been reported in recent years, most of which have been covered in excellent review articles. A Mini-Perspective article has appeared in this journal in 2006 by Tron et al. covering the medicinal chemistry of combretastatin A-4.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> A very detailed overview of tubulin inhibitors binding at the colchicine site was published by Miller and collaborators, covering compounds reported up to 2010.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Combretastatin A-4 derivatives have also been reviewed by Shan et al.,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Marrelli et al.,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> and very recently by Patil et al.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> A review focusing on <i>cis</i>-restricted isomers has been published by Rajak et al.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> For those particularly interested in the synthetic pathways applied to obtain these compounds, relevant information can be obtained in the review article of Kaur et al.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Other authors have performed a classification of the compounds based on structural and docking studies, as the exhaustive review of Alvarez et al.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> An overview of the role played by computational approaches in the context of the colchicine-binding domain has also been recently reported by Massarotti et al.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></div><div class="NLM_p">In our survey through the different families of compounds that behave as VDAs, we have centered our attention on those compounds that are active in the nM range in cell culture and/or for which animal experiments have been conducted as proof of concept of their VDA capacity. However, no comparison between data coming from different laboratories has been performed.</div><div id="sec2_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i7" class="anchor-spacer"></div><h4 class="article-section__title" id="_i7">2.4.1 Combretastatin and Analogues</h4><div class="NLM_p">Before introducing combretastatin A-4 and other combretastatins, it should be mentioned that there are a significant number of natural products whose structure resembles that of colchicine and for which binding at the colchicine site in tubulin and a combretastatin-like behavior has been proven. These include polygamain (<b>5</b>)<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> or podophyllotoxin (<b>6</b>)<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> as relevant examples (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). Among colchicine semisynthetic derivatives, the compound that has reached further development has been the phosphate prodrug of <i>N</i>-acetylcolchinol <b>7</b> (ZD6126). This compound presented a higher vascular disrupting than antimitotic activity, but its clinical development has been halted due to severe cardiotoxicity.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Examples of natural products binding tubulin at the colchicine site (<b>5</b>, <b>6</b>) and a colchicine derivative tested in clinical trials (<b>7</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Combretastatin A-4, described by Pettit et al.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> in 1995, is a <i>cis</i>-stilbene isolated from the bark of the African willow tree <i>Combretum caffrum</i>. Other combretastatins such as combretsatatin A-1 (<b>8</b>, CA-1), with an extra OH on ring B,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> or combretastatin A-2 (<b>9</b>, CA-2), with a methylenedioxy bridge at ring A<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>), described and studied by the same group, showed antivascular properties similar to CA-4. However, combretastatins are characterized by poor solubility and chemical instability. In the presence of light, heat, or acid media, but also after in vivo administration, the <i>cis</i>-stilbene easily isomerizes to the <i>trans</i>-stilbene (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>) that is significantly less potent at inhibiting tubulin polymerization and cancer cell growth.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> To improve solubility, prodrugs have been developed both for CA-4 and CA-1. The phosphate prodrugs CA-4P<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> (<b>10</b>, Zybrestat, Fosbretabulin) and CA-1P<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> (<b>11</b>, OXI4503) are currently being evaluated in phase II/III and phase I/II clinical trials, respectively, whereas ombrabulin (<b>12</b>), the serine derivative of 3′-amino-deoxycombretastatin A-4,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> was discontinued in 2013 after disappointing results from phase III clinical trials (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). It is relevant to mention that CA-1, and by extension its prodrug, can undergo activation to a cytotoxic <i>ortho</i>-quinone intermediate that may interact with protein thiols and nucleic acids and stimulate oxidative stress through superoxide/hydrogen peroxide production.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> This could help to explain the superior antitumor effect of CA-1 compared to CA-4 and illustrates how subtle differences in structure may account for the activation of different pathways relevant for the mechanism of action. We will refer to these prodrugs in a later section.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Relevant combretastatins and their prodrugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. <i>Cis</i>–<i>trans</i> isomerization of CA-4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Most efforts addressing the synthesis of structural analogues of combretastatins have been directed to fix the conformation of the <i>cis</i>-stilbene connecting the two aromatic rings (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). It should be kept in mind that the 3,4,5-trimethoxy substitution pattern in ring A is required for optimal activity, while modifications at ring B are tolerated. Still, the 4-methoxy-3-hydroxy or 4-methoxy-3-amino patterns are the most abundant B-rings in those compounds with better activity.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. <i>Cis</i>-restricted bridged compounds mimicking CA-4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A reasonable and highly explored approximation in order to stabilize the <i>cis</i>-disposition of rings A and B has been the incorporation of the stilbene into a <i>cis</i>-restricted bridge, as shown by the general formula <b>13</b> (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). A successful strategy has been the employment of (heterocyclic) rings, particularly through a five-membered ring, so that not only the conformation is fixed as <i>cis</i> but also the drug-like properties can be improved both in terms of solubility and chemical stability. Such heterocyclic rings include heteroaromatic rings like pyrazole, imidazole, thiadiazole, triazoles and tetrazoles, isozazoles, or 1,2,3-thiadiazoles, and a detailed revision of them can be found in Tron et al.,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Lu et al.,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> and Rajak et al.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Relevant examples include the 2-aminothiazoles, originally reported by Ohsumi<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> with compound <b>14</b> as a prototype and further explored by Romagnoli et al.,<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> affording compounds with IC<sub>50</sub> values ranging from 0.03 to 0.9 nM (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). Particularly, compound <b>15</b> (TR644) was found to be superior to CA-4 in inhibiting tubulin polymerization (0.61 ± 0.07 versus 1.2 ± 0.1 μM for CA-4) while a perfect overlapping with colchicine was shown by competition experiments.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></div><div class="NLM_p">Other interesting examples of <i>cis</i>-restricted bridges are the <i>N</i>-methyl imidazoles, as shown in compounds <b>16</b> and <b>17</b> (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). The rational in the design of these compounds was that the basic nitrogen on the imidazole ring might decrease lipophilicity while allowing the synthesis of water-soluble salts.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Indeed, compounds <b>16</b> and <b>17</b> showed cytotoxicity in the nM range and, more importantly, both compounds were found to present a good pharmacokinetic profile with high oral bioavailability and excellent in vivo activity against murine M5076 reticulum sarcoma tumors in mice.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> It is also interesting to highlight the presence of an indole as ring B in compound <b>17</b>. In fact, this ring has been extensively employed as a B-ring alternative. It is also present in <b>18</b> (T115), reported by Welsh and co-workers,<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> where a 1,2,4-triazole has been used to restrict the conformation of the bridge linking rings A and B. Also in this case, inhibition of tubulin polymerization and disruption of a microtubule network, similar to CA-4, was reported. In a mouse xenograft model using HT-29 human colon carcinoma or PC3 prostate cancer cells, a significant inhibition of tumor growth was observed after intraperitoneal administration.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></div><div class="NLM_p">Among nonaromatic heterocycles bridging rings A and B, the 2-azetidinones (β-lactams), described by Sun et al.,<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> have been proposed as a viable linking alternative. Indeed, compound <b>19</b><a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>) has shown antiproliferative activity in the sub-nM range and new compounds in this series still continue to be explored.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Compared to previous examples, these compounds include an additional substituent (an aryl in most cases as in <b>19</b>) and a <i>trans</i>-relationship between the substituents at positions 3 and 4.</div><div class="NLM_p">Very recently, quantum mechanics calculations have been used to study the instability of combretastatin A-4,<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> leading to bicyclic derivatives at rings A or B as an alternative strategy to stabilize the <i>cis</i>-configuration. Compound <b>20</b> (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>), belonging to this series, was found to provide IC<sub>50</sub> values in the nM range in cell culture and to be active in HT-29 tumor-bearing nude mice.</div><div class="NLM_p">Another highly explored way to link rings A and B has been through a simple carbonyl linker as exemplified by benzophenone derivatives. In such compounds, the carbonyl function significantly constrains the relative conformation of the two aryl rings in a quasi <i>cis</i> orientation. Indeed, phenstatin (<b>21</b>, <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>) can be seen as the closest analogue to CA-4 among benzophenones. Phenstatin and its phosphate prodrug <b>22</b><a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> showed inhibitory values similar to those of CA-4P in antiproliferative assays, while binding to tubulin was equivalent to that of CA-4. Other relevant examples of benzophenone derivatives were provided by Lee and co-workers,<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> who explored the incorporation of different five-membered heterocycles at positions 2, 4, and 5 of ring B of the benzophenone with the aim to improve chemical stability and, particularly, solubility and PK values. Compound <b>23</b> (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>) was identified as one of the most potent compounds in this series. Its <span class="smallcaps smallerCapital">l</span>-valine prodrug <b>24</b> (CKD-516) further improved its aqueous solubility and showed marked antitumor efficacy against murine (CT26 and 3LL9) and human (HCT116 and HCT15) xenografts in mice. Encouraging results from phase I clinical trials following intravenous administration have just been published.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. 1,1-Diaryl ketone derivatives mimicking CA-4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Very close in structure to benzophenones are 1,1-diarylketones, some of which have provided very interesting VDA activities. As mentioned in previous series, in most cases ring A is kept almost intact with the 3,4,5-trimethoxy substitution pattern, where ring B has been replaced by bicyclic aromatic heterocycles. An early example in this series is <b>25</b> (BPROL075),<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> an indole derivative with IC<sub>50</sub> values against a variety of human tumor cells in a single-digit nM range and activity in nude mice against xenografts of human gastric carcinoma MKN-45, human cervical carcinoma KB, and KB-derived P-gp170/MDR-overexpressing KB-VIN10 cells at intravenous doses of 50 mg/kg. Applying a scaffold-hoping approach looking for a backup drug candidate,<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> the 7-azaindole derivative <b>26</b> was synthesized, providing a significant improvement in oral bioavailability, metabolic stability, and aqueous solubility (as the HCl salt) although the antiproliferative activity was reduced 4-fold compared to <b>25</b>.</div><div class="NLM_p">Another relevant example is the benzo[<i>b</i>]furane derivative <b>27</b> (BNC105),<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> structurally related to the indole and whose phosphate prodrug <b>28</b> (BNC105P) is being evaluated in phase II clinical trials. Compound <b>27</b> was selected by Kremmidiotis et al.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> using an “in vitro” screening approach comparing the inhibitory activity of compounds on proliferating versus quiescent endothelial cells to improve the selectivity of VDAs. They reported that <b>27</b> displayed 80-fold higher potency against endothelial cells that were actively proliferating or forming capillary tubes compared with nonproliferating endothelial cells or endothelium found in stable capillaries, a selectivity that was not observed with CA-4.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> It is interesting to highlight that, compared to CA-4, <b>27</b> exhibited a longer half-life, larger AUC<sub>0–∝</sub>, and a lower level of plasma protein binding, resulting in a higher free drug exposure.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> The favorable pharmacokinetics and the wider selectivity compared to CA-4 are two important characteristics of <b>27</b>. It is also relevant to mention that the compound is cleared from healthy tissues over 24 h, but due to the vascular shutdown effect, a significant percentage of the drug is trapped in the tumor tissue after 24 h.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></div><div class="NLM_p">The number of benzo[<i>b</i>]furanes, indoles, benzo[<i>b</i>]thiophenes with or without substitutions at position 2 (represented by the general formula <b>29</b>, <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>), or alternative bicyclic heterocycles such as quinolines,<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> that have shown a CA-4 like behavior is very high. Detailed structural and biological information about these compounds is covered in recent review articles.<a onclick="showRef(event, 'ref36 ref40'); return false;" href="javascript:void(0);" class="ref ref36 ref40">(36, 40)</a> Also, the linker connecting both aryl rings is susceptible to modifications including sulfide, amine, sulfonamide, or ether linkages (as represented by the general formula <b>29</b>). Very recently, selenium has also been used as a linker.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> In many cases, the ketone provides the best inhibitory activity, but there are examples where an NH<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> or a sulfur linkage<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> also provides potent colchicine site binders with antiproliferative activity in the nM range. Very close in structure to 1,1-diarylketones are 1,1-diarylethenes, also designated as isocombretastatins. As a representative example, we refer to compound <b>30</b>, described by Alvarez et al.,<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> which shows antiproliferative activity in the sub-nM range and where the incorporation of the amide functionality at position 3 of the indole is meant to improve solubility.</div><div class="NLM_p">In these 1,1-diaryl ketone derivatives, ring B can be replaced by a five-membered heterocycle that is additionally substituted by an aryl ring directly attached to the heterocycle or linked through an NH and represented by the general formula <b>31</b> (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>). Examples of this series have been reported by different groups: the so-called PAT-compounds (as <b>32</b>)<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> where pharmacokinetic parameters are improved compared to previous series, the ARAP derivatives (as <b>33</b>)<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> that have also the potential to strongly inhibit the Hedgehog signaling pathway, or the 3-arylamino-5-amino-1,2,4-triazoles (as <b>34</b>) that have hampered the growth of syngeneic hepatocellular carcinoma in Balb/c mice.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Other modifications at B-ring on 1,1-diarylketone derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Chalcones represent another important group of colchicine site binders. They are abundantly present in natural products as precursors of flavonoids. Their biological activities are very diverse and include antitumoral properties.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> The antimitotic activity of chalcones and their capacity to affect tubulin assembly have been reviewed.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Chalcones mimicking the substitution pattern of CA-4, such as <b>35</b> (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>), have been reported by Ducki et al.,<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> showing antiproliferative activity in the nM range. More recently, chalcone <b>36</b> has shown in vivo antitumor activity in A549 tumor xenograft models. Interestingly, compound <b>36</b> and similar analogues were found to exhibit affinity-induced fluorescence during tubulin-binding.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Also within chalcones, the B-ring can accommodate indol rings, as exemplified by <b>37</b> (IPP51)<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> that inhibited tumor growth in a human bladder xenograft model. Other examples where the bridge connecting rings A and B contains a pyridine have been described by Zheng et al.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Chalcone derivatives with a combrestastatin-like behavior.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i8" class="anchor-spacer"></div><h4 class="article-section__title" id="_i8">2.4.2 Noncombretastatin Colchicine-Site Binders</h4><div class="NLM_p">Up to here, the compounds described might be considered as “inspired” by the structure of combretastatins. In this section, we will refer to compounds that are structurally unrelated to CA-4 but that have proven to efficiently bind tubulin at the colchicine site and behave as VDAs. We have centered our attention at those compounds that have reached clinical trials.</div><div class="NLM_p">The sulfonamide <b>38</b> (ABT-751, E7010) (<a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>) was reported as a colchicine site binder already in 1997,<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> around the same time the antivascular activity of CA-4 was described. This compound is active against a broad range of tumor cell lines in vitro and in xenograft models of human gastric, colorectal, lung, and breast cancer in vivo.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> In addition, compound <b>38</b> is well absorbed after oral administration with an overall mean <i>T</i><sub>max</sub> of about 2 h, and results from phase I clinical trials were reported in 2006.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> However, more recent results on phase I/II trials were quite discouraging.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> The sulfonamide <b>38</b> is also one of the first examples, besides DAMA–colchicine, whose complex with αβ-tubulin has been solved by X-ray crystallography.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Other sulfonamides are being explored, like <b>39</b>.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> This compound can be seen as a conformationally constrained analogue of <b>38</b> and is also a potent tubulin inhibitor and orally bioavailable.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Colchicine-site binders structurally different from CA-4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Plinabulin (<b>40</b>, NPI-2358) is a hydrophilic synthetic diketopiperazine arising from phenylahistin, a natural product isolated from <i>Aspergillus</i> sp.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Plinabulin exhibits potent antiproliferative activity against a panel of tumor cell lines in the low nM range and induces tubulin depolymerization. Because docking studies did not provide clear insights into the binding mode to tubulin, some chemical probes incorporating biotin and benzophenone were synthesized and used for photoaffinity studies.<a onclick="showRef(event, 'ref86 ref87'); return false;" href="javascript:void(0);" class="ref ref86 ref87">(86, 87)</a> Such studies finally concluded that plinabulin interacts in the boundary region between α- and β-tubulin near or at the colchicine binding site.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> An X-ray crystal structure of the recently solved complex<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> has afforded additional information on this subject. It is interesting to highlight that one of the requirements for activity among plinabulin derivatives is the presence of a rigid and planar pseudotricyclic structure formed by a hydrogen bond between the NH of the diketopiperazine and the N of the imidazole.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Such pseudotricyclic structures have also been proposed as a requisite for tubulin binding by unrelated compounds such as 1-aroylnaphthalene derivatives<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> or cyclohexanediones.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32, 33)</a> Results from phase I/II clinical trials with plinabulin are detailed in other reviews.<a onclick="showRef(event, 'ref26 ref28'); return false;" href="javascript:void(0);" class="ref ref26 ref28">(26, 28)</a></div><div class="NLM_p">Lexibulin (<b>41</b>, CYT997) is another colchicine site binder tested in phase I/II clinical trials and whose development has been discontinued. Its complex with tubulin has just been solved.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> The discovery of lexibulin started with the identification of the pyrazine analogue <b>42</b> while screening the antiproliferative activity of Cytopia’s library.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> By performing a focused analogue medicinal chemistry program, a 1000-fold more potent analogue with activity in the nM range (<b>43</b>) was identified. However, its solubility and pharmacokinetics were unacceptable. By replacing the core heteroaromatic ring pyrazine to a pyrimidine and by incorporation of a methyl substituent, as shown in <b>41</b>, potent antiproliferative activity was maintained while accompanied by a good pharmacokinetic profile.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Additional biological studies confirmed its VDA activity, with in vivo effects on tumor blood flow.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a></div><div class="NLM_p">Indibulin (<b>44</b>, D-24851) is another example of a compound class differing from colchicine and CA analogues, identified in a cell-based screening assay to discover cytotoxic drugs. Indibulin has potent cytotoxicity activity in vitro against different human tumor cell lines and in vivo after oral administration to rats bearing Yoshida AH13 sarcomas.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Results from phase I clinical trials indicated a plateau in drug exposure prior to reaching the maximum tolerated dose, probably related to its poor aqueous solubility.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> In this sense, there is a very recent article on indole-3-glyoxylamides that addresses solubility improvement among this series by reducing the number of aromatic rings and increasing the count of sp<sup>3</sup> atoms, exemplified by compound <b>45</b>.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> Significant growth inhibition in a mouse model of head and neck cancer has been reported for <b>45</b>.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a></div><div class="NLM_p">Denibulin (<b>46</b>, MN-029) is the <span class="smallcaps smallerCapital">l</span>-alanine prodrug of <b>47</b> (MN-022). Rapid metabolization of <b>46</b> to the free amine <b>47</b> and its <i>N</i>-acetyl derivative has been described. Phase I clinical trials further showed that denibulin is well tolerated and is able to decrease tumor vascular parameters following intravenous infusion.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> It is interesting to highlight that the structure of <b>47</b> very much resembles that of nocodazole (<b>48</b>), a well-known tubulin-depolymerizing agent whose complex with αβ-tubulin has recently been solved.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a></div><div class="NLM_p">Verubulin (<b>49</b>, MPC-6827, Azixa) represents another interesting VDA that has reached clinical trials and whose structure significantly differs from that of CA-4 and analogues. This quinazoline derivative was identified through a HTS campaign meant to identify proapoptotic compounds.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Its antimitotic properties were shown to be a consequence of the binding to αβ-tubulin at the colchicine site. Verubulin showed a high blood–brain barrier penetration<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> and has been detected in the cerebrospinal fluid. However, its high lipophilicity required a formulation with significant side effects, so clinical trials have been suspended. It has recently been highlighted<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> that a similar substitution pattern to that of verubulin is observed in fused-pyrimidine derivatives reported by Gangjee et al.<a onclick="showRef(event, 'ref100 ref101'); return false;" href="javascript:void(0);" class="ref ref100 ref101">(100, 101)</a> that not only target tubulin but are able to inhibit receptor tyrosine kinases involved in angiogenesis such as vascular endothelial growth factor receptor-2 (VEGFR-2) and platelet-derived growth factor receptor β (PDGFR-β).</div><div class="NLM_p last">2-Methoxyestradiol (<b>50</b>, 2-ME) is an endogenous estrogen metabolite implicated in different processes including inhibition of tumor vascularization and growth by binding at the colchicine site.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> However, its rapid metabolization and poor pharmacokinetics have launched the synthesis and biological evaluation of novel analogues. As an interesting example, we include the bis-sulfamate <b>51</b> (STX140)<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> with excellent oral bioavailability and whose mechanism of action, besides binding tubulin, seems to involve other targets including carbonic anhydrase.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> Other compounds being explored in this series include steroidomimetic tetrahydroquinolines<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> or steroid derivatives substituted at positions 3 and 17, positions that are quickly metabolized in methoxyestradiol.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">3 X-Ray Structures of Tubulin and Tubulin–Colchicine Site Ligands</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73465" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73465" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">3.1 Tubulin Structure</h3><div class="NLM_p">Tubulin is a heterodimer constituted of two monomers of 50 Kd designated as α and β subunits, with ca. 40% sequence identity between them. The first structural studies on the αβ-tubulin dimer appeared in 1998, when Nogales et al.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> reported a three-dimensional model fitted to a 3.7 Å density map obtained by electron crystallography of zinc-induced tubulin sheets stabilized with taxol. The atomic model of the tubulin dimer, in a straight conformation, was further refined to 3.5 Å resolution.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> In this model, the α and β subunits of tubulin presented the same overall compact structure, where each monomer could be divided into three domains (<a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>). The N-terminal domain (residues 1–205, magenta in <a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>) contains the nucleotide-binding domain and comprises six parallel β-strands (S1–S6) alternating with six helices (H1–H6). The loops (T1–T6) joining strands and helices are directly involved in the binding of the nucleotide. The interaction of the N-terminal end of the core helix H7 with the second, smaller domain (residues 206–381, yellow in <a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>), designated as intermediate domain, formed by three helices (H8–H11) and a mixed β-sheet (S7–S10), completes the nucleotide-binding site. The C-terminal domain (residues 385 to the c-terminus, green in <a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>) contains two antiparallel helices (H11–H12) that cross over the two other domains. This domain finishes with the highly acidic tail. Sequence variability in this C-terminal tail is related to the different isotypes of tubulin (six forms of α-tubulin and 7 forms of β-tubulin).<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a></div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Structure of αβ-tubulin in complex with taxol (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1JFF">1JFF</a>). Color code for the domain in each monomer: N-terminal in magenta, intermediate domain in orange, and C-terminal domain in green. Taxol (cyan), GDP, and GTP (green) are shown in sticks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Each tubulin monomer binds a guanine nucleotide. The nonexchangeable GTP is bound into the α subunit in the so-called N-site buried at the dimer interface, while the exchangeable GDP is bound into the β subunit (namely E-site) exposed on the surface of the dimer.</div><div class="NLM_p last">In 2000, using X-ray crystallography, Gigant  et al.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> were able to determine the structure of two αβ-tubulin dimers in complex with the stathmin-like domain of the neural protein RB3 (RB3-SLD) at 4 Å. In the overall structure, the RB3 protein adopted a hook-like shape able to accommodate two tubulin heterodimers so that the complex formed a curved structure that, as will later be discussed, has important consequences. Each dimer contained GTP and GDP molecules located inside α and β subunits, respectively. The strategy to use stathmin or other “tubulin sequestration” proteins to stabilize the complex has been critical in solving the structure of tubulin with different ligands.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">3.2 Overview of Colchicine–Tubulin Complexes Based on X-ray Data</h3><div class="NLM_p">Although the structure of the tubulin–taxol complex was already reported in the late 1990s,<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> atomic details of the colchicine-binding site became apparent only in 2004 when Ravelli  et al.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> solved the structure of αβ-tubulin with the stahmin-like domain of the RB3 protein in complex with <i>N</i>-deacetyl-<i>N</i>-(2-mercaptoacetyl)colchicine (DAMA–colchicine, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1SA0">1SA0</a>) (<a class="ref internalNav" href="#fig12" aria-label="Figure 12">Figure 12</a>), indicating that the <i>N</i>-acetyl group of DAMA–colchicine (<b>52</b>, <a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>) was definitive to unambiguously define the colchicine orientation in its asymmetric density. This pioneering work unraveled that the DAMA–colchicine binding site was located close to the interface between the α and β subunits of each tubulin dimer, mostly buried in the intermediate domain of the β subunit and boxed in by strands S8, S9, helices H7 and H8, and loop T7 from this subunit (<a class="ref internalNav" href="#fig12" aria-label="Figure 12">Figure 12</a>). In this binding mode, the methoxy group of ring A of DAMA–colchicine establishes a hydrogen-bond interaction with Cysβ241, while ring C interacts with loop T5 of the N-terminal nucleotide-binding domain of the α subunit by a H-bond between the carbonyl group of ring C and the backbone of Valα181. This model could also explain how colchicine binding might affect tubulin dynamics. The ternary tubulin–podophyllotoxin:RB3-SLD complex (<b>6</b>, <a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1SA1">1SA1</a>) was also described.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Overall structure of the DAMA–colchicine–tubulin complex and detailed insight into the binding mode of DAMA–colchicine. The α subunit is represented in light pink and the β subunit in light cyan. Colchicine is represented in green in sticks, and relevant amino acids at the colchicine site are also represented in sticks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Chemical structures of colchicine site ligands cocrystallized with αβ-tubulin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2009, making use of the RB3-SLD complex, the same research group reported on a set of structures that included an unliganded tubulin (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3HKB">3HKB</a>) and complexes with three known colchicine site ligands: the sulfonamide <b>38</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3HKC">3HKC</a>), the pyrrolidinedione <b>53</b> (TN-16, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3HKD">3HKD</a>), and the pentafluorophenyl derivative <b>54</b> (T13, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3HKE">3HKE</a>)<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> (chemical structures in <a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>). In all cases, van der Waals contacts between the ligand and the protein proved to be the most relevant for the interaction, while polar interactions were very few. The binding of <b>38</b> very much resembles the binding of colchicine, although <b>38</b> is more hidden in β-tubulin than colchicine with no contacts with the α-subunit. Concerning the binding of <b>53</b> (<a class="ref internalNav" href="#fig14" aria-label="Figure 14">Figure 14</a>), the ligand appears much more deeply buried in the β subunit, limiting the overlap to DAMA–colchicine only to the subsite where the colchicine A-ring is located. Therefore, <b>53</b> establishes fewer contacts with the tubulin intermediate domain, while making new interactions with the β strands S4, S5, and S6 of the nucleotide-binding domain of β tubulin. Because of the accessory pocket explored by <b>53</b> inside the β subunit of tubulin, these new structures allowed expansion of the definition of the colchicine-binding site to the more extensive term designated “colchicine-binding domain”.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Moreover, it was possible to identify local changes that contributed to tubulin curvature in the absence of colchicine site ligands. Local conformational changes were observed when the structures of the unliganded curved tubulin (T2RB3) and the colchicine–tubulin complex (T2RB3–colchicine) were compared.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> While the overall structure and curvature remained unchanged, a switch of the T7 loop was observed (<a class="ref internalNav" href="#fig15" aria-label="Figure 15">Figure 15</a>). This loop lies in the colchicine site when it is empty but moves toward the dimer interface upon ligand binding.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. (a) Crystal structure of the complex of tubulin with the pyrrolidinedione <b>53</b>. The α subunit of tubulin is represented in light pink and the β subunit in light cyan. (b) View of the binding mode of <b>53</b> represented in sticks (cyan) after a 180° rotation. For comparison, DAMA–colchicine is shown in green sticks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Conformation change of the T7-loop upon colchicine binding. α-Tubulin in the unbounded state is represented in magenta and β-tubulin is represented in blue; the α-tubulin in the colchicine complex is represented in light pink, while β-tubulin is represented in pale cyan.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2010 Barbier et al.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> demonstrated that the buried cavity described for <b>53</b> was also occupied by <b>55</b> (G2N, <a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3N2G">3N2G</a>) and <b>56</b> (K2N, <a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3N2K">3N2K</a>), the chiral <i>R</i> and <i>S</i> isomers, respectively, of the mitotic inhibitor ethyl-5-amino-2-methyl-1,2-dihydro-3-phenylpirido[3,4-<i>b</i>]pyrazine-7-yl-carbamate.</div><div class="NLM_p">It should be mentioned that all the complexes discussed so far have a low-to-medium resolution, with values between 3.58 and 4.20 Å. More recently, higher-resolution structures (<2.5 Å) have been obtained by Steinmetz’s group using tubulin tyrosine ligase (TTL), a well-known enzyme involved in the post-translational modifications at the C-terminal tail in tubulin,<a onclick="showRef(event, 'ref109 ref112'); return false;" href="javascript:void(0);" class="ref ref109 ref112">(109, 112)</a> as an additional structural protein. Therefore, crystals containing two heterodimers of tubulin (T2), the stathmin-like domain of RB3 (R), and TTL were solved at 2.6–1.8 Å resolution.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> Moreover, by using soaking techniques, T2RTTL complexes of either microtubule stabilizing<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> or destabilizing ligands<a onclick="showRef(event, 'ref115 ref116'); return false;" href="javascript:void(0);" class="ref ref115 ref116">(115, 116)</a> have been reported. In particular, the complexes of T2RTTL with <b>57</b> (BAL27862, <a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O2A">4O2A</a>) and with colchicine (<b>3</b>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O2B">4O2B</a>) were solved at 2.5 and 2.3 Å resolution, respectively.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a></div><div class="NLM_p last">During the last year, using the protein complex T2RTTL, other authors have determined the structures of structurally diverse colchicine site binders. Particularly the complexes with <b>58</b> (MI-181, <a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4YJ2">4YJ2</a>) and <b>59</b> (C2, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4YJ3">4YJ3</a>)<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> were reported in 2015, while early this year additional complexes with lexibulin (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CA0">5CA0</a>), nocodazole (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CA1">5CA1</a>), plinabulin (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5C8Y">5C8Y</a>), and tivantinib (<b>60</b>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CB4">5CB4</a>) have been published.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Surprisingly, although CA-4 is considered the prototype and best studied VDA, to date, no X-ray structural data of its binding mode with tubulin are available.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">3.3 Structural Details of the “Colchicine Domain”</h3><div class="NLM_p">The colchicine-binding site is a deep pocket, mostly buried in the intermediate domain of the β subunit, located near the interface between α and β subunits of a tubulin dimer. As already mentioned, the comparison between the crystal complexes of DAMA–colchicine and <b>53</b> with tubulin led to the proposal that colchicine site ligands bind to tubulin in a “colchicine domain” which comprises a main site (where colchicine itself binds) and additional neighboring pockets.</div><div class="NLM_p">Massaroti et al.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> nicely analyzed by structural interaction fingerprints (SIFt)<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> this colchicine-binding domain and proposed a division into three zones, designated as zones 1, 2, and 3, as shown in <a class="ref internalNav" href="#fig16" aria-label="Figure 16">Figure 16</a>a. Zone 1, considered an accessory pocket, is facing the α subunit interface, surrounded by residues Valα181, Serα178, Metβ259, and Asnβ258. Zone 2, or the main zone (in the center of the domain, <a class="ref internalNav" href="#fig16" aria-label="Figure 16">Figure 16</a>a), is a hydrophobic pocket located in the β subunit formed by residues Lysβ352, Asnβ350, Ileβ378, Valβ318, Alaβ317, Alaβ316, Leuβ255, Lysβ254, Leuβ252, Alaβ250, Leuβ248, Leuβ242, and Cysβ241. Finally, zone 3, the second accessory pocket, is buried deeper in the β subunit and is formed by residues Thrβ239, Valβ238, Tyrβ202, Gluβ200, Pheβ169, Asnβ167, Glnβ136, and Ileβ4.</div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. (a) The colchicine-binding domain. The α subunit of tubulin is represented in light pink and the β subunit in light cyan. Residues from zone 1 (yellow), zone 2 (green), and zone 3 (violet) are shown in sticks. (b) Superposition of the ligands mimicking the colchicine-binding mode: <b>6</b> (brown), <b>38</b> (light orange), <b>41</b> (white), <b>52</b> (blue), <b>54</b> (light-pink and cyan), <b>57</b> (green), <b>59</b> (pink), and <b>60</b> (yellow). (c) Superposition of ligands mimicking the pyrrolidinedione-binding mode: <b>40</b> (orange), <b>48</b> (marine blue), <b>53</b> (pink), <b>55</b> (light pink), <b>56</b> (light yellow), and <b>58</b> (cyan). For chemical structures of the ligands, see <a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Taking the crystal structure of colchicine complexes as reference, colchicine-domain ligands (CDLs) can be divided into two main groups. There are a number of ligands (<b>6</b>, <b>38</b>, <b>41</b>, <b>54</b>, <b>57</b>, and <b>60</b>, <a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>) that bind similarly to colchicine, occupying zones 1 and 2. A superposition of their binding modes can be seen in <a class="ref internalNav" href="#fig16" aria-label="Figure 16">Figure 16</a>b. The second group collects a number of ligands (<b>40</b>, <b>48</b>, <b>55</b>, <b>56</b>, and <b>58</b>, <a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>) that mimic the binding of the pyrrolidinedione <b>53</b>, occupying zones 2 and 3, and whose superpositions are shown in <a class="ref internalNav" href="#fig16" aria-label="Figure 16">Figure 16</a>c. When comparing the superposition in <a class="ref internalNav" href="#fig16" aria-label="Figure 16">Figure 16</a>b,c, it could be argued that planar compounds tend to locate deeper into the β-subunit making use of zones 2 and 3, whereas more globular or butterfly like shaped ligands occupy zones 1 and 2, mimicking the colchicine-binding mode. Moreover, none of the available crystal complexes shows ligands that occupy the entire colchicine domain.</div><div class="NLM_p last">It should also be mentioned that the pentafluorophenyl derivative <b>54</b> has been reported to covalently bind to tubulin.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Moreover, two binding modes have been described in the same crystal, shown in white in <a class="ref internalNav" href="#fig16" aria-label="Figure 16">Figure 16</a>b and in cyan in <a class="ref internalNav" href="#fig16" aria-label="Figure 16">Figure 16</a>c. Finally, the reader is referred to the original publications for a more detailed description of the binding mode of each of these ligands.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">3.4 Microtubule Destabilization by CDLs: Straight versus Curved Tubulin</h3><div class="NLM_p">As mentioned before, tubulin dimers in microtubules adopt a straight conformation<a onclick="showRef(event, 'ref107 ref108'); return false;" href="javascript:void(0);" class="ref ref107 ref108">(107, 108)</a> while a curved conformation is found for tubulin in solution.<a onclick="showRef(event, 'ref119 ref120'); return false;" href="javascript:void(0);" class="ref ref119 ref120">(119, 120)</a> Therefore, a “curved-to-straight” structural transition of the αβ-tubulin dimer is required for microtubule formation and needs the rearrangement of several secondary structural elements, especially concerning the intermediate domain.<a onclick="showRef(event, 'ref18 ref83'); return false;" href="javascript:void(0);" class="ref ref18 ref83">(18, 83)</a> Moreover, the comparison of the curved tubulin–colchicine structure with the straight state of tubulin<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> (<a class="ref internalNav" href="#fig17" aria-label="Figure 17">Figure 17</a>a) shows that this conformational change in tubulin leads to the movement of the T7-loop toward the colchicine site, closing the cavity. This switch in the T7-loop suggests that colchicine cannot bind into tubulin in preformed microtubules,<a onclick="showRef(event, 'ref18 ref83'); return false;" href="javascript:void(0);" class="ref ref18 ref83">(18, 83)</a> although tubulin–CDL complexes can be incorporated into growing microtubules.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> Thus, the microtubule-destabilizing activity of CDLs should consist in preventing the curved-to-straight transition in tubulin by the bound ligand, thus perturbing the microtubule end (<a class="ref internalNav" href="#fig17" aria-label="Figure 17">Figure 17</a>b). This behavior differs from other microtubule-destabilizing agents that do not behave as VDAs, such as vinca alkaloids, that bind at the interdimer interface and destabilize microtubule ends by producing a molecular wedge between two longitudinally aligned tubulin dimers, inducing curved protofilament assemblies incompatible with the straight conformation in microtubules.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> It is conceivable that these differences in destabilizing tubulin might account for the distinctive biological activities of vinca alkaloids and colchicine-based VDAs.</div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. (a) Superposition of the N-terminal domain of β-subunits of the straight (slate blue) and curved (light cyan) conformations of tubulin. The α-subunit of the straight state is shown in gray, and colchicine is shown in sticks (green). In the straight tubulin (slate blue), the T7-loop occludes the colchicine site when compared to the curved tubulin (light cyan). (b) Curved-to-straight conformational transition of αβ-tubulin upon GTP binding required for microtubule growth. Binding of colchicine (represented by a yellow pentagon) into the αβ-tubulin dimer prevents the conformational transition and suppresses microtubule dynamics.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">4 Prodrugs and Other Approaches to Improve Drug Delivery</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57318" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57318" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As shown in previous sections, combretastatins and most of their structural derivatives suffer from very low solubility so that prodrug formulation has been a must in order to progress to preclinical evaluation. For compounds containing a phenolic OH, such as CA-4 (<b>4</b>), CA-1 (<b>8</b>), phenstatin (<b>21</b>), or the benzofurane derivative <b>27</b>, the most applied strategy has been the derivatization as phosphate prodrugs, as recently summarized by Boyle et al.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> Such prodrugs have good chemical stability and are rapidly converted to the active drug in vivo due to the action of phosphatases. As an illustrative example, the half-life of CA-4P (<b>10</b>) is just a few minutes and the prodrug needs to be administered by infusion. Metabolism of CA-4 includes <i>Z</i> to <i>E</i> isomerization, <i>O</i>-demethylation, and glucuronidation, as recently reviewed.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Certainly, CA-1P (<b>11</b>) represents a particular case. As mentioned, CA-1 and its diphosphate prodrug have remarkable cytotoxicity, superior to that of CA-4. It has been proposed that this increased activity can be partially ascribed to its rapid metabolization, giving rise to reactive quinones. Still, it is difficult to quantify the contribution of these now well-characterized quinones to the overall antitumor activity of CA-1.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a></div><div class="NLM_p">Although the derivatization as phosphates has clearly improved the aqueous solubility of CA-4 and CA-1, the resulting prodrugs are charged at physiological pH and are cleaved by nonspecific phosphatases. Thus, phosphate prodrugs work nicely when administered parentally, but oral administration is generally unsuccessful.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a></div><div class="NLM_p">If the derivatization point in the parent drug is an amino group, coupling to amino acids is the reaction of choice, so that the prodrugs are cleaved by the action of aminopeptidases. The most relevant example in this series is ombrabulin (<b>12</b>), the serine derivative of 3′-amino-deoxycombretastatin A-4, a prodrug that has reached clinical trials. Pharmacokinetics have confirmed the rapid conversion of ombrabulin to its active amino metabolite so that the mean half-life of the prodrug is 12 min.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> Interestingly, the terminal half-life of the active metabolite was 8 h. This supports a greater metabolic stability of the amine-derived combretastatin analogues and derivatives in comparison with their OH counterparts. Intravenous infusion was also the way of administration for ombrabulin in the reported clinical studies.</div><div class="NLM_p">Another example is <b>24</b>, an <span class="smallcaps smallerCapital">l</span>-valine prodrug of a 2-aminothiazole derivative. Derivatization as prodrug made it feasible to get the solubility required for in vivo studies.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Results from phase I clinical trials<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> indicate that after intravenous infusion, biotransformation to the amino derivative was almost complete, with only <1% of unchanged <b>24</b> being excreted in the urine, whereas the half-life of the active amino metabolite ranged from 4 to 6 h.</div><div class="NLM_p">An interesting approach in the design of prodrugs is the work performed by You and co-workers<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> using photo-unclick chemistry to develop light-activatable prodrugs of combretastatin A-4. These prodrugs combine in their structure folic acid as a tumor targeting unit for folate receptor uptake, phthalocyanine as a photosensitizer and reporter, and the aminoacrylate bond as the linker for singlet-oxygen drug release. In addition, the length of the polyethylene spacer helps in the uptake of the prodrug by the tumor cells. The results obtained indicate that after prodrug administration to mice inoculated with folate-receptor colon 26 tumors and only after laser irradiation, a significant and selective antitumor effect was observed.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a></div><div class="NLM_p">Another way to improve the poor aqueous solubility and pharmacokinetic properties of CA-4 has been through alternative delivery systems such as polymeric micelles,<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> liposomes,<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> dendrimers,<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> or pH-sensitive nanocarriers.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> These systems do not only improve the solubility and pharmacokinetics but may allow the delivery of CA-4 to a particular cell population, using targeted drug delivery systems. One of the most cited and bright examples with this aim is the work reported by Sengupta et al. on a nanoscale delivery system, designated “nanocell” that enables the temporal release of CA-4 and doxorubicin.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> A more recent example directed toward a particular cell population involves nanocomplexes in which CA-4 or 2-ME have been encapsulated in poly(<span class="smallcaps smallerCapital">d</span>,<span class="smallcaps smallerCapital">l</span>-lactic-<i>co</i>-glycolic acid)-<i>b</i>-poly(ethylene glycol) (PLGA-<i>b</i>-PEG). The targeting moiety cetuximab, an antiepidermal growth factor receptor (EGFR) chimeric monoclonal antibody, is incorporated on the surface of the resulting coronas, which enables the targeted delivery to human hepatocellular carcinoma cells overexpressing the EGFR.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a></div><div class="NLM_p">Another interesting approach also in the nanomedicine field has been the coadministration of CA-4P with functionalized nanoparticles by exploiting the enhanced permeability and retention (EPR) effect. According to Song et al.,<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> in this system, CA-4P eradicates tumor cells in the central region of the solid tumor while the <i>cis</i>-diaminedichloroplatinum (CDDP) loaded nanoparticles (CDDP-NPs) mainly act at the tumor periphery. In vivo experiments using mouse xenograft models bearing C26 and MDA-MB-435 tumors evidenced that the coadministration shows a significantly higher anticancer efficacy compared to CDDP-NPs or CA-4P alone.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a></div><div class="NLM_p last">Related to this, it may be relevant to introduce the so-called “pharmacokinetic approaches” to cancer treatment, a concept that has also been recently reviewed.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> According to this approach, it should be considered that intratumoral pharmacokinetics within solid tumor microregions are crucial for efficacy of the treatment regimens: not only the biophysical properties of the intratumoral microenvironment significantly differ from normal tissues, but treatment with antivascular agents as CA-4 or <b>27</b> may further alter this microenvironment. This should be taken into account when selecting the combination protocol, drug doses, treatment sequence, and/or durations.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">5 Biological Activities That Contribute to the Antitumor Activity of Combretastatin A-4</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44055" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44055" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As mentioned earlier in this Perspective, key to the antitumor activity of CA-4 is the inhibition of tubulin polymerization thereby impairing the formation of functional microtubules, which are crucial to cell division, morphology, and movement. In particular, the tubulin-depolymerizing activity of CA-4 leads to (i) inhibition of endothelial and tumor cell mitosis, followed by mitotic catastrophe and/or apoptosis, (ii) cytoskeleton disruption of endothelial cells, resulting in endothelial cell shape changes, increased blood vessel permeability, and/or thrombus formation and vascular collapse, and (iii) inhibition of cell migration, resulting in antimetastatic activity. In the following sections, the different processes and molecular pathways involved have been summarized under three crucial aspects: antivascular effects, induction of cell death, and effects on cell movement and metastasis. Most of these effects have been described for CA-4 or its prodrug CA-4P but also for several combretastatin-like compounds.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">5.1 Antivascular Effects</h3><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17">5.1.1 Vascular-Disrupting Activity</h4><div class="NLM_p">As mentioned before, tubulin-binding VDAs take advantage of the unstable and immature intratumoral vasculature to selectively target tumor blood vessels as opposed to normal vessels. The kinetics of the antivascular effect of CA-4P have been extensively investigated using various methods, including dynamic bioluminescence imaging, intravital microscopy, magnetic resonance imaging, and histology.<a onclick="showRef(event, 'ref24 ref136 ref137 ref138 ref139'); return false;" href="javascript:void(0);" class="ref ref24 ref136 ref137 ref138 ref139">(24, 136-139)</a> Already in 1997, Dark et al.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> showed that CA-4P induces vascular shutdown at doses less than one-tenth of the maximum tolerated dose. Further studies demonstrated that tumor blood flow was reduced within 1 h and that CA-4P caused the loss of a large proportion of the smallest blood vessels,<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> resulting in a significant reduction in mean vessel radius, as shown later using MRI-based vessel size imaging.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> However, tumor perfusion and oxygenation status returned to normal after 24 h following a single injection of CA-4P.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a></div><div class="NLM_p">Lunt et al.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> demonstrated that the vascular-disrupting effect of CA-4P dominates the tumor response to CA-4P rather than direct tumor cell cytotoxicity. These authors showed that SW122 human colorectal carcinoma cells resistant to CA-4P in vitro (no inhibition of cell proliferation) were equally sensitive as nonresistant cells to CA-4P in vivo. Moreover, CA-4P induced tumor necrosis, rapid vessel disruption, and blood flow shutdown in xenografts derived from both cell lines.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a></div><div class="NLM_p last">The molecular and cellular pathways that support the maintenance and stability of the tumor microvasculature are not well-defined. However, important roles have been shown for pericytes, specialized smooth muscle cells that cover and stabilize microvessels, and for various adhesion molecules and integrins that provide survival signals to endothelial cells.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> As already mentioned, the destabilization of the endothelial cytoskeleton and increase in vascular permeability induced by combretastatins and analogues are thought to contribute to the occlusion of the tumor vasculature, which is immature and abnormal and lacks essential support by pericytes and basement membrane.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> In theory, increased permeability could cause a transient increase in interstitial fluid pressure, which in turn could induce intratumoral blood vessel collapse. However, there is no experimental evidence to corroborate this hypothesis.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Using a ROCK inhibitor, it was shown that activation of Rho/ROCK is crucial for the antivascular effects of CA-4P in tumor-bearing mice.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> Importantly, CA-4P was found to selectively induce regression of unstable tumor neovessels both in vitro and in mice by inhibiting cellular signaling through vascular endothelial-cadherin (VE-cadherin), a crucial cell-specific junctional molecule.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> Disruption of the VE-cadherin/β-catenin/Akt signaling pathway also increased endothelial cell permeability, leading to rapid vascular collapse and tumor necrosis. On the other hand, stabilization of VE-cadherin signaling in endothelial cells or enclosure of endothelial cells with smooth muscle cells conferred resistance to CA-4P.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> These data demonstrate the ability of tubulin-disrupting VDAs to discriminate between normal physiological vessels and unstable intratumoral vessels, a discrimination that is critical for their clinical applicability.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18">5.1.2 Antiangiogenic Activity</h4><div class="NLM_p last">Angiogenesis is a complex multistep process that requires, e.g., the proliferation, migration, and tube formation of endothelial cells. Besides their destructive effect on the existing vasculature, several VDAs, including CA-4 and its analogues<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> and deoxypodophyllotoxin<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> (DPT, the 5-deoxyderivative of compound <b>6</b>), a natural product isolated from <i>Anthriscus sylvestris</i>, have also been shown to inhibit the formation of new blood vessels. Interestingly, sprout formation and migration were reduced at concentrations that were not cytotoxic to endothelial cells.<a onclick="showRef(event, 'ref148 ref149'); return false;" href="javascript:void(0);" class="ref ref148 ref149">(148, 149)</a> Using the 2-aminothiazole derivative <b>15</b>,<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> it was shown that inhibition of angiogenesis and increase in vascular permeability involved the VE-cadherin/β-catenin signaling pathway. It has also been proposed that connective tissue growth factor (CTGF/CCN2), an endogenous antiangiogenic agent, is involved in the antiangiogenic activity of CA-4P.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> Upregulation of CTGF in microvascular endothelial cells by CA-4P was dependent on ROCK signaling and was increased by MAPK/Erk inhibitors, providing a possible explanation for the improved clinical efficacy of combretastatins when combined with kinase inhibitors.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a></div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">5.2 CA-4P Induces Endothelial and Tumor Cell Death</h3><div class="NLM_p">Several types of cell death may occur following treatment of cells with tubulin-binding VDAs, including apoptosis, mitotic catastrophe, necrosis, and autophagy, which are executed by distinct and sometimes overlapping pathways.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a></div><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20">5.2.1 CA-4P Induces Mitotic Arrest and Mitotic Catastrophe in Endothelial and Tumor Cells</h4><div class="NLM_p last">Microtubule-binding agents typically abrogate appropriate spindle formation during mitosis, leading to cell cycle arrest in G2/M phase. Mitotic arrest was demonstrated by elevated levels of cyclin B1 protein and increased cyclin-dependent kinase (cdc2) activity. Sustained cdc2 activity was responsible for metaphase arrest.<a onclick="showRef(event, 'ref152 ref153 ref154'); return false;" href="javascript:void(0);" class="ref ref152 ref153 ref154">(152-154)</a> Interestingly, Kanthou et al.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> showed that CA4P-induced endothelial cell death was restricted to proliferating (mitotic) cells. This may be linked to the fact that failure of cells to proceed through mitosis has been shown to result in mitotic catastrophe, a form of cell death induced by aberrant chromosome segregation during mitosis or DNA damage. This process is thought to protect normal cells with irregular mitosis from becoming aneuploid and potentially oncogenic, as reviewed in Vitale et al.,<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> but it is also induced by several DNA damaging and microtubule-binding compounds. Accordingly, experimental data obtained in a panel of human B-lymphoid tumors indicate that mitotic catastrophe is the primary form of cell death induced by CA-4.<a onclick="showRef(event, 'ref154 ref156'); return false;" href="javascript:void(0);" class="ref ref154 ref156">(154, 156)</a> Mitotic catastrophe has also been reported in various other cell lines treated with combretastatins, such as lung,<a onclick="showRef(event, 'ref157 ref158'); return false;" href="javascript:void(0);" class="ref ref157 ref158">(157, 158)</a> bladder,<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> cervical,<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> and breast cancer cells.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a></div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21">5.2.2 Combretastatins Induce Endothelial and Tumor Cell Apoptosis</h4><div class="NLM_p">Increasing data indicate that mitotic catastrophe may proceed toward other forms of cell death, such as apoptosis (or necrosis, depending on the pathways involved). Two different apoptotic pathways have been described: the intrinsic pathway, which results from mitochondrial damage and subsequent cytochrome c release from the mitochondria, and the extrinsic pathway, which is activated as a result of activation of cell death receptors on the cell surface. Both pathways typically converge on the activation of caspases, cysteine-dependent proteases responsible for the organized disassembly of the cell, as recently reviewed.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a></div><div class="NLM_p">Already in 1998, Iyer et al. showed that the cytotoxic effect of CA-4 was mediated by the induction of apoptosis, as characterized by increased caspase-3 activation and internucleosomal DNA fragmentation.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> Moreover, treatment of acute myeloid leukemias (AMLs) with CA-4P led to disruption of mitochondrial membrane potential and release of proapoptotic mitochondrial membrane proteins, resulting in cell death. This was partially ascribed to caspase activation, although an increase of the intracellular reactive oxygen species (ROS) also contributed to CA-4P-induced cytotoxicity in AML.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> Also in H460 lung cancer cells treated with CA-4, mitochondrial membrane permeabilization followed by cytochrome c release and caspase activation was observed.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> These data all point to a predominant mitochondrial involvement (i.e., intrinsic pathway) in combretastatin-mediated apoptosis.</div><div class="NLM_p">Further investigation of the molecular mediators involved revealed an important role for the Bcl-2 family of proteins. Using knock-down experiments, it was shown that the apoptosis-promoting protein Bim (BH3-only protein belonging to Bcl-2 family), which is sequestered on the microtubule array (type of interface microtubule organization independent of a centrosome), is essential for CA-4-induced cell death in H460 lung cancer cells. It has been proposed that Bim promotes the release of proapoptotic Bax from the prosurvival protein Bcl-2, resulting in increased tumor cell apoptosis.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> A subsequent study by these authors disclosed an essential role for the tumor-suppressor protein p53 in the mitochondrial accumulation of Bim and resulting apoptotic events in nonsmall cell lung cancer.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> Additionally, NF-κB and c-Jun N-terminal kinase (JNK) were found to be crucial for the apoptosis-inducing capacity of the CA-4 analogue Brimanin, an N-Me imidazole derivative analogue of <b>16</b> with a 3-bromo-3,4-dimethoxyphenyl as ring A in pancreas and breast carcinoma cell lines.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a></div><div class="NLM_p last">In contrast, several studies using solid as well as leukemia cell lines demonstrated CA-4P-induced cell death independent of caspase activation<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> or poly(ADP-ribose) polymerase (PARP) cleavage,<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> suggesting that apoptosis is not involved or only plays a minor role in cell death induced by CA-4P. Moreover, in vitro studies using a stilbene derivative (the 3,5-dimethoxyphenyl derivative at ring A of 3′-amino-deoxycombretastatin A-4) reported induction of mitotic catastrophe and apoptosis in HCT-116 human colon cancer cells but not in B16/F10 melanoma cells.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> In summary, despite some reports that show apoptosis-independent cell death induced by combretastatins, the majority of studies demonstrate an involvement of the mitochondrial apoptosis pathway. However, apoptosis induction by combretastatins seems to be context- and cell-dependent and the signaling pathways involved remain ill-defined.</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22">5.3 CA-4P Inhibits Cell Movement and Metastasis</h3><div class="NLM_p">Tubulin-binding VDAs do not only block cell mitosis but also affect endothelial and tumor cell morphology and movement and prevent tumor cell metastasis. Specifically, CA-4 reduced the attachment, migration, and invasiveness of gastric cancer cells by inhibition of the phosphoinositol (PI)3 kinase/AKT survival pathway.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> CA-4 also inhibited bladder cancer cell migration in vitro.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> CA-4P has been shown to attenuate gastric tumor metastasis and AKT activation in vivo, suggesting that reduced survival signals contribute to the observed antimetastatic effects.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> In addition, CA-4P inhibited the circulation of acute myeloid leukemia cells (AMLs) and the extent of perivascular leukemic infiltrates.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> This effect may be explained by CA-4P-induced downregulation of vascular endothelial adhesion molecule (VCAM)-1 expression on the endothelial cell surface, resulting in reduced interaction of AMLs with blood vessels and subsequent augmented leukemic cell death.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> Other combretastatin-like compounds also inhibited cell migration and/or metastasis.<a onclick="showRef(event, 'ref149 ref167 ref168'); return false;" href="javascript:void(0);" class="ref ref149 ref167 ref168">(149, 167, 168)</a> In particular, compound <b>12</b> reduced lymph node metastasis of LY80 Yoshida sarcoma in mice by shutting down the blood flow even in small metastases. These observations suggest that combretastatin-mediated vascular shutdown not only affects large primary tumors but also micrometastases.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a></div><div class="NLM_p">An important role has been attributed to the Rho/ROCK pathway in the CA-4-induced antimigration effect. Rho-associated kinases (ROCK) induce the formation of stress fibers and focal adhesions by phosphorylating the myosin light chain (MLC), leading to actin binding to myosin II and increased contractility as reviewed by Ridley.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> High levels of Rho/ROCK signaling may further lead to “bleb-driven” cell migration, in addition to the more frequently used “lamellipodium-based” migration.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> In endothelial cells, CA-4P caused within minutes the phosphorylation of MLC, leading to actinomyosin contractility, assembly of actin stress fibers, and formation of focal adhesions. However, some cells also rapidly acquired a blebbing morphology, which was associated with increased monolayer permeability and decreased cell viability. Cytoskeletal alterations as well as blebbling were abolished by inhibiting the Rho/ROCK pathway or by blocking activation of stress-activated protein kinase-2/p38.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> In contrast, the extracellular-regulated kinases 1 and 2 (ERK-1/2) were shown to protect against blebbing.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> Rho activation was also involved in cytoskeleton remodeling induced by other VDAs, including deoxypodophyllotoxin (DPT)<a onclick="showRef(event, 'ref147 ref171'); return false;" href="javascript:void(0);" class="ref ref147 ref171">(147, 171)</a> and the CA-4 analogue brimanin.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a></div><div class="NLM_p last">In summary, CA-4P-mediated inhibition of cell motility and invasion contributes to the observed antitumor and, in particular, to its antimetastatic activity, and may be the consequence of alterations in microtubule organization and associated signaling pathways and/or reduced expression of adhesion molecules that interfere with tumor cell adhesion to the vasculature.</div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">6 Mechanisms of Resistance against CA-4P</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27563" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27563" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The efficacy of VDAs in tumor therapy depends on both the immediate vascular shutdown and the subsequent revascularization and regrowth of the tumor from the remaining viable rim. To optimize anticancer treatment with VDAs, it is imperative to get insights into the process of revascularization and tumor regrowth, as summarized in this section.</div><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24">6.1 Regrowth from the Remaining Viable Tumor Rim</h3><div class="NLM_p last">Using <b>12</b>, it was shown that only intratumoral vessels are disrupted after treatment of sarcoma xenografts, whereas the vessels at the tumor–host interface remain unaffected.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> Thus, tumor cells at the necrotic border may survive because they remain fueled by the vessels at the tumor-host interface. Yao et al.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> further demonstrated that CA-4P-induced hypoxia in W256 tumor-bearing rats resulted in increased vascular mimicry (VM), a recently discovered form of angiogenesis, in which tumor cells form functional vascular channels without endothelial cell participation.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a></div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25">6.2 Induction of a More Aggressive and Hypoxic Environment</h3><div class="NLM_p">A general consequence of VDA treatment is blood vessel collapse, resulting in reduced blood flow and consequently hypoxia in the central tumor area. The major regulator of neovascularization in tumor tissue is hypoxia inducible factor (HIF)-1α, which is upregulated under hypoxia. This transcription factor induces the expression of various proangiogenic molecules, including cytokines such as vascular endothelial growth factor (VEGF) and stromal cell-derived factor (SDF)-1/CXCL12, proteolytic enzymes (e.g., matrix metalloproteinases (MMPs), and inducible nitric oxide synthase (iNOS). CA-4P was shown to induce widespread hypoxia in both peripheral and central parts of the tumor within 1 h after treatment.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> However, 24 h post treatment, when most of the tumor had turned necrotic, pathophysiological conditions in the surviving viable rim were returning to normal and hypoxia was restricted to regions bordering the necrotic tumor center.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> In vitro, CA-4P increased HIF-1α accumulation and VEGF expression under aerobic conditions. The compound also activated NF-κB via the small guanosine triphosphatase RhoA.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a></div><div class="NLM_p last">As mentioned above, hypoxia was also responsible for vascular mimicry induced by CA-4P in tumors through the HIF-1α-induced EphrinA2/PI3K/MMP signaling pathway, resulting in the regrowth of the damaged tumor.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> Thus, although originally proposed as a tumor-killing mechanism, deprivation of tumor blood flow by antiangiogenic agents and VDAs may paradoxically select for hypoxia-resistant tumor cells that may present increased angiogenic and metastatic potential.</div></div><div id="sec6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26">6.3 Recruitment of Endothelial Progenitor Cells</h3><div class="NLM_p">Circulating endothelial progenitor cells (EPC) are a subtype of stem cells with high proliferative potential that are capable of differentiating into mature endothelial cells. Emerging evidence suggests that these bone marrow-derived cells contribute to vascularization and tumor progression.<a onclick="showRef(event, 'ref176 ref177'); return false;" href="javascript:void(0);" class="ref ref176 ref177">(176, 177)</a> The recruitment of endothelial progenitors from the bone marrow to the peripheral blood and the tumor site is thought to be induced by vascular damage and hypoxia and is regulated predominantly by VEGF/VEGF receptor and SDF-1/CXCL12/CXCR4 pathways.<a onclick="showRef(event, 'ref178 ref179'); return false;" href="javascript:void(0);" class="ref ref178 ref179">(178, 179)</a> These factors are upregulated under hypoxia and activate their respective receptors, which are expressed on the surface of EPCs. Thus, acute systemic mobilization and homing of EPCs to the viable tumor rim could promote tumor regrowth following treatment with a VDA.</div><div class="NLM_p last">The CA-1 prodrug <b>11</b> was found to cause a rapid increase in circulating plasma VEGF, SDF-1, and granulocyte colony stimulating factor (G-CSF) levels in mice.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> Interestingly, G-CSF knockout mice failed to mobilize EPCs or to increase SDF-1 plasma levels, while treatment of tumors in these mice with <b>11</b> led to more necrosis compared with tumors treated in wild-type mice, suggesting that G-CSF may be a key player in VDA-induced EPC recruitment and tumor regrowth.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> Moreover, inhibition of EPC mobilization by antiangiogenic compounds resulted in a reduction in tumor rim size and enhanced VDA antitumor activity, thus providing a mechanistic rationale for the enhanced efficacy of VDAs when combined with antiangiogenic drugs.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a></div></div><div id="sec6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27">6.4 Recruitment of Neutrophils and Tumor-Associated Macrophages</h3><div class="NLM_p">The importance of the tumor microenvironment in tumor progression has been well established during past years. Besides the tumor vasculature, immune cells play an important role in tumor pathology. In particular, neutrophils produce various cytokines and enzymes with pro-angiogenic activity. In addition, pro-angiogenic TIE2-expressing macrophages (TEMs) have been shown to stimulate cell migration and invasion, angiogenesis, and tumor growth.<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> Thus, both cell types may increase tumor malignancy.</div><div class="NLM_p">CA-4P was shown to induce infiltration of TEMs in murine mammary tumors. Inhibition of TEM recruitment by abrogating the CXCL12/CXCR4 pathway or by genetically depleting TEMs in tumor-bearing mice increased the efficacy of CA-4P treatment, suggesting that TEMs contribute to tumor resistance to VDAs.<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a></div><div class="NLM_p last">CA4P-induced shutdown of tumor blood flow also resulted in a significant increase in neutrophil infiltration into the tumors.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> Neutrophil activity protected the tumor vasculature against CA4P-induced injury by the production of nitric oxide, a molecule with vasodilation and blood flow increasing capacities.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> Recently, Bohn et al.<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> added further proof to the importance of neutrophils in combretastatin resistance by demonstrating that neutrophil-depleted mice treated with CA-4P showed increased intratumoral necrosis. These authors also demonstrated that neutrophil recruitment induced by CA-4P in endothelial cells is the result of increased expression of endothelial cell adhesion molecules, which promote neutrophil attachment to the tumor vasculature.<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> Together, these data strongly suggest a role for TEMs and neutrophils in reducing the CA-4P-mediated antitumor effect. Thus, these immune cells may represent a potential target to be addressed in order to improve the clinical efficacy of VDA-based therapies.</div></div><div id="sec6_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28">6.5 Effects of CA-4P on Autophagy</h3><div class="NLM_p">Autophagy is a catabolic process that facilitates cell survival in conditions of stress by generating energy via lysosomal degradation of cytoplasmic constituents. In the context of cancer, autophagy may thus act as a tumor promotor by supporting survival of starving tumor cells, as recently reviewed.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a></div><div class="NLM_p">CA-4P was shown to cause autophagy in adenocarcinoma-derived, but not in fibrosarcoma-containing, tumor xenografts, suggesting a tumor-dependent mechanism of action.<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> Accordingly, inhibition of autophagy by the vacuolar H(+)ATPase inhibitor Bafilomycin-A1<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> or by pretreatment with autophagy inhibitors (3-methyladenine, 3-MA) or small interfering RNAs against autophagic genes<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> potentiated CA-4-mediated cell death. The enhanced anticancer activity of the combination of CA-4 and 3-MA was further confirmed in the SGC-7901 xenograft tumor model.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a></div><div class="NLM_p last">Using JNK inhibitors, it was shown that the JNK-Bcl-2 pathway is a critical regulator of CA-4-induced autophagy, which attenuates CA-4-induced apoptosis.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> Taken together, and although recent data indicate that components of the autophagic signaling pathway may promote cell death,<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> autophagy seems to play predominantly a tumor-promoting role in combretastatin-treated tumors. It may be proposed that inhibition of this process, by combination therapy with autophagy inhibitors, may force VDA-treated tumor cells to enter apoptosis.</div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">7 Combination Therapy</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42756" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42756" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The clinical success of VDAs relies on the elimination of the viable tumor rim that is resistant to these compounds, which can be achieved by combination with radio/chemotherapy or antiangiogenic therapy. However, the intrinsic strength of VDAs to cause rapid vascular shutdown also poses extra problems in that a reduction of intratumoral tumor blood flow and oxygen tension prevents the uptake of other anticancer agents and reduces the efficacy of radiation therapy. Consequently, scheduling, sequence, and timing become crucial when considering combination regimens involving VDAs in order to maximize the therapeutic efficacy.<a onclick="showRef(event, 'ref26 ref188 ref189'); return false;" href="javascript:void(0);" class="ref ref26 ref188 ref189">(26, 188, 189)</a> For an extensive overview of combination therapies involving VDAs, we refer to several excellent reviews that have recently appeared.<a onclick="showRef(event, 'ref25 ref190'); return false;" href="javascript:void(0);" class="ref ref25 ref190">(25, 190)</a> Here, we only highlight some specific concepts that illustrate the possibilities and pitfalls associated with VDA combination therapies.</div><div id="sec7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30">7.1 Combination with Antiangiogenic Agents</h3><div class="NLM_p">The mechanistic rational for combining VDAs with angiogenesis inhibitors is 2-fold, i.e., antiangiogenic agents may abrogate (i) neovascularization from the remaining vessels in the tumor rim and (ii) mobilization of EPC from the bone marrow, as already indicated in a previous section.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a></div><div class="NLM_p">Although angiogenesis involves various mediators and pathways, studies have, until recently, largely focused on the key angiogenic growth factor VEGF. Consequently, clinical VDA combinations have been limited to the evaluation of CA-4 prodrugs with bevacizumab, a clinically approved monoclonal antibody targeting VEGF.<a onclick="showRef(event, 'ref25 ref190'); return false;" href="javascript:void(0);" class="ref ref25 ref190">(25, 190)</a> Recent phase I trials in patients with advanced cancer treated with CA-4P 4 h before administration of bevacizumab showed reduced and sustained vascular permeability and perfusion compared with CA-4P alone.<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a></div><div class="NLM_p last">Despite these promising results, bevacizumab may not be the ideal antiangiogenic agent to combine with VDAs. Accumulating clinical data indicate that this monoclonal antibody affords only limited antitumor activity and causes rapid tumor resistance due to the expression of other angiogenic factors by the tumor.<a onclick="showRef(event, 'ref192 ref193'); return false;" href="javascript:void(0);" class="ref ref192 ref193">(192, 193)</a> As such, combination with already approved receptor tyrosine kinase inhibitors that target several angiogenic factors might provide a better therapeutic benefit.</div></div><div id="sec7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31">7.2 Combination with Chemo/Radiation Therapy</h3><div class="NLM_p">Because of limited perfusion in the center of the tumor, chemo- and radiotherapy are less effective in killing cells at the tumor core. Conversely, these therapies are particularly efficient in the well-vascularized VDA-resistant tumor rim. Therefore, the use of combinations of chemo/radiotherapy with VDAs seems a very promising strategy that has progressed to phase II clinical trials. Most of these studies are still ongoing (<a href="https://clinicaltrials.gov" class="extLink">https://clinicaltrials.gov</a>). However, the already disclosed results have not always been as encouraging as expected. Combination of CA-4P with carboplatin and paclitaxel gave a higher response rate in patients with relapsed ovarian cancer.<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a> However, CA-4P did not significantly improve the survival of patients suffering from anaplastic thyroid cancer treated with carboplatin/paclitaxel.<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> Also, addition of <b>12</b> to a taxane regime did not improve progression-free survival of patients with metastatic nonsmall cell lung cancer.<a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a></div><div class="NLM_p last">Additional studies should provide more insights into these variable data. However, appropriate scheduling of chemo/radiotherapy and VDAs is critical to maximize anticancer efficiency and minimize toxicity of these combinations. Because chemotherapeutic agents and radiotherapy require an adequate blood flow, they should theoretically be administered before VDAs. Indeed, preclinical data demonstrated that irradiation may prevent tumor recurrence in the tumor rim only when given before <b>12</b>.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> Also, cisplatin enhanced tumor killing only when administered before VDAs.<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a> Moreover, in a phase I trial involving patients with various tumors refractory to treatment, CA-4P increased carboplatin-associated toxicity when administered 1 h after the chemotherapeutic agent. Interestingly, bone marrow toxicity could be avoided when both compounds were administered on consecutive days.<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a> Also, the combination of paclitaxel and VDAs should be carefully monitored. Martinelli  et al.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> reported that treatment of mice bearing breast cancer with paclitaxel followed by the VDA <b>7</b>, a prodrug of <i>N</i>-acetylcolchinol, did not result in a beneficial outcome, probably because of a protective effect of paclitaxel against the vascular damage induced by <b>7</b>. By contrast, improved antitumor efficacy was observed when <b>7</b> was administered before paclitaxel. Thus, scheduling may be critical in the design of these combination approaches.</div></div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">8 Conclusions and Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72631" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72631" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Tubulin-depolymerizing agents acting at the colchicine site have been vastly re-explored in the last 20 years, mostly due to their vascular disrupting properties in the tumor environment. From a chemical point of view, compounds binding at the colchicine site are low molecular weight compounds whose synthesis, in most cases, can be accomplished by standard synthetic methods, which has allowed the testing of large families of compounds and the establishment of well-defined SAR. Using the structure of CA-4 as inspiration, there are now compounds for which chemical instability is not an issue but solubility is still a limitation that is mostly overcome by the derivatization as prodrugs. As mentioned throughout this Perspective, several prodrugs of combretastatin derivatives are being evaluated in clinical trials. There are other compounds, whose structure is not inspired by CA-4, for which oral bioavailability has been accomplished, and several of them are being evaluated in the clinic as well. None of them have yet been approved.</div><div class="NLM_p">In the last four years, making use of stathmin or other MAPs, the structure of αβ-tubulin complexed with a wide variety of ligands has been solved, shedding light into the detailed atomic features of their binding in the so-called colchicine-binding domain. The higher resolution of these complexes compared to the early examples in 2004 of DAMA–colchicine or podophyllotoxin tubulin-cocrystals have also revealed unknown features of the tubulin structure. Indeed, the insights obtained with these very recent complexes may lead to a reevaluation of the binding mode previously proposed for some ligands based on docking studies. As an example, the binding mode predicted for plinabulin by molecular modeling<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> does not correlate with the interactions observed when the complex of plinabulin with αβ-tubulin was very recently solved.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> The detailed information now available about the colchicine domain and the binding mode of the different ligands will facilitate a more accurate application of the molecular modeling tools to design new colchicine-domain ligands. Moreover, recent progress on the different conformations of the αβ-tubulin dimer and the activities of key proteins that regulate microtubule dynamics<a onclick="showRef(event, 'ref122 ref199'); return false;" href="javascript:void(0);" class="ref ref122 ref199">(122, 199)</a> may offer new possibilities for therapeutic intervention.</div><div class="NLM_p">From a biological point of view, and using CA-4 as a prototype, it is becoming clear that microtubule depolymerization in endothelial cells leads to distinct responses affecting chromosome organization, cell morphology and permeability, and cell death. Each of these processes involves several biological pathways that may be targeted by CA-4. Interestingly, even a very close analogue of CA-4, CA-1, exerts a more toxic effect than CA-4 due to the formation of a reactive quinone intermediate. This illustrates the difficulties in predicting the contribution of these different pathways to the antivascular and antitumor activity of CA-4 analogues.</div><div class="NLM_p">As has also been shown, P-glycoprotein or βIII tubulin overexpression is not relevant for resistance among these compounds. However, rapid tumor recurrence after monotherapy with these compounds occurs through the intrinsic resistance of more stabilized vessels at the tumor border. To surmount these limitations, VDAs are typically administered in combination with therapies that specifically target this viable tumor rim, such as radio- and chemotherapy. Relevant to this point, it should be mentioned that recent progress in understanding the biological actions of VDAs has led to potentially new combination therapies. So far, preclinical studies already demonstrated improved antitumor activity when combretastatins were combined with inhibitors of nitric oxide synthase,<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> autophagy,<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> or the recently discovered mediator of vascular disruption RhoJ,<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a> an endothelial-enriched Rho GTPase. In vitro studies further indicated that inhibitors of various intracellular kinases, such as p38 MAPK<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> and JNK,<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> may increase CA-4 anticancer efficacy. Also, neutrophils and TEMs may represent a potential target for improving the clinical efficacy of VDA-based therapies.<a onclick="showRef(event, 'ref183 ref185'); return false;" href="javascript:void(0);" class="ref ref183 ref185">(183, 185)</a> Clinically, combinations assayed so far have been limited to CA-4 prodrugs as VDA, but other VDAs, such as the more active compound CA-1P, or VDAs with a structure that is not related to combretastatins, should be included as well.</div><div class="NLM_p last">Finally, new delivery systems such as nanoparticles or nanocarriers are being explored for selective delivery of CA-4 and its prodrug CA-4P and also for combination therapy. Moreover, VDAs might be used to prime the host environment to become receptive to a second (therapeutic or diagnostic) agent in the so-called environment-primed nanosystems.<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a> For example, ombrabulin selectively increases the expression of p32 (a stress-related protein) on the surface of tumor cells, and this has been used to recruit nanoparticles decorated with p32-targeting peptides in the tumor environment.<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a> This field will certainly offer interesting perspectives for the future.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b00463" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55611" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55611" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">María-Jesús Pérez-Pérez</span> - <span class="hlFld-Affiliation affiliation">Instituto
de Química Médica (IQM-CSIC), Juan de la Cierva 3, E-28006 Madrid, Spain</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#abc6c1dbced9ced1ebc2dac685c8d8c2c885ced8"><span class="__cf_email__" data-cfemail="f29f988297809788b29b839fdc91819b91dc9781">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eva-María Priego</span> - <span class="hlFld-Affiliation affiliation">Instituto
de Química Médica (IQM-CSIC), Juan de la Cierva 3, E-28006 Madrid, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Oskía Bueno</span> - <span class="hlFld-Affiliation affiliation">Instituto
de Química Médica (IQM-CSIC), Juan de la Cierva 3, E-28006 Madrid, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maria Solange Martins</span> - <span class="hlFld-Affiliation affiliation">Rega
Institute for Medical Research, KU Leuven, B-3000 Leuven, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">María-Dolores Canela</span> - <span class="hlFld-Affiliation affiliation">Instituto
de Química Médica (IQM-CSIC), Juan de la Cierva 3, E-28006 Madrid, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sandra Liekens</span> - <span class="hlFld-Affiliation affiliation">Rega
Institute for Medical Research, KU Leuven, B-3000 Leuven, Belgium</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): Mara-Dolores Canela is currently working at Teva Pharmaceuticals as Medical Advisor.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38112" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38112" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="18" class="article__inlineFigure"><h2 class="fig-label">María-Jesús Pérez-Pérez</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=BIO-d281e2181-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Marı́a-Jesús Pérez-Pérez</b> is Research Professor at the Medicinal Chemistry Institute (IQM-CSIC) (Madrid, Spain). She studied Pharmacy at Universidad de Navarra and received her Ph.D. from Universidad Complutense (Madrid). She stayed as a postdoc for more than two years at Rega Institute (KU Leuven, Belgium) and got a tenured position at CSIC in 1995. She has been director of the IQM-CSIC for four years (2011–2015). Her research work has been linked to selective inhibitors against therapeutically relevant nucleoside processing enzymes (thymidine phosphorylase, nucleoside kinases, etc.) as well to the identification and optimization of antivirals, particularly against HIV, enterovirus, or alphavirus. Her currently active areas of research involve antivascular strategies in the antitumoral field and novel chemical entities against (re)-emerging viruses.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Eva-María Priego</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=BIO-d281e2188-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Eva-Marı́a Priego</b> received her degree in Chemistry at the Universidad Complutense de Madrid. After enjoying a postdoctoral position with Prof. Sir Tom L. Blundell in the Crystallography and Bioinformatics Unit at the Department of Biochemistry at the University of Cambridge, she returned in 2007 to the Instituto de Quı́mica Médica with a CSIC contract from the I3P programme, and since 2009 as Tenured Scientist. Her research interests are in the areas of computer-aided drug design, homology modeling, docking, molecular dynamic simulations of biomolecular systems, and virtual screening, and she is currently focused on the development of new antivascular agents.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Oskía Bueno</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=BIO-d281e2193-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Oskı́a Bueno</b> received her degree in Chemistry at University of Navarra in 2008 and performed an internship during three months in the area of Neurosciences in the Center for Applied Medical Research (University of Navarra). In 2010, she received a Master’s degree in Green Chemistry at the Public University of Navarra, being involved in a project at the Department of Applied Chemistry. In 2011, she joined the Medicinal Chemistry Institute (IQM-CSIC) in Madrid, working at the instrumental analysis unit. Since 2013, she is a predoctoral student on a project concerning antivascular strategies against tumor growth under the supervision of Prof. M.-J. Pérez-Pérez and Dr. E. M. Priego. Her research interests concern the design, synthesis, and biological evaluation of new tubulin binding agents with vascular disrupting capacity.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Maria Solange Martins</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=BIO-d281e2198-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Maria Solange Martins</b> graduated as Bachelor in Biology at the Faculty of Sciences of the University of Lisbon (FCUL, Portugal) in 2012. After an Erasmus program at the Aarhus University (Denmark), she returned to FCUL, where she acquired her Master’s degree in Molecular Biology and Genetics in 2014. Solange is currently a Ph.D. student at the Rega Institute (Laboratory of Virology and Chemotherapy, KU Leuven, Belgium) under the supervision of Prof. Sandra Liekens, focusing on the characterization of vascular-disrupting agents.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="22" class="article__inlineFigure"><h2 class="fig-label">María-Dolores Canela</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=BIO-d281e2203-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Marı́a-Dolores Canela</b> received her degree in Pharmacy in 2008 by the University of Seville and a Master’s degree in Clinical Trials in 2011 by the same university. She got the Pharmacy’s Extraordinary Award for the Best Student Record and National Education Award in Pharmacy’s degree. After two years working at the Spanish National Centre for Biotechnology (CNB-CSIC), she got a Postgraduate degree in Immunology. In September 2010, and through a JAE-Pre contract, she joined the IQM-CSIC to perform her thesis. She defended her Ph.D. thesis in July 2014, under the supervision of Dr. E.-M. Priego and Prof. M.-J. Pérez-Pérez, focused on the discovery, synthesis, and evaluation of novel tumor vascular disrupting agents. She is currently working at Teva Pharmaceuticals as Medical Advisor.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Sandra Liekens</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=BIO-d281e2208-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Sandra Liekens</b> graduated as Bio-Engineer in 1994 at the University of Leuven, Belgium. She obtained her Ph.D. degree (2000) in Applied Biological Sciences at the Rega Institute (Laboratory of Virology and Chemotherapy, KU Leuven, Belgium) on the inhibition of vascular tumor growth by antiangiogenic and apoptosis-inducing agents. After a postdoctoral stay at the New York University (laboratory of Prof. Rifkin), she returned to Leuven where she is currently holding a position of professor at the Rega Institute. Her research is focused on the study of endothelial cell activation by flaviviruses and the characterization of antiangiogenic and vascular-targeting agents.</p></figure></div><div class="ack" id="ACK-d281e2213-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i39">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13532" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13532" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Due to the amount of original research articles and reviews on this subject, we were unable to cite all of them; any omissions were unintentional. Author’s research in this subject has been financed by the Spanish Ministerio de Economı́a y Competitividad (SAF2012-39760-C02-01 and SAF2015-64629-C2-1-R (MINECO-FEDER) to M.-J.P.-P. and E.-M.P.) and Comunidad de Madrid (BIPEDD2; ref P2010/BMD-2457). S.L. and M.-J.P.-P. acknowledge networking contribution by COST Action CM1407 “Challenging organic synthesis inspired by nature-from natural products chemistry to drug discovery”. M.-D.C. thanks the Fondo Social Europeo (FSE) and the JAE Predoc Programme for a predoctoral fellowship.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i40" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i40"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i41" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i41"> Abbreviations Used</h2><tr><td class="NLM_term">2-ME</td><td class="NLM_def"><p class="first last">2-methoxyestradiol</p></td></tr><tr><td class="NLM_term">3-MA</td><td class="NLM_def"><p class="first last">3-methyladenine</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemias</p></td></tr><tr><td class="NLM_term">CA-1</td><td class="NLM_def"><p class="first last">combretastatin A-1</p></td></tr><tr><td class="NLM_term">CA-2</td><td class="NLM_def"><p class="first last">combretastatin A-2</p></td></tr><tr><td class="NLM_term">CA-4</td><td class="NLM_def"><p class="first last">combretastatin A-4</p></td></tr><tr><td class="NLM_term">CA-4P</td><td class="NLM_def"><p class="first last">the phosphate prodrug of CA-4</p></td></tr><tr><td class="NLM_term">CDDP-NPs</td><td class="NLM_def"><p class="first last"><i>cis</i>-diaminedichloroplatinum loaded nanoparticles</p></td></tr><tr><td class="NLM_term">CDL</td><td class="NLM_def"><p class="first last">colchicine-domain ligand</p></td></tr><tr><td class="NLM_term">CTGF/CCN2</td><td class="NLM_def"><p class="first last">connective tissue growth factor</p></td></tr><tr><td class="NLM_term">DAMA–colchicine</td><td class="NLM_def"><p class="first last"><i>N</i>-deacetyl-<i>N</i>-(2-mercaptoacetyl)colchicine</p></td></tr><tr><td class="NLM_term">DMXAA</td><td class="NLM_def"><p class="first last">5,6-dimethylxanthenone-4-acetic acid</p></td></tr><tr><td class="NLM_term">DPT</td><td class="NLM_def"><p class="first last">deoxypodophyllotoxin</p></td></tr><tr><td class="NLM_term">EBI</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>′-ethylene-bis(iodoacetamide)</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">EPC</td><td class="NLM_def"><p class="first last">endothelial progenitor cells</p></td></tr><tr><td class="NLM_term">ERK-1/2</td><td class="NLM_def"><p class="first last">extracellular-regulated kinases 1 and 2</p></td></tr><tr><td class="NLM_term">FAA</td><td class="NLM_def"><p class="first last">8-flavon acetic acid</p></td></tr><tr><td class="NLM_term">G-CSF</td><td class="NLM_def"><p class="first last">granulocyte colony stimulating factor</p></td></tr><tr><td class="NLM_term">(HIF)-1α</td><td class="NLM_def"><p class="first last">hypoxia inducible factor 1α</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high-throughput screening</p></td></tr><tr><td class="NLM_term">iNOS</td><td class="NLM_def"><p class="first last">inducible nitric oxide synthase</p></td></tr><tr><td class="NLM_term">JNK</td><td class="NLM_def"><p class="first last">c-Jun N-terminal kinase</p></td></tr><tr><td class="NLM_term">MAP</td><td class="NLM_def"><p class="first last">microtubule associated protein</p></td></tr><tr><td class="NLM_term">MLC</td><td class="NLM_def"><p class="first last">myosin light chain</p></td></tr><tr><td class="NLM_term">MMP</td><td class="NLM_def"><p class="first last">matrix metalloproteinase</p></td></tr><tr><td class="NLM_term">MRI</td><td class="NLM_def"><p class="first last">magnetic resonance imaging</p></td></tr><tr><td class="NLM_term">NF-κB</td><td class="NLM_def"><p class="first last">nuclear factor kB</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">nonsmall cell lung cancer</p></td></tr><tr><td class="NLM_term">PARP</td><td class="NLM_def"><p class="first last">poly(ADP-ribose) polymerase</p></td></tr><tr><td class="NLM_term">PDGFR-β</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor β</p></td></tr><tr><td class="NLM_term">RB3-SLD</td><td class="NLM_def"><p class="first last">stathmin-like domain of the neural protein RB3</p></td></tr><tr><td class="NLM_term">ROCK</td><td class="NLM_def"><p class="first last">Rho-associated kinase</p></td></tr><tr><td class="NLM_term">ROS</td><td class="NLM_def"><p class="first last">reactive oxygen species</p></td></tr><tr><td class="NLM_term">SDF-1</td><td class="NLM_def"><p class="first last">stromal cell-derived factor</p></td></tr><tr><td class="NLM_term">SIFt</td><td class="NLM_def"><p class="first last">structural interaction fingerprints</p></td></tr><tr><td class="NLM_term">T2RB3</td><td class="NLM_def"><p class="first last">two tubulin heterodimers–RB3 complex</p></td></tr><tr><td class="NLM_term">TEM</td><td class="NLM_def"><p class="first last">TIE2-expressing macrophages</p></td></tr><tr><td class="NLM_term">TNF-α</td><td class="NLM_def"><p class="first last">tumor necrosis factor-α</p></td></tr><tr><td class="NLM_term">TTL</td><td class="NLM_def"><p class="first last">tubulin tyrosine ligase</p></td></tr><tr><td class="NLM_term">(VCAM)-1</td><td class="NLM_def"><p class="first last">vascular endothelial adhesion molecule</p></td></tr><tr><td class="NLM_term">VDA</td><td class="NLM_def"><p class="first last">vascular disrupting agent</p></td></tr><tr><td class="NLM_term">VE-cadherin</td><td class="NLM_def"><p class="first last">vascular endothelial-cadherin</p></td></tr><tr><td class="NLM_term">VEGFR-2</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor-2</p></td></tr><tr><td class="NLM_term">VM</td><td class="NLM_def"><p class="first last">vascular mimicry</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36483" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36483" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 204 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Siemann, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bibby, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dark, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dicker, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eskens, F. A. L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horsman, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marmé, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P. M.</span><span> </span><span class="NLM_article-title">Differentiation and definition of vascular-targeted therapies</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">416</span><span class="NLM_x">–</span> <span class="NLM_lpage">420</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=15701823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD2MXislWgtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=416-420&author=D.+W.+Siemannauthor=M.+C.+Bibbyauthor=G.+G.+Darkauthor=A.+P.+Dickerauthor=F.+A.+L.+M.+Eskensauthor=M.+R.+Horsmanauthor=D.+Marm%C3%A9author=P.+M.+LoRusso&title=Differentiation+and+definition+of+vascular-targeted+therapies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Differentiation and Definition of Vascular-Targeted Therapies</span></div><div class="casAuthors">Siemann, Dietmar W.; Bibby, Michael C.; Dark, Graham G.; Dicker, Adam P.; Eskens, Ferry A. L. M.; Horsman, Michael R.; Marme, Dieter; LoRusso, Patricia M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2, Pt. 1</span>),
    <span class="NLM_cas:pages">416-420</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The therapeutic potential of targeting the tumor vascular supply is now widely recognized.  Intense research and development activity has resulted in a variety of investigational agents, a no. of which are currently in clin. development.  As these novel agents are quite distinct from the cytotoxic drugs conventionally used in the treatment of solid tumors, it will be particularly important to ensure early differentiation of these vascular-targeted therapies in order to encourage widespread understanding of their potential benefits and application in the clinic.  Two distinct groups of vascular-targeted therapies have evolved: antiangiogenic agents and vascular-disrupting approaches.  These differ in three key respects: their physiol. target, the type or extent of disease that is likely to be susceptible, and the treatment scheduling.  Inhibitors of angiogenesis interfere with new vessel formation and therefore have a preventative action, require chronic administration, and are likely to be of particular benefit in early-stage or asymptomatic metastatic disease.  Vascular-disrupting agents target the established tumor blood vessels, resulting in tumor ischemia and necrosis.  These agents are therefore given acutely, show more immediate effects, and may have particular efficacy against advanced disease.  It is essential that these agents can be readily distinguished from conventional therapies and that an understanding of key differences between the two types of vascular-targeted therapies is fostered.  Here, a simple taxonomy and nomenclature is proposed in anticipation that the therapeutic potential of this novel class can be realized as these approaches advance in clin. settings and a new anticancer strategy becomes available in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIEL4anGTuWbVg90H21EOLACvtfcHk0lhDGTo6jU0xvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXislWgtro%253D&md5=8a037771f2908fb5729425f7bdc9ae10</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSiemann%26aufirst%3DD.%2BW.%26aulast%3DBibby%26aufirst%3DM.%2BC.%26aulast%3DDark%26aufirst%3DG.%2BG.%26aulast%3DDicker%26aufirst%3DA.%2BP.%26aulast%3DEskens%26aufirst%3DF.%2BA.%2BL.%2BM.%26aulast%3DHorsman%26aufirst%3DM.%2BR.%26aulast%3DMarm%25C3%25A9%26aufirst%3DD.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26atitle%3DDifferentiation%2520and%2520definition%2520of%2520vascular-targeted%2520therapies%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D416%26epage%3D420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Tozer, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanthou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baguley, B. C.</span><span> </span><span class="NLM_article-title">Disrupting tumour blood vessels</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">423</span><span class="NLM_x">–</span> <span class="NLM_lpage">435</span><span class="refDoi"> DOI: 10.1038/nrc1628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1038%2Fnrc1628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=15928673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Gmsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=423-435&author=G.+M.+Tozerauthor=C.+Kanthouauthor=B.+C.+Baguley&title=Disrupting+tumour+blood+vessels&doi=10.1038%2Fnrc1628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Disrupting tumor blood vessels</span></div><div class="casAuthors">Tozer, Gillian M.; Kanthou, Chryso; Baguley, Bruce C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">423-435</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Low-mol.-wt. vascular-disrupting agents (VDAs) cause a pronounced shutdown in blood flow to solid tumors, resulting in extensive tumor-cell necrosis, while they leave the blood flow in normal tissues relatively intact.  The largest group of VDAs is the tubulin-binding combretastatins, several of which are now being tested in clin. trials.  DMXAA (5,6-dimethylxanthenone-4-acetic acid) - one of a structurally distinct group of drugs - is also being tested in clin. trials.  A full understanding of the action of these and other VDAs will provide insights into mechanisms that control tumor blood flow and will be the basis for the development of new therapeutic drugs for targeting the established tumor vasculature for therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjdnxmo6H1JrVg90H21EOLACvtfcHk0lj7f90NjTtwlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Gmsr0%253D&md5=869e9f19ba4b9b82b166b39f089e003b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc1628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1628%26sid%3Dliteratum%253Aachs%26aulast%3DTozer%26aufirst%3DG.%2BM.%26aulast%3DKanthou%26aufirst%3DC.%26aulast%3DBaguley%26aufirst%3DB.%2BC.%26atitle%3DDisrupting%2520tumour%2520blood%2520vessels%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D423%26epage%3D435%26doi%3D10.1038%2Fnrc1628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Kanthou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozer, G. M.</span><span> </span><span class="NLM_article-title">Selective destruction of the tumour vasculature by targeting the endothelial cytoskeleton</span> <span class="citation_source-journal">Drug Discovery Today: Ther. Strategies</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">237</span><span class="NLM_x">–</span> <span class="NLM_lpage">243</span><span class="refDoi"> DOI: 10.1016/j.ddstr.2008.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.ddstr.2008.03.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=237-243&author=C.+Kanthouauthor=G.+M.+Tozer&title=Selective+destruction+of+the+tumour+vasculature+by+targeting+the+endothelial+cytoskeleton&doi=10.1016%2Fj.ddstr.2008.03.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.ddstr.2008.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddstr.2008.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DKanthou%26aufirst%3DC.%26aulast%3DTozer%26aufirst%3DG.%2BM.%26atitle%3DSelective%2520destruction%2520of%2520the%2520tumour%2520vasculature%2520by%2520targeting%2520the%2520endothelial%2520cytoskeleton%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Ther.%2520Strategies%26date%3D2007%26volume%3D4%26spage%3D237%26epage%3D243%26doi%3D10.1016%2Fj.ddstr.2008.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Potente, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerhardt, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmeliet, P.</span><span> </span><span class="NLM_article-title">Basic and therapeutic aspects of angiogenesis</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">873</span><span class="NLM_x">–</span> <span class="NLM_lpage">887</span><span class="refDoi"> DOI: 10.1016/j.cell.2011.08.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.cell.2011.08.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=21925313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtF2ht7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2011&pages=873-887&author=M.+Potenteauthor=H.+Gerhardtauthor=P.+Carmeliet&title=Basic+and+therapeutic+aspects+of+angiogenesis&doi=10.1016%2Fj.cell.2011.08.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Basic and Therapeutic Aspects of Angiogenesis</span></div><div class="casAuthors">Potente, Michael; Gerhardt, Holger; Carmeliet, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">873-887</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Blood vessels form extensive networks that nurture all tissues in the body.  Abnormal vessel growth and function are hallmarks of cancer and ischemic and inflammatory diseases, and they contribute to disease progression.  Therapeutic approaches to block vascular supply have reached the clinic, but limited efficacy and resistance pose unresolved challenges.  Recent insights establish how endothelial cells communicate with each other and with their environment to form a branched vascular network.  The emerging principles of vascular growth provide exciting new perspectives, the translation of which might overcome the current limitations of pro- and antiangiogenic medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYIoNjjHU-iLVg90H21EOLACvtfcHk0lj7f90NjTtwlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtF2ht7fL&md5=60cb7dbf953d3c9c1c6fc50584c9e53a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.08.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.08.039%26sid%3Dliteratum%253Aachs%26aulast%3DPotente%26aufirst%3DM.%26aulast%3DGerhardt%26aufirst%3DH.%26aulast%3DCarmeliet%26aufirst%3DP.%26atitle%3DBasic%2520and%2520therapeutic%2520aspects%2520of%2520angiogenesis%26jtitle%3DCell%26date%3D2011%26volume%3D146%26spage%3D873%26epage%3D887%26doi%3D10.1016%2Fj.cell.2011.08.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Carmeliet, P.</span><span> </span><span class="NLM_article-title">Angiogenesis in life, disease and medicine</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">438</span><span class="NLM_x">, </span> <span class="NLM_fpage">932</span><span class="NLM_x">–</span> <span class="NLM_lpage">936</span><span class="refDoi"> DOI: 10.1038/nature04478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1038%2Fnature04478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=16355210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSksrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=438&publication_year=2005&pages=932-936&author=P.+Carmeliet&title=Angiogenesis+in+life%2C+disease+and+medicine&doi=10.1038%2Fnature04478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis in life, disease and medicine</span></div><div class="casAuthors">Carmeliet, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">438</span>
        (<span class="NLM_cas:issue">7070</span>),
    <span class="NLM_cas:pages">932-936</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The growth of blood vessels (a process known as angiogenesis) is essential for organ growth and repair.  An imbalance in this process contributes to numerous malignant, inflammatory, ischemic, infectious and immune disorders.  Recently, the first anti-angiogenic agents have been approved for the treatment of cancer and blindness.  Angiogenesis research will probably change the face of medicine in the next decades, with more than 500 million people worldwide predicted to benefit from pro- or anti-angiogenesis treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor5NqkaUGRfrVg90H21EOLACvtfcHk0lhtg9Wiym1SOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSksrjF&md5=e196d7203fa60d5ecd9182fa023cd30e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnature04478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04478%26sid%3Dliteratum%253Aachs%26aulast%3DCarmeliet%26aufirst%3DP.%26atitle%3DAngiogenesis%2520in%2520life%252C%2520disease%2520and%2520medicine%26jtitle%3DNature%26date%3D2005%26volume%3D438%26spage%3D932%26epage%3D936%26doi%3D10.1038%2Fnature04478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">El-Kenawi, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Remessy, A. B.</span><span> </span><span class="NLM_article-title">Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">170</span><span class="NLM_x">, </span> <span class="NLM_fpage">712</span><span class="NLM_x">–</span> <span class="NLM_lpage">729</span><span class="refDoi"> DOI: 10.1111/bph.12344</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1111%2Fbph.12344" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=23962094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFOgs7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2013&pages=712-729&author=A.+E.+El-Kenawiauthor=A.+B.+El-Remessy&title=Angiogenesis+inhibitors+in+cancer+therapy%3A+mechanistic+perspective+on+classification+and+treatment+rationales&doi=10.1111%2Fbph.12344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales</span></div><div class="casAuthors">El-Kenawi, Asmaa E.; El-Remessy, Azza B.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">712-729</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Angiogenesis, a process of new blood vessel formation, is a prerequisite for tumor growth to supply the proliferating tumor with oxygen and nutrients.  The angiogenic process may contribute to tumor progression, invasion and metastasis, and is generally accepted as an indicator of tumor prognosis.  Therefore, targeting tumor angiogenesis has become of high clin. relevance.  The current review aimed to highlight mechanistic details of anti-angiogenic therapies and how they relate to classification and treatment rationales.  Angiogenesis inhibitors are classified into either direct inhibitors that target endothelial cells in the growing vasculature or indirect inhibitors that prevent the expression or block the activity of angiogenesis inducers.  The latter class extends to include targeted therapy against oncogenes, conventional chemotherapeutic agents and drugs targeting other cells of the tumor micro-environment.  Angiogenesis inhibitors may be used as either monotherapy or in combination with other anticancer drugs.  In this context, many preclin. and clin. studies revealed higher therapeutic effectiveness of the combined treatments compared with individual treatments.  The proper understanding of synergistic treatment modalities of angiogenesis inhibitors as well as their wide range of cellular targets could provide effective tools for future therapies of many types of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou_Tt3ysAIULVg90H21EOLACvtfcHk0lhtg9Wiym1SOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFOgs7fO&md5=660db903fa77cbd241f0f9687fdfde89</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1111%2Fbph.12344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12344%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Kenawi%26aufirst%3DA.%2BE.%26aulast%3DEl-Remessy%26aufirst%3DA.%2BB.%26atitle%3DAngiogenesis%2520inhibitors%2520in%2520cancer%2520therapy%253A%2520mechanistic%2520perspective%2520on%2520classification%2520and%2520treatment%2520rationales%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D170%26spage%3D712%26epage%3D729%26doi%3D10.1111%2Fbph.12344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Vasudev, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, A. R.</span><span> </span><span class="NLM_article-title">Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions</span> <span class="citation_source-journal">Angiogenesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">471</span><span class="NLM_x">–</span> <span class="NLM_lpage">494</span><span class="refDoi"> DOI: 10.1007/s10456-014-9420-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1007%2Fs10456-014-9420-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=24482243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsVGrtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2014&pages=471-494&author=N.+S.+Vasudevauthor=A.+R.+Reynolds&title=Anti-angiogenic+therapy+for+cancer%3A+current+progress%2C+unresolved+questions+and+future+directions&doi=10.1007%2Fs10456-014-9420-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions</span></div><div class="casAuthors">Vasudev, Naveen S.; Reynolds, Andrew R.</div><div class="citationInfo"><span class="NLM_cas:title">Angiogenesis</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">471-494</span>CODEN:
                <span class="NLM_cas:coden">AGIOFT</span>;
        ISSN:<span class="NLM_cas:issn">0969-6970</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Tumors require a vascular supply to grow and can achieve this via the expression of pro-angiogenic growth factors, including members of the vascular endothelial growth factor (VEGF) family of ligands.  Since one or more of the VEGF ligand family is overexpressed in most solid cancers, there was great optimism that inhibition of the VEGF pathway would represent an effective anti-angiogenic therapy for most tumor types.  Encouragingly, VEGF pathway targeted drugs such as bevacizumab, sunitinib and aflibercept have shown activity in certain settings.  However, inhibition of VEGF signalling is not effective in all cancers, prompting the need to further understand how the vasculature can be effectively targeted in tumors.  Here we present a succinct review of the progress with VEGF-targeted therapy and the unresolved questions that exist in the field: including its use in different disease stages (metastatic, adjuvant, neoadjuvant), interactions with chemotherapy, duration and scheduling of therapy, potential predictive biomarkers and proposed mechanisms of resistance, including paradoxical effects such as enhanced tumor aggressiveness.  In terms of future directions, we discuss the need to delineate further the complexities of tumor vascularization if we are to develop more effective and personalized anti-angiogenic therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7sZyCdaihyrVg90H21EOLACvtfcHk0lhtg9Wiym1SOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsVGrtrk%253D&md5=ee472c1380b302319febb605695c8ba9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs10456-014-9420-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10456-014-9420-y%26sid%3Dliteratum%253Aachs%26aulast%3DVasudev%26aufirst%3DN.%2BS.%26aulast%3DReynolds%26aufirst%3DA.%2BR.%26atitle%3DAnti-angiogenic%2520therapy%2520for%2520cancer%253A%2520current%2520progress%252C%2520unresolved%2520questions%2520and%2520future%2520directions%26jtitle%3DAngiogenesis%26date%3D2014%26volume%3D17%26spage%3D471%26epage%3D494%26doi%3D10.1007%2Fs10456-014-9420-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Siemann, D. W.</span><span> </span><span class="NLM_article-title">The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents</span> <span class="citation_source-journal">Cancer Treat. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">63</span><span class="NLM_x">–</span> <span class="NLM_lpage">74</span><span class="refDoi"> DOI: 10.1016/j.ctrv.2010.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.ctrv.2010.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=20570444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFajs7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2011&pages=63-74&author=D.+W.+Siemann&title=The+unique+characteristics+of+tumor+vasculature+and+preclinical+evidence+for+its+selective+disruption+by+tumor-vascular+disrupting+agents&doi=10.1016%2Fj.ctrv.2010.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents</span></div><div class="casAuthors">Siemann, Dietmar W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-74</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The vasculature of solid tumors is fundamentally different from that of normal vasculature and offers a unique target for anti-cancer therapy.  Direct vascular-targeting with Tumor-Vascular Disrupting Agents (Tumor-VDAs) is distinctly different from anti-angiogenic strategies, and offers a complementary approach to std. therapies.  Tumor-VDAs therefore have significant potential when combined with chemotherapy, radiotherapy, and angiogenesis-inhibiting agents.  Preclin. studies with the different Tumor-VDA classes have demonstrated key tumor-selective anti-vascular and anti-tumor effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKL8nIIVWtVbVg90H21EOLACvtfcHk0liQx9c6rdO4Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFajs7vI&md5=85fe2cb36db459ad473bf53bbcae60af</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2010.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2010.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DSiemann%26aufirst%3DD.%2BW.%26atitle%3DThe%2520unique%2520characteristics%2520of%2520tumor%2520vasculature%2520and%2520preclinical%2520evidence%2520for%2520its%2520selective%2520disruption%2520by%2520tumor-vascular%2520disrupting%2520agents%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2011%26volume%3D37%26spage%3D63%26epage%3D74%26doi%3D10.1016%2Fj.ctrv.2010.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Siemann, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horsman, M. R.</span><span> </span><span class="NLM_article-title">Modulation of the tumor vasculature and oxygenation to improve therapy</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">153</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span><span class="refDoi"> DOI: 10.1016/j.pharmthera.2015.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.pharmthera.2015.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=26073310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWgu7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=2015&pages=107-124&author=D.+W.+Siemannauthor=M.+R.+Horsman&title=Modulation+of+the+tumor+vasculature+and+oxygenation+to+improve+therapy&doi=10.1016%2Fj.pharmthera.2015.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of the tumor vasculature and oxygenation to improve therapy</span></div><div class="casAuthors">Siemann, Dietmar W.; Horsman, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">153</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">107-124</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The tumor microenvironment is increasingly recognized as a major factor influencing the success of therapeutic treatments and has become a key focus for cancer research.  The progressive growth of a tumor results in an inability of normal tissue blood vessels to oxygenate and provide sufficient nutritional support to tumor cells.  As a consequence the expanding neoplastic cell population initiates its own vascular network which is both structurally and functionally abnormal.  This aberrant vasculature impacts all aspects of the tumor microenvironment including the cells, extracellular matrix, and extracellular mols. which together are essential for the initiation, progression and spread of tumor cells.  The phys. conditions that arise are imposing and manifold, and include elevated interstitial pressure, localized extracellular acidity, and regions of oxygen and nutrient deprivation.  No less important are the functional consequences experienced by the tumor cells residing in such environments: adaptation to hypoxia, cell quiescence, modulation of transporters and crit. signaling mols., immune escape, and enhanced metastatic potential.  Together these factors lead to therapeutic barriers that create a significant hindrance to the control of cancers by conventional anticancer therapies.  However, the aberrant nature of the tumor microenvironments also offers unique therapeutic opportunities.  Particularly interventions that seek to improve tumor physiol. and alleviate tumor hypoxia will selectively impair the neoplastic cell populations residing in these environments.  Ultimately, by combining such therapeutic strategies with conventional anticancer treatments it may be possible to bring cancer growth, invasion, and metastasis to a halt.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7Wh0bMP_sC7Vg90H21EOLACvtfcHk0liQx9c6rdO4Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWgu7jO&md5=7237bedb6225d6e3cab430b62cdc9121</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2015.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2015.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DSiemann%26aufirst%3DD.%2BW.%26aulast%3DHorsman%26aufirst%3DM.%2BR.%26atitle%3DModulation%2520of%2520the%2520tumor%2520vasculature%2520and%2520oxygenation%2520to%2520improve%2520therapy%26jtitle%3DPharmacol.%2520Ther.%26date%3D2015%26volume%3D153%26spage%3D107%26epage%3D124%26doi%3D10.1016%2Fj.pharmthera.2015.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Kanthou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozer, G. M.</span><span> </span><span class="NLM_article-title">Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies</span> <span class="citation_source-journal">Int. J. Exp. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">284</span><span class="NLM_x">–</span> <span class="NLM_lpage">294</span><span class="refDoi"> DOI: 10.1111/j.1365-2613.2009.00651.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1111%2Fj.1365-2613.2009.00651.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=19563611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotV2isr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2009&pages=284-294&author=C.+Kanthouauthor=G.+M.+Tozer&title=Microtubule+depolymerizing+vascular+disrupting+agents%3A+novel+therapeutic+agents+for+oncology+and+other+pathologies&doi=10.1111%2Fj.1365-2613.2009.00651.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies</span></div><div class="casAuthors">Kanthou, Chryso; Tozer, Gillian M.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Experimental Pathology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">284-294</span>CODEN:
                <span class="NLM_cas:coden">IJEPEI</span>;
        ISSN:<span class="NLM_cas:issn">0959-9673</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Vascular disrupting agents (VDAs) are a relatively new group of "vascular targeting" agents that exhibit selective activity against established tumor vascular networks, causing severe interruption of tumor blood flow and necrosis to the tumor mass.  Microtubule depolymg. agents form by far the largest group of small mol. wt. VDAs many of which, including lead compd. disodium combretastatin A-4 3-O-phosphate (CA-4-P), are under clin. development for cancer.  Although distinct from the angiogenesis inhibitors, VDAs can also interfere with angiogenesis and therefore constitute a potential group of novel drugs for the treatment of pathol. conditions characterized by excessive angiogenesis, in addn. to cancer.  The endothelial cytoskeleton is the primary cellular target of this family of drugs, and some progress in understanding the mol. and signalling mechanisms assocd. with their endothelial disrupting activity has been made in the last few years.  Susceptibility of tumor vessels to VDA damage is ascribed to their immature pericyte-defective nature, although the exact mol. mechanisms involved have not been clearly defined.  Despite causing profound damage to tumors, VDAs fail to halt tumor growth unless used together with conventional treatments.  This failure is attributed to resistance mechanisms, primarily assocd. with cells that remain viable within the tumor rim, and enhanced angiogenesis.  The focus is now to understand mechanisms of susceptibility and resistance to identify novel mol. targets and develop strategies that are more effective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmpN7il32X0rVg90H21EOLACvtfcHk0liQx9c6rdO4Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotV2isr4%253D&md5=42b728813bf9c53bbc6d32d262639d15</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2613.2009.00651.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2613.2009.00651.x%26sid%3Dliteratum%253Aachs%26aulast%3DKanthou%26aufirst%3DC.%26aulast%3DTozer%26aufirst%3DG.%2BM.%26atitle%3DMicrotubule%2520depolymerizing%2520vascular%2520disrupting%2520agents%253A%2520novel%2520therapeutic%2520agents%2520for%2520oncology%2520and%2520other%2520pathologies%26jtitle%3DInt.%2520J.%2520Exp.%2520Pathol.%26date%3D2009%26volume%3D90%26spage%3D284%26epage%3D294%26doi%3D10.1111%2Fj.1365-2613.2009.00651.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Thorpe, P. E.</span><span> </span><span class="NLM_article-title">Vascular targeting agents as cancer therapeutics</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">415</span><span class="NLM_x">–</span> <span class="NLM_lpage">427</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-0642-03</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1158%2F1078-0432.CCR-0642-03" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=14760060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A280%3ADC%252BD2c%252FntFWntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=415-427&author=P.+E.+Thorpe&title=Vascular+targeting+agents+as+cancer+therapeutics&doi=10.1158%2F1078-0432.CCR-0642-03"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular targeting agents as cancer therapeutics</span></div><div class="casAuthors">Thorpe Philip E</div><div class="citationInfo"><span class="NLM_cas:title">Clinical cancer research : an official journal of the American Association for Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">415-27</span>
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    </div><div class="casAbstract">Vascular targeting agents (VTAs) for the treatment of cancer are designed to cause a rapid and selective shutdown of the blood vessels of tumors.  Unlike antiangiogenic drugs that inhibit the formation of new vessels, VTAs occlude the pre-existing blood vessels of tumors to cause tumor cell death from ischemia and extensive hemorrhagic necrosis.  Tumor selectivity is conferred by differences in the pathophysiology of tumor versus normal tissue vessels (e.g., increased proliferation and fragility, and up-regulated proteins).  VTAs can kill indirectly the tumor cells that are resistant to conventional antiproliferative cancer therapies, i.e., cells in areas distant from blood vessels where drug penetration is poor, and hypoxia can lead to radiation and drug resistance.  VTAs are expected to show the greatest therapeutic benefit as part of combined modality regimens.  Preclinical studies have shown VTA-induced enhancement of the effects of conventional chemotherapeutic agents, radiation, hyperthermia, radioimmunotherapy, and antiangiogenic agents.  There are broadly two types of VTAs, small molecules and ligand-based, which are grouped together, because they both cause acute vascular shutdown in tumors leading to massive necrosis.  The small molecules include the microtubulin destabilizing drugs, combretastatin A-4 disodium phosphate, ZD6126, AVE8062, and Oxi 4503, and the flavonoid, DMXAA.  Ligand-based VTAs use antibodies, peptides, or growth factors that bind selectively to tumor versus normal vessels to target tumors with agents that occlude blood vessels.  The ligand-based VTAs include fusion proteins (e.g., vascular endothelial growth factor linked to the plant toxin gelonin), immunotoxins (e.g., monoclonal antibodies to endoglin conjugated to ricin A), antibodies linked to cytokines, liposomally encapsulated drugs, and gene therapy approaches.  Combretastatin A-4 disodium phosphate, ZD6126, AVE8062, and DMXAA are undergoing clinical evaluation.  Phase I monotherapy studies have shown that the agents are tolerated with some demonstration of single agent efficacy.  Because efficacy is expected when the agents are used with conventional chemotherapeutic drugs or radiation, the results of Phase II combination studies are eagerly awaited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRGxP3zCqIkxEewzGPswiWOfW6udTcc2eZL_ijpSSCSIbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c%252FntFWntg%253D%253D&md5=7fa217c143bb3950071a3c7de76ceafd</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-0642-03&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-0642-03%26sid%3Dliteratum%253Aachs%26aulast%3DThorpe%26aufirst%3DP.%2BE.%26atitle%3DVascular%2520targeting%2520agents%2520as%2520cancer%2520therapeutics%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D415%26epage%3D427%26doi%3D10.1158%2F1078-0432.CCR-0642-03" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Gaya, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G. J. S.</span><span> </span><span class="NLM_article-title">Vascular disrupting agents: a new class of drug in cancer therapy</span> <span class="citation_source-journal">Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">277</span><span class="NLM_x">–</span> <span class="NLM_lpage">290</span><span class="refDoi"> DOI: 10.1016/j.clon.2004.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.clon.2004.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=15997924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A280%3ADC%252BD2Mzks1Wmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2005&pages=277-290&author=A.+M.+Gayaauthor=G.+J.+S.+Rustin&title=Vascular+disrupting+agents%3A+a+new+class+of+drug+in+cancer+therapy&doi=10.1016%2Fj.clon.2004.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular disrupting agents: a new class of drug in cancer therapy</span></div><div class="casAuthors">Gaya A M; Rustin G J S</div><div class="citationInfo"><span class="NLM_cas:title">Clinical oncology (Royal College of Radiologists (Great Britain))</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">277-90</span>
        ISSN:<span class="NLM_cas:issn">0936-6555</span>.
    </div><div class="casAbstract">AIMS:  To provide a comprehensive overview of the current state of development of a novel class of anti-cancer drugs, the vascular disrupting agents (VDAs), previously known as vascular targeting agents (VTAs).  MATERIALS AND METHODS:  A comprehensive review, analysis and commentary of the published medical literature on VDAs was performed.  RESULTS:  Tumour vascular targeting therapy exploits known differences between normal and tumour blood vessels.  VDAs target the preexisting vessels of tumours (cf anti-angiogenics), and cause vascular shutdown leading to tumour cell death and rapid haemorrhagic necrosis within hours.  It is becoming clear that VDAs have overlapping activity with anti-angiogenic drugs, which prevent the formation of new blood vessels.  There are two types of VDA.  First, biological or ligand-directed VDAs use antibodies, peptides or growth factors to target toxins or pro-coagulants to the tumour endothelium.  In contrast, small molecule VDAs work either as tubulin-binding agents or through induction of local cytokine production.  VDAs can kill tumour cells resistant to conventional chemotherapy and radiotherapy, and work best on cells in the poorly perfused hypoxic core of tumours, leaving a viable rim of well-perfused tumour tissue at the periphery, which rapidly regrows.  Consequently, responses of tumours to VDAs given as single agents have been poor; however, combination therapy with cytotoxic chemotherapy, external-beam radiotherapy, and radioimmunotherapy, which target the peripheral tumour cells, has produced some excellent responses in animal tumours.  VDAs are generally well tolerated with different side-effect profiles to current oncological therapies.  Dynamic magnetic resonance imaging is most frequently used to obtain a pharmacodynamic end point to determine whether the VDA is acting on its intended target.  CONCLUSIONS:  VDAs are a promising new class of drug, which offer the attractive possibility of inducing responses in all tumour types with combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTnWiE5fGCD_Jw7prLlxLOzfW6udTcc2eb5MjyJiR1-Zbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mzks1Wmuw%253D%253D&md5=c4caf3ef1f6bd785bf1e74cbf0f05080</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.clon.2004.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clon.2004.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DGaya%26aufirst%3DA.%2BM.%26aulast%3DRustin%26aufirst%3DG.%2BJ.%2BS.%26atitle%3DVascular%2520disrupting%2520agents%253A%2520a%2520new%2520class%2520of%2520drug%2520in%2520cancer%2520therapy%26jtitle%3DClin.%2520Oncol.%26date%3D2005%26volume%3D17%26spage%3D277%26epage%3D290%26doi%3D10.1016%2Fj.clon.2004.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Lara, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douillard, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Pawel, J. v.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeage, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albert, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Losonczy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reck, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heo, D.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scagliotti, G.</span><span> </span><span class="NLM_article-title">Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">2965</span><span class="NLM_x">–</span> <span class="NLM_lpage">2971</span><span class="refDoi"> DOI: 10.1200/JCO.2011.35.0660</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1200%2FJCO.2011.35.0660" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=21709202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCqtLbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=2965-2971&author=P.+N.+Laraauthor=J.+Y.+Douillardauthor=K.+Nakagawaauthor=J.+v.+von+Pawelauthor=M.+J.+McKeageauthor=I.+Albertauthor=G.+Losonczyauthor=M.+Reckauthor=D.-S.+Heoauthor=X.+Fanauthor=A.+Fandiauthor=G.+Scagliotti&title=Randomized+phase+III+placebo-controlled+trial+of+carboplatin+and+paclitaxel+with+or+without+the+vascular+disrupting+agent+vadimezan+%28ASA404%29+in+advanced+non-small-cell+lung+cancer&doi=10.1200%2FJCO.2011.35.0660"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer</span></div><div class="casAuthors">Lara, Primo N., Jr.; Douillard, Jean-Yves; Nakagawa, Kazuhiko; von Pawel, Joachim; McKeage, Mark J.; Albert, Istvan; Losonczy, Gyorgy; Reck, Martin; Heo, Dae-Seog; Fan, Xiaolin; Fandi, Abderrahim; Scagliotti, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2965-2971</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: This phase III trial was conducted to test whether the novel vascular disrupting agent ASA404 (vadimezan), when combined with first-line platinum-based chemotherapy, improves survival in patients with advanced non-small-cell lung cancer (NSCLC) vs. chemotherapy alone.  Patients and Methods: Patients with advanced stage IIIB or IV NSCLC, stratified by sex and tumor histol., were randomly assigned 1:1 to paclitaxel (200 mg/m2) and carboplatin (area under the curve, 6.0) with or without ASA404 (1,800 mg m2), given i.v. once every 3 wk for six cycles followed by maintenance ASA404 or placebo.  Primary end point was overall survival (OS); secondary end points included overall response rate (ORR) and progression-free survival (PFS).  Results: One thousand two hundred ninety-nine patients were randomly assigned.  The trial was stopped for futility at interim anal.  At final anal., there was no difference in OS seen between ASA404 (n = 649) and placebo (n = 650) arms: median OS was 13.4 and 12.7 mo resp. (hazard ratio [HR], 1.01; 95% CI, 0.85 to 1.19; P = .535).  Similarly, no OS difference was seen in the histol. (squamous or nonsquamous) and sex (male or female) strata.  Median PFS was 5.5 mo in both arms (HR, 1.04; P = .727), while ORR was 25% in both arms (P = 1.0).  Overall rate of adverse events (AEs) was comparable between the ASA404 and placebo arms.  Grade 4 neutropenia (27% v 19%) and infusion site pain (10% v 0.5%) were reported more frequently in the ASA404 arm.  Conclusion: The addn. of ASA404 to carboplatin and paclitaxel, although generally well tolerated, failed to improve frontline efficacy in advanced NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiAainXGdqJbVg90H21EOLACvtfcHk0lhKc9lROIys9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCqtLbO&md5=c9a9400016724941dad3b9104f9d546f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.35.0660&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.35.0660%26sid%3Dliteratum%253Aachs%26aulast%3DLara%26aufirst%3DP.%2BN.%26aulast%3DDouillard%26aufirst%3DJ.%2BY.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3Dvon%2BPawel%26aufirst%3DJ.%2Bv.%26aulast%3DMcKeage%26aufirst%3DM.%2BJ.%26aulast%3DAlbert%26aufirst%3DI.%26aulast%3DLosonczy%26aufirst%3DG.%26aulast%3DReck%26aufirst%3DM.%26aulast%3DHeo%26aufirst%3DD.-S.%26aulast%3DFan%26aufirst%3DX.%26aulast%3DFandi%26aufirst%3DA.%26aulast%3DScagliotti%26aufirst%3DG.%26atitle%3DRandomized%2520phase%2520III%2520placebo-controlled%2520trial%2520of%2520carboplatin%2520and%2520paclitaxel%2520with%2520or%2520without%2520the%2520vascular%2520disrupting%2520agent%2520vadimezan%2520%2528ASA404%2529%2520in%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D2965%26epage%3D2971%26doi%3D10.1200%2FJCO.2011.35.0660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">LoRusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boerner, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunsberger, S.</span><span> </span><span class="NLM_article-title">Clinical development of vascular disrupting agents: what lessons can we learn from ASA404?</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">2952</span><span class="NLM_x">–</span> <span class="NLM_lpage">2955</span><span class="refDoi"> DOI: 10.1200/JCO.2011.36.1311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1200%2FJCO.2011.36.1311" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=21709201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A280%3ADC%252BC3MjhvF2jtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=2952-2955&author=P.+M.+LoRussoauthor=S.+A.+Boernerauthor=S.+Hunsberger&title=Clinical+development+of+vascular+disrupting+agents%3A+what+lessons+can+we+learn+from+ASA404%3F&doi=10.1200%2FJCO.2011.36.1311"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical development of vascular disrupting agents: what lessons can we learn from ASA404?</span></div><div class="casAuthors">Lorusso Patricia M; Boerner Scott A; Hunsberger Sally</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2952-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcScRNi03td6tynGiHuhFGv8fW6udTcc2eb5MjyJiR1-Zbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MjhvF2jtA%253D%253D&md5=e5e8407390c050c3ca9915ab6849df77</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.36.1311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.36.1311%26sid%3Dliteratum%253Aachs%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DBoerner%26aufirst%3DS.%2BA.%26aulast%3DHunsberger%26aufirst%3DS.%26atitle%3DClinical%2520development%2520of%2520vascular%2520disrupting%2520agents%253A%2520what%2520lessons%2520can%2520we%2520learn%2520from%2520ASA404%253F%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D2952%26epage%3D2955%26doi%3D10.1200%2FJCO.2011.36.1311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Kretzschmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fürst, R.</span><span> </span><span class="NLM_article-title">Plant-derived vascular disrupting agents: compounds, actions, and clinical trials</span> <span class="citation_source-journal">Phytochem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span><span class="refDoi"> DOI: 10.1007/s11101-013-9304-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1007%2Fs11101-013-9304-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislCht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=191-206&author=V.+Kretzschmannauthor=R.+F%C3%BCrst&title=Plant-derived+vascular+disrupting+agents%3A+compounds%2C+actions%2C+and+clinical+trials&doi=10.1007%2Fs11101-013-9304-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Plant-derived vascular disrupting agents: compounds, actions, and clinical trials</span></div><div class="casAuthors">Kretzschmann, Verena K.; Fuerst, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Phytochemistry Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">191-206</span>CODEN:
                <span class="NLM_cas:coden">PRHEBS</span>;
        ISSN:<span class="NLM_cas:issn">1568-7767</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The tumor vasculature of solid tumors offers unique characteristics compared to the normal vasculature and, therefore, represents an attractive target in anti-cancer therapy.  Besides the classic anti-angiogenic agents, which inhibit tumor neovascularization, a novel promising class of anti-tumor drugs has emerged in the last years, the vascular-disrupting agents (VDAs).  In contrast to angiogenesis inhibitors, VDAs act on already established tumor blood vessels of large solid tumors and induce a vascular shutdown by targeting tumor endothelial cells.  This results in extensive necrotic tumor cell death.  The sources of VDAs are quite divers, however, the plant-derived compds. represent the largest and most prominent class.  Plant-derived VDAs have undergone extensive preclin. investigations and are now tested in several advanced clin. trials.  In this review we summarize preclin. data, including drug-target relationships as well as functional in vitro and in vivo assays, discuss their mol. way of action, and update the clin. status of the most prominent plant-derived VDAs: FAA/DMXAA, CA-4-P, OXi4503, AVE8062, and ZD6126.  All these data emphasize the value of secondary plant metabolites and their (semi-)synthetic derivs. for current drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro7gqZKoAc2bVg90H21EOLACvtfcHk0lhVP6zVFMra6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislCht7o%253D&md5=e5563128a501c8c462ad9b5545365fad</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs11101-013-9304-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11101-013-9304-6%26sid%3Dliteratum%253Aachs%26aulast%3DKretzschmann%26aufirst%3DV.%26aulast%3DF%25C3%25BCrst%26aufirst%3DR.%26atitle%3DPlant-derived%2520vascular%2520disrupting%2520agents%253A%2520compounds%252C%2520actions%252C%2520and%2520clinical%2520trials%26jtitle%3DPhytochem.%2520Rev.%26date%3D2014%26volume%3D13%26spage%3D191%26epage%3D206%26doi%3D10.1007%2Fs11101-013-9304-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Risinger, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span> </span><span class="NLM_article-title">Microtubule dynamics as a target in oncology</span> <span class="citation_source-journal">Cancer Treat. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">–</span> <span class="NLM_lpage">261</span><span class="refDoi"> DOI: 10.1016/j.ctrv.2008.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.ctrv.2008.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=19117686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVantrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2009&pages=255-261&author=A.+L.+Risingerauthor=F.+J.+Gilesauthor=S.+L.+Mooberry&title=Microtubule+dynamics+as+a+target+in+oncology&doi=10.1016%2Fj.ctrv.2008.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule dynamics as a target in oncology</span></div><div class="casAuthors">Risinger, April L.; Giles, Francis J.; Mooberry, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">255-261</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: Drugs that affect microtubule dynamics, including the taxanes and vinca alkaloids, have been a mainstay in the treatment of leukemias and solid tumors for decades.  New, more effective microtubule-targeting agents continue to enter into clin. trials and some, including the epothilone ixapebilone, have been approved for use.  In contrast, several other drugs of this class with promising preclin. data were later shown to be ineffective or intolerable in animal models or clin. trials.  In this review, we discuss the mol. mechanisms as well as preclin. and clin. results for a variety of microtubule-targeting agents in various stages of development.  We also offer a frank discussion of which microtubule-targeting agents are amenable to further development based on their availability, efficacy and toxic profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh2wR_5ls3DLVg90H21EOLACvtfcHk0lhVP6zVFMra6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVantrg%253D&md5=2d18cb599b5c35f1e0bc0292c183826f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2008.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2008.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DRisinger%26aufirst%3DA.%2BL.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26atitle%3DMicrotubule%2520dynamics%2520as%2520a%2520target%2520in%2520oncology%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2009%26volume%3D35%26spage%3D255%26epage%3D261%26doi%3D10.1016%2Fj.ctrv.2008.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Shelanski, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, E. W.</span><span> </span><span class="NLM_article-title">Properties of the protein subunit of central-pair and outer-doublet microtubules of sea urchin flagella</span> <span class="citation_source-journal">J. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1968</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">304</span><span class="NLM_x">–</span> <span class="NLM_lpage">315</span><span class="refDoi"> DOI: 10.1083/jcb.38.2.304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1083%2Fjcb.38.2.304" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1968&pages=304-315&author=M.+L.+Shelanskiauthor=E.+W.+Taylor&title=Properties+of+the+protein+subunit+of+central-pair+and+outer-doublet+microtubules+of+sea+urchin+flagella&doi=10.1083%2Fjcb.38.2.304"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1083%2Fjcb.38.2.304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.38.2.304%26sid%3Dliteratum%253Aachs%26aulast%3DShelanski%26aufirst%3DM.%2BL.%26aulast%3DTaylor%26aufirst%3DE.%2BW.%26atitle%3DProperties%2520of%2520the%2520protein%2520subunit%2520of%2520central-pair%2520and%2520outer-doublet%2520microtubules%2520of%2520sea%2520urchin%2520flagella%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D1968%26volume%3D38%26spage%3D304%26epage%3D315%26doi%3D10.1083%2Fjcb.38.2.304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Ravelli, R. B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gigant, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curmi, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jourdain, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachkar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sobel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knossow, M.</span><span> </span><span class="NLM_article-title">Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">428</span><span class="NLM_x">, </span> <span class="NLM_fpage">198</span><span class="NLM_x">–</span> <span class="NLM_lpage">202</span><span class="refDoi"> DOI: 10.1038/nature02393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1038%2Fnature02393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=15014504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvFCls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=428&publication_year=2004&pages=198-202&author=R.+B.+G.+Ravelliauthor=B.+Gigantauthor=P.+A.+Curmiauthor=I.+Jourdainauthor=S.+Lachkarauthor=A.+Sobelauthor=M.+Knossow&title=Insight+into+tubulin+regulation+from+a+complex+with+colchicine+and+a+stathmin-like+domain&doi=10.1038%2Fnature02393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain</span></div><div class="casAuthors">Ravelli, Raimond B. G.; Gigant, Benoit; Curmi, Patrick A.; Jourdain, Isabelle; Lachkar, Sylvie; Sobel, Andre; Knossow, Marcel</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">428</span>
        (<span class="NLM_cas:issue">6979</span>),
    <span class="NLM_cas:pages">198-202</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Microtubules are cytoskeletal polymers of tubulin involved in many cellular functions.  Their dynamic instability is controlled by numerous compds. and proteins, including colchicine and stathmin family proteins.  The way in which microtubule instability is regulated at the mol. level has remained elusive, mainly because of the lack of appropriate structural data.  Here, the authors present the structure, at 3.5 Å resoln., of tubulin in complex with colchicine (I) and with the stathmin-like domain (SLD) of RB3.  It showed the interaction of RB3-SLD with 2 tubulin heterodimers in a curved complex capped by the SLD N-terminal domain, which prevented the incorporation of the complexed tubulin into microtubules.  A comparison with the structure of tubulin in protofilaments showed changes in the subunits of tubulin as it switched from its straight conformation to a curved one.  These changes correlated with the loss of lateral contacts and provided a rationale for the rapid microtubule depolymn. characteristic of dynamic instability.  Moreover, the tubulin-I complex shed light on the mechanism of I activity; it was shown that I binds at a location where it prevents curved tubulin from adopting a straight structure, which inhibits assembly.  Thus, the results establish a relation between the onset and speed of microtubule disassembly and the changes in tubulin subunits when tubulin switches from its straight to its curved conformation.  The results further provide a mol. description of the interaction of RB3-SLD and I with tubulin, and may be useful for the development of novel therapeutic I analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx2vePjtf347Vg90H21EOLACvtfcHk0lgaMC-_HwwfaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvFCls7g%253D&md5=9fbb1edfc64239638a3c2eac879bffe9</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnature02393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature02393%26sid%3Dliteratum%253Aachs%26aulast%3DRavelli%26aufirst%3DR.%2BB.%2BG.%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DCurmi%26aufirst%3DP.%2BA.%26aulast%3DJourdain%26aufirst%3DI.%26aulast%3DLachkar%26aufirst%3DS.%26aulast%3DSobel%26aufirst%3DA.%26aulast%3DKnossow%26aufirst%3DM.%26atitle%3DInsight%2520into%2520tubulin%2520regulation%2520from%2520a%2520complex%2520with%2520colchicine%2520and%2520a%2520stathmin-like%2520domain%26jtitle%3DNature%26date%3D2004%26volume%3D428%26spage%3D198%26epage%3D202%26doi%3D10.1038%2Fnature02393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Bhattacharyya, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panda, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerjee, M.</span><span> </span><span class="NLM_article-title">Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">155</span><span class="NLM_x">–</span> <span class="NLM_lpage">183</span><span class="refDoi"> DOI: 10.1002/med.20097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1002%2Fmed.20097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=17464966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvVSjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=155-183&author=B.+Bhattacharyyaauthor=D.+Pandaauthor=S.+Guptaauthor=M.+Banerjee&title=Anti-mitotic+activity+of+colchicine+and+the+structural+basis+for+its+interaction+with+tubulin&doi=10.1002%2Fmed.20097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin</span></div><div class="casAuthors">Bhattacharyya, Bhabatarak; Panda, Dulal; Gupta, Suvroma; Banerjee, Mithu</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">155-183</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">In this review, an attempt has been made to throw light on the mechanism of action of colchicine and its different analogs as anti-cancer agents.  Colchicine interacts with tubulin and perturbs the assembly dynamics of microtubules.  Though its use has been limited because of its toxicity, colchicine can still be used as a lead compd. for the generation of potent anti-cancer drugs.  Colchicine binds to tubulin in a poorly reversible manner with high activation energy.  The binding interaction is favored entropically.  In contrast, binding of its simple analogs AC or DAAC is enthalpically favored and commences with comparatively low activation energy.  Colchicine-tubulin interaction, which is normally pH dependent, has been found to be independent of pH in the presence of microtubule-assocd. proteins, salts or upon cleavage of carboxy termini of tubulin.  Biphasic kinetics of colchicines-tubulin interaction has been explained in light of the variation in the residues around the drug-binding site on β-tubulin.  Using the crystal structure of the tubulin-DAMAcolchicine complex, a detailed discussion on the pharmacophore concept that explains the variation of affinity for different colchicine site inhibitors (CSI) has been discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9F4KA4GVMr7Vg90H21EOLACvtfcHk0lgaMC-_HwwfaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvVSjsA%253D%253D&md5=720f26c98a40dd91634dbe558d982e98</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fmed.20097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20097%26sid%3Dliteratum%253Aachs%26aulast%3DBhattacharyya%26aufirst%3DB.%26aulast%3DPanda%26aufirst%3DD.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DBanerjee%26aufirst%3DM.%26atitle%3DAnti-mitotic%2520activity%2520of%2520colchicine%2520and%2520the%2520structural%2520basis%2520for%2520its%2520interaction%2520with%2520tubulin%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2008%26volume%3D28%26spage%3D155%26epage%3D183%26doi%3D10.1002%2Fmed.20097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Leung, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hui, L. L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraus, V. B.</span><span> </span><span class="NLM_article-title">Colchicine-Update on mechanisms of action and therapeutic uses</span> <span class="citation_source-journal">Semin. Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">350</span><span class="refDoi"> DOI: 10.1016/j.semarthrit.2015.06.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.semarthrit.2015.06.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=26228647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Gru73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2015&pages=341-350&author=Y.+Y.+Leungauthor=L.+L.+Y.+Huiauthor=V.+B.+Kraus&title=Colchicine-Update+on+mechanisms+of+action+and+therapeutic+uses&doi=10.1016%2Fj.semarthrit.2015.06.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Colchicine-Update on mechanisms of action and therapeutic uses</span></div><div class="casAuthors">Leung, Ying Ying; Hui, Laura Li Yao; Kraus, Virginia B.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Arthritis and Rheumatism</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">341-350</span>CODEN:
                <span class="NLM_cas:coden">SAHRBF</span>;
        ISSN:<span class="NLM_cas:issn">0049-0172</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">To review the literature and provide an update on the mechanisms of action and therapeutic uses of oral colchicine in arthritis and inflammatory conditions.  We performed PubMed database searches through June 2014 for relevant studies in the English literature published since the last update of colchicine in 2008.  Searches encompassed colchicine mechanisms of action and clin. applications in medical conditions.  A total of 381 articles were reviewed.  The primary mechanism of action of colchicine is tubulin disruption.  This leads to subsequent down regulation of multiple inflammatory pathways and modulation of innate immunity.  Newly described mechanisms include various inhibitory effects on macrophages including the inhibition of the NACHT-LRRPYD-contg. protein 3 (NALP3) inflammasome, inhibition of pore formation activated by purinergic receptors P2X7 and P2X2, and stimulation of dendritic cell maturation and antigen presentation.  Colchicine also has anti-fibrotic activities and various effects on endothelial function.  The therapeutic use of colchicine has extended beyond gouty arthritis and familial Mediterranean fever, to osteoarthritis, pericarditis, and atherosclerosis.  Further understanding of the mechanisms of action underlying the therapeutic efficacy of colchicine will lead to its potential use in a variety of conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVZcLsYpoWE7Vg90H21EOLACvtfcHk0lg52sy28jCiWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Gru73L&md5=963522f41dcdd97e15fee9c2bc22bd9b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.semarthrit.2015.06.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semarthrit.2015.06.013%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DY.%2BY.%26aulast%3DHui%26aufirst%3DL.%2BL.%2BY.%26aulast%3DKraus%26aufirst%3DV.%2BB.%26atitle%3DColchicine-Update%2520on%2520mechanisms%2520of%2520action%2520and%2520therapeutic%2520uses%26jtitle%3DSemin.%2520Arthritis%2520Rheum.%26date%3D2015%26volume%3D45%26spage%3D341%26epage%3D350%26doi%3D10.1016%2Fj.semarthrit.2015.06.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cragg, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S. B.</span><span> </span><span class="NLM_article-title">Antineoplastic agents 122. Constituents of <i>Combretum caffrum</i></span> <span class="citation_source-journal">J. Nat. Prod.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">386</span><span class="NLM_x">–</span> <span class="NLM_lpage">391</span><span class="refDoi"> DOI: 10.1021/np50051a008</span> </span><div class="citationLinks">[<a href="/doi/10.1021/np50051a008" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1987&pages=386-391&author=G.+R.+Pettitauthor=G.+M.+Craggauthor=S.+B.+Singh&title=Antineoplastic+agents+122.+Constituents+of+Combretum+caffrum&doi=10.1021%2Fnp50051a008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fnp50051a008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnp50051a008%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DCragg%26aufirst%3DG.%2BM.%26aulast%3DSingh%26aufirst%3DS.%2BB.%26atitle%3DAntineoplastic%2520agents%2520122.%2520Constituents%2520of%2520Combretum%2520caffrum%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D1987%26volume%3D50%26spage%3D386%26epage%3D391%26doi%3D10.1021%2Fnp50051a008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Temple, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narayanan, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyd, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rener, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bansal, N.</span><span> </span><span class="NLM_article-title">Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs</span> <span class="citation_source-journal">Anti-Cancer Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">299</span><span class="NLM_x">–</span> <span class="NLM_lpage">309</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=7786396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADyaK2MXms1Wktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1995&pages=299-309&author=G.+R.+Pettitauthor=C.+J.+Templeauthor=V.+L.+Narayananauthor=R.+Varmaauthor=M.+J.+Simpsonauthor=M.+R.+Boydauthor=G.+A.+Renerauthor=N.+Bansal&title=Antineoplastic+agents+322.+Synthesis+of+combretastatin+A-4+prodrugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Antineoplastic agents. 322. Synthesis of combretastatin A-4 prodrugs</span></div><div class="casAuthors">Pettit, George R.; Temple, Carroll, Jr.; Narayanan, Ven L.; Varma, Ravi; Simpson, Michael J.; Boyd, Michael R.; Rener, Gregory A.; Bansal, Namita</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drug Design</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">299-309</span>CODEN:
                <span class="NLM_cas:coden">ACDDEA</span>;
        ISSN:<span class="NLM_cas:issn">0266-9536</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Combretastatin A-4 (I, R = H), the principal cancer cell growth-inhibitory constituent of the Zulu medicinal plant (Combretum caffrum, has been undergoing preclin. development.  However, the very limited water soly. of this phenol has complicated drug formation.  Hence, derivs. of the combretastatin A-4 3'-phenol group were prepd. for evaluation as possible water-sol. prodrugs.  As obsd. for combretastatin A-4, the sodium salt (I, R = Na), potassium salt (I, R = K), and hemisuccinic acid ester (I, R = COCH2CH2CO2H) derivs. were essentially insol. in water.  Indeed, these substances regenerated combretastatin A-4 upon reaction with water.  A series of other simple derivs., e.g. I [R = COCH(NH2)CH2CH2CO2H], proved unsatisfactory in terms of water soly. or stability, or both.  The most sol. derivs. evaluated included the ammonium [I, R = P(O)(OH)ONH4], and potassium [I, R = P(O)(OK)2] and sodium [I, R = P(O)(ONa)2] phosphate salts, where the latter two proved most stable and suitable.  Both the potassium and sodium phosphate derivs. of combretastatin A-4 were also found to exhibit the requisite biol. properties necessary for a useful prodrug.  The sodium phosphate salt was selected for drug formulation and further pre-clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCWV9UApN5crVg90H21EOLACvtfcHk0lg52sy28jCiWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXms1Wktbs%253D&md5=0a16b2b4db491916a9a742c7af69669a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DTemple%26aufirst%3DC.%2BJ.%26aulast%3DNarayanan%26aufirst%3DV.%2BL.%26aulast%3DVarma%26aufirst%3DR.%26aulast%3DSimpson%26aufirst%3DM.%2BJ.%26aulast%3DBoyd%26aufirst%3DM.%2BR.%26aulast%3DRener%26aufirst%3DG.%2BA.%26aulast%3DBansal%26aufirst%3DN.%26atitle%3DAntineoplastic%2520agents%2520322.%2520Synthesis%2520of%2520combretastatin%2520A-4%2520prodrugs%26jtitle%3DAnti-Cancer%2520Drug%2520Des.%26date%3D1995%26volume%3D10%26spage%3D299%26epage%3D309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Lin, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span> </span><span class="NLM_article-title">Antimitotic natural products combretastatin A-4 and combretastatin A-2: Studies on the mechanism of their inhibition of the binding of colchicine to tubulin</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">6984</span><span class="NLM_x">–</span> <span class="NLM_lpage">6991</span><span class="refDoi"> DOI: 10.1021/bi00443a031</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00443a031" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADyaL1MXkvV2ru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1989&pages=6984-6991&author=C.+M.+Linauthor=H.+H.+Hoauthor=G.+R.+Pettitauthor=E.+Hamel&title=Antimitotic+natural+products+combretastatin+A-4+and+combretastatin+A-2%3A+Studies+on+the+mechanism+of+their+inhibition+of+the+binding+of+colchicine+to+tubulin&doi=10.1021%2Fbi00443a031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Antimitotic natural products combretastatin A-4 and combretastatin A-2:  studies on the mechanism of their inhibition of the binding of colchicine to tubulin</span></div><div class="casAuthors">Lin, Chii M.; Ho, Holly H.; Pettit, George R.; Hamel, Ernest</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6984-91</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">The mechanism of the binding of combretastatin A-4 (CS-A4) and combretastatin A-2 (CS-A2), isolated from Combretum caffrum, to tubulin was examd. indirectly by evaluating their effects on the binding of radiolabeled colchicine to the protein.  There was rapid binding of both compds. to tubulin even at 0° (binding was complete at the earliest times examd.), in contrast to the relatively slow and temp.-dependent binding of colchicine.  Although the binding of the C. caffrum compds. to tubulin was quite tight, permitting ready isolation of near-stoichiometric amts. of drug-tubulin complex even in the absence of free drug, both CS-A4 and CS-A2 dissocd. rapidly from tubulin in the presence of high concns. of radiolabeled colchicine.  Apparent rate consts. for drug dissocn. from tubulin at 37° were 3.2 × 10-3/s for CS-A4, 4.8 × 10-3/s for CS-A2, and 2.9 × 10-5/s for colchicine (half-lives of 3.6, 2.4, and 405 min, resp.).  Thus, the effectiveness of the C. caffrum compds. as antimitotic agents appears to derive primarily from the rapidity of their binding to tubulin.  A new model for the colchicine binding site on tubulin is proposed which envisages A-ring and C-ring subsites in homologous locations on the 2 tubulin subunits, with Ph rings binding as well as or better than the tropolone ring of colchicine in the C-ring subsite.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBVM6YQr13WbVg90H21EOLACvtfcHk0li6aHkJqmTr8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXkvV2ru78%253D&md5=4fc9bd899f65be38961729d7c51a6b16</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fbi00443a031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00443a031%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DC.%2BM.%26aulast%3DHo%26aufirst%3DH.%2BH.%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DHamel%26aufirst%3DE.%26atitle%3DAntimitotic%2520natural%2520products%2520combretastatin%2520A-4%2520and%2520combretastatin%2520A-2%253A%2520Studies%2520on%2520the%2520mechanism%2520of%2520their%2520inhibition%2520of%2520the%2520binding%2520of%2520colchicine%2520to%2520tubulin%26jtitle%3DBiochemistry%26date%3D1989%26volume%3D28%26spage%3D6984%26epage%3D6991%26doi%3D10.1021%2Fbi00443a031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Dark, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prise, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozer, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span> </span><span class="NLM_article-title">Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1829</span><span class="NLM_x">–</span> <span class="NLM_lpage">1834</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=9157969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADyaK2sXjtlGnsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=1829-1834&author=G.+G.+Darkauthor=S.+A.+Hillauthor=V.+E.+Priseauthor=G.+M.+Tozerauthor=G.+R.+Pettitauthor=D.+J.+Chaplin&title=Combretastatin+A-4%2C+an+agent+that+displays+potent+and+selective+toxicity+toward+tumor+vasculature"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature</span></div><div class="casAuthors">Dark, Graham G.; Hill, Sally A.; Prise, Vivien E.; Tozer, Gillian M.; Pettit, George R.; Chaplin, Dai J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1829-1834</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Selective induction of vascular damage within tumors represents an emerging approach to cancer treatment.  Histol. studies have shown that several tubulin-binding agents can induce vascular damage within tumors but only at doses approximating the max. tolerated dose, which has limited their clin. applicability.  In this study, we show that the combretastatin A-4 prodrug induces vascular shutdown within tumors at doses less than one-tenth of the max. tolerated dose.  In vitro studies indicate that a short drug exposure results in profound long-term antiproliferative/cytotoxic effects against proliferating endothelial cells but not cells that are quiescent prior to and during drug exposure.  Vascular shutdown, within exptl. and human breast cancer models in vivo following systemic drug administration, was demonstrated with a redn. in functional vascular vol. of 93% at 6 h following drug administration and persisted over the next 12 h, with corresponding histol. consistent with hemorrhagic necrosis resulting from vascular damage.  The actions against tumor vasculature and the broad therapeutic window demonstrate the clin. potential of these drugs and warrant further study to elucidate the mechanisms responsible for the antivascular effects of combretastatin A-4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEdUvgSGIqp7Vg90H21EOLACvtfcHk0li6aHkJqmTr8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjtlGnsbk%253D&md5=889e82f6a746aef44c2a28b77135e61f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDark%26aufirst%3DG.%2BG.%26aulast%3DHill%26aufirst%3DS.%2BA.%26aulast%3DPrise%26aufirst%3DV.%2BE.%26aulast%3DTozer%26aufirst%3DG.%2BM.%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26atitle%3DCombretastatin%2520A-4%252C%2520an%2520agent%2520that%2520displays%2520potent%2520and%2520selective%2520toxicity%2520toward%2520tumor%2520vasculature%26jtitle%3DCancer%2520Res.%26date%3D1997%26volume%3D57%26spage%3D1829%26epage%3D1834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Greene, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meegan, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zisterer, D. M.</span><span> </span><span class="NLM_article-title">Combretastatins: more than just vascular targeting agents?</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">355</span><span class="NLM_x">, </span> <span class="NLM_fpage">212</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span><span class="refDoi"> DOI: 10.1124/jpet.115.226225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1124%2Fjpet.115.226225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=26354991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslantLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2015&pages=212-227&author=L.+M.+Greeneauthor=M.+J.+Meeganauthor=D.+M.+Zisterer&title=Combretastatins%3A+more+than+just+vascular+targeting+agents%3F&doi=10.1124%2Fjpet.115.226225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatins: more than just vascular targeting agents?</span></div><div class="casAuthors">Greene, Lisa M.; Meegan, Mary J.; Zisterer, Daniela M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">212-227</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Several prodrugs of the naturally occurring combretastatins have undergone extensive clin. evaluation as vascular targeting agents (VTAs).  Their increased selectivity toward endothelial cells together with their innate ability to rapidly induce vascular shutdown and inhibit tumor growth at doses up to 10-fold less than the max. tolerated dose led to the clin. evaluation of combretastatins as VTAs.  Tubulin is well established as the mol. target of the combretastatins and the vast majority of its synthetic derivs.  Furthermore, tubulin is a highly validated mol. target of many direct anticancer agents routinely used as front-line chemotherapeutics.  The unique vascular targeting properties of the combretastatins have somewhat overshadowed their development as direct anticancer agents and the delineation of the various cell death pathways and anticancer properties assocd. with such chemotherapeutics.  Moreover, the ongoing clin. trial of OXi4503 (combretastatin-A1 diphosphate) together with preliminary preclin. evaluation for the treatment of refractory acute myelogenous leukemia has successfully highlighted both the indirect and direct anticancer properties of combretastatins.  In this review, we discuss the development of the combretastatins from nature to the clinic.  The various mechanisms underlying combretastatin-induced cell cycle arrest, mitotic catastrophe, cell death, and survival are also reviewed in an attempt to further enhance the clin. prospects of this unique class of VTAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonKpiV5x3vPLVg90H21EOLACvtfcHk0li6aHkJqmTr8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslantLY%253D&md5=7e965d3cd51715cec3f84fde9cd6e88e</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.226225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.226225%26sid%3Dliteratum%253Aachs%26aulast%3DGreene%26aufirst%3DL.%2BM.%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26aulast%3DZisterer%26aufirst%3DD.%2BM.%26atitle%3DCombretastatins%253A%2520more%2520than%2520just%2520vascular%2520targeting%2520agents%253F%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D355%26spage%3D212%26epage%3D227%26doi%3D10.1124%2Fjpet.115.226225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Mita, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sargsyan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mita, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spear, M.</span><span> </span><span class="NLM_article-title">Vascular-disrupting agents in oncology</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">317</span><span class="NLM_x">–</span> <span class="NLM_lpage">328</span><span class="refDoi"> DOI: 10.1517/13543784.2013.759557</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1517%2F13543784.2013.759557" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=23316880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1GhtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2013&pages=317-328&author=M.+M.+Mitaauthor=L.+Sargsyanauthor=A.+C.+Mitaauthor=M.+Spear&title=Vascular-disrupting+agents+in+oncology&doi=10.1517%2F13543784.2013.759557"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular-disrupting agents in oncology</span></div><div class="casAuthors">Mita, Monica M.; Sargsyan, Liza; Mita, Alain C.; Spear, Matt</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">317-328</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Vascular-disrupting agents (VDAs) are a new class of oncol. drugs, which specifically target established tumor neovasculature and have a relatively low toxicity profile.  VDAs generally have non-overlapping side effects when concomitantly used with conventional cytotoxics.  Several members of the VDA class have recently progressed through mid-to-late stages of clin. trials.Areas covered: We examd. recent publications on preclin. findings and Phase I/II/III clin. trial data on mechanisms of actions, toxicities, and optimal use of VDA class drugs.  It is becoming apparent that VDAs should be used in combination with other classes of cytotoxic agents for the optimization of their effect in treating various cancers.  In this article we describe doses, timing of delivery, and sequence of combined therapy.  We also address the combined mechanisms of actions of VDAs and conventional cytotoxic medications.Expert opinion: Vascular-disrupting agents represent a new class of promising anticancer agents, which exhibit synergistic and/or additive effects in combination with many conventional cytotoxics.  Pharmacol. evaluation of the optimal combinations of VDAs with agents of other classes and drug interactions need to be continued.  Further clin. and preclin. studies are required for distinguishing cancer patients' subpopulations that would most benefit from VDAs, identifying tumor biomarkers predictive of response as well as reliable and reproducible imaging and/or biol. assays indicative of pharmacodynamic effects, and establishing clin. algorithms for treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBLi8h_Pg11rVg90H21EOLACvtfcHk0lhak_U0hdliEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1GhtL8%253D&md5=fcb6a91e3b281192cceaa55c681127a0</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1517%2F13543784.2013.759557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2013.759557%26sid%3Dliteratum%253Aachs%26aulast%3DMita%26aufirst%3DM.%2BM.%26aulast%3DSargsyan%26aufirst%3DL.%26aulast%3DMita%26aufirst%3DA.%2BC.%26aulast%3DSpear%26aufirst%3DM.%26atitle%3DVascular-disrupting%2520agents%2520in%2520oncology%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2013%26volume%3D22%26spage%3D317%26epage%3D328%26doi%3D10.1517%2F13543784.2013.759557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Porcu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bortolozzi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basso, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viola, G.</span><span> </span><span class="NLM_article-title">Recent advances in vascular disrupting agents in cancer therapy</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1485</span><span class="NLM_x">–</span> <span class="NLM_lpage">1498</span><span class="refDoi"> DOI: 10.4155/fmc.14.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.4155%2Ffmc.14.104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=25365233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGltrjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=1485-1498&author=E.+Porcuauthor=R.+Bortolozziauthor=G.+Bassoauthor=G.+Viola&title=Recent+advances+in+vascular+disrupting+agents+in+cancer+therapy&doi=10.4155%2Ffmc.14.104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in vascular disrupting agents in cancer therapy</span></div><div class="casAuthors">Porcu, Elena; Bortolozzi, Roberta; Basso, Giuseppe; Viola, Giampietro</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1485-1498</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Vascular disrupting agents (VDAs) are an important class of compds. that exhibit selective activity against pre-existing tumor vasculature, causing rapid shutdown of the tumor blood flow and consequent necrosis of the tumor mass.  The VDAs can be divided into flavonoid compds., which are related to flavone acetic acid, and tubulin-binding agents.  Tubulin-binding agents represent the largest group of VDAs and are characterized by different chem. structures, although most of them are derivs. of the lead compd. combretastatin (CA-4).  They demonstrated clin. activity, although recent findings have established that they have insufficient activity as single agents.  Several resistance mechanisms occur, such as the resistance of the tumor rim cells, while promising results have been described in combination with other chemotherapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG_xRqLIL1wrVg90H21EOLACvtfcHk0lhak_U0hdliEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGltrjN&md5=daf2387ad5729d02e889bf0301dac807</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.104%26sid%3Dliteratum%253Aachs%26aulast%3DPorcu%26aufirst%3DE.%26aulast%3DBortolozzi%26aufirst%3DR.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DViola%26aufirst%3DG.%26atitle%3DRecent%2520advances%2520in%2520vascular%2520disrupting%2520agents%2520in%2520cancer%2520therapy%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D1485%26epage%3D1498%26doi%3D10.4155%2Ffmc.14.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Ji, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z. P.</span><span> </span><span class="NLM_article-title">Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1348</span><span class="NLM_x">–</span> <span class="NLM_lpage">1360</span><span class="refDoi"> DOI: 10.2174/0929867322666150114163732</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.2174%2F0929867322666150114163732" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=25620094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1amurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=1348-1360&author=Y.+T.+Jiauthor=Y.+N.+Liuauthor=Z.+P.+Liu&title=Tubulin+colchicine+binding+site+inhibitors+as+vascular+disrupting+agents+in+clinical+developments&doi=10.2174%2F0929867322666150114163732"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments</span></div><div class="casAuthors">Ji, Ya-Ting; Liu, Yan-Na; Liu, Zhao-Peng</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1348-1360</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Tumor vasculature is an important target in cancer treatment.  Two distinct vasculartargeting therapeutic strategies are applied to attack cancer cells indirectly.  The antiangiogenic approach intervenes in the neovascularization processes and blocks the formation of new blood vessels, while th e antivascular approach targets the established tumor blood vessels, making vascular shutdown and resulting in rapid haemorrhagic necrosis and tumor cell death.  A no. of compds. with diverse structural scaffolds have been designed to target tumor vasculature and they are called vascular disrupting agents (VDAs).  The biol. or ligand-directed VDAs utilize antibodies, peptides or growth factors to deliver toxins or pro-coagulants or proapoptotic affectors to tumor-related blood vessels, while the small-mol. VDAs selectively target tumor blood vessels and have little effects on the normal endothelium.  Among the small-mol. VDAs, the tubulin colchicine binding site inhibitors have been extensively studied and many of them have entered the clin. trials, including CA-4P, CA-1P, AVE8062, OXi4503, CKD-516, BNC105P, ABT-751, CYT- 997, ZD6126, NPI-2358, MN-029 and EPC2407.  This review makes a summary of the small-mol. VDAs in clin. developments and highlights some potential VDA leads or candidates for the treatment of tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-aHECQeEv7LVg90H21EOLACvtfcHk0lhak_U0hdliEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1amurg%253D&md5=65300d3649e348a5c3c66fbc2dac4f07</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2174%2F0929867322666150114163732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867322666150114163732%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DY.%2BT.%26aulast%3DLiu%26aufirst%3DY.%2BN.%26aulast%3DLiu%26aufirst%3DZ.%2BP.%26atitle%3DTubulin%2520colchicine%2520binding%2520site%2520inhibitors%2520as%2520vascular%2520disrupting%2520agents%2520in%2520clinical%2520developments%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2015%26volume%3D22%26spage%3D1348%26epage%3D1360%26doi%3D10.2174%2F0929867322666150114163732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Barbier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsvetkov, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breuzard, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devred, F.</span><span> </span><span class="NLM_article-title">Deciphering the molecular mechanisms of anti-tubulin plant derived drugs</span> <span class="citation_source-journal">Phytochem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span><span class="NLM_x">–</span> <span class="NLM_lpage">169</span><span class="refDoi"> DOI: 10.1007/s11101-013-9302-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1007%2Fs11101-013-9302-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislCksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=157-169&author=P.+Barbierauthor=P.+O.+Tsvetkovauthor=G.+Breuzardauthor=F.+Devred&title=Deciphering+the+molecular+mechanisms+of+anti-tubulin+plant+derived+drugs&doi=10.1007%2Fs11101-013-9302-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Deciphering the molecular mechanisms of anti-tubulin plant derived drugs</span></div><div class="casAuthors">Barbier, P.; Tsvetkov, P. O.; Breuzard, G.; Devred, F.</div><div class="citationInfo"><span class="NLM_cas:title">Phytochemistry Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">157-169</span>CODEN:
                <span class="NLM_cas:coden">PRHEBS</span>;
        ISSN:<span class="NLM_cas:issn">1568-7767</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Even though commercialized anticancer drugs are now produced by pharmaceutical companies, most of them were originally obtained from natural sources, and more particularly from plants.  Indeed, many structurally diverse compds. isolated from plants or marine flora have been purified and synthesized for their anticancer bioactivity.  Among these, several mols. belong to the class of anticancer drugs which target the microtubule cytoskeleton, either by stabilizing it or destabilizing it.  To characterize the activity of these drugs and to understand in which physiol. context they are more likely to be used as therapeutic agents, it is necessary to fully det. their interaction with tubulin.  Understanding the mol. basis of their effects on microtubule cytoskeleton is an important step in designing analogs with greater pharmacol. activity and with fewer side effects.  In addn., knowing the mol. mechanism of action of each drug that is already used in chemotherapy protocols will also help to find strategies to circumvent resistance.  By taking examples of known anti-tubulin plant derived drugs, we show how identification of microtubule targeting agents and further characterization of their activity can be achieved combining biophys. and biochem. approaches.  We also illustrate how continuing in depth study of mols. with already known primary mechanisms of action can lead to the discovery of new targets or biomarkers which can open new perspectives in anticancer strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi3RE25Y1WjLVg90H21EOLACvtfcHk0lhojbgRbotduA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislCksb0%253D&md5=080159383138e7ed1f86783ed272d360</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2Fs11101-013-9302-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11101-013-9302-8%26sid%3Dliteratum%253Aachs%26aulast%3DBarbier%26aufirst%3DP.%26aulast%3DTsvetkov%26aufirst%3DP.%2BO.%26aulast%3DBreuzard%26aufirst%3DG.%26aulast%3DDevred%26aufirst%3DF.%26atitle%3DDeciphering%2520the%2520molecular%2520mechanisms%2520of%2520anti-tubulin%2520plant%2520derived%2520drugs%26jtitle%3DPhytochem.%2520Rev.%26date%3D2014%26volume%3D13%26spage%3D157%26epage%3D169%26doi%3D10.1007%2Fs11101-013-9302-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Tsvetkov, P. O.; Barbier, P.; Breuzard, G.; Peyrot, V.; Devred, F.</span><span> </span><span class="NLM_article-title">Microtubule-associated proteins and tubulin interaction by isothermal titration calorimetry</span>. In  <span class="citation_source-book">Methods in Cell Biology</span>; <span class="NLM_contrib-group">John, J. C.; Leslie, W.</span>, Eds.; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">115</span>, pp  <span class="NLM_fpage">283</span><span class="NLM_x">–</span> <span class="NLM_lpage">302</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2FB978-0-12-407757-7.00018-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=283-302&author=P.+O.+Tsvetkov&author=P.+Barbier&author=G.+Breuzard&author=V.+Peyrot&author=F.+Devredauthor=J.+C.+John&author=W.+Leslie&title=Methods+in+Cell+Biology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-407757-7.00018-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-407757-7.00018-9%26sid%3Dliteratum%253Aachs%26aulast%3DTsvetkov%26aufirst%3DP.%2BO.%26atitle%3DMicrotubule-associated%2520proteins%2520and%2520tubulin%2520interaction%2520by%2520isothermal%2520titration%2520calorimetry%26btitle%3DMethods%2520in%2520Cell%2520Biology%26aulast%3DJohn%26aufirst%3DJ.%2BC.%26pub%3DAcademic%2520Press%26date%3D2013%26volume%3D115%26spage%3D283%26epage%3D302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Fortin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacroix, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Côté, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreau, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petitclerc, É.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">C.-Gaudreault, R.</span><span> </span><span class="NLM_article-title">Quick and simple detection technique to assess the binding of antimicrotubule agents to the colchicine-binding site</span> <span class="citation_source-journal">Biol. Proced. Online</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">117</span><span class="refDoi"> DOI: 10.1007/s12575-010-9029-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1007%2Fs12575-010-9029-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=21406120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFCqtrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=113-117&author=S.+Fortinauthor=J.+Lacroixauthor=M.+F.+C%C3%B4t%C3%A9author=E.+Moreauauthor=%C3%89.+Petitclercauthor=R.+C.-Gaudreault&title=Quick+and+simple+detection+technique+to+assess+the+binding+of+antimicrotubule+agents+to+the+colchicine-binding+site&doi=10.1007%2Fs12575-010-9029-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Quick and Simple Detection Technique to Assess the Binding of Antimicrotubule Agents to the Colchicine-Binding Site</span></div><div class="casAuthors">Fortin, Sebastien; Lacroix, Jacques; Cote, Marie-France; Moreau, Emmanuel; Petitclerc, Eric; C.-Gaudreault, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Biological Procedures Online</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">113-117</span>CODEN:
                <span class="NLM_cas:coden">BLPOF8</span>;
        ISSN:<span class="NLM_cas:issn">1480-9222</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Development of antimitotic binding to the colchicine-binding site for the treatment of cancer is rapidly expanding.  Numerous antimicrotubule agents are prepd. every year, and the detn. of their binding affinity to tubulin requires the use of purified tubulins and radiolabeled ligands.  Such a procedure is costly and time-consuming and therefore is limited to the most promising candidates.  Here, we report a quick and inexpensive method that requires only usual lab. resources to assess the binding of antimicrotubules to colchicine-binding site.  The method is based on the ability of N,N'-ethylene-bis(iodoacetamide) (EBI) to crosslink in living cells the cysteine residues at position 239 and 354 of β-tubulin, residues which are involved in the colchicine-binding site.  The β-tubulin adduct formed by EBI is easily detectable by Western blot as a second immunoreacting band of β-tubulin that migrates faster than β-tubulin.  The occupancy of colchicine-binding site by pertinent antimitotics inhibits the formation of the EBI: β-tubulin adduct, resulting in an assay that allows the screening of new mols. targeting this binding site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLYer3i2rYW7Vg90H21EOLACvtfcHk0lhojbgRbotduA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFCqtrnF&md5=e7650e076d02b8605a7be32d57a0ff4c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1007%2Fs12575-010-9029-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12575-010-9029-5%26sid%3Dliteratum%253Aachs%26aulast%3DFortin%26aufirst%3DS.%26aulast%3DLacroix%26aufirst%3DJ.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DM.%2BF.%26aulast%3DMoreau%26aufirst%3DE.%26aulast%3DPetitclerc%26aufirst%3D%25C3%2589.%26aulast%3DC.-Gaudreault%26aufirst%3DR.%26atitle%3DQuick%2520and%2520simple%2520detection%2520technique%2520to%2520assess%2520the%2520binding%2520of%2520antimicrotubule%2520agents%2520to%2520the%2520colchicine-binding%2520site%26jtitle%3DBiol.%2520Proced.%2520Online%26date%3D2010%26volume%3D12%26spage%3D113%26epage%3D117%26doi%3D10.1007%2Fs12575-010-9029-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Canela, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pérez-Pérez, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noppen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sáez-Calvo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Díaz, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camarasa, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liekens, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Priego, E. M.</span><span> </span><span class="NLM_article-title">Novel colchicine-site binders with a cyclohexanedione scaffold identified through a ligand-based virtual screening approach</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">3924</span><span class="NLM_x">–</span> <span class="NLM_lpage">3938</span><span class="refDoi"> DOI: 10.1021/jm401939g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401939g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3924-3938&author=M.+D.+Canelaauthor=M.+J.+P%C3%A9rez-P%C3%A9rezauthor=S.+Noppenauthor=G.+S%C3%A1ez-Calvoauthor=J.+F.+D%C3%ADazauthor=M.+J.+Camarasaauthor=S.+Liekensauthor=E.+M.+Priego&title=Novel+colchicine-site+binders+with+a+cyclohexanedione+scaffold+identified+through+a+ligand-based+virtual+screening+approach&doi=10.1021%2Fjm401939g"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm401939g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401939g%26sid%3Dliteratum%253Aachs%26aulast%3DCanela%26aufirst%3DM.%2BD.%26aulast%3DP%25C3%25A9rez-P%25C3%25A9rez%26aufirst%3DM.%2BJ.%26aulast%3DNoppen%26aufirst%3DS.%26aulast%3DS%25C3%25A1ez-Calvo%26aufirst%3DG.%26aulast%3DD%25C3%25ADaz%26aufirst%3DJ.%2BF.%26aulast%3DCamarasa%26aufirst%3DM.%2BJ.%26aulast%3DLiekens%26aufirst%3DS.%26aulast%3DPriego%26aufirst%3DE.%2BM.%26atitle%3DNovel%2520colchicine-site%2520binders%2520with%2520a%2520cyclohexanedione%2520scaffold%2520identified%2520through%2520a%2520ligand-based%2520virtual%2520screening%2520approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3924%26epage%3D3938%26doi%3D10.1021%2Fjm401939g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Canela, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bueno, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noppen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sáez Calvo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estévez Gallego, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Díaz, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camarasa, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liekens, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pérez-Pérez, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Priego, E. M.</span><span> </span><span class="NLM_article-title">Targeting the colchicine site in tubulin through cyclohexanedione derivatives</span> <span class="citation_source-journal">RSC Adv.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">19492</span><span class="NLM_x">–</span> <span class="NLM_lpage">19506</span><span class="refDoi"> DOI: 10.1039/C5RA26807A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1039%2FC5RA26807A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC28Xit1agu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=19492-19506&author=M.+D.+Canelaauthor=O.+Buenoauthor=S.+Noppenauthor=G.+S%C3%A1ez+Calvoauthor=J.+Est%C3%A9vez+Gallegoauthor=J.+F.+D%C3%ADazauthor=M.+J.+Camarasaauthor=S.+Liekensauthor=M.+J.+P%C3%A9rez-P%C3%A9rezauthor=E.+M.+Priego&title=Targeting+the+colchicine+site+in+tubulin+through+cyclohexanedione+derivatives&doi=10.1039%2FC5RA26807A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the colchicine site in tubulin through cyclohexanedione derivatives</span></div><div class="casAuthors">Canela, Maria-Dolores; Bueno, Oskia; Noppen, Sam; Saez Calvo, Gonzalo; Estevez Gallego, Juan; Diaz, J. F.; Camarasa, Maria-Jose; Liekens, Sandra; Perez-Perez, Maria-Jesus; Priego, Eva-Maria</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">19492-19506</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Cyclohexanedione derivs. represent a new family of colchicine-site binders that were identified through a ligand-based virtual screening approach.  Structural modifications have now been performed at both distal sites of our identified hit [2-(1-((2-methoxyphenyl)amino)ethylidene)-5-phenylcyclohexane-1,3-dione (4)] in order to improve tubulin binding affinity, anti-proliferative activity and/or aq. soly.  The results obtained indicate that the 2-methoxyphenyl ring, the fragment located closer to the αβ-tubulin interface according to docking studies, is the one that allows structural variation in order to improve the Ka value against tubulin (as in compd. 20a with a Ka = 1.3 × 107 M-1, analogous to colchicine) or to improve aq. soly., as in compd. 22c, being more than 10 times more sol. than the previous hit 4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIQ-6dxS59JbVg90H21EOLACvtfcHk0liGpzUSFJZkMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xit1agu7g%253D&md5=1d876707537340ad41d68132fd00e0dd</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1039%2FC5RA26807A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5RA26807A%26sid%3Dliteratum%253Aachs%26aulast%3DCanela%26aufirst%3DM.%2BD.%26aulast%3DBueno%26aufirst%3DO.%26aulast%3DNoppen%26aufirst%3DS.%26aulast%3DS%25C3%25A1ez%2BCalvo%26aufirst%3DG.%26aulast%3DEst%25C3%25A9vez%2BGallego%26aufirst%3DJ.%26aulast%3DD%25C3%25ADaz%26aufirst%3DJ.%2BF.%26aulast%3DCamarasa%26aufirst%3DM.%2BJ.%26aulast%3DLiekens%26aufirst%3DS.%26aulast%3DP%25C3%25A9rez-P%25C3%25A9rez%26aufirst%3DM.%2BJ.%26aulast%3DPriego%26aufirst%3DE.%2BM.%26atitle%3DTargeting%2520the%2520colchicine%2520site%2520in%2520tubulin%2520through%2520cyclohexanedione%2520derivatives%26jtitle%3DRSC%2520Adv.%26date%3D2016%26volume%3D6%26spage%3D19492%26epage%3D19506%26doi%3D10.1039%2FC5RA26807A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Hadimani, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonough, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghatak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strecker, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sriram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirali, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garner, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trawick, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinney, K. G.</span><span> </span><span class="NLM_article-title">Synthesis of a 2-aryl-3-aroyl indole salt (OXi8007) resembling Combretastatin A-4 with application as a vascular disrupting agent</span> <span class="citation_source-journal">J. Nat. Prod.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">1668</span><span class="NLM_x">–</span> <span class="NLM_lpage">1678</span><span class="refDoi"> DOI: 10.1021/np400374w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/np400374w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVWkur%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2013&pages=1668-1678&author=M.+B.+Hadimaniauthor=M.+T.+MacDonoughauthor=A.+Ghatakauthor=T.+E.+Streckerauthor=R.+Lopezauthor=M.+Sriramauthor=B.+L.+Nguyenauthor=J.+J.+Hallauthor=R.+J.+Kesslerauthor=A.+R.+Shiraliauthor=L.+Liuauthor=C.+M.+Garnerauthor=G.+R.+Pettitauthor=E.+Hamelauthor=D.+J.+Chaplinauthor=R.+P.+Masonauthor=M.+L.+Trawickauthor=K.+G.+Pinney&title=Synthesis+of+a+2-aryl-3-aroyl+indole+salt+%28OXi8007%29+resembling+Combretastatin+A-4+with+application+as+a+vascular+disrupting+agent&doi=10.1021%2Fnp400374w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of a 2-Aryl-3-aroyl Indole Salt (OXi8007) Resembling Combretastatin A-4 with Application as a Vascular Disrupting Agent</span></div><div class="casAuthors">Hadimani, Mallinath B.; MacDonough, Matthew T.; Ghatak, Anjan; Strecker, Tracy E.; Lopez, Ramona; Sriram, Madhavi; Nguyen, Benson L.; Hall, John J.; Kessler, Raymond J.; Shirali, Anupama R.; Liu, Li; Garner, Charles M.; Pettit, George R.; Hamel, Ernest; Chaplin, David J.; Mason, Ralph P.; Trawick, Mary Lynn; Pinney, Kevin G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Natural Products</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1668-1678</span>CODEN:
                <span class="NLM_cas:coden">JNPRDF</span>;
        ISSN:<span class="NLM_cas:issn">0163-3864</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society-American Society of Pharmacognosy</span>)
        </div><div class="casAbstract">The natural products colchicine and combretastatin A-4 are potent inhibitors of tubulin assembly, and they have inspired the design and synthesis of a large no. of small-mol., potential anticancer agents.  The indole-based mol. scaffold is prominent among these SAR modifications, leading to a rapidly increasing no. of agents.  The water-sol. phosphate prodrug I [R = P(O)(O-Na+)2] (OXi8007) (II) of 2-aryl-3-aroylindole-based phenol I (R = H) (OXi8006) (III) was prepd. by chem. synthesis and found to be strongly cytotoxic against selected human cancer cell lines (GI50 = 36 nM against DU-145 cells, for example).  The free phenol, III (OXi8006), was a strong inhibitor (IC50 = 1.1 μM) of tubulin assembly.  The corresponding phosphate prodrug II (OXi8007) also demonstrated pronounced interference with tumor vasculature in a preliminary in vivo study utilizing a SCID mouse model bearing an orthotopic PC-3 (prostate) tumor as imaged by color Doppler ultrasound.  The combination of these results provides evidence that the indole-based phosphate prodrug II (OXi8007) functions as a vascular disrupting agent that may prove useful for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBPuuWz4Lp4LVg90H21EOLACvtfcHk0liGpzUSFJZkMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVWkur%252FN&md5=d17de0d4667b5565c5715a956549c456</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fnp400374w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnp400374w%26sid%3Dliteratum%253Aachs%26aulast%3DHadimani%26aufirst%3DM.%2BB.%26aulast%3DMacDonough%26aufirst%3DM.%2BT.%26aulast%3DGhatak%26aufirst%3DA.%26aulast%3DStrecker%26aufirst%3DT.%2BE.%26aulast%3DLopez%26aufirst%3DR.%26aulast%3DSriram%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DB.%2BL.%26aulast%3DHall%26aufirst%3DJ.%2BJ.%26aulast%3DKessler%26aufirst%3DR.%2BJ.%26aulast%3DShirali%26aufirst%3DA.%2BR.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DGarner%26aufirst%3DC.%2BM.%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DMason%26aufirst%3DR.%2BP.%26aulast%3DTrawick%26aufirst%3DM.%2BL.%26aulast%3DPinney%26aufirst%3DK.%2BG.%26atitle%3DSynthesis%2520of%2520a%25202-aryl-3-aroyl%2520indole%2520salt%2520%2528OXi8007%2529%2520resembling%2520Combretastatin%2520A-4%2520with%2520application%2520as%2520a%2520vascular%2520disrupting%2520agent%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2013%26volume%3D76%26spage%3D1668%26epage%3D1678%26doi%3D10.1021%2Fnp400374w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Tron, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirali, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorba, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pagliai, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busacca, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genazzani, A. A.</span><span> </span><span class="NLM_article-title">Medicinal chemistry of combretastatin A4: present and future directions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">3033</span><span class="NLM_x">–</span> <span class="NLM_lpage">3044</span><span class="refDoi"> DOI: 10.1021/jm0512903</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0512903" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvFyjuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=3033-3044&author=G.+C.+Tronauthor=T.+Piraliauthor=G.+Sorbaauthor=F.+Pagliaiauthor=S.+Busaccaauthor=A.+A.+Genazzani&title=Medicinal+chemistry+of+combretastatin+A4%3A+present+and+future+directions&doi=10.1021%2Fjm0512903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of combretastatin A4: Present and future directions</span></div><div class="casAuthors">Tron, Gian Cesare; Pirali, Tracey; Sorba, Giovanni; Pagliai, Francesca; Busacca, Sara; Genazzani, Armando A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3033-3044</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with refs.  A review on the medicinal chem. of combretastatin A4 (CA-4), a compd. with antitumor properties.  The mechanism of action of CA-4, including its ability to inhibit tubulin polymn., is discussed, along with selected analogs of CA-4 modified on the arom. rings A and B, substituted Ph rings, heterocycling rings, non-substituted arom. rings, modifications on the double bond, and analogs where the olefinic group is replaced by a ring.  Some issues related to the pharmacol. of CA-4 and future directions in research are considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGNHvpiUH4mbVg90H21EOLACvtfcHk0liGpzUSFJZkMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvFyjuro%253D&md5=be023d8f1f059f952308bb06196459da</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm0512903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0512903%26sid%3Dliteratum%253Aachs%26aulast%3DTron%26aufirst%3DG.%2BC.%26aulast%3DPirali%26aufirst%3DT.%26aulast%3DSorba%26aufirst%3DG.%26aulast%3DPagliai%26aufirst%3DF.%26aulast%3DBusacca%26aufirst%3DS.%26aulast%3DGenazzani%26aufirst%3DA.%2BA.%26atitle%3DMedicinal%2520chemistry%2520of%2520combretastatin%2520A4%253A%2520present%2520and%2520future%2520directions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D3033%26epage%3D3044%26doi%3D10.1021%2Fjm0512903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, D. D.</span><span> </span><span class="NLM_article-title">An overview of tubulin inhibitors that interact with the colchicine binding site</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">2943</span><span class="NLM_x">–</span> <span class="NLM_lpage">2971</span><span class="refDoi"> DOI: 10.1007/s11095-012-0828-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1007%2Fs11095-012-0828-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=22814904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOis7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2012&pages=2943-2971&author=Y.+Luauthor=J.+Chenauthor=M.+Xiaoauthor=W.+Liauthor=D.+D.+Miller&title=An+overview+of+tubulin+inhibitors+that+interact+with+the+colchicine+binding+site&doi=10.1007%2Fs11095-012-0828-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site</span></div><div class="casAuthors">Lu, Yan; Chen, Jianjun; Xiao, Min; Li, Wei; Miller, Duane D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2943-2971</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Tubulin dynamics is a promising target for new chemotherapeutic agents.  The colchicine binding site is one of the most important pockets for potential tubulin polymn. destabilizers.  Colchicine binding site inhibitors (CBSI) exert their biol. effects by inhibiting tubulin assembly and suppressing microtubule formation.  A large no. of mols. interacting with the colchicine binding site have been designed and synthesized with significant structural diversity.  CBSIs have been modified as to chem. structure as well as pharmacokinetic properties, and tested in order to find a highly potent, low toxicity agent for treatment of cancers.  CBSIs are believed to act by a common mechanism via binding to the colchicine site on tubulin.  The present review is a synopsis of compds. that have been reported in the past decade that have provided an increase in our understanding of the actions of CBSIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFrFQVgeCbBbVg90H21EOLACvtfcHk0lhtuL-atFjKZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOis7vN&md5=dfe42e8eb1f0ff22b256641aaa8c17ab</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1007%2Fs11095-012-0828-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-012-0828-z%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26atitle%3DAn%2520overview%2520of%2520tubulin%2520inhibitors%2520that%2520interact%2520with%2520the%2520colchicine%2520binding%2520site%26jtitle%3DPharm.%2520Res.%26date%3D2012%26volume%3D29%26spage%3D2943%26epage%3D2971%26doi%3D10.1007%2Fs11095-012-0828-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Shan, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, Y.</span><span> </span><span class="NLM_article-title">Developments of combretastatin A-4 derivatives as anticancer agents</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">523</span><span class="NLM_x">–</span> <span class="NLM_lpage">538</span><span class="refDoi"> DOI: 10.2174/092986711794480221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.2174%2F092986711794480221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=21143124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsl2lt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=523-538&author=Y.+S.+Shanauthor=J.+Zhangauthor=Z.+Liuauthor=M.+Wangauthor=Y.+Dong&title=Developments+of+combretastatin+A-4+derivatives+as+anticancer+agents&doi=10.2174%2F092986711794480221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Developments of combretastatin A-4 derivatives as anticancer agents</span></div><div class="casAuthors">Shan, Y.; Zhang, J.; Liu, Z.; Wang, M.; Dong, Y.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">523-538</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Tubulin protein is one of several members of a small family of globular proteins.  It offers a potential target for anticancer drug design and development.  Combretastatin A-4 (CA-4) is a potent anticancer and antiangiogenesis natural substance isolated from Combretum caffrum.  Modifications on the Ca-4 structure have led to a great no. of novel CA-4 derivs. as potent tubulin inhibitors and high cytotoxic anticancer agents is becoming an interesting field, leading to a breakthrough in the treatment of cancer.  In this review, the recent developments of novel CA-4 derivs. via the modifications on the A- and B-ring and the double bond as anticancer agents are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUzBhk-7FdB7Vg90H21EOLACvtfcHk0lhtuL-atFjKZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsl2lt70%253D&md5=81b78f1ee900478f3771ba7e9b7ef1d9</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.2174%2F092986711794480221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711794480221%26sid%3Dliteratum%253Aachs%26aulast%3DShan%26aufirst%3DY.%2BS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DY.%26atitle%3DDevelopments%2520of%2520combretastatin%2520A-4%2520derivatives%2520as%2520anticancer%2520agents%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D523%26epage%3D538%26doi%3D10.2174%2F092986711794480221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Marrelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conforti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Statti, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cachet, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tillequin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menichini, F.</span><span> </span><span class="NLM_article-title">Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: An overview of new derivatives of natural combretastatin A-4</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3035</span><span class="NLM_x">–</span> <span class="NLM_lpage">3081</span><span class="refDoi"> DOI: 10.2174/092986711796391642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.2174%2F092986711796391642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=21651481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsl2ru7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=3035-3081&author=M.+Marrelliauthor=F.+Confortiauthor=G.+A.+Stattiauthor=X.+Cachetauthor=S.+Michelauthor=F.+Tillequinauthor=F.+Menichini&title=Biological+potential+and+structure-activity+relationships+of+most+recently+developed+vascular+disrupting+agents%3A+An+overview+of+new+derivatives+of+natural+combretastatin+A-4&doi=10.2174%2F092986711796391642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: an overview of new derivatives of natural combretastatin A-4</span></div><div class="casAuthors">Marrelli, M.; Conforti, F.; Statti, G. A.; Cachet, X.; Michel, S.; Tillequin, F.; Menichini, F.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3035-3081</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Tumor blood vessels are an important emerging target for anti-cancer therapy.  The antimitotic agent combretastatin A-4 (CA-4), a cis-stilbene natural product isolated from the South African tree Combretum caffrum Kuntze, is the lead compd. of a new class of anti-cancer drugs that target tumor vasculature.  CA-4 inhibits tubulin polymn. by interacting at the colchicine binding site on tubulin.  This alters the morphol. of endothelial cells and causes vascular shutdown and regression of tumor vasculature.  Some tubulin-binding vascular-disrupting agents (VDAs) are currently in clin. trials for cancer therapy.  As a consequence of the potential favorable applications of these compds., several analogs projected to induce rapid and selective vascular shutdown in tumors have been synthesized during the last few years.  Many of these mols. have already been tested for their effects on tubulin polymn. as well as for their antiproliferative activity and other biol. properties, and possible mechanisms of action have been investigated.  The aim of the present review is to offer an overview of most recently developed combretastatin derivs., focusing on biol. effects exerted by these compds.  The published data about new analogs are presented and compared, and a detailed investigation of structure-activity relationships is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrl-P26R4lDYbVg90H21EOLACvtfcHk0lhtuL-atFjKZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsl2ru7k%253D&md5=de9cc466fef8e21d30ded33457377545</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.2174%2F092986711796391642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711796391642%26sid%3Dliteratum%253Aachs%26aulast%3DMarrelli%26aufirst%3DM.%26aulast%3DConforti%26aufirst%3DF.%26aulast%3DStatti%26aufirst%3DG.%2BA.%26aulast%3DCachet%26aufirst%3DX.%26aulast%3DMichel%26aufirst%3DS.%26aulast%3DTillequin%26aufirst%3DF.%26aulast%3DMenichini%26aufirst%3DF.%26atitle%3DBiological%2520potential%2520and%2520structure-activity%2520relationships%2520of%2520most%2520recently%2520developed%2520vascular%2520disrupting%2520agents%253A%2520An%2520overview%2520of%2520new%2520derivatives%2520of%2520natural%2520combretastatin%2520A-4%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D3035%26epage%3D3081%26doi%3D10.2174%2F092986711796391642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Patil, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patil, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rane, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patil, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bari, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patil, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naphade, S. S.</span><span> </span><span class="NLM_article-title">Recent advancement in discovery and development of natural product combretastatin-inspired anticancer agents</span> <span class="citation_source-journal">Anti-Cancer Agents Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">955</span><span class="NLM_x">–</span> <span class="NLM_lpage">969</span><span class="refDoi"> DOI: 10.2174/1871520615666150526141259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.2174%2F1871520615666150526141259" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=955-969&author=P.+O.+Patilauthor=A.+G.+Patilauthor=R.+A.+Raneauthor=P.+C.+Patilauthor=P.+K.+Deshmukhauthor=S.+B.+Bariauthor=D.+A.+Patilauthor=S.+S.+Naphade&title=Recent+advancement+in+discovery+and+development+of+natural+product+combretastatin-inspired+anticancer+agents&doi=10.2174%2F1871520615666150526141259"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.2174%2F1871520615666150526141259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520615666150526141259%26sid%3Dliteratum%253Aachs%26aulast%3DPatil%26aufirst%3DP.%2BO.%26aulast%3DPatil%26aufirst%3DA.%2BG.%26aulast%3DRane%26aufirst%3DR.%2BA.%26aulast%3DPatil%26aufirst%3DP.%2BC.%26aulast%3DDeshmukh%26aufirst%3DP.%2BK.%26aulast%3DBari%26aufirst%3DS.%2BB.%26aulast%3DPatil%26aufirst%3DD.%2BA.%26aulast%3DNaphade%26aufirst%3DS.%2BS.%26atitle%3DRecent%2520advancement%2520in%2520discovery%2520and%2520development%2520of%2520natural%2520product%2520combretastatin-inspired%2520anticancer%2520agents%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2015%26volume%3D15%26spage%3D955%26epage%3D969%26doi%3D10.2174%2F1871520615666150526141259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Rajak, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar Dewangan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar Jain, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veerasamy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chander Sharma, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixit, A.</span><span> </span><span class="NLM_article-title">Design of combretastatin A-4 analogs as tubulin targeted vascular disrupting agent with special emphasis on their cis-restricted isomers</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1923</span><span class="NLM_x">–</span> <span class="NLM_lpage">1955</span><span class="refDoi"> DOI: 10.2174/1381612811319100013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.2174%2F1381612811319100013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=23237054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1Gntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1923-1955&author=H.+Rajakauthor=P.+Kumar+Dewanganauthor=V.+Patelauthor=D.+Kumar+Jainauthor=A.+Singhauthor=R.+Veerasamyauthor=P.+Chander+Sharmaauthor=A.+Dixit&title=Design+of+combretastatin+A-4+analogs+as+tubulin+targeted+vascular+disrupting+agent+with+special+emphasis+on+their+cis-restricted+isomers&doi=10.2174%2F1381612811319100013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Design of combretastatin A-4 analogs as tubulin targeted vascular disrupting agent with special emphasis on their cis-restricted isomers</span></div><div class="casAuthors">Rajak, Harish; Dewangan, Pramod Kumar; Patel, Vijay; Jain, Deepak Kumar; Singh, Avineesh; Veerasamy, Ravichandran; Sharma, Prabodh Chander; Dixit, Anshuman</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1923-1955</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Tubulin protein is a highly imperative and feasible goal for anticancer drug discovery.  Hundreds of naturally occurring, semi synthetic and synthetic antitubulin agents have been reported till now.  Among these, Combretastatin A - 4 (CA - 4) is effective antimitotic agent possessing potent cytotoxicity against a panel of cancer cells, including multi-drug resistant cancer cell lines.  The inadequate water soly. and inactivation of these analogs during storage limit their use as clin. anticancer agents.  To overcome these short-comings, numerous water sol. amino analogs, amino acid deriv., phosphate prodrug (CA - 4P) and cis-locked CA - 4 have been developed with distinctive attributes of antitubulin and antivascular properties in a wide variety of preclin. tumor models.  Subsequently, several heterocycle based cis restricted CA - 4 analogs are being reported for antitumor activity against collection of cancer cell lines.  This review recapitulates the rational design, structure activity relationship, pharmacokinetic and pharmacodynamic profile of synthesized cis restricted CA - 4 analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVkQxS7xaDPLVg90H21EOLACvtfcHk0lgLgwv2qjGc9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1Gntr4%253D&md5=4aaa3f776e46ef2c0e4b18e8a163dee2</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.2174%2F1381612811319100013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612811319100013%26sid%3Dliteratum%253Aachs%26aulast%3DRajak%26aufirst%3DH.%26aulast%3DKumar%2BDewangan%26aufirst%3DP.%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DKumar%2BJain%26aufirst%3DD.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DVeerasamy%26aufirst%3DR.%26aulast%3DChander%2BSharma%26aufirst%3DP.%26aulast%3DDixit%26aufirst%3DA.%26atitle%3DDesign%2520of%2520combretastatin%2520A-4%2520analogs%2520as%2520tubulin%2520targeted%2520vascular%2520disrupting%2520agent%2520with%2520special%2520emphasis%2520on%2520their%2520cis-restricted%2520isomers%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2013%26volume%3D19%26spage%3D1923%26epage%3D1955%26doi%3D10.2174%2F1381612811319100013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Kaur, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bariwal, J.</span><span> </span><span class="NLM_article-title">Recent developments in tubulin polymerization inhibitors: An overview</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2014.09.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.ejmech.2014.09.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=25240869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFOltbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2014&pages=89-124&author=R.+Kaurauthor=G.+Kaurauthor=R.+K.+Gillauthor=R.+Soniauthor=J.+Bariwal&title=Recent+developments+in+tubulin+polymerization+inhibitors%3A+An+overview&doi=10.1016%2Fj.ejmech.2014.09.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in tubulin polymerization inhibitors: An overview</span></div><div class="casAuthors">Kaur, Ramandeep; Kaur, Gurneet; Gill, Rupinder Kaur; Soni, Richard; Bariwal, Jitender</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89-124</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Microtubules are protein biopolymers formed through polymn. of heterodimers of α- and β-tubulins.  Disruption of microtubules can induce cell cycle arrest in G2-M phase and formation of abnormal mitotic spindles.  Their importance in mitosis and cell division makes microtubules an attractive target for anticancer drug discovery.  A no. of naturally occurring compds. such as paclitaxel, epothilones, vinblastine, combretastatin, and colchicines exert their effect by changing dynamics of tubulin such as polymn. and depolymn.  During past few years, rapid development of the novel tubulin polymn. inhibitors has been witnessed.  Diverse classes of chem. compds. from the natural as well as from the synthetic origin have been extensively studied.  This review highlights the various classes of synthetically derived chem. compds. those have been reported in last few years as potential tubulin polymn. inhibitors.  A brief synthetic methodol. to access these compds. has been highlighted along with the brief SAR studies.  We strongly believe that this review will provide a platform to the synthetic chemists and biologists to design and synthesize new and potent compds. to inhibit the tubulin polymn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV6nQysY8nvbVg90H21EOLACvtfcHk0lgLgwv2qjGc9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFOltbzE&md5=2ffd2f9bb073a7830f4aae7c29f070d9</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.09.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.09.051%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DR.%26aulast%3DKaur%26aufirst%3DG.%26aulast%3DGill%26aufirst%3DR.%2BK.%26aulast%3DSoni%26aufirst%3DR.%26aulast%3DBariwal%26aufirst%3DJ.%26atitle%3DRecent%2520developments%2520in%2520tubulin%2520polymerization%2520inhibitors%253A%2520An%2520overview%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D87%26spage%3D89%26epage%3D124%26doi%3D10.1016%2Fj.ejmech.2014.09.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Álvarez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medarde, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peláez, R.</span><span> </span><span class="NLM_article-title">New ligands of the tubulin colchicine site based on X-ray structures</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2231</span><span class="NLM_x">–</span> <span class="NLM_lpage">2252</span><span class="refDoi"> DOI: 10.2174/1568026614666141130092637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.2174%2F1568026614666141130092637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=25434358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVSru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=2231-2252&author=R.+%C3%81lvarezauthor=M.+Medardeauthor=R.+Pel%C3%A1ez&title=New+ligands+of+the+tubulin+colchicine+site+based+on+X-ray+structures&doi=10.2174%2F1568026614666141130092637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">New Ligands of the Tubulin Colchicine Site Based on X-Ray Structures</span></div><div class="casAuthors">Alvarez, Raquel; Medarde, Manuel; Pelaez, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2231-2252</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Colchicine site ligands have proved to be potent inhibitors of tubulin polymn., which leads them not only to display cytotoxic effects but also vascular disrupting effects on tumor neovasculature.  In recent years, many compds. have been designed, synthesized and evaluated in order to improve the potency, stability and physicochem. properties of these agents with the aim of developing an agent that could reach the clin. assay level.  Here we analyze the eleven X-ray structures of tubulin in complex with ligands at the colchicine site by dividing it into four different zones of interaction, we review the new compds. that have appeared in the literature since 2008 and that were designed based on any of these X-ray structures and, finally, we describe our latest results in the design of new potent antimitotic indole derivs. that have confirmed the flexibility of one of the zones described for the colchicine site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB6HvmgggtxbVg90H21EOLACvtfcHk0ljiU6vURTV8cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVSru78%253D&md5=a7a289b0e6b986e59c8e0f875d4ae51e</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.2174%2F1568026614666141130092637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026614666141130092637%26sid%3Dliteratum%253Aachs%26aulast%3D%25C3%2581lvarez%26aufirst%3DR.%26aulast%3DMedarde%26aufirst%3DM.%26aulast%3DPel%25C3%25A1ez%26aufirst%3DR.%26atitle%3DNew%2520ligands%2520of%2520the%2520tubulin%2520colchicine%2520site%2520based%2520on%2520X-ray%2520structures%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2014%26volume%3D14%26spage%3D2231%26epage%3D2252%26doi%3D10.2174%2F1568026614666141130092637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Massarotti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coluccia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvestri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorba, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brancale, A.</span><span> </span><span class="NLM_article-title">The tubulin colchicine domain: a molecular modeling perspective</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">33</span><span class="NLM_x">–</span> <span class="NLM_lpage">42</span><span class="refDoi"> DOI: 10.1002/cmdc.201100361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1002%2Fcmdc.201100361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=21990124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht12qt7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=33-42&author=A.+Massarottiauthor=A.+Colucciaauthor=R.+Silvestriauthor=G.+Sorbaauthor=A.+Brancale&title=The+tubulin+colchicine+domain%3A+a+molecular+modeling+perspective&doi=10.1002%2Fcmdc.201100361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">The Tubulin Colchicine Domain: a Molecular Modeling Perspective</span></div><div class="casAuthors">Massarotti, Alberto; Coluccia, Antonio; Silvestri, Romano; Sorba, Giovanni; Brancale, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-42</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Computational approaches have been increasingly applied to drug design over the past three decades and have already provided some useful results in the discovery of anticancer drugs.  Given the increased availability of crystal structures in recent years, a growing no. of mol. modeling studies on tubulin have been reported.  Herein we present a brief overview of the role played by computational methods in anti-tubulin research, specifically in the context of colchicine binding agent research.  An overview of current structures is reported, along with a brief discussion on the issues assocd. with the various tubulin isotypes.  Finally, a summary of the most recent and relevant results is presented, highlighting the challenges and opportunities faced by researchers in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpomkM8Gy2eS7Vg90H21EOLACvtfcHk0ljiU6vURTV8cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht12qt7zO&md5=84b4f8c78b635c2b7df31bbd1e4a89de</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201100361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201100361%26sid%3Dliteratum%253Aachs%26aulast%3DMassarotti%26aufirst%3DA.%26aulast%3DColuccia%26aufirst%3DA.%26aulast%3DSilvestri%26aufirst%3DR.%26aulast%3DSorba%26aufirst%3DG.%26aulast%3DBrancale%26aufirst%3DA.%26atitle%3DThe%2520tubulin%2520colchicine%2520domain%253A%2520a%2520molecular%2520modeling%2520perspective%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D33%26epage%3D42%26doi%3D10.1002%2Fcmdc.201100361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Hartley, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fest, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dakshanamurthy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frantz, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span> </span><span class="NLM_article-title">Polygamain, a new microtubule depolymerizing agent that occupies a unique pharmacophore in the colchicine site</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">431</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span><span class="refDoi"> DOI: 10.1124/mol.111.075838</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1124%2Fmol.111.075838" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2012&pages=431-439&author=R.+M.+Hartleyauthor=J.+Pengauthor=G.+A.+Festauthor=S.+Dakshanamurthyauthor=D.+E.+Frantzauthor=M.+L.+Brownauthor=S.+L.+Mooberry&title=Polygamain%2C+a+new+microtubule+depolymerizing+agent+that+occupies+a+unique+pharmacophore+in+the+colchicine+site&doi=10.1124%2Fmol.111.075838"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1124%2Fmol.111.075838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.111.075838%26sid%3Dliteratum%253Aachs%26aulast%3DHartley%26aufirst%3DR.%2BM.%26aulast%3DPeng%26aufirst%3DJ.%26aulast%3DFest%26aufirst%3DG.%2BA.%26aulast%3DDakshanamurthy%26aufirst%3DS.%26aulast%3DFrantz%26aufirst%3DD.%2BE.%26aulast%3DBrown%26aufirst%3DM.%2BL.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26atitle%3DPolygamain%252C%2520a%2520new%2520microtubule%2520depolymerizing%2520agent%2520that%2520occupies%2520a%2520unique%2520pharmacophore%2520in%2520the%2520colchicine%2520site%26jtitle%3DMol.%2520Pharmacol.%26date%3D2012%26volume%3D81%26spage%3D431%26epage%3D439%26doi%3D10.1124%2Fmol.111.075838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Jordan, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, L.</span><span> </span><span class="NLM_article-title">Microtubules as target for anticancer drugs</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">253</span><span class="NLM_x">–</span> <span class="NLM_lpage">265</span><span class="refDoi"> DOI: 10.1038/nrc1317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1038%2Fnrc1317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=15057285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=253-265&author=M.+A.+Jordanauthor=L.+Wilson&title=Microtubules+as+target+for+anticancer+drugs&doi=10.1038%2Fnrc1317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubules as a target for anticancer drugs</span></div><div class="casAuthors">Jordan, Mary Ann; Wilson, Leslie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">253-265</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Highly dynamic mitotic-spindle microtubules are among the most successful targets for anticancer therapy.  Microtubule-targeted drugs, including paclitaxel and Vinca alkaloids, were previously considered to work primarily by increasing or decreasing the cellular microtubule mass.  Although these effects might have a role in their chemotherapeutic actions, we now know that at lower concns., microtubule-targeted drugs can suppress microtubule dynamics without changing microtubule mass; this action leads to mitotic block and apoptosis.  In addn. to the expanding array of chem. diverse antimitotic agents, some microtubule-targeted drugs can act as vascular-targeting agents, rapidly depolymg. microtubules of newly formed vasculature to shut down the blood supply to tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRJbrFnzwqjbVg90H21EOLACvtfcHk0ljiU6vURTV8cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D&md5=bbbf212e03ffe6763098fc41f21a8158</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnrc1317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1317%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DM.%2BA.%26aulast%3DWilson%26aufirst%3DL.%26atitle%3DMicrotubules%2520as%2520target%2520for%2520anticancer%2520drugs%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D253%26epage%3D265%26doi%3D10.1038%2Fnrc1317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyd, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettit, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogan, F.</span><span> </span><span class="NLM_article-title">Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1666</span><span class="NLM_x">–</span> <span class="NLM_lpage">1672</span><span class="refDoi"> DOI: 10.1021/jm00010a011</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00010a011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=1666-1672&author=G.+R.+Pettitauthor=S.+B.+Singhauthor=M.+R.+Boydauthor=E.+Hamelauthor=R.+K.+Pettitauthor=J.+M.+Schmidtauthor=F.+Hogan&title=Antineoplastic+agents.+291.+Isolation+and+synthesis+of+combretastatins+A-4%2C+A-5%2C+and+A-6&doi=10.1021%2Fjm00010a011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm00010a011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00010a011%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DSingh%26aufirst%3DS.%2BB.%26aulast%3DBoyd%26aufirst%3DM.%2BR.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DPettit%26aufirst%3DR.%2BK.%26aulast%3DSchmidt%26aufirst%3DJ.%2BM.%26aulast%3DHogan%26aufirst%3DF.%26atitle%3DAntineoplastic%2520agents.%2520291.%2520Isolation%2520and%2520synthesis%2520of%2520combretastatins%2520A-4%252C%2520A-5%252C%2520and%2520A-6%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D1666%26epage%3D1672%26doi%3D10.1021%2Fjm00010a011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhodes, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herald, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratford, M. R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettit, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapuis, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliva, D.</span><span> </span><span class="NLM_article-title">Antineoplastic agents 393. Synthesis of the trans-isomer of combretastatin A-4 prodrug</span> <span class="citation_source-journal">Anti-Cancer Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">981</span><span class="NLM_x">–</span> <span class="NLM_lpage">993</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1998&pages=981-993&author=G.+R.+Pettitauthor=M.+R.+Rhodesauthor=D.+L.+Heraldauthor=D.+J.+Chaplinauthor=M.+R.+L.+Stratfordauthor=E.+Hamelauthor=R.+K.+Pettitauthor=J.+C.+Chapuisauthor=D.+Oliva&title=Antineoplastic+agents+393.+Synthesis+of+the+trans-isomer+of+combretastatin+A-4+prodrug"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DRhodes%26aufirst%3DM.%2BR.%26aulast%3DHerald%26aufirst%3DD.%2BL.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DStratford%26aufirst%3DM.%2BR.%2BL.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DPettit%26aufirst%3DR.%2BK.%26aulast%3DChapuis%26aufirst%3DJ.%2BC.%26aulast%3DOliva%26aufirst%3DD.%26atitle%3DAntineoplastic%2520agents%2520393.%2520Synthesis%2520of%2520the%2520trans-isomer%2520of%2520combretastatin%2520A-4%2520prodrug%26jtitle%3DAnti-Cancer%2520Drug%2520Des.%26date%3D1998%26volume%3D13%26spage%3D981%26epage%3D993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippert, J. W.</span><span> </span><span class="NLM_article-title">Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs</span> <span class="citation_source-journal">Anti-Cancer Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">216</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2000&pages=203-216&author=G.+R.+Pettitauthor=J.+W.+Lippert&title=Antineoplastic+agents+429.+Syntheses+of+the+combretastatin+A-1+and+combretastatin+B-1+prodrugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DLippert%26aufirst%3DJ.%2BW.%26atitle%3DAntineoplastic%2520agents%2520429.%2520Syntheses%2520of%2520the%2520combretastatin%2520A-1%2520and%2520combretastatin%2520B-1%2520prodrugs%26jtitle%3DAnti-Cancer%2520Drug%2520Des.%26date%3D2000%26volume%3D15%26spage%3D203%26epage%3D216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Ohsumi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morinaga, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nihei, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohishi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suga, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuji, T.</span><span> </span><span class="NLM_article-title">Novel combretastatin analogues effective against murine solid tumors: Design and structure–activity relationships</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">3022</span><span class="NLM_x">–</span> <span class="NLM_lpage">3032</span><span class="refDoi"> DOI: 10.1021/jm980101w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm980101w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=3022-3032&author=K.+Ohsumiauthor=R.+Nakagawaauthor=Y.+Fukudaauthor=T.+Hatanakaauthor=Y.+Morinagaauthor=Y.+Niheiauthor=K.+Ohishiauthor=Y.+Sugaauthor=Y.+Akiyamaauthor=T.+Tsuji&title=Novel+combretastatin+analogues+effective+against+murine+solid+tumors%3A+Design+and+structure%E2%80%93activity+relationships&doi=10.1021%2Fjm980101w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm980101w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm980101w%26sid%3Dliteratum%253Aachs%26aulast%3DOhsumi%26aufirst%3DK.%26aulast%3DNakagawa%26aufirst%3DR.%26aulast%3DFukuda%26aufirst%3DY.%26aulast%3DHatanaka%26aufirst%3DT.%26aulast%3DMorinaga%26aufirst%3DY.%26aulast%3DNihei%26aufirst%3DY.%26aulast%3DOhishi%26aufirst%3DK.%26aulast%3DSuga%26aufirst%3DY.%26aulast%3DAkiyama%26aufirst%3DY.%26aulast%3DTsuji%26aufirst%3DT.%26atitle%3DNovel%2520combretastatin%2520analogues%2520effective%2520against%2520murine%2520solid%2520tumors%253A%2520Design%2520and%2520structure%25E2%2580%2593activity%2520relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D3022%26epage%3D3032%26doi%3D10.1021%2Fjm980101w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Folkes, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christlieb, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madej, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratford, M. R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardman, P.</span><span> </span><span class="NLM_article-title">Oxidative metabolism of combretastatin A-1 produces quinone intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1885</span><span class="NLM_x">–</span> <span class="NLM_lpage">1894</span><span class="refDoi"> DOI: 10.1021/tx7002195</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx7002195" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=1885-1894&author=L.+K.+Folkesauthor=M.+Christliebauthor=E.+Madejauthor=M.+R.+L.+Stratfordauthor=P.+Wardman&title=Oxidative+metabolism+of+combretastatin+A-1+produces+quinone+intermediates+with+the+potential+to+bind+to+nucleophiles+and+to+enhance+oxidative+stress+via+free+radicals&doi=10.1021%2Ftx7002195"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Ftx7002195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx7002195%26sid%3Dliteratum%253Aachs%26aulast%3DFolkes%26aufirst%3DL.%2BK.%26aulast%3DChristlieb%26aufirst%3DM.%26aulast%3DMadej%26aufirst%3DE.%26aulast%3DStratford%26aufirst%3DM.%2BR.%2BL.%26aulast%3DWardman%26aufirst%3DP.%26atitle%3DOxidative%2520metabolism%2520of%2520combretastatin%2520A-1%2520produces%2520quinone%2520intermediates%2520with%2520the%2520potential%2520to%2520bind%2520to%2520nucleophiles%2520and%2520to%2520enhance%2520oxidative%2520stress%2520via%2520free%2520radicals%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2007%26volume%3D20%26spage%3D1885%26epage%3D1894%26doi%3D10.1021%2Ftx7002195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Ohsumi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nihei, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suga, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morinaga, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuji, T.</span><span> </span><span class="NLM_article-title">Syntheses and antitumor activity of cis-restricted combretastatins: 5-Membered heterocyclic analogues</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">3153</span><span class="NLM_x">–</span> <span class="NLM_lpage">3158</span><span class="refDoi"> DOI: 10.1016/S0960-894X(98)00579-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2FS0960-894X%2898%2900579-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=3153-3158&author=K.+Ohsumiauthor=T.+Hatanakaauthor=K.+Fujitaauthor=R.+Nakagawaauthor=Y.+Fukudaauthor=Y.+Niheiauthor=Y.+Sugaauthor=Y.+Morinagaauthor=Y.+Akiyamaauthor=T.+Tsuji&title=Syntheses+and+antitumor+activity+of+cis-restricted+combretastatins%3A+5-Membered+heterocyclic+analogues&doi=10.1016%2FS0960-894X%2898%2900579-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2898%2900579-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252898%252900579-4%26sid%3Dliteratum%253Aachs%26aulast%3DOhsumi%26aufirst%3DK.%26aulast%3DHatanaka%26aufirst%3DT.%26aulast%3DFujita%26aufirst%3DK.%26aulast%3DNakagawa%26aufirst%3DR.%26aulast%3DFukuda%26aufirst%3DY.%26aulast%3DNihei%26aufirst%3DY.%26aulast%3DSuga%26aufirst%3DY.%26aulast%3DMorinaga%26aufirst%3DY.%26aulast%3DAkiyama%26aufirst%3DY.%26aulast%3DTsuji%26aufirst%3DT.%26atitle%3DSyntheses%2520and%2520antitumor%2520activity%2520of%2520cis-restricted%2520combretastatins%253A%25205-Membered%2520heterocyclic%2520analogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1998%26volume%3D8%26spage%3D3153%26epage%3D3158%26doi%3D10.1016%2FS0960-894X%2898%2900579-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Romagnoli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baraldi, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brancale, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricci, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bortolozzi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basso, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viola, G.</span><span> </span><span class="NLM_article-title">Convergent synthesis and biological evaluation of 2-amino-4-(3′,4′,5′-trimethoxyphenyl)-5-aryl thiazoles as microtubule targeting agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">5144</span><span class="NLM_x">–</span> <span class="NLM_lpage">5153</span><span class="refDoi"> DOI: 10.1021/jm200392p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200392p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVaksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=5144-5153&author=R.+Romagnoliauthor=P.+G.+Baraldiauthor=A.+Brancaleauthor=A.+Ricciauthor=E.+Hamelauthor=R.+Bortolozziauthor=G.+Bassoauthor=G.+Viola&title=Convergent+synthesis+and+biological+evaluation+of+2-amino-4-%283%E2%80%B2%2C4%E2%80%B2%2C5%E2%80%B2-trimethoxyphenyl%29-5-aryl+thiazoles+as+microtubule+targeting+agents&doi=10.1021%2Fjm200392p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Convergent Synthesis and Biological Evaluation of 2-Amino-4-(3',4',5'-trimethoxyphenyl)-5-aryl Thiazoles as Microtubule Targeting Agents</span></div><div class="casAuthors">Romagnoli, Romeo; Baraldi, Pier Giovanni; Brancale, Andrea; Ricci, Antonio; Hamel, Ernest; Bortolozzi, Roberta; Basso, Giuseppe; Viola, Giampietro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5144-5153</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Combretastatin A-4, a potent tubulin polymn. inhibitor, caused us to synthesize a novel series of 2-amino-4-(3',4',5'-trimethoxyphenyl)-5-aryl thiazoles with the goal of evaluating the effects of substituents on the Ph at the 5-position of the thiazole skeleton on biol. activities.  An ethoxy group at the para-position produced the most active compd. in the series, with IC50 values of 0.03-0.9 nM against five of seven cancer cell lines.  The most active compds. retained full activity in multidrug resistant cancer cells and acted through the colchicine site of tubulin.  Treated cells were arrested in the G2/M phase of the cell cycle, with cell death proceeding through an apoptotic pathway that was only partially caspase-dependent.  Preliminary results suggest that, in addn. to cell death by apoptosis, cells were also killed via mitotic catastrophe as an alternative cell death mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphsFMgTMUUn7Vg90H21EOLACvtfcHk0ljfk5GyGQZ-UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVaksL0%253D&md5=9bd8f076b8c49a3894cda6c47d8cabb0</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm200392p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200392p%26sid%3Dliteratum%253Aachs%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DBrancale%26aufirst%3DA.%26aulast%3DRicci%26aufirst%3DA.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DBortolozzi%26aufirst%3DR.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DViola%26aufirst%3DG.%26atitle%3DConvergent%2520synthesis%2520and%2520biological%2520evaluation%2520of%25202-amino-4-%25283%25E2%2580%25B2%252C4%25E2%2580%25B2%252C5%25E2%2580%25B2-trimethoxyphenyl%2529-5-aryl%2520thiazoles%2520as%2520microtubule%2520targeting%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D5144%26epage%3D5153%26doi%3D10.1021%2Fjm200392p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barr, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCroskey, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannick, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gherke, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Credo, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hui, Y.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zielinski-Mozng, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sham, H. L.</span><span> </span><span class="NLM_article-title">Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure–activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">1697</span><span class="NLM_x">–</span> <span class="NLM_lpage">1711</span><span class="refDoi"> DOI: 10.1021/jm010523x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm010523x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=1697-1711&author=L.+Wangauthor=K.+W.+Woodsauthor=Q.+Liauthor=K.+J.+Barrauthor=R.+W.+McCroskeyauthor=S.+M.+Hannickauthor=L.+Gherkeauthor=R.+B.+Credoauthor=Y.-H.+Huiauthor=K.+Marshauthor=R.+Warnerauthor=J.+Y.+Leeauthor=N.+Zielinski-Mozngauthor=D.+Frostauthor=S.+H.+Rosenbergauthor=H.+L.+Sham&title=Potent%2C+orally+active+heterocycle-based+combretastatin+A-4+analogues%3A+synthesis%2C+structure%E2%80%93activity+relationship%2C+pharmacokinetics%2C+and+in+vivo+antitumor+activity+evaluation&doi=10.1021%2Fjm010523x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fjm010523x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010523x%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWoods%26aufirst%3DK.%2BW.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DBarr%26aufirst%3DK.%2BJ.%26aulast%3DMcCroskey%26aufirst%3DR.%2BW.%26aulast%3DHannick%26aufirst%3DS.%2BM.%26aulast%3DGherke%26aufirst%3DL.%26aulast%3DCredo%26aufirst%3DR.%2BB.%26aulast%3DHui%26aufirst%3DY.-H.%26aulast%3DMarsh%26aufirst%3DK.%26aulast%3DWarner%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DZielinski-Mozng%26aufirst%3DN.%26aulast%3DFrost%26aufirst%3DD.%26aulast%3DRosenberg%26aufirst%3DS.%2BH.%26aulast%3DSham%26aufirst%3DH.%2BL.%26atitle%3DPotent%252C%2520orally%2520active%2520heterocycle-based%2520combretastatin%2520A-4%2520analogues%253A%2520synthesis%252C%2520structure%25E2%2580%2593activity%2520relationship%252C%2520pharmacokinetics%252C%2520and%2520in%2520vivo%2520antitumor%2520activity%2520evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D1697%26epage%3D1711%26doi%3D10.1021%2Fjm010523x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keenan, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arora, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welsh, W. J.</span><span> </span><span class="NLM_article-title">Highly potent triazole-based tubulin polymerization inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">749</span><span class="NLM_x">–</span> <span class="NLM_lpage">754</span><span class="refDoi"> DOI: 10.1021/jm061142s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061142s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=749-754&author=Q.+Zhangauthor=Y.+Pengauthor=X.+I.+Wangauthor=S.+M.+Keenanauthor=S.+Aroraauthor=W.+J.+Welsh&title=Highly+potent+triazole-based+tubulin+polymerization+inhibitors&doi=10.1021%2Fjm061142s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjm061142s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061142s%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%2BI.%26aulast%3DKeenan%26aufirst%3DS.%2BM.%26aulast%3DArora%26aufirst%3DS.%26aulast%3DWelsh%26aufirst%3DW.%2BJ.%26atitle%3DHighly%2520potent%2520triazole-based%2520tubulin%2520polymerization%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D749%26epage%3D754%26doi%3D10.1021%2Fjm061142s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Arora, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keenan, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andaya, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welsh, W. J.</span><span> </span><span class="NLM_article-title">Novel microtubule polymerization inhibitor with potent antiproliferative and antitumor activity</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">1910</span><span class="NLM_x">–</span> <span class="NLM_lpage">1915</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-0877</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1158%2F0008-5472.CAN-08-0877" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=1910-1915&author=S.+Aroraauthor=X.+I.+Wangauthor=S.+M.+Keenanauthor=C.+Andayaauthor=Q.+Zhangauthor=Y.+Pengauthor=W.+J.+Welsh&title=Novel+microtubule+polymerization+inhibitor+with+potent+antiproliferative+and+antitumor+activity&doi=10.1158%2F0008-5472.CAN-08-0877"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-0877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-0877%26sid%3Dliteratum%253Aachs%26aulast%3DArora%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%2BI.%26aulast%3DKeenan%26aufirst%3DS.%2BM.%26aulast%3DAndaya%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DWelsh%26aufirst%3DW.%2BJ.%26atitle%3DNovel%2520microtubule%2520polymerization%2520inhibitor%2520with%2520potent%2520antiproliferative%2520and%2520antitumor%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D1910%26epage%3D1915%26doi%3D10.1158%2F0008-5472.CAN-08-0877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasilevich, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuselier, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hocart, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coy, D. H.</span><span> </span><span class="NLM_article-title">Examination of the 1,4-disubstituted azetidinone ring system as a template for combretastatin A-4 conformationally restricted analogue design</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2041</span><span class="NLM_x">–</span> <span class="NLM_lpage">2046</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2004.02.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.bmcl.2004.02.050" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=2041-2046&author=L.+Sunauthor=N.+I.+Vasilevichauthor=J.+A.+Fuselierauthor=S.+J.+Hocartauthor=D.+H.+Coy&title=Examination+of+the+1%2C4-disubstituted+azetidinone+ring+system+as+a+template+for+combretastatin+A-4+conformationally+restricted+analogue+design&doi=10.1016%2Fj.bmcl.2004.02.050"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.02.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.02.050%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DVasilevich%26aufirst%3DN.%2BI.%26aulast%3DFuselier%26aufirst%3DJ.%2BA.%26aulast%3DHocart%26aufirst%3DS.%2BJ.%26aulast%3DCoy%26aufirst%3DD.%2BH.%26atitle%3DExamination%2520of%2520the%25201%252C4-disubstituted%2520azetidinone%2520ring%2520system%2520as%2520a%2520template%2520for%2520combretastatin%2520A-4%2520conformationally%2520restricted%2520analogue%2520design%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D2041%26epage%3D2046%26doi%3D10.1016%2Fj.bmcl.2004.02.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">O’Boyle, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergin, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathwani, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCabe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lloyd, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zisterer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meegan, M. J.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8569</span><span class="NLM_x">–</span> <span class="NLM_lpage">8584</span><span class="refDoi"> DOI: 10.1021/jm101115u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101115u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8569-8584&author=N.+M.+O%E2%80%99Boyleauthor=M.+Carrauthor=L.+M.+Greeneauthor=O.+Berginauthor=S.+M.+Nathwaniauthor=T.+McCabeauthor=D.+G.+Lloydauthor=D.+M.+Zistererauthor=M.+J.+Meegan&title=Synthesis+and+evaluation+of+azetidinone+analogues+of+combretastatin+A-4+as+tubulin+targeting+agents&doi=10.1021%2Fjm101115u"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fjm101115u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101115u%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DN.%2BM.%26aulast%3DCarr%26aufirst%3DM.%26aulast%3DGreene%26aufirst%3DL.%2BM.%26aulast%3DBergin%26aufirst%3DO.%26aulast%3DNathwani%26aufirst%3DS.%2BM.%26aulast%3DMcCabe%26aufirst%3DT.%26aulast%3DLloyd%26aufirst%3DD.%2BG.%26aulast%3DZisterer%26aufirst%3DD.%2BM.%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520azetidinone%2520analogues%2520of%2520combretastatin%2520A-4%2520as%2520tubulin%2520targeting%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8569%26epage%3D8584%26doi%3D10.1021%2Fjm101115u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Greene, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathwani, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollock, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malebari, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCabe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Twamley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zisterer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meegan, M. J.</span><span> </span><span class="NLM_article-title">Synthesis and biochemical evaluation of 3-phenoxy-1,4-diarylazetidin-2-ones as tubulin-targeting antitumor agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">90</span><span class="NLM_x">–</span> <span class="NLM_lpage">113</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01086</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01086" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=90-113&author=T.+F.+Greeneauthor=S.+Wangauthor=L.+M.+Greeneauthor=S.+M.+Nathwaniauthor=J.+K.+Pollockauthor=A.+M.+Malebariauthor=T.+McCabeauthor=B.+Twamleyauthor=N.+M.+O%E2%80%99Boyleauthor=D.+M.+Zistererauthor=M.+J.+Meegan&title=Synthesis+and+biochemical+evaluation+of+3-phenoxy-1%2C4-diarylazetidin-2-ones+as+tubulin-targeting+antitumor+agents&doi=10.1021%2Facs.jmedchem.5b01086"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01086%26sid%3Dliteratum%253Aachs%26aulast%3DGreene%26aufirst%3DT.%2BF.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DGreene%26aufirst%3DL.%2BM.%26aulast%3DNathwani%26aufirst%3DS.%2BM.%26aulast%3DPollock%26aufirst%3DJ.%2BK.%26aulast%3DMalebari%26aufirst%3DA.%2BM.%26aulast%3DMcCabe%26aufirst%3DT.%26aulast%3DTwamley%26aufirst%3DB.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DN.%2BM.%26aulast%3DZisterer%26aufirst%3DD.%2BM.%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26atitle%3DSynthesis%2520and%2520biochemical%2520evaluation%2520of%25203-phenoxy-1%252C4-diarylazetidin-2-ones%2520as%2520tubulin-targeting%2520antitumor%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D90%26epage%3D113%26doi%3D10.1021%2Facs.jmedchem.5b01086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span> </span><span class="NLM_article-title">Quantum chemistry calculation-aided structural optimization of combretastatin A-4-like tubulin polymerization inhibitors: improved stability and biological activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">2538</span><span class="NLM_x">–</span> <span class="NLM_lpage">2546</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00118</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00118" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2538-2546&author=J.+Jiangauthor=C.+Zhengauthor=K.+Zhuauthor=J.+Liuauthor=N.+Sunauthor=C.+Wangauthor=H.+Jiangauthor=J.+Zhuauthor=C.+Luoauthor=Y.+Zhou&title=Quantum+chemistry+calculation-aided+structural+optimization+of+combretastatin+A-4-like+tubulin+polymerization+inhibitors%3A+improved+stability+and+biological+activity&doi=10.1021%2Facs.jmedchem.5b00118"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00118%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DY.%26atitle%3DQuantum%2520chemistry%2520calculation-aided%2520structural%2520optimization%2520of%2520combretastatin%2520A-4-like%2520tubulin%2520polymerization%2520inhibitors%253A%2520improved%2520stability%2520and%2520biological%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2538%26epage%3D2546%26doi%3D10.1021%2Facs.jmedchem.5b00118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toki, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herald, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verdier-Pinard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyd, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettit, R. K.</span><span> </span><span class="NLM_article-title">Antineoplastic agents. 379. Synthesis of phenstatin phosphate1a</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1688</span><span class="NLM_x">–</span> <span class="NLM_lpage">1695</span><span class="refDoi"> DOI: 10.1021/jm970644q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm970644q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=1688-1695&author=G.+R.+Pettitauthor=B.+Tokiauthor=D.+L.+Heraldauthor=P.+Verdier-Pinardauthor=M.+R.+Boydauthor=E.+Hamelauthor=R.+K.+Pettit&title=Antineoplastic+agents.+379.+Synthesis+of+phenstatin+phosphate1a&doi=10.1021%2Fjm970644q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fjm970644q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm970644q%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DToki%26aufirst%3DB.%26aulast%3DHerald%26aufirst%3DD.%2BL.%26aulast%3DVerdier-Pinard%26aufirst%3DP.%26aulast%3DBoyd%26aufirst%3DM.%2BR.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DPettit%26aufirst%3DR.%2BK.%26atitle%3DAntineoplastic%2520agents.%2520379.%2520Synthesis%2520of%2520phenstatin%2520phosphate1a%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D1688%26epage%3D1695%26doi%3D10.1021%2Fjm970644q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H.-m.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moon, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. J.</span><span> </span><span class="NLM_article-title">Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">6337</span><span class="NLM_x">–</span> <span class="NLM_lpage">6354</span><span class="refDoi"> DOI: 10.1021/jm1002414</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1002414" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVaqsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6337-6354&author=J.+Leeauthor=S.+J.+Kimauthor=H.+Choiauthor=Y.+H.+Kimauthor=I.+T.+Limauthor=H.-m.+Yangauthor=C.+S.+Leeauthor=H.+R.+Kangauthor=S.+K.+Ahnauthor=S.+K.+Moonauthor=D.-H.+Kimauthor=S.+Leeauthor=N.+S.+Choiauthor=K.+J.+Lee&title=Identification+of+CKD-516%3A+a+potent+tubulin+polymerization+inhibitor+with+marked+antitumor+activity+against+murine+and+human+solid+tumors&doi=10.1021%2Fjm1002414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of CKD-516: A Potent Tubulin Polymerization Inhibitor with Marked Antitumor Activity against Murine and Human Solid Tumors</span></div><div class="casAuthors">Lee, Jaekwang; Kim, Soo Jin; Choi, Hojin; Kim, Young Hoon; Lim, In Taek; Yang, Hyun-mo; Lee, Chang Sik; Kang, Hee Ryong; Ahn, Soon Kil; Moon, Seung Kee; Kim, Dal-Hyun; Lee, Sungsook; Choi, Nam Song; Lee, Kyung Joo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6337-6354</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tubulin polymn. inhibitors had emerged as one of promising anticancer therapeutics because of their dual mechanism of action, i.e. apoptosis by cell-cycle arrest and VDA, vascular disrupting agent.  VDAs are believed to be more efficient, less toxic, and several of them are currently undergoing clin. trials.  To identify novel tubulin inhibitors that possess potent cytotoxicity and strong inhibition of tubulin polymn. as well as potent in vivo antitumor efficacy, we have utilized benzophenone scaffold.  Complete SAR anal. of newly synthesized analogs that were prepd. by incorporation of small heterocycles (C2, C4, and C5 position) into B-ring along with the evaluation of their in vitro cytotoxicity, tubulin polymn. inhibition, and in vivo antitumor activity allowed us to identify I [R = H] (II)(S516).  Compd. II was found to have potent cytotoxicity against several cancer cells including P-gp overexpressing MDR pos. cell line (HCT15).  It also induced cell cycle arrest at G2/M phase, which is assocd. with strong inhibition of tubulin polymn.  Its in vivo efficacy was improved by prepg. its (L)-valine prodrug, I [ R = (S)- COCH(i-Pr)NH2·HCl] (CKD-516), which together with greatly improved aq. soly. has shown marked antitumor efficacy against both murine tumors (CT26 and 3LL) and human xenografts (HCT116 and HCT15) in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGre7093jjHolLVg90H21EOLACvtfcHk0lhhVTWUeuFgQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVaqsbs%253D&md5=17d60d54b31b7b75bbf6d2b41bfe6975</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm1002414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1002414%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BJ.%26aulast%3DChoi%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DLim%26aufirst%3DI.%2BT.%26aulast%3DYang%26aufirst%3DH.-m.%26aulast%3DLee%26aufirst%3DC.%2BS.%26aulast%3DKang%26aufirst%3DH.%2BR.%26aulast%3DAhn%26aufirst%3DS.%2BK.%26aulast%3DMoon%26aufirst%3DS.%2BK.%26aulast%3DKim%26aufirst%3DD.-H.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DChoi%26aufirst%3DN.%2BS.%26aulast%3DLee%26aufirst%3DK.%2BJ.%26atitle%3DIdentification%2520of%2520CKD-516%253A%2520a%2520potent%2520tubulin%2520polymerization%2520inhibitor%2520with%2520marked%2520antitumor%2520activity%2520against%2520murine%2520and%2520human%2520solid%2520tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6337%26epage%3D6354%26doi%3D10.1021%2Fjm1002414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Oh, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y. J.</span><span> </span><span class="NLM_article-title">Phase I study of CKD-516, a novel vascular disrupting agent, in patients with advanced solid tumors</span> <span class="citation_source-journal">Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">36</span><span class="refDoi"> DOI: 10.4143/crt.2014.258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.4143%2Fcrt.2014.258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=25715767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A280%3ADC%252BC2MroslKnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2016&pages=28-36&author=D.+Y.+Ohauthor=T.+M.+Kimauthor=S.+W.+Hanauthor=D.+Y.+Shinauthor=Y.+G.+Leeauthor=K.+W.+Leeauthor=J.+H.+Kimauthor=T.+Y.+Kimauthor=I.+J.+Jangauthor=J.+S.+Leeauthor=Y.+J.+Bang&title=Phase+I+study+of+CKD-516%2C+a+novel+vascular+disrupting+agent%2C+in+patients+with+advanced+solid+tumors&doi=10.4143%2Fcrt.2014.258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Oh Do-Youn; Kim Tae-Min; Han Sae-Won; Kim Tae-You; Bang Yung-Jue; Shin Dong-Yeop; Lee Yun Gyoo; Lee Keun-Wook; Kim Jee Hyun; Lee Jong-Seok; Jang In-Jin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer research and treatment : official journal of Korean Cancer Association</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-36</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  CKD-516 is a newly developed vascular disrupting agent.  This phase I dose-escalation study of CKD-516 was conducted to determine maximum-tolerated dose (MTD), safety, pharmacokinetics, and preliminary antitumor efficacy in patients with advanced solid tumors.  MATERIALS AND METHODS:  Patients received CKD-516 intravenously on D1 and D8 every 3 weeks, in a standard 3+3 design.  Safety was evaluated by National Cancer Institute Common Terminology Criteria for Adverse Events ver. 4.02 and response was assessed by Response Evaluation Criteria in Solid Tumor ver. 1.1.  RESULTS:  Twenty-three patients were treated with CKD-516 at seven dosing levels: 1 mg/m(2)/day (n=3), 2 mg/m(2)/day (n=3), 3.3 mg/m(2)/day (n=3), 5 mg/m(2)/day (n=3), 7 mg/m(2)/day (n=3), 9 mg/m(2)/day (n=6), and 12 mg/m(2)/day (n=2).  Mean age was 54 and 56.5% of patients were male.  Two dose-limiting toxicities, which were both grade 3 hypertension, were observed in two patients at 12 mg/m(2)/day.  The MTD was determined as 12 mg/m(2)/day.  Most common adverse events were gastrointestinal adverse events (diarrhea, 34.8% [30.4% grade 1/2, 13.0% grade 3]; nausea, 21.7% [all grade 1/2]; vomiting, 21.7% [all grade 1/2]), myalgia (17.4%, all grade 1/2), and abdominal pain (21.7% [21.7% grade 1/2, 4.3% grade 3]).  The pharmacokinetic study showed the dose-linearity of all dosing levels.  Among 23 patients, six patients (26.1%) showed stable disease.  Median progression-free survival was 39 days (95% confidence interval, 37 to 41 days).  CONCLUSION:  This study demonstrates feasibility of CKD-516, novel vascular disrupting agent, in patients with advanced solid tumor.  MTD of CKD-516 was defined as 12 mg/m(2)/day on D1 and D8 every 3 weeks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQO4HjIonre9q2q3xNe7a7QfW6udTcc2eYXSv6lbJWHPrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MroslKnsA%253D%253D&md5=718d6c3621f564ee53d20961432ea061</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.4143%2Fcrt.2014.258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4143%252Fcrt.2014.258%26sid%3Dliteratum%253Aachs%26aulast%3DOh%26aufirst%3DD.%2BY.%26aulast%3DKim%26aufirst%3DT.%2BM.%26aulast%3DHan%26aufirst%3DS.%2BW.%26aulast%3DShin%26aufirst%3DD.%2BY.%26aulast%3DLee%26aufirst%3DY.%2BG.%26aulast%3DLee%26aufirst%3DK.%2BW.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DT.%2BY.%26aulast%3DJang%26aufirst%3DI.%2BJ.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DBang%26aufirst%3DY.%2BJ.%26atitle%3DPhase%2520I%2520study%2520of%2520CKD-516%252C%2520a%2520novel%2520vascular%2520disrupting%2520agent%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Res.%2520Treat.%26date%3D2016%26volume%3D48%26spage%3D28%26epage%3D36%26doi%3D10.4143%2Fcrt.2014.258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Kuo, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liou, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. Y.</span><span> </span><span class="NLM_article-title">BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">4621</span><span class="NLM_x">–</span> <span class="NLM_lpage">4628</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-03-3474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1158%2F0008-5472.CAN-03-3474" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=15231674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltlOrsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=4621-4628&author=C.+C.+Kuoauthor=H.+P.+Hsiehauthor=W.+Y.+Panauthor=C.+P.+Chenauthor=J.+P.+Liouauthor=S.+J.+Leeauthor=Y.+L.+Changauthor=L.+T.+Chenauthor=C.+T.+Chenauthor=J.+Y.+Chang&title=BPR0L075%2C+a+novel+synthetic+indole+compound+with+antimitotic+activity+in+human+cancer+cells%2C+exerts+effective+antitumoral+activity+in+vivo&doi=10.1158%2F0008-5472.CAN-03-3474"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">BPR0L075, a Novel Synthetic Indole Compound with Antimitotic Activity in Human Cancer Cells, Exerts Effective Antitumoral Activity in Vivo</span></div><div class="casAuthors">Kuo, Ching-Chuan; Hsieh, Hsing-Pang; Pan, Wen-Yu; Chen, Ching-Ping; Liou, Jing-Ping; Lee, Shiow-Ju; Chang, Yi-Ling; Chen, Li-Tzong; Chen, Chiung-Tong; Chang, Jang-Yang</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4621-4628</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">BPR0L075 is a novel synthetic compd. discovered through research to identify new microtubule inhibitors.  BPR0L075 inhibits tubulin polymn. through binding to the colchicine-binding site of tubulin.  Cytotoxic activity of BPR0L075 in a variety of human tumor cell lines has been ascertained, with IC50 values in single-digit nanomolar ranges.  As detd. by flow cytometry, human cervical carcinoma KB cells are arrested in G2-M phases in a time-dependent manner before cell death occurs.  Terminal deoxynucleotidyl transferase-mediated nick end labeling assay indicates that cell death proceeds through an apoptotic pathway.  Addnl. studies indicate that the effect of BPR0L075 on cell cycle arrest is assocd. with an increase in cyclin B1 levels and a mobility shift of Cdc2 and Cdc25C.  The changes in Cdc2 and Cdc25C coincide with the appearance of phosphoepitopes recognized by a marker of mitosis, MPM-2.  Furthermore, phosphorylated forms of Bcl-2, perturbed mitochondrial membrane potential, and activation of the caspase-3 cascade may be involved in BPR0L075-induced apoptosis.  Notably, several KB-derived multidrug-resistant cell lines overexpressing P-gp170/MDR and MRP are resistant to vincristine, paclitaxel, and colchicine but not to BPR0L075.  Moreover, BPR0L075 shows potent activity against the growth of xenograft tumors of the gastric carcinoma MKN-45, human cervical carcinoma KB, and KB-derived P-gp170/MDR-overexpressing KB-VIN10 cells at i.v. doses of 50 mg/kg in nude mice.  These findings indicate BPR0L075 is a promising anticancer compd. with antimitotic activity that has potential for management of various malignancies, particularly for patients with drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoSqx6pRirD7Vg90H21EOLACvtfcHk0lj80ajGcAEMPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltlOrsbc%253D&md5=c828eca8875e66dc0780c6a61574828b</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-03-3474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-03-3474%26sid%3Dliteratum%253Aachs%26aulast%3DKuo%26aufirst%3DC.%2BC.%26aulast%3DHsieh%26aufirst%3DH.%2BP.%26aulast%3DPan%26aufirst%3DW.%2BY.%26aulast%3DChen%26aufirst%3DC.%2BP.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DChang%26aufirst%3DY.%2BL.%26aulast%3DChen%26aufirst%3DL.%2BT.%26aulast%3DChen%26aufirst%3DC.%2BT.%26aulast%3DChang%26aufirst%3DJ.%2BY.%26atitle%3DBPR0L075%252C%2520a%2520novel%2520synthetic%2520indole%2520compound%2520with%2520antimitotic%2520activity%2520in%2520human%2520cancer%2520cells%252C%2520exerts%2520effective%2520antitumoral%2520activity%2520in%2520vivo%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D4621%26epage%3D4628%26doi%3D10.1158%2F0008-5472.CAN-03-3474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Tung, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coumar, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiao, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liou, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shukla, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H. P.</span><span> </span><span class="NLM_article-title">Scaffold-hopping strategy: synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">3076</span><span class="NLM_x">–</span> <span class="NLM_lpage">3080</span><span class="refDoi"> DOI: 10.1021/jm101027s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101027s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsleksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=3076-3080&author=Y.+S.+Tungauthor=M.+S.+Coumarauthor=Y.+S.+Wuauthor=H.+Y.+Shiaoauthor=J.+Y.+Changauthor=J.+P.+Liouauthor=P.+Shuklaauthor=C.+W.+Changauthor=C.+Y.+Changauthor=C.+C.+Kuoauthor=T.+K.+Yehauthor=C.+Y.+Linauthor=J.+S.+Wuauthor=S.+Y.+Wuauthor=C.+C.+Liaoauthor=H.+P.+Hsieh&title=Scaffold-hopping+strategy%3A+synthesis+and+biological+evaluation+of+5%2C6-fused+bicyclic+heteroaromatics+to+identify+orally+bioavailable+anticancer+agents&doi=10.1021%2Fjm101027s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Scaffold-hopping strategy: synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents</span></div><div class="casAuthors">Tung, Yen-Shih; Coumar, Mohane Selvaraj; Wu, Yu-Shan; Shiao, Hui-Yi; Chang, Jang-Yang; Liou, Jing-Ping; Shukla, Paritosh; Chang, Chun-Wei; Chang, Chi-Yen; Kuo, Ching-Chuan; Yeh, Teng-Kuang; Lin, Chin-Yu; Wu, Jian-Sung; Wu, Su-Ying; Liao, Chun-Chen; Hsieh, Hsing-Pang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3076-3080</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Utilizing scaffold-hopping drug-design strategy, we sought to identify a backup drug candidate for BPR0L075 I, an indole-based anticancer agent.  For this purpose, 5,6-fused bicyclic heteroarom. scaffolds were designed and synthesized through shuffling of the nitrogen from the N-1 position or by insertion of one or two nitrogen atoms into the indole core of I.  Among these, 7-azaindole core II showed potent in vitro anticancer activity and improved oral bioavailability (F = 35%) compared with I (F < 10%).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGjnmU15CEwrVg90H21EOLACvtfcHk0lj80ajGcAEMPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsleksbk%253D&md5=0b8adad6e78a680d54de3ba893ed5d62</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fjm101027s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101027s%26sid%3Dliteratum%253Aachs%26aulast%3DTung%26aufirst%3DY.%2BS.%26aulast%3DCoumar%26aufirst%3DM.%2BS.%26aulast%3DWu%26aufirst%3DY.%2BS.%26aulast%3DShiao%26aufirst%3DH.%2BY.%26aulast%3DChang%26aufirst%3DJ.%2BY.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DShukla%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DC.%2BW.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DKuo%26aufirst%3DC.%2BC.%26aulast%3DYeh%26aufirst%3DT.%2BK.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DWu%26aufirst%3DJ.%2BS.%26aulast%3DWu%26aufirst%3DS.%2BY.%26aulast%3DLiao%26aufirst%3DC.%2BC.%26aulast%3DHsieh%26aufirst%3DH.%2BP.%26atitle%3DScaffold-hopping%2520strategy%253A%2520synthesis%2520and%2520biological%2520evaluation%2520of%25205%252C6-fused%2520bicyclic%2520heteroaromatics%2520to%2520identify%2520orally%2520bioavailable%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D3076%26epage%3D3080%26doi%3D10.1021%2Fjm101027s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Flynn, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grobelny, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leske, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavranos, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chalmers, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charman, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kostewicz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shackleford, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morizzi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kremmidiotis, G.</span><span> </span><span class="NLM_article-title">Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6014</span><span class="NLM_x">–</span> <span class="NLM_lpage">6027</span><span class="refDoi"> DOI: 10.1021/jm200454y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200454y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvVWlsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6014-6027&author=B.+L.+Flynnauthor=G.+S.+Gillauthor=D.+W.+Grobelnyauthor=J.+H.+Chaplinauthor=D.+Paulauthor=A.+F.+Leskeauthor=T.+C.+Lavranosauthor=D.+K.+Chalmersauthor=S.+A.+Charmanauthor=E.+Kostewiczauthor=D.+M.+Shacklefordauthor=J.+Morizziauthor=E.+Hamelauthor=M.+K.+Jungauthor=G.+Kremmidiotis&title=Discovery+of+7-hydroxy-6-methoxy-2-methyl-3-%283%2C4%2C5-trimethoxybenzoyl%29benzo%5Bb%5Dfuran+%28BNC105%29%2C+a+tubulin+polymerization+inhibitor+with+potent+antiproliferative+and+tumor+vascular+disrupting+properties&doi=10.1021%2Fjm200454y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 7-Hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a Tubulin Polymerization Inhibitor with Potent Antiproliferative and Tumor Vascular Disrupting Properties</span></div><div class="casAuthors">Flynn, Bernard L.; Gill, Gurmit S.; Grobelny, Damian W.; Chaplin, Jason H.; Paul, Dharam; Leske, Annabell F.; Lavranos, Tina C.; Chalmers, David K.; Charman, Susan A.; Kostewicz, Edmund; Shackleford, David M.; Morizzi, Julia; Hamel, Ernest; Jung, M. Katherine; Kremmidiotis, Gabriel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6014-6027</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Trimethoxybenzoyl benzofurans such as I [R = H, (NaO)2P:O] were prepd. as analogs of combretastatin A4 for use as antitumor agents and tested for their inhibition of tubulin polymn.  Structure-activity relationships were detd. for the inhibition of tubulin polymn. by benzoyl benzofurans; introduction of a conformation bias and addn. of a hydrogen bond donor improved the activities of the compds.  I (R = H) was found by screening for selectivity against cancer cells and activated endothelial cells over quiescent endothelial cells; its activity against nonresistant and resistant human cancer cell lines and pharmacokinetics in rats were detd.  I [R = (NaO)2P:O] has improved soly., improved ability to disrupt tumor vasculature, and improved tumor growth inhibition over both I (R = H) and combretastatin A-4 disodium phosphate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV_WE1ggYIxLVg90H21EOLACvtfcHk0lgKXpGy4j9fxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvVWlsb8%253D&md5=7c9a9ea031ebbb02d2c262015ff3df25</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fjm200454y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200454y%26sid%3Dliteratum%253Aachs%26aulast%3DFlynn%26aufirst%3DB.%2BL.%26aulast%3DGill%26aufirst%3DG.%2BS.%26aulast%3DGrobelny%26aufirst%3DD.%2BW.%26aulast%3DChaplin%26aufirst%3DJ.%2BH.%26aulast%3DPaul%26aufirst%3DD.%26aulast%3DLeske%26aufirst%3DA.%2BF.%26aulast%3DLavranos%26aufirst%3DT.%2BC.%26aulast%3DChalmers%26aufirst%3DD.%2BK.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DKostewicz%26aufirst%3DE.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DMorizzi%26aufirst%3DJ.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DJung%26aufirst%3DM.%2BK.%26aulast%3DKremmidiotis%26aufirst%3DG.%26atitle%3DDiscovery%2520of%25207-hydroxy-6-methoxy-2-methyl-3-%25283%252C4%252C5-trimethoxybenzoyl%2529benzo%255Bb%255Dfuran%2520%2528BNC105%2529%252C%2520a%2520tubulin%2520polymerization%2520inhibitor%2520with%2520potent%2520antiproliferative%2520and%2520tumor%2520vascular%2520disrupting%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6014%26epage%3D6027%26doi%3D10.1021%2Fjm200454y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Kremmidiotis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leske, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavranos, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaumont, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasic, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Callaghan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, B.</span><span> </span><span class="NLM_article-title">BNC105: A novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1562</span><span class="NLM_x">–</span> <span class="NLM_lpage">1573</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0815</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1158%2F1535-7163.MCT-09-0815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=20515948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntFGgsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1562-1573&author=G.+Kremmidiotisauthor=A.+F.+Leskeauthor=T.+C.+Lavranosauthor=D.+Beaumontauthor=J.+Gasicauthor=A.+Hallauthor=M.+O%E2%80%99Callaghanauthor=C.+A.+Matthewsauthor=B.+Flynn&title=BNC105%3A+A+novel+tubulin+polymerization+inhibitor+that+selectively+disrupts+tumor+vasculature+and+displays+single-agent+antitumor+efficacy&doi=10.1158%2F1535-7163.MCT-09-0815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">BNC105: A Novel Tubulin Polymerization Inhibitor That Selectively Disrupts Tumor Vasculature and Displays Single-Agent Antitumor Efficacy</span></div><div class="casAuthors">Kremmidiotis, Gabriel; Leske, Annabell F.; Lavranos, Tina C.; Beaumont, Donna; Gasic, Jelena; Hall, Allison; O'Callaghan, Michael; Matthews, Clayton A.; Flynn, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1562-1573</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Vascular disruption agents (VDA) cause occlusion of tumor vasculature, resulting in hypoxia-driven tumor cell necrosis.  Tumor vascular disruption is a therapeutic strategy of great potential; however, VDAs currently under development display a narrow therapeutic margin, with cardiovascular toxicity posing a dose-limiting obstacle.  Discovery of new VDAs, which display a wider therapeutic margin, may allow attainment of improved clin. outcomes.  To identify such compds., we used an in vitro selectivity screening approach that exploits the fact that tumor endothelial cells are in a const. state of activation and angiogenesis and do not undergo senescence.  Our effort yielded the compd. BNC105.  This compd. acts as a tubulin polymn. inhibitor and displays 80-fold higher potency against endothelial cells that are actively proliferating or are engaged in the formation of in vitro capillaries compared with nonproliferating endothelial cells or endothelium found in stable capillaries.  This selectivity was not obsd. with CA4, a VDA currently under evaluation in phase III clin. trials.  BNC105 is more potent and offers a wider therapeutic window.  CA4 produces 90% vascular disruption at its no obsd. adverse event level (NOAEL), whereas BNC105 causes 95% vascular disruption at 1/8th of its NOAEL.  Tissue distribution anal. of BNC105 in tumor-bearing mice showed that while the drug is cleared from all tissues 24 h after administration, it is still present at high concns. within the solid tumor mass.  Furthermore, BNC105 treatment causes tumor regressions with complete tumor clearance in 20% of treated animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLcKlwS1G0NrVg90H21EOLACvtfcHk0lgKXpGy4j9fxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntFGgsLk%253D&md5=94a9f916319585f07bd4b8467b1b5a89</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0815%26sid%3Dliteratum%253Aachs%26aulast%3DKremmidiotis%26aufirst%3DG.%26aulast%3DLeske%26aufirst%3DA.%2BF.%26aulast%3DLavranos%26aufirst%3DT.%2BC.%26aulast%3DBeaumont%26aufirst%3DD.%26aulast%3DGasic%26aufirst%3DJ.%26aulast%3DHall%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Callaghan%26aufirst%3DM.%26aulast%3DMatthews%26aufirst%3DC.%2BA.%26aulast%3DFlynn%26aufirst%3DB.%26atitle%3DBNC105%253A%2520A%2520novel%2520tubulin%2520polymerization%2520inhibitor%2520that%2520selectively%2520disrupts%2520tumor%2520vasculature%2520and%2520displays%2520single-agent%2520antitumor%2520efficacy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D1562%26epage%3D1573%26doi%3D10.1158%2F1535-7163.MCT-09-0815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Nien, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liou, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. Y.</span><span> </span><span class="NLM_article-title">5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2309</span><span class="NLM_x">–</span> <span class="NLM_lpage">2313</span><span class="refDoi"> DOI: 10.1021/jm900685y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900685y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvFKhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2309-2313&author=C.+Y.+Nienauthor=Y.+C.+Chenauthor=C.+C.+Kuoauthor=H.+P.+Hsiehauthor=C.+Y.+Changauthor=J.+S.+Wuauthor=S.+Y.+Wuauthor=J.+P.+Liouauthor=J.+Y.+Chang&title=5-Amino-2-aroylquinolines+as+highly+potent+tubulin+polymerization+inhibitors&doi=10.1021%2Fjm900685y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">5-Amino-2-Aroylquinolines as Highly Potent Tubulin Polymerization Inhibitors</span></div><div class="casAuthors">Nien, Chih-Ying; Chen, Yun-Ching; Kuo, Ching-Chuan; Hsieh, Hsing-Pang; Chang, Chi-Yen; Wu, Jian-Sung; Wu, Su-Ying; Liou, Jing-Ping; Chang, Jang-Yang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2309-2313</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of aroylquinoline derivs. were synthesized and evaluated for anticancer activity. 5-Amino-6-methoxy-2-aroylquinoline 15(I) showed more potent antiproliferative activity (IC50 values ranging from 0.2 to 0.4 nM) as compared to 1a (II) (combretastatin A-4) (IC50 = 1.9-835 nM) against various human cancer cell lines and a MDR-resistant cancer cell line.  Compd. 15 (IC50 = 1.6 μM) exhibited more potent inhibition of tubulin polymn. than 1a (IC50 = 2.1 μM) and showed strong binding property to the colchicine binding site of microtubules.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq735xVDh1uqLVg90H21EOLACvtfcHk0lgKXpGy4j9fxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvFKhs7s%253D&md5=fb47dc7b2c00383517cfbbeb8cc274c8</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Fjm900685y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900685y%26sid%3Dliteratum%253Aachs%26aulast%3DNien%26aufirst%3DC.%2BY.%26aulast%3DChen%26aufirst%3DY.%2BC.%26aulast%3DKuo%26aufirst%3DC.%2BC.%26aulast%3DHsieh%26aufirst%3DH.%2BP.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DWu%26aufirst%3DJ.%2BS.%26aulast%3DWu%26aufirst%3DS.%2BY.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DChang%26aufirst%3DJ.%2BY.%26atitle%3D5-Amino-2-aroylquinolines%2520as%2520highly%2520potent%2520tubulin%2520polymerization%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2309%26epage%3D2313%26doi%3D10.1021%2Fjm900685y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Wen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span> </span><span class="NLM_article-title">3-(3,4,5-Trimethoxyphenylselenyl)-1H-indoles and their selenoxides as combretastatin A-4 analogs: Microwave-assisted synthesis and biological evaluation</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">184</span><span class="NLM_x">–</span> <span class="NLM_lpage">194</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2014.11.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.ejmech.2014.11.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=25461319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGisL7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2015&pages=184-194&author=Z.+Wenauthor=J.+Xuauthor=Z.+Wangauthor=H.+Qiauthor=Q.+Xuauthor=Z.+Baiauthor=Q.+Zhangauthor=K.+Baoauthor=Y.+Wuauthor=W.+Zhang&title=3-%283%2C4%2C5-Trimethoxyphenylselenyl%29-1H-indoles+and+their+selenoxides+as+combretastatin+A-4+analogs%3A+Microwave-assisted+synthesis+and+biological+evaluation&doi=10.1016%2Fj.ejmech.2014.11.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">3-(3,4,5-Trimethoxyphenylselenyl)-1H-indoles and their selenoxides as combretastatin A-4 analogs: Microwave-assisted synthesis and biological evaluation</span></div><div class="casAuthors">Wen, Zhiyong; Xu, Jingwen; Wang, Zhiwei; Qi, Huan; Xu, Qile; Bai, Zhaoshi; Zhang, Qian; Bao, Kai; Wu, Yingling; Zhang, Weige</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">184-194</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 3-(3,4,5-trimethoxyphenylselenyl)-1H-indoles and their selenoxides were designed as a new class of combretastatin A-4 (CA-4) analogs.  The B ring and the cis double bond of CA-4 were replaced by an indole moiety and selenium atom, resp.  A facile and efficient microwave-assisted synthesis of 3-arylselenylindoles was developed to prep. the target compds., which were then evaluated for antiproliferative activity against three human cancer cell lines using an MTT assay.  Most of these compds. exhibited significant antiproliferative activity, with some showing nanomolar IC50 values.  Tubulin polymn. and immunostaining expts. revealed that I potently inhibited tubulin polymn. and disrupted tubulin microtubule dynamics in a similar manner to CA-4.  Docking studies demonstrated that I adopts an orientation similar to that of CA-4 at the colchicine binding site on tubulin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY8hKuwuW35LVg90H21EOLACvtfcHk0ljVE9LC-E48HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGisL7N&md5=d38286bbc411759251da9eac04d1f76b</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.11.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.11.024%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DQi%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DBai%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DBao%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DW.%26atitle%3D3-%25283%252C4%252C5-Trimethoxyphenylselenyl%2529-1H-indoles%2520and%2520their%2520selenoxides%2520as%2520combretastatin%2520A-4%2520analogs%253A%2520Microwave-assisted%2520synthesis%2520and%2520biological%2520evaluation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D90%26spage%3D184%26epage%3D194%26doi%3D10.1016%2Fj.ejmech.2014.11.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Romagnoli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baraldi, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvador, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prencipe, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Cara, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiaffino Ortega, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brancale, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castagliuolo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitola, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ronca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bortolozzi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porcù, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basso, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viola, G.</span><span> </span><span class="NLM_article-title">Design, synthesis, in vitro, and in vivo anticancer and antiangiogenic activity of novel 3-arylaminobenzofuran derivatives targeting the colchicine site on tubulin</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3209</span><span class="NLM_x">–</span> <span class="NLM_lpage">3222</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00155</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00155" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksl2gtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3209-3222&author=R.+Romagnoliauthor=P.+G.+Baraldiauthor=M.+K.+Salvadorauthor=F.+Prencipeauthor=C.+Lopez-Caraauthor=S.+Schiaffino+Ortegaauthor=A.+Brancaleauthor=E.+Hamelauthor=I.+Castagliuoloauthor=S.+Mitolaauthor=R.+Roncaauthor=R.+Bortolozziauthor=E.+Porc%C3%B9author=G.+Bassoauthor=G.+Viola&title=Design%2C+synthesis%2C+in+vitro%2C+and+in+vivo+anticancer+and+antiangiogenic+activity+of+novel+3-arylaminobenzofuran+derivatives+targeting+the+colchicine+site+on+tubulin&doi=10.1021%2Facs.jmedchem.5b00155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, in Vitro, and in Vivo Anticancer and Antiangiogenic Activity of Novel 3-Arylaminobenzofuran Derivatives Targeting the Colchicine Site on Tubulin</span></div><div class="casAuthors">Romagnoli, Romeo; Baraldi, Pier Giovanni; Salvador, Maria Kimatrai; Prencipe, Filippo; Lopez-Cara, Carlota; Schiaffino Ortega, Santiago; Brancale, Andrea; Hamel, Ernest; Castagliuolo, Ignazio; Mitola, Stefania; Ronca, Roberto; Bortolozzi, Roberta; Porcu, Elena; Basso, Giuseppe; Viola, Giampietro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3209-3222</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">(Trimethoxyphenylamino)benzofurancarboxylates I (R, R1, R2 = H, MeO; R3 = H, MeO, EtO; R4 = Me, Et) were prepd. as potential antitumor agents; the growth inhibition of the compds. in human cancer cell lines was detd.  The toxicity of I (R = H; R1 = MeO; R2 = R3 = H; R4 = Me) and I (R = R1 = H; R2 = MeO; R3 = H; R4 = Me) to human noncancer cells was detd.  I (R = R1 = H; R2 = MeO; R3 = H; R4 = Me) inhibited cancer cell growth at concs. of 0.3-27 nM and had in vivo antitumor activity in a murine model comparable to the activity obtained with combretastatin A-4 phosphate.  I (R = R1 = H; R2 = MeO; R3 = H; R4 = Me, Et) inhibited tubulin polymn. and bound to the colchicine binding site of tubulin.  I (R = R1 = H; R2 = MeO; R3 = H; R4 = Me, Et) induced apoptosis through the mitochondrial pathway, inducing activation of caspases 3 and 9 and downregulating the antiapoptotic proteins Bcl-2 and Mcl-1.  I (R = R1 = H; R2 = MeO; R3 = H; R4 = Me) inhibited angiogenesis in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMDBCGQx4elbVg90H21EOLACvtfcHk0ljVE9LC-E48HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksl2gtrs%253D&md5=1219975a7865db5d56a784eab8c0dd66</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00155%26sid%3Dliteratum%253Aachs%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DSalvador%26aufirst%3DM.%2BK.%26aulast%3DPrencipe%26aufirst%3DF.%26aulast%3DLopez-Cara%26aufirst%3DC.%26aulast%3DSchiaffino%2BOrtega%26aufirst%3DS.%26aulast%3DBrancale%26aufirst%3DA.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DCastagliuolo%26aufirst%3DI.%26aulast%3DMitola%26aufirst%3DS.%26aulast%3DRonca%26aufirst%3DR.%26aulast%3DBortolozzi%26aufirst%3DR.%26aulast%3DPorc%25C3%25B9%26aufirst%3DE.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DViola%26aufirst%3DG.%26atitle%3DDesign%252C%2520synthesis%252C%2520in%2520vitro%252C%2520and%2520in%2520vivo%2520anticancer%2520and%2520antiangiogenic%2520activity%2520of%2520novel%25203-arylaminobenzofuran%2520derivatives%2520targeting%2520the%2520colchicine%2520site%2520on%2520tubulin%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3209%26epage%3D3222%26doi%3D10.1021%2Facs.jmedchem.5b00155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">La Regina, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coluccia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Famiglini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelliccia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Passacantilli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzoccoli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggieri, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verrico, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miele, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nalli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfonsi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Marcotullio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricci, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soriani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caraglia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Da Pozzo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brancale, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marinelli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novellino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vultaggio, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varasi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercurio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigogno, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dondio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavia, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvestri, R.</span><span> </span><span class="NLM_article-title">New indole tubulin assembly inhibitors cause stable arrest of mitotic progression, enhanced stimulation of natural killer cell cytotoxic activity, and repression of Hedgehog-dependent cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">5789</span><span class="NLM_x">–</span> <span class="NLM_lpage">5807</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00310</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00310" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5789-5807&author=G.+La+Reginaauthor=R.+Baiauthor=A.+Colucciaauthor=V.+Famigliniauthor=S.+Pellicciaauthor=S.+Passacantilliauthor=C.+Mazzoccoliauthor=V.+Ruggieriauthor=A.+Verricoauthor=A.+Mieleauthor=L.+Montiauthor=M.+Nalliauthor=R.+Alfonsiauthor=L.+Di+Marcotullioauthor=A.+Gulinoauthor=B.+Ricciauthor=A.+Sorianiauthor=A.+Santoniauthor=M.+Caragliaauthor=S.+Portoauthor=E.+Da+Pozzoauthor=C.+Martiniauthor=A.+Brancaleauthor=L.+Marinelliauthor=E.+Novellinoauthor=S.+Vultaggioauthor=M.+Varasiauthor=C.+Mercurioauthor=C.+Bigognoauthor=G.+Dondioauthor=E.+Hamelauthor=P.+Laviaauthor=R.+Silvestri&title=New+indole+tubulin+assembly+inhibitors+cause+stable+arrest+of+mitotic+progression%2C+enhanced+stimulation+of+natural+killer+cell+cytotoxic+activity%2C+and+repression+of+Hedgehog-dependent+cancer&doi=10.1021%2Facs.jmedchem.5b00310"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00310%26sid%3Dliteratum%253Aachs%26aulast%3DLa%2BRegina%26aufirst%3DG.%26aulast%3DBai%26aufirst%3DR.%26aulast%3DColuccia%26aufirst%3DA.%26aulast%3DFamiglini%26aufirst%3DV.%26aulast%3DPelliccia%26aufirst%3DS.%26aulast%3DPassacantilli%26aufirst%3DS.%26aulast%3DMazzoccoli%26aufirst%3DC.%26aulast%3DRuggieri%26aufirst%3DV.%26aulast%3DVerrico%26aufirst%3DA.%26aulast%3DMiele%26aufirst%3DA.%26aulast%3DMonti%26aufirst%3DL.%26aulast%3DNalli%26aufirst%3DM.%26aulast%3DAlfonsi%26aufirst%3DR.%26aulast%3DDi%2BMarcotullio%26aufirst%3DL.%26aulast%3DGulino%26aufirst%3DA.%26aulast%3DRicci%26aufirst%3DB.%26aulast%3DSoriani%26aufirst%3DA.%26aulast%3DSantoni%26aufirst%3DA.%26aulast%3DCaraglia%26aufirst%3DM.%26aulast%3DPorto%26aufirst%3DS.%26aulast%3DDa%2BPozzo%26aufirst%3DE.%26aulast%3DMartini%26aufirst%3DC.%26aulast%3DBrancale%26aufirst%3DA.%26aulast%3DMarinelli%26aufirst%3DL.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DVultaggio%26aufirst%3DS.%26aulast%3DVarasi%26aufirst%3DM.%26aulast%3DMercurio%26aufirst%3DC.%26aulast%3DBigogno%26aufirst%3DC.%26aulast%3DDondio%26aufirst%3DG.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DLavia%26aufirst%3DP.%26aulast%3DSilvestri%26aufirst%3DR.%26atitle%3DNew%2520indole%2520tubulin%2520assembly%2520inhibitors%2520cause%2520stable%2520arrest%2520of%2520mitotic%2520progression%252C%2520enhanced%2520stimulation%2520of%2520natural%2520killer%2520cell%2520cytotoxic%2520activity%252C%2520and%2520repression%2520of%2520Hedgehog-dependent%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5789%26epage%3D5807%26doi%3D10.1021%2Facs.jmedchem.5b00310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Álvarez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puebla, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Díaz, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bento, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Navas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de la Iglesia-Vicente, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mollinedo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreu, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medarde, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peláez, R.</span><span> </span><span class="NLM_article-title">Endowing indole-based tubulin inhibitors with an anchor for derivatization: highly potent 3-substituted indolephenstatins and indoleisocombretastatins</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">2813</span><span class="NLM_x">–</span> <span class="NLM_lpage">2827</span><span class="refDoi"> DOI: 10.1021/jm3015603</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3015603" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2813-2827&author=R.+%C3%81lvarezauthor=P.+Pueblaauthor=J.+F.+D%C3%ADazauthor=A.+C.+Bentoauthor=R.+Garc%C3%ADa-Navasauthor=J.+de+la+Iglesia-Vicenteauthor=F.+Mollinedoauthor=J.+M.+Andreuauthor=M.+Medardeauthor=R.+Pel%C3%A1ez&title=Endowing+indole-based+tubulin+inhibitors+with+an+anchor+for+derivatization%3A+highly+potent+3-substituted+indolephenstatins+and+indoleisocombretastatins&doi=10.1021%2Fjm3015603"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Fjm3015603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3015603%26sid%3Dliteratum%253Aachs%26aulast%3D%25C3%2581lvarez%26aufirst%3DR.%26aulast%3DPuebla%26aufirst%3DP.%26aulast%3DD%25C3%25ADaz%26aufirst%3DJ.%2BF.%26aulast%3DBento%26aufirst%3DA.%2BC.%26aulast%3DGarc%25C3%25ADa-Navas%26aufirst%3DR.%26aulast%3Dde%2Bla%2BIglesia-Vicente%26aufirst%3DJ.%26aulast%3DMollinedo%26aufirst%3DF.%26aulast%3DAndreu%26aufirst%3DJ.%2BM.%26aulast%3DMedarde%26aufirst%3DM.%26aulast%3DPel%25C3%25A1ez%26aufirst%3DR.%26atitle%3DEndowing%2520indole-based%2520tubulin%2520inhibitors%2520with%2520an%2520anchor%2520for%2520derivatization%253A%2520highly%2520potent%25203-substituted%2520indolephenstatins%2520and%2520indoleisocombretastatins%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2813%26epage%3D2827%26doi%3D10.1021%2Fjm3015603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohler, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalton, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, D. D.</span><span> </span><span class="NLM_article-title">Design, synthesis, and SAR studies of 4-substituted methoxylbenzoyl-aryl- thiazoles analogues as potent and orally bioavailable anticancer agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4678</span><span class="NLM_x">–</span> <span class="NLM_lpage">4693</span><span class="refDoi"> DOI: 10.1021/jm2003427</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2003427" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4678-4693&author=Y.+Luauthor=C.+M.+Liauthor=Z.+Wangauthor=J.+Chenauthor=M.+L.+Mohlerauthor=W.+Liauthor=J.+T.+Daltonauthor=D.+D.+Miller&title=Design%2C+synthesis%2C+and+SAR+studies+of+4-substituted+methoxylbenzoyl-aryl-+thiazoles+analogues+as+potent+and+orally+bioavailable+anticancer+agents&doi=10.1021%2Fjm2003427"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Fjm2003427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2003427%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DC.%2BM.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMohler%26aufirst%3DM.%2BL.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520SAR%2520studies%2520of%25204-substituted%2520methoxylbenzoyl-aryl-%2520thiazoles%2520analogues%2520as%2520potent%2520and%2520orally%2520bioavailable%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4678%26epage%3D4693%26doi%3D10.1021%2Fjm2003427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">La Regina, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coluccia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Famiglini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelliccia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Passacantilli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzoccoli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggieri, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sisinni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolognesi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rensen, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miele, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nalli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfonsi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Marcotullio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brancale, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novellino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dondio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vultaggio, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varasi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercurio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavia, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvestri, R.</span><span> </span><span class="NLM_article-title">New pyrrole derivatives with potent tubulin polymerization inhibiting activity as anticancer agents including Hedgehog-dependent cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">6531</span><span class="NLM_x">–</span> <span class="NLM_lpage">6552</span><span class="refDoi"> DOI: 10.1021/jm500561a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500561a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6531-6552&author=G.+La+Reginaauthor=R.+Baiauthor=A.+Colucciaauthor=V.+Famigliniauthor=S.+Pellicciaauthor=S.+Passacantilliauthor=C.+Mazzoccoliauthor=V.+Ruggieriauthor=L.+Sisinniauthor=A.+Bolognesiauthor=W.+M.+Rensenauthor=A.+Mieleauthor=M.+Nalliauthor=R.+Alfonsiauthor=L.+Di+Marcotullioauthor=A.+Gulinoauthor=A.+Brancaleauthor=E.+Novellinoauthor=G.+Dondioauthor=S.+Vultaggioauthor=M.+Varasiauthor=C.+Mercurioauthor=E.+Hamelauthor=P.+Laviaauthor=R.+Silvestri&title=New+pyrrole+derivatives+with+potent+tubulin+polymerization+inhibiting+activity+as+anticancer+agents+including+Hedgehog-dependent+cancer&doi=10.1021%2Fjm500561a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Fjm500561a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500561a%26sid%3Dliteratum%253Aachs%26aulast%3DLa%2BRegina%26aufirst%3DG.%26aulast%3DBai%26aufirst%3DR.%26aulast%3DColuccia%26aufirst%3DA.%26aulast%3DFamiglini%26aufirst%3DV.%26aulast%3DPelliccia%26aufirst%3DS.%26aulast%3DPassacantilli%26aufirst%3DS.%26aulast%3DMazzoccoli%26aufirst%3DC.%26aulast%3DRuggieri%26aufirst%3DV.%26aulast%3DSisinni%26aufirst%3DL.%26aulast%3DBolognesi%26aufirst%3DA.%26aulast%3DRensen%26aufirst%3DW.%2BM.%26aulast%3DMiele%26aufirst%3DA.%26aulast%3DNalli%26aufirst%3DM.%26aulast%3DAlfonsi%26aufirst%3DR.%26aulast%3DDi%2BMarcotullio%26aufirst%3DL.%26aulast%3DGulino%26aufirst%3DA.%26aulast%3DBrancale%26aufirst%3DA.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DDondio%26aufirst%3DG.%26aulast%3DVultaggio%26aufirst%3DS.%26aulast%3DVarasi%26aufirst%3DM.%26aulast%3DMercurio%26aufirst%3DC.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DLavia%26aufirst%3DP.%26aulast%3DSilvestri%26aufirst%3DR.%26atitle%3DNew%2520pyrrole%2520derivatives%2520with%2520potent%2520tubulin%2520polymerization%2520inhibiting%2520activity%2520as%2520anticancer%2520agents%2520including%2520Hedgehog-dependent%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6531%26epage%3D6552%26doi%3D10.1021%2Fjm500561a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Romagnoli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baraldi, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvador, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prencipe, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertolasi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cancellieri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brancale, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castagliuolo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Consolaro, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porcù, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basso, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viola, G.</span><span> </span><span class="NLM_article-title">Synthesis, antimitotic and antivascular activity of 1-(3′,4′,5′-trimethoxybenzoyl)-3-arylamino-5-amino-1,2,4-triazoles</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">6795</span><span class="NLM_x">–</span> <span class="NLM_lpage">6808</span><span class="refDoi"> DOI: 10.1021/jm5008193</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5008193" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6795-6808&author=R.+Romagnoliauthor=P.+G.+Baraldiauthor=M.+K.+Salvadorauthor=F.+Prencipeauthor=V.+Bertolasiauthor=M.+Cancellieriauthor=A.+Brancaleauthor=E.+Hamelauthor=I.+Castagliuoloauthor=F.+Consolaroauthor=E.+Porc%C3%B9author=G.+Bassoauthor=G.+Viola&title=Synthesis%2C+antimitotic+and+antivascular+activity+of+1-%283%E2%80%B2%2C4%E2%80%B2%2C5%E2%80%B2-trimethoxybenzoyl%29-3-arylamino-5-amino-1%2C2%2C4-triazoles&doi=10.1021%2Fjm5008193"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Fjm5008193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5008193%26sid%3Dliteratum%253Aachs%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DSalvador%26aufirst%3DM.%2BK.%26aulast%3DPrencipe%26aufirst%3DF.%26aulast%3DBertolasi%26aufirst%3DV.%26aulast%3DCancellieri%26aufirst%3DM.%26aulast%3DBrancale%26aufirst%3DA.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DCastagliuolo%26aufirst%3DI.%26aulast%3DConsolaro%26aufirst%3DF.%26aulast%3DPorc%25C3%25B9%26aufirst%3DE.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DViola%26aufirst%3DG.%26atitle%3DSynthesis%252C%2520antimitotic%2520and%2520antivascular%2520activity%2520of%25201-%25283%25E2%2580%25B2%252C4%25E2%2580%25B2%252C5%25E2%2580%25B2-trimethoxybenzoyl%2529-3-arylamino-5-amino-1%252C2%252C4-triazoles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6795%26epage%3D6808%26doi%3D10.1021%2Fjm5008193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">León-González, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acero, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muñoz-Mingarro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navarro, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martín-Cordero, C.</span><span> </span><span class="NLM_article-title">Chalcones as promising lead compounds on cancer therapy</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3407</span><span class="NLM_x">–</span> <span class="NLM_lpage">3425</span><span class="refDoi"> DOI: 10.2174/0929867322666150729114829</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.2174%2F0929867322666150729114829" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=26219392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslGitbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=3407-3425&author=A.+J.+Le%C3%B3n-Gonz%C3%A1lezauthor=N.+Aceroauthor=D.+Mu%C3%B1oz-Mingarroauthor=I.+Navarroauthor=C.+Mart%C3%ADn-Cordero&title=Chalcones+as+promising+lead+compounds+on+cancer+therapy&doi=10.2174%2F0929867322666150729114829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Chalcones as Promising Lead Compounds on Cancer Therapy</span></div><div class="casAuthors">Leon-Gonzalez, Antonio J.; Acero, Nuria; Munoz-Mingarro, Dolores; Navarro, Inmaculada; Martin-Cordero, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">3407-3425</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Chalcones constitute a group of phenolic compds. that command an increasing interest on cancer research.  Natural chalcones are widespread through the plant kingdom.  The most abundant and investigated chalcones are isoliquiritigenin, flavokawain and xanthohumol, which are present in the Fabaceae, Piperaceae, Cannabaceae, and Moraceae families.  These chalcones have been shown to be promising lead antitumor-chemopreventive drugs by three different activities: antioxidants, cytotoxic and apoptosis inducers.  In the recent years, SAR (structure-activity relationship) has contributed towards the improvement of anticancer properties of chalcones by substituting aryl rings and introducing heterocyclic moieties.  This review summarizes the anticancer activities shown by natural chalcones and the SAR and describes how different chem. moiety modifications could lead them to be therapeutically useful in the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLg8VAf9Rj7bVg90H21EOLACvtfcHk0lj0dz8enT1cyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslGitbbK&md5=667ae49e0b8bcf0d8c3423cd3ad24303</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.2174%2F0929867322666150729114829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867322666150729114829%26sid%3Dliteratum%253Aachs%26aulast%3DLe%25C3%25B3n-Gonz%25C3%25A1lez%26aufirst%3DA.%2BJ.%26aulast%3DAcero%26aufirst%3DN.%26aulast%3DMu%25C3%25B1oz-Mingarro%26aufirst%3DD.%26aulast%3DNavarro%26aufirst%3DI.%26aulast%3DMart%25C3%25ADn-Cordero%26aufirst%3DC.%26atitle%3DChalcones%2520as%2520promising%2520lead%2520compounds%2520on%2520cancer%2520therapy%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2015%26volume%3D22%26spage%3D3407%26epage%3D3425%26doi%3D10.2174%2F0929867322666150729114829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Ducki, S.</span><span> </span><span class="NLM_article-title">Antimitotic chalcones and related compounds as inhibitors of tubulin assembly</span> <span class="citation_source-journal">Anti-Cancer Agents Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">336</span><span class="NLM_x">–</span> <span class="NLM_lpage">347</span><span class="refDoi"> DOI: 10.2174/1871520610909030336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.2174%2F1871520610909030336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=19275525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks1Cgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=336-347&author=S.+Ducki&title=Antimitotic+chalcones+and+related+compounds+as+inhibitors+of+tubulin+assembly&doi=10.2174%2F1871520610909030336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Antimitotic chalcones and related compounds as inhibitors of tubulin assembly</span></div><div class="casAuthors">Ducki, Sylvie</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">336-347</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of chalcones as antimitotic agents has led to the design of other analogs able to interact with tubulin and inhibit its assembly into microtubules.  This activity has also been assocd. with their anti-vascular activity.  This review focuses on the development of chalcones and related analogs as antimitotic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4udbevzeoA7Vg90H21EOLACvtfcHk0lj0dz8enT1cyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks1Cgu7c%253D&md5=de9d119eedd2f60dc9f3f9783b3d6495</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.2174%2F1871520610909030336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520610909030336%26sid%3Dliteratum%253Aachs%26aulast%3DDucki%26aufirst%3DS.%26atitle%3DAntimitotic%2520chalcones%2520and%2520related%2520compounds%2520as%2520inhibitors%2520of%2520tubulin%2520assembly%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D336%26epage%3D347%26doi%3D10.2174%2F1871520610909030336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Ducki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rennison, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabert, J. F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGown, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, N. J.</span><span> </span><span class="NLM_article-title">Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: Synthesis and biological evaluation of antivascular activity</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">7698</span><span class="NLM_x">–</span> <span class="NLM_lpage">7710</span><span class="refDoi"> DOI: 10.1016/j.bmc.2009.09.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.bmc.2009.09.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=19837593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCrsLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=7698-7710&author=S.+Duckiauthor=D.+Rennisonauthor=M.+Wooauthor=A.+Kendallauthor=J.+F.+D.+Chabertauthor=A.+T.+McGownauthor=N.+J.+Lawrence&title=Combretastatin-like+chalcones+as+inhibitors+of+microtubule+polymerization.+Part+1%3A+Synthesis+and+biological+evaluation+of+antivascular+activity&doi=10.1016%2Fj.bmc.2009.09.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: Synthesis and biological evaluation of antivascular activity</span></div><div class="casAuthors">Ducki, Sylvie; Rennison, David; Woo, Meiko; Kendall, Alexander; Fournier Dit Chabert, Jeremie; McGown, Alan T.; Lawrence, Nicholas J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7698-7710</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The α-Me chalcone SD400 is a potent inhibitor of tubulin assembly and possesses potent anticancer activity.  Various chalcone analogs were synthesized and evaluated for their cell growth inhibitory properties against the K562 human chronic myelogenous leukemia cell line (SD400, IC50 0.21 nM; combretastatin A4 CA4, IC50 2.0 nM).  Cell cycle anal. by flow cytometry indicated that these agents are antimitotic (SD400, 83% of the cells are in G2/M phase; CA4 90%).  They inhibit tubulin assembly at low concn. (SD400, IC50 0.46 μM; CA4, 0.10 μM) and compete with [3H]colchicine for binding to tubulin (8% [3H]colchicine remained bound to tubulin after competition with SD400 or CA4).  Upon treatment with SD400, remarkable cell shape changes were elicited in HUVEC cells, consistent with vasculature damaging activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo372LoP6iI8rVg90H21EOLACvtfcHk0lj0dz8enT1cyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCrsLbE&md5=486602f554293d500f9794150be4c31f</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2009.09.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2009.09.039%26sid%3Dliteratum%253Aachs%26aulast%3DDucki%26aufirst%3DS.%26aulast%3DRennison%26aufirst%3DD.%26aulast%3DWoo%26aufirst%3DM.%26aulast%3DKendall%26aufirst%3DA.%26aulast%3DChabert%26aufirst%3DJ.%2BF.%2BD.%26aulast%3DMcGown%26aufirst%3DA.%2BT.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26atitle%3DCombretastatin-like%2520chalcones%2520as%2520inhibitors%2520of%2520microtubule%2520polymerization.%2520Part%25201%253A%2520Synthesis%2520and%2520biological%2520evaluation%2520of%2520antivascular%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D7698%26epage%3D7710%26doi%3D10.1016%2Fj.bmc.2009.09.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Zhu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yue, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shang, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bu, X.</span><span> </span><span class="NLM_article-title">Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">6364</span><span class="NLM_x">–</span> <span class="NLM_lpage">6382</span><span class="refDoi"> DOI: 10.1021/jm500024v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500024v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6364-6382&author=C.+Zhuauthor=Y.+Zuoauthor=R.+Wangauthor=B.+Liangauthor=X.+Yueauthor=G.+Wenauthor=N.+Shangauthor=L.+Huangauthor=Y.+Chenauthor=J.+Duauthor=X.+Bu&title=Discovery+of+potent+cytotoxic+ortho-aryl+chalcones+as+new+scaffold+targeting+tubulin+and+mitosis+with+affinity-based+fluorescence&doi=10.1021%2Fjm500024v"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fjm500024v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500024v%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DZuo%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DLiang%26aufirst%3DB.%26aulast%3DYue%26aufirst%3DX.%26aulast%3DWen%26aufirst%3DG.%26aulast%3DShang%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DBu%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520potent%2520cytotoxic%2520ortho-aryl%2520chalcones%2520as%2520new%2520scaffold%2520targeting%2520tubulin%2520and%2520mitosis%2520with%2520affinity-based%2520fluorescence%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6364%26epage%3D6382%26doi%3D10.1021%2Fjm500024v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Martel-Frachet, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keramidas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nurisso, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeBonis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rome, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coll, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boumendjel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skoufias, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ronot, X.</span><span> </span><span class="NLM_article-title">IPP51, a chalcone acting as a microtubule inhibitor with in vivo antitumor activity against bladder carcinoma</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">14669</span><span class="NLM_x">–</span> <span class="NLM_lpage">14686</span><span class="refDoi"> DOI: 10.18632/oncotarget.4144</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.18632%2Foncotarget.4144" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=14669-14686&author=V.+Martel-Frachetauthor=M.+Keramidasauthor=A.+Nurissoauthor=S.+DeBonisauthor=C.+Romeauthor=J.+L.+Collauthor=A.+Boumendjelauthor=D.+A.+Skoufiasauthor=X.+Ronot&title=IPP51%2C+a+chalcone+acting+as+a+microtubule+inhibitor+with+in+vivo+antitumor+activity+against+bladder+carcinoma&doi=10.18632%2Foncotarget.4144"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.4144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.4144%26sid%3Dliteratum%253Aachs%26aulast%3DMartel-Frachet%26aufirst%3DV.%26aulast%3DKeramidas%26aufirst%3DM.%26aulast%3DNurisso%26aufirst%3DA.%26aulast%3DDeBonis%26aufirst%3DS.%26aulast%3DRome%26aufirst%3DC.%26aulast%3DColl%26aufirst%3DJ.%2BL.%26aulast%3DBoumendjel%26aufirst%3DA.%26aulast%3DSkoufias%26aufirst%3DD.%2BA.%26aulast%3DRonot%26aufirst%3DX.%26atitle%3DIPP51%252C%2520a%2520chalcone%2520acting%2520as%2520a%2520microtubule%2520inhibitor%2520with%2520in%2520vivo%2520antitumor%2520activity%2520against%2520bladder%2520carcinoma%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D14669%26epage%3D14686%26doi%3D10.18632%2Foncotarget.4144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Zheng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mottamal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeMelle, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFerrin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, G.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel pyridine-bridged analogues of combretastatin-A4 as anticancer agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">3369</span><span class="NLM_x">–</span> <span class="NLM_lpage">3381</span><span class="refDoi"> DOI: 10.1021/jm500002k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500002k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVCrsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3369-3381&author=S.+Zhengauthor=Q.+Zhongauthor=M.+Mottamalauthor=Q.+Zhangauthor=C.+Zhangauthor=E.+LeMelleauthor=H.+McFerrinauthor=G.+Wang&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+pyridine-bridged+analogues+of+combretastatin-A4+as+anticancer+agents&doi=10.1021%2Fjm500002k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Novel Pyridine-Bridged Analogues of Combretastatin-A4 as Anticancer Agents</span></div><div class="casAuthors">Zheng, Shilong; Zhong, Qiu; Mottamal, Madhusoodanan; Zhang, Qiang; Zhang, Changde; LeMelle, Elise; McFerrin, Harris; Wang, Guangdi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3369-3381</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel pyridine-bridged analogs of combretastatin-A4 (CA-4) were designed and synthesized.  As expected, the 4-atom linker configuration retained little cytotoxicities.  Activities of the analogs with 3-atom linker varied widely depending on the Ph ring substitutions, and the 3-atom linker contg. nitrogen represents the more favorable linker structure.  Among them, three analogs (4h, 4s, and 4t; I - III, resp.) potently inhibited cell survival and growth, arrested cell cycle, and blocked angiogenesis and vasculature formation in vivo in ways comparable to CA-4.  The superposition of 4h and 4s in the colchicine-binding pocket of tubulin shows the binding posture of CA-4, 4h, and 4s are similar, as confirmed by the competitive binding assay where the ability of the ligands to replace tubulin-bound colchicine was measured.  The binding data are consistent with the obsd. biol. activities in antiproliferation and suppression of angiogenesis but are not predictive of their antitubulin polymn. activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe8RTj0wT9RLVg90H21EOLACvtfcHk0lgmIqawprZGJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVCrsLc%253D&md5=818f0a1793ce803a0b48e827004aa1e5</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fjm500002k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500002k%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DZhong%26aufirst%3DQ.%26aulast%3DMottamal%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLeMelle%26aufirst%3DE.%26aulast%3DMcFerrin%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DG.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520pyridine-bridged%2520analogues%2520of%2520combretastatin-A4%2520as%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3369%26epage%3D3381%26doi%3D10.1021%2Fjm500002k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Yoshimatsu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshino, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koyanagi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitoh, K.</span><span> </span><span class="NLM_article-title">Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">3208</span><span class="NLM_x">–</span> <span class="NLM_lpage">3213</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=9242451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADyaK2sXkvFKqs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=3208-3213&author=K.+Yoshimatsuauthor=A.+Yamaguchiauthor=H.+Yoshinoauthor=N.+Koyanagiauthor=K.+Kitoh&title=Mechanism+of+action+of+E7010%2C+an+orally+active+sulfonamide+antitumor+agent%3A+inhibition+of+mitosis+by+binding+to+the+colchicine+site+of+tubulin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin</span></div><div class="casAuthors">Yoshimatsu, Kentaro; Yamaguchi, Atsumi; Yoshino, Hiroshi; Koyanagi, Nozomu; Kitoh, Kyosuke</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3208-3213</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">E7010 (N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide), an orally active sulfonamide antitumor agent that is currently in a Phase I clin. trial, showed rather consistent growth-inhibitory activities against a panel of 26 human tumor cell lines (IC50 = 0.06-0.8 μg/mL), in contrast to vincristine (VCR; IC50 = 0.0002-0.04 μg/mL), 5-fluorouracil (IC50 = 0.2-30 -μg/mL), Adriamycin (IC50 = 0.002-0.7 μg/mL), mitomycin C (IC50 = 0.007-3 μg/mL), 1-β-D-arabionfuranoxylcytosine (IC50 = 0.005 to >30 μg/mL), camptothecin (IC50 = 0.002-0.4 μg/mL), and cisplatin (IC50 = 0.5-20 μg/mL).  It caused a dose-dependent increase in the percentage or mitotic cells in parallel with a decrease in cell proliferation, like VCR.  It also showed a dose-dependent inhibition of tubulin polymn., which correlated well with the cell growth-inhibitory activity.  14C-labeled E7010 bound to purified tubulin, and this binding was inhibited by colchicine but not by VCR.  However, its binding properties were different from those of colchicine, as well as those of VCR.  E7010 was active against two kind of VCR-resistant P388 cell lines, one of which showed multidrug resistance due to the overexpression of P-glycoprotein (resistant to Taxol), and the other did not show multidrug resistance (sensitive to Taxol).  Furthermore, four E7010-resistant P388 cell lines showed no cross-resistance to VCR, a different pattern of resistance to podophyllotoxin, and collateral sensitivity to Taxol.  Therefore, E7010 is a novel tubulin-binding agent that has a wider antitumor spectrum than VCR and has different properties from those of VCR or Taxol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVpxr7g_T5H7Vg90H21EOLACvtfcHk0lgmIqawprZGJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkvFKqs7Y%253D&md5=8e3c1d8dd4d82dad09ee5e930d58b6c6</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYoshimatsu%26aufirst%3DK.%26aulast%3DYamaguchi%26aufirst%3DA.%26aulast%3DYoshino%26aufirst%3DH.%26aulast%3DKoyanagi%26aufirst%3DN.%26aulast%3DKitoh%26aufirst%3DK.%26atitle%3DMechanism%2520of%2520action%2520of%2520E7010%252C%2520an%2520orally%2520active%2520sulfonamide%2520antitumor%2520agent%253A%2520inhibition%2520of%2520mitosis%2520by%2520binding%2520to%2520the%2520colchicine%2520site%2520of%2520tubulin%26jtitle%3DCancer%2520Res.%26date%3D1997%26volume%3D57%26spage%3D3208%26epage%3D3213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Hande, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berlin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meek, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothenberg, M. L.</span><span> </span><span class="NLM_article-title">The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2834</span><span class="NLM_x">–</span> <span class="NLM_lpage">2840</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-05-2159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1158%2F1078-0432.CCR-05-2159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=16675578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD28Xltlamt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=2834-2840&author=K.+R.+Handeauthor=A.+Hageyauthor=J.+Berlinauthor=Y.+Caiauthor=K.+Meekauthor=H.+Kobayashiauthor=A.+C.+Lockhartauthor=D.+Medinaauthor=J.+Sosmanauthor=G.+B.+Gordonauthor=M.+L.+Rothenberg&title=The+pharmacokinetics+and+safety+of+ABT-751%2C+a+novel%2C+orally+bioavailable+sulfonamide+antimitotic+agent%3A+results+of+a+phase+1+study&doi=10.1158%2F1078-0432.CCR-05-2159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study</span></div><div class="casAuthors">Hande, Kenneth R.; Hagey, Anne; Berlin, Jordan; Cai, Yingna; Meek, Kysa; Kobayashi, Hiro; Lockhart, A. Craig; Medina, Diane; Sosman, Jeffrey; Gordon, Gary B.; Rothenberg, Mace L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2834-2840</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Microtubules play a crit. role in many cellular functions, including cell division and mitosis.  ABT-751 is a novel sulfonamide antimitotic that binds to the colchicine site on β-tubulin that leads to a block in the cell cycle at the G2M phase, resulting in cellular apoptosis.  ABT-751 was investigated in this phase 1 trial designed to assess its max. tolerated dose (MTD), dose-limiting toxicity (DLT), tolerability, and pharmacokinetics.  Exptl. Design: ABT-751 was administered on a daily (q.d.) or twice daily (b.i.d.) oral schedule for 7 days every 3 wk to 39 patients with refractory solid tumors.  Toxicity was monitored weekly.  Plasma and urine ABT-751 and metabolite pharmacokinetics were detd.  Results: The MTD for the q.d. schedule was 250 mg/d.  DLTs during cycle 1 were abdominal pain, constipation, and fatigue.  The MTD on the b.i.d. schedule was 150 mg.  Cycle 1 of therapy with the 175 mg b.i.d. schedule was tolerated without DLT.  However, six of seven patients reported grade 3 toxicity (ileus, constipation, abdominal pain, or fatigue), which occurred in cycle 2 or 3.  ABT-751 was absorbed after oral administration with an overall mean Tmax of about 2 h.  The pharmacokinetics of ABT-751 were dose-proportional and time-independent.  There was minimal accumulation of ABT-751 after multiple q.d. and b.i.d. doses.  Efficacious concns., as detd. from preclin. models (0.5-1.5 μg/mL), were achieved in all subjects.  ABT-751 metab. occurred primarily by glucuronidation and sulfation.  No complete or partial tumor responses were noted, but one patient had a minor response, and four patients had stable disease lasting at least 6 mo.  Conclusions: The MTD and recommended phase 2 doses for ABT-751 were 250 mg q.d. and 150 mg b.i.d. on a 7-day schedule given every 3 wk, due to subsequent cycle toxicities at 175 mg b.i.d. dosing.  Toxicities were abdominal pain, constipation, and neuropathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBiv6KDudi_7Vg90H21EOLACvtfcHk0li7ncB5npeegg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xltlamt70%253D&md5=26b14f0577a4531cd93a7245044fa286</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-2159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-2159%26sid%3Dliteratum%253Aachs%26aulast%3DHande%26aufirst%3DK.%2BR.%26aulast%3DHagey%26aufirst%3DA.%26aulast%3DBerlin%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DY.%26aulast%3DMeek%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DH.%26aulast%3DLockhart%26aufirst%3DA.%2BC.%26aulast%3DMedina%26aufirst%3DD.%26aulast%3DSosman%26aufirst%3DJ.%26aulast%3DGordon%26aufirst%3DG.%2BB.%26aulast%3DRothenberg%26aufirst%3DM.%2BL.%26atitle%3DThe%2520pharmacokinetics%2520and%2520safety%2520of%2520ABT-751%252C%2520a%2520novel%252C%2520orally%2520bioavailable%2520sulfonamide%2520antimitotic%2520agent%253A%2520results%2520of%2520a%2520phase%25201%2520study%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D2834%26epage%3D2840%26doi%3D10.1158%2F1078-0432.CCR-05-2159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Dorléans, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gigant, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravelli, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mailliet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikol, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knossow, M.</span><span> </span><span class="NLM_article-title">Variations in the colchicine-binding domain provide insight into the structural switch of tubulin</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">13775</span><span class="NLM_x">–</span> <span class="NLM_lpage">13779</span><span class="refDoi"> DOI: 10.1073/pnas.0904223106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1073%2Fpnas.0904223106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=19666559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFWksLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=13775-13779&author=A.+Dorl%C3%A9ansauthor=B.+Gigantauthor=R.+B.+Ravelliauthor=P.+Maillietauthor=V.+Mikolauthor=M.+Knossow&title=Variations+in+the+colchicine-binding+domain+provide+insight+into+the+structural+switch+of+tubulin&doi=10.1073%2Fpnas.0904223106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Variations in the colchicine-binding domain provide insight into the structural switch of tubulin</span></div><div class="casAuthors">Dorleans, Audrey; Gigant, Benoit; Ravelli, Raimond B. G.; Mailliet, Patrick; Mikol, Vincent; Knossow, Marcel</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">13775-13779, S13775/1-S13775/8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Structural changes occur in the αβ-tubulin heterodimer during the microtubule assembly/disassembly cycle.  Their most prominent feature is a transition from a straight, microtubular structure to a curved structure.  There is a broad range of small mol. compds. that disturbs the microtubule cycle, a class of which targets the colchicine-binding site and prevents microtubule assembly.  This class includes compds. with very different chem. structures, and it is presently unknown whether they prevent tubulin polymn. by the same mechanism.  To address this issue, we have detd. the structures of tubulin complexed with a set of such ligands and show that they interfere with several of the movements of tubulin subunit structural elements upon its transition from curved to straight.  We also detd. the structure of tubulin unliganded at the colchicine site; this reveals that a β-tubulin loop (termed T7) flips into this site.  As with colchicine site ligands, this prevents a helix which is at the interface with α-tubulin from stacking onto a β-tubulin P sheet as in straight protofilaments.  Whereas in the presence of these ligands the interference with microtubule assembly gets frozen, by flipping in and out, the β-subunit T7 loop participates in a reversible way in the resistance to straightening that opposes microtubule assembly.  Our results suggest that it thereby contributes to microtubule dynamic instability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDDUQBAmYNvbVg90H21EOLACvtfcHk0li7ncB5npeegg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFWksLrO&md5=6d18732f78ac484b9db09ad1ec52aa5c</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0904223106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0904223106%26sid%3Dliteratum%253Aachs%26aulast%3DDorl%25C3%25A9ans%26aufirst%3DA.%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DRavelli%26aufirst%3DR.%2BB.%26aulast%3DMailliet%26aufirst%3DP.%26aulast%3DMikol%26aufirst%3DV.%26aulast%3DKnossow%26aufirst%3DM.%26atitle%3DVariations%2520in%2520the%2520colchicine-binding%2520domain%2520provide%2520insight%2520into%2520the%2520structural%2520switch%2520of%2520tubulin%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26spage%3D13775%26epage%3D13779%26doi%3D10.1073%2Fpnas.0904223106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Chang, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liou, J. P.</span><span> </span><span class="NLM_article-title">7-Aroyl-aminoindoline-1-sulfonamides as a novel class of potent antitubulin agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6656</span><span class="NLM_x">–</span> <span class="NLM_lpage">6659</span><span class="refDoi"> DOI: 10.1021/jm061076u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061076u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6656-6659&author=J.+Y.+Changauthor=H.+P.+Hsiehauthor=C.+Y.+Changauthor=K.+S.+Hsuauthor=Y.+F.+Chiangauthor=C.+M.+Chenauthor=C.+C.+Kuoauthor=J.+P.+Liou&title=7-Aroyl-aminoindoline-1-sulfonamides+as+a+novel+class+of+potent+antitubulin+agents&doi=10.1021%2Fjm061076u"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1021%2Fjm061076u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061076u%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DJ.%2BY.%26aulast%3DHsieh%26aufirst%3DH.%2BP.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DHsu%26aufirst%3DK.%2BS.%26aulast%3DChiang%26aufirst%3DY.%2BF.%26aulast%3DChen%26aufirst%3DC.%2BM.%26aulast%3DKuo%26aufirst%3DC.%2BC.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26atitle%3D7-Aroyl-aminoindoline-1-sulfonamides%2520as%2520a%2520novel%2520class%2520of%2520potent%2520antitubulin%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6656%26epage%3D6659%26doi%3D10.1021%2Fjm061076u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Nicholson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lloyd, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palladino, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiso, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuteboom, S. T. C.</span><span> </span><span class="NLM_article-title">NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">31</span><span class="refDoi"> DOI: 10.1097/01.cad.0000182745.01612.8a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1097%2F01.cad.0000182745.01612.8a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=16317287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A280%3ADC%252BD2MnjsFCqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=25-31&author=B.+Nicholsonauthor=G.+K.+Lloydauthor=B.+R.+Millerauthor=M.+A.+Palladinoauthor=Y.+Kisoauthor=Y.+Hayashiauthor=S.+T.+C.+Neuteboom&title=NPI-2358+is+a+tubulin-depolymerizing+agent%3A+in-vitro+evidence+for+activity+as+a+tumor+vascular-disrupting+agent&doi=10.1097%2F01.cad.0000182745.01612.8a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent</span></div><div class="casAuthors">Nicholson Benjamin; Lloyd G Kenneth; Miller Brian R; Palladino Michael A; Kiso Yoshiaki; Hayashi Yoshio; Neuteboom Saskia T C</div><div class="citationInfo"><span class="NLM_cas:title">Anti-cancer drugs</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-31</span>
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    </div><div class="casAbstract">The diketopiperazine NPI-2358 is a synthetic analog of NPI-2350, a natural product isolated from Aspergillus sp., which depolymerizes microtubules in A549 human lung carcinoma cells.  Although structurally different from the colchicine-binding site agents reported to date, NPI-2358 binds to the colchicine-binding site of tubulin.  NPI-2358 has potent in-vitro anti-tumor activity against various human tumor cell lines and maintains activity against tumor cell lines with various multidrug-resistant (MDR) profiles.  In addition, when evaluated in proliferating human umbilical vein endothelial cells (HUVECs), concentrations as low as 10 nmol/l NPI-2358 induced tubulin depolymerization within 30 min.  Furthermore, NPI-2358 dose dependently increases HUVEC monolayer permeability--an in-vitro model of tumor vascular collapse.  NPI-2358 was compared with three tubulin-depolymerizing agents with vascular-disrupting activity: colchicine, vincristine and combretastatin A-4 (CA4).  Results showed that the activity of NPI-2358 in HUVECs was more potent than either colchicine or vincristine; the profile of CA4 approached that of NPI-2358.  Altogether, our data show that NPI-2358 is a potent anti-tumor agent which is active in MDR tumor cell lines, and is able to rapidly induce tubulin depolymerization and monolayer permeability in HUVECs.  These data warrant further evaluation of NPI-2358 as a vascular-disrupting agent in vivo.  Currently, NPI-2358 is in preclinical development for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ6ysYjEuHQMxcr74wzj5o5fW6udTcc2ebhvX8F-ZMYv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MnjsFCqug%253D%253D&md5=c8f8e21db08175e196ea0d673fc0322b</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1097%2F01.cad.0000182745.01612.8a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.cad.0000182745.01612.8a%26sid%3Dliteratum%253Aachs%26aulast%3DNicholson%26aufirst%3DB.%26aulast%3DLloyd%26aufirst%3DG.%2BK.%26aulast%3DMiller%26aufirst%3DB.%2BR.%26aulast%3DPalladino%26aufirst%3DM.%2BA.%26aulast%3DKiso%26aufirst%3DY.%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DNeuteboom%26aufirst%3DS.%2BT.%2BC.%26atitle%3DNPI-2358%2520is%2520a%2520tubulin-depolymerizing%2520agent%253A%2520in-vitro%2520evidence%2520for%2520activity%2520as%2520a%2520tumor%2520vascular-disrupting%2520agent%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2006%26volume%3D17%26spage%3D25%26epage%3D31%26doi%3D10.1097%2F01.cad.0000182745.01612.8a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Yamazaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sumikura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hidaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasui, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiso, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakushiji, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, Y.</span><span> </span><span class="NLM_article-title">Anti-microtubule ‘plinabulin’ chemical probe KPU-244-B3 labeled both α- and β-tubulin</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3169</span><span class="NLM_x">–</span> <span class="NLM_lpage">3174</span><span class="refDoi"> DOI: 10.1016/j.bmc.2010.03.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.bmc.2010.03.037" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=3169-3174&author=Y.+Yamazakiauthor=M.+Sumikuraauthor=K.+Hidakaauthor=H.+Yasuiauthor=Y.+Kisoauthor=F.+Yakushijiauthor=Y.+Hayashi&title=Anti-microtubule+%E2%80%98plinabulin%E2%80%99+chemical+probe+KPU-244-B3+labeled+both+%CE%B1-+and+%CE%B2-tubulin&doi=10.1016%2Fj.bmc.2010.03.037"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.03.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.03.037%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DY.%26aulast%3DSumikura%26aufirst%3DM.%26aulast%3DHidaka%26aufirst%3DK.%26aulast%3DYasui%26aufirst%3DH.%26aulast%3DKiso%26aufirst%3DY.%26aulast%3DYakushiji%26aufirst%3DF.%26aulast%3DHayashi%26aufirst%3DY.%26atitle%3DAnti-microtubule%2520%25E2%2580%2598plinabulin%25E2%2580%2599%2520chemical%2520probe%2520KPU-244-B3%2520labeled%2520both%2520%25CE%25B1-%2520and%2520%25CE%25B2-tubulin%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D3169%26epage%3D3174%26doi%3D10.1016%2Fj.bmc.2010.03.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Yamazaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kido, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hidaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasui, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiso, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakushiji, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, Y.</span><span> </span><span class="NLM_article-title">Tubulin photoaffinity labeling study with a plinabulin chemical probe possessing a biotin tag at the oxazole</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">595</span><span class="NLM_x">–</span> <span class="NLM_lpage">602</span><span class="refDoi"> DOI: 10.1016/j.bmc.2010.10.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.bmc.2010.10.055" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=595-602&author=Y.+Yamazakiauthor=Y.+Kidoauthor=K.+Hidakaauthor=H.+Yasuiauthor=Y.+Kisoauthor=F.+Yakushijiauthor=Y.+Hayashi&title=Tubulin+photoaffinity+labeling+study+with+a+plinabulin+chemical+probe+possessing+a+biotin+tag+at+the+oxazole&doi=10.1016%2Fj.bmc.2010.10.055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.10.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.10.055%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DY.%26aulast%3DKido%26aufirst%3DY.%26aulast%3DHidaka%26aufirst%3DK.%26aulast%3DYasui%26aufirst%3DH.%26aulast%3DKiso%26aufirst%3DY.%26aulast%3DYakushiji%26aufirst%3DF.%26aulast%3DHayashi%26aufirst%3DY.%26atitle%3DTubulin%2520photoaffinity%2520labeling%2520study%2520with%2520a%2520plinabulin%2520chemical%2520probe%2520possessing%2520a%2520biotin%2520tag%2520at%2520the%2520oxazole%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D595%26epage%3D602%26doi%3D10.1016%2Fj.bmc.2010.10.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gigant, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span> </span><span class="NLM_article-title">Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery</span> <span class="citation_source-journal">FEBS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">102</span><span class="NLM_x">–</span> <span class="NLM_lpage">111</span><span class="refDoi"> DOI: 10.1111/febs.13555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1111%2Ffebs.13555" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=26462166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKktrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2016&pages=102-111&author=Y.+Wangauthor=H.+Zhangauthor=B.+Gigantauthor=Y.+Yuauthor=Y.+Wuauthor=X.+Chenauthor=Q.+Laiauthor=Z.+Yangauthor=Q.+Chenauthor=J.+Yang&title=Structures+of+a+diverse+set+of+colchicine+binding+site+inhibitors+in+complex+with+tubulin+provide+a+rationale+for+drug+discovery&doi=10.1111%2Ffebs.13555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery</span></div><div class="casAuthors">Wang, Yuxi; Zhang, Hang; Gigant, Benoit; Yu, Yamei; Wu, Yangping; Chen, Xiangzheng; Lai, Qinhuai; Yang, Zhaoya; Chen, Qiang; Yang, Jinliang</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-111</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Microtubules are dynamic assemblies of αβ-tubulin heterodimers and have been recognized as highly attractive targets for cancer chemotherapy.  A broad range of agents bind to tubulin and interfere with microtubule assembly.  Despite having a long history of characterization, colchicine binding site inhibitors (CBSIs) have not yet reached the com. phase as anti-cancer drugs to date.  We detd. the structures of tubulin complexed with a set of structurally diverse CBSIs (lexibulin, nocodazole, plinabulin and tivantinib), among which nocodazole and tivantinib are both binary-function inhibitors targeting cancer-related kinases and microtubules simultaneously.  High resoln. structures revealed the detailed interactions between these ligands and tubulin.  Our results showed that the binding modes of the CBSIs were different from previous docking models, highlighting the importance of crystal structure information in structure-based drug design.  A real structure-based pharmacophore was proposed to rationalize key common interactions of the CBSIs at the colchicine domain.  Our studies provide a solid structural basis for developing new anti-cancer agents for the colchicine binding site.  Database : The at. coordinates and structure factors for tubulin complexed with lexibulin, nocodazole, plinabulin and tivantinib have been deposited in the Protein Data Bank under accession codes , , and , resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSIAVSS_EsIbVg90H21EOLACvtfcHk0lgrSwlHycoBPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKktrzP&md5=d5a17d9a3ac54d8eda44d0543ffa5fbd</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1111%2Ffebs.13555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Ffebs.13555%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLai%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DStructures%2520of%2520a%2520diverse%2520set%2520of%2520colchicine%2520binding%2520site%2520inhibitors%2520in%2520complex%2520with%2520tubulin%2520provide%2520a%2520rationale%2520for%2520drug%2520discovery%26jtitle%3DFEBS%2520J.%26date%3D2016%26volume%3D283%26spage%3D102%26epage%3D111%26doi%3D10.1111%2Ffebs.13555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Yamazaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deyanat-Yazdi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potts, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitagawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orikasa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiso, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasui, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akamatsu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chinen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Usui, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinozaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakushiji, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuteboom, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palladino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanoh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lloyd, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, Y.</span><span> </span><span class="NLM_article-title">Synthesis and structure–activity relationship study of antimicrotubule agents phenylahistin derivatives with a didehydropiperazine-2,5-dione structure</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1056</span><span class="NLM_x">–</span> <span class="NLM_lpage">1071</span><span class="refDoi"> DOI: 10.1021/jm2009088</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2009088" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1056-1071&author=Y.+Yamazakiauthor=K.+Tanakaauthor=B.+Nicholsonauthor=G.+Deyanat-Yazdiauthor=B.+Pottsauthor=T.+Yoshidaauthor=A.+Odaauthor=T.+Kitagawaauthor=S.+Orikasaauthor=Y.+Kisoauthor=H.+Yasuiauthor=M.+Akamatsuauthor=T.+Chinenauthor=T.+Usuiauthor=Y.+Shinozakiauthor=F.+Yakushijiauthor=B.+R.+Millerauthor=S.+Neuteboomauthor=M.+Palladinoauthor=K.+Kanohauthor=G.+K.+Lloydauthor=Y.+Hayashi&title=Synthesis+and+structure%E2%80%93activity+relationship+study+of+antimicrotubule+agents+phenylahistin+derivatives+with+a+didehydropiperazine-2%2C5-dione+structure&doi=10.1021%2Fjm2009088"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Fjm2009088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2009088%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DK.%26aulast%3DNicholson%26aufirst%3DB.%26aulast%3DDeyanat-Yazdi%26aufirst%3DG.%26aulast%3DPotts%26aufirst%3DB.%26aulast%3DYoshida%26aufirst%3DT.%26aulast%3DOda%26aufirst%3DA.%26aulast%3DKitagawa%26aufirst%3DT.%26aulast%3DOrikasa%26aufirst%3DS.%26aulast%3DKiso%26aufirst%3DY.%26aulast%3DYasui%26aufirst%3DH.%26aulast%3DAkamatsu%26aufirst%3DM.%26aulast%3DChinen%26aufirst%3DT.%26aulast%3DUsui%26aufirst%3DT.%26aulast%3DShinozaki%26aufirst%3DY.%26aulast%3DYakushiji%26aufirst%3DF.%26aulast%3DMiller%26aufirst%3DB.%2BR.%26aulast%3DNeuteboom%26aufirst%3DS.%26aulast%3DPalladino%26aufirst%3DM.%26aulast%3DKanoh%26aufirst%3DK.%26aulast%3DLloyd%26aufirst%3DG.%2BK.%26aulast%3DHayashi%26aufirst%3DY.%26atitle%3DSynthesis%2520and%2520structure%25E2%2580%2593activity%2520relationship%2520study%2520of%2520antimicrotubule%2520agents%2520phenylahistin%2520derivatives%2520with%2520a%2520didehydropiperazine-2%252C5-dione%2520structure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1056%26epage%3D1071%26doi%3D10.1021%2Fjm2009088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Reddy, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, C.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, U.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coumar, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liou, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H.-P.</span><span> </span><span class="NLM_article-title">Synthesis and structure–activity relationships of 2-amino-1-aroylnaphthalene and 2-hydroxy-1-aroylnaphthalenes as potent antitubulin agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">8163</span><span class="NLM_x">–</span> <span class="NLM_lpage">8167</span><span class="refDoi"> DOI: 10.1021/jm8008635</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8008635" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=8163-8167&author=G.+R.+Reddyauthor=C.-C.+Kuoauthor=U.-K.+Tanauthor=M.+S.+Coumarauthor=C.-Y.+Changauthor=Y.-K.+Chiangauthor=M.-J.+Laiauthor=J.-Y.+Yehauthor=S.-Y.+Wuauthor=J.-Y.+Changauthor=J.-P.+Liouauthor=H.-P.+Hsieh&title=Synthesis+and+structure%E2%80%93activity+relationships+of+2-amino-1-aroylnaphthalene+and+2-hydroxy-1-aroylnaphthalenes+as+potent+antitubulin+agents&doi=10.1021%2Fjm8008635"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Fjm8008635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8008635%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DG.%2BR.%26aulast%3DKuo%26aufirst%3DC.-C.%26aulast%3DTan%26aufirst%3DU.-K.%26aulast%3DCoumar%26aufirst%3DM.%2BS.%26aulast%3DChang%26aufirst%3DC.-Y.%26aulast%3DChiang%26aufirst%3DY.-K.%26aulast%3DLai%26aufirst%3DM.-J.%26aulast%3DYeh%26aufirst%3DJ.-Y.%26aulast%3DWu%26aufirst%3DS.-Y.%26aulast%3DChang%26aufirst%3DJ.-Y.%26aulast%3DLiou%26aufirst%3DJ.-P.%26aulast%3DHsieh%26aufirst%3DH.-P.%26atitle%3DSynthesis%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%25202-amino-1-aroylnaphthalene%2520and%25202-hydroxy-1-aroylnaphthalenes%2520as%2520potent%2520antitubulin%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D8163%26epage%3D8167%26doi%3D10.1021%2Fjm8008635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Burns, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harte, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joffe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sikanyika, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tranberg, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charman, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shackleford, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilks, A. F.</span><span> </span><span class="NLM_article-title">Discovery of CYT997: a structurally novel orally active microtubule targeting agent</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4639</span><span class="NLM_x">–</span> <span class="NLM_lpage">4642</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.06.079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.bmcl.2009.06.079" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4639-4642&author=C.+J.+Burnsauthor=M.+F.+Harteauthor=X.+Buauthor=E.+Fantinoauthor=M.+Joffeauthor=H.+Sikanyikaauthor=S.+Suauthor=C.+E.+Tranbergauthor=N.+Wilsonauthor=S.+A.+Charmanauthor=D.+M.+Shacklefordauthor=A.+F.+Wilks&title=Discovery+of+CYT997%3A+a+structurally+novel+orally+active+microtubule+targeting+agent&doi=10.1016%2Fj.bmcl.2009.06.079"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.06.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.06.079%26sid%3Dliteratum%253Aachs%26aulast%3DBurns%26aufirst%3DC.%2BJ.%26aulast%3DHarte%26aufirst%3DM.%2BF.%26aulast%3DBu%26aufirst%3DX.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DJoffe%26aufirst%3DM.%26aulast%3DSikanyika%26aufirst%3DH.%26aulast%3DSu%26aufirst%3DS.%26aulast%3DTranberg%26aufirst%3DC.%2BE.%26aulast%3DWilson%26aufirst%3DN.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26atitle%3DDiscovery%2520of%2520CYT997%253A%2520a%2520structurally%2520novel%2520orally%2520active%2520microtubule%2520targeting%2520agent%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4639%26epage%3D4642%26doi%3D10.1016%2Fj.bmcl.2009.06.079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Burns, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harte, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bukczynska, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frazzetto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joffe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruszelnicki, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dilley, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charman, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shackleford, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fida, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malcontenti-Wilson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilks, A. F.</span><span> </span><span class="NLM_article-title">CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">3036</span><span class="NLM_x">–</span> <span class="NLM_lpage">3045</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1158%2F1535-7163.MCT-09-0076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=19887548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlyrt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=3036-3045&author=C.+J.+Burnsauthor=E.+Fantinoauthor=I.+D.+Phillipsauthor=S.+Suauthor=M.+F.+Harteauthor=P.+E.+Bukczynskaauthor=M.+Frazzettoauthor=M.+Joffeauthor=I.+Kruszelnickiauthor=B.+Wangauthor=Y.+Wangauthor=N.+Wilsonauthor=R.+J.+Dilleyauthor=S.+S.+Wanauthor=S.+A.+Charmanauthor=D.+M.+Shacklefordauthor=R.+Fidaauthor=C.+Malcontenti-Wilsonauthor=A.+F.+Wilks&title=CYT997%3A+a+novel+orally+active+tubulin+polymerization+inhibitor+with+potent+cytotoxic+and+vascular+disrupting+activity+in+vitro+and+in+vivo&doi=10.1158%2F1535-7163.MCT-09-0076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo</span></div><div class="casAuthors">Burns, Christopher J.; Fantino, Emmanuelle; Phillips, Ian D.; Su, Stephen; Harte, Michael F.; Bukczynska, Patricia E.; Frazzetto, Mark; Joffe, Max; Kruszelnicki, Irma; Wang, Bing; Wang, Yue; Wilson, Neil; Dilley, Rodney J.; Wan, Soo S.; Charman, Susan A.; Shackleford, David M.; Fida, Rosa; Malcontenti-Wilson, Cathy; Wilks, Andrew F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3036-3045</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">CYT997 is a wholly synthetic compd. that possesses highly potent cytotoxic activity in vitro through inhibition of microtubule polymn.  CYT997 blocks the cell cycle at the G2-M boundary, and Western blot anal. indicates an increase in phosphorylated Bcl-2, along with increased expression of cyclin B1.  Caspase-3 activation is also obsd. in cells treated with CYT997 along with the generation of poly(ADP-ribose) polymerase.  The compd. possesses favorable pharmacokinetic properties, is orally bioavailable, and is efficacious per os in a range of in vivo cancer models, including some refractory to paclitaxel treatment.  CYT997 exhibits vascular disrupting activity as measured in vitro by effects on the permeability of human umbilical vein endothelial cell monolayers, and in vivo by effects on tumor blood flow.  CYT997 possesses a useful combination of pharmacol. and pharmacokinetic properties and has considerable potential as a novel anticancer agent. [Mol Cancer Ther 2009;8(11):3036-45].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr09YoJx33QQ7Vg90H21EOLACvtfcHk0lgPnVBzf-3vLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlyrt7%252FM&md5=76f883c9aa6a5bbde05b11c0e3f42fd0</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0076%26sid%3Dliteratum%253Aachs%26aulast%3DBurns%26aufirst%3DC.%2BJ.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DPhillips%26aufirst%3DI.%2BD.%26aulast%3DSu%26aufirst%3DS.%26aulast%3DHarte%26aufirst%3DM.%2BF.%26aulast%3DBukczynska%26aufirst%3DP.%2BE.%26aulast%3DFrazzetto%26aufirst%3DM.%26aulast%3DJoffe%26aufirst%3DM.%26aulast%3DKruszelnicki%26aufirst%3DI.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWilson%26aufirst%3DN.%26aulast%3DDilley%26aufirst%3DR.%2BJ.%26aulast%3DWan%26aufirst%3DS.%2BS.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DFida%26aufirst%3DR.%26aulast%3DMalcontenti-Wilson%26aufirst%3DC.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26atitle%3DCYT997%253A%2520a%2520novel%2520orally%2520active%2520tubulin%2520polymerization%2520inhibitor%2520with%2520potent%2520cytotoxic%2520and%2520vascular%2520disrupting%2520activity%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D3036%26epage%3D3045%26doi%3D10.1158%2F1535-7163.MCT-09-0076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Bacher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emig, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanhoefer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shandra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klenner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckers, T.</span><span> </span><span class="NLM_article-title">D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">392</span><span class="NLM_x">–</span> <span class="NLM_lpage">399</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=392-399&author=G.+Bacherauthor=B.+Nickelauthor=P.+Emigauthor=U.+Vanhoeferauthor=S.+Seeberauthor=A.+Shandraauthor=T.+Klennerauthor=T.+Beckers&title=D-24851%2C+a+novel+synthetic+microtubule+inhibitor%2C+exerts+curative+antitumoral+activity+in+vivo%2C+shows+efficacy+toward+multidrug-resistant+tumor+cells%2C+and+lacks+neurotoxicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBacher%26aufirst%3DG.%26aulast%3DNickel%26aufirst%3DB.%26aulast%3DEmig%26aufirst%3DP.%26aulast%3DVanhoefer%26aufirst%3DU.%26aulast%3DSeeber%26aufirst%3DS.%26aulast%3DShandra%26aufirst%3DA.%26aulast%3DKlenner%26aufirst%3DT.%26aulast%3DBeckers%26aufirst%3DT.%26atitle%3DD-24851%252C%2520a%2520novel%2520synthetic%2520microtubule%2520inhibitor%252C%2520exerts%2520curative%2520antitumoral%2520activity%2520in%2520vivo%252C%2520shows%2520efficacy%2520toward%2520multidrug-resistant%2520tumor%2520cells%252C%2520and%2520lacks%2520neurotoxicity%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D392%26epage%3D399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group">Oostendorp, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witteveen, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vainchtein, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schot, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nol, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosing, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beijnen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voest, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellens, J. H. M.</span><span> </span><span class="NLM_article-title">Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">163</span><span class="NLM_x">–</span> <span class="NLM_lpage">170</span><span class="refDoi"> DOI: 10.1007/s10637-009-9244-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1007%2Fs10637-009-9244-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=163-170&author=R.+L.+Oostendorpauthor=P.+O.+Witteveenauthor=B.+Schwartzauthor=L.+D.+Vainchteinauthor=M.+Schotauthor=A.+Nolauthor=H.+Rosingauthor=J.+H.+Beijnenauthor=E.+E.+Voestauthor=J.+H.+M.+Schellens&title=Dose-finding+and+pharmacokinetic+study+of+orally+administered+indibulin+%28D-24851%29+to+patients+with+advanced+solid+tumors&doi=10.1007%2Fs10637-009-9244-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1007%2Fs10637-009-9244-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-009-9244-6%26sid%3Dliteratum%253Aachs%26aulast%3DOostendorp%26aufirst%3DR.%2BL.%26aulast%3DWitteveen%26aufirst%3DP.%2BO.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DVainchtein%26aufirst%3DL.%2BD.%26aulast%3DSchot%26aufirst%3DM.%26aulast%3DNol%26aufirst%3DA.%26aulast%3DRosing%26aufirst%3DH.%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3DVoest%26aufirst%3DE.%2BE.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%2BM.%26atitle%3DDose-finding%2520and%2520pharmacokinetic%2520study%2520of%2520orally%2520administered%2520indibulin%2520%2528D-24851%2529%2520to%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2010%26volume%3D28%26spage%3D163%26epage%3D170%26doi%3D10.1007%2Fs10637-009-9244-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">Colley, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muthana, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danson, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brett, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coole, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tulasi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockey, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dossetter, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffen, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, M. J.</span><span> </span><span class="NLM_article-title">An orally bioavailable, indole-3-glyoxylamide based series of tubulin polymerization inhibitors showing tumor growth inhibition in a mouse xenograft model of head and neck cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">9309</span><span class="NLM_x">–</span> <span class="NLM_lpage">9333</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01312</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01312" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9309-9333&author=H.+E.+Colleyauthor=M.+Muthanaauthor=S.+J.+Dansonauthor=L.+V.+Jacksonauthor=M.+L.+Brettauthor=J.+Harrisonauthor=S.+F.+Cooleauthor=D.+P.+Masonauthor=L.+R.+Jenningsauthor=M.+Wongauthor=V.+Tulasiauthor=D.+Normanauthor=P.+M.+Lockeyauthor=L.+Williamsauthor=A.+G.+Dossetterauthor=E.+J.+Griffenauthor=M.+J.+Thompson&title=An+orally+bioavailable%2C+indole-3-glyoxylamide+based+series+of+tubulin+polymerization+inhibitors+showing+tumor+growth+inhibition+in+a+mouse+xenograft+model+of+head+and+neck+cancer&doi=10.1021%2Facs.jmedchem.5b01312"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01312%26sid%3Dliteratum%253Aachs%26aulast%3DColley%26aufirst%3DH.%2BE.%26aulast%3DMuthana%26aufirst%3DM.%26aulast%3DDanson%26aufirst%3DS.%2BJ.%26aulast%3DJackson%26aufirst%3DL.%2BV.%26aulast%3DBrett%26aufirst%3DM.%2BL.%26aulast%3DHarrison%26aufirst%3DJ.%26aulast%3DCoole%26aufirst%3DS.%2BF.%26aulast%3DMason%26aufirst%3DD.%2BP.%26aulast%3DJennings%26aufirst%3DL.%2BR.%26aulast%3DWong%26aufirst%3DM.%26aulast%3DTulasi%26aufirst%3DV.%26aulast%3DNorman%26aufirst%3DD.%26aulast%3DLockey%26aufirst%3DP.%2BM.%26aulast%3DWilliams%26aufirst%3DL.%26aulast%3DDossetter%26aufirst%3DA.%2BG.%26aulast%3DGriffen%26aufirst%3DE.%2BJ.%26aulast%3DThompson%26aufirst%3DM.%2BJ.%26atitle%3DAn%2520orally%2520bioavailable%252C%2520indole-3-glyoxylamide%2520based%2520series%2520of%2520tubulin%2520polymerization%2520inhibitors%2520showing%2520tumor%2520growth%2520inhibition%2520in%2520a%2520mouse%2520xenograft%2520model%2520of%2520head%2520and%2520neck%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9309%26epage%3D9333%26doi%3D10.1021%2Facs.jmedchem.5b01312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group">Ricart, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooney, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarantopoulos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brell, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruby, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munsey, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zambito, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolcher, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remick, S. C.</span><span> </span><span class="NLM_article-title">A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">959</span><span class="NLM_x">–</span> <span class="NLM_lpage">970</span><span class="refDoi"> DOI: 10.1007/s00280-011-1565-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1007%2Fs00280-011-1565-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=21305290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1eiu7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2011&pages=959-970&author=A.+D.+Ricartauthor=E.+A.+Ashtonauthor=M.+M.+Cooneyauthor=J.+Sarantopoulosauthor=J.+M.+Brellauthor=M.+A.+Feldmanauthor=K.+E.+Rubyauthor=K.+Matsudaauthor=M.+S.+Munseyauthor=G.+Medinaauthor=A.+Zambitoauthor=A.+W.+Tolcherauthor=S.+C.+Remick&title=A+phase+I+study+of+MN-029+%28denibulin%29%2C+a+novel+vascular-disrupting+agent%2C+in+patients+with+advanced+solid+tumors&doi=10.1007%2Fs00280-011-1565-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors</span></div><div class="casAuthors">Ricart, Alejandro D.; Ashton, Edward A.; Cooney, Matthew M.; Sarantopoulos, John; Brell, Joanna M.; Feldman, Maria A.; Ruby, Kale E.; Matsuda, Kazuko; Munsey, Mark S.; Medina, Gerardo; Zambito, Angela; Tolcher, Anthony W.; Remick, Scot C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">959-970</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose MN-029 (denibulin HCl) is a novel vascular-disrupting agent that reversibly inhibits microtubule assembly, resulting in disruption of the cytoskeleton of tumor vascular endothelial cells.  This study detd. the safety, pharmacokinetics, and acute anti-vascular effects of MN-029.  Methods Patients were treated with escalating doses of MN-029 (4.0-225 mg/m2) administered IV at 3-wk intervals.  This first-in-human study followed an accelerated titrn. design, with intra-patient dose escalation.  Plasma samples were assayed to det. PK parameters.  DCE-MRI scans were acquired at baseline and at 6-8 h post-dose.  Results Thirty-four patients received 151 infusions of MN-029.  The most common toxicities of MN-029 included nausea and vomiting (which appeared to be dose related), diarrhea, fatigue, headache, and anorexia.  No clin. significant myelotoxicity, stomatitis or alopecia was obsd.  There was no evidence of cumulative toxicity in patients receiving multiple courses of therapy.  The cohort at 180 mg/m2 was expanded to six patients due to a reversible episode of acute coronary ischemia, without sequelae and with preservation of myocardial function.  Two dose-limiting toxicities occurred at 225 mg/m2, a transient ischemic attack and grade 3 transaminitis, thus ending dose escalation.  Pharmacokinetic data indicated dose-related increases in C max and AUC values, although substantial inter-subject variability was obsd.  No objective responses were noted; however, five patients had stable disease ≥6 mo.  A significant linear correlation was found between redn. in K trans and exposure to MN-029.  Conclusions MN-029 was generally well tolerated and showed decrease in tumor vascular parameters.  The max. tolerated dose was 180 mg/m2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxgyxrtbsON7Vg90H21EOLACvtfcHk0lgd2fGYbXDcYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1eiu7%252FL&md5=53ffe56de2b460a865da4c36d57a7ed1</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1007%2Fs00280-011-1565-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-011-1565-4%26sid%3Dliteratum%253Aachs%26aulast%3DRicart%26aufirst%3DA.%2BD.%26aulast%3DAshton%26aufirst%3DE.%2BA.%26aulast%3DCooney%26aufirst%3DM.%2BM.%26aulast%3DSarantopoulos%26aufirst%3DJ.%26aulast%3DBrell%26aufirst%3DJ.%2BM.%26aulast%3DFeldman%26aufirst%3DM.%2BA.%26aulast%3DRuby%26aufirst%3DK.%2BE.%26aulast%3DMatsuda%26aufirst%3DK.%26aulast%3DMunsey%26aufirst%3DM.%2BS.%26aulast%3DMedina%26aufirst%3DG.%26aulast%3DZambito%26aufirst%3DA.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DRemick%26aufirst%3DS.%2BC.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520MN-029%2520%2528denibulin%2529%252C%2520a%2520novel%2520vascular-disrupting%2520agent%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2011%26volume%3D68%26spage%3D959%26epage%3D970%26doi%3D10.1007%2Fs00280-011-1565-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group">Kasibhatla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baichwal, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, S. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skvortsova, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skvortsov, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">English, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirisoma, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drewe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pervin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, R. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pleiman, C. M.</span><span> </span><span class="NLM_article-title">MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">5865</span><span class="NLM_x">–</span> <span class="NLM_lpage">5871</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-0127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1158%2F0008-5472.CAN-07-0127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=17575155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsFCqtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=5865-5871&author=S.+Kasibhatlaauthor=V.+Baichwalauthor=S.+X.+Caiauthor=B.+Rothauthor=I.+Skvortsovaauthor=S.+Skvortsovauthor=P.+Lukasauthor=N.+M.+Englishauthor=N.+Sirisomaauthor=J.+Dreweauthor=A.+Pervinauthor=B.+Tsengauthor=R.+O.+Carlsonauthor=C.+M.+Pleiman&title=MPC-6827%3A+a+small-molecule+inhibitor+of+microtubule+formation+that+is+not+a+substrate+for+multidrug+resistance+pumps&doi=10.1158%2F0008-5472.CAN-07-0127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">MPC-6827: A small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps</span></div><div class="casAuthors">Kasibhatla, Shailaja; Baichwal, Vijay; Cai, Sui Xiong; Roth, Bruce; Skvortsova, Ira; Skvortsov, Sergej; Lukas, Peter; English, Nicole M.; Sirisoma, Nilantha; Drewe, John; Pervin, Azra; Tseng, Ben; Carlson, Robert O.; Pleiman, Christopher M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5865-5871</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A novel series of 4-arylaminoquinazolines were identified from a cell-based screening assay as potent apoptosis inducers.  Through structure-activity relationship studies, MPC-6827 and its close structural analog, MPI-0441138, were discovered as proapoptotic mols. and mitotic inhibitors with potencies at low nanomolar concns. in multiple tumor cell lines.  Photoaffinity and radiolabeled analogs of MPC-6827 were found to bind a 55-kDa protein, and this binding was competed by MPC-6827, paclitaxel, and colchicine, but not vinblastine.  MPC-6827 effectively inhibited the polymn. of tubulin in vitro, competed with colchicine binding, and disrupted the formation of microtubules in a variety of tumor cell lines, which together showed the mol. target as tubulin.  Treatment of MCF-7 breast carcinoma or Jurkat leukemia cells with MPC-6827 led to pronounced G2-M cell cycle arrest followed by apoptosis.  Apoptosis, as detd. by terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling assay, was preceded by loss of mitochondrial membrane potential, cytochrome c translocation from mitochondria to nuclei, activation of caspase-3, and cleavage of poly(ADP-ribose) polymerase.  MPC-6827 was equipotent in an in vitro growth inhibition assay in several cancer cell lines regardless of the expression levels of the multidrug resistance ABC transporters MDR-1 (Pgp-1), MRP-1, and BCRP-1.  In B16-F1 allografts and in OVCAR-3, MIAPaCa-2, MCF-7, HT-29, MDA-MB-435, and MX-1 xenografts, statistically significant tumor growth inhibition was obsd. with MPC-6827.  These studies show that MPC-6827 is a microtubule-disrupting agent with potent and broad-spectrum in vitro and in vivo cytotoxic activities and, therefore, MPC-6827 is a promising candidate for development as a novel therapeutic for multiple cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqo-qab7pG6E7Vg90H21EOLACvtfcHk0lgd2fGYbXDcYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsFCqtrg%253D&md5=3ce57c281fdc663115a794ac7e91f177</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-0127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-0127%26sid%3Dliteratum%253Aachs%26aulast%3DKasibhatla%26aufirst%3DS.%26aulast%3DBaichwal%26aufirst%3DV.%26aulast%3DCai%26aufirst%3DS.%2BX.%26aulast%3DRoth%26aufirst%3DB.%26aulast%3DSkvortsova%26aufirst%3DI.%26aulast%3DSkvortsov%26aufirst%3DS.%26aulast%3DLukas%26aufirst%3DP.%26aulast%3DEnglish%26aufirst%3DN.%2BM.%26aulast%3DSirisoma%26aufirst%3DN.%26aulast%3DDrewe%26aufirst%3DJ.%26aulast%3DPervin%26aufirst%3DA.%26aulast%3DTseng%26aufirst%3DB.%26aulast%3DCarlson%26aufirst%3DR.%2BO.%26aulast%3DPleiman%26aufirst%3DC.%2BM.%26atitle%3DMPC-6827%253A%2520a%2520small-molecule%2520inhibitor%2520of%2520microtubule%2520formation%2520that%2520is%2520not%2520a%2520substrate%2520for%2520multidrug%2520resistance%2520pumps%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D5865%26epage%3D5871%26doi%3D10.1158%2F0008-5472.CAN-07-0127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group">Sirisoma, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pervin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willardsen, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mather, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pleiman, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasibhatla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drewe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, S. X.</span><span> </span><span class="NLM_article-title">Discovery of N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine, a potent apoptosis inducer and efficacious anticancer agent with high blood brain barrier penetration</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">2341</span><span class="NLM_x">–</span> <span class="NLM_lpage">2351</span><span class="refDoi"> DOI: 10.1021/jm801315b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801315b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtlensL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2341-2351&author=N.+Sirisomaauthor=A.+Pervinauthor=H.+Zhangauthor=S.+Jiangauthor=J.+A.+Willardsenauthor=M.+B.+Andersonauthor=G.+Matherauthor=C.+M.+Pleimanauthor=S.+Kasibhatlaauthor=B.+Tsengauthor=J.+Dreweauthor=S.+X.+Cai&title=Discovery+of+N-%284-methoxyphenyl%29-N%2C2-dimethylquinazolin-4-amine%2C+a+potent+apoptosis+inducer+and+efficacious+anticancer+agent+with+high+blood+brain+barrier+penetration&doi=10.1021%2Fjm801315b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-(4-Methoxyphenyl)-N,2-dimethylquinazolin-4-amine, a Potent Apoptosis Inducer and Efficacious Anticancer Agent with High Blood Brain Barrier Penetration</span></div><div class="casAuthors">Sirisoma, Nilantha; Pervin, Azra; Zhang, Hong; Jiang, Songchun; Willardsen, J. Adam; Anderson, Mark B.; Mather, Gary; Pleiman, Christopher M.; Kasibhatla, Shailaja; Tseng, Ben; Drewe, John; Cai, Sui Xiong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2341-2351</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">As a continuation of our structure-activity relationship (SAR) studies on 4-anilinoquinazolines as potent apoptosis inducers and to identify anticancer development candidates, we explored the replacement of the 2-Cl group in our lead compd. 2-chloro-N-(4-methoxyphenyl)-N-methylquinazolin-4-amine (I) (, EP128265, MPI-0441138) by other functional groups.  This SAR study and lead optimization resulted in the identification of N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine ( (II), EP128495, MPC-6827) as an anticancer clin. candidate.  Compd.(I) was found to be a potent apoptosis inducer with EC50 of 2 nM in our cell-based apoptosis induction assay.  It also has excellent blood brain barrier penetration, and is highly efficacious in human MX-1 breast and other mouse xenograft cancer models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkdiJFWdOwYrVg90H21EOLACvtfcHk0lhULVbniaUeQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtlensL0%253D&md5=811ef9a923d386a43d7f0d010f996566</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Fjm801315b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801315b%26sid%3Dliteratum%253Aachs%26aulast%3DSirisoma%26aufirst%3DN.%26aulast%3DPervin%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DWillardsen%26aufirst%3DJ.%2BA.%26aulast%3DAnderson%26aufirst%3DM.%2BB.%26aulast%3DMather%26aufirst%3DG.%26aulast%3DPleiman%26aufirst%3DC.%2BM.%26aulast%3DKasibhatla%26aufirst%3DS.%26aulast%3DTseng%26aufirst%3DB.%26aulast%3DDrewe%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DS.%2BX.%26atitle%3DDiscovery%2520of%2520N-%25284-methoxyphenyl%2529-N%252C2-dimethylquinazolin-4-amine%252C%2520a%2520potent%2520apoptosis%2520inducer%2520and%2520efficacious%2520anticancer%2520agent%2520with%2520high%2520blood%2520brain%2520barrier%2520penetration%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2341%26epage%3D2351%26doi%3D10.1021%2Fjm801315b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group">Canela, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liekens, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camarasa, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Priego, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pérez-Pérez, M. J.</span><span> </span><span class="NLM_article-title">Synthesis and antiproliferative activity of 6-phenylaminopurines</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">421</span><span class="NLM_x">–</span> <span class="NLM_lpage">428</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2014.09.093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.ejmech.2014.09.093" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2014&pages=421-428&author=M.+D.+Canelaauthor=S.+Liekensauthor=M.+J.+Camarasaauthor=E.+M.+Priegoauthor=M.+J.+P%C3%A9rez-P%C3%A9rez&title=Synthesis+and+antiproliferative+activity+of+6-phenylaminopurines&doi=10.1016%2Fj.ejmech.2014.09.093"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.09.093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.09.093%26sid%3Dliteratum%253Aachs%26aulast%3DCanela%26aufirst%3DM.%2BD.%26aulast%3DLiekens%26aufirst%3DS.%26aulast%3DCamarasa%26aufirst%3DM.%2BJ.%26aulast%3DPriego%26aufirst%3DE.%2BM.%26aulast%3DP%25C3%25A9rez-P%25C3%25A9rez%26aufirst%3DM.%2BJ.%26atitle%3DSynthesis%2520and%2520antiproliferative%2520activity%2520of%25206-phenylaminopurines%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D87%26spage%3D421%26epage%3D428%26doi%3D10.1016%2Fj.ejmech.2014.09.093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghavan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risinger, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span> </span><span class="NLM_article-title">Synthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistance</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8116</span><span class="NLM_x">–</span> <span class="NLM_lpage">8128</span><span class="refDoi"> DOI: 10.1021/jm101010n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101010n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8116-8128&author=A.+Gangjeeauthor=Y.+Zhaoauthor=L.+Linauthor=S.+Raghavanauthor=E.+G.+Robertsauthor=A.+L.+Risingerauthor=E.+Hamelauthor=S.+L.+Mooberry&title=Synthesis+and+discovery+of+water-soluble+microtubule+targeting+agents+that+bind+to+the+colchicine+site+on+tubulin+and+circumvent+Pgp+mediated+resistance&doi=10.1021%2Fjm101010n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Fjm101010n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101010n%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DRaghavan%26aufirst%3DS.%26aulast%3DRoberts%26aufirst%3DE.%2BG.%26aulast%3DRisinger%26aufirst%3DA.%2BL.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26atitle%3DSynthesis%2520and%2520discovery%2520of%2520water-soluble%2520microtubule%2520targeting%2520agents%2520that%2520bind%2520to%2520the%2520colchicine%2520site%2520on%2520tubulin%2520and%2520circumvent%2520Pgp%2520mediated%2520resistance%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8116%26epage%3D8128%26doi%3D10.1021%2Fjm101010n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghavan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihnat, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorpe, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Disch, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey-Downs, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dybdal-Hargreaves, N. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohena, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gangjee, A.</span><span> </span><span class="NLM_article-title">The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2, 3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3753</span><span class="NLM_x">–</span> <span class="NLM_lpage">3772</span><span class="refDoi"> DOI: 10.1016/j.bmc.2014.04.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.bmc.2014.04.049" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=3753-3772&author=X.+Zhangauthor=S.+Raghavanauthor=M.+Ihnatauthor=J.+E.+Thorpeauthor=B.+C.+Dischauthor=A.+Bastianauthor=L.+C.+Bailey-Downsauthor=N.+F.+Dybdal-Hargreavesauthor=C.+C.+Rohenaauthor=E.+Hamelauthor=S.+L.+Mooberryauthor=A.+Gangjee&title=The+design+and+discovery+of+water+soluble+4-substituted-2%2C6-dimethylfuro%5B2%2C+3-d%5Dpyrimidines+as+multitargeted+receptor+tyrosine+kinase+inhibitors+and+microtubule+targeting+antitumor+agents&doi=10.1016%2Fj.bmc.2014.04.049"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.04.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.04.049%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DRaghavan%26aufirst%3DS.%26aulast%3DIhnat%26aufirst%3DM.%26aulast%3DThorpe%26aufirst%3DJ.%2BE.%26aulast%3DDisch%26aufirst%3DB.%2BC.%26aulast%3DBastian%26aufirst%3DA.%26aulast%3DBailey-Downs%26aufirst%3DL.%2BC.%26aulast%3DDybdal-Hargreaves%26aufirst%3DN.%2BF.%26aulast%3DRohena%26aufirst%3DC.%2BC.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26aulast%3DGangjee%26aufirst%3DA.%26atitle%3DThe%2520design%2520and%2520discovery%2520of%2520water%2520soluble%25204-substituted-2%252C6-dimethylfuro%255B2%252C%25203-d%255Dpyrimidines%2520as%2520multitargeted%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520and%2520microtubule%2520targeting%2520antitumor%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D3753%26epage%3D3772%26doi%3D10.1016%2Fj.bmc.2014.04.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">D’Amato, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span> </span><span class="NLM_article-title">2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">3964</span><span class="NLM_x">–</span> <span class="NLM_lpage">3968</span><span class="refDoi"> DOI: 10.1073/pnas.91.9.3964</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1073%2Fpnas.91.9.3964" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=3964-3968&author=R.+J.+D%E2%80%99Amatoauthor=C.+M.+Linauthor=E.+Flynnauthor=J.+Folkmanauthor=E.+Hamel&title=2-Methoxyestradiol%2C+an+endogenous+mammalian+metabolite%2C+inhibits+tubulin+polymerization+by+interacting+at+the+colchicine+site&doi=10.1073%2Fpnas.91.9.3964"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.9.3964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.9.3964%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Amato%26aufirst%3DR.%2BJ.%26aulast%3DLin%26aufirst%3DC.%2BM.%26aulast%3DFlynn%26aufirst%3DE.%26aulast%3DFolkman%26aufirst%3DJ.%26aulast%3DHamel%26aufirst%3DE.%26atitle%3D2-Methoxyestradiol%252C%2520an%2520endogenous%2520mammalian%2520metabolite%252C%2520inhibits%2520tubulin%2520polymerization%2520by%2520interacting%2520at%2520the%2520colchicine%2520site%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1994%26volume%3D91%26spage%3D3964%26epage%3D3968%26doi%3D10.1073%2Fpnas.91.9.3964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">Leese, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leblond, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Fiore, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Simone, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supuran, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Purohit, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potter, B. V. L.</span><span> </span><span class="NLM_article-title">2-Substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">7683</span><span class="NLM_x">–</span> <span class="NLM_lpage">7696</span><span class="refDoi"> DOI: 10.1021/jm060705x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060705x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=7683-7696&author=M.+P.+Leeseauthor=B.+Leblondauthor=A.+Smithauthor=S.+P.+Newmanauthor=A.+Di+Fioreauthor=G.+De+Simoneauthor=C.+T.+Supuranauthor=A.+Purohitauthor=M.+J.+Reedauthor=B.+V.+L.+Potter&title=2-Substituted+estradiol+bis-sulfamates%2C+multitargeted+antitumor+agents%3A+synthesis%2C+in+vitro+SAR%2C+protein+crystallography%2C+and+in+vivo+activity&doi=10.1021%2Fjm060705x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Fjm060705x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060705x%26sid%3Dliteratum%253Aachs%26aulast%3DLeese%26aufirst%3DM.%2BP.%26aulast%3DLeblond%26aufirst%3DB.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DNewman%26aufirst%3DS.%2BP.%26aulast%3DDi%2BFiore%26aufirst%3DA.%26aulast%3DDe%2BSimone%26aufirst%3DG.%26aulast%3DSupuran%26aufirst%3DC.%2BT.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DReed%26aufirst%3DM.%2BJ.%26aulast%3DPotter%26aufirst%3DB.%2BV.%2BL.%26atitle%3D2-Substituted%2520estradiol%2520bis-sulfamates%252C%2520multitargeted%2520antitumor%2520agents%253A%2520synthesis%252C%2520in%2520vitro%2520SAR%252C%2520protein%2520crystallography%252C%2520and%2520in%2520vivo%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D7683%26epage%3D7696%26doi%3D10.1021%2Fjm060705x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group">Stengel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leese, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potter, B. V. L</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Purohit, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, P. A.</span><span> </span><span class="NLM_article-title">The in vitro and in vivo activity of the microtubule disruptor STX140 is mediated by HIF-1 alpha and CAIX expression</span> <span class="citation_source-journal">Anticancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">5249</span><span class="NLM_x">–</span> <span class="NLM_lpage">5262</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=26408684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlt1arur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=5249-5262&author=C.+Stengelauthor=S.+P.+Newmanauthor=M.+P.+Leeseauthor=M.+P.+Thomasauthor=B.+V.+L+Potterauthor=M.+J.+Reedauthor=A.+Purohitauthor=P.+A.+Foster&title=The+in+vitro+and+in+vivo+activity+of+the+microtubule+disruptor+STX140+is+mediated+by+HIF-1+alpha+and+CAIX+expression"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">The In Vitro and In Vivo activity of the microtubule disruptor STX140 is mediated by Hif-1 Alpha and CAIX expression</span></div><div class="casAuthors">Stengel, Chloe; Newman, Simon P.; Leese, Mathew P.; Thomas, Mark p.; Potter, Barry V. l.; Reed, Michael j.; Purohit, Atul; Foster, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5249-5262</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">Tumor neo-angiogenesis is regulated, in part, by the hypoxia-inducible gene HIFI.  Evidence suggests HIFI assocs. with polymd. microtubules and traffics to the nucleus.  This study investigated the role of HIFI in mediating the antitumor activity of two steroid-based sulfamate ester microtubule disruptors, STX140 and STX243, in vitro and in vivo.  The effects of STX140, STX243 and the parental compd. 2-tnethoxyestradiol (STX66) can HIF 1α and H1F2α protein expression were assessed in vitro in MCF-7 and MDA-MB-231 cells cultured under hypoxia.  More pertinently, their effects were examd. on HIFI-regulated genes in vivo in mice bearing MCF-7 or MDA-MB-231 tumors.  The level of mRNA expression of vascular endothelial growth factor (VEGF), glucose transporter 1 (GLUTI), phosphoglycerate kinase (PGK), ATP-binding cassette sub family B member I (ABCB1) and carbonic anhydrase IX (CAIX) was quantified by Real-time Polymerase Chain Reaction (RT-PCR).  Despite inhibiting nuclear HIFI a protein accumulation under hypoxia in vitro, STX140 and STX243 did not significantly regulate the expression of four out of five HIF lα -regulated genes in vitro and in vivo.  Only CAIX mRNA expression was down-regulated both in vitro and in vivo.  Immunoblor anal. showed that STX140 and STX243 reduced CAIX protein expression in vitro.  These compds. had no effect on H1F2a translocation.  The potential for inhibition of CAIX by STX140 and STX243 was examd. by docking the ligands to the active site in comparison with a known sulfwnate-based inhibitor.  Microtubule disruption and antitumor activity of STX140 and STX243 is most likely HIFI-independent and may, at least in part, be mediated by inhibition of CAIX expression and activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_YLkURrop_LVg90H21EOLACvtfcHk0ljxD3Q9cMkHJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlt1arur4%253D&md5=c7a07b09751f132c2e43a8ff0c058c68</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStengel%26aufirst%3DC.%26aulast%3DNewman%26aufirst%3DS.%2BP.%26aulast%3DLeese%26aufirst%3DM.%2BP.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DPotter%26aufirst%3DB.%2BV.%2BL%26aulast%3DReed%26aufirst%3DM.%2BJ.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DFoster%26aufirst%3DP.%2BA.%26atitle%3DThe%2520in%2520vitro%2520and%2520in%2520vivo%2520activity%2520of%2520the%2520microtubule%2520disruptor%2520STX140%2520is%2520mediated%2520by%2520HIF-1%2520alpha%2520and%2520CAIX%2520expression%26jtitle%3DAnticancer%2520Res.%26date%3D2015%26volume%3D35%26spage%3D5249%26epage%3D5262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group">Leese, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jourdan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dohle, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimberley, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrandis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potter, B. V. L.</span><span> </span><span class="NLM_article-title">Steroidomimetic tetrahydroisoquinolines for the design of new microtubule disruptors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span><span class="refDoi"> DOI: 10.1021/ml200232c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200232c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=5-9&author=M.+P.+Leeseauthor=F.+Jourdanauthor=W.+Dohleauthor=M.+R.+Kimberleyauthor=M.+P.+Thomasauthor=R.+Baiauthor=E.+Hamelauthor=E.+Ferrandisauthor=B.+V.+L.+Potter&title=Steroidomimetic+tetrahydroisoquinolines+for+the+design+of+new+microtubule+disruptors&doi=10.1021%2Fml200232c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Fml200232c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200232c%26sid%3Dliteratum%253Aachs%26aulast%3DLeese%26aufirst%3DM.%2BP.%26aulast%3DJourdan%26aufirst%3DF.%26aulast%3DDohle%26aufirst%3DW.%26aulast%3DKimberley%26aufirst%3DM.%2BR.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DBai%26aufirst%3DR.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DFerrandis%26aufirst%3DE.%26aulast%3DPotter%26aufirst%3DB.%2BV.%2BL.%26atitle%3DSteroidomimetic%2520tetrahydroisoquinolines%2520for%2520the%2520design%2520of%2520new%2520microtubule%2520disruptors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D5%26epage%3D9%26doi%3D10.1021%2Fml200232c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group">Pasquier, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinnappan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munoz, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kavallaris, M.</span><span> </span><span class="NLM_article-title">ENMD-1198, a new analogue of 2-methoxyestradiol, displays both antiangiogenic and vascular-disrupting properties</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1408</span><span class="NLM_x">–</span> <span class="NLM_lpage">1418</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0894</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1158%2F1535-7163.MCT-09-0894" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=20442304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlslektLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1408-1418&author=E.+Pasquierauthor=S.+Sinnappanauthor=M.+A.+Munozauthor=M.+Kavallaris&title=ENMD-1198%2C+a+new+analogue+of+2-methoxyestradiol%2C+displays+both+antiangiogenic+and+vascular-disrupting+properties&doi=10.1158%2F1535-7163.MCT-09-0894"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">ENMD-1198, a New Analogue of 2-Methoxyestradiol, Displays Both Antiangiogenic and Vascular-Disrupting Properties</span></div><div class="casAuthors">Pasquier, Eddy; Sinnappan, Snega; Munoz, Marcia A.; Kavallaris, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1408-1418</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The formation of a new vascular network by angiogenesis is a key driver in tumor growth and metastasis, making this an attractive therapeutic target.  Different strategies are being developed to either prevent tumor angiogenesis or disrupt the tumor vasculature already in place.  In this in vitro study, we investigated the antivascular properties of ENMD-1198, a new anticancer drug currently in clin. trials.  ENMD-1198 is a new analog of 2-methoxyestradiol, a microtubule-targeting agent that has shown promising results in the treatment of multiple myeloma and hormone-refractory prostate cancer.  Using both bone marrow-derived and dermal microvascular endothelial cell lines, we analyzed the effect of ENMD-1198 on the different functions of endothelial cells involved in angiogenesis.  In both cell lines, ENMD-1198 was more potent than 2-methoxyestradiol at inhibiting endothelial cell proliferation, motility, migration, and morphogenesis.  In addn., ENMD-1198 induced a significant decrease in vascular endothelial growth factor receptor-2 protein expression in endothelial cells.  Furthermore, videomicroscopy expts. showed that ENMD-1198 was able to completely disrupt preformed vascular structures within 2 h.  This vascular-disrupting activity was assocd. with extensive depolymn. of the microtubule network and accumulation of actin stress fibers and large focal adhesions in vascular endothelial cells.  Collectively, our results show that this new compd. displays potent antivascular properties, and this study provides important insights into the mechanism of action of this promising new anticancer drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3pqJlCJsshrVg90H21EOLACvtfcHk0lhLVmL0guTkQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlslektLc%253D&md5=a0582514ec05fc4a03b3cea635d2df17</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0894%26sid%3Dliteratum%253Aachs%26aulast%3DPasquier%26aufirst%3DE.%26aulast%3DSinnappan%26aufirst%3DS.%26aulast%3DMunoz%26aufirst%3DM.%2BA.%26aulast%3DKavallaris%26aufirst%3DM.%26atitle%3DENMD-1198%252C%2520a%2520new%2520analogue%2520of%25202-methoxyestradiol%252C%2520displays%2520both%2520antiangiogenic%2520and%2520vascular-disrupting%2520properties%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D1408%26epage%3D1418%26doi%3D10.1158%2F1535-7163.MCT-09-0894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group">Nogales, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downing, K. H.</span><span> </span><span class="NLM_article-title">Structure of the αβ tubulin dimer by electron crystallography</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">391</span><span class="NLM_x">, </span> <span class="NLM_fpage">199</span><span class="NLM_x">–</span> <span class="NLM_lpage">203</span><span class="refDoi"> DOI: 10.1038/34465</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1038%2F34465" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=9428769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADyaK1cXmt1Kisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=391&publication_year=1998&pages=199-203&author=E.+Nogalesauthor=S.+G.+Wolfauthor=K.+H.+Downing&title=Structure+of+the+%CE%B1%CE%B2+tubulin+dimer+by+electron+crystallography&doi=10.1038%2F34465"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the αβ tubulin dimer by electron crystallography</span></div><div class="casAuthors">Nogales, Eva; Wolf, Sharon G.; Downing, Kenneth H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">391</span>
        (<span class="NLM_cas:issue">6663</span>),
    <span class="NLM_cas:pages">199-203</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">The αβ tubulin heterodimer is the structural subunit of microtubules, which are cytoskeletal elements that are essential for intracellular transport and cell division in all eukaryotes.  Each tubulin monomer binds a guanine nucleotide, which is nonexchangeable when it is bound in the α subunit, or N site, and exchangeable when bound in the β subunit, or E site.  The α- and β-tubulins share 40% amino-acid sequence identity, both exist in several isotype forms, and both undergo a variety of post-translational modifications.  Limited sequence homol. has been found with the proteins FtsZ and Misato, which are involved in cell division in bacteria and Drosophila, resp.  Here, the authors present an at. model of the αβ tubulin dimer fitted to a 3.7-Å d. map obtained by electron crystallog. of zinc-induced tubulin sheets.  The structures of α- and β-tubulin are basically identical: each monomer is formed by a core of two β-sheets surrounded by α-helixes.  The monomer structure is very compact, but can be divided into three functional domains: the amino-terminal domain contg. the nucleotide-binding region, an intermediate domain contg. the Taxol-binding site, and the carboxy-terminal domain, which probably constitutes the binding surface for motor proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKgcRV89nSo7Vg90H21EOLACvtfcHk0lhLVmL0guTkQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmt1Kisw%253D%253D&md5=6aa8d1a79a039f4f1ee7e665a6b4039d</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1038%2F34465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F34465%26sid%3Dliteratum%253Aachs%26aulast%3DNogales%26aufirst%3DE.%26aulast%3DWolf%26aufirst%3DS.%2BG.%26aulast%3DDowning%26aufirst%3DK.%2BH.%26atitle%3DStructure%2520of%2520the%2520%25CE%25B1%25CE%25B2%2520tubulin%2520dimer%2520by%2520electron%2520crystallography%26jtitle%3DNature%26date%3D1998%26volume%3D391%26spage%3D199%26epage%3D203%26doi%3D10.1038%2F34465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group">Löwe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downing, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nogales, E.</span><span> </span><span class="NLM_article-title">Refined structure of α,β-tubulin at 3.5 Å resolution</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">313</span><span class="NLM_x">, </span> <span class="NLM_fpage">1045</span><span class="NLM_x">–</span> <span class="NLM_lpage">1057</span><span class="refDoi"> DOI: 10.1006/jmbi.2001.5077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1006%2Fjmbi.2001.5077" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2001&pages=1045-1057&author=J.+L%C3%B6weauthor=H.+Liauthor=K.+H.+Downingauthor=E.+Nogales&title=Refined+structure+of+%CE%B1%2C%CE%B2-tubulin+at+3.5+%C3%85+resolution&doi=10.1006%2Fjmbi.2001.5077"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.2001.5077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.2001.5077%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6we%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DDowning%26aufirst%3DK.%2BH.%26aulast%3DNogales%26aufirst%3DE.%26atitle%3DRefined%2520structure%2520of%2520%25CE%25B1%252C%25CE%25B2-tubulin%2520at%25203.5%2520%25C3%2585%2520resolution%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2001%26volume%3D313%26spage%3D1045%26epage%3D1057%26doi%3D10.1006%2Fjmbi.2001.5077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Janke, C.</span><span> </span><span class="NLM_article-title">The tubulin code Molecular components, readout mechanisms, and functions</span> <span class="citation_source-journal">J. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">206</span><span class="NLM_x">, </span> <span class="NLM_fpage">461</span><span class="NLM_x">–</span> <span class="NLM_lpage">472</span><span class="refDoi"> DOI: 10.1083/jcb.201406055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1083%2Fjcb.201406055" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=206&publication_year=2014&pages=461-472&author=C.+Janke&title=The+tubulin+code+Molecular+components%2C+readout+mechanisms%2C+and+functions&doi=10.1083%2Fjcb.201406055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1083%2Fjcb.201406055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.201406055%26sid%3Dliteratum%253Aachs%26aulast%3DJanke%26aufirst%3DC.%26atitle%3DThe%2520tubulin%2520code%2520Molecular%2520components%252C%2520readout%2520mechanisms%252C%2520and%2520functions%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2014%26volume%3D206%26spage%3D461%26epage%3D472%26doi%3D10.1083%2Fjcb.201406055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Gigant, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curmi, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Barbey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charbaut, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachkar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebeau, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siavoshian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sobel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knossow, M.</span><span> </span><span class="NLM_article-title">The 4 Å X-Ray structure of a tubulin:stathmin-like domain complex</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">–</span> <span class="NLM_lpage">816</span><span class="refDoi"> DOI: 10.1016/S0092-8674(00)00069-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2FS0092-8674%2800%2900069-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2000&pages=809-816&author=B.+Gigantauthor=P.+A.+Curmiauthor=C.+Martin-Barbeyauthor=E.+Charbautauthor=S.+Lachkarauthor=L.+Lebeauauthor=S.+Siavoshianauthor=A.+Sobelauthor=M.+Knossow&title=The+4+%C3%85+X-Ray+structure+of+a+tubulin%3Astathmin-like+domain+complex&doi=10.1016%2FS0092-8674%2800%2900069-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2900069-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252900069-6%26sid%3Dliteratum%253Aachs%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DCurmi%26aufirst%3DP.%2BA.%26aulast%3DMartin-Barbey%26aufirst%3DC.%26aulast%3DCharbaut%26aufirst%3DE.%26aulast%3DLachkar%26aufirst%3DS.%26aulast%3DLebeau%26aufirst%3DL.%26aulast%3DSiavoshian%26aufirst%3DS.%26aulast%3DSobel%26aufirst%3DA.%26aulast%3DKnossow%26aufirst%3DM.%26atitle%3DThe%25204%2520%25C3%2585%2520X-Ray%2520structure%2520of%2520a%2520tubulin%253Astathmin-like%2520domain%2520complex%26jtitle%3DCell%26date%3D2000%26volume%3D102%26spage%3D809%26epage%3D816%26doi%3D10.1016%2FS0092-8674%2800%2900069-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group">Barbier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorléans, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devred, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanz, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allegro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfonso, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knossow, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peyrot, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreu, J. M.</span><span> </span><span class="NLM_article-title">Stathmin and interfacial microtubule inhibitors recognize a naturally curved conformation of tubulin dimers</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">285</span><span class="NLM_x">, </span> <span class="NLM_fpage">31672</span><span class="NLM_x">–</span> <span class="NLM_lpage">31681</span><span class="refDoi"> DOI: 10.1074/jbc.M110.141929</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1074%2Fjbc.M110.141929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=20675373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1aqt7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2010&pages=31672-31681&author=P.+Barbierauthor=A.+Dorl%C3%A9ansauthor=F.+Devredauthor=L.+Sanzauthor=D.+Allegroauthor=C.+Alfonsoauthor=M.+Knossowauthor=V.+Peyrotauthor=J.+M.+Andreu&title=Stathmin+and+interfacial+microtubule+inhibitors+recognize+a+naturally+curved+conformation+of+tubulin+dimers&doi=10.1074%2Fjbc.M110.141929"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Stathmin and Interfacial Microtubule Inhibitors Recognize a Naturally Curved Conformation of Tubulin Dimers</span></div><div class="casAuthors">Barbier, Pascale; Dorleans, Audrey; Devred, Francois; Sanz, Laura; Allegro, Diane; Alfonso, Carlos; Knossow, Marcel; Peyrot, Vincent; Andreu, Jose M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">31672-31681</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Tubulin is able to switch between a straight microtubule-like structure and a curved structure in complex with the stathmin-like domain (SLD) of the RB3 protein (T2RB3).  GTP hydrolysis following microtubule assembly induces protofilament curvature and disassembly.  The conformation of the labile αβ-tubulin heterodimers is unknown.  One important question is whether free GDP-tubulin dimers are straightened by GTP binding or whether GTP-tubulin is also curved and switches into a straight conformation upon assembly.  We have obtained insight into the bending flexibility of tubulin by analyzing the interplay of tubulin-stathmin assocn. with the binding of several small mol. inhibitors to the colchicine domain at the tubulin intradimer interface, combining structural and biochem. approaches.  The crystal structures of T2RB3 complexes with the chiral R and S isomers of ethyl-5-amino-2-methyl-1,2-dihydro-3-phenylpyrido[3,4-b]pyrazin-7-yl-carbamate, show that their binding site overlaps with colchicine ring A and that both complexes have the same curvature as unliganded T2RB3.  The binding of these ligands is incompatible with a straight tubulin structure in microtubules.  Anal. ultracentrifugation and binding measurements show that tubulin-stathmin assocns. (T2RB3, T2Stath) and binding of ligands (R, S, TN-16, or the colchicine analog MTC) are thermodynamically independent from one another, irresp. of tubulin being bound to GTP or GDP.  The fact that the interfacial ligands bind equally well to tubulin dimers or stathmin complexes supports a bent conformation of the free tubulin dimers.  It is tempting to speculate that stathmin evolved to recognize curved structures in unassembled and disassembling tubulin, thus regulating microtubule assembly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ08-xYl4OcbVg90H21EOLACvtfcHk0lghMthw5bGQhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1aqt7%252FP&md5=d889f62c22d8c6fcefb9dd8ab7d21e0e</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110.141929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110.141929%26sid%3Dliteratum%253Aachs%26aulast%3DBarbier%26aufirst%3DP.%26aulast%3DDorl%25C3%25A9ans%26aufirst%3DA.%26aulast%3DDevred%26aufirst%3DF.%26aulast%3DSanz%26aufirst%3DL.%26aulast%3DAllegro%26aufirst%3DD.%26aulast%3DAlfonso%26aufirst%3DC.%26aulast%3DKnossow%26aufirst%3DM.%26aulast%3DPeyrot%26aufirst%3DV.%26aulast%3DAndreu%26aufirst%3DJ.%2BM.%26atitle%3DStathmin%2520and%2520interfacial%2520microtubule%2520inhibitors%2520recognize%2520a%2520naturally%2520curved%2520conformation%2520of%2520tubulin%2520dimers%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2010%26volume%3D285%26spage%3D31672%26epage%3D31681%26doi%3D10.1074%2Fjbc.M110.141929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">Arce, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barra, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caputto, R.</span><span> </span><span class="NLM_article-title">Incorporation of L-tyrosine, L-phenylalanine and L-3,4-dihydroxyphenylalanine as single units into rat-brain tubulin</span> <span class="citation_source-journal">Eur. J. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1975</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">145</span><span class="NLM_x">–</span> <span class="NLM_lpage">149</span><span class="refDoi"> DOI: 10.1111/j.1432-1033.1975.tb02435.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1111%2Fj.1432-1033.1975.tb02435.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1204603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADyaE28XhtlKitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1975&pages=145-149&author=C.+A.+Arceauthor=J.+A.+Rodriguezauthor=H.+S.+Barraauthor=R.+Caputto&title=Incorporation+of+L-tyrosine%2C+L-phenylalanine+and+L-3%2C4-dihydroxyphenylalanine+as+single+units+into+rat-brain+tubulin&doi=10.1111%2Fj.1432-1033.1975.tb02435.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Incorporation of L-tyrosine, L-phenylalanine, and L-3,4-dihydroxyphenylalanine as single units into rat brain tubulin</span></div><div class="casAuthors">Arce, Carlos A.; Rodriguez, Julio A.; Barra, Hector S.; Caputto, Ranwel</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">145-9</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    </div><div class="casAbstract">The product of the incorporation of tyrosine-14C as single unit into a protein of the sol. fraction of rat brain homogenate was purified by following a procedure used to purify tubulin.  Na dodecyl sulfate-polyacrylamide gel electrophoresis of the purified material showed a single protein band contg. all the radioactivity and accounting for 10.2% of the total protein of the supernatant fraction.  The incorporated tyrosine was found in the α-subunit of tubulin.  Protein labeled with colchicine-3H and tyrosine-14C was pptd. with vinblastine sulfate and the radioactivity of 3H and that of 14C were quant. recovered in the ppt. (98%).  Na dodecyl sulfate-polyacrylamide gel electrophoresis of the vinblastine ppt. showed that the 14C radioactivity moved with the tubulin band.  Results obtained in expts. with phenylalanine and 3,4-dihydroxyphenylalanine were identical to those obtained for tyrosine.  About 30% of tubulin from rat brain supernatant fraction could incorporate tyrosine as single unit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVas0MpjDTO7Vg90H21EOLACvtfcHk0lghMthw5bGQhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28XhtlKitA%253D%253D&md5=9f81b33a07940656529a268934cb1c7d</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1111%2Fj.1432-1033.1975.tb02435.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1432-1033.1975.tb02435.x%26sid%3Dliteratum%253Aachs%26aulast%3DArce%26aufirst%3DC.%2BA.%26aulast%3DRodriguez%26aufirst%3DJ.%2BA.%26aulast%3DBarra%26aufirst%3DH.%2BS.%26aulast%3DCaputto%26aufirst%3DR.%26atitle%3DIncorporation%2520of%2520L-tyrosine%252C%2520L-phenylalanine%2520and%2520L-3%252C4-dihydroxyphenylalanine%2520as%2520single%2520units%2520into%2520rat-brain%2520tubulin%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1975%26volume%3D59%26spage%3D145%26epage%3D149%26doi%3D10.1111%2Fj.1432-1033.1975.tb02435.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group">Prota, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magiera, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuijpers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bargsten, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frey, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wieser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaussi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoogenraad, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kammerer, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janke, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmetz, M. O.</span><span> </span><span class="NLM_article-title">Structural basis of tubulin tyrosination by tubulin tyrosine ligase</span> <span class="citation_source-journal">J. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">200</span><span class="NLM_x">, </span> <span class="NLM_fpage">259</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span><span class="refDoi"> DOI: 10.1083/jcb.201211017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1083%2Fjcb.201211017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=23358242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitFemsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=200&publication_year=2013&pages=259-270&author=A.+E.+Protaauthor=M.+M.+Magieraauthor=M.+Kuijpersauthor=K.+Bargstenauthor=D.+Freyauthor=M.+Wieserauthor=R.+Jaussiauthor=C.+C.+Hoogenraadauthor=R.+A.+Kammererauthor=C.+Jankeauthor=M.+O.+Steinmetz&title=Structural+basis+of+tubulin+tyrosination+by+tubulin+tyrosine+ligase&doi=10.1083%2Fjcb.201211017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of tubulin tyrosination by tubulin tyrosine ligase</span></div><div class="casAuthors">Prota, Andrea E.; Magiera, Maria M.; Kuijpers, Marijn; Bargsten, Katja; Frey, Daniel; Wieser, Mara; Jaussi, Rolf; Hoogenraad, Casper C.; Kammerer, Richard A.; Janke, Carsten; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">200</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">259-270</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Tubulin tyrosine ligase (TTL) catalyzes the post-translational retyrosination of detyrosinated α-tubulin.  Despite the indispensable role of TTL in cell and organism development, its mol. mechanism of action is poorly understood.  By solving crystal structures of TTL in complex with tubulin, we here demonstrate that TTL binds to the α and β subunits of tubulin and recognizes the curved conformation of the dimer.  Biochem. and cellular assays revealed that specific tubulin dimer recognition controls the activity of the enzyme, and as a consequence, neuronal development.  The TTL-tubulin structure further illustrates how the enzyme binds the functionally crucial C-terminal tail sequence of α-tubulin and how this interaction catalyzes the tyrosination reaction.  It also reveals how TTL discriminates between α- and β-tubulin, and between different post-translationally modified forms of α-tubulin.  Together, our data suggest that TTL has specifically evolved to recognize and modify tubulin, thus highlighting a fundamental role of the evolutionary conserved tubulin tyrosination cycle in regulating the microtubule cytoskeleton.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC0GnzXPTwGrVg90H21EOLACvtfcHk0lghMthw5bGQhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitFemsb8%253D&md5=fac60a4c8cefab58a1a8df0d2eaea949</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1083%2Fjcb.201211017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.201211017%26sid%3Dliteratum%253Aachs%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DMagiera%26aufirst%3DM.%2BM.%26aulast%3DKuijpers%26aufirst%3DM.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DFrey%26aufirst%3DD.%26aulast%3DWieser%26aufirst%3DM.%26aulast%3DJaussi%26aufirst%3DR.%26aulast%3DHoogenraad%26aufirst%3DC.%2BC.%26aulast%3DKammerer%26aufirst%3DR.%2BA.%26aulast%3DJanke%26aufirst%3DC.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DStructural%2520basis%2520of%2520tubulin%2520tyrosination%2520by%2520tubulin%2520tyrosine%2520ligase%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2013%26volume%3D200%26spage%3D259%26epage%3D270%26doi%3D10.1083%2Fjcb.201211017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group">Prota, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bargsten, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zurwerra, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Field, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altmann, K.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmetz, M. O.</span><span> </span><span class="NLM_article-title">Molecular mechanism of action of microtubule-stabilizing anticancer agents</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">339</span><span class="NLM_x">, </span> <span class="NLM_fpage">587</span><span class="NLM_x">–</span> <span class="NLM_lpage">590</span><span class="refDoi"> DOI: 10.1126/science.1230582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1126%2Fscience.1230582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=23287720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFGrsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2013&pages=587-590&author=A.+E.+Protaauthor=K.+Bargstenauthor=D.+Zurwerraauthor=J.+J.+Fieldauthor=J.+F.+Diazauthor=K.-H.+Altmannauthor=M.+O.+Steinmetz&title=Molecular+mechanism+of+action+of+microtubule-stabilizing+anticancer+agents&doi=10.1126%2Fscience.1230582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Mechanism of Action of Microtubule-Stabilizing Anticancer Agents</span></div><div class="casAuthors">Prota, Andrea E.; Bargsten, Katja; Zurwerra, Didier; Field, Jessica J.; Diaz, Jose Fernando; Altmann, Karl-Heinz; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">6119</span>),
    <span class="NLM_cas:pages">587-590</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Microtubule-stabilizing agents (MSAs) are efficacious chemotherapeutic drugs widely used for the treatment of cancer.  Despite the importance of MSAs for medical applications and basic research, their mol. mechanisms of action on tubulin and microtubules remain elusive.  We detd. high-resoln. crystal structures of αβ-tubulin in complex with two unrelated MSAs, zampanolide and epothilone A.  Both compds. were bound to the taxane pocket of β-tubulin and used their resp. side chains to induce structuring of the M-loop into a short helix.  Because the M-loop establishes lateral tubulin contacts in microtubules, these findings explain how taxane-site MSAs promote microtubule assembly and stability.  Further, our results offer fundamental structural insights into the control mechanisms of microtubule dynamics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_p8NfCWTU-rVg90H21EOLACvtfcHk0lgCsXsfa1NhzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFGrsrw%253D&md5=b253c015f75f5eac4857d01e34d65f54</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1126%2Fscience.1230582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1230582%26sid%3Dliteratum%253Aachs%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DZurwerra%26aufirst%3DD.%26aulast%3DField%26aufirst%3DJ.%2BJ.%26aulast%3DDiaz%26aufirst%3DJ.%2BF.%26aulast%3DAltmann%26aufirst%3DK.-H.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DMolecular%2520mechanism%2520of%2520action%2520of%2520microtubule-stabilizing%2520anticancer%2520agents%26jtitle%3DScience%26date%3D2013%26volume%3D339%26spage%3D587%26epage%3D590%26doi%3D10.1126%2Fscience.1230582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group">Prota, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danel, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bargsten, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buey, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pohlmann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinelt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmetz, M. O.</span><span> </span><span class="NLM_article-title">The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">426</span><span class="NLM_x">, </span> <span class="NLM_fpage">1848</span><span class="NLM_x">–</span> <span class="NLM_lpage">1860</span><span class="refDoi"> DOI: 10.1016/j.jmb.2014.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.jmb.2014.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=24530796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlSrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=426&publication_year=2014&pages=1848-1860&author=A.+E.+Protaauthor=F.+Danelauthor=F.+Bachmannauthor=K.+Bargstenauthor=R.+M.+Bueyauthor=J.+Pohlmannauthor=S.+Reineltauthor=H.+Laneauthor=M.+O.+Steinmetz&title=The+novel+microtubule-destabilizing+drug+BAL27862+binds+to+the+colchicine+site+of+tubulin+with+distinct+effects+on+microtubule+organization&doi=10.1016%2Fj.jmb.2014.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">The Novel Microtubule-Destabilizing Drug BAL27862 Binds to the Colchicine Site of Tubulin with Distinct Effects on Microtubule Organization</span></div><div class="casAuthors">Prota, Andrea E.; Danel, Franck; Bachmann, Felix; Bargsten, Katja; Buey, Ruben M.; Pohlmann, Jens; Reinelt, Stefan; Lane, Heidi; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">426</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1848-1860</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Microtubule-targeting agents are widely used for the treatment of cancer and as tool compds. to study the microtubule cytoskeleton.  BAL27862 is a novel microtubule-destabilizing drug that is currently undergoing phase I clin. evaluation as the prodrug BAL101553.  The drug is a potent inhibitor of tumor cell growth and shows a promising activity profile in a panel of human cancer models resistant to clin. relevant microtubule-targeting agents.  Here, we evaluated the mol. mechanism of the tubulin-BAL27862 interaction using a combination of cell biol., biochem. and structural biol. methods.  Tubulin-binding assays revealed that BAL27862 potently inhibited tubulin assembly at 37 °C with an IC50 of 1.4 μM and bound to unassembled tubulin with a stoichiometry of 1 mol/mol tubulin and a dissocn. const. of 244 ± 30 nM.  BAL27862 bound to tubulin independently of vinblastine, without the formation of tubulin oligomers.  The kinetics of BAL27862 binding to tubulin were distinct from those of colchicine, with evidence of competition between BAL27862 and colchicine for binding.  Detn. of the tubulin-BAL27862 structure by X-ray crystallog. demonstrated that BAL27862 binds to the same site as colchicine at the intradimer interface.  Comparison of crystal structures of tubulin-BAL27862 and tubulin-colchicine complexes shows that the binding mode of BAL27862 to tubulin is similar to that of colchicine.  However, comparative analyses of the effects of BAL27862 and colchicine on the microtubule mitotic spindle and in tubulin protease-protection expts. suggest different outcomes of tubulin binding.  Taken together, our data define BAL27862 as a potent, colchicine site-binding, microtubule-destabilizing agent with distinct effects on microtubule organization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIsVCA_6rcHLVg90H21EOLACvtfcHk0lgCsXsfa1NhzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlSrtrs%253D&md5=147ddbbfe5b90157cb8b2e04e1791668</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2014.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2014.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DDanel%26aufirst%3DF.%26aulast%3DBachmann%26aufirst%3DF.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DBuey%26aufirst%3DR.%2BM.%26aulast%3DPohlmann%26aufirst%3DJ.%26aulast%3DReinelt%26aufirst%3DS.%26aulast%3DLane%26aufirst%3DH.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DThe%2520novel%2520microtubule-destabilizing%2520drug%2520BAL27862%2520binds%2520to%2520the%2520colchicine%2520site%2520of%2520tubulin%2520with%2520distinct%2520effects%2520on%2520microtubule%2520organization%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2014%26volume%3D426%26spage%3D1848%26epage%3D1860%26doi%3D10.1016%2Fj.jmb.2014.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group">Prota, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bargsten, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuevas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liniger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuhaus, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreu, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altmann, K.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmetz, M. O.</span><span> </span><span class="NLM_article-title">A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">13817</span><span class="NLM_x">–</span> <span class="NLM_lpage">13821</span><span class="refDoi"> DOI: 10.1073/pnas.1408124111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1073%2Fpnas.1408124111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=25114240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCju7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=13817-13821&author=A.+E.+Protaauthor=K.+Bargstenauthor=J.+F.+Diazauthor=M.+Marshauthor=C.+Cuevasauthor=M.+Linigerauthor=C.+Neuhausauthor=J.+M.+Andreuauthor=K.-H.+Altmannauthor=M.+O.+Steinmetz&title=A+new+tubulin-binding+site+and+pharmacophore+for+microtubule-destabilizing+anticancer+drugs&doi=10.1073%2Fpnas.1408124111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs</span></div><div class="casAuthors">Prota, Andrea E.; Bargsten, Katja; Diaz, J. Fernando; Marsh, May; Cuevas, Carmen; Liniger, Marc; Neuhaus, Christian; Andreu, Jose M.; Altmann, Karl-Heinz; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">13817-13821</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The recent success of antibody-drug conjugates (ADCs) in the treatment of cancer has led to a revived interest in microtubule-destabilizing agents.  Here, we detd. the high-resoln. crystal structure of the complex between tubulin and maytansine, which is part of an ADC that is approved by the US Food and Drug Administration (FDA) for the treatment of advanced breast cancer.  We found that the drug binds to a site on β-tubulin that is distinct from the vinca domain and that blocks the formation of longitudinal tubulin interactions in microtubules.  We also solved crystal structures of tubulin in complex with both a variant of rhizoxin and the phase 1 drug PM060184.  Consistent with biochem. and mutagenesis data, we found that the two compds. bound to the same site as maytansine and that the structures revealed a common pharmacophore for the three ligands.  Our results delineate a distinct mol. mechanism of action for the inhibition of microtubule assembly by clin. relevant agents.  They further provide a structural basis for the rational design of potent microtubule-destabilizing agents, thus opening opportunities for the development of next-generation ADCs for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX4icqk698gLVg90H21EOLACvtfcHk0lgCsXsfa1NhzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCju7vM&md5=798cae320e427ff76c2099387d9e6ba4</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1408124111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1408124111%26sid%3Dliteratum%253Aachs%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DDiaz%26aufirst%3DJ.%2BF.%26aulast%3DMarsh%26aufirst%3DM.%26aulast%3DCuevas%26aufirst%3DC.%26aulast%3DLiniger%26aufirst%3DM.%26aulast%3DNeuhaus%26aufirst%3DC.%26aulast%3DAndreu%26aufirst%3DJ.%2BM.%26aulast%3DAltmann%26aufirst%3DK.-H.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DA%2520new%2520tubulin-binding%2520site%2520and%2520pharmacophore%2520for%2520microtubule-destabilizing%2520anticancer%2520drugs%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D13817%26epage%3D13821%26doi%3D10.1073%2Fpnas.1408124111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group">McNamara, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senese, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeates, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torres, J. Z.</span><span> </span><span class="NLM_article-title">Structures of potent anticancer compounds bound to tubulin</span> <span class="citation_source-journal">Protein Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1164</span><span class="NLM_x">–</span> <span class="NLM_lpage">1172</span><span class="refDoi"> DOI: 10.1002/pro.2704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1002%2Fpro.2704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=25970265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2MXovV2ksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=1164-1172&author=D.+E.+McNamaraauthor=S.+Seneseauthor=T.+O.+Yeatesauthor=J.+Z.+Torres&title=Structures+of+potent+anticancer+compounds+bound+to+tubulin&doi=10.1002%2Fpro.2704"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of potent anticancer compounds bound to tubulin</span></div><div class="casAuthors">McNamara, Dan E.; Senese, Silvia; Yeates, Todd O.; Torres, Jorge Z.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1164-1172</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Small mols. that bind to tubulin exert powerful effects on cell division and apoptosis (programmed cell death).  Cell-based high-throughput screening combined with chemo/bioinformatic and biochem. analyses recently revealed a novel compd. MI-181 as a potent mitotic inhibitor with heightened activity towards melanomas.  MI-181 causes tubulin depolymn., activates the spindle assembly checkpoint arresting cells in mitosis, and induces apoptotic cell death.  C2 is an unrelated compd. previously shown to have lethal effects on microtubules in tumorigenic cell lines.  We report 2.60 Å and 3.75 Å resoln. structures of MI-181 and C2, resp., bound to a ternary complex of αβ-tubulin, the tubulin-binding protein stathmin, and tubulin tyrosine ligase.  In the first of these structures, our crystallog. results reveal a unique binding mode for MI-181 extending unusually deep into the well-studied colchicine-binding site on β-tubulin.  In the second structure the C2 compd. occupies the colchicine-binding site on β-tubulin with two chem. moieties recapitulating contacts made by colchicine, in combination with another system of at. contacts.  These insights reveal the source of the obsd. effects of MI-181 and C2 on microtubules, mitosis, and cultured cancer cell lines.  The structural details of the interaction between tubulin and the described compds. may guide the development of improved deriv. compds. as therapeutic candidates or mol. probes to study cancer cell division.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUeszHaBRf07Vg90H21EOLACvtfcHk0lg_v73e20qiXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXovV2ksbs%253D&md5=7a37db0aa66e0d2281bcf8f6c8140825</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1002%2Fpro.2704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.2704%26sid%3Dliteratum%253Aachs%26aulast%3DMcNamara%26aufirst%3DD.%2BE.%26aulast%3DSenese%26aufirst%3DS.%26aulast%3DYeates%26aufirst%3DT.%2BO.%26aulast%3DTorres%26aufirst%3DJ.%2BZ.%26atitle%3DStructures%2520of%2520potent%2520anticancer%2520compounds%2520bound%2520to%2520tubulin%26jtitle%3DProtein%2520Sci.%26date%3D2015%26volume%3D24%26spage%3D1164%26epage%3D1172%26doi%3D10.1002%2Fpro.2704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group">Deng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuaqui, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span> </span><span class="NLM_article-title">Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein–ligand binding interactions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">337</span><span class="NLM_x">–</span> <span class="NLM_lpage">344</span><span class="refDoi"> DOI: 10.1021/jm030331x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030331x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1yrsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=337-344&author=Z.+Dengauthor=C.+Chuaquiauthor=J.+Singh&title=Structural+interaction+fingerprint+%28SIFt%29%3A+a+novel+method+for+analyzing+three-dimensional+protein%E2%80%93ligand+binding+interactions&doi=10.1021%2Fjm030331x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Interaction Fingerprint (SIFt): A Novel Method for Analyzing Three-Dimensional Protein-Ligand Binding Interactions</span></div><div class="casAuthors">Deng, Zhan; Chuaqui, Claudio; Singh, Juswinder</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">337-344</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Representing and understanding the three-dimensional (3D) structural information of protein-ligand complexes is a crit. step in the rational drug discovery process.  Traditional anal. methods are proving inadequate and inefficient in dealing with the massive amt. of structural information being generated from x-ray crystallog., NMR, and in silico approaches such as structure-based docking expts.  Here, we present SIFt (structural interaction fingerprint), a novel method for representing and analyzing 3D protein-ligand binding interactions.  Key to this approach is the generation of an interaction fingerprint that translates 3D structural binding information from a protein-ligand complex into a one-dimensional binary string.  Each fingerprint represents the "structural interaction profile" of the complex that can be used to organize, analyze, and visualize the rich amt. of information encoded in ligand-receptor complexes and also to assist database mining.  We have applied SIFt to tackle three common tasks in structure-based drug design.  The first involved the anal. and organization of a typical set of results generated from a docking study.  Using SIFt, docking poses with similar binding modes were identified, clustered, and subsequently compared with conventional scoring function information.  A second application of SIFt was to analyze ∼90 known x-ray crystal structures of protein kinase-inhibitor complexes obtained from the Protein Databank.  Using SIFt, we were able to organize the structures and reveal striking similarities and diversity between their small mol. binding interactions.  Finally, we have shown how SIFt can be used as an effective mol. filter during the virtual chem. library screening process to select mols. with desirable binding mode(s) and/or desirable interaction patterns with the protein target.  In summary, SIFt shows promise to fully leverage the wealth of information being generated in rational drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkjji1ni0HHbVg90H21EOLACvtfcHk0lg_v73e20qiXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1yrsrs%253D&md5=a652b70184155c107202cbe3bc74596a</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1021%2Fjm030331x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030331x%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DZ.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DSingh%26aufirst%3DJ.%26atitle%3DStructural%2520interaction%2520fingerprint%2520%2528SIFt%2529%253A%2520a%2520novel%2520method%2520for%2520analyzing%2520three-dimensional%2520protein%25E2%2580%2593ligand%2520binding%2520interactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D337%26epage%3D344%26doi%3D10.1021%2Fjm030331x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group">Pecqueur, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duellberg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plueckthun, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surrey, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gigant, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knossow, M.</span><span> </span><span class="NLM_article-title">A designed ankyrin repeat protein selected to bind to tubulin caps the microtubule plus end</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">12011</span><span class="NLM_x">–</span> <span class="NLM_lpage">12016</span><span class="refDoi"> DOI: 10.1073/pnas.1204129109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1073%2Fpnas.1204129109" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=12011-12016&author=L.+Pecqueurauthor=C.+Duellbergauthor=B.+Dreierauthor=Q.+Jiangauthor=C.+Wangauthor=A.+Plueckthunauthor=T.+Surreyauthor=B.+Gigantauthor=M.+Knossow&title=A+designed+ankyrin+repeat+protein+selected+to+bind+to+tubulin+caps+the+microtubule+plus+end&doi=10.1073%2Fpnas.1204129109"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1204129109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1204129109%26sid%3Dliteratum%253Aachs%26aulast%3DPecqueur%26aufirst%3DL.%26aulast%3DDuellberg%26aufirst%3DC.%26aulast%3DDreier%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DPlueckthun%26aufirst%3DA.%26aulast%3DSurrey%26aufirst%3DT.%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DKnossow%26aufirst%3DM.%26atitle%3DA%2520designed%2520ankyrin%2520repeat%2520protein%2520selected%2520to%2520bind%2520to%2520tubulin%2520caps%2520the%2520microtubule%2520plus%2520end%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D12011%26epage%3D12016%26doi%3D10.1073%2Fpnas.1204129109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group">Ayaz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huddleston, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brautigam, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, L. M.</span><span> </span><span class="NLM_article-title">A TOG:alpha beta-tubulin complex structure reveals conformation-based mechanisms for a microtubule polymerase</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">337</span><span class="NLM_x">, </span> <span class="NLM_fpage">857</span><span class="NLM_x">–</span> <span class="NLM_lpage">860</span><span class="refDoi"> DOI: 10.1126/science.1221698</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1126%2Fscience.1221698" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=337&publication_year=2012&pages=857-860&author=P.+Ayazauthor=X.+Yeauthor=P.+Huddlestonauthor=C.+A.+Brautigamauthor=L.+M.+Rice&title=A+TOG%3Aalpha+beta-tubulin+complex+structure+reveals+conformation-based+mechanisms+for+a+microtubule+polymerase&doi=10.1126%2Fscience.1221698"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1126%2Fscience.1221698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1221698%26sid%3Dliteratum%253Aachs%26aulast%3DAyaz%26aufirst%3DP.%26aulast%3DYe%26aufirst%3DX.%26aulast%3DHuddleston%26aufirst%3DP.%26aulast%3DBrautigam%26aufirst%3DC.%2BA.%26aulast%3DRice%26aufirst%3DL.%2BM.%26atitle%3DA%2520TOG%253Aalpha%2520beta-tubulin%2520complex%2520structure%2520reveals%2520conformation-based%2520mechanisms%2520for%2520a%2520microtubule%2520polymerase%26jtitle%3DScience%26date%3D2012%26volume%3D337%26spage%3D857%26epage%3D860%26doi%3D10.1126%2Fscience.1221698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group">Skoufias, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, L.</span><span> </span><span class="NLM_article-title">Mechanism of inhibition of microtubule polymerization by colchicine - inhibitory potencies of unliganded colchicine and tubulin colchicine complexes</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">738</span><span class="NLM_x">–</span> <span class="NLM_lpage">746</span><span class="refDoi"> DOI: 10.1021/bi00118a015</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00118a015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1992&pages=738-746&author=D.+A.+Skoufiasauthor=L.+Wilson&title=Mechanism+of+inhibition+of+microtubule+polymerization+by+colchicine+-+inhibitory+potencies+of+unliganded+colchicine+and+tubulin+colchicine+complexes&doi=10.1021%2Fbi00118a015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1021%2Fbi00118a015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00118a015%26sid%3Dliteratum%253Aachs%26aulast%3DSkoufias%26aufirst%3DD.%2BA.%26aulast%3DWilson%26aufirst%3DL.%26atitle%3DMechanism%2520of%2520inhibition%2520of%2520microtubule%2520polymerization%2520by%2520colchicine%2520-%2520inhibitory%2520potencies%2520of%2520unliganded%2520colchicine%2520and%2520tubulin%2520colchicine%2520complexes%26jtitle%3DBiochemistry%26date%3D1992%26volume%3D31%26spage%3D738%26epage%3D746%26doi%3D10.1021%2Fbi00118a015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group">Akhmanova, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmetz, M. O.</span><span> </span><span class="NLM_article-title">Control of microtubule organization and dynamics: two ends in the limelight</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">711</span><span class="NLM_x">–</span> <span class="NLM_lpage">726</span><span class="refDoi"> DOI: 10.1038/nrm4084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1038%2Fnrm4084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=26562752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVOgt7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=711-726&author=A.+Akhmanovaauthor=M.+O.+Steinmetz&title=Control+of+microtubule+organization+and+dynamics%3A+two+ends+in+the+limelight&doi=10.1038%2Fnrm4084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Control of microtubule organization and dynamics: two ends in the limelight</span></div><div class="casAuthors">Akhmanova, Anna; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">711-726</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Microtubules have fundamental roles in many essential biol. processes, including cell division and intracellular transport.  They assemble and disassemble from their two ends, denoted the plus end and the minus end.  Significant advances have been made in our understanding of microtubule plus-end-tracking proteins (+TIPs) such as end-binding protein 1 (EB1), XMAP215, selected kinesins and dynein.  By contrast, information on microtubule minus-end-targeting proteins (-TIPs), such as the calmodulin-regulated spectrin-assocd. proteins (CAMSAPs) and Patronin, has only recently started to emerge.  Here, we review our current knowledge of factors, including microtubule-targeting agents, that assoc. with microtubule ends to control the dynamics and function of microtubules during the cell cycle and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps4xzvh0o6PbVg90H21EOLACvtfcHk0ljzVsBEu6xC3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVOgt7%252FI&md5=7c941bcce8d5d51aef6a8deb140356d3</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1038%2Fnrm4084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm4084%26sid%3Dliteratum%253Aachs%26aulast%3DAkhmanova%26aufirst%3DA.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DControl%2520of%2520microtubule%2520organization%2520and%2520dynamics%253A%2520two%2520ends%2520in%2520the%2520limelight%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2015%26volume%3D16%26spage%3D711%26epage%3D726%26doi%3D10.1038%2Fnrm4084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group">O’Boyle, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keely, N. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cotter, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zisterer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meegan, M. J.</span><span> </span><span class="NLM_article-title">Synthesis and biochemical activities of antiproliferative amino acid and phosphate derivatives of microtubule-disrupting β-lactam combretastatins</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">705</span><span class="NLM_x">–</span> <span class="NLM_lpage">721</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2013.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.ejmech.2013.01.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2013&pages=705-721&author=N.+M.+O%E2%80%99Boyleauthor=L.+M.+Greeneauthor=N.+O.+Keelyauthor=S.+Wangauthor=T.+S.+Cotterauthor=D.+M.+Zistererauthor=M.+J.+Meegan&title=Synthesis+and+biochemical+activities+of+antiproliferative+amino+acid+and+phosphate+derivatives+of+microtubule-disrupting+%CE%B2-lactam+combretastatins&doi=10.1016%2Fj.ejmech.2013.01.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DN.%2BM.%26aulast%3DGreene%26aufirst%3DL.%2BM.%26aulast%3DKeely%26aufirst%3DN.%2BO.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DCotter%26aufirst%3DT.%2BS.%26aulast%3DZisterer%26aufirst%3DD.%2BM.%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26atitle%3DSynthesis%2520and%2520biochemical%2520activities%2520of%2520antiproliferative%2520amino%2520acid%2520and%2520phosphate%2520derivatives%2520of%2520microtubule-disrupting%2520%25CE%25B2-lactam%2520combretastatins%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D62%26spage%3D705%26epage%3D721%26doi%3D10.1016%2Fj.ejmech.2013.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group">Aprile, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaninetti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Del Grosso, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genazzani, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosa, G.</span><span> </span><span class="NLM_article-title">Metabolic fate of combretastatin A-1: LC-DAD-MS/MS investigation and biological evaluation of its reactive metabolites</span> <span class="citation_source-journal">J. Pharm. Biomed. Anal.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">78–79</span><span class="NLM_x">, </span> <span class="NLM_fpage">233</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span><span class="refDoi"> DOI: 10.1016/j.jpba.2013.02.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.jpba.2013.02.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=23501444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVGisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78%E2%80%9379&publication_year=2013&pages=233-242&author=S.+Aprileauthor=R.+Zaninettiauthor=E.+Del+Grossoauthor=A.+A.+Genazzaniauthor=G.+Grosa&title=Metabolic+fate+of+combretastatin+A-1%3A+LC-DAD-MS%2FMS+investigation+and+biological+evaluation+of+its+reactive+metabolites&doi=10.1016%2Fj.jpba.2013.02.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic fate of combretastatin A-1: LC-DAD-MS/MS investigation and biological evaluation of its reactive metabolites</span></div><div class="casAuthors">Aprile, Silvio; Zaninetti, Roberta; Del Grosso, Erika; Genazzani, Armando A.; Grosa, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical and Biomedical Analysis</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">78-79</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">233-242</span>CODEN:
                <span class="NLM_cas:coden">JPBADA</span>;
        ISSN:<span class="NLM_cas:issn">0731-7085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Combretastatin A-1, an antineoplastic agent characterized by a remarkable cytotoxicity and a strong antitubulinic activity, is currently under investigation in phase I clin. trials.  Yet a comprehensive metabolic study of CA-1 in human and animal models has so far not been reported in the literature.  We have therefore investigated, through LC-UV and LC-MS anal. the in vitro/in vivo metab. of CA-1, have synthesized its reactive quinone metabolite Q1, and have evaluated its cytotoxic and antitubulinic activities.  In vitro CA-1 metab. was studied in rat and human liver microsomes in the presence of the nucleophilic trapping agent GSH were performed while urine samples of the CA-1-treated rats were analyzed to establish the in vivo metabolic pathways.  The metabolite Q1, that was synthesized in good yield using a polymer supported oxidant, displayed a significant cytotoxicity but was devoid of significant antitubulinic activity.  Finally the chem. interaction of Q1 and the other combretastatin quinone metabolites with sulfydryl groups of tubulin was measured by Ellman's method: the results suggested the haptenization of the tubulin through the formation of a covalent bond.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbAvvJUDy4CbVg90H21EOLACvtfcHk0ljzVsBEu6xC3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVGisr8%253D&md5=1feeb591fc4b43b87a70d094f29c8a30</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.jpba.2013.02.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpba.2013.02.030%26sid%3Dliteratum%253Aachs%26aulast%3DAprile%26aufirst%3DS.%26aulast%3DZaninetti%26aufirst%3DR.%26aulast%3DDel%2BGrosso%26aufirst%3DE.%26aulast%3DGenazzani%26aufirst%3DA.%2BA.%26aulast%3DGrosa%26aufirst%3DG.%26atitle%3DMetabolic%2520fate%2520of%2520combretastatin%2520A-1%253A%2520LC-DAD-MS%252FMS%2520investigation%2520and%2520biological%2520evaluation%2520of%2520its%2520reactive%2520metabolites%26jtitle%3DJ.%2520Pharm.%2520Biomed.%2520Anal.%26date%3D2013%26volume%3D78%25E2%2580%259379%26spage%3D233%26epage%3D242%26doi%3D10.1016%2Fj.jpba.2013.02.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group">Rautio, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumpulainen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heimbach, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliyai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarvinen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savolainen, J.</span><span> </span><span class="NLM_article-title">Prodrugs: design and clinical applications</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span><span class="refDoi"> DOI: 10.1038/nrd2468</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1038%2Fnrd2468" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=18219308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFOrs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=255-270&author=J.+Rautioauthor=H.+Kumpulainenauthor=T.+Heimbachauthor=R.+Oliyaiauthor=D.+Ohauthor=T.+Jarvinenauthor=J.+Savolainen&title=Prodrugs%3A+design+and+clinical+applications&doi=10.1038%2Fnrd2468"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs: design and clinical applications</span></div><div class="casAuthors">Rautio, Jarkko; Kumpulainen, Hanna; Heimbach, Tycho; Oliyai, Reza; Oh, Dooman; Jaervinen, Tomi; Savolainen, Jouko</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">255-270</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Prodrugs are bioreversible derivs. of drug mols. that undergo an enzymic and/or chem. transformation in vivo to release the active parent drug, which can then exert the desired pharmacol. effect.  In both drug discovery and development, prodrugs have become an established tool for improving physicochem., biopharmaceutical or pharmacokinetic properties of pharmacol. active agents.  About 5-7% of drugs approved worldwide can be classified as prodrugs, and the implementation of a prodrug approach in the early stages of drug discovery is a growing trend.  To illustrate the applicability of the prodrug strategy, this article describes the most common functional groups that are amenable to prodrug design, and highlights examples of prodrugs that are either launched or are undergoing human trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxnlEXYMLCVbVg90H21EOLACvtfcHk0lhxqHCABx-ZYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFOrs7w%253D&md5=481a088ad2ee4da062779b5b28a33cbb</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1038%2Fnrd2468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2468%26sid%3Dliteratum%253Aachs%26aulast%3DRautio%26aufirst%3DJ.%26aulast%3DKumpulainen%26aufirst%3DH.%26aulast%3DHeimbach%26aufirst%3DT.%26aulast%3DOliyai%26aufirst%3DR.%26aulast%3DOh%26aufirst%3DD.%26aulast%3DJarvinen%26aufirst%3DT.%26aulast%3DSavolainen%26aufirst%3DJ.%26atitle%3DProdrugs%253A%2520design%2520and%2520clinical%2520applications%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D255%26epage%3D270%26doi%3D10.1038%2Fnrd2468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group">Eskens, F. A. L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tresca, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tosi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Doorn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontaine, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van der Gaast, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veyrat-Follet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oprea, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hospitel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dieras, V.</span><span> </span><span class="NLM_article-title">A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">2170</span><span class="NLM_x">–</span> <span class="NLM_lpage">2177</span><span class="refDoi"> DOI: 10.1038/bjc.2014.137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1038%2Fbjc.2014.137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=24714750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtFSqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2014&pages=2170-2177&author=F.+A.+L.+M.+Eskensauthor=P.+Trescaauthor=D.+Tosiauthor=L.+Van+Doornauthor=H.+Fontaineauthor=A.+Van+der+Gaastauthor=C.+Veyrat-Folletauthor=C.+Opreaauthor=M.+Hospitelauthor=V.+Dieras&title=A+phase+I+pharmacokinetic+study+of+the+vascular+disrupting+agent+ombrabulin+%28AVE8062%29+and+docetaxel+in+advanced+solid+tumours&doi=10.1038%2Fbjc.2014.137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours</span></div><div class="casAuthors">Eskens, F. A. L. M.; Tresca, P.; Tosi, D.; Van Doorn, L.; Fontaine, H.; Van der Gaast, A.; Veyrat-Follet, C.; Oprea, C.; Hospitel, M.; Dieras, V.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2170-2177</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: The vascular disrupting agent ombrabulin shows synergy with docetaxel in vivo.  Recommended phase II doses were detd. in a dose escalation study in advanced solid tumors.  Methods: Ombrabulin (30-min infusion, day 1) followed by docetaxel (1-h infusion, day 2) every 3 wk was explored.  Ombrabulin was escalated from 11.5 to 42 mg m-2 with 75 mg m-2 docetaxel, then from 30 to 35 mg m-2 with 100 mg m-2 docetaxel.  Recommended phase II dose cohorts were expanded.  Results: Fifty-eight patients were treated.  Recommended phase II doses were 35 mg m-2 ombrabulin with 75 mg m-2 docetaxel (35/75 mg m-2; 13 patients) and 30 mg m-2 ombrabulin with 100 mg m-2 docetaxel (30/100 mg m-2; 16 patients).  Dose-limiting toxicities were grade 3 fatigue (two patients; 42/75, 35/100), grade 3 neutropaenic infection (25/75), grade 3 headache (42/75), grade 4 febrile neutropaenia (30/100), and grade 3 thrombosis (35/100).  Toxicities were consistent with each agent; mild nausea/vomiting, asthaenia/fatigue, alopecia, and anemia were common, as were neutropaenia and leukopaenia.  Diarrhoea, nail disorders and neurol. symptoms were frequent at 100 mg m-2 docetaxel.  Pharmacokinetic analyses did not show any relevant drug interactions.  Ten patients had partial responses (seven at 30 mg m-2 ombrabulin), eight lasting >3 mo.  Conclusions: Sequential administration of ombrabulin with 75 or 100 mg m-2 docetaxel every 3 wk is feasible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDxQcFD-TwWLVg90H21EOLACvtfcHk0lhxqHCABx-ZYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtFSqurg%253D&md5=e95bf24299e4bb43e89b19509d305f69</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2014.137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2014.137%26sid%3Dliteratum%253Aachs%26aulast%3DEskens%26aufirst%3DF.%2BA.%2BL.%2BM.%26aulast%3DTresca%26aufirst%3DP.%26aulast%3DTosi%26aufirst%3DD.%26aulast%3DVan%2BDoorn%26aufirst%3DL.%26aulast%3DFontaine%26aufirst%3DH.%26aulast%3DVan%2Bder%2BGaast%26aufirst%3DA.%26aulast%3DVeyrat-Follet%26aufirst%3DC.%26aulast%3DOprea%26aufirst%3DC.%26aulast%3DHospitel%26aufirst%3DM.%26aulast%3DDieras%26aufirst%3DV.%26atitle%3DA%2520phase%2520I%2520pharmacokinetic%2520study%2520of%2520the%2520vascular%2520disrupting%2520agent%2520ombrabulin%2520%2528AVE8062%2529%2520and%2520docetaxel%2520in%2520advanced%2520solid%2520tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2014%26volume%3D110%26spage%3D2170%26epage%3D2177%26doi%3D10.1038%2Fbjc.2014.137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group">Nkepang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajaputra, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awuah, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">You, Y.</span><span> </span><span class="NLM_article-title">Folate receptor-mediated enhanced and specific delivery of far-red light-activatable prodrugs of combretastatin A-4 to FR-positive tumor</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">2175</span><span class="NLM_x">–</span> <span class="NLM_lpage">2188</span><span class="refDoi"> DOI: 10.1021/bc500376j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc500376j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVWlt7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=2175-2188&author=G.+Nkepangauthor=M.+Bioauthor=P.+Rajaputraauthor=S.+G.+Awuahauthor=Y.+You&title=Folate+receptor-mediated+enhanced+and+specific+delivery+of+far-red+light-activatable+prodrugs+of+combretastatin+A-4+to+FR-positive+tumor&doi=10.1021%2Fbc500376j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Folate Receptor-Mediated Enhanced and Specific Delivery of Far-Red Light-Activatable Prodrugs of Combretastatin A-4 to FR-Positive Tumor</span></div><div class="casAuthors">Nkepang, Gregory; Bio, Moses; Rajaputra, Pallavi; Awuah, Samuel G.; You, Youngjae</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2175-2188</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We examd. the concept of a novel prodrug strategy in which anticancer drug can be locally released by visible/near IR light, taking advantage of the photodynamic process and photo-unclick chem.  Our most recently formulated prodrug of combretastatin A-4, Pc-(L-CA4)2, showed multifunctionality for fluorescence imaging, light-activated drug release, and the combined effects of PDT and local chemotherapy.  In this formulation, L is a singlet oxygen cleavable linker.  Here, we advanced this multifunctional prodrug by adding a tumor-targeting group, folic acid (FA).  We designed and prepd. four FA-conjugated prodrugs 1-4 (CA4-L-Pc-PEGn-FA: n = 0, 2, 18, ∼45) and one non-FA-conjugated prodrug 5 (CA4-L-Pc-PEG18-boc).  Prodrugs 3 and 4 had a longer PEG spacer and showed higher hydrophilicity, enhanced uptake to colon 26 cells via FR-mediated mechanisms, and more specific localization to SC colon 26 tumors in Balb/c mice than prodrugs 1 and 2.  Prodrug 4 also showed higher and more specific uptake to tumors, resulting in selective tumor damage and more effective antitumor efficacy than non-FA-conjugated prodrug 5.  FR-mediated targeting seemed to be an effective strategy to spare normal tissues surrounding tumors in the illuminated area during treatment with this prodrug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJfkU0m3ozN7Vg90H21EOLACvtfcHk0lj5gPxp9xuVeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVWlt7vJ&md5=7b8c839db1b6a44873d3bb734a9b8405</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1021%2Fbc500376j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc500376j%26sid%3Dliteratum%253Aachs%26aulast%3DNkepang%26aufirst%3DG.%26aulast%3DBio%26aufirst%3DM.%26aulast%3DRajaputra%26aufirst%3DP.%26aulast%3DAwuah%26aufirst%3DS.%2BG.%26aulast%3DYou%26aufirst%3DY.%26atitle%3DFolate%2520receptor-mediated%2520enhanced%2520and%2520specific%2520delivery%2520of%2520far-red%2520light-activatable%2520prodrugs%2520of%2520combretastatin%2520A-4%2520to%2520FR-positive%2520tumor%26jtitle%3DBioconjugate%2520Chem.%26date%3D2014%26volume%3D25%26spage%3D2175%26epage%3D2188%26doi%3D10.1021%2Fbc500376j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group">Yang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ying, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span> </span><span class="NLM_article-title">Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature</span> <span class="citation_source-journal">Nanomedicine</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">92</span><span class="refDoi"> DOI: 10.1016/j.nano.2011.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.nano.2011.05.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=81-92&author=T.+Yangauthor=Y.+Wangauthor=Z.+Liauthor=W.+Daiauthor=J.+Yinauthor=L.+Liangauthor=X.+Yingauthor=S.+Zhouauthor=J.+Wangauthor=X.+Zhangauthor=Q.+Zhang&title=Targeted+delivery+of+a+combination+therapy+consisting+of+combretastatin+A4+and+low-dose+doxorubicin+against+tumor+neovasculature&doi=10.1016%2Fj.nano.2011.05.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.nano.2011.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nano.2011.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DDai%26aufirst%3DW.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DYing%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DQ.%26atitle%3DTargeted%2520delivery%2520of%2520a%2520combination%2520therapy%2520consisting%2520of%2520combretastatin%2520A4%2520and%2520low-dose%2520doxorubicin%2520against%2520tumor%2520neovasculature%26jtitle%3DNanomedicine%26date%3D2012%26volume%3D8%26spage%3D81%26epage%3D92%26doi%3D10.1016%2Fj.nano.2011.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bian, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span> </span><span class="NLM_article-title">Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: In vitro and in vivo studies</span> <span class="citation_source-journal">Eur. J. Pharm. Biopharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">467</span><span class="NLM_x">–</span> <span class="NLM_lpage">473</span><span class="refDoi"> DOI: 10.1016/j.ejpb.2010.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.ejpb.2010.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=20064608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivFGrsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2010&pages=467-473&author=Y.+Zhangauthor=J.+Wangauthor=D.+Bianauthor=X.+Zhangauthor=Q.+Zhang&title=Targeted+delivery+of+RGD-modified+liposomes+encapsulating+both+combretastatin+A-4+and+doxorubicin+for+tumor+therapy%3A+In+vitro+and+in+vivo+studies&doi=10.1016%2Fj.ejpb.2010.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: In vitro and in vivo studies</span></div><div class="casAuthors">Zhang, Yi-fei; Wang, Jian-cheng; Bian, Dong-yan; Zhang, Xuan; Zhang, Qiang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutics and Biopharmaceutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">467-473</span>CODEN:
                <span class="NLM_cas:coden">EJPBEL</span>;
        ISSN:<span class="NLM_cas:issn">0939-6411</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Arg-Gly-Asp (RGD) modified doxorubicin-loaded liposomes could improve anticancer effect, and vascular disrupting agents (VDAs) could induce a rapid and selective shutdown of the blood vessels of tumors.  We propose that RGD-modified liposomes for co-encapsulation and sequential release of vascular disrupting agent combretastatin A-4 (CA-4) and cytotoxic agent doxorubicin (Dox) could enhance tumor inhibition responses.  In this study, we encapsulated Dox and CA-4 in RGD-modified liposomes.  The release rate of Dox was proved to be much slower than that of CA-4 in vitro.  Flow cytometry and laser confocal scanning microscopy clearly showed that RGD-modification promoted intracellular uptake of liposomal drugs by B16/B16F10 melanoma tumor cells and human umbilical vein endothelial cells (HUVECs).  Cytotoxicity assay showed that the IC50 of RGD-modified liposomes was lower than that of the corresponding unmodified liposomes.  Therapeutic benefits were examd. on B16F10 melanoma tumors s.c. growing in C57BL/6 mice.  In vivo study demonstrated that RGD-modified liposomes exhibited the most pronounced tumor regression effect when both CA-4 and Dox were co-encapsulated.  These results suggest that the targeted drug delivery system for co-encapsulation of vascular disrupting agents and anticancer agents may be a promising strategy for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf0bsFcQy_prVg90H21EOLACvtfcHk0lj5gPxp9xuVeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivFGrsb0%253D&md5=376e51f67b9f121c8999516f53a709f0</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2Fj.ejpb.2010.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejpb.2010.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DBian%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DQ.%26atitle%3DTargeted%2520delivery%2520of%2520RGD-modified%2520liposomes%2520encapsulating%2520both%2520combretastatin%2520A-4%2520and%2520doxorubicin%2520for%2520tumor%2520therapy%253A%2520In%2520vitro%2520and%2520in%2520vivo%2520studies%26jtitle%3DEur.%2520J.%2520Pharm.%2520Biopharm.%26date%3D2010%26volume%3D74%26spage%3D467%26epage%3D473%26doi%3D10.1016%2Fj.ejpb.2010.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group">Zhang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span> </span><span class="NLM_article-title">Multifunctional dendrimer/combretastatin A4 inclusion complexes enable in vitro targeted cancer therapy</span> <span class="citation_source-journal">Int. J. Nanomed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2337</span><span class="NLM_x">–</span> <span class="NLM_lpage">2349</span><span class="refDoi"> DOI: 10.2147/IJN.S24705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.2147%2FIJN.S24705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=22072871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Sjs77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=2337-2349&author=M.+Zhangauthor=R.+Guoauthor=Y.+Wangauthor=X.+Caoauthor=M.+Shenauthor=X.+Shi&title=Multifunctional+dendrimer%2Fcombretastatin+A4+inclusion+complexes+enable+in+vitro+targeted+cancer+therapy&doi=10.2147%2FIJN.S24705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Multifunctional dendrimer/combretastatin A4 inclusion complexes enable in vitro targeted cancer therapy</span></div><div class="casAuthors">Zhang, Mengen; Guo, Rui; Wang, Yin; Cao, Xueyan; Shen, Mingwu; Shi, Xiangyang</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Nanomedicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2337-2349</span>CODEN:
                <span class="NLM_cas:coden">IJNNHQ</span>;
        ISSN:<span class="NLM_cas:issn">1178-2013</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: We report here a unique approach to using multifunctional dendrimer/combretastatin A4 (CA4) inclusion complexes for targeted cancer therapeutics.  Methods: Amine-terminated generation 5 polyamidoamine dendrimers were first partially acetylated to neutralize a significant portion of the terminal amines, and then the remaining dendrimer terminal amines were sequentially modified with fluorescein isothiocyanate as an imaging agent and folic acid as a targeting ligand.  The multifunctional dendrimers formed (G5.NHAc-FI-FA) were utilized to encapsulate the anticancer drug, CA4, for targeted delivery into cancer cells overexpressing folic acid receptors.  Results: The inclusion complexes of G5.NHAc-FI-FA/CA4 formed were stable and are able to significantly improve the water soly. of CA4 from 11.8 to 240 μg/mL.  In vitro release studies showed that the multifunctional dendrimers complexed with CA4 could be released in a sustained manner.  Both 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide colorimetric assay and morphol. cell observation showed that the inhibitory effect of the G5.NHAc-FI-FA/CA4 complexes was similar to that of free CA4 at the same selected drug concn.  More importantly, the complexes were able to target selectively and display specific therapeutic efficacy to cancer cells overexpressing high-affinity folic acid receptors.  Conclusion: Multifunctional dendrimers may serve as a valuable carrier to form stable inclusion complexes with various hydrophobic anticancer drugs with improved water soly., for targeting chemotherapy to different types of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnbxiWphITV7Vg90H21EOLACvtfcHk0lj5gPxp9xuVeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Sjs77E&md5=e0c8be71e76e2ae08e1a797e9e810cb9</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.2147%2FIJN.S24705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S24705%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DGuo%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DShen%26aufirst%3DM.%26aulast%3DShi%26aufirst%3DX.%26atitle%3DMultifunctional%2520dendrimer%252Fcombretastatin%2520A4%2520inclusion%2520complexes%2520enable%2520in%2520vitro%2520targeted%2520cancer%2520therapy%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2011%26volume%3D6%26spage%3D2337%26epage%3D2349%26doi%3D10.2147%2FIJN.S24705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, N.</span><span> </span><span class="NLM_article-title">pH-sensitive pullulan-based nanoparticle carrier of methotrexate and combretastatin A4 for the combination therapy against hepatocellular carcinoma</span> <span class="citation_source-journal">Biomaterials</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">7181</span><span class="NLM_x">–</span> <span class="NLM_lpage">7190</span><span class="refDoi"> DOI: 10.1016/j.biomaterials.2013.05.081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.biomaterials.2013.05.081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=23791500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvFCjsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=7181-7190&author=Y.+Wangauthor=H.+Chenauthor=Y.+Liuauthor=J.+Wuauthor=P.+Zhouauthor=Y.+Wangauthor=R.+Liauthor=X.+Yangauthor=N.+Zhang&title=pH-sensitive+pullulan-based+nanoparticle+carrier+of+methotrexate+and+combretastatin+A4+for+the+combination+therapy+against+hepatocellular+carcinoma&doi=10.1016%2Fj.biomaterials.2013.05.081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">pH-sensitive pullulan-based nanoparticle carrier of methotrexate and combretastatin A4 for the combination therapy against hepatocellular carcinoma</span></div><div class="casAuthors">Wang, Yinsong; Chen, Hongli; Liu, Yuanyuan; Wu, Jing; Zhou, Ping; Wang, Yan; Li, Rongshan; Yang, Xiaoying; Zhang, Ning</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">7181-7190</span>CODEN:
                <span class="NLM_cas:coden">BIMADU</span>;
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">This study designs a pH-sensitive nanoparticle carrier of methotrexate (MTX) and combretastatin A4 (CA4) based on pullulan for the combination therapy against hepatocellular carcinoma (HCC).  Briefly, N-urocanyl pullulan (URPA) with the degree of substitution (DS) of 5.2% was synthesized and then conjugated with MTX to form MTX-URPA, in which MTX content was 17.8%.  MTX-URPA nanoparticles prepd. by the dialysis method had spherical shape and the mean size of 187.1 nm, and showed high affinity for HepG2 cells.  CA4 was successfully loaded into MTX-URPA nanoparticles and exhibited pH-sensitive in vitro release property.  After i.v. injection to PLC/PRF/5-bearing nude mice, CA4 loaded MTX-URPA (CA4/MTX-URPA) nanoparticles achieved the enhanced antitumor and anti-angiogenic effects, the prolonged circulation time in blood, and the increased distributions both in the liver and the tumor.  In conclusion, this drug carrier system has significant liver-targeting property and exhibits advantages for the combination therapy against hepatocellular carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9ZeO6rAlDJLVg90H21EOLACvtfcHk0liQvv-CtLnRTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvFCjsL4%253D&md5=251ad018ee1fa4fbc6438a53a611b9c7</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2013.05.081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2013.05.081%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DN.%26atitle%3DpH-sensitive%2520pullulan-based%2520nanoparticle%2520carrier%2520of%2520methotrexate%2520and%2520combretastatin%2520A4%2520for%2520the%2520combination%2520therapy%2520against%2520hepatocellular%2520carcinoma%26jtitle%3DBiomaterials%26date%3D2013%26volume%3D34%26spage%3D7181%26epage%3D7190%26doi%3D10.1016%2Fj.biomaterials.2013.05.081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group">Sengupta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eavarone, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capila, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiziltepe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasisekharan, R.</span><span> </span><span class="NLM_article-title">Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">436</span><span class="NLM_x">, </span> <span class="NLM_fpage">568</span><span class="NLM_x">–</span> <span class="NLM_lpage">572</span><span class="refDoi"> DOI: 10.1038/nature03794</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1038%2Fnature03794" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=16049491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmsFCgs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=436&publication_year=2005&pages=568-572&author=S.+Senguptaauthor=D.+Eavaroneauthor=I.+Capilaauthor=G.+Zhaoauthor=N.+Watsonauthor=T.+Kiziltepeauthor=R.+Sasisekharan&title=Temporal+targeting+of+tumour+cells+and+neovasculature+with+a+nanoscale+delivery+system&doi=10.1038%2Fnature03794"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Temporal targeting of tumor cells and neovasculature with a nanoscale delivery system</span></div><div class="casAuthors">Sengupta, Shiladitya; Eavarone, David; Capila, Ishan; Zhao, Ganlin; Watson, Nicki; Kiziltepe, Tanyel; Sasisekharan, Ram</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">436</span>
        (<span class="NLM_cas:issue">7050</span>),
    <span class="NLM_cas:pages">568-572</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In the continuing search for effective treatments for cancer, the emerging model is the combination of traditional chemotherapy with anti-angiogenesis agents that inhibit blood vessel growth.  However, the implementation of this strategy has faced two major obstacles.  First, the long-term shutdown of tumor blood vessels by the anti-angiogenesis agent can prevent the tumor from receiving a therapeutic concn. of the chemotherapy agent.  Second, inhibiting blood supply drives the intra-tumoral accumulation of hypoxia-inducible factor-1α (HIF1-α); overexpression of HIF1-α is correlated with increased tumor invasiveness and resistance to chemotherapy.  Here we report the disease-driven engineering of a drug delivery system, a 'nanocell', which overcomes these barriers unique to solid tumors.  The nanocell comprises a nuclear nanoparticle within an extranuclear pegylated-lipid envelope, and is preferentially taken up by the tumor.  The nanocell enables a temporal release of two drugs: the outer envelope first releases an anti-angiogenesis agent, causing a vascular shutdown; the inner nanoparticle, which is trapped inside the tumor, then releases a chemotherapy agent.  This focal release within a tumor results in improved therapeutic index with reduced toxicity.  The technol. can be extended to addnl. agents, so as to target multiple signalling pathways or distinct tumor compartments, enabling the model of an 'integrative' approach in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0HlLud2V1hLVg90H21EOLACvtfcHk0liQvv-CtLnRTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmsFCgs70%253D&md5=9a29315c805eca28d022832368f1b5c9</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1038%2Fnature03794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03794%26sid%3Dliteratum%253Aachs%26aulast%3DSengupta%26aufirst%3DS.%26aulast%3DEavarone%26aufirst%3DD.%26aulast%3DCapila%26aufirst%3DI.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DWatson%26aufirst%3DN.%26aulast%3DKiziltepe%26aufirst%3DT.%26aulast%3DSasisekharan%26aufirst%3DR.%26atitle%3DTemporal%2520targeting%2520of%2520tumour%2520cells%2520and%2520neovasculature%2520with%2520a%2520nanoscale%2520delivery%2520system%26jtitle%3DNature%26date%3D2005%26volume%3D436%26spage%3D568%26epage%3D572%26doi%3D10.1038%2Fnature03794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group">Poojari, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srivastava, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panda, D.</span><span> </span><span class="NLM_article-title">A chimeric cetuximab-functionalized corona as a potent delivery system for microtubule-destabilizing nanocomplexes to hepatocellular carcinoma cells: a focus on EGFR and tubulin intracellular dynamics</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">3908</span><span class="NLM_x">–</span> <span class="NLM_lpage">3923</span><span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.5b00337</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.5b00337" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2iu77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=3908-3923&author=R.+Poojariauthor=S.+Kiniauthor=R.+Srivastavaauthor=D.+Panda&title=A+chimeric+cetuximab-functionalized+corona+as+a+potent+delivery+system+for+microtubule-destabilizing+nanocomplexes+to+hepatocellular+carcinoma+cells%3A+a+focus+on+EGFR+and+tubulin+intracellular+dynamics&doi=10.1021%2Facs.molpharmaceut.5b00337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">A Chimeric Cetuximab-Functionalized Corona as a Potent Delivery System for Microtubule-Destabilizing Nanocomplexes to Hepatocellular Carcinoma Cells: A Focus on EGFR and Tubulin Intracellular Dynamics</span></div><div class="casAuthors">Poojari, Radhika; Kini, Sudarshan; Srivastava, Rohit; Panda, Dulal</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3908-3923</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this s tudy, we have developed microtubule destabilizing agents combretastatin A4 (CA4) or 2-methoxyestradiol (2ME) encapsulated poly(D,L-lactide-co-glycolide)-b-poly(ethylene glycol) (PLGA-b-PEG) nanocomplexes for targeted delivery to human hepatocellular carcinoma (HCC) cells.  An epidermal growth factor receptor (EGFR) is known to be overexpressed in HCC cells.  Therefore, the targeting moiety cetuximab (Cet), an anti-EGFR chimeric monoclonal antibody, is functionalized on the surface of these diblock copolymeric coronas.  Cetuximab is assocd. with the extracellular domain of the EGFR; therefore, the uptake of the cetuximab conjugated nanocomplexes occurred efficiently in EGFR overexpressing HCC cells indicating potent internalization of the complex.  The cetuximab targeted-PLGA-b-PEG nanocomplexes encapsulating CA4 or 2ME strongly inhibited phospho-EGFR expression, depolymd. microtubules, produced spindle abnormalities, stalled mitosis, and induced apoptosis in Huh7 cells compared to the free drugs, CA4 or 2ME.  Further, the combinatorial strategy of targeted nanocomplexes, Cet-PLGA-b-PEG-CA4 NP and Cet-PLGA-b-PEG-2ME NP, significantly reduced the migration of Huh7 cells, and markedly enhanced the anticancer effects of the microtubule-targeted drugs in Huh7 cells compared to the free drugs, CA4 or 2ME.  The results indicated that EGFR receptor-mediated internalization via cetuximab facilitated enhanced uptake of the nanocomplexes leading to potent anticancer efficacy in Huh7 cells.  Cetuximab-functionalized PLGA-b-PEG nanocomplexes possess a strong potential for the targeted delivery of CA4 or 2ME in EGFR overexpressed HCC cells, and the strategy may be useful for selectively targeting microtubules in these cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8ckb30rnN4rVg90H21EOLACvtfcHk0liQvv-CtLnRTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2iu77P&md5=b8812064316746378a193d1640cb8119</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.5b00337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.5b00337%26sid%3Dliteratum%253Aachs%26aulast%3DPoojari%26aufirst%3DR.%26aulast%3DKini%26aufirst%3DS.%26aulast%3DSrivastava%26aufirst%3DR.%26aulast%3DPanda%26aufirst%3DD.%26atitle%3DA%2520chimeric%2520cetuximab-functionalized%2520corona%2520as%2520a%2520potent%2520delivery%2520system%2520for%2520microtubule-destabilizing%2520nanocomplexes%2520to%2520hepatocellular%2520carcinoma%2520cells%253A%2520a%2520focus%2520on%2520EGFR%2520and%2520tubulin%2520intracellular%2520dynamics%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2015%26volume%3D12%26spage%3D3908%26epage%3D3923%26doi%3D10.1021%2Facs.molpharmaceut.5b00337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group">Song, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span> </span><span class="NLM_article-title">Coadministration of vascular disrupting agents and nanomedicines to eradicate tumors from peripheral and central regions</span> <span class="citation_source-journal">Small</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">3755</span><span class="NLM_x">–</span> <span class="NLM_lpage">3761</span><span class="refDoi"> DOI: 10.1002/smll.201500324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1002%2Fsmll.201500324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=25919954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnt1WhsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=3755-3761&author=W.+Songauthor=Z.+Tangauthor=D.+Zhangauthor=H.+Yuauthor=X.+Chen&title=Coadministration+of+vascular+disrupting+agents+and+nanomedicines+to+eradicate+tumors+from+peripheral+and+central+regions&doi=10.1002%2Fsmll.201500324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Coadministration of Vascular Disrupting Agents and Nanomedicines to Eradicate Tumors from Peripheral and Central Regions</span></div><div class="casAuthors">Song, Wantong; Tang, Zhaohui; Zhang, Dawei; Yu, Haiyang; Chen, Xuesi</div><div class="citationInfo"><span class="NLM_cas:title">Small</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">3755-3761</span>CODEN:
                <span class="NLM_cas:coden">SMALBC</span>;
        ISSN:<span class="NLM_cas:issn">1613-6810</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">We developed a strategy for coadministering CDDP-NPs plus free small-mol. VDAs in order to improve treatment ef cacy within the central region of solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS8QuLnh2Ov7Vg90H21EOLACvtfcHk0lg3hekmSUNYYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnt1WhsLk%253D&md5=6cf76235b5e4eeb7ebf83e12146ae4c7</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1002%2Fsmll.201500324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsmll.201500324%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DW.%26aulast%3DTang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DCoadministration%2520of%2520vascular%2520disrupting%2520agents%2520and%2520nanomedicines%2520to%2520eradicate%2520tumors%2520from%2520peripheral%2520and%2520central%2520regions%26jtitle%3DSmall%26date%3D2015%26volume%3D11%26spage%3D3755%26epage%3D3761%26doi%3D10.1002%2Fsmll.201500324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group">Al-Abd, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aljehani, Z. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazzaz, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fakhri, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jabbad, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alahdal, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torchilin, V. P.</span><span> </span><span class="NLM_article-title">Pharmacokinetic strategies to improve drug penetration and entrapment within solid tumors</span> <span class="citation_source-journal">J. Controlled Release</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">219</span><span class="NLM_x">, </span> <span class="NLM_fpage">269</span><span class="NLM_x">–</span> <span class="NLM_lpage">277</span><span class="refDoi"> DOI: 10.1016/j.jconrel.2015.08.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.jconrel.2015.08.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=26342660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVygtbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=219&publication_year=2015&pages=269-277&author=A.+M.+Al-Abdauthor=Z.+K.+Aljehaniauthor=R.+W.+Gazzazauthor=S.+H.+Fakhriauthor=A.+H.+Jabbadauthor=A.+M.+Alahdalauthor=V.+P.+Torchilin&title=Pharmacokinetic+strategies+to+improve+drug+penetration+and+entrapment+within+solid+tumors&doi=10.1016%2Fj.jconrel.2015.08.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic strategies to improve drug penetration and entrapment within solid tumors</span></div><div class="casAuthors">Al-Abd, Ahmed M.; Aljehani, Zekra K.; Gazzaz, Rana W.; Fakhri, Sarah H.; Jabbad, Aisha H.; Alahdal, Abdulrahman M.; Torchilin, Vladimir P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">219</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">269-277</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Despite the discovery of a large no. of anticancer agents, cancer still remains among the leading causes of death since the middle of the twentieth century.  Solid tumors possess a high degree of genetic instability and emergence of treatment resistance.  Tumor resistance has emerged for almost all approved anticancer drugs and will most probably emerge for newly discovered anticancer agents as well.  The use of pharmacokinetic approaches to increase anticancer drug concns. within the solid tumor compartment and prolong its entrapment might diminish the possibility of resistance emergence at the mol. pharmacodynamic level and might even reverse tumor resistance.  Several novel treatment modalities such as metronomic therapy, angiogenesis inhibitors, vascular disrupting agents and tumor priming have been introduced to improve solid tumor treatment outcomes.  In the current review we will discuss the pharmacokinetic aspect of these treatment modalities in addn. to other older treatment modalities, such as extracellular matrix dissolving agents, extracellular matrix synthesis inhibitors, chemoembolization and cellular efflux pump inhibition.  Many of these strategies showed variable degrees of success/failure; however, reallocating these modalities based on their influence on the intratumoral pharmacokinetics might improve their understanding and treatment outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrf-2BeX0FbBbVg90H21EOLACvtfcHk0lg3hekmSUNYYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVygtbjI&md5=c43a87fc1e85c63268b2d71d691b074d</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2015.08.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2015.08.055%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Abd%26aufirst%3DA.%2BM.%26aulast%3DAljehani%26aufirst%3DZ.%2BK.%26aulast%3DGazzaz%26aufirst%3DR.%2BW.%26aulast%3DFakhri%26aufirst%3DS.%2BH.%26aulast%3DJabbad%26aufirst%3DA.%2BH.%26aulast%3DAlahdal%26aufirst%3DA.%2BM.%26aulast%3DTorchilin%26aufirst%3DV.%2BP.%26atitle%3DPharmacokinetic%2520strategies%2520to%2520improve%2520drug%2520penetration%2520and%2520entrapment%2520within%2520solid%2520tumors%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2015%26volume%3D219%26spage%3D269%26epage%3D277%26doi%3D10.1016%2Fj.jconrel.2015.08.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group">Tozer, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prise, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilso, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cemazar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewhirst, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barber, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vojnovic, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span> </span><span class="NLM_article-title">Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: Intravital microscopy and measurement of vascular permeability</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">6413</span><span class="NLM_x">–</span> <span class="NLM_lpage">6422</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=6413-6422&author=G.+M.+Tozerauthor=V.+E.+Priseauthor=J.+Wilsoauthor=M.+Cemazarauthor=S.+Shanauthor=M.+W.+Dewhirstauthor=P.+R.+Barberauthor=B.+Vojnovicauthor=D.+J.+Chaplin&title=Mechanisms+associated+with+tumor+vascular+shut-down+induced+by+combretastatin+A-4+phosphate%3A+Intravital+microscopy+and+measurement+of+vascular+permeability"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTozer%26aufirst%3DG.%2BM.%26aulast%3DPrise%26aufirst%3DV.%2BE.%26aulast%3DWilso%26aufirst%3DJ.%26aulast%3DCemazar%26aufirst%3DM.%26aulast%3DShan%26aufirst%3DS.%26aulast%3DDewhirst%26aufirst%3DM.%2BW.%26aulast%3DBarber%26aufirst%3DP.%2BR.%26aulast%3DVojnovic%26aufirst%3DB.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26atitle%3DMechanisms%2520associated%2520with%2520tumor%2520vascular%2520shut-down%2520induced%2520by%2520combretastatin%2520A-4%2520phosphate%253A%2520Intravital%2520microscopy%2520and%2520measurement%2520of%2520vascular%2520permeability%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D6413%26epage%3D6422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group">McPhail, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, S. P.</span><span> </span><span class="NLM_article-title">Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging</span> <span class="citation_source-journal">Int. J. Radiat. Oncol., Biol., Phys.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">1238</span><span class="NLM_x">–</span> <span class="NLM_lpage">1245</span><span class="refDoi"> DOI: 10.1016/j.ijrobp.2007.08.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.ijrobp.2007.08.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=17967313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1aktbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2007&pages=1238-1245&author=L.+D.+McPhailauthor=J.+R.+Griffithsauthor=S.+P.+Robinson&title=Assessment+of+tumor+response+to+the+vascular+disrupting+agents+5%2C6-dimethylxanthenone-4-acetic+acid+or+combretastatin-A4-phosphate+by+intrinsic+susceptibility+magnetic+resonance+imaging&doi=10.1016%2Fj.ijrobp.2007.08.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of Tumor Response to the Vascular Disrupting Agents 5,6-Dimethylxanthenone-4-Acetic Acid or Combretastatin-A4-Phosphate by Intrinsic Susceptibility Magnetic Resonance Imaging</span></div><div class="casAuthors">McPhail, Lesley D.; Griffiths, John R.; Robinson, Simon P.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Radiation Oncology, Biology, Physics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1238-1245</span>CODEN:
                <span class="NLM_cas:coden">IOBPD3</span>;
        ISSN:<span class="NLM_cas:issn">0360-3016</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Purpose: To investigate the use of the transverse magnetic resonance imaging (MRI) relaxation rate R2* (s-1) as a biomarker of tumor vascular response to monitor vascular disrupting agent (VDA) therapy.  Methods and Materials: Multigradient echo MRI was used to quantify R2* in rat GH3 prolactinomas.  R2 is a sensitive index of deoxyHb in the blood and can therefore be used to give an index of tissue oxygenation.  Tumor R2* was measured before and up to 35 min after treatment, and 24 h after treatment with either 350 mg/kg 5,6-dimethylxanthenone-4-acetic acid (DMXAA) or 100 mg/kg combretastatin-A4-phosphate (CA4P).  After acquisition of the MRI data, functional tumor blood vessels remaining after VDA treatment were quantified using fluorescence microscopy of the perfusion marker Hoechst 33342.  Results: DMXAA induced a transient, significant (p < 0.05) increase in tumor R2* 7 min after treatment, whereas CA4P induced no significant changes in tumor R2* over the first 35 min.  Twenty-four hours after treatment, some DMXAA-treated tumors demonstrated a decrease in R2*, but overall, redn. in R2* was not significant for this cohort.  Tumors treated with CA4P showed a significant (p < 0.05) redn. in R2* 24 h after treatment.  The degree of Hoechst 33342 uptake was assocd. with the degree of R2* redn. at 24 h for both agents.  Conclusions: The redn. in tumor R2 * or deoxyHb levels 24 h after VDA treatment was a result of reduced blood vol. caused by prolonged vascular collapse.  Our results suggest that DMXAA was less effective than CA4P in this rat tumor model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrWzZPX3W1nbVg90H21EOLACvtfcHk0lj-aIbr_1wQWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1aktbzF&md5=c6aa34ca0a42a80193caab54d66bbd48</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.ijrobp.2007.08.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijrobp.2007.08.025%26sid%3Dliteratum%253Aachs%26aulast%3DMcPhail%26aufirst%3DL.%2BD.%26aulast%3DGriffiths%26aufirst%3DJ.%2BR.%26aulast%3DRobinson%26aufirst%3DS.%2BP.%26atitle%3DAssessment%2520of%2520tumor%2520response%2520to%2520the%2520vascular%2520disrupting%2520agents%25205%252C6-dimethylxanthenone-4-acetic%2520acid%2520or%2520combretastatin-A4-phosphate%2520by%2520intrinsic%2520susceptibility%2520magnetic%2520resonance%2520imaging%26jtitle%3DInt.%2520J.%2520Radiat.%2520Oncol.%252C%2520Biol.%252C%2520Phys.%26date%3D2007%26volume%3D69%26spage%3D1238%26epage%3D1245%26doi%3D10.1016%2Fj.ijrobp.2007.08.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horsman, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedersen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stødkilde-Jørgensen, H.</span><span> </span><span class="NLM_article-title">The effect of combretastatin A4 disodium phosphate and 5,6- dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours</span> <span class="citation_source-journal">Acta Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1071</span><span class="NLM_x">–</span> <span class="NLM_lpage">1076</span><span class="refDoi"> DOI: 10.1080/02841860701769750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1080%2F02841860701769750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=18770061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOrur%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=1071-1076&author=G.+Chenauthor=M.+R.+Horsmanauthor=M.+Pedersenauthor=Q.+Pangauthor=H.+St%C3%B8dkilde-J%C3%B8rgensen&title=The+effect+of+combretastatin+A4+disodium+phosphate+and+5%2C6-+dimethylxanthenone-4-acetic+acid+on+water+diffusion+and+blood+perfusion+in+tumours&doi=10.1080%2F02841860701769750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of combretastatin A4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours</span></div><div class="casAuthors">Chen, Gang; Horsman, Michael R.; Pedersen, Michael; Pang, Qi; Stodkilde-jorgensen, Hans</div><div class="citationInfo"><span class="NLM_cas:title">Acta Oncologica</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1071-1076</span>CODEN:
                <span class="NLM_cas:coden">ACTOEL</span>;
        ISSN:<span class="NLM_cas:issn">0284-186X</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Purpose: To evaluate the effect of the vascular disrupting drugs combretastatin A-4 disodium phosphate (CA4DP) and 5,6-dimethylxanthenone-4-acetic acid (DMXAA) on the intra/extracellular vol. fraction of water and blood perfusion in tumors using MRI.  Methods and Materials: Mice with C3H mammary carcinomas underwent repeated MRI T2-weighted imaging, water-diffusion and perfusion measurements before and up to 6-h following CA4DP and DMXAA treatment.  Results: CA4DP treatment caused an increase in water diffusion in those tumor areas that presented the lowest blood perfusion, however this appeared only after five hours.  The blood perfusion in highly perfused tumor regions decreased immediately after administration of CA4DP.  DMXAA treatment caused an early decrease in water diffusion in the low-perfused tumor segments and followed by a subsequent decrease in the remaining part of the tumor.  The blood perfusion decreased early in all parts of the tumor.  Conclusion: The effect of CA4DP and DMXAA on tumor blood flow was comparable.  The redn. in regional blood flow caused by CA4DP in the whole tumor segment occurred early, however, changes in ADC after DMXAA appeared more extended and earlier than after CA4DP treatment, esp. in tumor areas already suffering from a low blood perfusion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqso2Qfo2FQrLVg90H21EOLACvtfcHk0lj-aIbr_1wQWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOrur%252FO&md5=8a198c9a1d3d95a9be566507d5073903</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1080%2F02841860701769750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F02841860701769750%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DG.%26aulast%3DHorsman%26aufirst%3DM.%2BR.%26aulast%3DPedersen%26aufirst%3DM.%26aulast%3DPang%26aufirst%3DQ.%26aulast%3DSt%25C3%25B8dkilde-J%25C3%25B8rgensen%26aufirst%3DH.%26atitle%3DThe%2520effect%2520of%2520combretastatin%2520A4%2520disodium%2520phosphate%2520and%25205%252C6-%2520dimethylxanthenone-4-acetic%2520acid%2520on%2520water%2520diffusion%2520and%2520blood%2520perfusion%2520in%2520tumours%26jtitle%3DActa%2520Oncol.%26date%3D2008%26volume%3D47%26spage%3D1071%26epage%3D1076%26doi%3D10.1080%2F02841860701769750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group">Zhao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antich, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, R. P.</span><span> </span><span class="NLM_article-title">Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging and confirmed by MRI</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2445</span><span class="NLM_x">–</span> <span class="NLM_lpage">2451</span><span class="refDoi"> DOI: 10.1096/fj.07-103713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1096%2Ffj.07-103713" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=2445-2451&author=D.+Zhaoauthor=E.+Richerauthor=P.+P.+Antichauthor=R.+P.+Mason&title=Antivascular+effects+of+combretastatin+A4+phosphate+in+breast+cancer+xenograft+assessed+using+dynamic+bioluminescence+imaging+and+confirmed+by+MRI&doi=10.1096%2Ffj.07-103713"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1096%2Ffj.07-103713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.07-103713%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DD.%26aulast%3DRicher%26aufirst%3DE.%26aulast%3DAntich%26aufirst%3DP.%2BP.%26aulast%3DMason%26aufirst%3DR.%2BP.%26atitle%3DAntivascular%2520effects%2520of%2520combretastatin%2520A4%2520phosphate%2520in%2520breast%2520cancer%2520xenograft%2520assessed%2520using%2520dynamic%2520bioluminescence%2520imaging%2520and%2520confirmed%2520by%2520MRI%26jtitle%3DFASEB%2520J.%26date%3D2008%26volume%3D22%26spage%3D2445%26epage%3D2451%26doi%3D10.1096%2Ffj.07-103713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group">Nielsen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentzen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedersen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tramm, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rijken, P. F. J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bussink, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horsman, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ostergaard, L.</span><span> </span><span class="NLM_article-title">Combretastatin A-4 phosphate affects tumor vessel volume and size distribution as assessed using MRI-based vessel size imaging</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">6469</span><span class="NLM_x">–</span> <span class="NLM_lpage">6477</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-2014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1158%2F1078-0432.CCR-12-2014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=23071260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslKgurjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=6469-6477&author=T.+Nielsenauthor=L.+Bentzenauthor=M.+Pedersenauthor=T.+Trammauthor=P.+F.+J.+W.+Rijkenauthor=J.+Bussinkauthor=M.+R.+Horsmanauthor=L.+Ostergaard&title=Combretastatin+A-4+phosphate+affects+tumor+vessel+volume+and+size+distribution+as+assessed+using+MRI-based+vessel+size+imaging&doi=10.1158%2F1078-0432.CCR-12-2014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatin A-4 Phosphate Affects Tumor Vessel Volume and Size Distribution as Assessed Using MRI-Based Vessel Size Imaging</span></div><div class="casAuthors">Nielsen, Thomas; Bentzen, Lise; Pedersen, Michael; Tramm, Trine; Rijken, Paul F. J. W.; Bussink, Johan; Horsman, Michael R.; Ostergaard, Leif</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6469-6477</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Combretastatin A-4 disodium phosphate (CA4P) is a promising vascular disrupting agent (VDA) in clin. trials.  As CA4P acts on dividing endothelial cells, we hypothesize that CA4P affects vessels of certain sizes.  The aim of this study was to evaluate the effect of CA4P by the MRI-based vessel size imaging (VSI).  Exptl. Design: C3H mammary carcinomas were grown to 200 mm3 in the right rear foot of female CDF1 mice.  A control group of mice received no treatment, and a treatment group had CA4P administered i.p. at a dose of 250 mg/kg.  VSI was conducted on a 3 T MR scanner to est. the tumor blood vol. (ζ0) and mean vessel radius (R).  Vascularization was also estd. histol. by endothelial and Hoechst 33342 staining.  Results: ζ0 and R showed different spatial heterogeneity.  Tumor median and quartile values of ζ0 were all significantly reduced by about 35% in the CA4P-treated group as compared with the control group, and the median and upper quartile of R were significantly increased.  Histograms of ζ0 and R showed a general decrease in ζ0 following treatment, and values of R in a certain range (≈20-30 μm) were decreased in the treatment group.  The drug-induced change in ζ0 was in agreement with histol. and our previous dynamic contrast enhanced MRI (DCE-MRI) data.  Conclusions: Tumor blood vol. and mean vessel radius showed a clear response following treatment with CA4P.  VSI may prove valuable in estn. of tumor angiogenesis and prediction of response to VDAs.  Clin Cancer Res; 18(23); 6469-77. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMyMKTh5kSQ7Vg90H21EOLACvtfcHk0lj-aIbr_1wQWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslKgurjE&md5=1394edb3198d2e601903c171f6f379c0</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-2014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-2014%26sid%3Dliteratum%253Aachs%26aulast%3DNielsen%26aufirst%3DT.%26aulast%3DBentzen%26aufirst%3DL.%26aulast%3DPedersen%26aufirst%3DM.%26aulast%3DTramm%26aufirst%3DT.%26aulast%3DRijken%26aufirst%3DP.%2BF.%2BJ.%2BW.%26aulast%3DBussink%26aufirst%3DJ.%26aulast%3DHorsman%26aufirst%3DM.%2BR.%26aulast%3DOstergaard%26aufirst%3DL.%26atitle%3DCombretastatin%2520A-4%2520phosphate%2520affects%2520tumor%2520vessel%2520volume%2520and%2520size%2520distribution%2520as%2520assessed%2520using%2520MRI-based%2520vessel%2520size%2520imaging%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D6469%26epage%3D6477%26doi%3D10.1158%2F1078-0432.CCR-12-2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group">Horsman, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murata, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breidahl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, F. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maxwell, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stødkiled-Jørgensen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overgaard, J.</span><span> </span><span class="NLM_article-title">Combretastatins novel vascular targeting drugs for improving anti-cancer therapy: Combretastatins and conventional therapy</span> <span class="citation_source-journal">Adv. Exp. Med. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">476</span><span class="NLM_x">, </span> <span class="NLM_fpage">311</span><span class="NLM_x">–</span> <span class="NLM_lpage">323</span><span class="refDoi"> DOI: 10.1007/978-1-4615-4221-6_26</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1007%2F978-1-4615-4221-6_26" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=476&publication_year=2000&pages=311-323&author=M.+R.+Horsmanauthor=R.+Murataauthor=T.+Breidahlauthor=F.+U.+Nielsenauthor=R.+J.+Maxwellauthor=H.+St%C3%B8dkiled-J%C3%B8rgensenauthor=J.+Overgaard&title=Combretastatins+novel+vascular+targeting+drugs+for+improving+anti-cancer+therapy%3A+Combretastatins+and+conventional+therapy&doi=10.1007%2F978-1-4615-4221-6_26"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1007%2F978-1-4615-4221-6_26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4615-4221-6_26%26sid%3Dliteratum%253Aachs%26aulast%3DHorsman%26aufirst%3DM.%2BR.%26aulast%3DMurata%26aufirst%3DR.%26aulast%3DBreidahl%26aufirst%3DT.%26aulast%3DNielsen%26aufirst%3DF.%2BU.%26aulast%3DMaxwell%26aufirst%3DR.%2BJ.%26aulast%3DSt%25C3%25B8dkiled-J%25C3%25B8rgensen%26aufirst%3DH.%26aulast%3DOvergaard%26aufirst%3DJ.%26atitle%3DCombretastatins%2520novel%2520vascular%2520targeting%2520drugs%2520for%2520improving%2520anti-cancer%2520therapy%253A%2520Combretastatins%2520and%2520conventional%2520therapy%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2000%26volume%3D476%26spage%3D311%26epage%3D323%26doi%3D10.1007%2F978-1-4615-4221-6_26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group">Lunt, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akerman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyes-Aldasoro, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozer, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanthou, C.</span><span> </span><span class="NLM_article-title">Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">1979</span><span class="NLM_x">–</span> <span class="NLM_lpage">1989</span><span class="refDoi"> DOI: 10.1002/ijc.25848</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1002%2Fijc.25848" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=21154772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVKlsrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2011&pages=1979-1989&author=S.+J.+Luntauthor=S.+Akermanauthor=S.+A.+Hillauthor=M.+Fisherauthor=V.+J.+Wrightauthor=C.+C.+Reyes-Aldasoroauthor=G.+M.+Tozerauthor=C.+Kanthou&title=Vascular+effects+dominate+solid+tumor+response+to+treatment+with+combretastatin+A-4-phosphate&doi=10.1002%2Fijc.25848"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate</span></div><div class="casAuthors">Lunt, Sarah Jane; Akerman, Simon; Hill, Sally A.; Fisher, Matthew; Wright, Victoria J.; Reyes-Aldasoro, Constantino C.; Tozer, Gillian M.; Kanthou, Chryso</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1979-1989</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Vascular-targeted therapeutics are increasingly used in the clinic.  However, less is known about the direct response of tumor cells to these agents.  We have developed a combretastatin-A-4-phosphate (CA4P) resistant variant of SW1222 human colorectal carcinoma cells to examine the relative importance of vascular vs. tumor cell targeting in the ultimate treatment response.  SW1222Res cells were generated through exposure of wild-type cells (SW1222WT) to increasing CA4P concns. in vitro.  Increased resistance was confirmed through analyses of cell viability, apoptosis and multidrug-resistance (MDR) protein expression.  In vivo, comparative studies examd. tumor cell necrosis, apoptosis, vessel morphol. and functional vascular end-points following treatment with CA4P (single 100 mg/kg dose).  Tumor response to repeated CA4P dosing (50 mg/kg/day, 5 days/wk for 2 wk) was examd. through growth measurement, and ultimate tumor cell survival was studied by ex vivo clonogenic assay.  In vitro, SW1222Res cells showed reduced CA4P sensitivity, enhanced MDR protein expression and a reduced apoptotic index.  In vivo, CA4P induced significantly lower apoptotic cell death in SW1222Res vs. SW1222WT tumors indicating maintenance of resistance characteristics.  However, CA4P-induced tumor necrosis was equiv. in both lines.  Similarly, rapid CA4P-mediated vessel disruption and blood flow shut-down were obsd. in both lines.  Cell surviving fraction was comparable in the two tumor types following single dose CA4P and SW1222Res tumors were at least as sensitive as SW1222WT tumors to repeated dosing.  Despite tumor cell resistance to CA4P, SW1222Res response in vivo was not impaired, strongly supporting the view that vascular damage dominates the therapeutic response to this agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXfeiOzwb1brVg90H21EOLACvtfcHk0lh8KhClUlCkSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVKlsrvI&md5=155f50bc021c9117845b47f4b63268b8</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1002%2Fijc.25848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.25848%26sid%3Dliteratum%253Aachs%26aulast%3DLunt%26aufirst%3DS.%2BJ.%26aulast%3DAkerman%26aufirst%3DS.%26aulast%3DHill%26aufirst%3DS.%2BA.%26aulast%3DFisher%26aufirst%3DM.%26aulast%3DWright%26aufirst%3DV.%2BJ.%26aulast%3DReyes-Aldasoro%26aufirst%3DC.%2BC.%26aulast%3DTozer%26aufirst%3DG.%2BM.%26aulast%3DKanthou%26aufirst%3DC.%26atitle%3DVascular%2520effects%2520dominate%2520solid%2520tumor%2520response%2520to%2520treatment%2520with%2520combretastatin%2520A-4-phosphate%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2011%26volume%3D129%26spage%3D1979%26epage%3D1989%26doi%3D10.1002%2Fijc.25848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group">Ley, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horsman, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kristjansen, P. E. G.</span><span> </span><span class="NLM_article-title">Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure</span> <span class="citation_source-journal">Neoplasia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">108</span><span class="NLM_x">–</span> <span class="NLM_lpage">112</span><span class="refDoi"> DOI: 10.1593/neo.06733</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1593%2Fneo.06733" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2007&pages=108-112&author=C.+D.+Leyauthor=M.+R.+Horsmanauthor=P.+E.+G.+Kristjansen&title=Early+effects+of+combretastatin-A4+disodium+phosphate+on+tumor+perfusion+and+interstitial+fluid+pressure&doi=10.1593%2Fneo.06733"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1593%2Fneo.06733&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Fneo.06733%26sid%3Dliteratum%253Aachs%26aulast%3DLey%26aufirst%3DC.%2BD.%26aulast%3DHorsman%26aufirst%3DM.%2BR.%26aulast%3DKristjansen%26aufirst%3DP.%2BE.%2BG.%26atitle%3DEarly%2520effects%2520of%2520combretastatin-A4%2520disodium%2520phosphate%2520on%2520tumor%2520perfusion%2520and%2520interstitial%2520fluid%2520pressure%26jtitle%3DNeoplasia%26date%3D2007%26volume%3D9%26spage%3D108%26epage%3D112%26doi%3D10.1593%2Fneo.06733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group">Williams, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukherjee, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyes-Aldasoro, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akerman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanthou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozer, G. M.</span><span> </span><span class="NLM_article-title">An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">171</span><span class="NLM_x">, </span> <span class="NLM_fpage">4902</span><span class="NLM_x">–</span> <span class="NLM_lpage">4913</span><span class="refDoi"> DOI: 10.1111/bph.12817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1111%2Fbph.12817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=24930520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVSjsLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2014&pages=4902-4913&author=L.+J.+Williamsauthor=D.+Mukherjeeauthor=M.+Fisherauthor=C.+C.+Reyes-Aldasoroauthor=S.+Akermanauthor=C.+Kanthouauthor=G.+M.+Tozer&title=An+in+vivo+role+for+Rho+kinase+activation+in+the+tumour+vascular+disrupting+activity+of+combretastatin+A-4+3-O-phosphate&doi=10.1111%2Fbph.12817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate</span></div><div class="casAuthors">Williams, L. J.; Mukherjee, D.; Fisher, M.; Reyes-Aldasoro, C. C.; Akerman, S.; Kanthou, C.; Tozer, G. M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4902-4913</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Combretastatin A-4 3-O-phosphate (CA4P) is in clin. trial as a tumor vascular disrupting agent (VDA) but the cause of blood flow disruption is unclear.  We tested the hypothesis that activation of Rho/Rho kinase (ROCK) is fundamental to the effects of this drug in vivo.  Mouse models of human colorectal carcinoma (SW1222 and LS174T) were used.  Effects of the ROCK inhibitor, Y27632, alone or in combination with CA4P, on ROCK activity, vascular function, necrosis and immune cell infiltration in solid tumors were detd.  Mean arterial BP (MABP) was measured to monitor systemic interactions and the vasodilator, hydralazine, was used to control for the hypotensive effects of Y27632.  Y27632 caused a rapid drop in blood flow in SW1222 tumors, with recovery by around 3 h, which was paralleled by MABP changes.  Y27632 pretreatment reduced CA4P-induced ROCK activation and partially blocked CA4P-induced tumor vascular effects, in both tumor types.  Y27632 also partially inhibited CA4P-induced tumor necrosis and was assocd. with reduced immune cell infiltration in SW1222 tumors.  Hydralazine caused a similar hypotensive effect as Y27632 but had no protective effect against CA4P treatment.  These results demonstrate that ROCK activity is crit. for full manifestation of the vascular activity of CA4P in vivo, providing the evidence for pharmacol. intervention to enhance the anti-tumor efficacy of CA4P and related VDAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb3sOB9jdFIrVg90H21EOLACvtfcHk0lh8KhClUlCkSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVSjsLbF&md5=044a7f085749c5ca6d8f3eac8438375d</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1111%2Fbph.12817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12817%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DL.%2BJ.%26aulast%3DMukherjee%26aufirst%3DD.%26aulast%3DFisher%26aufirst%3DM.%26aulast%3DReyes-Aldasoro%26aufirst%3DC.%2BC.%26aulast%3DAkerman%26aufirst%3DS.%26aulast%3DKanthou%26aufirst%3DC.%26aulast%3DTozer%26aufirst%3DG.%2BM.%26atitle%3DAn%2520in%2520vivo%2520role%2520for%2520Rho%2520kinase%2520activation%2520in%2520the%2520tumour%2520vascular%2520disrupting%2520activity%2520of%2520combretastatin%2520A-4%25203-O-phosphate%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D171%26spage%3D4902%26epage%3D4913%26doi%3D10.1111%2Fbph.12817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group">Vincent, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kermani, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shido, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bompais-Vincent, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohlen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">May, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafii, S.</span><span> </span><span class="NLM_article-title">Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">2992</span><span class="NLM_x">–</span> <span class="NLM_lpage">3006</span><span class="refDoi"> DOI: 10.1172/JCI24586</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1172%2FJCI24586" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=16224539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtF2kt73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2005&pages=2992-3006&author=L.+Vincentauthor=P.+Kermaniauthor=L.+M.+Youngauthor=J.+Chengauthor=F.+Zhangauthor=K.+Shidoauthor=G.+Lamauthor=H.+Bompais-Vincentauthor=Z.+Zhuauthor=D.+J.+Hicklinauthor=P.+Bohlenauthor=D.+J.+Chaplinauthor=C.+Mayauthor=S.+Rafii&title=Combretastatin+A4+phosphate+induces+rapid+regression+of+tumor+neovessels+and+growth+through+interference+with+vascular+endothelial-cadherin+signaling&doi=10.1172%2FJCI24586"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling</span></div><div class="casAuthors">Vincent, Loic; Kermani, Pouneh; Young, Lauren M.; Cheng, Joseph; Zhang, Fan; Shido, Koji; Lam, George; Bompais-Vincent, Heidi; Zhu, Zhenping; Hicklin, Daniel J.; Bohlen, Peter; Chaplin, David J.; May, Chad; Rafii, Shahin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2992-3006</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">The mol. and cellular pathways that support the maintenance and stability of tumor neovessels are not well defined.  The efficacy of microtubule-disrupting agents, such as combretastatin A4 phosphate (CA4P), in inducing rapid regression of specific subsets of tumor neovessels has opened up new avenues of research to identify factors that support tumor neoangiogenesis.  Herein, we show that CA4P selectively targeted endothelial cells, but not smooth muscle cells, and induced regression of unstable nascent tumor neovessels by rapidly disrupting the mol. engagement of the endothelial cell-specific junctional mol. vascular endothelial-cadherin (VE-cadherin) in vitro and in vivo in mice.  CA4P increases endothelial cell permeability, while inhibiting endothelial cell migration and capillary tube formation predominantly through disruption of VE-cadherin/β-catenin/Akt signaling pathway, thereby leading to rapid vascular collapse and tumor necrosis.  Remarkably, stabilization of VE-cadherin signaling in endothelial cells with adenovirus E4 gene or ensheathment with smooth muscle cells confers resistance to CA4P.  CA4P synergizes with low and nontoxic doses of neutralizing mAbs to VE-cadherin by blocking assembly of neovessels, thereby inhibiting tumor growth.  These data suggest that the microtubule-targeting agent CA4P selectively induces regression of unstable tumor neovessels, in part through disruption of VE-cadherin signaling.  Combined treatment with anti-VE-cadherin agents in conjunction with microtubule-disrupting agents provides a novel synergistic strategy to selectively disrupt assembly and induce regression of nascent tumor neovessels, with minimal toxicity and without affecting normal stabilized vasculature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKFBiwt81RFbVg90H21EOLACvtfcHk0ljzrOlzBjzr4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtF2kt73M&md5=b36f1e2a344823daaacccd7925b4b4ce</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1172%2FJCI24586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI24586%26sid%3Dliteratum%253Aachs%26aulast%3DVincent%26aufirst%3DL.%26aulast%3DKermani%26aufirst%3DP.%26aulast%3DYoung%26aufirst%3DL.%2BM.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DShido%26aufirst%3DK.%26aulast%3DLam%26aufirst%3DG.%26aulast%3DBompais-Vincent%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DBohlen%26aufirst%3DP.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DMay%26aufirst%3DC.%26aulast%3DRafii%26aufirst%3DS.%26atitle%3DCombretastatin%2520A4%2520phosphate%2520induces%2520rapid%2520regression%2520of%2520tumor%2520neovessels%2520and%2520growth%2520through%2520interference%2520with%2520vascular%2520endothelial-cadherin%2520signaling%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2005%26volume%3D115%26spage%3D2992%26epage%3D3006%26doi%3D10.1172%2FJCI24586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group">Hussain, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steimle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoppeler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egginton, S.</span><span> </span><span class="NLM_article-title">The vascular-disrupting agent combretastatin impairs splitting and sprouting forms of physiological angiogenesis</span> <span class="citation_source-journal">Microcirculation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">296</span><span class="NLM_x">–</span> <span class="NLM_lpage">305</span><span class="refDoi"> DOI: 10.1111/j.1549-8719.2012.00160.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1111%2Fj.1549-8719.2012.00160.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=296-305&author=A.+Hussainauthor=M.+Steimleauthor=H.+Hoppelerauthor=O.+Baumauthor=S.+Egginton&title=The+vascular-disrupting+agent+combretastatin+impairs+splitting+and+sprouting+forms+of+physiological+angiogenesis&doi=10.1111%2Fj.1549-8719.2012.00160.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1111%2Fj.1549-8719.2012.00160.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1549-8719.2012.00160.x%26sid%3Dliteratum%253Aachs%26aulast%3DHussain%26aufirst%3DA.%26aulast%3DSteimle%26aufirst%3DM.%26aulast%3DHoppeler%26aufirst%3DH.%26aulast%3DBaum%26aufirst%3DO.%26aulast%3DEgginton%26aufirst%3DS.%26atitle%3DThe%2520vascular-disrupting%2520agent%2520combretastatin%2520impairs%2520splitting%2520and%2520sprouting%2520forms%2520of%2520physiological%2520angiogenesis%26jtitle%3DMicrocirculation%26date%3D2012%26volume%3D19%26spage%3D296%26epage%3D305%26doi%3D10.1111%2Fj.1549-8719.2012.00160.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group">Jiang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span> </span><span class="NLM_article-title">Deoxypodophyllotoxin exerts both anti-angiogenic and vascular disrupting effects</span> <span class="citation_source-journal">Int. J. Biochem. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">1710</span><span class="NLM_x">–</span> <span class="NLM_lpage">1719</span><span class="refDoi"> DOI: 10.1016/j.biocel.2013.04.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.biocel.2013.04.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=23702033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFaktLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2013&pages=1710-1719&author=Z.+Jiangauthor=M.+Wuauthor=J.+Miaoauthor=H.+Duanauthor=S.+Zhangauthor=M.+Chenauthor=L.+Sunauthor=Y.+Wangauthor=X.+Zhangauthor=X.+Zhuauthor=L.+Zhang&title=Deoxypodophyllotoxin+exerts+both+anti-angiogenic+and+vascular+disrupting+effects&doi=10.1016%2Fj.biocel.2013.04.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Deoxypodophyllotoxin exerts both anti-angiogenic and vascular disrupting effects</span></div><div class="casAuthors">Jiang, Zhenzhou; Wu, Meijuan; Miao, Jingshan; Duan, Huaqin; Zhang, Shuang; Chen, Mi; Sun, Lixin; Wang, Yurong; Zhang, Xueji; Zhu, Xiong; Zhang, Luyong</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1710-1719</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A functioning vascular supply is essential for solid tumor growth and metastases, which means that blood vessels are an ideal target for antitumor drug discovery.  Targeting tumor vasculature involves two main approaches, anti-angiogenesis and vascular disruption.  The anti-angiogenic and vascular disrupting activities of deoxypodophyllotoxin (DPT), a natural microtubule destabilizer, were examd. with several in vitro, ex vivo and/or in vivo models.  First, we demonstrated that DPT significantly inhibits the proliferation, migration and tube formation of endothelial cells and inhibits angiogenesis in rat aortic ring and chick chorioallantoic membrane assays.  In further studies, DPT induced cytoskeleton reorganization in endothelial cells, which likely contributed to the anti-angiogenic effect at non-cytotoxic concns.  DPT treatment at higher concns. for longer time induced the cell cycle arrest, which may contributes to its anti-proliferation effect and anti-angiogenic activity.  And DPT dramatically inducted the expression of cyclin B1 and p21 (WAF1/CIP1).  Meanwhile, DPT disrupted capillary-like networks in vitro and newly formed vessels from rat aortic rings.  Endothelial cell contraction assocd. with an increase in F-actin via the Rho/Rho kinase pathway likely contributed to the vascular disrupting activity.  Taken together, our results provided the initial evidence that DPT exerts potent anti-angiogenic and vascular disrupting effects.  This study also provides important insight into the mechanism of action of promising new anticancer drugs with both anti-angiogenic and vascular disrupting activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWcp6tQaGNWrVg90H21EOLACvtfcHk0ljzrOlzBjzr4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFaktLfJ&md5=c5a4c8b11434b89318286dcae35bd3ce</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1016%2Fj.biocel.2013.04.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biocel.2013.04.030%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DMiao%26aufirst%3DJ.%26aulast%3DDuan%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DDeoxypodophyllotoxin%2520exerts%2520both%2520anti-angiogenic%2520and%2520vascular%2520disrupting%2520effects%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2013%26volume%3D45%26spage%3D1710%26epage%3D1719%26doi%3D10.1016%2Fj.biocel.2013.04.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group">Ahmed, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Eijk, L. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouma-ter Steege, J. C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Der Schaft, D. W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Esch, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joosten-Achjanie, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landuyt, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffioen, A. W.</span><span> </span><span class="NLM_article-title">Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">20</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span><span class="refDoi"> DOI: 10.1002/ijc.11010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1002%2Fijc.11010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=12672025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtVWrsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2003&pages=20-25&author=B.+Ahmedauthor=L.+I.+Van+Eijkauthor=J.+C.+A.+Bouma-ter+Steegeauthor=D.+W.+J.+Van+Der+Schaftauthor=A.+M.+Van+Eschauthor=S.+R.+Joosten-Achjanieauthor=P.+Lambinauthor=W.+Landuytauthor=A.+W.+Griffioen&title=Vascular+targeting+effect+of+combretastatin+A-4+phosphate+dominates+the+inherent+angiogenesis+inhibitory+activity&doi=10.1002%2Fijc.11010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity</span></div><div class="casAuthors">Ahmed, Bisan; van Eijk, Loes I.; Bouma-ter Steege, Jessica C. A.; van der Schaft, Daisy W. J.; van Esch, Anita M.; Joosten-Achjanie, Susan R.; Lambin, Philippe; Landuyt, Willy; Griffioen, Arjan W.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-25</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The current research aimed to define hypothesis-based anti-angiogenic properties of the vascular targeting agent combretastatin A-4 phosphate (combreAp).  The in vitro wound assay indicated that combreAp potently inhibited migration of endothelial cells (EC).  A significant inhibition of migration could already be measured after 2 h of treatment.  In a three-dimensional (3D) tube formation assay, combreAp inhibited sprout formation at concns. that did not inhibit the proliferation of EC.  At sub-ng concns. the half-maximal response was reached.  Interestingly, although combreAp is considered a vascular targeting agent, the human tumor cell lines tested were found to be 20-30 times more sensitive for combreAp than the human umbilical vein endothelial cells (HUVEC).  A similar response difference between rat EC and RI rat rhabdomyosarcoma tumor cells was obsd.  The growth inhibition in EC was only in part mediated by induction of apoptosis.  The growth delay results obtained with the in vivo rodent tumor models involving repeat dosing of combreAp can partly be explained by anti-angiogenic activity of the compd.  The results obtained with the various in vitro and in vivo assays substantiate an anti-angiogenic profile of combreAp, largely at the level of EC migration.  This mechanism may operate to a different extent in different tumor types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeVFxAZLthCbVg90H21EOLACvtfcHk0lhAaddPcSFFRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtVWrsr4%253D&md5=fa5c45dc32672fe33b7dd33398398d10</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1002%2Fijc.11010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.11010%26sid%3Dliteratum%253Aachs%26aulast%3DAhmed%26aufirst%3DB.%26aulast%3DVan%2BEijk%26aufirst%3DL.%2BI.%26aulast%3DBouma-ter%2BSteege%26aufirst%3DJ.%2BC.%2BA.%26aulast%3DVan%2BDer%2BSchaft%26aufirst%3DD.%2BW.%2BJ.%26aulast%3DVan%2BEsch%26aufirst%3DA.%2BM.%26aulast%3DJoosten-Achjanie%26aufirst%3DS.%2BR.%26aulast%3DLambin%26aufirst%3DP.%26aulast%3DLanduyt%26aufirst%3DW.%26aulast%3DGriffioen%26aufirst%3DA.%2BW.%26atitle%3DVascular%2520targeting%2520effect%2520of%2520combretastatin%2520A-4%2520phosphate%2520dominates%2520the%2520inherent%2520angiogenesis%2520inhibitory%2520activity%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2003%26volume%3D105%26spage%3D20%26epage%3D25%26doi%3D10.1002%2Fijc.11010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group">Porcù, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viola, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bortolozzi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persano, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitola, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ronca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Presta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romagnoli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baraldi, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basso, G.</span><span> </span><span class="NLM_article-title">TR-644 a novel potent tubulin binding agent induces impairment of endothelial cells function and inhibits angiogenesis</span> <span class="citation_source-journal">Angiogenesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">647</span><span class="NLM_x">–</span> <span class="NLM_lpage">662</span><span class="refDoi"> DOI: 10.1007/s10456-013-9343-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1007%2Fs10456-013-9343-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=23456551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXps1yksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2013&pages=647-662&author=E.+Porc%C3%B9author=G.+Violaauthor=R.+Bortolozziauthor=L.+Persanoauthor=S.+Mitolaauthor=R.+Roncaauthor=M.+Prestaauthor=R.+Romagnoliauthor=P.+G.+Baraldiauthor=G.+Basso&title=TR-644+a+novel+potent+tubulin+binding+agent+induces+impairment+of+endothelial+cells+function+and+inhibits+angiogenesis&doi=10.1007%2Fs10456-013-9343-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">TR-644 a novel potent tubulin binding agent induces impairment of endothelial cells function and inhibits angiogenesis</span></div><div class="casAuthors">Porcu, Elena; Viola, Giampietro; Bortolozzi, Roberta; Persano, Luca; Mitola, Stefania; Ronca, Roberto; Presta, Marco; Romagnoli, Romeo; Baraldi, Pier Giovanni; Basso, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Angiogenesis</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">647-662</span>CODEN:
                <span class="NLM_cas:coden">AGIOFT</span>;
        ISSN:<span class="NLM_cas:issn">0969-6970</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">TR-644 is a novel combretastatin A-4 (CA-4) analog endowed with potent microtubule depolymg. activity superior to that of the lead compd. and it also has high affinity to colchicines binding site of tubulin.  We tested TR-644 anti-angiogenic effects in human umbilical endothelial cells (HUVEC).  It showed no significant effects on the growth of HUVEC cells at concns. below 1,000 nM, but at much lower concns. (10-100 nM) it induced inhibition of capillary tube formation, inhibition of endothelial cell migration and affected endothelial cell morphol. as demonstrated by the disruption of the microtubule network.  TR-644 also increased permeability of HUVEC cells in a time dependent manner.  The mol. mechanism for the anti-vascular activity of TR-644 was investigated in detail.  TR-644 caused G2/M arrest in endothelial cells and this effect correlated with downregulation of the expression of Cdc25C and Cdc2Tyr15.  Moreover TR-644 inhibited VEGF-induced phosphorylation of VE-cadherin but did not prevent the VEGF-induced phosphorylation of FAK.  In chick chorioallantoic membrane in vivo assay, TR-644 (0.1-1.0 pmol/egg) efficiently counteracted the strong angiogenic response induced by FGF.  Also CA-4, used as ref. compd., caused an antagonistic effect, but in contrast, it induced per se, a remarkable angiogenic response probably due to an inflammatory reaction in the site of treatment.  In a mice allogenic tumor model, immunohistochem. staining of tumors with anti-CD31 antibody showed that TR-644 significantly reduced the no. of vessel, after 24 h from the administration of a single dose (30 mg/Kg).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjdcGwvsKlwbVg90H21EOLACvtfcHk0lhAaddPcSFFRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXps1yksbk%253D&md5=701845b28683c4a73edd13455485c742</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1007%2Fs10456-013-9343-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10456-013-9343-z%26sid%3Dliteratum%253Aachs%26aulast%3DPorc%25C3%25B9%26aufirst%3DE.%26aulast%3DViola%26aufirst%3DG.%26aulast%3DBortolozzi%26aufirst%3DR.%26aulast%3DPersano%26aufirst%3DL.%26aulast%3DMitola%26aufirst%3DS.%26aulast%3DRonca%26aufirst%3DR.%26aulast%3DPresta%26aufirst%3DM.%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DBasso%26aufirst%3DG.%26atitle%3DTR-644%2520a%2520novel%2520potent%2520tubulin%2520binding%2520agent%2520induces%2520impairment%2520of%2520endothelial%2520cells%2520function%2520and%2520inhibits%2520angiogenesis%26jtitle%3DAngiogenesis%26date%3D2013%26volume%3D16%26spage%3D647%26epage%3D662%26doi%3D10.1007%2Fs10456-013-9343-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group">Samarin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rehm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waschke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goppelt-Struebe, M.</span><span> </span><span class="NLM_article-title">Up-regulation of connective tissue growth factor in endothelial cells by the microtubule-destabilizing agent combretastatin A-4</span> <span class="citation_source-journal">Mol. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">180</span><span class="NLM_x">–</span> <span class="NLM_lpage">188</span><span class="refDoi"> DOI: 10.1158/1541-7786.MCR-08-0292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1158%2F1541-7786.MCR-08-0292" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=19208742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitlWgsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=180-188&author=J.+Samarinauthor=M.+Rehmauthor=B.+Kruegerauthor=J.+Waschkeauthor=M.+Goppelt-Struebe&title=Up-regulation+of+connective+tissue+growth+factor+in+endothelial+cells+by+the+microtubule-destabilizing+agent+combretastatin+A-4&doi=10.1158%2F1541-7786.MCR-08-0292"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Up-Regulation of Connective Tissue Growth Factor in Endothelial Cells by the Microtubule-Destabilizing Agent Combretastatin A-4</span></div><div class="casAuthors">Samarin, Jana; Rehm, Margot; Krueger, Bettina; Waschke, Jens; Goppelt-Struebe, Margarete</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">180-188</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Incubation of microvascular endothelial cells with combretastatin A-4 phosphate (CA-4P), a microtubule-destabilizing compd. that preferentially targets tumor vessels, altered cell morphol. and induced scattering of Golgi stacks.  Concomitantly, CA-4P up-regulated connective tissue growth factor (CTGF/CCN2), a pleiotropic factor with antiangiogenic properties.  In contrast to the effects of other microtubule-targeting agents such as colchicine or nocodazole, up-regulation of CTGF was only detectable in sparse cells, which were not embedded in a cell monolayer.  Furthermore, CA-4P induced CTGF expression in endothelial cells, forming tube-like structures on basement membrane gels.  Up-regulation of CTGF by CA-4P was dependent on Rho kinase signaling and was increased when p42/44 mitogen-activated protein kinase was inhibited.  Addnl., FoxO transcription factors were identified as potent regulators of CTGF expression in endothelial cells.  Activation of FoxO transcription factors by inhibition of phosphatidylinositol 3-kinase/AKT signaling resulted in a synergistic increase in CA-4P-mediated CTGF induction.  CA-4P-mediated expression of CTGF was thus potentiated by the inhibition of kinase pathways, which are targets of novel antineoplastic drugs.  Up-regulation of CTGF by low concns. of CA-4P may thus occur in newly formed tumor vessels and contribute to the microvessel destabilization and antiangiogenic effects of CA-4P obsd. in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5clL-00SGILVg90H21EOLACvtfcHk0lhAaddPcSFFRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitlWgsb8%253D&md5=4095a38d90ccae5cdf980a22415e72d8</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-08-0292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-08-0292%26sid%3Dliteratum%253Aachs%26aulast%3DSamarin%26aufirst%3DJ.%26aulast%3DRehm%26aufirst%3DM.%26aulast%3DKrueger%26aufirst%3DB.%26aulast%3DWaschke%26aufirst%3DJ.%26aulast%3DGoppelt-Struebe%26aufirst%3DM.%26atitle%3DUp-regulation%2520of%2520connective%2520tissue%2520growth%2520factor%2520in%2520endothelial%2520cells%2520by%2520the%2520microtubule-destabilizing%2520agent%2520combretastatin%2520A-4%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2009%26volume%3D7%26spage%3D180%26epage%3D188%26doi%3D10.1158%2F1541-7786.MCR-08-0292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group">Alotaibi, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asnake, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durrant, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simoni, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baruchello, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gewirtz, D. A.</span><span> </span><span class="NLM_article-title">Stilbene 5c, a microtubule poison with vascular disrupting properties that induces multiple modes of growth arrest and cell death</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">1688</span><span class="NLM_x">–</span> <span class="NLM_lpage">1698</span><span class="refDoi"> DOI: 10.1016/j.bcp.2013.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.bcp.2013.10.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2013&pages=1688-1698&author=M.+R.+Alotaibiauthor=B.+Asnakeauthor=X.+Diauthor=M.+J.+Beckmanauthor=D.+Durrantauthor=D.+Simoniauthor=R.+Baruchelloauthor=R.+M.+Leeauthor=E.+L.+Schwartzauthor=D.+A.+Gewirtz&title=Stilbene+5c%2C+a+microtubule+poison+with+vascular+disrupting+properties+that+induces+multiple+modes+of+growth+arrest+and+cell+death&doi=10.1016%2Fj.bcp.2013.10.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2013.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2013.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DAlotaibi%26aufirst%3DM.%2BR.%26aulast%3DAsnake%26aufirst%3DB.%26aulast%3DDi%26aufirst%3DX.%26aulast%3DBeckman%26aufirst%3DM.%2BJ.%26aulast%3DDurrant%26aufirst%3DD.%26aulast%3DSimoni%26aufirst%3DD.%26aulast%3DBaruchello%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DR.%2BM.%26aulast%3DSchwartz%26aufirst%3DE.%2BL.%26aulast%3DGewirtz%26aufirst%3DD.%2BA.%26atitle%3DStilbene%25205c%252C%2520a%2520microtubule%2520poison%2520with%2520vascular%2520disrupting%2520properties%2520that%2520induces%2520multiple%2520modes%2520of%2520growth%2520arrest%2520and%2520cell%2520death%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2013%26volume%3D86%26spage%3D1688%26epage%3D1698%26doi%3D10.1016%2Fj.bcp.2013.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group">Shen, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shee, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y. W.</span><span> </span><span class="NLM_article-title">Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">160</span><span class="NLM_x">, </span> <span class="NLM_fpage">2008</span><span class="NLM_x">–</span> <span class="NLM_lpage">2027</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.00861.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1111%2Fj.1476-5381.2010.00861.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=20649598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Kjur3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2010&pages=2008-2027&author=C.+H.+Shenauthor=J.+J.+Sheeauthor=J.+Y.+Wuauthor=Y.+W.+Linauthor=J.+D.+Wuauthor=Y.+W.+Liu&title=Combretastatin+A-4+inhibits+cell+growth+and+metastasis+in+bladder+cancer+cells+and+retards+tumour+growth+in+a+murine+orthotopic+bladder+tumour+model&doi=10.1111%2Fj.1476-5381.2010.00861.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model</span></div><div class="casAuthors">Shen, Cheng-Huang; Shee, Jia-Jen; Wu, Jin-Yi; Lin, Yi-Wen; Wu, Jiann-Der; Liu, Yi-Wen</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2008-2027</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Bladder cancer is a highly recurrent cancer after intravesical therapy, so new drugs are needed to treat this cancer.  Hence, we investigated the anti-cancer activity of combretastatin A-4 (CA-4), an anti-tubulin agent, in human bladder cancer cells and in a murine orthotopic bladder tumor model.  Cytotoxicity of CA-4 was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, propidium iodide (PI) staining assay and clonogenic survival assay.  In vivo microtubule assembly assay, cell cycle analyses, Western blot and cell migration assay were used to study the mechanism of CA-4.  The effect of intravesical CA-4 therapy on the development of tumors was studied in the murine orthotopic bladder tumor model.  CA-4 inhibited microtubule polymn. in vivo.  Cytotoxic IC50 values of CA-4 in human bladder cancer cells were below 4 nM.  Analyses of cell-cycle distribution showed CA-4 obviously induced G2-M phase arrest with sub-G1 formation.  The analyses of apoptosis showed that CA-4 induced caspase-3 activation and decreased BubR1 and Bub3 in cancer cells.  In addn. to apoptosis, CA-4 was also found to induce the formation of multinucleated cells.  CA-4 had a significantly reduced cell migration in vitro.  Importantly, the in vivo study revealed that intravesical CA-4 therapy retarded the development of murine bladder tumors.  These data demonstrate that CA-4 kills bladder cancer cells by inducing apoptosis and mitotic catastrophe.  It inhibited cell migration in vitro and tumor growth in vivo.  Hence, CA-4 intravesical therapy could provide another strategy for treating superficial bladder cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2ISb0EU1aD7Vg90H21EOLACvtfcHk0lglSuxaDcBjFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Kjur3K&md5=e65336da5df600b9c02b8f26b7649f23</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00861.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00861.x%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DC.%2BH.%26aulast%3DShee%26aufirst%3DJ.%2BJ.%26aulast%3DWu%26aufirst%3DJ.%2BY.%26aulast%3DLin%26aufirst%3DY.%2BW.%26aulast%3DWu%26aufirst%3DJ.%2BD.%26aulast%3DLiu%26aufirst%3DY.%2BW.%26atitle%3DCombretastatin%2520A-4%2520inhibits%2520cell%2520growth%2520and%2520metastasis%2520in%2520bladder%2520cancer%2520cells%2520and%2520retards%2520tumour%2520growth%2520in%2520a%2520murine%2520orthotopic%2520bladder%2520tumour%2520model%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D160%26spage%3D2008%26epage%3D2027%26doi%3D10.1111%2Fj.1476-5381.2010.00861.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group">Kanthou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greco, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratford, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benzakour, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozer, G.</span><span> </span><span class="NLM_article-title">The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">165</span><span class="NLM_x">, </span> <span class="NLM_fpage">1401</span><span class="NLM_x">–</span> <span class="NLM_lpage">1411</span><span class="refDoi"> DOI: 10.1016/S0002-9440(10)63398-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2FS0002-9440%2810%2963398-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=15466404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptFSlsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2004&pages=1401-1411&author=C.+Kanthouauthor=O.+Grecoauthor=A.+Stratfordauthor=I.+Cookauthor=R.+Knightauthor=O.+Benzakourauthor=G.+Tozer&title=The+tubulin-binding+agent+combretastatin+A-4-phosphate+arrests+endothelial+cells+in+mitosis+and+induces+mitotic+cell+death&doi=10.1016%2FS0002-9440%2810%2963398-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death</span></div><div class="casAuthors">Kanthou, Chryso; Greco, Olga; Stratford, Anna; Cook, Ian; Knight, Richard; Benzakour, Omar; Tozer, Gillian</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1401-1411</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">The tubulin-binding agent combretastatin A-4-phosphate (CA-4-P), rapidly disrupts the vascular network of tumors leading to secondary tumor cell death.  In vitro, CA-4-P destabilizes microtubules and causes endothelial cell death.  In this study we analyze the mechanisms by which CA-4-P induces the death of proliferating endothelial cells, we demonstrate that at ≥7.5 nmol/L, CA-4-P damages mitotic spindles, arrests cells at metaphase, and leads to the death of mitotic veils with characteristic G2/M DNA content.  Mitotic arrest was assocd. with elevated levels of cyclin B1 protein and p34cdc2 activity.  Inhibition of P34odc2 activity by purvalanol A caused mitotic arrested cells to rapidly exit mitosis, suggesting that sustained p34cdc2 activity was responsible for metaphase arrest.  Pharmacol. prevention of entry into mitosis protected cells from undergoing cell death, further establishing the link between mitosis and cell death induction by CA-4-P.  CA-4-P-mediated cell death shared characteristics of apoptosis but was independent of caspase activation suggesting the involvement of a noncaspase pathway(s).  These data suggest that induction of apoptosis in endothelial cells by CA-4-P is assocd. with prolonged mitotic arrest.  Therefore, by activating cell death pathways, CA-4-P, in addn. to being an effective and vascular agent, tray also interfere with regrowth of blood vessels in the tumor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGog1b4gtWsXSLVg90H21EOLACvtfcHk0lglSuxaDcBjFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptFSlsr4%253D&md5=5419cef021fb851390f47a5048c63072</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2963398-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252963398-6%26sid%3Dliteratum%253Aachs%26aulast%3DKanthou%26aufirst%3DC.%26aulast%3DGreco%26aufirst%3DO.%26aulast%3DStratford%26aufirst%3DA.%26aulast%3DCook%26aufirst%3DI.%26aulast%3DKnight%26aufirst%3DR.%26aulast%3DBenzakour%26aufirst%3DO.%26aulast%3DTozer%26aufirst%3DG.%26atitle%3DThe%2520tubulin-binding%2520agent%2520combretastatin%2520A-4-phosphate%2520arrests%2520endothelial%2520cells%2520in%2520mitosis%2520and%2520induces%2520mitotic%2520cell%2520death%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2004%26volume%3D165%26spage%3D1401%26epage%3D1411%26doi%3D10.1016%2FS0002-9440%2810%2963398-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group">Nabha, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammad, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dandashi, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coupaye-Gerard, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aboukameel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Katib, A. M.</span><span> </span><span class="NLM_article-title">Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2735</span><span class="NLM_x">–</span> <span class="NLM_lpage">2741</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=12171907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD38XmvVahtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=2735-2741&author=S.+M.+Nabhaauthor=R.+M.+Mohammadauthor=M.+H.+Dandashiauthor=B.+Coupaye-Gerardauthor=A.+Aboukameelauthor=G.+R.+Pettitauthor=A.+M.+Al-Katib&title=Combretastatin-A4+prodrug+induces+mitotic+catastrophe+in+chronic+lymphocytic+leukemia+cell+line+independent+of+caspase+activation+and+poly%28ADP-ribose%29+polymerase+cleavage"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage</span></div><div class="casAuthors">Nabha, Sanaa M.; Mohammad, Ramzi M.; Dandashi, Mahmoud H.; Coupaye-Gerard, Brigitte; Aboukameel, Amro; Pettit, George R.; Al-Katib, Ayad M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2735-2741</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The authors have previously reported that combretastatin-A4 prodrug (CA4P), an antitubulin/antiangiogenic agent isolated from the South African willow tree Combretum caffrum, induced cell death primarily through mitotic catastrophe in a panel of human B-lymphoid tumors.  In this study, the authors investigated the mol. aspects of the mitotic catastrophe and whether or not it shares the same pathways of apoptosis.  For this the authors studied the effect of CA4P on selected markers of apoptosis [caspases 9 and 3, poly(ADP-ribose) polymerase (PARP), bcl-2, and bax] and G2-M protein regulators (p53, MDM2, 14-3-3.vsigma., GADD45, cdc2, cdc25, chk1, wee1, p21, and cyclin B1).  The chronic lymphocytic leukemia cell line WSU-CLL was used for this purpose.  Western blot anal. showed that 24 h of CA4P (5 nM) exposure induces caspase 9 activation and PARP cleavage.  However, the addn. of Z-Val-Ala-Asp-fluoromethylketone (a general caspase inhibitor) or Z-Leu-Glu(OMe)-His-Asp(OMe)-CH2F (a caspase 9 inhibitor) before CA4P treatment did not block cell death.  No change in bcl-2 or bax protein expression was obsd.  Exposure of WSU-CLL cells to 4 and 5 nM CA4P was assocd. with overprodn. of total p53 and no dramatic change in MDM2, 14-3-3.vsigma., GADD45, the cyclin-dependent kinase cdc2, its inhibitory phosphorylation, the cdc2-inhibitory kinase (wee1), chk1, or cdc25 hyperphosphorylation.  The overaccumulation of p21 and cyclin B1 protein was obvious at 24 h.  Furthermore, CA4P treatment showed an increase in the expression of a marker of mitosis (mitotic protein monoclonal-2 antibody) and an overaccumulation of the cyclin B in the nucleus.  The authors' findings suggest that CA4P induces mitotic catastrophe and arrest of WSU-CLL cells mostly in the M phase independent of p53 and independent of chk1 and cdc2 phosphorylation pathways.  Apoptosis is a 2ndary mechanism of death in a small proportion of cells through activation of caspase 9 and PARP cleavage.  The 2 mechanisms of cell death, i.e., mitotic catastrophe and apoptosis, are independent of each other in the authors' model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIOrpvUlDuxLVg90H21EOLACvtfcHk0ljHZaVFAIB9xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmvVahtL4%253D&md5=523b6c765d14abae0aaae2994e78c8e4</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNabha%26aufirst%3DS.%2BM.%26aulast%3DMohammad%26aufirst%3DR.%2BM.%26aulast%3DDandashi%26aufirst%3DM.%2BH.%26aulast%3DCoupaye-Gerard%26aufirst%3DB.%26aulast%3DAboukameel%26aufirst%3DA.%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DAl-Katib%26aufirst%3DA.%2BM.%26atitle%3DCombretastatin-A4%2520prodrug%2520induces%2520mitotic%2520catastrophe%2520in%2520chronic%2520lymphocytic%2520leukemia%2520cell%2520line%2520independent%2520of%2520caspase%2520activation%2520and%2520poly%2528ADP-ribose%2529%2520polymerase%2520cleavage%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2002%26volume%3D8%26spage%3D2735%26epage%3D2741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group">Vitale, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galluzzi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castedo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroemer, G.</span><span> </span><span class="NLM_article-title">Mitotic catastrophe: a mechanism for avoiding genomic instability</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">392</span><span class="refDoi"> DOI: 10.1038/nrm3115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1038%2Fnrm3115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=21527953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVSjs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=385-392&author=I.+Vitaleauthor=L.+Galluzziauthor=M.+Castedoauthor=G.+Kroemer&title=Mitotic+catastrophe%3A+a+mechanism+for+avoiding+genomic+instability&doi=10.1038%2Fnrm3115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Mitotic catastrophe: a mechanism for avoiding genomic instability</span></div><div class="casAuthors">Vitale, Ilio; Galluzzi, Lorenzo; Castedo, Maria; Kroemer, Guido</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">385-392</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The improper distribution of chromosomes during mitosis compromises cellular functions and can reduce cellular fitness or contribute to malignant transformation.  As a countermeasure, higher eukaryotes have developed strategies for eliminating mitosis-incompetent cells, one of which is mitotic catastrophe.  Mitotic catastrophe is driven by a complex and poorly understood signalling cascade but, from a functional perspective, it can be defined as an oncosuppressive mechanism that precedes (and is distinct from) apoptosis, necrosis or senescence.  Accordingly, the disruption of mitotic catastrophe ppts. tumorigenesis and cancer progression, and its induction constitutes a therapeutic endpoint.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_SWBPBcc957Vg90H21EOLACvtfcHk0ljHZaVFAIB9xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVSjs7o%253D&md5=1af21f749fca1bf75d526c38a75df61b</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1038%2Fnrm3115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3115%26sid%3Dliteratum%253Aachs%26aulast%3DVitale%26aufirst%3DI.%26aulast%3DGalluzzi%26aufirst%3DL.%26aulast%3DCastedo%26aufirst%3DM.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DMitotic%2520catastrophe%253A%2520a%2520mechanism%2520for%2520avoiding%2520genomic%2520instability%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2011%26volume%3D12%26spage%3D385%26epage%3D392%26doi%3D10.1038%2Fnrm3115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group">Nabha, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wall, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammad, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Katib, A. M.</span><span> </span><span class="NLM_article-title">Effects of Combretastatin A-4 prodrug against a panel of malignant human B-lymphoid cell lines</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">392</span><span class="refDoi"> DOI: 10.1097/00001813-200006000-00009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1097%2F00001813-200006000-00009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2000&pages=385-392&author=S.+M.+Nabhaauthor=N.+R.+Wallauthor=R.+M.+Mohammadauthor=G.+R.+Pettitauthor=A.+M.+Al-Katib&title=Effects+of+Combretastatin+A-4+prodrug+against+a+panel+of+malignant+human+B-lymphoid+cell+lines&doi=10.1097%2F00001813-200006000-00009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1097%2F00001813-200006000-00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00001813-200006000-00009%26sid%3Dliteratum%253Aachs%26aulast%3DNabha%26aufirst%3DS.%2BM.%26aulast%3DWall%26aufirst%3DN.%2BR.%26aulast%3DMohammad%26aufirst%3DR.%2BM.%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DAl-Katib%26aufirst%3DA.%2BM.%26atitle%3DEffects%2520of%2520Combretastatin%2520A-4%2520prodrug%2520against%2520a%2520panel%2520of%2520malignant%2520human%2520B-lymphoid%2520cell%2520lines%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2000%26volume%3D11%26spage%3D385%26epage%3D392%26doi%3D10.1097%2F00001813-200006000-00009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group">Cenciarelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanzarella, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitale, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pisano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crateri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meschini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arancia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antoccia, A.</span><span> </span><span class="NLM_article-title">The tubulin-depolymerising agent combretastatin-4 induces ectopic aster assembly and mitotic catastrophe in lung cancer cells H460</span> <span class="citation_source-journal">Apoptosis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">659</span><span class="NLM_x">–</span> <span class="NLM_lpage">669</span><span class="refDoi"> DOI: 10.1007/s10495-008-0200-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1007%2Fs10495-008-0200-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=659-669&author=C.+Cenciarelliauthor=C.+Tanzarellaauthor=I.+Vitaleauthor=C.+Pisanoauthor=P.+Crateriauthor=S.+Meschiniauthor=G.+Aranciaauthor=A.+Antoccia&title=The+tubulin-depolymerising+agent+combretastatin-4+induces+ectopic+aster+assembly+and+mitotic+catastrophe+in+lung+cancer+cells+H460&doi=10.1007%2Fs10495-008-0200-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1007%2Fs10495-008-0200-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10495-008-0200-2%26sid%3Dliteratum%253Aachs%26aulast%3DCenciarelli%26aufirst%3DC.%26aulast%3DTanzarella%26aufirst%3DC.%26aulast%3DVitale%26aufirst%3DI.%26aulast%3DPisano%26aufirst%3DC.%26aulast%3DCrateri%26aufirst%3DP.%26aulast%3DMeschini%26aufirst%3DS.%26aulast%3DArancia%26aufirst%3DG.%26aulast%3DAntoccia%26aufirst%3DA.%26atitle%3DThe%2520tubulin-depolymerising%2520agent%2520combretastatin-4%2520induces%2520ectopic%2520aster%2520assembly%2520and%2520mitotic%2520catastrophe%2520in%2520lung%2520cancer%2520cells%2520H460%26jtitle%3DApoptosis%26date%3D2008%26volume%3D13%26spage%3D659%26epage%3D669%26doi%3D10.1007%2Fs10495-008-0200-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group">Vitale, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antoccia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cenciarelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crateri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meschini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arancia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pisano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanzarella, C.</span><span> </span><span class="NLM_article-title">Combretastatin CA-4 and combretastatin derivative induce mitotic catastrophe dependent on spindle checkpoint and caspase-3 activation in non-small cell lung cancer cells</span> <span class="citation_source-journal">Apoptosis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">155</span><span class="NLM_x">–</span> <span class="NLM_lpage">166</span><span class="refDoi"> DOI: 10.1007/s10495-006-0491-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1007%2Fs10495-006-0491-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=155-166&author=I.+Vitaleauthor=A.+Antocciaauthor=C.+Cenciarelliauthor=P.+Crateriauthor=S.+Meschiniauthor=G.+Aranciaauthor=C.+Pisanoauthor=C.+Tanzarella&title=Combretastatin+CA-4+and+combretastatin+derivative+induce+mitotic+catastrophe+dependent+on+spindle+checkpoint+and+caspase-3+activation+in+non-small+cell+lung+cancer+cells&doi=10.1007%2Fs10495-006-0491-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1007%2Fs10495-006-0491-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10495-006-0491-0%26sid%3Dliteratum%253Aachs%26aulast%3DVitale%26aufirst%3DI.%26aulast%3DAntoccia%26aufirst%3DA.%26aulast%3DCenciarelli%26aufirst%3DC.%26aulast%3DCrateri%26aufirst%3DP.%26aulast%3DMeschini%26aufirst%3DS.%26aulast%3DArancia%26aufirst%3DG.%26aulast%3DPisano%26aufirst%3DC.%26aulast%3DTanzarella%26aufirst%3DC.%26atitle%3DCombretastatin%2520CA-4%2520and%2520combretastatin%2520derivative%2520induce%2520mitotic%2520catastrophe%2520dependent%2520on%2520spindle%2520checkpoint%2520and%2520caspase-3%2520activation%2520in%2520non-small%2520cell%2520lung%2520cancer%2520cells%26jtitle%3DApoptosis%26date%3D2007%26volume%3D12%26spage%3D155%26epage%3D166%26doi%3D10.1007%2Fs10495-006-0491-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group">O’Boyle, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keely, N. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knox, A. J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCabe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lloyd, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zisterer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meegan, M. J.</span><span> </span><span class="NLM_article-title">Synthesis, biochemical and molecular modelling studies of antiproliferative azetidinones causing microtubule disruption and mitotic catastrophe</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">4595</span><span class="NLM_x">–</span> <span class="NLM_lpage">4607</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2011.07.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.ejmech.2011.07.039" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=4595-4607&author=N.+M.+O%E2%80%99Boyleauthor=M.+Carrauthor=L.+M.+Greeneauthor=N.+O.+Keelyauthor=A.+J.+S.+Knoxauthor=T.+McCabeauthor=D.+G.+Lloydauthor=D.+M.+Zistererauthor=M.+J.+Meegan&title=Synthesis%2C+biochemical+and+molecular+modelling+studies+of+antiproliferative+azetidinones+causing+microtubule+disruption+and+mitotic+catastrophe&doi=10.1016%2Fj.ejmech.2011.07.039"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2011.07.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2011.07.039%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DN.%2BM.%26aulast%3DCarr%26aufirst%3DM.%26aulast%3DGreene%26aufirst%3DL.%2BM.%26aulast%3DKeely%26aufirst%3DN.%2BO.%26aulast%3DKnox%26aufirst%3DA.%2BJ.%2BS.%26aulast%3DMcCabe%26aufirst%3DT.%26aulast%3DLloyd%26aufirst%3DD.%2BG.%26aulast%3DZisterer%26aufirst%3DD.%2BM.%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26atitle%3DSynthesis%252C%2520biochemical%2520and%2520molecular%2520modelling%2520studies%2520of%2520antiproliferative%2520azetidinones%2520causing%2520microtubule%2520disruption%2520and%2520mitotic%2520catastrophe%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2011%26volume%3D46%26spage%3D4595%26epage%3D4607%26doi%3D10.1016%2Fj.ejmech.2011.07.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group">Green, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llambi, F.</span><span> </span><span class="NLM_article-title">Cell death signaling</span> <span class="citation_source-journal">Cold Spring Harbor Perspect. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">a006080</span><span class="refDoi"> DOI: 10.1101/cshperspect.a006080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1101%2Fcshperspect.a006080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=26626938" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=a006080&author=D.+R.+Greenauthor=F.+Llambi&title=Cell+death+signaling&doi=10.1101%2Fcshperspect.a006080"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a006080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a006080%26sid%3Dliteratum%253Aachs%26aulast%3DGreen%26aufirst%3DD.%2BR.%26aulast%3DLlambi%26aufirst%3DF.%26atitle%3DCell%2520death%2520signaling%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Biol.%26date%3D2015%26volume%3D7%26spage%3Da006080%26doi%3D10.1101%2Fcshperspect.a006080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group">Iyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenthal, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulares, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smulson, M. E.</span><span> </span><span class="NLM_article-title">Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4510</span><span class="NLM_x">–</span> <span class="NLM_lpage">4514</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=4510-4514&author=S.+Iyerauthor=D.+J.+Chaplinauthor=D.+S.+Rosenthalauthor=A.+H.+Boularesauthor=L.+Y.+Liauthor=M.+E.+Smulson&title=Induction+of+apoptosis+in+proliferating+human+endothelial+cells+by+the+tumor-specific+antiangiogenesis+agent+combretastatin+A-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIyer%26aufirst%3DS.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DRosenthal%26aufirst%3DD.%2BS.%26aulast%3DBoulares%26aufirst%3DA.%2BH.%26aulast%3DLi%26aufirst%3DL.%2BY.%26aulast%3DSmulson%26aufirst%3DM.%2BE.%26atitle%3DInduction%2520of%2520apoptosis%2520in%2520proliferating%2520human%2520endothelial%2520cells%2520by%2520the%2520tumor-specific%2520antiangiogenesis%2520agent%2520combretastatin%2520A-4%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26spage%3D4510%26epage%3D4514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group">Petit, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karajannis, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooper, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shido, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steller, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafii, S.</span><span> </span><span class="NLM_article-title">The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">1951</span><span class="NLM_x">–</span> <span class="NLM_lpage">1961</span><span class="refDoi"> DOI: 10.1182/blood-2007-05-089219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1182%2Fblood-2007-05-089219" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=1951-1961&author=I.+Petitauthor=M.+A.+Karajannisauthor=L.+Vincentauthor=L.+Youngauthor=J.+Butlerauthor=A.+T.+Hooperauthor=K.+Shidoauthor=H.+Stellerauthor=D.+J.+Chaplinauthor=E.+Feldmanauthor=S.+Rafii&title=The+microtubule-targeting+agent+CA4P+regresses+leukemic+xenografts+by+disrupting+interaction+with+vascular+cells+and+mitochondrial-dependent+cell+death&doi=10.1182%2Fblood-2007-05-089219"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-05-089219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-05-089219%26sid%3Dliteratum%253Aachs%26aulast%3DPetit%26aufirst%3DI.%26aulast%3DKarajannis%26aufirst%3DM.%2BA.%26aulast%3DVincent%26aufirst%3DL.%26aulast%3DYoung%26aufirst%3DL.%26aulast%3DButler%26aufirst%3DJ.%26aulast%3DHooper%26aufirst%3DA.%2BT.%26aulast%3DShido%26aufirst%3DK.%26aulast%3DSteller%26aufirst%3DH.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DFeldman%26aufirst%3DE.%26aulast%3DRafii%26aufirst%3DS.%26atitle%3DThe%2520microtubule-targeting%2520agent%2520CA4P%2520regresses%2520leukemic%2520xenografts%2520by%2520disrupting%2520interaction%2520with%2520vascular%2520cells%2520and%2520mitochondrial-dependent%2520cell%2520death%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D1951%26epage%3D1961%26doi%3D10.1182%2Fblood-2007-05-089219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group">Mendez, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Policarpi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cenciarelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanzarella, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antoccia, A.</span><span> </span><span class="NLM_article-title">Role of Bim in apoptosis induced in H460 lung tumor cells by the spindle poison combretastatin-A4</span> <span class="citation_source-journal">Apoptosis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">940</span><span class="NLM_x">–</span> <span class="NLM_lpage">949</span><span class="refDoi"> DOI: 10.1007/s10495-011-0619-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1007%2Fs10495-011-0619-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=21671007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVSlu7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=940-949&author=G.+Mendezauthor=C.+Policarpiauthor=C.+Cenciarelliauthor=C.+Tanzarellaauthor=A.+Antoccia&title=Role+of+Bim+in+apoptosis+induced+in+H460+lung+tumor+cells+by+the+spindle+poison+combretastatin-A4&doi=10.1007%2Fs10495-011-0619-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Bim in apoptosis induced in H460 lung tumor cells by the spindle poison Combretastatin-A4</span></div><div class="casAuthors">Mendez, G.; Policarpi, C.; Cenciarelli, C.; Tanzarella, C.; Antoccia, A.</div><div class="citationInfo"><span class="NLM_cas:title">Apoptosis</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">940-949</span>CODEN:
                <span class="NLM_cas:coden">APOPFN</span>;
        ISSN:<span class="NLM_cas:issn">1360-8185</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The BH3-only Bcl-2 subfamily member Bim is a well known apoptosis promoting protein.  However, the mechanisms upstream of mitochondrion membrane permeability by which Bim is involved in apoptosis have been poorly investigated, particularly in response to agents capable of interfering with the cytoskeleton architecture and arresting cells in mitosis.  Based on the observation that Bim is sequestered on the microtubule-array by interaction with the light chain of dynein, we have investigated upon depolymn., whether Bim could be involved in the commitment of apoptosis.  With this purpose H460 Non Small Lung Cancer Cells (NSLC) were treated with the microtubule damaging agent combretastatin-A4 (CA-4) (7.5 nM; 8-48 h), and various parameters were investigated.  Upon treatment, cells arrested in mitosis and died through a caspase-3-dependent mitotic catastrophe.  Transient knock down of Bim drastically reduced apoptosis, indicating that this protein was involved in cell death as induced by microtubules disorganisation.  In response to increasing conditions of microtubules depolymn., we found that the protein level of Bim was strongly upregulated in a time-dependent manner at transcriptional level.  Furthermore, Bim was released from microtubule-assocd. components.  Bim was translocated to mitochondria, even in a condition of protein synthesis inhibition, where it showed a markedly increased interaction with Bcl-2.  In turn, the fraction of Bax bound to Bcl-2 decreases in response to treatment, thereby indicating that Bim possibly promotes Bax release from the pro-survival protein Bcl-2.  Overall, we demonstrated that Bim is required for the CA-4-induced cell death in the H460 lung cancer cell line via activation of the mitochondrial signalling pathway.  Defining the contribution of Bim to the mechanism of apoptosis may offer some different clues in view of developing new strategies for chemotherapy with CA-4, underlining the relevance of the cytoskeleton integrity in the apoptotic response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFAXUMi6LRGLVg90H21EOLACvtfcHk0ljvATxk0LcCCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVSlu7bF&md5=f2c8e59481098e10b8939421d59170b9</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1007%2Fs10495-011-0619-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10495-011-0619-8%26sid%3Dliteratum%253Aachs%26aulast%3DMendez%26aufirst%3DG.%26aulast%3DPolicarpi%26aufirst%3DC.%26aulast%3DCenciarelli%26aufirst%3DC.%26aulast%3DTanzarella%26aufirst%3DC.%26aulast%3DAntoccia%26aufirst%3DA.%26atitle%3DRole%2520of%2520Bim%2520in%2520apoptosis%2520induced%2520in%2520H460%2520lung%2520tumor%2520cells%2520by%2520the%2520spindle%2520poison%2520combretastatin-A4%26jtitle%3DApoptosis%26date%3D2011%26volume%3D16%26spage%3D940%26epage%3D949%26doi%3D10.1007%2Fs10495-011-0619-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group">Méndez-Callejas, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leone, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanzarella, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antoccia, A.</span><span> </span><span class="NLM_article-title">Combretastatin A-4 induces p53 mitochondrial-relocalisation independent-apoptosis in non-small lung cancer cells</span> <span class="citation_source-journal">Cell Biol. Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">296</span><span class="NLM_x">–</span> <span class="NLM_lpage">308</span><span class="refDoi"> DOI: 10.1002/cbin.10199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1002%2Fcbin.10199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=24155061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFajuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2014&pages=296-308&author=G.+M.+M%C3%A9ndez-Callejasauthor=S.+Leoneauthor=C.+Tanzarellaauthor=A.+Antoccia&title=Combretastatin+A-4+induces+p53+mitochondrial-relocalisation+independent-apoptosis+in+non-small+lung+cancer+cells&doi=10.1002%2Fcbin.10199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatin A-4 induces p53 mitochondrial-relocalisation independent-apoptosis in non-small lung cancer cells</span></div><div class="casAuthors">Mendez-Callejas, Gina Marcela; Leone, Stefano; Tanzarella, Caterina; Antoccia, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Cell Biology International</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">296-308</span>CODEN:
                <span class="NLM_cas:coden">CBIIEV</span>;
        ISSN:<span class="NLM_cas:issn">1065-6995</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Combretastatin A-4 (CA-4) is one of the most effective agents used in chemotherapy.  Nevertheless, the contribution of p53 and Bim proteins in the CA-4-induced apoptosis in non-small lung cancer cells (NSCLC) remains unresolved, specifically on involving of p53 in the mitochondrial pathway activation by a transcription-independent mechanism.  In this context, the p53-null H1299 and wt-p53 H460 NSCLC cells, in the absence and presence of pifithrin-μ (PFTμ), an inhibitor of p53 mitochondrial-translocation, were treated with CA-4 and different cellular endpoints were analyzed.  In contrast to previous observations in H460 cells, CA-4 failed in the activation of an apoptotic response in H1299 cells, thus indicating an involvement of p53 in the cell death induced by the drug.  We found that CA-4 led to p53 cellular re-localisation in H460 cells; in particular, p53 was released from the microtubular network and accumulated at mitochondria where it interacts with Bim protein and other proteins of the Bcl-2 (B-cell leukemia-2) family, leading to cytochrome c release, alteration in the mitochondrial membrane polarisation, cell cycle arrest at the G2/M-phase, and cell death.  Interestingly, the cytosolic and the mitochondrial accumulation of protein Bim was strictly dependent on p53 status.  The extent of cell death was not reduced in H460 after combined treatment of PFTμ with CA-4.  Overall, the data support a model of CA-4-induced apoptosis in NSCLC, for which the expression of p53 protein is essential, but its mitochondrial function, linked to p53-transcription independent apoptosis pathway, is negligible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqso_tnnoRArLVg90H21EOLACvtfcHk0ljvATxk0LcCCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFajuro%253D&md5=b1ea8bc6519a362a56b9ebe25ce8c164</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1002%2Fcbin.10199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbin.10199%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25A9ndez-Callejas%26aufirst%3DG.%2BM.%26aulast%3DLeone%26aufirst%3DS.%26aulast%3DTanzarella%26aufirst%3DC.%26aulast%3DAntoccia%26aufirst%3DA.%26atitle%3DCombretastatin%2520A-4%2520induces%2520p53%2520mitochondrial-relocalisation%2520independent-apoptosis%2520in%2520non-small%2520lung%2520cancer%2520cells%26jtitle%3DCell%2520Biol.%2520Int.%26date%3D2014%26volume%3D38%26spage%3D296%26epage%3D308%26doi%3D10.1002%2Fcbin.10199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group">Mahal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmad, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sethi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Resch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ficner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkar, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schobert, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biersack, B.</span><span> </span><span class="NLM_article-title">Role of JNK and NF-κB in mediating the effect of combretastatin A-4 and brimamin on endothelial and carcinoma cells</span> <span class="citation_source-journal">Cell. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">478</span><span class="refDoi"> DOI: 10.1007/s13402-015-0243-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1007%2Fs13402-015-0243-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFagtbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2015&pages=463-478&author=K.+Mahalauthor=A.+Ahmadauthor=S.+Sethiauthor=M.+Reschauthor=R.+Ficnerauthor=F.+H.+Sarkarauthor=R.+Schobertauthor=B.+Biersack&title=Role+of+JNK+and+NF-%CE%BAB+in+mediating+the+effect+of+combretastatin+A-4+and+brimamin+on+endothelial+and+carcinoma+cells&doi=10.1007%2Fs13402-015-0243-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Role of JNK and NF-κB in mediating the effect of combretastatin A-4 and brimamin on endothelial and carcinoma cells</span></div><div class="casAuthors">Mahal, Katharina; Ahmad, Aamir; Sethi, Seema; Resch, Marcus; Ficner, Ralf; Sarkar, Fazlul H.; Schobert, Rainer; Biersack, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">463-478</span>CODEN:
                <span class="NLM_cas:coden">COENGH</span>;
        ISSN:<span class="NLM_cas:issn">2211-3436</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: The 4,5-diarylimidazole brimamin is an analog of the natural vascular-disrupting agent combretastatin A-4 (CA-4) with improved water soly., tolerance by animals and efficacy in multidrug-resistant tumors.  Here, we aimed at identifying the major mechanisms underlying the in vitro and in vivo actions of brimamin on endothelial and carcinoma cells, including vascularization.  Methods: The contribution of specific signaling kinases to the effects of brimamin on cytoskeleton organization and the viability and differentiation of endothelial cells was assessed by MTT and tube formation assays in the presence or absence of specific kinase inhibitors.  Changes in DNA affinity and expression of NF-κB in endothelial and carcinoma-derived cells and their solid tumors (xenografts) treated with brimamin were ascertained by electrophoretic mobility shift assays and Western blotting.  The anti-vascular effect of brimamin in solid tumors was verified by CD31 immunostaining.  Results: We found that brimamin can inhibit tubulin polymn. and cause a reorganization of F-actin in Ea.hy926 endothelial cells.  Its inhibitory effect on tube formation was found to depend on functional Rho kinase and JNK.  JNK inhibition was found to suppress the induction of endothelial cell apoptosis by brimamin.  In CA-4-refractory human BxPC-3 pancreas carcinoma-derived and triple-neg. MDA-MB-231 breast carcinoma-derived cells brimamin was found to inhibit growth and to induce apoptosis at low nanomolar concns. by blocking NF-κB activation in a dose-dependent manner.  Brimamin was also found to reduce the in vivo growth rate and vascularization of MDA-MB-231 xenografts in mice.  Residual tumor cells of these treated xenografts showed a relatively low expression of the p65 subunit of NF-κB.  Conclusions: Our data indicate that cellular JNK and Rho kinase activities are crucial for the cytotoxic and cytoskeleton reorganizing effects of brimamin on endothelial cells.  In addn., we found that in resistant carcinoma cells and xenografts brimamin can induce down-regulation of anti-apoptotic NF-κB expression and signaling.  Its chem. properties and efficacy against clin. relevant cancer entities make brimamin a promising candidate vascular-disrupting agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGv3M16a_pYLVg90H21EOLACvtfcHk0ljvATxk0LcCCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFagtbnE&md5=598a584b17aaed4ab396258af920ca60</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1007%2Fs13402-015-0243-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13402-015-0243-7%26sid%3Dliteratum%253Aachs%26aulast%3DMahal%26aufirst%3DK.%26aulast%3DAhmad%26aufirst%3DA.%26aulast%3DSethi%26aufirst%3DS.%26aulast%3DResch%26aufirst%3DM.%26aulast%3DFicner%26aufirst%3DR.%26aulast%3DSarkar%26aufirst%3DF.%2BH.%26aulast%3DSchobert%26aufirst%3DR.%26aulast%3DBiersack%26aufirst%3DB.%26atitle%3DRole%2520of%2520JNK%2520and%2520NF-%25CE%25BAB%2520in%2520mediating%2520the%2520effect%2520of%2520combretastatin%2520A-4%2520and%2520brimamin%2520on%2520endothelial%2520and%2520carcinoma%2520cells%26jtitle%3DCell.%2520Oncol.%26date%3D2015%26volume%3D38%26spage%3D463%26epage%3D478%26doi%3D10.1007%2Fs13402-015-0243-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group">Lin, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiou, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uen, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liou, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chi, C. W.</span><span> </span><span class="NLM_article-title">Combretastatin A4-induced differential cytotoxicity and reduced metastatic ability by inhibition of AKT function in human gastric cancer cells</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">323</span><span class="NLM_x">, </span> <span class="NLM_fpage">365</span><span class="NLM_x">–</span> <span class="NLM_lpage">373</span><span class="refDoi"> DOI: 10.1124/jpet.107.124966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1124%2Fjpet.107.124966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=17646428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFahsb%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2007&pages=365-373&author=H.+L.+Linauthor=S.+H.+Chiouauthor=C.+W.+Wuauthor=W.+B.+Linauthor=L.+H.+Chenauthor=Y.+P.+Yangauthor=M.+L.+Tsaiauthor=Y.+H.+Uenauthor=J.+P.+Liouauthor=C.+W.+Chi&title=Combretastatin+A4-induced+differential+cytotoxicity+and+reduced+metastatic+ability+by+inhibition+of+AKT+function+in+human+gastric+cancer+cells&doi=10.1124%2Fjpet.107.124966"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatin A4-induced differential cytotoxicity and reduced metastatic ability by inhibition of AKT function in human gastric cancer cells</span></div><div class="casAuthors">Lin, Heng-Liang; Chiou, Shih-Hwa; Wu, Chew-Wun; Lin, Wen-Bin; Chen, Li-Hsin; Yang, Yi-Ping; Tsai, Ming-Long; Uen, Yih-Huei; Liou, Jing-Ping; Chi, Chin-Wen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">365-373</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Combretastatin A4 (CA4) is a drug that targets tumor vasculature to inhibit angiogenesis.  Whether CA4 has a direct effect on gastric cancer is not known.  We herein investigated the effect of CA4 on growth and metastasis of gastric cancer cells at clin. achievable concn. and explored the assocd. antitumor mechanisms.  Nine human gastric cancer cell lines, including two metastatic gastric cancer cell lines (AGS-GFPM1/2), constitutively expressing green fluorescence protein (GFP) were used.  These metastatic AGS-GFPM1/2 cells expressed a higher level of phosphorylated serine 473 on AKT (p-AKT).  Our results showed that CA4 (0.02-20 μM) has significant in vitro effects on reducing cell attachment, migration, invasiveness, as well as cell G2/M disturbance on p-AKT-pos. gastric cancer cells.  In addn., a phosphoinositide 3-kinase inhibitor, LY294002 [2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride], a specific AKT inhibitor, and 0.2 to 20 μM CA4 displayed a similar response profile on p-AKT-pos. cells, suggesting that CA4-induced effect was mediated by inhibition of the PI3 kinase/AKT pathway.  The results from in vivo GFP monitoring system indicated that CA4 phosphate (CA4-P; 200 mg/kg) significantly inhibited the s.c. and intra-abdominal growth of xenotransplanted AGS-GFPM2 cells in nude mice.  Furthermore, CA4-P treatment showed a remarkable ability to inhibit gastric tumor metastasis as well as attenuate p-AKT expression.  In conclusion, our study is the first to find that CA4 inhibited AKT activity in human gastric cancer cells.  The decreased AKT activity correlated well with the CA4 antitumor growth response and decrease of metastasis.  Further investigation on drugs targeting the PI3 kinase-AKT pathway may provide a new approach for the treatment of human gastric cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9B2XNKJAQPrVg90H21EOLACvtfcHk0lhMSuWGsIWTpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFahsb%252FP&md5=ca153b2393c7fbb7eece677e2e2937bb</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.124966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.124966%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DH.%2BL.%26aulast%3DChiou%26aufirst%3DS.%2BH.%26aulast%3DWu%26aufirst%3DC.%2BW.%26aulast%3DLin%26aufirst%3DW.%2BB.%26aulast%3DChen%26aufirst%3DL.%2BH.%26aulast%3DYang%26aufirst%3DY.%2BP.%26aulast%3DTsai%26aufirst%3DM.%2BL.%26aulast%3DUen%26aufirst%3DY.%2BH.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DChi%26aufirst%3DC.%2BW.%26atitle%3DCombretastatin%2520A4-induced%2520differential%2520cytotoxicity%2520and%2520reduced%2520metastatic%2520ability%2520by%2520inhibition%2520of%2520AKT%2520function%2520in%2520human%2520gastric%2520cancer%2520cells%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D323%26spage%3D365%26epage%3D373%26doi%3D10.1124%2Fjpet.107.124966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group">Pollock, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verma, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meegan, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zisterer, D. M.</span><span> </span><span class="NLM_article-title">Combretastatin (CA)-4 and its novel analogue CA-432 impair T-cell migration through the Rho/ROCK signalling pathway</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">544</span><span class="NLM_x">–</span> <span class="NLM_lpage">557</span><span class="refDoi"> DOI: 10.1016/j.bcp.2014.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.bcp.2014.10.002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2014&pages=544-557&author=J.+K.+Pollockauthor=N.+K.+Vermaauthor=N.+M.+O%E2%80%99Boyleauthor=M.+Carrauthor=M.+J.+Meeganauthor=D.+M.+Zisterer&title=Combretastatin+%28CA%29-4+and+its+novel+analogue+CA-432+impair+T-cell+migration+through+the+Rho%2FROCK+signalling+pathway&doi=10.1016%2Fj.bcp.2014.10.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2014.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2014.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DPollock%26aufirst%3DJ.%2BK.%26aulast%3DVerma%26aufirst%3DN.%2BK.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DN.%2BM.%26aulast%3DCarr%26aufirst%3DM.%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26aulast%3DZisterer%26aufirst%3DD.%2BM.%26atitle%3DCombretastatin%2520%2528CA%2529-4%2520and%2520its%2520novel%2520analogue%2520CA-432%2520impair%2520T-cell%2520migration%2520through%2520the%2520Rho%252FROCK%2520signalling%2520pathway%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2014%26volume%3D92%26spage%3D544%26epage%3D557%26doi%3D10.1016%2Fj.bcp.2014.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group">Hori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubota, K.</span><span> </span><span class="NLM_article-title">A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">1604</span><span class="NLM_x">–</span> <span class="NLM_lpage">1614</span><span class="refDoi"> DOI: 10.1038/sj.bjc.6600296</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1038%2Fsj.bjc.6600296" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=12085211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvVaitbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2002&pages=1604-1614&author=K.+Horiauthor=S.+Saitoauthor=K.+Kubota&title=A+novel+combretastatin+A-4+derivative%2C+AC7700%2C+strongly+stanches+tumour+blood+flow+and+inhibits+growth+of+tumours+developing+in+various+tissues+and+organs&doi=10.1038%2Fsj.bjc.6600296"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs</span></div><div class="casAuthors">Hori, K.; Saito, S.; Kubota, K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1604-1614</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In a previous study, the authors used s.c. LY80 tumors (a subline of Yoshida sarcoma), Sato lung carcinoma, and methylcholanthrene-induced primary tumors, to demonstrate that a novel water-sol. combretastatin A-4 deriv., AC7700, abruptly and irreversibly stopped tumor blood flow.  As a result of this interrupted supply of nutrients, extensive necrosis was induced within the tumor.  In the present study, the authors investigated whether AC7700 acts in the same way against solid tumors growing in the liver, stomach, kidney, muscle, and lymph nodes.  Tumor blood flow and the change in tumor blood flow induced by AC7700 were measured by the hydrogen clearance method.  In a model of cancer chemotherapy against metastases, LY80 cells (2×106) were injected into the lateral tail vein, and AC7700 at 10 mg kg-1 was injected i.v. 5 times at intervals of 2 days, starting on day 7 after tumor cell injection.  The no. and size of tumors were compared with those in the control group.  The change in tumor blood flow and the therapeutic effect of AC7700 on microtumors were obsd. directly by Sato lung carcinoma implanted in a rat transparent chamber.  AC7700 caused a marked decrease in the tumor blood flow of all LY80 tumors developing in various tissues and organs and growth of all tumors including lymph node metastases and microtumors was inhibited.  In every tumor, tumor blood flow began to decrease immediately after AC7700 administration and reached a min. at approx. 30 min after injection.  In many tumor capillaries, blood flow completely stopped within 3 min after AC7700 administration.  These results demonstrate that AC7700 is effective for tumors growing in various tissues and organs and for metastases.  The authors conclude that tumor blood flow stanching induced by AC7700 may become an effective therapeutic strategy for all cancers, including refractory cancers because the therapeutic effect is independent of tumor site and specific type of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO13kBP3gkhLVg90H21EOLACvtfcHk0lgqu-Z1ocUWfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvVaitbc%253D&md5=ece92f90ba2de5ad260829429e4699fc</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6600296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6600296%26sid%3Dliteratum%253Aachs%26aulast%3DHori%26aufirst%3DK.%26aulast%3DSaito%26aufirst%3DS.%26aulast%3DKubota%26aufirst%3DK.%26atitle%3DA%2520novel%2520combretastatin%2520A-4%2520derivative%252C%2520AC7700%252C%2520strongly%2520stanches%2520tumour%2520blood%2520flow%2520and%2520inhibits%2520growth%2520of%2520tumours%2520developing%2520in%2520various%2520tissues%2520and%2520organs%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2002%26volume%3D86%26spage%3D1604%26epage%3D1614%26doi%3D10.1038%2Fsj.bjc.6600296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group">Ridley, A. J.</span><span> </span><span class="NLM_article-title">Rho GTPase signalling in cell migration</span> <span class="citation_source-journal">Curr. Opin. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">112</span><span class="refDoi"> DOI: 10.1016/j.ceb.2015.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.ceb.2015.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=26363959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVentr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=103-112&author=A.+J.+Ridley&title=Rho+GTPase+signalling+in+cell+migration&doi=10.1016%2Fj.ceb.2015.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Rho GTPase signalling in cell migration</span></div><div class="casAuthors">Ridley, Anne J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103-112</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Cells migrate in multiple different ways depending on their environment, which includes the extracellular matrix compn., interactions with other cells, and chem. stimuli.  For all types of cell migration, Rho GTPases play a central role, although the relative contribution of each Rho GTPase depends on the environment and cell type.  Here, I review recent advances in our understanding of how Rho GTPases contribute to different types of migration, comparing lamellipodium-driven vs. bleb-driven migration modes.  I also describe how cells migrate across the endothelium.  In addn. to Rho, Rac and Cdc42, which are well known to regulate migration, I discuss the roles of other less-well characterized members of the Rho family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9u3iM9PoTD7Vg90H21EOLACvtfcHk0lgqu-Z1ocUWfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVentr3K&md5=12f9e17652641d59d3d8566b039733c4</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2015.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2015.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DRidley%26aufirst%3DA.%2BJ.%26atitle%3DRho%2520GTPase%2520signalling%2520in%2520cell%2520migration%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2015%26volume%3D36%26spage%3D103%26epage%3D112%26doi%3D10.1016%2Fj.ceb.2015.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group">Kanthou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozer, G. M.</span><span> </span><span class="NLM_article-title">The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">2060</span><span class="NLM_x">–</span> <span class="NLM_lpage">2069</span><span class="refDoi"> DOI: 10.1182/blood.V99.6.2060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1182%2Fblood.V99.6.2060" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=2060-2069&author=C.+Kanthouauthor=G.+M.+Tozer&title=The+tumor+vascular+targeting+agent+combretastatin+A-4-phosphate+induces+reorganization+of+the+actin+cytoskeleton+and+early+membrane+blebbing+in+human+endothelial+cells&doi=10.1182%2Fblood.V99.6.2060"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1182%2Fblood.V99.6.2060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V99.6.2060%26sid%3Dliteratum%253Aachs%26aulast%3DKanthou%26aufirst%3DC.%26aulast%3DTozer%26aufirst%3DG.%2BM.%26atitle%3DThe%2520tumor%2520vascular%2520targeting%2520agent%2520combretastatin%2520A-4-phosphate%2520induces%2520reorganization%2520of%2520the%2520actin%2520cytoskeleton%2520and%2520early%2520membrane%2520blebbing%2520in%2520human%2520endothelial%2520cells%26jtitle%3DBlood%26date%3D2002%26volume%3D99%26spage%3D2060%26epage%3D2069%26doi%3D10.1182%2Fblood.V99.6.2060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span> </span><span class="NLM_article-title">Deoxypodophyllotoxin suppresses tumor vasculature in HUVECs by promoting cytoskeleton remodeling through LKB1-AMPK dependent Rho A activation</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">29497</span><span class="NLM_x">–</span> <span class="NLM_lpage">29512</span><span class="refDoi"> DOI: 10.18632/oncotarget.4985</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.18632%2Foncotarget.4985" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=29497-29512&author=Y.+Wangauthor=B.+Wangauthor=M.+Guerramauthor=L.+Sunauthor=W.+Shiauthor=C.+Tianauthor=X.+Zhuauthor=Z.+Jiangauthor=L.+Zhang&title=Deoxypodophyllotoxin+suppresses+tumor+vasculature+in+HUVECs+by+promoting+cytoskeleton+remodeling+through+LKB1-AMPK+dependent+Rho+A+activation&doi=10.18632%2Foncotarget.4985"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.4985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.4985%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DGuerram%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DW.%26aulast%3DTian%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DDeoxypodophyllotoxin%2520suppresses%2520tumor%2520vasculature%2520in%2520HUVECs%2520by%2520promoting%2520cytoskeleton%2520remodeling%2520through%2520LKB1-AMPK%2520dependent%2520Rho%2520A%2520activation%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D29497%26epage%3D29512%26doi%3D10.18632%2Foncotarget.4985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group">Hori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akita, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sumiyoshi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taki, Y.</span><span> </span><span class="NLM_article-title">Prevention of cancer recurrence in tumor margins by stopping microcirculation in the tumor and tumor-host interface</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">1196</span><span class="NLM_x">–</span> <span class="NLM_lpage">1204</span><span class="refDoi"> DOI: 10.1111/cas.12477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1111%2Fcas.12477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=24981848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFymu7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2014&pages=1196-1204&author=K.+Horiauthor=H.+Akitaauthor=H.+Nonakaauthor=A.+Sumiyoshiauthor=Y.+Taki&title=Prevention+of+cancer+recurrence+in+tumor+margins+by+stopping+microcirculation+in+the+tumor+and+tumor-host+interface&doi=10.1111%2Fcas.12477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of cancer recurrence in tumor margins by stopping microcirculation in the tumor and tumor-host interface</span></div><div class="casAuthors">Hori, Katsuyoshi; Akita, Hirotoshi; Nonaka, Hiroi; Sumiyoshi, Akira; Taki, Yasuyuki</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1196-1204</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Combretastatins interrupt blood flow of solid tumor vascular networks and lead to necrosis by blocking nutrients.  However, tumors recover from tumor blood flow interruption-induced damage and develop viable rims.  To investigate why cancer recurs and its prevention, we used a combretastatin deriv., Cderiv (=AC7700), and analyzed changes in tumor-host interface (T-HI) vessels, which were closest to cancer cells in the tumor margin after tumor vessel disruption, and the microenvironment surrounding them.  Treatment with Cderiv (10 mg/kg) interrupted tumor blood flow in all regions of LY80 (a variant of Yoshida sarcoma) tumor, but not T-HI vessel blood flow.  The same Cderiv dose given 72 h after 5 Gy irradn. stopped T-HI vessel blood flow and prevented cancer recurrence.  Treatment in the reverse order, however, did not affect T-HI vessel blood flow.  The greatest difference between the two treatments was the occurrence of gradual T-HI edema with the former.  Severe T-HI edema compressed T-HI blood vessels, so that circulation stopped.  Thus, the distance between a tumor margin and its nearest functioning host vessel became much larger, and the tumor marginal region became a microenvironment that lacked a nutritional supply.  Cancer cells in tumor margins received nutrients through two circulation routes: tumor vessels and T-HI vessels.  Our starvation methods, which involved treatment with Cderiv 72 h after 5 Gy irradn., blocked both circulation routes and may have great potential as a clin. strategy to prevent cancer recurrence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYut25JtLfEbVg90H21EOLACvtfcHk0lhVuUZc0nMO0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFymu7zI&md5=df5115837beea89bd44316f173755cbc</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1111%2Fcas.12477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.12477%26sid%3Dliteratum%253Aachs%26aulast%3DHori%26aufirst%3DK.%26aulast%3DAkita%26aufirst%3DH.%26aulast%3DNonaka%26aufirst%3DH.%26aulast%3DSumiyoshi%26aufirst%3DA.%26aulast%3DTaki%26aufirst%3DY.%26atitle%3DPrevention%2520of%2520cancer%2520recurrence%2520in%2520tumor%2520margins%2520by%2520stopping%2520microcirculation%2520in%2520the%2520tumor%2520and%2520tumor-host%2520interface%26jtitle%3DCancer%2520Sci.%26date%3D2014%26volume%3D105%26spage%3D1196%26epage%3D1204%26doi%3D10.1111%2Fcas.12477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group">Yao, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ni, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span> </span><span class="NLM_article-title">Combretastatin A4 phosphate treatment induces vasculogenic mimicry formation of W256 breast carcinoma tumor in vitro and in vivo</span> <span class="citation_source-journal">Tumor Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">8499</span><span class="NLM_x">–</span> <span class="NLM_lpage">8510</span><span class="refDoi"> DOI: 10.1007/s13277-015-3508-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1007%2Fs13277-015-3508-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=26026583" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsVynsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=8499-8510&author=N.+Yaoauthor=K.+Renauthor=C.+Jiangauthor=M.+Gaoauthor=D.+Huangauthor=X.+Luauthor=B.+Louauthor=F.+Pengauthor=A.+Yangauthor=X.+Wangauthor=Y.+Niauthor=J.+Zhang&title=Combretastatin+A4+phosphate+treatment+induces+vasculogenic+mimicry+formation+of+W256+breast+carcinoma+tumor+in+vitro+and+in+vivo&doi=10.1007%2Fs13277-015-3508-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatin A4 phosphate treatment induces vasculogenic mimicry formation of W256 breast carcinoma tumor in vitro and in vivo</span></div><div class="casAuthors">Yao, Nan; Ren, Ke; Jiang, Cuihua; Gao, Meng; Huang, Dejian; Lu, Xiao; Lou, Bin; Peng, Fei; Yang, Aizhen; Wang, Xiaoning; Ni, Yicheng; Zhang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Tumor Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">8499-8510</span>CODEN:
                <span class="NLM_cas:coden">TUMBEA</span>;
        ISSN:<span class="NLM_cas:issn">1010-4283</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The purpose of this study was to investigate the effect of combretastatin A4 phosphate (CA4P) on vasculogenic mimicry (VM) channel formation in vitro and in vivo after a single-dose treatment and the underlying mechanism involved in supporting VM.  In vitro model of three-dimensional cultures was used to test the effect of CA4P on the tube formation of Walker 256 cells.  Western blot anal. was conducted to assess the expression of hypoxia-inducible factor (HIF)-1α and VM-assocd. markers.  W256 tumor-bearing rat model was established to demonstrate the effect of CA4P on VM formation and tumor hypoxia by double staining and a hypoxic marker pimonidazole.  Anti-tumor efficacy of CA4P treatment was evaluated by tumor growth curve.  Under hypoxic conditions for 48 h in vitro, W256 cells formed VM network assocd. with increased expression of VM markers.  Pretreatment with CA4P did not influence the amt. of VM in 3-D culture as well as the expression of these key mols.  In vivo, W256 tumors showed marked intratumoral hypoxia after CA4P treatment, accompanied by increased VM formation.  CA4P exhibited only a delay in tumor growth within 2 days but rapid tumor regrowth afterward.  VM d. was pos. related to tumor vol. and tumor wt. at day 8.  CA4P causes hypoxia which induces VM formation in W256 tumors through HIF-1α/EphA2/PI3K/matrix metalloproteinase (MMP) signaling pathway, resulting in the consequent regrowth of the damaged tumor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzjp_ytrU0WrVg90H21EOLACvtfcHk0lhVuUZc0nMO0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsVynsLs%253D&md5=b885509f7094abad46daa1b8af3736a7</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1007%2Fs13277-015-3508-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13277-015-3508-x%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DN.%26aulast%3DRen%26aufirst%3DK.%26aulast%3DJiang%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DD.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DLou%26aufirst%3DB.%26aulast%3DPeng%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DNi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DCombretastatin%2520A4%2520phosphate%2520treatment%2520induces%2520vasculogenic%2520mimicry%2520formation%2520of%2520W256%2520breast%2520carcinoma%2520tumor%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DTumor%2520Biol.%26date%3D2015%26volume%3D36%26spage%3D8499%26epage%3D8510%26doi%3D10.1007%2Fs13277-015-3508-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group">El-Emir, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxer, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrie, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boden, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dearling, J. L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Begent, R. H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedley, R. B.</span><span> </span><span class="NLM_article-title">Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">799</span><span class="NLM_x">–</span> <span class="NLM_lpage">806</span><span class="refDoi"> DOI: 10.1016/j.ejca.2005.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.ejca.2005.01.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2005&pages=799-806&author=E.+El-Emirauthor=G.+M.+Boxerauthor=I.+A.+Petrieauthor=R.+W.+Bodenauthor=J.+L.+J.+Dearlingauthor=R.+H.+J.+Begentauthor=R.+B.+Pedley&title=Tumour+parameters+affected+by+combretastatin+A-4+phosphate+therapy+in+a+human+colorectal+xenograft+model+in+nude+mice&doi=10.1016%2Fj.ejca.2005.01.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2005.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2005.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Emir%26aufirst%3DE.%26aulast%3DBoxer%26aufirst%3DG.%2BM.%26aulast%3DPetrie%26aufirst%3DI.%2BA.%26aulast%3DBoden%26aufirst%3DR.%2BW.%26aulast%3DDearling%26aufirst%3DJ.%2BL.%2BJ.%26aulast%3DBegent%26aufirst%3DR.%2BH.%2BJ.%26aulast%3DPedley%26aufirst%3DR.%2BB.%26atitle%3DTumour%2520parameters%2520affected%2520by%2520combretastatin%2520A-4%2520phosphate%2520therapy%2520in%2520a%2520human%2520colorectal%2520xenograft%2520model%2520in%2520nude%2520mice%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2005%26volume%3D41%26spage%3D799%26epage%3D806%26doi%3D10.1016%2Fj.ejca.2005.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group">Dachs, G. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steele, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coralli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanthou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunningham, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozer, G. M.</span><span> </span><span class="NLM_article-title">Anti-vascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression</span> <span class="citation_source-journal">BMC Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">280</span><span class="refDoi"> DOI: 10.1186/1471-2407-6-280</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1186%2F1471-2407-6-280" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=280&author=G.+U.+Dachsauthor=A.+J.+Steeleauthor=C.+Coralliauthor=C.+Kanthouauthor=A.+C.+Brooksauthor=S.+P.+Gunninghamauthor=M.+J.+Currieauthor=A.+I.+Watsonauthor=B.+A.+Robinsonauthor=G.+M.+Tozer&title=Anti-vascular+agent+Combretastatin+A-4-P+modulates+hypoxia+inducible+factor-1+and+gene+expression&doi=10.1186%2F1471-2407-6-280"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-6-280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-6-280%26sid%3Dliteratum%253Aachs%26aulast%3DDachs%26aufirst%3DG.%2BU.%26aulast%3DSteele%26aufirst%3DA.%2BJ.%26aulast%3DCoralli%26aufirst%3DC.%26aulast%3DKanthou%26aufirst%3DC.%26aulast%3DBrooks%26aufirst%3DA.%2BC.%26aulast%3DGunningham%26aufirst%3DS.%2BP.%26aulast%3DCurrie%26aufirst%3DM.%2BJ.%26aulast%3DWatson%26aufirst%3DA.%2BI.%26aulast%3DRobinson%26aufirst%3DB.%2BA.%26aulast%3DTozer%26aufirst%3DG.%2BM.%26atitle%3DAnti-vascular%2520agent%2520Combretastatin%2520A-4-P%2520modulates%2520hypoxia%2520inducible%2520factor-1%2520and%2520gene%2520expression%26jtitle%3DBMC%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D280%26doi%3D10.1186%2F1471-2407-6-280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group">Peichev, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naiyer, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pereira, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oz, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, M. A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafii, S.</span><span> </span><span class="NLM_article-title">Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">952</span><span class="NLM_x">–</span> <span class="NLM_lpage">958</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2000&pages=952-958&author=M.+Peichevauthor=A.+J.+Naiyerauthor=D.+Pereiraauthor=Z.+Zhuauthor=W.+J.+Laneauthor=M.+Williamsauthor=M.+C.+Ozauthor=D.+J.+Hicklinauthor=L.+Witteauthor=M.+A.+S.+Mooreauthor=S.+Rafii&title=Expression+of+VEGFR-2+and+AC133+by+circulating+human+CD34%2B+cells+identifies+a+population+of+functional+endothelial+precursors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeichev%26aufirst%3DM.%26aulast%3DNaiyer%26aufirst%3DA.%2BJ.%26aulast%3DPereira%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DLane%26aufirst%3DW.%2BJ.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DOz%26aufirst%3DM.%2BC.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DWitte%26aufirst%3DL.%26aulast%3DMoore%26aufirst%3DM.%2BA.%2BS.%26aulast%3DRafii%26aufirst%3DS.%26atitle%3DExpression%2520of%2520VEGFR-2%2520and%2520AC133%2520by%2520circulating%2520human%2520CD34%252B%2520cells%2520identifies%2520a%2520population%2520of%2520functional%2520endothelial%2520precursors%26jtitle%3DBlood%26date%3D2000%26volume%3D95%26spage%3D952%26epage%3D958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group">Nolan, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciarrocchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellick, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaggi, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bambino, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heikamp, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDevitt, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheinberg, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benezra, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mittal, V.</span><span> </span><span class="NLM_article-title">Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1546</span><span class="NLM_x">–</span> <span class="NLM_lpage">1558</span><span class="refDoi"> DOI: 10.1101/gad.436307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1101%2Fgad.436307" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=1546-1558&author=D.+J.+Nolanauthor=A.+Ciarrocchiauthor=A.+S.+Mellickauthor=J.+S.+Jaggiauthor=K.+Bambinoauthor=S.+Guptaauthor=E.+Heikampauthor=M.+R.+McDevittauthor=D.+A.+Scheinbergauthor=R.+Benezraauthor=V.+Mittal&title=Bone+marrow-derived+endothelial+progenitor+cells+are+a+major+determinant+of+nascent+tumor+neovascularization&doi=10.1101%2Fgad.436307"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1101%2Fgad.436307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.436307%26sid%3Dliteratum%253Aachs%26aulast%3DNolan%26aufirst%3DD.%2BJ.%26aulast%3DCiarrocchi%26aufirst%3DA.%26aulast%3DMellick%26aufirst%3DA.%2BS.%26aulast%3DJaggi%26aufirst%3DJ.%2BS.%26aulast%3DBambino%26aufirst%3DK.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DHeikamp%26aufirst%3DE.%26aulast%3DMcDevitt%26aufirst%3DM.%2BR.%26aulast%3DScheinberg%26aufirst%3DD.%2BA.%26aulast%3DBenezra%26aufirst%3DR.%26aulast%3DMittal%26aufirst%3DV.%26atitle%3DBone%2520marrow-derived%2520endothelial%2520progenitor%2520cells%2520are%2520a%2520major%2520determinant%2520of%2520nascent%2520tumor%2520neovascularization%26jtitle%3DGenes%2520Dev.%26date%3D2007%26volume%3D21%26spage%3D1546%26epage%3D1558%26doi%3D10.1101%2Fgad.436307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group">Ceradini, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulkarni, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callaghan, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tepper, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastidas, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleinman, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capla, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galiano, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurtner, G. C.</span><span> </span><span class="NLM_article-title">Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">858</span><span class="NLM_x">–</span> <span class="NLM_lpage">864</span><span class="refDoi"> DOI: 10.1038/nm1075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1038%2Fnm1075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=15235597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtFWrtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=858-864&author=D.+J.+Ceradiniauthor=A.+R.+Kulkarniauthor=M.+J.+Callaghanauthor=O.+M.+Tepperauthor=N.+Bastidasauthor=M.+E.+Kleinmanauthor=J.+M.+Caplaauthor=R.+D.+Galianoauthor=J.+P.+Levineauthor=G.+C.+Gurtner&title=Progenitor+cell+trafficking+is+regulated+by+hypoxic+gradients+through+HIF-1+induction+of+SDF-1&doi=10.1038%2Fnm1075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1</span></div><div class="casAuthors">Ceradini, Daniel J.; Kulkarni, Anita R.; Callaghan, Matthew J.; Tepper, Oren M.; Bastidas, Nicholas; Kleinman, Mark E.; Capla, Jennifer M.; Galiano, Robert D.; Levine, Jamie P.; Gurtner, Geoffrey C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">858-864</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The trafficking of circulating stem and progenitor cells to areas of tissue damage is poorly understood.  The chemokine stromal cell-derived factor-1 (SDF-1 or CXCL12) mediates homing of stem cells to bone marrow by binding to CXCR4 on circulating cells.  SDF-1 and CXCR4 are expressed in complementary patterns during embryonic organogenesis and guide primordial stem cells to sites of rapid vascular expansion.  However, the regulation of SDF-1 and its physiol. role in peripheral tissue repair remain incompletely understood.  Here the authors show that SDF-1 gene expression is regulated by the transcription factor hypoxia-inducible factor-1 (HIF-1) in endothelial cells, resulting in selective in vivo expression of SDF-1 in ischemic tissue in direct proportion to reduced oxygen tension.  HIF-1-induced SDF-1 expression increases the adhesion, migration and homing of circulating CXCR4-pos. progenitor cells to ischemic tissue.  Blockade of SDF-1 in ischemic tissue or CXCR4 on circulating cells prevents progenitor cell recruitment to sites of injury.  Discrete regions of hypoxia in the bone marrow compartment also show increased SDF-1 expression and progenitor cell tropism.  These data show that the recruitment of CXCR4-pos. progenitor cells to regenerating tissues is mediated by hypoxic gradients via HIF-1-induced expression of SDF-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrV1Q85cyOcb7Vg90H21EOLACvtfcHk0lhDakMwFeyxJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtFWrtr0%253D&md5=6d0bef060be512c348fd2e453b6e19df</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1038%2Fnm1075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1075%26sid%3Dliteratum%253Aachs%26aulast%3DCeradini%26aufirst%3DD.%2BJ.%26aulast%3DKulkarni%26aufirst%3DA.%2BR.%26aulast%3DCallaghan%26aufirst%3DM.%2BJ.%26aulast%3DTepper%26aufirst%3DO.%2BM.%26aulast%3DBastidas%26aufirst%3DN.%26aulast%3DKleinman%26aufirst%3DM.%2BE.%26aulast%3DCapla%26aufirst%3DJ.%2BM.%26aulast%3DGaliano%26aufirst%3DR.%2BD.%26aulast%3DLevine%26aufirst%3DJ.%2BP.%26aulast%3DGurtner%26aufirst%3DG.%2BC.%26atitle%3DProgenitor%2520cell%2520trafficking%2520is%2520regulated%2520by%2520hypoxic%2520gradients%2520through%2520HIF-1%2520induction%2520of%2520SDF-1%26jtitle%3DNat.%2520Med.%26date%3D2004%26volume%3D10%26spage%3D858%26epage%3D864%26doi%3D10.1038%2Fnm1075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group">Moschetta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mishima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahin, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glavey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roccaro, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghobrial, I. M.</span><span> </span><span class="NLM_article-title">Role of endothelial progenitor cells in cancer progression</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">1846</span><span class="NLM_x">, </span> <span class="NLM_fpage">26</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span><span class="refDoi"> DOI: 10.1016/j.bbcan.2014.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.bbcan.2014.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=24709008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1OqsrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1846&publication_year=2014&pages=26-39&author=M.+Moschettaauthor=Y.+Mishimaauthor=I.+Sahinauthor=S.+Manierauthor=S.+Glaveyauthor=A.+Vaccaauthor=A.+M.+Roccaroauthor=I.+M.+Ghobrial&title=Role+of+endothelial+progenitor+cells+in+cancer+progression&doi=10.1016%2Fj.bbcan.2014.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Role of endothelial progenitor cells in cancer progression</span></div><div class="casAuthors">Moschetta, Michele; Mishima, Yuji; Sahin, Ilyas; Manier, Salomon; Glavey, Siobhan; Vacca, Angelo; Roccaro, Aldo M.; Ghobrial, Irene M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Reviews on Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1846</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26-39</span>CODEN:
                <span class="NLM_cas:coden">BBACEU</span>;
        ISSN:<span class="NLM_cas:issn">0304-419X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Tumor-assocd. neovasculature is a crit. therapeutic target; however, despite significant progress made in the clin. efficacy of anti-vessel drugs, the effect of these agents remains transient: over time, most patients develop resistance, which inevitably leads to tumor progression.  To develop more effective treatments, it is imperative that we better understand the mechanisms involved in tumor vessel formation, how they participate to the tumor progression and metastasis, and the best way to target them.  Several mechanisms contribute to the formation of tumor-assocd. vasculature: i) neoangiogenesis; ii) vascular co-option; iii) mosaicism; iv) vasculogenic mimicry, and v) postnatal vasculogenesis.  These mechanisms can also play a role in the development of resistance to anti-angiogenic drugs, and could serve as targets for designing new anti-vascular mols. to treat solid as well as hematol. malignancies.  Bone marrow-derived endothelial progenitor cell (EPC)-mediated vasculogenesis represents an important new target, esp. at the early stage of tumor growth (when EPCs are crit. for promoting the "angiogenic switch"), and during metastasis, when EPCs promote the transition from micro- to macro-metastases.  In hematol. malignancies, the EPC population could be related to the neoplastic clone, and both may share a common ontogeny.  Thus, characterization of tumor-assocd. EPCs in blood cancers may provide clues for more specific anti-vascular therapy that has both direct and indirect anti-tumor effects.  Here, we review the role of vasculogenesis, mediated by bone marrow-derived EPCs, in the progression of cancer, with a particular focus on the role of these cells in promoting progression of hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSltj3sCnUQrVg90H21EOLACvtfcHk0lgEpON9Yhmz0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1OqsrzK&md5=f7441312b188aee8838d30b7cef3818f</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1016%2Fj.bbcan.2014.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbcan.2014.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DMoschetta%26aufirst%3DM.%26aulast%3DMishima%26aufirst%3DY.%26aulast%3DSahin%26aufirst%3DI.%26aulast%3DManier%26aufirst%3DS.%26aulast%3DGlavey%26aufirst%3DS.%26aulast%3DVacca%26aufirst%3DA.%26aulast%3DRoccaro%26aufirst%3DA.%2BM.%26aulast%3DGhobrial%26aufirst%3DI.%2BM.%26atitle%3DRole%2520of%2520endothelial%2520progenitor%2520cells%2520in%2520cancer%2520progression%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Rev.%2520Cancer%26date%3D2014%26volume%3D1846%26spage%3D26%26epage%3D39%26doi%3D10.1016%2Fj.bbcan.2014.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group">Shaked, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woloszynek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daenen, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Man, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arbeit, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voest, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smythe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertolini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Link, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerbel, R. S.</span><span> </span><span class="NLM_article-title">Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">7524</span><span class="NLM_x">–</span> <span class="NLM_lpage">7528</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-0381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1158%2F0008-5472.CAN-09-0381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=19738066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Skt7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=7524-7528&author=Y.+Shakedauthor=T.+Tangauthor=J.+Woloszynekauthor=L.+G.+Daenenauthor=S.+Manauthor=P.+Xuauthor=S.+R.+Caiauthor=J.+M.+Arbeitauthor=E.+E.+Voestauthor=D.+J.+Chaplinauthor=J.+Smytheauthor=A.+Harrisauthor=P.+Nathanauthor=I.+Judsonauthor=G.+Rustinauthor=F.+Bertoliniauthor=D.+C.+Linkauthor=R.+S.+Kerbel&title=Contribution+of+granulocyte+colony-stimulating+factor+to+the+acute+mobilization+of+endothelial+precursor+cells+by+vascular+disrupting+agents&doi=10.1158%2F0008-5472.CAN-09-0381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Contribution of Granulocyte Colony-Stimulating Factor to the Acute Mobilization of Endothelial Precursor Cells by Vascular Disrupting Agents</span></div><div class="casAuthors">Shaked, Yuval; Tang, Terence; Woloszynek, Jill; Daenen, Laura G.; Man, Shan; Xu, Ping; Cai, Shi-Rong; Arbeit, Jeffrey M.; Voest, Emile E.; Chaplin, David J.; Smythe, Jon; Harris, Adrian; Nathan, Paul; Judson, Ian; Rustin, Gordon; Bertolini, Francesco; Link, Daniel C.; Kerbel, Robert S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7524-7528</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Vascular disrupting agents (VDA) cause acute shutdown of abnormal established tumor vasculature, followed by massive intratumoral hypoxia and necrosis.  However, a viable rim of tumor tissue invariably remains from which tumor regrowth rapidly resumes.  We have recently shown that an acute systemic mobilization and homing of bone marrow-derived circulating endothelial precursor (CEP) cells could promote tumor regrowth following treatment with either a VDA or certain chemotherapy drugs.  The mol. mediators of this systemic reactive host process are unknown.  Here, we show that following treatment of mice with OXi-4503, a second-generation potent prodrug deriv. of combretastatin-A4 phosphate, rapid increases in circulating plasma vascular endothelial growth factor, stromal derived factor-1 (SDF-1), and granulocyte colony-stimulating factor (G-CSF) levels are detected.  With the aim of detg. whether G-CSF is involved in VDA-induced CEP mobilization, mutant G-CSF-R-/- mice were treated with OXi-4503.  We found that as opposed to wild-type controls, G-CSF-R-/- mice failed to mobilize CEPs or show induction of SDF-1 plasma levels.  Furthermore, Lewis lung carcinomas grown in such mice treated with OXi-4503 showed greater levels of necrosis compared with tumors treated in wild-type mice.  Evidence for rapid elevations in circulating plasma G-CSF, vascular endothelial growth factor, and SDF-1 were also obsd. in patients with VDA (combretastatin-A4 phosphate)-treated cancer.  These results highlight the possible effect of drug-induced G-CSF on tumor regrowth following certain cytotoxic drug therapies, in this case using a VDA, and hence G-CSF as a possible therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2jpuiF1WWrLVg90H21EOLACvtfcHk0lgEpON9Yhmz0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Skt7rI&md5=d84f9c870de167454b3251c751d948f9</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-0381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-0381%26sid%3Dliteratum%253Aachs%26aulast%3DShaked%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DT.%26aulast%3DWoloszynek%26aufirst%3DJ.%26aulast%3DDaenen%26aufirst%3DL.%2BG.%26aulast%3DMan%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DP.%26aulast%3DCai%26aufirst%3DS.%2BR.%26aulast%3DArbeit%26aufirst%3DJ.%2BM.%26aulast%3DVoest%26aufirst%3DE.%2BE.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DSmythe%26aufirst%3DJ.%26aulast%3DHarris%26aufirst%3DA.%26aulast%3DNathan%26aufirst%3DP.%26aulast%3DJudson%26aufirst%3DI.%26aulast%3DRustin%26aufirst%3DG.%26aulast%3DBertolini%26aufirst%3DF.%26aulast%3DLink%26aufirst%3DD.%2BC.%26aulast%3DKerbel%26aufirst%3DR.%2BS.%26atitle%3DContribution%2520of%2520granulocyte%2520colony-stimulating%2520factor%2520to%2520the%2520acute%2520mobilization%2520of%2520endothelial%2520precursor%2520cells%2520by%2520vascular%2520disrupting%2520agents%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D7524%26epage%3D7528%26doi%3D10.1158%2F0008-5472.CAN-09-0381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group">Shaked, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciarrocchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Man, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benezra, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerbel, R. S.</span><span> </span><span class="NLM_article-title">Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">313</span><span class="NLM_x">, </span> <span class="NLM_fpage">1785</span><span class="NLM_x">–</span> <span class="NLM_lpage">1787</span><span class="refDoi"> DOI: 10.1126/science.1127592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1126%2Fscience.1127592" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=16990548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD28Xpsl2qs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2006&pages=1785-1787&author=Y.+Shakedauthor=A.+Ciarrocchiauthor=M.+Francoauthor=C.+R.+Leeauthor=S.+Manauthor=A.+M.+Cheungauthor=D.+J.+Hicklinauthor=D.+Chaplinauthor=F.+S.+Fosterauthor=R.+Benezraauthor=R.+S.+Kerbel&title=Therapy-induced+acute+recruitment+of+circulating+endothelial+progenitor+cells+to+tumors&doi=10.1126%2Fscience.1127592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors</span></div><div class="casAuthors">Shaked, Yuval; Ciarrocchi, Alessia; Franco, Marcela; Lee, Christina R.; Man, Shan; Cheung, Alison M.; Hicklin, Daniel J.; Chaplin, David; Stuart Foster, F.; Benezra, Robert; Kerbel, Robert S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">313</span>
        (<span class="NLM_cas:issue">5794</span>),
    <span class="NLM_cas:pages">1785-1787</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The contribution of bone marrow-derived circulating endothelial progenitor cells (CEPs) to tumor angiogenesis has been controversial, primarily because of their low nos. in blood vessels of untreated tumors.  We show that treatment of tumor-bearing mice with vascular disrupting agents (VDAs) leads to an acute mobilization of CEPs, which home to the viable tumor rim that characteristically remains after such therapy.  Disruption of this CEP spike by antiangiogenic drugs or by genetic manipulation resulted in marked redns. in tumor rim size and blood flow as well as enhanced VDA antitumor activity.  These findings also provide a mechanistic rationale for the enhanced efficacy of VDAs when combined with antiangiogenic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt4x1ShGytGbVg90H21EOLACvtfcHk0lhtYJrFe8_lcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xpsl2qs74%253D&md5=b0cd350a081f69bd889a250e1a704c17</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1126%2Fscience.1127592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1127592%26sid%3Dliteratum%253Aachs%26aulast%3DShaked%26aufirst%3DY.%26aulast%3DCiarrocchi%26aufirst%3DA.%26aulast%3DFranco%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DC.%2BR.%26aulast%3DMan%26aufirst%3DS.%26aulast%3DCheung%26aufirst%3DA.%2BM.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DChaplin%26aufirst%3DD.%26aulast%3DFoster%26aufirst%3DF.%2BS.%26aulast%3DBenezra%26aufirst%3DR.%26aulast%3DKerbel%26aufirst%3DR.%2BS.%26atitle%3DTherapy-induced%2520acute%2520recruitment%2520of%2520circulating%2520endothelial%2520progenitor%2520cells%2520to%2520tumors%26jtitle%3DScience%26date%3D2006%26volume%3D313%26spage%3D1785%26epage%3D1787%26doi%3D10.1126%2Fscience.1127592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group">Lewis, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Palma, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naldini, L.</span><span> </span><span class="NLM_article-title">Tie2-expressing monocytes and tumor angiogenesis: Regulation by hypoxia and angiopoietin-2</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">8429</span><span class="NLM_x">–</span> <span class="NLM_lpage">8432</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-1684</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1158%2F0008-5472.CAN-07-1684" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=8429-8432&author=C.+E.+Lewisauthor=M.+De+Palmaauthor=L.+Naldini&title=Tie2-expressing+monocytes+and+tumor+angiogenesis%3A+Regulation+by+hypoxia+and+angiopoietin-2&doi=10.1158%2F0008-5472.CAN-07-1684"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-1684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-1684%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DC.%2BE.%26aulast%3DDe%2BPalma%26aufirst%3DM.%26aulast%3DNaldini%26aufirst%3DL.%26atitle%3DTie2-expressing%2520monocytes%2520and%2520tumor%2520angiogenesis%253A%2520Regulation%2520by%2520hypoxia%2520and%2520angiopoietin-2%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D8429%26epage%3D8432%26doi%3D10.1158%2F0008-5472.CAN-07-1684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group">Welford, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biziato, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coffelt, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nucera, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pucci, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Serio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naldini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Palma, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozer, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C. E.</span><span> </span><span class="NLM_article-title">TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">1969</span><span class="NLM_x">–</span> <span class="NLM_lpage">1973</span><span class="refDoi"> DOI: 10.1172/JCI44562</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1172%2FJCI44562" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=21490397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvFKntLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2011&pages=1969-1973&author=A.+F.+Welfordauthor=D.+Biziatoauthor=S.+B.+Coffeltauthor=S.+Nuceraauthor=M.+Fisherauthor=F.+Pucciauthor=C.+Di+Serioauthor=L.+Naldiniauthor=M.+De+Palmaauthor=G.+M.+Tozerauthor=C.+E.+Lewis&title=TIE2-expressing+macrophages+limit+the+therapeutic+efficacy+of+the+vascular-disrupting+agent+combretastatin+A4+phosphate+in+mice&doi=10.1172%2FJCI44562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice</span></div><div class="casAuthors">Welford, Abigail F.; Biziato, Daniela; Coffelt, Seth B.; Nucera, Silvia; Fisher, Matthew; Pucci, Ferdinando; Di Serio, Clelia; Naldini, Luigi; De Palma, Michele; Tozer, Gillian M.; Lewis, Claire E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1969-1973</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Vascular-disrupting agents (VDAs) such as combretastatin A4 phosphate (CA4P) selectively disrupt blood vessels in tumors and induce tumor necrosis.  However, tumors rapidly repopulate after treatment with such compds.  Here, we show that CA4P-induced vessel narrowing, hypoxia, and hemorrhagic necrosis in murine mammary tumors were accompanied by elevated tumor levels of the chemokine CXCL12 and infiltration by proangiogenic TIE2-expressing macrophages (TEMs).  Inhibiting TEM recruitment to CA4P-treated tumors either by interfering pharmacol. with the CXCL12/CXCR4 axis or by genetically depleting TEMs in tumor-bearing mice markedly increased the efficacy of CA4P treatment.  These data suggest that TEMs limit VDA-induced tumor injury and represent a potential target for improving the clin. efficacy of VDA-based therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocb26kJmJmKrVg90H21EOLACvtfcHk0lhtYJrFe8_lcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvFKntLY%253D&md5=d54a510e428639e16fd9e6c94ecfd181</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1172%2FJCI44562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI44562%26sid%3Dliteratum%253Aachs%26aulast%3DWelford%26aufirst%3DA.%2BF.%26aulast%3DBiziato%26aufirst%3DD.%26aulast%3DCoffelt%26aufirst%3DS.%2BB.%26aulast%3DNucera%26aufirst%3DS.%26aulast%3DFisher%26aufirst%3DM.%26aulast%3DPucci%26aufirst%3DF.%26aulast%3DDi%2BSerio%26aufirst%3DC.%26aulast%3DNaldini%26aufirst%3DL.%26aulast%3DDe%2BPalma%26aufirst%3DM.%26aulast%3DTozer%26aufirst%3DG.%2BM.%26aulast%3DLewis%26aufirst%3DC.%2BE.%26atitle%3DTIE2-expressing%2520macrophages%2520limit%2520the%2520therapeutic%2520efficacy%2520of%2520the%2520vascular-disrupting%2520agent%2520combretastatin%2520A4%2520phosphate%2520in%2520mice%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2011%26volume%3D121%26spage%3D1969%26epage%3D1973%26doi%3D10.1172%2FJCI44562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group">Parkins, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holder, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozer, G. M.</span><span> </span><span class="NLM_article-title">Determinants of anti-vascular action by combretastatin A-4 phosphate: Role of nitric oxide</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">811</span><span class="NLM_x">–</span> <span class="NLM_lpage">816</span><span class="refDoi"> DOI: 10.1054/bjoc.2000.1361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1054%2Fbjoc.2000.1361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10952787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntFOhsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2000&pages=811-816&author=C.+S.+Parkinsauthor=A.+L.+Holderauthor=S.+A.+Hillauthor=D.+J.+Chaplinauthor=G.+M.+Tozer&title=Determinants+of+anti-vascular+action+by+combretastatin+A-4+phosphate%3A+Role+of+nitric+oxide&doi=10.1054%2Fbjoc.2000.1361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide</span></div><div class="casAuthors">Parkins, C. S.; Holder, A. L.; Hill, S. A.; Chaplin, D. J.; Tozer, G. M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">811-816</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Harcourt Publishers Ltd.</span>)
        </div><div class="casAbstract">The anti-vascular action of the tubulin binding agent combretastatin A-4 phosphate (CA-4-P) has been quantified in two types of murine tumor, the breast adenocarcinoma CaNT and the round cell sarcoma SaS.  The functional vascular vol., assessed using a fluorescent carbocyanine dye, was significantly reduced at 18 h after CA-4-P treatment in both tumor types, although the degree of redn. was very different in the two tumors.  The SaS tumor, which has a higher nitric oxide synthase (NOS) activity than the CaNT tumor, showed ∼10-fold greater resistance to vascular damage by CA-4-P.  This is consistent with our previous findings, which showed that NO exerts a protective action against this drug.  Simultaneous administration of CA-4-P with a NOS inhibitor, Nω-nitro-L-arginine (L-NNA), resulted in enhanced vascular damage and cytotoxicity in both tumor types.  Administration of diethylamine NO, an NO donor, conferred protection against the vascular damaging effects.  Following treatment with CA-4-P, neutrophil infiltration into the tumors, measured by myeloperoxidase (MPO) activity, was significantly increased.  Levels of MPO activity also correlated with the levels of vascular injury and cytotoxicity measured in both tumor types.  Neutrophilic MPO generates free radicals and may therefore contribute to the vascular damage assocd. with CA-4-P treatment.  MPO activity was significantly increased in the presence of L-NNA, suggesting that the protective effect of NO against CA-4-P-induced vascular injury may be, at least partially, mediated by limiting neutrophil infiltration.  The data are consistent with the hypothesis that neutrophil action contributes to vascular injury by CA-4-P and that NO generation acts to protect the tumor vasculature against CA4-P-induced injury.  The protective effect of NO is probably assocd. with an anti-neutrophil action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqibguGCtOqGLVg90H21EOLACvtfcHk0ljeMdSDAoFkyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntFOhsL0%253D&md5=9eb82cbaff18333d42eaef00087491d9</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1054%2Fbjoc.2000.1361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1054%252Fbjoc.2000.1361%26sid%3Dliteratum%253Aachs%26aulast%3DParkins%26aufirst%3DC.%2BS.%26aulast%3DHolder%26aufirst%3DA.%2BL.%26aulast%3DHill%26aufirst%3DS.%2BA.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DTozer%26aufirst%3DG.%2BM.%26atitle%3DDeterminants%2520of%2520anti-vascular%2520action%2520by%2520combretastatin%2520A-4%2520phosphate%253A%2520Role%2520of%2520nitric%2520oxide%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2000%26volume%3D83%26spage%3D811%26epage%3D816%26doi%3D10.1054%2Fbjoc.2000.1361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group">Bohn, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittenborn, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brems-Eskildsen, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertelsen, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stødkilde-Jørgensen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Møller, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horsman, M. R.</span><span> </span><span class="NLM_article-title">A combretastatin-mediated decrease in neutrophil concentration in peripheral blood and the impact on the anti-tumor activity of this drug in two different murine tumor models</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">e110091</span><span class="refDoi"> DOI: 10.1371/journal.pone.0110091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1371%2Fjournal.pone.0110091" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e110091&author=A.+B.+Bohnauthor=T.+Wittenbornauthor=A.+S.+Brems-Eskildsenauthor=T.+Laurbergauthor=L.+B.+Bertelsenauthor=T.+Nielsenauthor=H.+St%C3%B8dkilde-J%C3%B8rgensenauthor=B.+K.+M%C3%B8llerauthor=M.+R.+Horsman&title=A+combretastatin-mediated+decrease+in+neutrophil+concentration+in+peripheral+blood+and+the+impact+on+the+anti-tumor+activity+of+this+drug+in+two+different+murine+tumor+models&doi=10.1371%2Fjournal.pone.0110091"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0110091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0110091%26sid%3Dliteratum%253Aachs%26aulast%3DBohn%26aufirst%3DA.%2BB.%26aulast%3DWittenborn%26aufirst%3DT.%26aulast%3DBrems-Eskildsen%26aufirst%3DA.%2BS.%26aulast%3DLaurberg%26aufirst%3DT.%26aulast%3DBertelsen%26aufirst%3DL.%2BB.%26aulast%3DNielsen%26aufirst%3DT.%26aulast%3DSt%25C3%25B8dkilde-J%25C3%25B8rgensen%26aufirst%3DH.%26aulast%3DM%25C3%25B8ller%26aufirst%3DB.%2BK.%26aulast%3DHorsman%26aufirst%3DM.%2BR.%26atitle%3DA%2520combretastatin-mediated%2520decrease%2520in%2520neutrophil%2520concentration%2520in%2520peripheral%2520blood%2520and%2520the%2520impact%2520on%2520the%2520anti-tumor%2520activity%2520of%2520this%2520drug%2520in%2520two%2520different%2520murine%2520tumor%2520models%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De110091%26doi%3D10.1371%2Fjournal.pone.0110091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group">Greene, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolan, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meegan, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zisterer, D. M.</span><span> </span><span class="NLM_article-title">The vascular targeting agent Combretastatin-A4 directly induces autophagy in adenocarcinoma-derived colon cancer cells</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">612</span><span class="NLM_x">–</span> <span class="NLM_lpage">624</span><span class="refDoi"> DOI: 10.1016/j.bcp.2012.06.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.bcp.2012.06.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2012&pages=612-624&author=L.+M.+Greeneauthor=N.+M.+O%E2%80%99Boyleauthor=D.+P.+Nolanauthor=M.+J.+Meeganauthor=D.+M.+Zisterer&title=The+vascular+targeting+agent+Combretastatin-A4+directly+induces+autophagy+in+adenocarcinoma-derived+colon+cancer+cells&doi=10.1016%2Fj.bcp.2012.06.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2012.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2012.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DGreene%26aufirst%3DL.%2BM.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DN.%2BM.%26aulast%3DNolan%26aufirst%3DD.%2BP.%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26aulast%3DZisterer%26aufirst%3DD.%2BM.%26atitle%3DThe%2520vascular%2520targeting%2520agent%2520Combretastatin-A4%2520directly%2520induces%2520autophagy%2520in%2520adenocarcinoma-derived%2520colon%2520cancer%2520cells%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2012%26volume%3D84%26spage%3D612%26epage%3D624%26doi%3D10.1016%2Fj.bcp.2012.06.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Q.</span><span> </span><span class="NLM_article-title">Autophagy blockade sensitizes the anticancer activity of CA-4 via JNK-Bcl-2 pathway</span> <span class="citation_source-journal">Toxicol. Appl. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">274</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">327</span><span class="refDoi"> DOI: 10.1016/j.taap.2013.11.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.taap.2013.11.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=24321340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksFemsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=2014&pages=319-327&author=Y.+Liauthor=P.+Luoauthor=J.+Wangauthor=J.+Daiauthor=X.+Yangauthor=H.+Wuauthor=B.+Yangauthor=Q.+He&title=Autophagy+blockade+sensitizes+the+anticancer+activity+of+CA-4+via+JNK-Bcl-2+pathway&doi=10.1016%2Fj.taap.2013.11.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Autophagy blockade sensitizes the anticancer activity of CA-4 via JNK-Bcl-2 pathway</span></div><div class="casAuthors">Li, Yangling; Luo, Peihua; Wang, Jincheng; Dai, Jiabin; Yang, Xiaochun; Wu, Honghai; Yang, Bo; He, Qiaojun</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">274</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">319-327</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Combretastatin A-4 (CA-4) has already entered clin. trials of solid tumors over ten years.  However, the limited anticancer activity and dose-dependent toxicity restrict its clin. application.  Here, we offered convincing evidence that CA-4 induced autophagy in various cancer cells, which was demonstrated by acridine orange staining of intracellular acidic vesicles, the degrdn. of p62, the conversion of LC3-I to LC3-II and GFP-LC3 punctate fluorescence.  Interestingly, CA-4-mediated apoptotic cell death was further potentiated by pretreatment with autophagy inhibitors (3-methyladenine and bafilomycin A1) or small interfering RNAs against the autophagic genes (Atg5 and Beclin 1).  The enhanced anticancer activity of CA-4 and 3-MA was further confirmed in the SGC-7901 xenograft tumor model.  These findings suggested that CA-4-elicited autophagic response played a protective role that impeded the eventual cell death while autophagy inhibition was expected to improve chemotherapeutic efficacy of CA-4.  Meanwhile, CA-4 treatment led to phosphorylation/activation of JNK and JNK-dependent phosphorylation of Bcl-2.  Importantly, JNK inhibitor or JNK siRNA inhibited autophagy but promoted CA-4-induced apoptosis, indicating a key requirement of JNK-Bcl-2 pathway in the activation of autophagy by CA-4.  We also identified that pretreatment of Bcl-2 inhibitor (ABT-737) could significantly enhance anticancer activity of CA-4 due to inhibition of autophagy.  Taken together, our data suggested that the JNK-Bcl-2 pathway was considered as the crit. regulator of CA-4-induced protective autophagy and a potential drug target for chemotherapeutic combination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHZSB2u4cjH7Vg90H21EOLACvtfcHk0lhgg0g_jLkzHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksFemsw%253D%253D&md5=4d0cdca9cef0bc9c58135d244940a4b6</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2013.11.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2013.11.018%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DQ.%26atitle%3DAutophagy%2520blockade%2520sensitizes%2520the%2520anticancer%2520activity%2520of%2520CA-4%2520via%2520JNK-Bcl-2%2520pathway%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2014%26volume%3D274%26spage%3D319%26epage%3D327%26doi%3D10.1016%2Fj.taap.2013.11.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group">Clémenson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jouannot, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merino-Trigo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin-Carrez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deutsch, E.</span><span> </span><span class="NLM_article-title">The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">–</span> <span class="NLM_lpage">284</span><span class="refDoi"> DOI: 10.1007/s10637-012-9852-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1007%2Fs10637-012-9852-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=273-284&author=C.+Cl%C3%A9mensonauthor=E.+Jouannotauthor=A.+Merino-Trigoauthor=C.+Rubin-Carrezauthor=E.+Deutsch&title=The+vascular+disrupting+agent+ombrabulin+%28AVE8062%29+enhances+the+efficacy+of+standard+therapies+in+head+and+neck+squamous+cell+carcinoma+xenograft+models&doi=10.1007%2Fs10637-012-9852-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1007%2Fs10637-012-9852-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-012-9852-4%26sid%3Dliteratum%253Aachs%26aulast%3DCl%25C3%25A9menson%26aufirst%3DC.%26aulast%3DJouannot%26aufirst%3DE.%26aulast%3DMerino-Trigo%26aufirst%3DA.%26aulast%3DRubin-Carrez%26aufirst%3DC.%26aulast%3DDeutsch%26aufirst%3DE.%26atitle%3DThe%2520vascular%2520disrupting%2520agent%2520ombrabulin%2520%2528AVE8062%2529%2520enhances%2520the%2520efficacy%2520of%2520standard%2520therapies%2520in%2520head%2520and%2520neck%2520squamous%2520cell%2520carcinoma%2520xenograft%2520models%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2013%26volume%3D31%26spage%3D273%26epage%3D284%26doi%3D10.1007%2Fs10637-012-9852-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group">Martinelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonezzi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riccardi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frapolli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zucchetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taraboletti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giavazzi, R.</span><span> </span><span class="NLM_article-title">Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">888</span><span class="NLM_x">–</span> <span class="NLM_lpage">894</span><span class="refDoi"> DOI: 10.1038/sj.bjc.6603969</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1038%2Fsj.bjc.6603969" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=17848949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSnurbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2007&pages=888-894&author=M.+Martinelliauthor=K.+Bonezziauthor=E.+Riccardiauthor=E.+Kuhnauthor=R.+Frapolliauthor=M.+Zucchettiauthor=A.+J.+Ryanauthor=G.+Tarabolettiauthor=R.+Giavazzi&title=Sequence+dependent+antitumour+efficacy+of+the+vascular+disrupting+agent+ZD6126+in+combination+with+paclitaxel&doi=10.1038%2Fsj.bjc.6603969"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel</span></div><div class="casAuthors">Martinelli, M.; Bonezzi, K.; Riccardi, E.; Kuhn, E.; Frapolli, R.; Zucchetti, M.; Ryan, A. J.; Taraboletti, G.; Giavazzi, R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">888-894</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. success of small-mol. vascular disrupting agents (VDAs) depends on their combination with conventional therapies.  Scheduling and sequencing remain key issues in the design of VDA-chemotherapy combination treatments.  This study examd. the antitumor activity of ZD6126, a microtubule destabilizing VDA, in combination with paclitaxel (PTX), a microtubule-stabilizing cytotoxic drug, and the influence of schedule and sequence on the efficacy of the combination.  Nude mice bearing MDA-MB-435 xenografts received weekly cycles of ZD6126 (200 mg kg-1 i.p.) administered at different times before or after PTX (10, 20, and 40 mg kg-1 i.v.).  ZD6126 given 2 or 24 h after PTX showed no significant benefit, a result that was attributed to a protective effect of PTX against ZD6126-induced vascular damage and tumor necrosis, a hallmark of VDA activity.  Paclitaxel counteracting activity was reduced by distancing drug administrations, and ZD6126 given 72 h after PTX potentiated the VDA's antitumor activity.  Schedules with ZD6126 given before PTX improved therapeutic activity, which was paralleled by a VDA-induced increase in cell proliferation in the viable tumor tissue.  Paclitaxel given 72 h after ZD6126 yielded the best response (50% tumors regressing).  A single treatment with ZD6126 followed by weekly administration of PTX was sufficient to achieve a similar response (57% remissions).  These findings show that schedule, sequence and timing are crucial in detg. the antitumor efficacy of PTX in combination with ZD6126.  Induction of tumor necrosis and increased proliferation in the remaining viable tumor tissue could be exploited as readouts to optimize schedules and maximize therapeutic efficacy.  Published online 11 Sept. 2007.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGru-Vn3DW8o37Vg90H21EOLACvtfcHk0livel5QxibR_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSnurbP&md5=b2ee948386407ba60e97a7aea52c5cf9</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6603969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6603969%26sid%3Dliteratum%253Aachs%26aulast%3DMartinelli%26aufirst%3DM.%26aulast%3DBonezzi%26aufirst%3DK.%26aulast%3DRiccardi%26aufirst%3DE.%26aulast%3DKuhn%26aufirst%3DE.%26aulast%3DFrapolli%26aufirst%3DR.%26aulast%3DZucchetti%26aufirst%3DM.%26aulast%3DRyan%26aufirst%3DA.%2BJ.%26aulast%3DTaraboletti%26aufirst%3DG.%26aulast%3DGiavazzi%26aufirst%3DR.%26atitle%3DSequence%2520dependent%2520antitumour%2520efficacy%2520of%2520the%2520vascular%2520disrupting%2520agent%2520ZD6126%2520in%2520combination%2520with%2520paclitaxel%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2007%26volume%3D97%26spage%3D888%26epage%3D894%26doi%3D10.1038%2Fsj.bjc.6603969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group">Wu, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurung, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, C. H.</span><span> </span><span class="NLM_article-title">Mechanisms of tumor resistance to small-molecule vascular disrupting agents: Treatment and rationale of combination therapy</span> <span class="citation_source-journal">J. Formosan Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">115</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span><span class="refDoi"> DOI: 10.1016/j.jfma.2012.09.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.jfma.2012.09.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=23473523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1GksbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2013&pages=115-124&author=X.+Y.+Wuauthor=W.+Maauthor=K.+Gurungauthor=C.+H.+Guo&title=Mechanisms+of+tumor+resistance+to+small-molecule+vascular+disrupting+agents%3A+Treatment+and+rationale+of+combination+therapy&doi=10.1016%2Fj.jfma.2012.09.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of tumor resistance to small-molecule vascular disrupting agents: Treatment and rationale of combination therapy</span></div><div class="casAuthors">Wu, Xue-Yuan; Ma, Wei; Gurung, Kiran; Guo, Chi-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Formosan Medical Association</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">115-124</span>CODEN:
                <span class="NLM_cas:coden">JFASEO</span>;
        ISSN:<span class="NLM_cas:issn">0929-6646</span>.
    
            (<span class="NLM_cas:orgname">Elsevier (Singapore) Pte Ltd.</span>)
        </div><div class="casAbstract">A review.  Small-mol. vascular disrupting agents (VDAs) target the established tumor blood vessels, resulting in rapidly and selectively widespread ischemia and necrosis of central tumor; meanwhile, blood flow in normal tissues is relatively unaffected.  Although VDAs therapy is considered an important option for treatment, its use is still limited.  The tumor cells at the periphery are less sensitive to vascular shutdown than those at the center, and subsequently avoid a nutrient-deprived environment.  This phenomenon is referred to as tumor resistance to VDAs treatment.  The viable periphery rim of tumor cells contributes to tumor regeneration, metastasis, and ongoing progression.  However, there is no systematic review of the plausible mechanisms of repopulation of the viable tumor cells following VDAs therapy.  The purpose of this review is to provide insights into mechanisms of tumor surviving small-mol. VDAs therapy, and the synergetic treatment to the remaining viable tumor cells at the periphery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXeMYvM5f5krVg90H21EOLACvtfcHk0livel5QxibR_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1GksbbP&md5=9c85a37cb31674fd5a48a78b4f205b32</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1016%2Fj.jfma.2012.09.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jfma.2012.09.017%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DX.%2BY.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DGurung%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DC.%2BH.%26atitle%3DMechanisms%2520of%2520tumor%2520resistance%2520to%2520small-molecule%2520vascular%2520disrupting%2520agents%253A%2520Treatment%2520and%2520rationale%2520of%2520combination%2520therapy%26jtitle%3DJ.%2520Formosan%2520Med.%2520Assoc.%26date%3D2013%26volume%3D112%26spage%3D115%26epage%3D124%26doi%3D10.1016%2Fj.jfma.2012.09.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group">Nathan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zweifel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padhani, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smythe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stirling, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G. J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I.</span><span> </span><span class="NLM_article-title">Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3428</span><span class="NLM_x">–</span> <span class="NLM_lpage">3439</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-3376</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1158%2F1078-0432.CCR-11-3376" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=22645052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1Oks70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=3428-3439&author=P.+Nathanauthor=M.+Zweifelauthor=A.+R.+Padhaniauthor=D.+M.+Kohauthor=M.+Ngauthor=D.+J.+Collinsauthor=A.+Harrisauthor=C.+Cardenauthor=J.+Smytheauthor=N.+Fisherauthor=N.+J.+Taylorauthor=J.+J.+Stirlingauthor=S.+P.+Luauthor=M.+O.+Leachauthor=G.+J.+S.+Rustinauthor=I.+Judson&title=Phase+I+trial+of+combretastatin+A4+phosphate+%28CA4P%29+in+combination+with+bevacizumab+in+patients+with+advanced+cancer&doi=10.1158%2F1078-0432.CCR-11-3376"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer</span></div><div class="casAuthors">Nathan, Paul; Zweifel, Martin; Padhani, Anwar R.; Koh, Dow-Mu; Ng, Matthew; Collins, David J.; Harris, Adrian; Carden, Craig; Smythe, Jon; Fisher, Nita; Taylor, N. Jane; Stirling, J. James; Lu, Shiao-Ping; Leach, Martin O.; Rustin, Gordon J. S.; Judson, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3428-3439</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The vascular disrupting agent (VDA) combretastatin A4 phosphate (CA4P) induces significant tumor necrosis as a single agent.  Preclin. models have shown that the addn. of an anti-VEGF antibody to a VDA attenuates the revascularization of the surviving tumor rim and thus significantly increases antitumor activity.  Exptl. Design: Patients with advanced solid malignancies received CA4P at 45, 54, or 63 mg/m2 on day 1, day 8, and then every 14 days.  Bevacizumab 10 mg/kg was given on day 8 and at subsequent cycles four hours after CA4P.  Functional imaging with dynamic contrast enhanced-MRI (DCE-MRI) was conducted at baseline, after CA4P alone, and after cycle 1 CA4P + bevacizumab.  Results: A total of 63 mg/m2 CA4P + 10 mg/kg bevacizumab q14 is the recommended phase II dose.  A total of 15 patients were enrolled.  Dose-limiting toxicities were grade III asymptomatic atrial fibrillation and grade IV liver hemorrhage in a patient with a history of hemorrhage.  Most common toxicities were hypertension, headache, lymphopenia, pruritus, and pyrexia.  Asymptomatic electrocardiog. changes were seen in five patients.  Nine of 14 patients experienced disease stabilization.  A patient with ovarian cancer had a CA125 response lasting for more than a year.  DCE-MRI showed statistically significant redns. in tumor perfusion/vascular permeability, which reversed after CA4P alone but which were sustained following bevacizumab.  Circulating CD34+ and CD133+ bone marrow progenitors increased following CA4P as did VEGF and granulocyte colony-stimulating factor levels.  Conclusions: CA4P in combination with bevacizumab appears safe and well tolerated in this dosing schedule.  CA4P induced profound vascular changes, which were maintained by the presence of bevacizumab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDhWR6xfmKNbVg90H21EOLACvtfcHk0livel5QxibR_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1Oks70%253D&md5=b7d93331d8ad4e6d21fff0ddf35fe461</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-3376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-3376%26sid%3Dliteratum%253Aachs%26aulast%3DNathan%26aufirst%3DP.%26aulast%3DZweifel%26aufirst%3DM.%26aulast%3DPadhani%26aufirst%3DA.%2BR.%26aulast%3DKoh%26aufirst%3DD.%2BM.%26aulast%3DNg%26aufirst%3DM.%26aulast%3DCollins%26aufirst%3DD.%2BJ.%26aulast%3DHarris%26aufirst%3DA.%26aulast%3DCarden%26aufirst%3DC.%26aulast%3DSmythe%26aufirst%3DJ.%26aulast%3DFisher%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DN.%2BJ.%26aulast%3DStirling%26aufirst%3DJ.%2BJ.%26aulast%3DLu%26aufirst%3DS.%2BP.%26aulast%3DLeach%26aufirst%3DM.%2BO.%26aulast%3DRustin%26aufirst%3DG.%2BJ.%2BS.%26aulast%3DJudson%26aufirst%3DI.%26atitle%3DPhase%2520I%2520trial%2520of%2520combretastatin%2520A4%2520phosphate%2520%2528CA4P%2529%2520in%2520combination%2520with%2520bevacizumab%2520in%2520patients%2520with%2520advanced%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D3428%26epage%3D3439%26doi%3D10.1158%2F1078-0432.CCR-11-3376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group">Moens, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goveia, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stapor, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantelmo, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmeliet, P.</span><span> </span><span class="NLM_article-title">The multifaceted activity of VEGF in angiogenesis - Implications for therapy responses</span> <span class="citation_source-journal">Cytokine Growth Factor Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">473</span><span class="NLM_x">–</span> <span class="NLM_lpage">482</span><span class="refDoi"> DOI: 10.1016/j.cytogfr.2014.07.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.cytogfr.2014.07.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=25169850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVKnurvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=473-482&author=S.+Moensauthor=J.+Goveiaauthor=P.+C.+Staporauthor=A.+R.+Cantelmoauthor=P.+Carmeliet&title=The+multifaceted+activity+of+VEGF+in+angiogenesis+-+Implications+for+therapy+responses&doi=10.1016%2Fj.cytogfr.2014.07.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">The multifaceted activity of VEGF in angiogenesis - Implications for therapy responses</span></div><div class="casAuthors">Moens, Stijn; Goveia, Jermaine; Stapor, Peter C.; Cantelmo, Anna Rita; Carmeliet, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">473-482</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Vascular endothelial growth factor (VEGF) is a key growth factor driving angiogenesis (i.e. the formation of new blood vessels) in health and disease.  Pharmacol. blockade of VEGF signaling to inhibit tumor angiogenesis is clin. approved but the survival benefit is limited as patients invariably acquire resistance.  This is partially mediated by the intrinsic flexibility of tumor cells to adapt to VEGF-blockade.  However, it has become clear that tumor stromal cells also contribute to the resistance.  Originally, VEGF was thought to specifically target endothelial cells (ECs) but it is now clear that many stromal cells also respond to VEGF signaling, making anti-VEGF therapy more complex than initially anticipated.  A more comprehensive understanding of the complex responses of stromal cells to VEGF-blockade might inform the design of improved anti-angiogenic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOhBOfmgezwbVg90H21EOLACvtfcHk0lg-xzCPnExVew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVKnurvE&md5=8823c2f4eee6593d96db325032cb823c</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2014.07.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2014.07.009%26sid%3Dliteratum%253Aachs%26aulast%3DMoens%26aufirst%3DS.%26aulast%3DGoveia%26aufirst%3DJ.%26aulast%3DStapor%26aufirst%3DP.%2BC.%26aulast%3DCantelmo%26aufirst%3DA.%2BR.%26aulast%3DCarmeliet%26aufirst%3DP.%26atitle%3DThe%2520multifaceted%2520activity%2520of%2520VEGF%2520in%2520angiogenesis%2520-%2520Implications%2520for%2520therapy%2520responses%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2014%26volume%3D25%26spage%3D473%26epage%3D482%26doi%3D10.1016%2Fj.cytogfr.2014.07.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group">Lambrechts, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Haas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmeliet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherer, S. J.</span><span> </span><span class="NLM_article-title">Markers of response for the antiangiogenic agent bevacizumab</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1219</span><span class="NLM_x">–</span> <span class="NLM_lpage">1230</span><span class="refDoi"> DOI: 10.1200/JCO.2012.46.2762</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1200%2FJCO.2012.46.2762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=23401453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVyhu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=1219-1230&author=D.+Lambrechtsauthor=H.+J.+Lenzauthor=S.+De+Haasauthor=P.+Carmelietauthor=S.+J.+Scherer&title=Markers+of+response+for+the+antiangiogenic+agent+bevacizumab&doi=10.1200%2FJCO.2012.46.2762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Markers of response for the antiangiogenic agent bevacizumab</span></div><div class="casAuthors">Lambrechts, Diether; Lenz, Heinz-Josef; de Haas, Sanne; Carmeliet, Peter; Scherer, Stefan J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1219-1230</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Bevacizumab is the first antiangiogenic therapy proven to slow metastatic disease progression in patients with cancer.  Although it has changed clin. practice, some patients do not respond or gradually develop resistance, resulting in rather modest gains in terms of overall survival.  A major challenge is to develop robust biomarkers that can guide selection of patients for whom bevacizumab therapy is most beneficial.  Here, we discuss recent progress in finding such markers, including the first results from randomized phase III clin. trials evaluating the efficacy of bevacizumab in combination with comprehensive biomarker analyses.  In particular, these studies suggest that circulating levels of short vascular endothelial growth factor A (VEGF-A) isoforms, expression of neuropilin-1 and VEGF receptor 1 in tumors or plasma, and genetic variants in VEGFA or its receptors are strong biomarker candidates.  The current challenge is to expand this first set of markers and to validate it and implement it into clin. practice.  A first prospective biomarker study known as MERiDiAN, which will treat patients stratified for circulating levels of short VEGF-A isoforms with bevacizumab and paclitaxel, is planned and will hopefully provide us with new directions on how to treat patients more efficiently.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpEt-mPtftaLVg90H21EOLACvtfcHk0lg-xzCPnExVew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVyhu74%253D&md5=5d7841b2cd2ff58ac32116c972432dbe</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.46.2762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.46.2762%26sid%3Dliteratum%253Aachs%26aulast%3DLambrechts%26aufirst%3DD.%26aulast%3DLenz%26aufirst%3DH.%2BJ.%26aulast%3DDe%2BHaas%26aufirst%3DS.%26aulast%3DCarmeliet%26aufirst%3DP.%26aulast%3DScherer%26aufirst%3DS.%2BJ.%26atitle%3DMarkers%2520of%2520response%2520for%2520the%2520antiangiogenic%2520agent%2520bevacizumab%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D1219%26epage%3D1230%26doi%3D10.1200%2FJCO.2012.46.2762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group">Zweifel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayson, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ledermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shreeves, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balkissoon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G. J. S.</span><span> </span><span class="NLM_article-title">Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2036</span><span class="NLM_x">–</span> <span class="NLM_lpage">2041</span><span class="refDoi"> DOI: 10.1093/annonc/mdq708</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1093%2Fannonc%2Fmdq708" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=21273348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A280%3ADC%252BC3MjpvVSrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=2036-2041&author=M.+Zweifelauthor=G.+C.+Jaysonauthor=N.+S.+Reedauthor=R.+Osborneauthor=B.+Hassanauthor=J.+Ledermannauthor=G.+Shreevesauthor=L.+Poupardauthor=S.+P.+Luauthor=J.+Balkissoonauthor=D.+J.+Chaplinauthor=G.+J.+S.+Rustin&title=Phase+II+trial+of+combretastatin+A4+phosphate%2C+carboplatin%2C+and+paclitaxel+in+patients+with+platinum-resistant+ovarian+cancer&doi=10.1093%2Fannonc%2Fmdq708"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer</span></div><div class="casAuthors">Zweifel M; Jayson G C; Reed N S; Osborne R; Hassan B; Ledermann J; Shreeves G; Poupard L; Lu S-P; Balkissoon J; Chaplin D J; Rustin G J S</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2036-41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  A previous dose-escalation trial of the vascular disrupting agent combretastatin A4 phosphate (CA4P) given before carboplatin, paclitaxel, or both showed responses in 7 of 18 patients with relapsed ovarian cancer.  PATIENTS AND METHODS:  Patients with ovarian cancer that had relapsed and who could start trial therapy within 6 months of their last platinum chemotherapy were given CA4P 63 mg/m(2) minimum 18 h before paclitaxel 175 mg/m(2) and carboplatin AUC (area under the concentration curve) 5, repeated every 3 weeks.  RESULTS:  Five of the first 18 patients' disease responded, so the study was extended and closed after 44 patients were recruited.  Grade ≥2 toxic effects were neutropenia in 75% and thrombocytopenia in 9% of patients (weekly blood counts), tumour pain, fatigue, and neuropathy, with one patient with rapidly reversible ataxia.  Hypertension (23% of patients) was controlled by glyceryl trinitrate or prophylactic amlodipine.  The response rate by RECIST was 13.5% and by Gynecologic Cancer InterGroup CA 125 criteria 34%.  CONCLUSIONS:  The addition of CA4P to paclitaxel and carboplatin is well tolerated and appears to produce a higher response rate in this patient population than if the chemotherapy was given without CA4P.  A planned randomised trial will test this hypothesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTKPQKWSYY7Sqe0F5ixvZgXfW6udTcc2eYxodZP2w6qIrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MjpvVSrsQ%253D%253D&md5=6b960ad4dcccdbbc67ffa9398e85d2be</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdq708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdq708%26sid%3Dliteratum%253Aachs%26aulast%3DZweifel%26aufirst%3DM.%26aulast%3DJayson%26aufirst%3DG.%2BC.%26aulast%3DReed%26aufirst%3DN.%2BS.%26aulast%3DOsborne%26aufirst%3DR.%26aulast%3DHassan%26aufirst%3DB.%26aulast%3DLedermann%26aufirst%3DJ.%26aulast%3DShreeves%26aufirst%3DG.%26aulast%3DPoupard%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DS.%2BP.%26aulast%3DBalkissoon%26aufirst%3DJ.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DRustin%26aufirst%3DG.%2BJ.%2BS.%26atitle%3DPhase%2520II%2520trial%2520of%2520combretastatin%2520A4%2520phosphate%252C%2520carboplatin%252C%2520and%2520paclitaxel%2520in%2520patients%2520with%2520platinum-resistant%2520ovarian%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2011%26volume%3D22%26spage%3D2036%26epage%3D2041%26doi%3D10.1093%2Fannonc%2Fmdq708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group">Sosa, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balkissoon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langecker, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elisei, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarzab, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bal, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gramza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ondrey, F.</span><span> </span><span class="NLM_article-title">Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer</span> <span class="citation_source-journal">Surgery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">152</span><span class="NLM_x">, </span> <span class="NLM_fpage">1078</span><span class="NLM_x">–</span> <span class="NLM_lpage">1087</span><span class="refDoi"> DOI: 10.1016/j.surg.2012.08.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.surg.2012.08.036" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2012&pages=1078-1087&author=J.+A.+Sosaauthor=J.+Balkissoonauthor=S.+P.+Luauthor=P.+Langeckerauthor=R.+Eliseiauthor=B.+Jarzabauthor=C.+S.+Balauthor=S.+Marurauthor=A.+Gramzaauthor=F.+Ondrey&title=Thyroidectomy+followed+by+fosbretabulin+%28CA4P%29+combination+regimen+appears+to+suggest+improvement+in+patient+survival+in+anaplastic+thyroid+cancer&doi=10.1016%2Fj.surg.2012.08.036"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1016%2Fj.surg.2012.08.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.surg.2012.08.036%26sid%3Dliteratum%253Aachs%26aulast%3DSosa%26aufirst%3DJ.%2BA.%26aulast%3DBalkissoon%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DS.%2BP.%26aulast%3DLangecker%26aufirst%3DP.%26aulast%3DElisei%26aufirst%3DR.%26aulast%3DJarzab%26aufirst%3DB.%26aulast%3DBal%26aufirst%3DC.%2BS.%26aulast%3DMarur%26aufirst%3DS.%26aulast%3DGramza%26aufirst%3DA.%26aulast%3DOndrey%26aufirst%3DF.%26atitle%3DThyroidectomy%2520followed%2520by%2520fosbretabulin%2520%2528CA4P%2529%2520combination%2520regimen%2520appears%2520to%2520suggest%2520improvement%2520in%2520patient%2520survival%2520in%2520anaplastic%2520thyroid%2520cancer%26jtitle%3DSurgery%26date%3D2012%26volume%3D152%26spage%3D1078%26epage%3D1087%26doi%3D10.1016%2Fj.surg.2012.08.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group">von Pawel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorbounova, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reck, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowalski, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allard, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chadjaa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennouna, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grossi, F.</span><span> </span><span class="NLM_article-title">DISRUPT: A randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer</span> <span class="citation_source-journal">Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">224</span><span class="NLM_x">–</span> <span class="NLM_lpage">229</span><span class="refDoi"> DOI: 10.1016/j.lungcan.2014.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.lungcan.2014.05.013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2014&pages=224-229&author=J.+von+Pawelauthor=V.+Gorbounovaauthor=M.+Reckauthor=D.+M.+Kowalskiauthor=A.+Allardauthor=M.+Chadjaaauthor=A.+Reyauthor=J.+Bennounaauthor=F.+Grossi&title=DISRUPT%3A+A+randomised+phase+2+trial+of+ombrabulin+%28AVE8062%29+plus+a+taxane-platinum+regimen+as+first-line+therapy+for+metastatic+non-small+cell+lung+cancer&doi=10.1016%2Fj.lungcan.2014.05.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2014.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2014.05.013%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BPawel%26aufirst%3DJ.%26aulast%3DGorbounova%26aufirst%3DV.%26aulast%3DReck%26aufirst%3DM.%26aulast%3DKowalski%26aufirst%3DD.%2BM.%26aulast%3DAllard%26aufirst%3DA.%26aulast%3DChadjaa%26aufirst%3DM.%26aulast%3DRey%26aufirst%3DA.%26aulast%3DBennouna%26aufirst%3DJ.%26aulast%3DGrossi%26aufirst%3DF.%26atitle%3DDISRUPT%253A%2520A%2520randomised%2520phase%25202%2520trial%2520of%2520ombrabulin%2520%2528AVE8062%2529%2520plus%2520a%2520taxane-platinum%2520regimen%2520as%2520first-line%2520therapy%2520for%2520metastatic%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DLung%2520Cancer%26date%3D2014%26volume%3D85%26spage%3D224%26epage%3D229%26doi%3D10.1016%2Fj.lungcan.2014.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group">Siemann, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lepler, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rojiani, A. M.</span><span> </span><span class="NLM_article-title">Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span><span class="refDoi"> DOI: 10.1002/ijc.10316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1002%2Fijc.10316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=11948484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD38XivVCgsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=1-6&author=D.+W.+Siemannauthor=E.+Mercerauthor=S.+Leplerauthor=A.+M.+Rojiani&title=Vascular+targeting+agents+enhance+chemotherapeutic+agent+activities+in+solid+tumor+therapy&doi=10.1002%2Fijc.10316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy</span></div><div class="casAuthors">Siemann, Dietmar W.; Mercer, Emma; Lepler, Sharon; Rojiani, Amyn M.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The utility of combining the vascular targeting agents 5,6-dimethyl-xanthenone-4 acetic acid (DMXAA) and combretastatin A-4 disodium phosphate (CA4DP) with the anticancer drugs cisplatin and cyclophosphamide (CP) was evaluated in exptl. rodent (KHT sarcoma), human breast (SKBR3) and ovarian (OW-1) tumor models.  Doses of the vascular targeting agents that led to rapid vascular shutdown and subsequent extensive central tumor necrosis were identified.  Histol. evaluation showed morphol. damage of tumor cells within a few hours after treatment, followed by extensive hemorrhagic necrosis and dose-dependent neoplastic cell death as a result of prolonged ischemia.  Whereas these effects were induced by a range of CA4DP doses (10-150 mg/kg), the dose response to DMXAA was extremely steep; doses ≤ 15 mg/kg were ineffective and doses ≥ 20 mg/kg were toxic.  DMXAA also enhanced the tumor cell killing of cisplatin, but doses > 15 mg/kg were required.  In contrast, CA4DP increased cisplatin-induced tumor cell killing at all doses studied.  This enhancement of cisplatin efficacy was dependent on the sequence and interval between the agents.  The greatest effects were achieved when the vascular targeting agents were administered 1-3 h after cisplatin.  When CA4DP (100 mg/kg) or DMXAA (17.5 mg/kg) were administered 1 h after a range of doses of cisplatin or CP, the tumor cell kill was 10-500-fold greater than that seen with chemotherapy alone.  In addn., the inclusion of the antivascular agents did not increase bone marrow stem cell toxicity assocd. with these anticancer drugs, thus giving rise to a therapeutic gain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_DC9QCS350rVg90H21EOLACvtfcHk0ljAOUg3A8Laig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivVCgsr4%253D&md5=746a75652465a9bf12f9b1a7d694ff98</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1002%2Fijc.10316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.10316%26sid%3Dliteratum%253Aachs%26aulast%3DSiemann%26aufirst%3DD.%2BW.%26aulast%3DMercer%26aufirst%3DE.%26aulast%3DLepler%26aufirst%3DS.%26aulast%3DRojiani%26aufirst%3DA.%2BM.%26atitle%3DVascular%2520targeting%2520agents%2520enhance%2520chemotherapeutic%2520agent%2520activities%2520in%2520solid%2520tumor%2520therapy%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2002%26volume%3D99%26spage%3D1%26epage%3D6%26doi%3D10.1002%2Fijc.10316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group">Bilenker, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallagher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevenson, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaughn, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giantonio, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span> </span><span class="NLM_article-title">Phase I trial of combretastatin A-4 phosphate with carboplatin</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1527</span><span class="NLM_x">–</span> <span class="NLM_lpage">1533</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-04-1434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1158%2F1078-0432.CCR-04-1434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=15746056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhvVSrsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=1527-1533&author=J.+H.+Bilenkerauthor=K.+T.+Flahertyauthor=M.+Rosenauthor=L.+Davisauthor=M.+Gallagherauthor=J.+P.+Stevensonauthor=W.+Sunauthor=D.+Vaughnauthor=B.+Giantonioauthor=R.+Zimmerauthor=M.+Schnallauthor=P.+J.+O%E2%80%99Dwyer&title=Phase+I+trial+of+combretastatin+A-4+phosphate+with+carboplatin&doi=10.1158%2F1078-0432.CCR-04-1434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I trial of combretastatin A-4 phosphate with carboplatin</span></div><div class="casAuthors">Bilenker, Joshua H.; Flaherty, Keith T.; Rosen, Mark; Davis, Lisa; Gallagher, Maryann; Stevenson, James P.; Sun, Weijing; Vaughn, David; Giantonio, Bruce; Zimmer, Ross; Schnall, Mitchell; O'Dwyer, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1527-1533</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Preclin. evidence of synergy led to a phase I trial employing combretastatin A-4 phosphate (CA4P), a novel tubulin-binding antivascular drug, in combination with carboplatin.  Based on preclin. scheduling studies, patients were treated on day 1 of a 21-day cycle.  Carboplatin was given as a 30-min i.v. infusion and CA4P was given 60 min later as a 10-min infusion.  Sixteen patients with solid tumors received 40 cycles of therapy at CA4P doses of 27 and 36 mg/m2 together with carboplatin at area under the concn.-time curve (AUC) values of 4 and 5 mg min/mL.  The dose-limiting toxicity of thrombocytopenia halted the dose escalation phase of the study.  Four patients were treated at an amended dose level of CA4P of 36 mg/m2 and carboplatin AUC of 4 mg min/mL although grade 3 neutropenia and thrombocytopenia were still obsd.  Three lines of evidence are adduced to suggest that a pharmacokinetic interaction between the drugs results in greater thrombocytopenia than anticipated: the carboplatin exposure (as AUC) was greater than predicted; the platelet nadirs were lower than predicted; and the deviation of the carboplatin exposure from predicted was proportional to the AUC of CA4, the active metabolite of CA4P.  Patient benefit included six patients with stable disease lasting at least four cycles.  This study of CA4P and carboplatin given in combination showed dose-limiting thrombocytopenia.  Pharmacokinetic/pharmacodynamic modeling permitted the inference that altered carboplatin pharmacokinetics caused the increment in platelet toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaLdRoEnkhG7Vg90H21EOLACvtfcHk0li_Xs1Ka6TheA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhvVSrsbc%253D&md5=3f49677885a550ccfef2e25faaa4cf53</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-1434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-1434%26sid%3Dliteratum%253Aachs%26aulast%3DBilenker%26aufirst%3DJ.%2BH.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DRosen%26aufirst%3DM.%26aulast%3DDavis%26aufirst%3DL.%26aulast%3DGallagher%26aufirst%3DM.%26aulast%3DStevenson%26aufirst%3DJ.%2BP.%26aulast%3DSun%26aufirst%3DW.%26aulast%3DVaughn%26aufirst%3DD.%26aulast%3DGiantonio%26aufirst%3DB.%26aulast%3DZimmer%26aufirst%3DR.%26aulast%3DSchnall%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26atitle%3DPhase%2520I%2520trial%2520of%2520combretastatin%2520A-4%2520phosphate%2520with%2520carboplatin%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D1527%26epage%3D1533%26doi%3D10.1158%2F1078-0432.CCR-04-1434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group">Brouhard, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, L. M.</span><span> </span><span class="NLM_article-title">The contribution of αβ-tubulin curvature to microtubule dynamics</span> <span class="citation_source-journal">J. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">207</span><span class="NLM_x">, </span> <span class="NLM_fpage">323</span><span class="NLM_x">–</span> <span class="NLM_lpage">334</span><span class="refDoi"> DOI: 10.1083/jcb.201407095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1083%2Fjcb.201407095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=25385183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGhs7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=207&publication_year=2014&pages=323-334&author=G.+J.+Brouhardauthor=L.+M.+Rice&title=The+contribution+of+%CE%B1%CE%B2-tubulin+curvature+to+microtubule+dynamics&doi=10.1083%2Fjcb.201407095"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">The contribution of αβ-tubulin curvature to microtubule dynamics</span></div><div class="casAuthors">Brouhard, Gary J.; Rice, Luke M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">207</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">323-334</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">A review.  Microtubules are dynamic polymers of αβ-tubulin that form diverse cellular structures, such as the mitotic spindle for cell division, the backbone of neurons, and axonemes.  To control the architecture of microtubule networks, microtubule-assocd. proteins (MAPs) and motor proteins regulate microtubule growth, shrinkage, and the transitions between these states.  Recent evidence shows that many MAPs exert their effects by selectively binding to distinct conformations of polymd. or unpolymd. αβ-tubulin.  The ability of αβ-tubulin to adopt distinct conformations contributes to the intrinsic polymn. dynamics of microtubules.  αβ-Tubulin conformation is a fundamental property that MAPs monitor and control to build proper microtubule networks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGyoU-iIkFELVg90H21EOLACvtfcHk0li_Xs1Ka6TheA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGhs7jE&md5=5ff241f0a021843f7678daec3f7476f1</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1083%2Fjcb.201407095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.201407095%26sid%3Dliteratum%253Aachs%26aulast%3DBrouhard%26aufirst%3DG.%2BJ.%26aulast%3DRice%26aufirst%3DL.%2BM.%26atitle%3DThe%2520contribution%2520of%2520%25CE%25B1%25CE%25B2-tubulin%2520curvature%2520to%2520microtubule%2520dynamics%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2014%26volume%3D207%26spage%3D323%26epage%3D334%26doi%3D10.1083%2Fjcb.201407095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group">Tozer, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prise, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locke, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vojnovic, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratford, M. R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dennis, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span> </span><span class="NLM_article-title">Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1626</span><span class="NLM_x">–</span> <span class="NLM_lpage">1634</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=1626-1634&author=G.+M.+Tozerauthor=V.+E.+Priseauthor=J.+Wilsonauthor=R.+J.+Lockeauthor=B.+Vojnovicauthor=M.+R.+L.+Stratfordauthor=M.+F.+Dennisauthor=D.+J.+Chaplin&title=Combretastatin+A-4+phosphate+as+a+tumor+vascular-targeting+agent%3A+Early+effects+in+tumors+and+normal+tissues"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTozer%26aufirst%3DG.%2BM.%26aulast%3DPrise%26aufirst%3DV.%2BE.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DLocke%26aufirst%3DR.%2BJ.%26aulast%3DVojnovic%26aufirst%3DB.%26aulast%3DStratford%26aufirst%3DM.%2BR.%2BL.%26aulast%3DDennis%26aufirst%3DM.%2BF.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26atitle%3DCombretastatin%2520A-4%2520phosphate%2520as%2520a%2520tumor%2520vascular-targeting%2520agent%253A%2520Early%2520effects%2520in%2520tumors%2520and%2520normal%2520tissues%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D1626%26epage%3D1634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group">Kim, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukushima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saw, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kataoka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DoHeo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishikawa, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uemura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, G.</span><span> </span><span class="NLM_article-title">Vascular RhoJ is an effective and selective target for tumor angiogenesis and vascular disruption</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">102</span><span class="NLM_x">–</span> <span class="NLM_lpage">117</span><span class="refDoi"> DOI: 10.1016/j.ccr.2013.12.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.ccr.2013.12.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=24434213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFWgs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=102-117&author=C.+Kimauthor=H.+Yangauthor=Y.+Fukushimaauthor=P.+Sawauthor=J.+Leeauthor=J.+S.+Parkauthor=I.+Parkauthor=J.+Jungauthor=H.+Kataokaauthor=D.+Leeauthor=W.+DoHeoauthor=I.+Kimauthor=S.+Jonauthor=R.+H.+Adamsauthor=S.+I.+Nishikawaauthor=A.+Uemuraauthor=G.+Koh&title=Vascular+RhoJ+is+an+effective+and+selective+target+for+tumor+angiogenesis+and+vascular+disruption&doi=10.1016%2Fj.ccr.2013.12.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular RhoJ Is an Effective and Selective Target for Tumor Angiogenesis and Vascular Disruption</span></div><div class="casAuthors">Kim, Chan; Yang, Hanseul; Fukushima, Yoko; Saw, Phei Er; Lee, Junyeop; Park, Jin-Sung; Park, Intae; Jung, Jinmyung; Kataoka, Hiroshi; Lee, Doheon; Do Heo, Won; Kim, Injune; Jon, Sangyong; Adams, Ralf H.; Nishikawa, Shin-ichi; Uemura, Akiyoshi; Koh, Gou Young</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-117</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Current antiangiogenic therapy is limited by its cytostatic nature and systemic side effects.  To address these limitations, we have unveiled the role of RhoJ, an endothelial-enriched Rho GTPase, during tumor progression.  RhoJ blockade provides a double assault on tumor vessels by both inhibiting tumor angiogenesis and disrupting the preformed tumor vessels through the activation of the RhoA-ROCK (Rho kinase) signaling pathway in tumor endothelial cells, consequently resulting in a functional failure of tumor vasculatures.  Moreover, enhanced anticancer effects were obsd. when RhoJ blockade was employed in concert with a cytotoxic chemotherapeutic agent, angiogenesis-inhibiting agent, or vascular-disrupting agent.  These results identify RhoJ blockade as a selective and effective therapeutic strategy for targeting tumor vasculature with minimal side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbBDBnLIA7PbVg90H21EOLACvtfcHk0li_Xs1Ka6TheA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFWgs70%253D&md5=6d3ce24689b3db48d588f12a521ef136</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2013.12.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2013.12.010%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DFukushima%26aufirst%3DY.%26aulast%3DSaw%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DJ.%2BS.%26aulast%3DPark%26aufirst%3DI.%26aulast%3DJung%26aufirst%3DJ.%26aulast%3DKataoka%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DDoHeo%26aufirst%3DW.%26aulast%3DKim%26aufirst%3DI.%26aulast%3DJon%26aufirst%3DS.%26aulast%3DAdams%26aufirst%3DR.%2BH.%26aulast%3DNishikawa%26aufirst%3DS.%2BI.%26aulast%3DUemura%26aufirst%3DA.%26aulast%3DKoh%26aufirst%3DG.%26atitle%3DVascular%2520RhoJ%2520is%2520an%2520effective%2520and%2520selective%2520target%2520for%2520tumor%2520angiogenesis%2520and%2520vascular%2520disruption%26jtitle%3DCancer%2520Cell%26date%3D2014%26volume%3D25%26spage%3D102%26epage%3D117%26doi%3D10.1016%2Fj.ccr.2013.12.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group">Quan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, L.</span><span> </span><span class="NLM_article-title">p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">1730</span><span class="NLM_x">–</span> <span class="NLM_lpage">1737</span><span class="refDoi"> DOI: 10.1002/ijc.23262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1002%2Fijc.23262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=18074350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD1cXksFeitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2008&pages=1730-1737&author=H.+Quanauthor=Y.+Xuauthor=L.+Lou&title=p38+MAPK%2C+but+not+ERK1%2F2%2C+is+critically+involved+in+the+cytotoxicity+of+the+novel+vascular+disrupting+agent+combretastatin+A4&doi=10.1002%2Fijc.23262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4</span></div><div class="casAuthors">Quan, Haitian; Xu, Yongping; Lou, Liguang</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1730-1737</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Combretastatin A4 (CA4) is a novel vascular disrupting agent that has promising clin. efficacy because of its ability to inhibit microtubule assembly and subsequently disrupt tumor blood flow.  In this study, we demonstrate that mitogen-activated protein kinases (MAPKs) are critically involved in the cytotoxicity of CA4.  CA4 stimulates both extracellular signal-regulated kinases (ERK1/2) and p38 MAPK in the BEL-7402 hepatocellular carcinoma cell line in a time- and dose-dependent manner.  This stimulation is a result of CA4-induced microtubule disassembly, which is a reversible process.  Reversibility of microtubule disassembly is evidenced by the ability of disassembled microtubules to reassemble just a few hours after CA4 treatment.  P38 MAPK, but not ERK1/2, contributes to this microtubule reassembly following CA4 exposure, and only inhibition of p38 MAPK, but not ERK1/2, synergistically enhances CA4-induced G2/M cell cycle arrest.  Consistent with this, p38 MAPK inhibitors such as SB203580 and SB202190 also synergistically enhance the cytotoxicity of CA4 in cells where p38 MAPK is activated by CA4.  This enhancement appears to be specific for CA4 because the cytotoxicity of other microtubule-targeted agents such as paclitaxel, vinorelbine and colchicine was not affected by p38 MAPK inhibitors.  These data indicate that p38 MAPK is a potential anticancer target and that the combination of CA4 with p38 MAPK inhibitors may be a novel and promising strategy for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGkvgxgmXwtrVg90H21EOLACvtfcHk0ljIY3HO7aBKcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXksFeitrw%253D&md5=69e7503d5e46f544daba821bf1105190</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1002%2Fijc.23262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.23262%26sid%3Dliteratum%253Aachs%26aulast%3DQuan%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DLou%26aufirst%3DL.%26atitle%3Dp38%2520MAPK%252C%2520but%2520not%2520ERK1%252F2%252C%2520is%2520critically%2520involved%2520in%2520the%2520cytotoxicity%2520of%2520the%2520novel%2520vascular%2520disrupting%2520agent%2520combretastatin%2520A4%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2008%26volume%3D122%26spage%3D1730%26epage%3D1737%26doi%3D10.1002%2Fijc.23262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group">Kwon, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatia, S. N.</span><span> </span><span class="NLM_article-title">Smart nanosystems: Bio-inspired technologies that interact with the host environment</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">14460</span><span class="NLM_x">–</span> <span class="NLM_lpage">14466</span><span class="refDoi"> DOI: 10.1073/pnas.1508522112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1073%2Fpnas.1508522112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=14460-14466&author=E.+J.+Kwonauthor=J.+H.+Loauthor=S.+N.+Bhatia&title=Smart+nanosystems%3A+Bio-inspired+technologies+that+interact+with+the+host+environment&doi=10.1073%2Fpnas.1508522112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1508522112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1508522112%26sid%3Dliteratum%253Aachs%26aulast%3DKwon%26aufirst%3DE.%2BJ.%26aulast%3DLo%26aufirst%3DJ.%2BH.%26aulast%3DBhatia%26aufirst%3DS.%2BN.%26atitle%3DSmart%2520nanosystems%253A%2520Bio-inspired%2520technologies%2520that%2520interact%2520with%2520the%2520host%2520environment%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D14460%26epage%3D14466%26doi%3D10.1073%2Fpnas.1508522112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group">Lin, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatia, S. N.</span><span> </span><span class="NLM_article-title">Drug-induced amplification of nanoparticle targeting to tumors</span> <span class="citation_source-journal">Nano Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">550</span><span class="NLM_x">–</span> <span class="NLM_lpage">559</span><span class="refDoi"> DOI: 10.1016/j.nantod.2014.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.nantod.2014.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=29731806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyrtrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=550-559&author=K.+Y.+Linauthor=E.+J.+Kwonauthor=J.+H.+Loauthor=S.+N.+Bhatia&title=Drug-induced+amplification+of+nanoparticle+targeting+to+tumors&doi=10.1016%2Fj.nantod.2014.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced amplification of nanoparticle targeting to tumors</span></div><div class="casAuthors">Lin, Kevin Y.; Kwon, Ester J.; Lo, Justin H.; Bhatia, Sangeeta N.</div><div class="citationInfo"><span class="NLM_cas:title">Nano Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">550-559</span>CODEN:
                <span class="NLM_cas:coden">NTAOCG</span>;
        ISSN:<span class="NLM_cas:issn">1748-0132</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Nanomedicines have the potential to significantly impact cancer therapy by improving drug efficacy and decreasing off-target effects, yet our ability to efficiently home nanoparticles to disease sites remains limited.  One frequently overlooked constraint of current active targeting schemes is the relative dearth of targetable antigens within tumors, which restricts the amt. of cargo that can be delivered in a tumor-specific manner.  To address this limitation, we exploit tumor-specific responses to drugs to construct a cooperative targeting system where a small mol. therapeutic modulates the disease microenvironment to amplify nanoparticle recruitment in vivo.  We first administer a vascular disrupting agent, ombrabulin, which selectively affects tumors and leads to locally elevated presentation of the stress-related protein, p32.  This increase in p32 levels provides more binding sites for circulating p32-targeted nanoparticles, enhancing their delivery of diagnostic or therapeutic cargos to tumors.  We show that this cooperative targeting system recruits over five times higher doses of nanoparticles to tumors and decreases tumor burden when compared with non-cooperative controls.  These results suggest that using nanomedicine in conjunction with drugs that enhance the presentation of target antigens in the tumor environment may be an effective strategy for improving the diagnosis and treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQdjHn60fTfrVg90H21EOLACvtfcHk0ljIY3HO7aBKcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyrtrjM&md5=b13791ae4dc7c03050eb72f5ee93f6ed</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1016%2Fj.nantod.2014.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nantod.2014.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DK.%2BY.%26aulast%3DKwon%26aufirst%3DE.%2BJ.%26aulast%3DLo%26aufirst%3DJ.%2BH.%26aulast%3DBhatia%26aufirst%3DS.%2BN.%26atitle%3DDrug-induced%2520amplification%2520of%2520nanoparticle%2520targeting%2520to%2520tumors%26jtitle%3DNano%2520Today%26date%3D2014%26volume%3D9%26spage%3D550%26epage%3D559%26doi%3D10.1016%2Fj.nantod.2014.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 86 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Wen Shuai, Guan Wang, Yiwen Zhang, Faqian Bu, Sicheng Zhang, Duane D. Miller, Wei Li, Liang Ouyang, <span class="NLM_string-name hlFld-ContribAuthor">Yuxi Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 7963-7990. <a href="https://doi.org/10.1021/acs.jmedchem.1c00100" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00100</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00100%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BProgress%252Bon%252BTubulin%252BInhibitors%252Bwith%252BDual%252BTargeting%252BCapabilities%252Bfor%252BCancer%252BTherapy%26aulast%3DShuai%26aufirst%3DWen%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D19012021%26date%3D08062021%26volume%3D64%26issue%3D12%26spage%3D7963%26epage%3D7990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Virginia Spanò, Roberta Rocca, Marilia Barreca, Daniele Giallombardo, Alessandra Montalbano, Anna Carbone, Maria Valeria Raimondi, Eugenio Gaudio, Roberta Bortolozzi, Ruoli Bai, Pierfrancesco Tassone, Stefano Alcaro, Ernest Hamel, Giampietro Viola, Francesco Bertoni, <span class="NLM_string-name hlFld-ContribAuthor">Paola Barraja</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrrolo[2′,3′:3,4]cyclohepta[1,2-d][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 12023-12042. <a href="https://doi.org/10.1021/acs.jmedchem.0c01315" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01315</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01315%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyrrolo%25255B2%2525E2%252580%2525B2%25252C3%2525E2%252580%2525B2%25253A3%25252C4%25255Dcyclohepta%25255B1%25252C2-d%25255D%25255B1%25252C2%25255Doxazoles%25252C%252Ba%252BNew%252BClass%252Bof%252BAntimitotic%252BAgents%252BActive%252Bagainst%252BMultiple%252BMalignant%252BCell%252BTypes%26aulast%3DSpan%25C3%25B2%26aufirst%3DVirginia%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D29072020%26date%3D12102020%26date%3D28092020%26volume%3D63%26issue%3D20%26spage%3D12023%26epage%3D12042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Li Jiang, Masuo Goto, Dong-Qing Zhu, Pei-Ling Hsu, Kang-Po Li, Mutian Cui, Xiaoyang He, Susan Lynne Morris-Natschke, Kuo-Hsiung Lee, <span class="NLM_string-name hlFld-ContribAuthor">Lan Xie</span>. </span><span class="cited-content_cbyCitation_article-title">Scaffold Hopping-Driven Optimization of 4-(Quinazolin-4-yl)-3,4-dihydroquinoxalin-2(1H)-ones as Novel Tubulin Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (1)
                                     , 83-89. <a href="https://doi.org/10.1021/acsmedchemlett.9b00352" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00352</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00352%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DScaffold%252BHopping-Driven%252BOptimization%252Bof%252B4-%252528Quinazolin-4-yl%252529-3%25252C4-dihydroquinoxalin-2%2525281H%252529-ones%252Bas%252BNovel%252BTubulin%252BInhibitors%26aulast%3DJiang%26aufirst%3DLi%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D31072019%26date%3D16122019%26date%3D30122019%26volume%3D11%26issue%3D1%26spage%3D83%26epage%3D89" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kinsie E. Arnst, Souvik Banerjee, Yuxi Wang, Hao Chen, Yong Li, Lei Yang, Weimin Li, Duane D. Miller, <span class="NLM_string-name hlFld-ContribAuthor">Wei Li</span>. </span><span class="cited-content_cbyCitation_article-title">X-ray Crystal Structure Guided Discovery and Antitumor Efficacy of Dihydroquinoxalinone as Potent Tubulin Polymerization Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2019,</strong> <em>14 </em>
                                    (12)
                                     , 2810-2821. <a href="https://doi.org/10.1021/acschembio.9b00696" title="DOI URL">https://doi.org/10.1021/acschembio.9b00696</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.9b00696&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.9b00696%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DX-ray%252BCrystal%252BStructure%252BGuided%252BDiscovery%252Band%252BAntitumor%252BEfficacy%252Bof%252BDihydroquinoxalinone%252Bas%252BPotent%252BTubulin%252BPolymerization%252BInhibitors%26aulast%3DArnst%26aufirst%3DKinsie%2BE.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D30082019%26date%3D12112019%26date%3D25112019%26date%3D12112019%26volume%3D14%26issue%3D12%26spage%3D2810%26epage%3D2821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jianxun Ding, Xiangru Feng, Zhongyu Jiang, Weiguo Xu, Hui Guo, Xiuli Zhuang, <span class="NLM_string-name hlFld-ContribAuthor">Xuesi Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Polymer-Mediated Penetration-Independent Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Biomacromolecules</span><span> <strong>2019,</strong> <em>20 </em>
                                    (12)
                                     , 4258-4271. <a href="https://doi.org/10.1021/acs.biomac.9b01263" title="DOI URL">https://doi.org/10.1021/acs.biomac.9b01263</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.biomac.9b01263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.biomac.9b01263%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomacromolecules%26atitle%3DPolymer-Mediated%252BPenetration-Independent%252BCancer%252BTherapy%26aulast%3DDing%26aufirst%3DJianxun%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D12092019%26date%3D30102019%26date%3D19112019%26date%3D31102019%26volume%3D20%26issue%3D12%26spage%3D4258%26epage%3D4271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kensuke Yamamoto, Yusei Mohara, Yuichiro Mutoh, <span class="NLM_string-name hlFld-ContribAuthor">Shinichi Saito</span>. </span><span class="cited-content_cbyCitation_article-title">Ruthenium-Catalyzed (Z)-Selective Hydroboration of Terminal Alkynes with Naphthalene-1,8-diaminatoborane. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2019,</strong> <em>141 </em>
                                    (43)
                                     , 17042-17047. <a href="https://doi.org/10.1021/jacs.9b06910" title="DOI URL">https://doi.org/10.1021/jacs.9b06910</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.9b06910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.9b06910%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DRuthenium-Catalyzed%252B%252528Z%252529-Selective%252BHydroboration%252Bof%252BTerminal%252BAlkynes%252Bwith%252BNaphthalene-1%25252C8-diaminatoborane%26aulast%3DYamamoto%26aufirst%3DKensuke%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D29062019%26date%3D18092019%26date%3D14092019%26volume%3D141%26issue%3D43%26spage%3D17042%26epage%3D17047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Timothée Naret, Ilhem Khelifi, Olivier Provot, Jérôme Bignon, Hélène Levaique, Joelle Dubois, Martin Souce, Athena Kasselouri, Alain Deroussent, Angélo Paci, Paloma F. Varela, Benoît Gigant, Mouad Alami, <span class="NLM_string-name hlFld-ContribAuthor">Abdallah Hamze</span>. </span><span class="cited-content_cbyCitation_article-title">1,1-Diheterocyclic Ethylenes Derived from Quinaldine and Carbazole as New Tubulin-Polymerization Inhibitors: Synthesis, Metabolism, and Biological Evaluation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (4)
                                     , 1902-1916. <a href="https://doi.org/10.1021/acs.jmedchem.8b01386" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01386</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01386%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D1%25252C1-Diheterocyclic%252BEthylenes%252BDerived%252Bfrom%252BQuinaldine%252Band%252BCarbazole%252Bas%252BNew%252BTubulin-Polymerization%252BInhibitors%25253A%252BSynthesis%25252C%252BMetabolism%25252C%252Band%252BBiological%252BEvaluation%26aulast%3DNaret%26aufirst%3DTimoth%25C3%25A9e%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D05092018%26date%3D21122018%26date%3D10122018%26volume%3D62%26issue%3D4%26spage%3D1902%26epage%3D1916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Wenlong Li, Feijie Xu, Wen Shuai, Honghao Sun, Hong Yao, Cong Ma, Shengtao Xu, Hequan Yao, Zheying Zhu, Dong-Hua Yang, Zhe-Sheng Chen, <span class="NLM_string-name hlFld-ContribAuthor">Jinyi Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Quinoline–Chalcone Derivatives as Potent Antitumor Agents with Microtubule Polymerization Inhibitory Activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (2)
                                     , 993-1013. <a href="https://doi.org/10.1021/acs.jmedchem.8b01755" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01755</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01755%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BQuinoline%2525E2%252580%252593Chalcone%252BDerivatives%252Bas%252BPotent%252BAntitumor%252BAgents%252Bwith%252BMicrotubule%252BPolymerization%252BInhibitory%252BActivity%26aulast%3DLi%26aufirst%3DWenlong%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D11112018%26date%3D24122018%26date%3D11122018%26volume%3D62%26issue%3D2%26spage%3D993%26epage%3D1013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Wenlong Li, Wen Shuai, Feijie Xu, Honghao Sun, Shengtao Xu, Hong Yao, Jie Liu, Hequan Yao, Zheying Zhu, <span class="NLM_string-name hlFld-ContribAuthor">Jinyi Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel 4-Arylisochromenes as Anticancer Agents Inhibiting Tubulin Polymerization. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (10)
                                     , 974-979. <a href="https://doi.org/10.1021/acsmedchemlett.8b00217" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00217</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00217%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BNovel%252B4-Arylisochromenes%252Bas%252BAnticancer%252BAgents%252BInhibiting%252BTubulin%252BPolymerization%26aulast%3DLi%26aufirst%3DWenlong%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D10052018%26date%3D25092018%26date%3D27092018%26date%3D25092018%26volume%3D9%26issue%3D10%26spage%3D974%26epage%3D979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Souvik  Banerjee</span>, <span class="hlFld-ContribAuthor ">Kinsie E.  Arnst</span>, <span class="hlFld-ContribAuthor ">Yuxi  Wang</span>, <span class="hlFld-ContribAuthor ">Gyanendra  Kumar</span>, <span class="hlFld-ContribAuthor ">Shanshan  Deng</span>, <span class="hlFld-ContribAuthor ">Lei  Yang</span>, <span class="hlFld-ContribAuthor ">Guo-bo  Li</span>, <span class="hlFld-ContribAuthor ">Jinliang  Yang</span>, <span class="hlFld-ContribAuthor ">Stephen W.  White</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, and <span class="hlFld-ContribAuthor ">Duane D.  Miller</span>  . </span><span class="cited-content_cbyCitation_article-title">Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (4)
                                     , 1704-1718. <a href="https://doi.org/10.1021/acs.jmedchem.7b01858" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01858</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01858%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHeterocyclic-Fused%252BPyrimidines%252Bas%252BNovel%252BTubulin%252BPolymerization%252BInhibitors%252BTargeting%252Bthe%252BColchicine%252BBinding%252BSite%25253A%252BStructural%252BBasis%252Band%252BAntitumor%252BEfficacy%26aulast%3DBanerjee%26aufirst%3DSouvik%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D21122017%26date%3D12022018%26date%3D22022018%26date%3D06022018%26volume%3D61%26issue%3D4%26spage%3D1704%26epage%3D1718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mu-Tian  Cui</span>, <span class="hlFld-ContribAuthor ">Li  Jiang</span>, <span class="hlFld-ContribAuthor ">Masuo  Goto</span>, <span class="hlFld-ContribAuthor ">Pei-Ling  Hsu</span>, <span class="hlFld-ContribAuthor ">Linna  Li</span>, <span class="hlFld-ContribAuthor ">Qi  Zhang</span>, <span class="hlFld-ContribAuthor ">Lei  Wei</span>, <span class="hlFld-ContribAuthor ">Shou-Jun  Yuan</span>, <span class="hlFld-ContribAuthor ">Ernest  Hamel</span>, <span class="hlFld-ContribAuthor ">Susan L.  Morris-Natschke</span>, <span class="hlFld-ContribAuthor ">Kuo-Hsiung  Lee</span>, and <span class="hlFld-ContribAuthor ">Lan  Xie</span>  . </span><span class="cited-content_cbyCitation_article-title">In Vivo and Mechanistic Studies on Antitumor Lead 7-Methoxy-4-(2-methylquinazolin-4-yl)-3,4-dihydroquinoxalin-2(1H)-one and Its Modification as a Novel Class of Tubulin-Binding Tumor-Vascular Disrupting Agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (13)
                                     , 5586-5598. <a href="https://doi.org/10.1021/acs.jmedchem.7b00273" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00273</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00273%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIn%252BVivo%252Band%252BMechanistic%252BStudies%252Bon%252BAntitumor%252BLead%252B7-Methoxy-4-%2525282-methylquinazolin-4-yl%252529-3%25252C4-dihydroquinoxalin-2%2525281H%252529-one%252Band%252BIts%252BModification%252Bas%252Ba%252BNovel%252BClass%252Bof%252BTubulin-Binding%252BTumor-Vascular%252BDisrupting%252BAgents%26aulast%3DCui%26aufirst%3DMu-Tian%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D21022017%26date%3D27062017%26date%3D13072017%26volume%3D60%26issue%3D13%26spage%3D5586%26epage%3D5598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuhao  Zheng</span>, <span class="hlFld-ContribAuthor ">Yilong  Cheng</span>, <span class="hlFld-ContribAuthor ">Jinjin  Chen</span>, <span class="hlFld-ContribAuthor ">Jianxun  Ding</span>, <span class="hlFld-ContribAuthor ">Mingqiang  Li</span>, <span class="hlFld-ContribAuthor ">Chen  Li</span>, <span class="hlFld-ContribAuthor ">Jin-cheng  Wang</span>, and <span class="hlFld-ContribAuthor ">Xuesi  Chen</span>  . </span><span class="cited-content_cbyCitation_article-title">Injectable Hydrogel–Microsphere Construct with Sequential Degradation for Locally Synergistic Chemotherapy. </span><span class="cited-content_cbyCitation_journal-name">ACS Applied Materials & Interfaces</span><span> <strong>2017,</strong> <em>9 </em>
                                    (4)
                                     , 3487-3496. <a href="https://doi.org/10.1021/acsami.6b15245" title="DOI URL">https://doi.org/10.1021/acsami.6b15245</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsami.6b15245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsami.6b15245%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Applied%2520Materials%2520%2526%2520Interfaces%26atitle%3DInjectable%252BHydrogel%2525E2%252580%252593Microsphere%252BConstruct%252Bwith%252BSequential%252BDegradation%252Bfor%252BLocally%252BSynergistic%252BChemotherapy%26aulast%3DZheng%26aufirst%3DYuhao%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D28112016%26date%3D09012017%26date%3D20012017%26date%3D01022017%26date%3D09012017%26volume%3D9%26issue%3D4%26spage%3D3487%26epage%3D3496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pengfei  Zhou</span>, <span class="hlFld-ContribAuthor ">Yan  Liu</span>, <span class="hlFld-ContribAuthor ">Lu  Zhou</span>, <span class="hlFld-ContribAuthor ">Kongkai  Zhu</span>, <span class="hlFld-ContribAuthor ">Kechang  Feng</span>, <span class="hlFld-ContribAuthor ">Hao  Zhang</span>, <span class="hlFld-ContribAuthor ">Yuru  Liang</span>, <span class="hlFld-ContribAuthor ">Hualiang  Jiang</span>, <span class="hlFld-ContribAuthor ">Cheng  Luo</span>, <span class="hlFld-ContribAuthor ">Mingming  Liu</span>, and <span class="hlFld-ContribAuthor ">Yang  Wang</span>  . </span><span class="cited-content_cbyCitation_article-title">Potent Antitumor Activities and Structure Basis of the Chiral β-Lactam Bridged Analogue of Combretastatin A-4 Binding to Tubulin. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (22)
                                     , 10329-10334. <a href="https://doi.org/10.1021/acs.jmedchem.6b01268" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01268</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01268%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPotent%252BAntitumor%252BActivities%252Band%252BStructure%252BBasis%252Bof%252Bthe%252BChiral%252B%2525CE%2525B2-Lactam%252BBridged%252BAnalogue%252Bof%252BCombretastatin%252BA-4%252BBinding%252Bto%252BTubulin%26aulast%3DZhou%26aufirst%3DPengfei%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D24082016%26date%3D14112016%26date%3D23112016%26date%3D02112016%26volume%3D59%26issue%3D22%26spage%3D10329%26epage%3D10334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hairong  Tang</span>, <span class="hlFld-ContribAuthor ">Yuru  Liang</span>, <span class="hlFld-ContribAuthor ">Jiayi  Cheng</span>, <span class="hlFld-ContribAuthor ">Kuiling  Ding</span>, <span class="hlFld-ContribAuthor ">Yang  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Bifunctional chiral selenium-containing 1,4-diarylazetidin-2-ones with potent antitumor activities by disrupting tubulin polymerization and inducing reactive oxygen species production. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>221 </em>, 113531. <a href="https://doi.org/10.1016/j.ejmech.2021.113531" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113531</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113531%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBifunctional%252Bchiral%252Bselenium-containing%252B1%25252C4-diarylazetidin-2-ones%252Bwith%252Bpotent%252Bantitumor%252Bactivities%252Bby%252Bdisrupting%252Btubulin%252Bpolymerization%252Band%252Binducing%252Breactive%252Boxygen%252Bspecies%252Bproduction%26aulast%3DTang%26aufirst%3DHairong%26date%3D2021%26volume%3D221%26spage%3D113531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Janet Sabina  Xavier</span>, <span class="hlFld-ContribAuthor ">Karthikeyan  Jayabalan</span>, <span class="hlFld-ContribAuthor ">V.  Ragavendran</span>, <span class="hlFld-ContribAuthor ">Muthu Tamizh  Manoharan</span>, <span class="hlFld-ContribAuthor ">A.  Nityananda Shetty</span>. </span><span class="cited-content_cbyCitation_article-title">Virtual and experimental high throughput screening of substituted hydrazones on β-Tubulin polymerization. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>114 </em>, 105094. <a href="https://doi.org/10.1016/j.bioorg.2021.105094" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.105094</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.105094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.105094%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DVirtual%252Band%252Bexperimental%252Bhigh%252Bthroughput%252Bscreening%252Bof%252Bsubstituted%252Bhydrazones%252Bon%252B%2525CE%2525B2-Tubulin%252Bpolymerization%26aulast%3DXavier%26aufirst%3DJanet%2BSabina%26date%3D2021%26volume%3D114%26spage%3D105094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laura  Gallego-Yerga</span>, <span class="hlFld-ContribAuthor ">Rodrigo  Ochoa</span>, <span class="hlFld-ContribAuthor ">Isaías  Lans</span>, <span class="hlFld-ContribAuthor ">Carlos  Peña-Varas</span>, <span class="hlFld-ContribAuthor ">Melissa  Alegría-Arcos</span>, <span class="hlFld-ContribAuthor ">Pilar  Cossio</span>, <span class="hlFld-ContribAuthor ">David  Ramírez</span>, <span class="hlFld-ContribAuthor ">Rafael  Peláez</span>. </span><span class="cited-content_cbyCitation_article-title">Application of ensemble Pharmacophore-Based Virtual Screening to the discovery of novel antimitotic tubulin inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Computational and Structural Biotechnology Journal</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.1016/j.csbj.2021.07.039" title="DOI URL">https://doi.org/10.1016/j.csbj.2021.07.039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.csbj.2021.07.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.csbj.2021.07.039%26sid%3Dliteratum%253Aachs%26jtitle%3DComputational%2520and%2520Structural%2520Biotechnology%2520Journal%26atitle%3DApplication%252Bof%252Bensemble%252BPharmacophore-Based%252BVirtual%252BScreening%252Bto%252Bthe%252Bdiscovery%252Bof%252Bnovel%252Bantimitotic%252Btubulin%252Binhibitors%26aulast%3DGallego-Yerga%26aufirst%3DLaura%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chen  Cheng</span>, <span class="hlFld-ContribAuthor ">Chunhong  Hu</span>, <span class="hlFld-ContribAuthor ">Shengli  Zhou</span>, <span class="hlFld-ContribAuthor ">Hongyan  Zhao</span>, <span class="hlFld-ContribAuthor ">Ming  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Qualitative Diagnosis of Solid Breast Mass by Blood Flow in Solid Breast Mass. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medical Imaging and Health Informatics</span><span> <strong>2021,</strong> <em>11 </em>
                                    (7)
                                     , 1887-1894. <a href="https://doi.org/10.1166/jmihi.2021.3593" title="DOI URL">https://doi.org/10.1166/jmihi.2021.3593</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1166/jmihi.2021.3593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1166%2Fjmihi.2021.3593%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medical%2520Imaging%2520and%2520Health%2520Informatics%26atitle%3DQualitative%252BDiagnosis%252Bof%252BSolid%252BBreast%252BMass%252Bby%252BBlood%252BFlow%252Bin%252BSolid%252BBreast%252BMass%26aulast%3DCheng%26aufirst%3DChen%26date%3D2021%26volume%3D11%26issue%3D7%26spage%3D1887%26epage%3D1894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jia-Hong  Lei</span>, <span class="hlFld-ContribAuthor ">Ling-Ling  Ma</span>, <span class="hlFld-ContribAuthor ">Jing-Hong  Xian</span>, <span class="hlFld-ContribAuthor ">Hai  Chen</span>, <span class="hlFld-ContribAuthor ">Jian-Jian  Zhou</span>, <span class="hlFld-ContribAuthor ">Hao  Chen</span>, <span class="hlFld-ContribAuthor ">Qian  Lei</span>, <span class="hlFld-ContribAuthor ">Yu-Yan  Li</span>, <span class="hlFld-ContribAuthor ">Yan-Yan  Wang</span>, <span class="hlFld-ContribAuthor ">Yu-Xi  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Structural insights into targeting of the colchicine binding site by ELR510444 and parbendazole to achieve rational drug design. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2021,</strong> <em>11 </em>
                                    (31)
                                     , 18938-18944. <a href="https://doi.org/10.1039/D1RA01173A" title="DOI URL">https://doi.org/10.1039/D1RA01173A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1RA01173A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1RA01173A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DStructural%252Binsights%252Binto%252Btargeting%252Bof%252Bthe%252Bcolchicine%252Bbinding%252Bsite%252Bby%252BELR510444%252Band%252Bparbendazole%252Bto%252Bachieve%252Brational%252Bdrug%252Bdesign%26aulast%3DLei%26aufirst%3DJia-Hong%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D31%26spage%3D18938%26epage%3D18944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuichiro  Mutoh</span>, <span class="hlFld-ContribAuthor ">Kensuke  Yamamoto</span>, <span class="hlFld-ContribAuthor ">Yusei  Mohara</span>, <span class="hlFld-ContribAuthor ">Shinichi  Saito</span>. </span><span class="cited-content_cbyCitation_article-title">(
              Z
              )‐Selective Hydrosilylation and Hydroboration of Terminal Alkynes Enabled by Ruthenium Complexes with an N‐Heterocyclic Carbene Ligand. </span><span class="cited-content_cbyCitation_journal-name">The Chemical Record</span><span> <strong>2021,</strong> <em>2 </em><a href="https://doi.org/10.1002/tcr.202100083" title="DOI URL">https://doi.org/10.1002/tcr.202100083</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/tcr.202100083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Ftcr.202100083%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Chemical%2520Record%26atitle%3D%252528%252BZ%252B%252529%2525E2%252580%252590Selective%252BHydrosilylation%252Band%252BHydroboration%252Bof%252BTerminal%252BAlkynes%252BEnabled%252Bby%252BRuthenium%252BComplexes%252Bwith%252Ban%252BN%2525E2%252580%252590Heterocyclic%252BCarbene%252BLigand%26aulast%3DMutoh%26aufirst%3DYuichiro%26date%3D2021%26date%3D2021%26volume%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li  Liu</span>, <span class="hlFld-ContribAuthor ">Devin  O’Kelly</span>, <span class="hlFld-ContribAuthor ">Regan  Schuetze</span>, <span class="hlFld-ContribAuthor ">Graham  Carlson</span>, <span class="hlFld-ContribAuthor ">Heling  Zhou</span>, <span class="hlFld-ContribAuthor ">Mary Lynn  Trawick</span>, <span class="hlFld-ContribAuthor ">Kevin G.  Pinney</span>, <span class="hlFld-ContribAuthor ">Ralph P.  Mason</span>. </span><span class="cited-content_cbyCitation_article-title">Non-Invasive Evaluation of Acute Effects of Tubulin Binding Agents: A Review of Imaging Vascular Disruption in Tumors. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (9)
                                     , 2551. <a href="https://doi.org/10.3390/molecules26092551" title="DOI URL">https://doi.org/10.3390/molecules26092551</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26092551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26092551%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DNon-Invasive%252BEvaluation%252Bof%252BAcute%252BEffects%252Bof%252BTubulin%252BBinding%252BAgents%25253A%252BA%252BReview%252Bof%252BImaging%252BVascular%252BDisruption%252Bin%252BTumors%26aulast%3DLiu%26aufirst%3DLi%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D9%26spage%3D2551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ruiqiang  Zhang</span>, <span class="hlFld-ContribAuthor ">Hualong  Mo</span>, <span class="hlFld-ContribAuthor ">Yan-Yan  Ma</span>, <span class="hlFld-ContribAuthor ">Deng-Gao  Zhao</span>, <span class="hlFld-ContribAuthor ">Kun  Zhang</span>, <span class="hlFld-ContribAuthor ">Tingwen  Zhang</span>, <span class="hlFld-ContribAuthor ">Xuecheng  Chen</span>, <span class="hlFld-ContribAuthor ">Xi  Zheng</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and structure–activity relationships of 5-phenyloxazole-2-carboxylic acid derivatives as novel inhibitors of tubulin polymerization. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>40 </em>, 127968. <a href="https://doi.org/10.1016/j.bmcl.2021.127968" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127968</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127968%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bstructure%2525E2%252580%252593activity%252Brelationships%252Bof%252B5-phenyloxazole-2-carboxylic%252Bacid%252Bderivatives%252Bas%252Bnovel%252Binhibitors%252Bof%252Btubulin%252Bpolymerization%26aulast%3DZhang%26aufirst%3DRuiqiang%26date%3D2021%26volume%3D40%26spage%3D127968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Libang  Zhang</span>, <span class="hlFld-ContribAuthor ">Dongjian  Zhang</span>, <span class="hlFld-ContribAuthor ">Meng  Gao</span>, <span class="hlFld-ContribAuthor ">Qiaomei  Jin</span>, <span class="hlFld-ContribAuthor ">Cuihua  Jiang</span>, <span class="hlFld-ContribAuthor ">Tianze  Wu</span>, <span class="hlFld-ContribAuthor ">Yuanbo  Feng</span>, <span class="hlFld-ContribAuthor ">Yicheng  Ni</span>, <span class="hlFld-ContribAuthor ">Zhiqi  Yin</span>, <span class="hlFld-ContribAuthor ">Jian  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Evaluation of Rhein-Based MRI Contrast Agents for Visualization of Tumor Necrosis Induced by Combretastatin A-4 Disodium Phosphate. </span><span class="cited-content_cbyCitation_journal-name">Molecular Imaging and Biology</span><span> <strong>2021,</strong> <em>23 </em>
                                    (2)
                                     , 220-229. <a href="https://doi.org/10.1007/s11307-020-01551-3" title="DOI URL">https://doi.org/10.1007/s11307-020-01551-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11307-020-01551-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11307-020-01551-3%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Imaging%2520and%2520Biology%26atitle%3DDesign%252Band%252BEvaluation%252Bof%252BRhein-Based%252BMRI%252BContrast%252BAgents%252Bfor%252BVisualization%252Bof%252BTumor%252BNecrosis%252BInduced%252Bby%252BCombretastatin%252BA-4%252BDisodium%252BPhosphate%26aulast%3DZhang%26aufirst%3DLibang%26date%3D2021%26date%3D2020%26volume%3D23%26issue%3D2%26spage%3D220%26epage%3D229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huajian  Zhu</span>, <span class="hlFld-ContribAuthor ">Wenlong  Li</span>, <span class="hlFld-ContribAuthor ">Wen  Shuai</span>, <span class="hlFld-ContribAuthor ">Yang  Liu</span>, <span class="hlFld-ContribAuthor ">Limei  Yang</span>, <span class="hlFld-ContribAuthor ">Yuchen  Tan</span>, <span class="hlFld-ContribAuthor ">Tiandong  Zheng</span>, <span class="hlFld-ContribAuthor ">Hong  Yao</span>, <span class="hlFld-ContribAuthor ">Jinyi  Xu</span>, <span class="hlFld-ContribAuthor ">Zheying  Zhu</span>, <span class="hlFld-ContribAuthor ">Dong-Hua  Yang</span>, <span class="hlFld-ContribAuthor ">Zhe-Sheng  Chen</span>, <span class="hlFld-ContribAuthor ">Shengtao  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel N-benzylbenzamide derivatives as tubulin polymerization inhibitors with potent antitumor activities. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>216 </em>, 113316. <a href="https://doi.org/10.1016/j.ejmech.2021.113316" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113316</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113316%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252BN-benzylbenzamide%252Bderivatives%252Bas%252Btubulin%252Bpolymerization%252Binhibitors%252Bwith%252Bpotent%252Bantitumor%252Bactivities%26aulast%3DZhu%26aufirst%3DHuajian%26date%3D2021%26volume%3D216%26spage%3D113316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maruf M.  Hoque</span>, <span class="hlFld-ContribAuthor ">Hanaa  Abdelazim</span>, <span class="hlFld-ContribAuthor ">Clifton  Jenkins‐Houk</span>, <span class="hlFld-ContribAuthor ">Dawn  Wright</span>, <span class="hlFld-ContribAuthor ">Biraj M.  Patel</span>, <span class="hlFld-ContribAuthor ">John C.  Chappell</span>. </span><span class="cited-content_cbyCitation_article-title">The cerebral microvasculature: Basic and clinical perspectives on stroke and glioma. </span><span class="cited-content_cbyCitation_journal-name">Microcirculation</span><span> <strong>2021,</strong> <em>28 </em>
                                    (3)
                                     <a href="https://doi.org/10.1111/micc.12671" title="DOI URL">https://doi.org/10.1111/micc.12671</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/micc.12671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fmicc.12671%26sid%3Dliteratum%253Aachs%26jtitle%3DMicrocirculation%26atitle%3DThe%252Bcerebral%252Bmicrovasculature%25253A%252BBasic%252Band%252Bclinical%252Bperspectives%252Bon%252Bstroke%252Band%252Bglioma%26aulast%3DHoque%26aufirst%3DMaruf%2BM.%26date%3D2021%26date%3D2020%26volume%3D28%26issue%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bin  Wang</span>, <span class="hlFld-ContribAuthor ">Li-Ren  Wang</span>, <span class="hlFld-ContribAuthor ">Lu-Lu  Liu</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Ruo-Jun  Man</span>, <span class="hlFld-ContribAuthor ">Da-Jun  Zheng</span>, <span class="hlFld-ContribAuthor ">Yu-Shan  Deng</span>, <span class="hlFld-ContribAuthor ">Yu-Shun  Yang</span>, <span class="hlFld-ContribAuthor ">Chen  Xu</span>, <span class="hlFld-ContribAuthor ">Hai-Liang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">A novel series of benzothiazepine derivatives as tubulin polymerization inhibitors with anti-tumor potency. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>108 </em>, 104585. <a href="https://doi.org/10.1016/j.bioorg.2020.104585" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104585</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104585%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DA%252Bnovel%252Bseries%252Bof%252Bbenzothiazepine%252Bderivatives%252Bas%252Btubulin%252Bpolymerization%252Binhibitors%252Bwith%252Banti-tumor%252Bpotency%26aulast%3DWang%26aufirst%3DBin%26date%3D2021%26volume%3D108%26spage%3D104585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Romeo  Romagnoli</span>, <span class="hlFld-ContribAuthor ">Paola  Oliva</span>, <span class="hlFld-ContribAuthor ">Maria Kimatrai  Salvador</span>, <span class="hlFld-ContribAuthor ">Stefano  Manfredini</span>, <span class="hlFld-ContribAuthor ">Chiara  Padroni</span>, <span class="hlFld-ContribAuthor ">Andrea  Brancale</span>, <span class="hlFld-ContribAuthor ">Salvatore  Ferla</span>, <span class="hlFld-ContribAuthor ">Ernest  Hamel</span>, <span class="hlFld-ContribAuthor ">Roberto  Ronca</span>, <span class="hlFld-ContribAuthor ">Federica  Maccarinelli</span>, <span class="hlFld-ContribAuthor ">Fatlum  Rruga</span>, <span class="hlFld-ContribAuthor ">Elena  Mariotto</span>, <span class="hlFld-ContribAuthor ">Giampietro  Viola</span>, <span class="hlFld-ContribAuthor ">Roberta  Bortolozzi</span>. </span><span class="cited-content_cbyCitation_article-title">A facile synthesis of diaryl pyrroles led to the discovery of potent colchicine site antimitotic agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>214 </em>, 113229. <a href="https://doi.org/10.1016/j.ejmech.2021.113229" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113229</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113229%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Bfacile%252Bsynthesis%252Bof%252Bdiaryl%252Bpyrroles%252Bled%252Bto%252Bthe%252Bdiscovery%252Bof%252Bpotent%252Bcolchicine%252Bsite%252Bantimitotic%252Bagents%26aulast%3DRomagnoli%26aufirst%3DRomeo%26date%3D2021%26volume%3D214%26spage%3D113229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gloria  Ana</span>, <span class="hlFld-ContribAuthor ">Patrick M.  Kelly</span>, <span class="hlFld-ContribAuthor ">Azizah M.  Malebari</span>, <span class="hlFld-ContribAuthor ">Sara  Noorani</span>, <span class="hlFld-ContribAuthor ">Seema M.  Nathwani</span>, <span class="hlFld-ContribAuthor ">Brendan  Twamley</span>, <span class="hlFld-ContribAuthor ">Darren  Fayne</span>, <span class="hlFld-ContribAuthor ">Niamh M.  O’Boyle</span>, <span class="hlFld-ContribAuthor ">Daniela M.  Zisterer</span>, <span class="hlFld-ContribAuthor ">Elisangela Flavia  Pimentel</span>, <span class="hlFld-ContribAuthor ">Denise Coutinho  Endringer</span>, <span class="hlFld-ContribAuthor ">Mary J.  Meegan</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Biological Evaluation of 1-(Diarylmethyl)-1H-1,2,4-triazoles and 1-(Diarylmethyl)-1H-imidazoles as a Novel Class of Anti-Mitotic Agent for Activity in Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2021,</strong> <em>14 </em>
                                    (2)
                                     , 169. <a href="https://doi.org/10.3390/ph14020169" title="DOI URL">https://doi.org/10.3390/ph14020169</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph14020169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph14020169%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252B1-%252528Diarylmethyl%252529-1H-1%25252C2%25252C4-triazoles%252Band%252B1-%252528Diarylmethyl%252529-1H-imidazoles%252Bas%252Ba%252BNovel%252BClass%252Bof%252BAnti-Mitotic%252BAgent%252Bfor%252BActivity%252Bin%252BBreast%252BCancer%26aulast%3DAna%26aufirst%3DGloria%26date%3D2021%26date%3D2021%26volume%3D14%26issue%3D2%26spage%3D169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laura  Gallego-Yerga</span>, <span class="hlFld-ContribAuthor ">Cristina  de la Torre</span>, <span class="hlFld-ContribAuthor ">Francesco  Sansone</span>, <span class="hlFld-ContribAuthor ">Alessandro  Casnati</span>, <span class="hlFld-ContribAuthor ">Carmen Ortiz  Mellet</span>, <span class="hlFld-ContribAuthor ">José M.  García Fernández</span>, <span class="hlFld-ContribAuthor ">Valentín  Ceña</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, self-assembly and anticancer drug encapsulation and delivery properties of cyclodextrin-based giant amphiphiles. </span><span class="cited-content_cbyCitation_journal-name">Carbohydrate Polymers</span><span> <strong>2021,</strong> <em>252 </em>, 117135. <a href="https://doi.org/10.1016/j.carbpol.2020.117135" title="DOI URL">https://doi.org/10.1016/j.carbpol.2020.117135</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.carbpol.2020.117135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.carbpol.2020.117135%26sid%3Dliteratum%253Aachs%26jtitle%3DCarbohydrate%2520Polymers%26atitle%3DSynthesis%25252C%252Bself-assembly%252Band%252Banticancer%252Bdrug%252Bencapsulation%252Band%252Bdelivery%252Bproperties%252Bof%252Bcyclodextrin-based%252Bgiant%252Bamphiphiles%26aulast%3DGallego-Yerga%26aufirst%3DLaura%26date%3D2021%26volume%3D252%26spage%3D117135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raquel  Álvarez</span>, <span class="hlFld-ContribAuthor ">Laura  Aramburu</span>, <span class="hlFld-ContribAuthor ">Consuelo  Gajate</span>, <span class="hlFld-ContribAuthor ">Alba  Vicente-Blázquez</span>, <span class="hlFld-ContribAuthor ">Faustino  Mollinedo</span>, <span class="hlFld-ContribAuthor ">Manuel  Medarde</span>, <span class="hlFld-ContribAuthor ">Rafael  Peláez</span>. </span><span class="cited-content_cbyCitation_article-title">Methylsulfanylpyridine based diheteroaryl isocombretastatin analogs as potent anti-proliferative agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112933. <a href="https://doi.org/10.1016/j.ejmech.2020.112933" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112933</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112933%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMethylsulfanylpyridine%252Bbased%252Bdiheteroaryl%252Bisocombretastatin%252Banalogs%252Bas%252Bpotent%252Banti-proliferative%252Bagents%26aulast%3D%25C3%2581lvarez%26aufirst%3DRaquel%26date%3D2021%26volume%3D209%26spage%3D112933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tarek S.  Ibrahim</span>, <span class="hlFld-ContribAuthor ">Mohamed M.  Hawwas</span>, <span class="hlFld-ContribAuthor ">Azizah M.  Malebari</span>, <span class="hlFld-ContribAuthor ">Ehab S.  Taher</span>, <span class="hlFld-ContribAuthor ">Abdelsattar M.  Omar</span>, <span class="hlFld-ContribAuthor ">Thikryat  Neamatallah</span>, <span class="hlFld-ContribAuthor ">Zakaria K.  Abdel-Samii</span>, <span class="hlFld-ContribAuthor ">Martin K.  Safo</span>, <span class="hlFld-ContribAuthor ">Yaseen A. M. M.  Elshaier</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel quinoline-based analogues of combretastatin A-4 as tubulin polymerisation inhibitors with apoptosis inducing activity and potent anticancer effect. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2021,</strong> <em>36 </em>
                                    (1)
                                     , 802-818. <a href="https://doi.org/10.1080/14756366.2021.1899168" title="DOI URL">https://doi.org/10.1080/14756366.2021.1899168</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2021.1899168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2021.1899168%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bquinoline-based%252Banalogues%252Bof%252Bcombretastatin%252BA-4%252Bas%252Btubulin%252Bpolymerisation%252Binhibitors%252Bwith%252Bapoptosis%252Binducing%252Bactivity%252Band%252Bpotent%252Banticancer%252Beffect%26aulast%3DIbrahim%26aufirst%3DTarek%2BS.%26date%3D2021%26date%3D2021%26volume%3D36%26issue%3D1%26spage%3D802%26epage%3D818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tarek S.  Ibrahim</span>, <span class="hlFld-ContribAuthor ">Mohamed M.  Hawwas</span>, <span class="hlFld-ContribAuthor ">Azizah M.  Malebari</span>, <span class="hlFld-ContribAuthor ">Ehab S.  Taher</span>, <span class="hlFld-ContribAuthor ">Abdelsattar M.  Omar</span>, <span class="hlFld-ContribAuthor ">Niamh M.  O'Boyle</span>, <span class="hlFld-ContribAuthor ">Eavan  McLoughlin</span>, <span class="hlFld-ContribAuthor ">Zakaria K.  Abdel-Samii</span>, <span class="hlFld-ContribAuthor ">Yaseen A. M. M.  Elshaier</span>. </span><span class="cited-content_cbyCitation_article-title">Potent Quinoline-Containing Combretastatin A-4 Analogues: Design, Synthesis, Antiproliferative, and Anti-Tubulin Activity. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2020,</strong> <em>13 </em>
                                    (11)
                                     , 393. <a href="https://doi.org/10.3390/ph13110393" title="DOI URL">https://doi.org/10.3390/ph13110393</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph13110393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph13110393%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DPotent%252BQuinoline-Containing%252BCombretastatin%252BA-4%252BAnalogues%25253A%252BDesign%25252C%252BSynthesis%25252C%252BAntiproliferative%25252C%252Band%252BAnti-Tubulin%252BActivity%26aulast%3DIbrahim%26aufirst%3DTarek%2BS.%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D11%26spage%3D393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jian  Song</span>, <span class="hlFld-ContribAuthor ">Qiu-Lei  Gao</span>, <span class="hlFld-ContribAuthor ">Bo-Wen  Wu</span>, <span class="hlFld-ContribAuthor ">Ting  Zhu</span>, <span class="hlFld-ContribAuthor ">Xin-Xin  Cui</span>, <span class="hlFld-ContribAuthor ">Cheng-Jun  Jin</span>, <span class="hlFld-ContribAuthor ">Shu-Yu  Wang</span>, <span class="hlFld-ContribAuthor ">Sheng-Hui  Wang</span>, <span class="hlFld-ContribAuthor ">Dong-Jun  Fu</span>, <span class="hlFld-ContribAuthor ">Hong-Min  Liu</span>, <span class="hlFld-ContribAuthor ">Sai-Yang  Zhang</span>, <span class="hlFld-ContribAuthor ">Yan-Bing  Zhang</span>, <span class="hlFld-ContribAuthor ">Yong-Chun  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of tertiary amide derivatives incorporating benzothiazole moiety as anti-gastric cancer agents in vitro via inhibiting tubulin polymerization and activating the Hippo signaling pathway. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>203 </em>, 112618. <a href="https://doi.org/10.1016/j.ejmech.2020.112618" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112618</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112618%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Btertiary%252Bamide%252Bderivatives%252Bincorporating%252Bbenzothiazole%252Bmoiety%252Bas%252Banti-gastric%252Bcancer%252Bagents%252Bin%2525C2%2525A0vitro%252Bvia%252Binhibiting%252Btubulin%252Bpolymerization%252Band%252Bactivating%252Bthe%252BHippo%252Bsignaling%252Bpathway%26aulast%3DSong%26aufirst%3DJian%26date%3D2020%26volume%3D203%26spage%3D112618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangping  Deng</span>, <span class="hlFld-ContribAuthor ">Yiyuan  Pi</span>, <span class="hlFld-ContribAuthor ">Zhongli  Li</span>, <span class="hlFld-ContribAuthor ">Runde  Xiong</span>, <span class="hlFld-ContribAuthor ">Juan  Liu</span>, <span class="hlFld-ContribAuthor ">Jingduo  Zhao</span>, <span class="hlFld-ContribAuthor ">Zhizhong  Xie</span>, <span class="hlFld-ContribAuthor ">Xiaoyong  Lei</span>, <span class="hlFld-ContribAuthor ">Guotao  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">FB-15 inhibits MGC-803 cells growth by regulating energy metabolism. </span><span class="cited-content_cbyCitation_journal-name">Chemico-Biological Interactions</span><span> <strong>2020,</strong> <em>327 </em>, 109186. <a href="https://doi.org/10.1016/j.cbi.2020.109186" title="DOI URL">https://doi.org/10.1016/j.cbi.2020.109186</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbi.2020.109186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbi.2020.109186%26sid%3Dliteratum%253Aachs%26jtitle%3DChemico-Biological%2520Interactions%26atitle%3DFB-15%252Binhibits%252BMGC-803%252Bcells%252Bgrowth%252Bby%252Bregulating%252Benergy%252Bmetabolism%26aulast%3DDeng%26aufirst%3DXiangping%26date%3D2020%26volume%3D327%26spage%3D109186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paola  Oliva</span>, <span class="hlFld-ContribAuthor ">Romeo  Romagnoli</span>, <span class="hlFld-ContribAuthor ">Stefano  Manfredini</span>, <span class="hlFld-ContribAuthor ">Andrea  Brancale</span>, <span class="hlFld-ContribAuthor ">Salvatore  Ferla</span>, <span class="hlFld-ContribAuthor ">Ernest  Hamel</span>, <span class="hlFld-ContribAuthor ">Roberto  Ronca</span>, <span class="hlFld-ContribAuthor ">Federica  Maccarinelli</span>, <span class="hlFld-ContribAuthor ">Arianna  Giacomini</span>, <span class="hlFld-ContribAuthor ">Fatlum  Rruga</span>, <span class="hlFld-ContribAuthor ">Elena  Mariotto</span>, <span class="hlFld-ContribAuthor ">Giampietro  Viola</span>, <span class="hlFld-ContribAuthor ">Roberta  Bortolozzi</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, in vitro and in vivo biological evaluation of 2-amino-3-aroylbenzo[b]furan derivatives as highly potent tubulin polymerization inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>200 </em>, 112448. <a href="https://doi.org/10.1016/j.ejmech.2020.112448" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112448</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112448%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Bin%2525C2%2525A0vitro%252Band%252Bin%2525C2%2525A0vivo%252Bbiological%252Bevaluation%252Bof%252B2-amino-3-aroylbenzo%25255Bb%25255Dfuran%252Bderivatives%252Bas%252Bhighly%252Bpotent%252Btubulin%252Bpolymerization%252Binhibitors%26aulast%3DOliva%26aufirst%3DPaola%26date%3D2020%26volume%3D200%26spage%3D112448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hairong  Tang</span>, <span class="hlFld-ContribAuthor ">Jiayi  Cheng</span>, <span class="hlFld-ContribAuthor ">Yuru  Liang</span>, <span class="hlFld-ContribAuthor ">Yang  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a chiral fluorinated azetidin-2-one as a tubulin polymerisation inhibitor with potent antitumour efficacy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>197 </em>, 112323. <a href="https://doi.org/10.1016/j.ejmech.2020.112323" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112323</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112323%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252Bchiral%252Bfluorinated%252Bazetidin-2-one%252Bas%252Ba%252Btubulin%252Bpolymerisation%252Binhibitor%252Bwith%252Bpotent%252Bantitumour%252Befficacy%26aulast%3DTang%26aufirst%3DHairong%26date%3D2020%26volume%3D197%26spage%3D112323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raquel  Álvarez</span>, <span class="hlFld-ContribAuthor ">Laura  Aramburu</span>, <span class="hlFld-ContribAuthor ">Consuelo  Gajate</span>, <span class="hlFld-ContribAuthor ">Alba  Vicente-Blázquez</span>, <span class="hlFld-ContribAuthor ">Faustino  Mollinedo</span>, <span class="hlFld-ContribAuthor ">Manuel  Medarde</span>, <span class="hlFld-ContribAuthor ">Rafael  Peláez</span>. </span><span class="cited-content_cbyCitation_article-title">Potent colchicine-site ligands with improved intrinsic solubility by replacement of the 3,4,5-trimethoxyphenyl ring with a 2-methylsulfanyl-6-methoxypyridine ring. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>98 </em>, 103755. <a href="https://doi.org/10.1016/j.bioorg.2020.103755" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103755</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103755%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DPotent%252Bcolchicine-site%252Bligands%252Bwith%252Bimproved%252Bintrinsic%252Bsolubility%252Bby%252Breplacement%252Bof%252Bthe%252B3%25252C4%25252C5-trimethoxyphenyl%252Bring%252Bwith%252Ba%252B2-methylsulfanyl-6-methoxypyridine%252Bring%26aulast%3D%25C3%2581lvarez%26aufirst%3DRaquel%26date%3D2020%26volume%3D98%26spage%3D103755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Romeo  Romagnoli</span>, <span class="hlFld-ContribAuthor ">Filippo  Prencipe</span>, <span class="hlFld-ContribAuthor ">Paola  Oliva</span>, <span class="hlFld-ContribAuthor ">Maria  Kimatrai Salvador</span>, <span class="hlFld-ContribAuthor ">Andrea  Brancale</span>, <span class="hlFld-ContribAuthor ">Salvatore  Ferla</span>, <span class="hlFld-ContribAuthor ">Ernest  Hamel</span>, <span class="hlFld-ContribAuthor ">Giampietro  Viola</span>, <span class="hlFld-ContribAuthor ">Roberta  Bortolozzi</span>, <span class="hlFld-ContribAuthor ">Leentje  Persoons</span>, <span class="hlFld-ContribAuthor ">Jan  Balzarini</span>, <span class="hlFld-ContribAuthor ">Sandra  Liekens</span>, <span class="hlFld-ContribAuthor ">Dominique  Schols</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of 2-alkoxycarbonyl-3-anilinoindoles as a new class of potent inhibitors of tubulin polymerization. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>97 </em>, 103665. <a href="https://doi.org/10.1016/j.bioorg.2020.103665" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103665</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103665%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B2-alkoxycarbonyl-3-anilinoindoles%252Bas%252Ba%252Bnew%252Bclass%252Bof%252Bpotent%252Binhibitors%252Bof%252Btubulin%252Bpolymerization%26aulast%3DRomagnoli%26aufirst%3DRomeo%26date%3D2020%26volume%3D97%26spage%3D103665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David  Cáceres-Castillo</span>, <span class="hlFld-ContribAuthor ">Rubén M.  Carballo</span>, <span class="hlFld-ContribAuthor ">Ramiro  Quijano-Quiñones</span>, <span class="hlFld-ContribAuthor ">Gumersindo  Mirón-López</span>, <span class="hlFld-ContribAuthor ">Manlio  Graniel-Sabido</span>, <span class="hlFld-ContribAuthor ">Rosa E.  Moo-Puc</span>, <span class="hlFld-ContribAuthor ">Gonzalo J.  Mena-Rejón</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, in vitro antigiardial activity, SAR analysis and docking study of substituted chalcones. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2020,</strong> <em>29 </em>
                                    (3)
                                     , 431-441. <a href="https://doi.org/10.1007/s00044-019-02492-5" title="DOI URL">https://doi.org/10.1007/s00044-019-02492-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-019-02492-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-019-02492-5%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DSynthesis%25252C%252Bin%252Bvitro%252Bantigiardial%252Bactivity%25252C%252BSAR%252Banalysis%252Band%252Bdocking%252Bstudy%252Bof%252Bsubstituted%252Bchalcones%26aulast%3DC%25C3%25A1ceres-Castillo%26aufirst%3DDavid%26date%3D2020%26date%3D2019%26volume%3D29%26issue%3D3%26spage%3D431%26epage%3D441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Azizah M.  Malebari</span>, <span class="hlFld-ContribAuthor ">Darren  Fayne</span>, <span class="hlFld-ContribAuthor ">Seema M.  Nathwani</span>, <span class="hlFld-ContribAuthor ">Fiona  O’Connell</span>, <span class="hlFld-ContribAuthor ">Sara  Noorani</span>, <span class="hlFld-ContribAuthor ">Brendan  Twamley</span>, <span class="hlFld-ContribAuthor ">Niamh M.  O’Boyle</span>, <span class="hlFld-ContribAuthor ">Jacintha  O’Sullivan</span>, <span class="hlFld-ContribAuthor ">Daniela M.  Zisterer</span>, <span class="hlFld-ContribAuthor ">Mary J.  Meegan</span>. </span><span class="cited-content_cbyCitation_article-title">β-Lactams with antiproliferative and antiapoptotic activity in breast and chemoresistant colon cancer cells. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>189 </em>, 112050. <a href="https://doi.org/10.1016/j.ejmech.2020.112050" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112050%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D%2525CE%2525B2-Lactams%252Bwith%252Bantiproliferative%252Band%252Bantiapoptotic%252Bactivity%252Bin%252Bbreast%252Band%252Bchemoresistant%252Bcolon%252Bcancer%252Bcells%26aulast%3DMalebari%26aufirst%3DAzizah%2BM.%26date%3D2020%26volume%3D189%26spage%3D112050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu-Ying  Shao</span>, <span class="hlFld-ContribAuthor ">Yong  Yin</span>, <span class="hlFld-ContribAuthor ">Bao-Ping  Lian</span>, <span class="hlFld-ContribAuthor ">Jia-Fu  Leng</span>, <span class="hlFld-ContribAuthor ">Yuan-Zheng  Xia</span>, <span class="hlFld-ContribAuthor ">Ling-Yi  Kong</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>190 </em>, 112105. <a href="https://doi.org/10.1016/j.ejmech.2020.112105" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112105</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112105%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bshikonin-benzo%25255Bb%25255Dfuran%252Bderivatives%252Bas%252Btubulin%252Bpolymerization%252Binhibitors%252Btargeting%252Bthe%252Bcolchicine%252Bbinding%252Bsite%26aulast%3DShao%26aufirst%3DYu-Ying%26date%3D2020%26volume%3D190%26spage%3D112105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amit Kumar  Verma</span>, <span class="hlFld-ContribAuthor ">Kaneez  Fatima</span>, <span class="hlFld-ContribAuthor ">Rajesh Kumar  Dudi</span>, <span class="hlFld-ContribAuthor ">Misbah  Tabassum</span>, <span class="hlFld-ContribAuthor ">Hina  Iqbal</span>, <span class="hlFld-ContribAuthor ">Yogesh  Kumar</span>, <span class="hlFld-ContribAuthor ">Suaib  Luqman</span>, <span class="hlFld-ContribAuthor ">D.M.  Mondhe</span>, <span class="hlFld-ContribAuthor ">Debabrata  Chanda</span>, <span class="hlFld-ContribAuthor ">Feroz  Khan</span>, <span class="hlFld-ContribAuthor ">Karuna  Shanker</span>, <span class="hlFld-ContribAuthor ">Arvind S.  Negi</span>. </span><span class="cited-content_cbyCitation_article-title">Antiproliferative activity of diarylnaphthylpyrrolidine derivative via dual target inhibition. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>188 </em>, 111986. <a href="https://doi.org/10.1016/j.ejmech.2019.111986" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111986</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111986%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAntiproliferative%252Bactivity%252Bof%252Bdiarylnaphthylpyrrolidine%252Bderivative%252Bvia%252Bdual%252Btarget%252Binhibition%26aulast%3DVerma%26aufirst%3DAmit%2BKumar%26date%3D2020%26volume%3D188%26spage%3D111986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abdullah A.  Ghawanmeh</span>, <span class="hlFld-ContribAuthor ">Hussein M.  Al-Bajalan</span>, <span class="hlFld-ContribAuthor ">Mukram Mohamed  Mackeen</span>, <span class="hlFld-ContribAuthor ">Feras Q.  Alali</span>, <span class="hlFld-ContribAuthor ">Kwok Feng  Chong</span>. </span><span class="cited-content_cbyCitation_article-title">Recent developments on (−)-colchicine derivatives: Synthesis and structure-activity relationship. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>185 </em>, 111788. <a href="https://doi.org/10.1016/j.ejmech.2019.111788" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111788</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111788%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bdevelopments%252Bon%252B%252528%2525E2%252588%252592%252529-colchicine%252Bderivatives%25253A%252BSynthesis%252Band%252Bstructure-activity%252Brelationship%26aulast%3DGhawanmeh%26aufirst%3DAbdullah%2BA.%26date%3D2020%26volume%3D185%26spage%3D111788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangping  Deng</span>, <span class="hlFld-ContribAuthor ">Yijiao  Peng</span>, <span class="hlFld-ContribAuthor ">Jingduo  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiaoyong  Lei</span>, <span class="hlFld-ContribAuthor ">Xing  Zheng</span>, <span class="hlFld-ContribAuthor ">Zhizhong  Xie</span>, <span class="hlFld-ContribAuthor ">Guotao  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Anticancer Activity of Natural Flavonoids: Inhibition of HIF-1α Signaling Pathway. </span><span class="cited-content_cbyCitation_journal-name">Current Organic Chemistry</span><span> <strong>2020,</strong> <em>23 </em>
                                    (26)
                                     , 2945-2959. <a href="https://doi.org/10.2174/1385272823666191203122030" title="DOI URL">https://doi.org/10.2174/1385272823666191203122030</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1385272823666191203122030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1385272823666191203122030%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Organic%2520Chemistry%26atitle%3DAnticancer%252BActivity%252Bof%252BNatural%252BFlavonoids%25253A%252BInhibition%252Bof%252BHIF-1%2525CE%2525B1%252BSignaling%252BPathway%26aulast%3DDeng%26aufirst%3DXiangping%26date%3D2020%26volume%3D23%26issue%3D26%26spage%3D2945%26epage%3D2959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yong  Yin</span>, <span class="hlFld-ContribAuthor ">Bao-Ping  Lian</span>, <span class="hlFld-ContribAuthor ">Yuan-Zheng  Xia</span>, <span class="hlFld-ContribAuthor ">Yu-Ying  Shao</span>, <span class="hlFld-ContribAuthor ">Ling-Yi  Kong</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of resveratrol-cinnamoyl derivates as tubulin polymerization inhibitors targeting the colchicine binding site. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>93 </em>, 103319. <a href="https://doi.org/10.1016/j.bioorg.2019.103319" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.103319</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.103319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.103319%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bresveratrol-cinnamoyl%252Bderivates%252Bas%252Btubulin%252Bpolymerization%252Binhibitors%252Btargeting%252Bthe%252Bcolchicine%252Bbinding%252Bsite%26aulast%3DYin%26aufirst%3DYong%26date%3D2019%26volume%3D93%26spage%3D103319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chao  Tian</span>, <span class="hlFld-ContribAuthor ">Xuanzhen  Chen</span>, <span class="hlFld-ContribAuthor ">Zhili  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaowei  Wang</span>, <span class="hlFld-ContribAuthor ">Junyi  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of (2-(phenylamino)thieno[3,2-d]pyrimidin-4-yl)(3,4,5-trimethoxyphenyl)methanone analogues as potent anti-tubulin polymerization agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>183 </em>, 111679. <a href="https://doi.org/10.1016/j.ejmech.2019.111679" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111679</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111679%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252B%2525282-%252528phenylamino%252529thieno%25255B3%25252C2-d%25255Dpyrimidin-4-yl%252529%2525283%25252C4%25252C5-trimethoxyphenyl%252529methanone%252Banalogues%252Bas%252Bpotent%252Banti-tubulin%252Bpolymerization%252Bagents%26aulast%3DTian%26aufirst%3DChao%26date%3D2019%26volume%3D183%26spage%3D111679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Muhamad  Mustafa</span>, <span class="hlFld-ContribAuthor ">Sirajudheen  Anwar</span>, <span class="hlFld-ContribAuthor ">Firgani  Elgamal</span>, <span class="hlFld-ContribAuthor ">Esam R.  Ahmed</span>, <span class="hlFld-ContribAuthor ">Omar M.  Aly</span>. </span><span class="cited-content_cbyCitation_article-title">Potent combretastatin A-4 analogs containing 1,2,4-triazole: Synthesis, antiproliferative, anti-tubulin activity, and docking study. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>183 </em>, 111697. <a href="https://doi.org/10.1016/j.ejmech.2019.111697" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111697</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111697%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPotent%252Bcombretastatin%252BA-4%252Banalogs%252Bcontaining%252B1%25252C2%25252C4-triazole%25253A%252BSynthesis%25252C%252Bantiproliferative%25252C%252Banti-tubulin%252Bactivity%25252C%252Band%252Bdocking%252Bstudy%26aulast%3DMustafa%26aufirst%3DMuhamad%26date%3D2019%26volume%3D183%26spage%3D111697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cuartas</span>, <span class="hlFld-ContribAuthor ">Crespo</span>, <span class="hlFld-ContribAuthor ">Priego</span>, <span class="hlFld-ContribAuthor ">Persoons</span>, <span class="hlFld-ContribAuthor ">Daelemans</span>, <span class="hlFld-ContribAuthor ">Camarasa</span>, <span class="hlFld-ContribAuthor ">Insuasty</span>, <span class="hlFld-ContribAuthor ">Pérez-Pérez</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of New 6-Nitro and 6-Amino-3,3a,4,5-Tetrahydro-2H-Benzo[g]indazole Derivatives: Antiproliferative and Antibacterial Activity. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (23)
                                     , 4236. <a href="https://doi.org/10.3390/molecules24234236" title="DOI URL">https://doi.org/10.3390/molecules24234236</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24234236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24234236%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BNew%252B6-Nitro%252Band%252B6-Amino-3%25252C3a%25252C4%25252C5-Tetrahydro-2H-Benzo%25255Bg%25255Dindazole%252BDerivatives%25253A%252BAntiproliferative%252Band%252BAntibacterial%252BActivity%26aulast%3DCuartas%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D23%26spage%3D4236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">González</span>, <span class="hlFld-ContribAuthor ">Ellahioui</span>, <span class="hlFld-ContribAuthor ">Álvarez</span>, <span class="hlFld-ContribAuthor ">Gallego-Yerga</span>, <span class="hlFld-ContribAuthor ">Caballero</span>, <span class="hlFld-ContribAuthor ">Vicente-Blázquez</span>, <span class="hlFld-ContribAuthor ">Ramudo</span>, <span class="hlFld-ContribAuthor ">Marín</span>, <span class="hlFld-ContribAuthor ">Sanz</span>, <span class="hlFld-ContribAuthor ">Medarde</span>, <span class="hlFld-ContribAuthor ">Pelaéz</span>. </span><span class="cited-content_cbyCitation_article-title">The Masked Polar Group Incorporation (MPGI) Strategy in Drug Design: Effects of Nitrogen Substitutions on Combretastatin and Isocombretastatin Tubulin Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (23)
                                     , 4319. <a href="https://doi.org/10.3390/molecules24234319" title="DOI URL">https://doi.org/10.3390/molecules24234319</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24234319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24234319%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DThe%252BMasked%252BPolar%252BGroup%252BIncorporation%252B%252528MPGI%252529%252BStrategy%252Bin%252BDrug%252BDesign%25253A%252BEffects%252Bof%252BNitrogen%252BSubstitutions%252Bon%252BCombretastatin%252Band%252BIsocombretastatin%252BTubulin%252BInhibitors%26aulast%3DGonz%25C3%25A1lez%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D23%26spage%3D4319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Romeo  Romagnoli</span>, <span class="hlFld-ContribAuthor ">Paola  Oliva</span>, <span class="hlFld-ContribAuthor ">Maria Kimatrai  Salvador</span>, <span class="hlFld-ContribAuthor ">Maria Encarnacion  Camacho</span>, <span class="hlFld-ContribAuthor ">Chiara  Padroni</span>, <span class="hlFld-ContribAuthor ">Andrea  Brancale</span>, <span class="hlFld-ContribAuthor ">Salvatore  Ferla</span>, <span class="hlFld-ContribAuthor ">Ernest  Hamel</span>, <span class="hlFld-ContribAuthor ">Roberto  Ronca</span>, <span class="hlFld-ContribAuthor ">Elisabetta  Grillo</span>, <span class="hlFld-ContribAuthor ">Roberta  Bortolozzi</span>, <span class="hlFld-ContribAuthor ">Fatlum  Rruga</span>, <span class="hlFld-ContribAuthor ">Elena  Mariotto</span>, <span class="hlFld-ContribAuthor ">Giampietro  Viola</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel vicinal diaryl-substituted 1H-Pyrazole analogues of combretastatin A-4 as highly potent tubulin polymerization inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>181 </em>, 111577. <a href="https://doi.org/10.1016/j.ejmech.2019.111577" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111577</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111577%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bvicinal%252Bdiaryl-substituted%252B1H-Pyrazole%252Banalogues%252Bof%252Bcombretastatin%252BA-4%252Bas%252Bhighly%252Bpotent%252Btubulin%252Bpolymerization%252Binhibitors%26aulast%3DRomagnoli%26aufirst%3DRomeo%26date%3D2019%26volume%3D181%26spage%3D111577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Florian  Schmitt</span>, <span class="hlFld-ContribAuthor ">Rainer  Schobert</span>, <span class="hlFld-ContribAuthor ">Bernhard  Biersack</span>. </span><span class="cited-content_cbyCitation_article-title">New pyranoquinoline derivatives as vascular-disrupting anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2019,</strong> <em>28 </em>
                                    (10)
                                     , 1694-1703. <a href="https://doi.org/10.1007/s00044-019-02406-5" title="DOI URL">https://doi.org/10.1007/s00044-019-02406-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-019-02406-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-019-02406-5%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DNew%252Bpyranoquinoline%252Bderivatives%252Bas%252Bvascular-disrupting%252Banticancer%252Bagents%26aulast%3DSchmitt%26aufirst%3DFlorian%26date%3D2019%26date%3D2019%26volume%3D28%26issue%3D10%26spage%3D1694%26epage%3D1703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiajia  Liang</span>, <span class="hlFld-ContribAuthor ">Qi  Luo</span>, <span class="hlFld-ContribAuthor ">Dongjian  Zhang</span>, <span class="hlFld-ContribAuthor ">Qiaomei  Jin</span>, <span class="hlFld-ContribAuthor ">Lichao  Liu</span>, <span class="hlFld-ContribAuthor ">Wei  Liu</span>, <span class="hlFld-ContribAuthor ">Meng  Gao</span>, <span class="hlFld-ContribAuthor ">Jian  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhiqi  Yin</span>. </span><span class="cited-content_cbyCitation_article-title">SPECT Imaging of Treatment-Related Tumor Necrosis Using Technetium-99m-Labeled Rhein. </span><span class="cited-content_cbyCitation_journal-name">Molecular Imaging and Biology</span><span> <strong>2019,</strong> <em>21 </em>
                                    (4)
                                     , 660-668. <a href="https://doi.org/10.1007/s11307-018-1285-9" title="DOI URL">https://doi.org/10.1007/s11307-018-1285-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11307-018-1285-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11307-018-1285-9%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Imaging%2520and%2520Biology%26atitle%3DSPECT%252BImaging%252Bof%252BTreatment-Related%252BTumor%252BNecrosis%252BUsing%252BTechnetium-99m-Labeled%252BRhein%26aulast%3DLiang%26aufirst%3DJiajia%26date%3D2019%26date%3D2018%26volume%3D21%26issue%3D4%26spage%3D660%26epage%3D668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Oskia  Bueno</span>, <span class="hlFld-ContribAuthor ">Marta  Gargantilla</span>, <span class="hlFld-ContribAuthor ">Juan  Estévez-Gallego</span>, <span class="hlFld-ContribAuthor ">Solange  Martins</span>, <span class="hlFld-ContribAuthor ">J. Fernando  Díaz</span>, <span class="hlFld-ContribAuthor ">María-José  Camarasa</span>, <span class="hlFld-ContribAuthor ">Sandra  Liekens</span>, <span class="hlFld-ContribAuthor ">María-Jesús  Pérez-Pérez</span>, <span class="hlFld-ContribAuthor ">Eva-María  Priego</span>. </span><span class="cited-content_cbyCitation_article-title">Diphenyl ether derivatives occupy the expanded binding site of cyclohexanedione compounds at the colchicine site in tubulin by movement of the αT5 loop. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>171 </em>, 195-208. <a href="https://doi.org/10.1016/j.ejmech.2019.03.045" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.03.045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.03.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.03.045%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiphenyl%252Bether%252Bderivatives%252Boccupy%252Bthe%252Bexpanded%252Bbinding%252Bsite%252Bof%252Bcyclohexanedione%252Bcompounds%252Bat%252Bthe%252Bcolchicine%252Bsite%252Bin%252Btubulin%252Bby%252Bmovement%252Bof%252Bthe%252B%2525CE%2525B1T5%252Bloop%26aulast%3DBueno%26aufirst%3DOskia%26date%3D2019%26volume%3D171%26spage%3D195%26epage%3D208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alba  Vicente‐Blázquez</span>, <span class="hlFld-ContribAuthor ">Myriam  González</span>, <span class="hlFld-ContribAuthor ">Raquel  Álvarez</span>, <span class="hlFld-ContribAuthor ">Sara  del Mazo</span>, <span class="hlFld-ContribAuthor ">Manuel  Medarde</span>, <span class="hlFld-ContribAuthor ">Rafael  Peláez</span>. </span><span class="cited-content_cbyCitation_article-title">Antitubulin sulfonamides: The successful combination of an established drug class and a multifaceted target. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2019,</strong> <em>39 </em>
                                    (3)
                                     , 775-830. <a href="https://doi.org/10.1002/med.21541" title="DOI URL">https://doi.org/10.1002/med.21541</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21541%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DAntitubulin%252Bsulfonamides%25253A%252BThe%252Bsuccessful%252Bcombination%252Bof%252Ban%252Bestablished%252Bdrug%252Bclass%252Band%252Ba%252Bmultifaceted%252Btarget%26aulast%3DVicente%25E2%2580%2590Bl%25C3%25A1zquez%26aufirst%3DAlba%26date%3D2019%26date%3D2018%26volume%3D39%26issue%3D3%26spage%3D775%26epage%3D830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dongjian  Zhang</span>, <span class="hlFld-ContribAuthor ">Meng  Gao</span>, <span class="hlFld-ContribAuthor ">Qiaomei  Jin</span>, <span class="hlFld-ContribAuthor ">Yicheng  Ni</span>, <span class="hlFld-ContribAuthor ">Jian  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Updated developments on molecular imaging and therapeutic strategies directed against necrosis. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2019,</strong> <em>9 </em>
                                    (3)
                                     , 455-468. <a href="https://doi.org/10.1016/j.apsb.2019.02.002" title="DOI URL">https://doi.org/10.1016/j.apsb.2019.02.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2019.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2019.02.002%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DUpdated%252Bdevelopments%252Bon%252Bmolecular%252Bimaging%252Band%252Btherapeutic%252Bstrategies%252Bdirected%252Bagainst%252Bnecrosis%26aulast%3DZhang%26aufirst%3DDongjian%26date%3D2019%26volume%3D9%26issue%3D3%26spage%3D455%26epage%3D468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenlong  Li</span>, <span class="hlFld-ContribAuthor ">Honghao  Sun</span>, <span class="hlFld-ContribAuthor ">Feijie  Xu</span>, <span class="hlFld-ContribAuthor ">Wen  Shuai</span>, <span class="hlFld-ContribAuthor ">Jie  Liu</span>, <span class="hlFld-ContribAuthor ">Shengtao  Xu</span>, <span class="hlFld-ContribAuthor ">Hequan  Yao</span>, <span class="hlFld-ContribAuthor ">Cong  Ma</span>, <span class="hlFld-ContribAuthor ">Zheying  Zhu</span>, <span class="hlFld-ContribAuthor ">Jinyi  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, molecular properties prediction and biological evaluation of indole-vinyl sulfone derivatives as novel tubulin polymerization inhibitors targeting the colchicine binding site. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>85 </em>, 49-59. <a href="https://doi.org/10.1016/j.bioorg.2018.12.015" title="DOI URL">https://doi.org/10.1016/j.bioorg.2018.12.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2018.12.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2018.12.015%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DSynthesis%25252C%252Bmolecular%252Bproperties%252Bprediction%252Band%252Bbiological%252Bevaluation%252Bof%252Bindole-vinyl%252Bsulfone%252Bderivatives%252Bas%252Bnovel%252Btubulin%252Bpolymerization%252Binhibitors%252Btargeting%252Bthe%252Bcolchicine%252Bbinding%252Bsite%26aulast%3DLi%26aufirst%3DWenlong%26date%3D2019%26volume%3D85%26spage%3D49%26epage%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenlong  Li</span>, <span class="hlFld-ContribAuthor ">Ying  Yin</span>, <span class="hlFld-ContribAuthor ">Wen  Shuai</span>, <span class="hlFld-ContribAuthor ">Feijie  Xu</span>, <span class="hlFld-ContribAuthor ">Hong  Yao</span>, <span class="hlFld-ContribAuthor ">Jie  Liu</span>, <span class="hlFld-ContribAuthor ">Keguang  Cheng</span>, <span class="hlFld-ContribAuthor ">Jinyi  Xu</span>, <span class="hlFld-ContribAuthor ">Zheying  Zhu</span>, <span class="hlFld-ContribAuthor ">Shengtao  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel quinazolines as potential anti-tubulin agents occupying three zones of colchicine domain. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>83 </em>, 380-390. <a href="https://doi.org/10.1016/j.bioorg.2018.10.027" title="DOI URL">https://doi.org/10.1016/j.bioorg.2018.10.027</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2018.10.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2018.10.027%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bquinazolines%252Bas%252Bpotential%252Banti-tubulin%252Bagents%252Boccupying%252Bthree%252Bzones%252Bof%252Bcolchicine%252Bdomain%26aulast%3DLi%26aufirst%3DWenlong%26date%3D2019%26volume%3D83%26spage%3D380%26epage%3D390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Budaganaboyina  Prasad</span>, <span class="hlFld-ContribAuthor ">V.  Lakshma Nayak</span>, <span class="hlFld-ContribAuthor ">P.S.  Srikanth</span>, <span class="hlFld-ContribAuthor ">Mirza Feroz  Baig</span>, <span class="hlFld-ContribAuthor ">N.V.  Subba Reddy</span>, <span class="hlFld-ContribAuthor ">Korrapati Suresh  Babu</span>, <span class="hlFld-ContribAuthor ">Ahmed  Kamal</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of 1-benzyl-N-(2-(phenylamino)pyridin-3-yl)-1H-1,2,3-triazole-4-carboxamides as antimitotic agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>83 </em>, 535-548. <a href="https://doi.org/10.1016/j.bioorg.2018.11.002" title="DOI URL">https://doi.org/10.1016/j.bioorg.2018.11.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2018.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2018.11.002%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B1-benzyl-N-%2525282-%252528phenylamino%252529pyridin-3-yl%252529-1H-1%25252C2%25252C3-triazole-4-carboxamides%252Bas%252Bantimitotic%252Bagents%26aulast%3DPrasad%26aufirst%3DBudaganaboyina%26date%3D2019%26volume%3D83%26spage%3D535%26epage%3D548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ya-Liang  Zhang</span>, <span class="hlFld-ContribAuthor ">Bo-Yan  Li</span>, <span class="hlFld-ContribAuthor ">Rong  Yang</span>, <span class="hlFld-ContribAuthor ">Lin-Ying  Xia</span>, <span class="hlFld-ContribAuthor ">A-Li  Fan</span>, <span class="hlFld-ContribAuthor ">Yi-Chun  Chu</span>, <span class="hlFld-ContribAuthor ">Lin-Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Zhong-Chang  Wang</span>, <span class="hlFld-ContribAuthor ">Ai-Qin  Jiang</span>, <span class="hlFld-ContribAuthor ">Hai-Liang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">A class of novel tubulin polymerization inhibitors exert effective anti-tumor activity via mitotic catastrophe. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>163 </em>, 896-910. <a href="https://doi.org/10.1016/j.ejmech.2018.12.030" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.12.030</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.12.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.12.030%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Bclass%252Bof%252Bnovel%252Btubulin%252Bpolymerization%252Binhibitors%252Bexert%252Beffective%252Banti-tumor%252Bactivity%252Bvia%252Bmitotic%252Bcatastrophe%26aulast%3DZhang%26aufirst%3DYa-Liang%26date%3D2019%26volume%3D163%26spage%3D896%26epage%3D910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangping  Deng</span>, <span class="hlFld-ContribAuthor ">Renbo  Liu</span>, <span class="hlFld-ContribAuthor ">Junjian  Li</span>, <span class="hlFld-ContribAuthor ">Zhongli  Li</span>, <span class="hlFld-ContribAuthor ">Juan  Liu</span>, <span class="hlFld-ContribAuthor ">Runde  Xiong</span>, <span class="hlFld-ContribAuthor ">Xiaoyong  Lei</span>, <span class="hlFld-ContribAuthor ">Xing  Zheng</span>, <span class="hlFld-ContribAuthor ">Zhizhong  Xie</span>, <span class="hlFld-ContribAuthor ">Guotao  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and preliminary biological evaluation of 3′,4′,5′-trimethoxy flavonoid salicylate derivatives as potential anti-tumor agents. </span><span class="cited-content_cbyCitation_journal-name">New Journal of Chemistry</span><span> <strong>2019,</strong> <em>43 </em>
                                    (4)
                                     , 1874-1884. <a href="https://doi.org/10.1039/C8NJ04533J" title="DOI URL">https://doi.org/10.1039/C8NJ04533J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8NJ04533J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8NJ04533J%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Journal%2520of%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bpreliminary%252Bbiological%252Bevaluation%252Bof%252B3%2525E2%252580%2525B2%25252C4%2525E2%252580%2525B2%25252C5%2525E2%252580%2525B2-trimethoxy%252Bflavonoid%252Bsalicylate%252Bderivatives%252Bas%252Bpotential%252Banti-tumor%252Bagents%26aulast%3DDeng%26aufirst%3DXiangping%26date%3D2019%26date%3D2019%26volume%3D43%26issue%3D4%26spage%3D1874%26epage%3D1884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mei-Jung  Lai</span>, <span class="hlFld-ContribAuthor ">Ritu  Ojha</span>, <span class="hlFld-ContribAuthor ">Mei-Hsiang  Lin</span>, <span class="hlFld-ContribAuthor ">Yi-Min  Liu</span>, <span class="hlFld-ContribAuthor ">Hsueh-Yun  Lee</span>, <span class="hlFld-ContribAuthor ">Tony Eight  Lin</span>, <span class="hlFld-ContribAuthor ">Kai-Cheng  Hsu</span>, <span class="hlFld-ContribAuthor ">Chi-Yen  Chang</span>, <span class="hlFld-ContribAuthor ">Mei-Chuan  Chen</span>, <span class="hlFld-ContribAuthor ">Kunal  Nepali</span>, <span class="hlFld-ContribAuthor ">Jang-Yang  Chang</span>, <span class="hlFld-ContribAuthor ">Jing-Ping  Liou</span>. </span><span class="cited-content_cbyCitation_article-title">1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>162 </em>, 612-630. <a href="https://doi.org/10.1016/j.ejmech.2018.10.066" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.10.066</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.10.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.10.066%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D1-Arylsulfonyl%252Bindoline-benzamides%252Bas%252Ba%252Bnew%252Bantitubulin%252Bagents%25252C%252Bwith%252Binhibition%252Bof%252Bhistone%252Bdeacetylase%26aulast%3DLai%26aufirst%3DMei-Jung%26date%3D2019%26volume%3D162%26spage%3D612%26epage%3D630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangping  Deng</span>, <span class="hlFld-ContribAuthor ">Zhongli  Li</span>, <span class="hlFld-ContribAuthor ">Runde  Xiong</span>, <span class="hlFld-ContribAuthor ">Juan  Liu</span>, <span class="hlFld-ContribAuthor ">Renbo  Liu</span>, <span class="hlFld-ContribAuthor ">Junmei  Peng</span>, <span class="hlFld-ContribAuthor ">Yanming  Chen</span>, <span class="hlFld-ContribAuthor ">Xiaoyong  Lei</span>, <span class="hlFld-ContribAuthor ">Xuan  Cao</span>, <span class="hlFld-ContribAuthor ">Xing  Zheng</span>, <span class="hlFld-ContribAuthor ">Zhizhong  Xie</span>, <span class="hlFld-ContribAuthor ">Guotao  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">FS-7 inhibits MGC-803 cells growth in vitro and in vivo via down-regulating glycolysis. </span><span class="cited-content_cbyCitation_journal-name">Biomedicine & Pharmacotherapy</span><span> <strong>2019,</strong> <em>109 </em>, 1659-1669. <a href="https://doi.org/10.1016/j.biopha.2018.11.001" title="DOI URL">https://doi.org/10.1016/j.biopha.2018.11.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biopha.2018.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biopha.2018.11.001%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedicine%2520%2526%2520Pharmacotherapy%26atitle%3DFS-7%252Binhibits%252BMGC-803%252Bcells%252Bgrowth%252Bin%252Bvitro%252Band%252Bin%252Bvivo%252Bvia%252Bdown-regulating%252Bglycolysis%26aulast%3DDeng%26aufirst%3DXiangping%26date%3D2019%26volume%3D109%26spage%3D1659%26epage%3D1669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Oskía  Bueno</span>, <span class="hlFld-ContribAuthor ">Juan  Estévez Gallego</span>, <span class="hlFld-ContribAuthor ">Solange  Martins</span>, <span class="hlFld-ContribAuthor ">Andrea E.  Prota</span>, <span class="hlFld-ContribAuthor ">Federico  Gago</span>, <span class="hlFld-ContribAuthor ">Asier  Gómez-SanJuan</span>, <span class="hlFld-ContribAuthor ">María-José  Camarasa</span>, <span class="hlFld-ContribAuthor ">Isabel  Barasoain</span>, <span class="hlFld-ContribAuthor ">Michel O.  Steinmetz</span>, <span class="hlFld-ContribAuthor ">J. Fernando  Díaz</span>, <span class="hlFld-ContribAuthor ">María-Jesús  Pérez-Pérez</span>, <span class="hlFld-ContribAuthor ">Sandra  Liekens</span>, <span class="hlFld-ContribAuthor ">Eva-María  Priego</span>. </span><span class="cited-content_cbyCitation_article-title">High-affinity ligands of the colchicine domain in tubulin based on a structure-guided design. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2018,</strong> <em>8 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-018-22382-x" title="DOI URL">https://doi.org/10.1038/s41598-018-22382-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-018-22382-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-018-22382-x%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DHigh-affinity%252Bligands%252Bof%252Bthe%252Bcolchicine%252Bdomain%252Bin%252Btubulin%252Bbased%252Bon%252Ba%252Bstructure-guided%252Bdesign%26aulast%3DBueno%26aufirst%3DOsk%25C3%25ADa%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Romeo  Romagnoli</span>, <span class="hlFld-ContribAuthor ">Filippo  Prencipe</span>, <span class="hlFld-ContribAuthor ">Paola  Oliva</span>, <span class="hlFld-ContribAuthor ">Stefania  Baraldi</span>, <span class="hlFld-ContribAuthor ">Pier Giovanni  Baraldi</span>, <span class="hlFld-ContribAuthor ">Andrea  Brancale</span>, <span class="hlFld-ContribAuthor ">Salvatore  Ferla</span>, <span class="hlFld-ContribAuthor ">Ernest  Hamel</span>, <span class="hlFld-ContribAuthor ">Roberta  Bortolozzi</span>, <span class="hlFld-ContribAuthor ">Giampietro  Viola</span>. </span><span class="cited-content_cbyCitation_article-title">3-Aryl/Heteroaryl-5-amino-1-(3′,4′,5′-trimethoxybenzoyl)-1,2,4-triazoles as antimicrotubule agents. Design, synthesis, antiproliferative activity and inhibition of tubulin polymerization. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2018,</strong> <em>80 </em>, 361-374. <a href="https://doi.org/10.1016/j.bioorg.2018.06.037" title="DOI URL">https://doi.org/10.1016/j.bioorg.2018.06.037</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2018.06.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2018.06.037%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3D3-Aryl%25252FHeteroaryl-5-amino-1-%2525283%2525E2%252580%2525B2%25252C4%2525E2%252580%2525B2%25252C5%2525E2%252580%2525B2-trimethoxybenzoyl%252529-1%25252C2%25252C4-triazoles%252Bas%252Bantimicrotubule%252Bagents.%252BDesign%25252C%252Bsynthesis%25252C%252Bantiproliferative%252Bactivity%252Band%252Binhibition%252Bof%252Btubulin%252Bpolymerization%26aulast%3DRomagnoli%26aufirst%3DRomeo%26date%3D2018%26volume%3D80%26spage%3D361%26epage%3D374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raquel  Álvarez</span>, <span class="hlFld-ContribAuthor ">Consuelo  Gajate</span>, <span class="hlFld-ContribAuthor ">Pilar  Puebla</span>, <span class="hlFld-ContribAuthor ">Faustino  Mollinedo</span>, <span class="hlFld-ContribAuthor ">Manuel  Medarde</span>, <span class="hlFld-ContribAuthor ">Rafael  Peláez</span>. </span><span class="cited-content_cbyCitation_article-title">Substitution at the indole 3 position yields highly potent indolecombretastatins against human tumor cells. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>158 </em>, 167-183. <a href="https://doi.org/10.1016/j.ejmech.2018.08.078" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.08.078</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.08.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.08.078%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSubstitution%252Bat%252Bthe%252Bindole%252B3%252Bposition%252Byields%252Bhighly%252Bpotent%252Bindolecombretastatins%252Bagainst%252Bhuman%252Btumor%252Bcells%26aulast%3D%25C3%2581lvarez%26aufirst%3DRaquel%26date%3D2018%26volume%3D158%26spage%3D167%26epage%3D183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yue  Wu</span>, <span class="hlFld-ContribAuthor ">Qi  Guan</span>, <span class="hlFld-ContribAuthor ">Dayong  Zheng</span>, <span class="hlFld-ContribAuthor ">Peng  Yan</span>, <span class="hlFld-ContribAuthor ">Dongjie  Feng</span>, <span class="hlFld-ContribAuthor ">Jianan  Du</span>, <span class="hlFld-ContribAuthor ">Jingbo  Zhang</span>, <span class="hlFld-ContribAuthor ">Daiying  Zuo</span>, <span class="hlFld-ContribAuthor ">Kai  Bao</span>, <span class="hlFld-ContribAuthor ">Weige  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Conformation impacts on the bioactivities of SMART analogues. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>158 </em>, 733-742. <a href="https://doi.org/10.1016/j.ejmech.2018.09.045" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.09.045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.09.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.09.045%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DConformation%252Bimpacts%252Bon%252Bthe%252Bbioactivities%252Bof%252BSMART%252Banalogues%26aulast%3DWu%26aufirst%3DYue%26date%3D2018%26volume%3D158%26spage%3D733%26epage%3D742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michel O.  Steinmetz</span>, <span class="hlFld-ContribAuthor ">Andrea E.  Prota</span>. </span><span class="cited-content_cbyCitation_article-title">Microtubule-Targeting Agents: Strategies To Hijack the Cytoskeleton. </span><span class="cited-content_cbyCitation_journal-name">Trends in Cell Biology</span><span> <strong>2018,</strong> <em>28 </em>
                                    (10)
                                     , 776-792. <a href="https://doi.org/10.1016/j.tcb.2018.05.001" title="DOI URL">https://doi.org/10.1016/j.tcb.2018.05.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tcb.2018.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tcb.2018.05.001%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Cell%2520Biology%26atitle%3DMicrotubule-Targeting%252BAgents%25253A%252BStrategies%252BTo%252BHijack%252Bthe%252BCytoskeleton%26aulast%3DSteinmetz%26aufirst%3DMichel%2BO.%26date%3D2018%26volume%3D28%26issue%3D10%26spage%3D776%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huijun  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiong  Fang</span>, <span class="hlFld-ContribAuthor ">Qian  Meng</span>, <span class="hlFld-ContribAuthor ">Yujia  Mao</span>, <span class="hlFld-ContribAuthor ">Yan  Xu</span>, <span class="hlFld-ContribAuthor ">Tingting  Fan</span>, <span class="hlFld-ContribAuthor ">Jing  An</span>, <span class="hlFld-ContribAuthor ">Ziwei  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and characterization of potent microtubule inhibitors with dual anti-proliferative and anti-angiogenic activities. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>157 </em>, 380-396. <a href="https://doi.org/10.1016/j.ejmech.2018.07.043" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.07.043</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.07.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.07.043%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bcharacterization%252Bof%252Bpotent%252Bmicrotubule%252Binhibitors%252Bwith%252Bdual%252Banti-proliferative%252Band%252Banti-angiogenic%252Bactivities%26aulast%3DZhang%26aufirst%3DHuijun%26date%3D2018%26volume%3D157%26spage%3D380%26epage%3D396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fabian  Hulpia</span>, <span class="hlFld-ContribAuthor ">Sam  Noppen</span>, <span class="hlFld-ContribAuthor ">Dominique  Schols</span>, <span class="hlFld-ContribAuthor ">Graciela  Andrei</span>, <span class="hlFld-ContribAuthor ">Robert  Snoeck</span>, <span class="hlFld-ContribAuthor ">Sandra  Liekens</span>, <span class="hlFld-ContribAuthor ">Peter  Vervaeke</span>, <span class="hlFld-ContribAuthor ">Serge  Van Calenbergh</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of a 3′-C-ethynyl-β-d-ribofuranose purine nucleoside library: Discovery of C7-deazapurine analogs as potent antiproliferative nucleosides. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>157 </em>, 248-267. <a href="https://doi.org/10.1016/j.ejmech.2018.07.062" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.07.062</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.07.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.07.062%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Bof%252Ba%252B3%2525E2%252580%2525B2-C-ethynyl-%2525CE%2525B2-d-ribofuranose%252Bpurine%252Bnucleoside%252Blibrary%25253A%252BDiscovery%252Bof%252BC7-deazapurine%252Banalogs%252Bas%252Bpotent%252Bantiproliferative%252Bnucleosides%26aulast%3DHulpia%26aufirst%3DFabian%26date%3D2018%26volume%3D157%26spage%3D248%26epage%3D267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenlong  Li</span>, <span class="hlFld-ContribAuthor ">Ying  Yin</span>, <span class="hlFld-ContribAuthor ">Hong  Yao</span>, <span class="hlFld-ContribAuthor ">Wen  Shuai</span>, <span class="hlFld-ContribAuthor ">Honghao  Sun</span>, <span class="hlFld-ContribAuthor ">Shengtao  Xu</span>, <span class="hlFld-ContribAuthor ">Jie  Liu</span>, <span class="hlFld-ContribAuthor ">Hequan  Yao</span>, <span class="hlFld-ContribAuthor ">Zheying  Zhu</span>, <span class="hlFld-ContribAuthor ">Jinyi  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel vinyl sulfone derivatives as anti-tumor agents with microtubule polymerization inhibitory and vascular disrupting activities. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>157 </em>, 1068-1080. <a href="https://doi.org/10.1016/j.ejmech.2018.08.074" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.08.074</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.08.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.08.074%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bvinyl%252Bsulfone%252Bderivatives%252Bas%252Banti-tumor%252Bagents%252Bwith%252Bmicrotubule%252Bpolymerization%252Binhibitory%252Band%252Bvascular%252Bdisrupting%252Bactivities%26aulast%3DLi%26aufirst%3DWenlong%26date%3D2018%26volume%3D157%26spage%3D1068%26epage%3D1080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Khalid  El Bairi</span>, <span class="hlFld-ContribAuthor ">Mariam  Amrani</span>, <span class="hlFld-ContribAuthor ">Said  Afqir</span>. </span><span class="cited-content_cbyCitation_article-title">Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers. </span><span class="cited-content_cbyCitation_journal-name">Cancer Medicine</span><span> <strong>2018,</strong> <em>7 </em>
                                    (6)
                                     , 2221-2246. <a href="https://doi.org/10.1002/cam4.1467" title="DOI URL">https://doi.org/10.1002/cam4.1467</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cam4.1467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcam4.1467%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Medicine%26atitle%3DStarvation%252Btactics%252Busing%252Bnatural%252Bcompounds%252Bfor%252Badvanced%252Bcancers%25253A%252Bpharmacodynamics%25252C%252Bclinical%252Befficacy%25252C%252Band%252Bpredictive%252Bbiomarkers%26aulast%3DEl%2BBairi%26aufirst%3DKhalid%26date%3D2018%26date%3D2018%26volume%3D7%26issue%3D6%26spage%3D2221%26epage%3D2246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laura  Conesa-Milián</span>, <span class="hlFld-ContribAuthor ">Eva  Falomir</span>, <span class="hlFld-ContribAuthor ">Juan  Murga</span>, <span class="hlFld-ContribAuthor ">Miguel  Carda</span>, <span class="hlFld-ContribAuthor ">Eef  Meyen</span>, <span class="hlFld-ContribAuthor ">Sandra  Liekens</span>, <span class="hlFld-ContribAuthor ">J.  Alberto Marco</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of carbamates derived from aminocombretastatin A-4 as vascular disrupting agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>147 </em>, 183-193. <a href="https://doi.org/10.1016/j.ejmech.2018.01.058" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.01.058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.01.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.01.058%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bcarbamates%252Bderived%252Bfrom%252Baminocombretastatin%252BA-4%252Bas%252Bvascular%252Bdisrupting%252Bagents%26aulast%3DConesa-Mili%25C3%25A1n%26aufirst%3DLaura%26date%3D2018%26volume%3D147%26spage%3D183%26epage%3D193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Oskía  Bueno</span>, <span class="hlFld-ContribAuthor ">Gloria  Tobajas</span>, <span class="hlFld-ContribAuthor ">Ernesto  Quesada</span>, <span class="hlFld-ContribAuthor ">Juan  Estévez-Gallego</span>, <span class="hlFld-ContribAuthor ">Sam  Noppen</span>, <span class="hlFld-ContribAuthor ">María-José  Camarasa</span>, <span class="hlFld-ContribAuthor ">José-Fernando  Díaz</span>, <span class="hlFld-ContribAuthor ">Sandra  Liekens</span>, <span class="hlFld-ContribAuthor ">Eva-María  Priego</span>, <span class="hlFld-ContribAuthor ">María-Jesús  Pérez-Pérez</span>. </span><span class="cited-content_cbyCitation_article-title">Conformational mimetics of the α-methyl chalcone TUB091 binding tubulin: Design, synthesis and antiproliferative activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>148 </em>, 337-348. <a href="https://doi.org/10.1016/j.ejmech.2018.02.019" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.02.019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.02.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.02.019%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DConformational%252Bmimetics%252Bof%252Bthe%252B%2525CE%2525B1-methyl%252Bchalcone%252BTUB091%252Bbinding%252Btubulin%25253A%252BDesign%25252C%252Bsynthesis%252Band%252Bantiproliferative%252Bactivity%26aulast%3DBueno%26aufirst%3DOsk%25C3%25ADa%26date%3D2018%26volume%3D148%26spage%3D337%26epage%3D348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timothée  Naret</span>, <span class="hlFld-ContribAuthor ">Jérôme  Bignon</span>, <span class="hlFld-ContribAuthor ">Guillaume  Bernadat</span>, <span class="hlFld-ContribAuthor ">Mohamed  Benchekroun</span>, <span class="hlFld-ContribAuthor ">Helene  Levaique</span>, <span class="hlFld-ContribAuthor ">Christine  Lenoir</span>, <span class="hlFld-ContribAuthor ">Joelle  Dubois</span>, <span class="hlFld-ContribAuthor ">Alain  Pruvost</span>, <span class="hlFld-ContribAuthor ">François  Saller</span>, <span class="hlFld-ContribAuthor ">Delphine  Borgel</span>, <span class="hlFld-ContribAuthor ">Boris  Manoury</span>, <span class="hlFld-ContribAuthor ">Veronique  Leblais</span>, <span class="hlFld-ContribAuthor ">Romain  Darrigrand</span>, <span class="hlFld-ContribAuthor ">Sébastien  Apcher</span>, <span class="hlFld-ContribAuthor ">Jean-Daniel  Brion</span>, <span class="hlFld-ContribAuthor ">Etienne  Schmitt</span>, <span class="hlFld-ContribAuthor ">Frédéric R.  Leroux</span>, <span class="hlFld-ContribAuthor ">Mouad  Alami</span>, <span class="hlFld-ContribAuthor ">Abdallah  Hamze</span>. </span><span class="cited-content_cbyCitation_article-title">A fluorine scan of a tubulin polymerization inhibitor isocombretastatin A-4: Design, synthesis, molecular modelling, and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 473-490. <a href="https://doi.org/10.1016/j.ejmech.2017.11.055" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.11.055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.11.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.11.055%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Bfluorine%252Bscan%252Bof%252Ba%252Btubulin%252Bpolymerization%252Binhibitor%252Bisocombretastatin%252BA-4%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Bmolecular%252Bmodelling%25252C%252Band%252Bbiological%252Bevaluation%26aulast%3DNaret%26aufirst%3DTimoth%25C3%25A9e%26date%3D2018%26volume%3D143%26spage%3D473%26epage%3D490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Romeo  Romagnoli</span>, <span class="hlFld-ContribAuthor ">Maria  Kimatrai Salvador</span>, <span class="hlFld-ContribAuthor ">Santiago  Schiaffino Ortega</span>, <span class="hlFld-ContribAuthor ">Pier Giovanni  Baraldi</span>, <span class="hlFld-ContribAuthor ">Paola  Oliva</span>, <span class="hlFld-ContribAuthor ">Stefania  Baraldi</span>, <span class="hlFld-ContribAuthor ">Luisa Carlota  Lopez-Cara</span>, <span class="hlFld-ContribAuthor ">Andrea  Brancale</span>, <span class="hlFld-ContribAuthor ">Salvatore  Ferla</span>, <span class="hlFld-ContribAuthor ">Ernest  Hamel</span>, <span class="hlFld-ContribAuthor ">Jan  Balzarini</span>, <span class="hlFld-ContribAuthor ">Sandra  Liekens</span>, <span class="hlFld-ContribAuthor ">Elena  Mattiuzzo</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Basso</span>, <span class="hlFld-ContribAuthor ">Giampietro  Viola</span>. </span><span class="cited-content_cbyCitation_article-title">2-Alkoxycarbonyl-3-arylamino-5-substituted thiophenes as a novel class of antimicrotubule agents: Design, synthesis, cell growth and tubulin polymerization inhibition. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 683-698. <a href="https://doi.org/10.1016/j.ejmech.2017.11.096" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.11.096</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.11.096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.11.096%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D2-Alkoxycarbonyl-3-arylamino-5-substituted%252Bthiophenes%252Bas%252Ba%252Bnovel%252Bclass%252Bof%252Bantimicrotubule%252Bagents%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Bcell%252Bgrowth%252Band%252Btubulin%252Bpolymerization%252Binhibition%26aulast%3DRomagnoli%26aufirst%3DRomeo%26date%3D2018%26volume%3D143%26spage%3D683%26epage%3D698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Delia  Preti</span>, <span class="hlFld-ContribAuthor ">Romeo  Romagnoli</span>, <span class="hlFld-ContribAuthor ">Riccardo  Rondanin</span>, <span class="hlFld-ContribAuthor ">Barbara  Cacciari</span>, <span class="hlFld-ContribAuthor ">Ernest  Hamel</span>, <span class="hlFld-ContribAuthor ">Jan  Balzarini</span>, <span class="hlFld-ContribAuthor ">Sandra  Liekens</span>, <span class="hlFld-ContribAuthor ">Dominique  Schols</span>, <span class="hlFld-ContribAuthor ">Francisco  Estévez-Sarmiento</span>, <span class="hlFld-ContribAuthor ">José  Quintana</span>, <span class="hlFld-ContribAuthor ">Francisco  Estévez</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis,
              in vitro
              antiproliferative activity and apoptosis-inducing studies of 1-(3′,4′,5′-trimethoxyphenyl)-3-(2′-alkoxycarbonylindolyl)-2-propen-1-one derivatives obtained by a molecular hybridisation approach. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2018,</strong> <em>33 </em>
                                    (1)
                                     , 1225-1238. <a href="https://doi.org/10.1080/14756366.2018.1493473" title="DOI URL">https://doi.org/10.1080/14756366.2018.1493473</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2018.1493473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2018.1493473%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Bin%252Bvitro%252Bantiproliferative%252Bactivity%252Band%252Bapoptosis-inducing%252Bstudies%252Bof%252B1-%2525283%2525E2%252580%2525B2%25252C4%2525E2%252580%2525B2%25252C5%2525E2%252580%2525B2-trimethoxyphenyl%252529-3-%2525282%2525E2%252580%2525B2-alkoxycarbonylindolyl%252529-2-propen-1-one%252Bderivatives%252Bobtained%252Bby%252Ba%252Bmolecular%252Bhybridisation%252Bapproach%26aulast%3DPreti%26aufirst%3DDelia%26date%3D2018%26date%3D2018%26volume%3D33%26issue%3D1%26spage%3D1225%26epage%3D1238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dongjian  Zhang</span>, <span class="hlFld-ContribAuthor ">Meng  Gao</span>, <span class="hlFld-ContribAuthor ">Nan  Yao</span>, <span class="hlFld-ContribAuthor ">Cuihua  Jiang</span>, <span class="hlFld-ContribAuthor ">Wei  Liu</span>, <span class="hlFld-ContribAuthor ">Tiannv  Li</span>, <span class="hlFld-ContribAuthor ">Shaoli  Song</span>, <span class="hlFld-ContribAuthor ">Dejian  Huang</span>, <span class="hlFld-ContribAuthor ">Zhiqi  Yin</span>, <span class="hlFld-ContribAuthor ">Yunliang  Qiu</span>, <span class="hlFld-ContribAuthor ">Qiaomei  Jin</span>. </span><span class="cited-content_cbyCitation_article-title">Preclinical Evaluation of Radioiodinated Hoechst 33258 for Early Prediction of Tumor Response to Treatment of Vascular-Disrupting Agents. </span><span class="cited-content_cbyCitation_journal-name">Contrast Media & Molecular Imaging</span><span> <strong>2018,</strong> <em>2018 </em>, 1-9. <a href="https://doi.org/10.1155/2018/5237950" title="DOI URL">https://doi.org/10.1155/2018/5237950</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1155/2018/5237950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1155%2F2018%2F5237950%26sid%3Dliteratum%253Aachs%26jtitle%3DContrast%2520Media%2520%2526%2520Molecular%2520Imaging%26atitle%3DPreclinical%252BEvaluation%252Bof%252BRadioiodinated%252BHoechst%252B33258%252Bfor%252BEarly%252BPrediction%252Bof%252BTumor%252BResponse%252Bto%252BTreatment%252Bof%252BVascular-Disrupting%252BAgents%26aulast%3DZhang%26aufirst%3DDongjian%26date%3D2018%26volume%3D2018%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mao  Zhang</span>, <span class="hlFld-ContribAuthor ">Yu-Ru  Liang</span>, <span class="hlFld-ContribAuthor ">Huan  Li</span>, <span class="hlFld-ContribAuthor ">Ming-Ming  Liu</span>, <span class="hlFld-ContribAuthor ">Yang  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of hydantoin bridged analogues of combretastatin A-4 as potential anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2017,</strong> <em>25 </em>
                                    (24)
                                     , 6623-6634. <a href="https://doi.org/10.1016/j.bmc.2017.10.045" title="DOI URL">https://doi.org/10.1016/j.bmc.2017.10.045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2017.10.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2017.10.045%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Bhydantoin%252Bbridged%252Banalogues%252Bof%252Bcombretastatin%252BA-4%252Bas%252Bpotential%252Banticancer%252Bagents%26aulast%3DZhang%26aufirst%3DMao%26date%3D2017%26volume%3D25%26issue%3D24%26spage%3D6623%26epage%3D6634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Roberto  Ronca</span>, <span class="hlFld-ContribAuthor ">Mohammed  Benkheil</span>, <span class="hlFld-ContribAuthor ">Stefania  Mitola</span>, <span class="hlFld-ContribAuthor ">Sofie  Struyf</span>, <span class="hlFld-ContribAuthor ">Sandra  Liekens</span>. </span><span class="cited-content_cbyCitation_article-title">Tumor angiogenesis revisited: Regulators and clinical implications. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2017,</strong> <em>37 </em>
                                    (6)
                                     , 1231-1274. <a href="https://doi.org/10.1002/med.21452" title="DOI URL">https://doi.org/10.1002/med.21452</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21452%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DTumor%252Bangiogenesis%252Brevisited%25253A%252BRegulators%252Band%252Bclinical%252Bimplications%26aulast%3DRonca%26aufirst%3DRoberto%26date%3D2017%26date%3D2017%26volume%3D37%26issue%3D6%26spage%3D1231%26epage%3D1274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenlong  Li</span>, <span class="hlFld-ContribAuthor ">Honghao  Sun</span>, <span class="hlFld-ContribAuthor ">Shengtao  Xu</span>, <span class="hlFld-ContribAuthor ">Zheying  Zhu</span>, <span class="hlFld-ContribAuthor ">Jinyi  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Tubulin inhibitors targeting the colchicine binding site: a perspective of privileged structures. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2017,</strong> <em>9 </em>
                                    (15)
                                     , 1765-1794. <a href="https://doi.org/10.4155/fmc-2017-0100" title="DOI URL">https://doi.org/10.4155/fmc-2017-0100</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2017-0100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2017-0100%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DTubulin%252Binhibitors%252Btargeting%252Bthe%252Bcolchicine%252Bbinding%252Bsite%25253A%252Ba%252Bperspective%252Bof%252Bprivileged%252Bstructures%26aulast%3DLi%26aufirst%3DWenlong%26date%3D2017%26volume%3D9%26issue%3D15%26spage%3D1765%26epage%3D1794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mukund P.  Tantak</span>, <span class="hlFld-ContribAuthor ">Linus  Klingler</span>, <span class="hlFld-ContribAuthor ">V.  Arun</span>, <span class="hlFld-ContribAuthor ">Anil  Kumar</span>, <span class="hlFld-ContribAuthor ">Rachna  Sadana</span>, <span class="hlFld-ContribAuthor ">Dalip  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of bis(indolyl)ketohydrazide-hydrazones: Identification of potent and selective novel tubulin inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>136 </em>, 184-194. <a href="https://doi.org/10.1016/j.ejmech.2017.04.078" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.04.078</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.04.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.04.078%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bbis%252528indolyl%252529ketohydrazide-hydrazones%25253A%252BIdentification%252Bof%252Bpotent%252Band%252Bselective%252Bnovel%252Btubulin%252Binhibitors%26aulast%3DTantak%26aufirst%3DMukund%2BP.%26date%3D2017%26volume%3D136%26spage%3D184%26epage%3D194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Koen Van  Gansbeke</span>, <span class="hlFld-ContribAuthor ">Eirik Johansson  Solum</span>, <span class="hlFld-ContribAuthor ">Sandra  Liekens</span>, <span class="hlFld-ContribAuthor ">Anders  Vik</span>, <span class="hlFld-ContribAuthor ">Trond Vidar  Hansen</span>. </span><span class="cited-content_cbyCitation_article-title">Regioselective monoalkylation of 17β-estradiol for the synthesis of cytotoxic estrogens. </span><span class="cited-content_cbyCitation_journal-name">Steroids</span><span> <strong>2017,</strong> <em>124 </em>, 54-59. <a href="https://doi.org/10.1016/j.steroids.2017.06.001" title="DOI URL">https://doi.org/10.1016/j.steroids.2017.06.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.steroids.2017.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.steroids.2017.06.001%26sid%3Dliteratum%253Aachs%26jtitle%3DSteroids%26atitle%3DRegioselective%252Bmonoalkylation%252Bof%252B17%2525CE%2525B2-estradiol%252Bfor%252Bthe%252Bsynthesis%252Bof%252Bcytotoxic%252Bestrogens%26aulast%3DGansbeke%26aufirst%3DKoen%2BVan%26date%3D2017%26volume%3D124%26spage%3D54%26epage%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Azizah M.  Malebari</span>, <span class="hlFld-ContribAuthor ">Lisa M.  Greene</span>, <span class="hlFld-ContribAuthor ">Seema M.  Nathwani</span>, <span class="hlFld-ContribAuthor ">Darren  Fayne</span>, <span class="hlFld-ContribAuthor ">Niamh M.  O'Boyle</span>, <span class="hlFld-ContribAuthor ">Shu  Wang</span>, <span class="hlFld-ContribAuthor ">Brendan  Twamley</span>, <span class="hlFld-ContribAuthor ">Daniela M.  Zisterer</span>, <span class="hlFld-ContribAuthor ">Mary J.  Meegan</span>. </span><span class="cited-content_cbyCitation_article-title">β-Lactam analogues of combretastatin A-4 prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cells. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>130 </em>, 261-285. <a href="https://doi.org/10.1016/j.ejmech.2017.02.049" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.02.049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.02.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.02.049%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D%2525CE%2525B2-Lactam%252Banalogues%252Bof%252Bcombretastatin%252BA-4%252Bprevent%252Bmetabolic%252Binactivation%252Bby%252Bglucuronidation%252Bin%252Bchemoresistant%252BHT-29%252Bcolon%252Bcancer%252Bcells%26aulast%3DMalebari%26aufirst%3DAzizah%2BM.%26date%3D2017%26volume%3D130%26spage%3D261%26epage%3D285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bin  Sun</span>, <span class="hlFld-ContribAuthor ">Lin  Li</span>, <span class="hlFld-ContribAuthor ">Qing-wen  Hu</span>, <span class="hlFld-ContribAuthor ">Hong-bo  Zheng</span>, <span class="hlFld-ContribAuthor ">Hui  Tang</span>, <span class="hlFld-ContribAuthor ">Huan-min  Niu</span>, <span class="hlFld-ContribAuthor ">Hui-qing  Yuan</span>, <span class="hlFld-ContribAuthor ">Hong-xiang  Lou</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, biological evaluation and molecular modeling study of novel macrocyclic bisbibenzyl analogues as antitubulin agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>129 </em>, 186-208. <a href="https://doi.org/10.1016/j.ejmech.2017.02.021" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.02.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.02.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.02.021%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Bbiological%252Bevaluation%252Band%252Bmolecular%252Bmodeling%252Bstudy%252Bof%252Bnovel%252Bmacrocyclic%252Bbisbibenzyl%252Banalogues%252Bas%252Bantitubulin%252Bagents%26aulast%3DSun%26aufirst%3DBin%26date%3D2017%26volume%3D129%26spage%3D186%26epage%3D208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Blake A.  Winn</span>, <span class="hlFld-ContribAuthor ">Zhe  Shi</span>, <span class="hlFld-ContribAuthor ">Graham J.  Carlson</span>, <span class="hlFld-ContribAuthor ">Yifan  Wang</span>, <span class="hlFld-ContribAuthor ">Benson L.  Nguyen</span>, <span class="hlFld-ContribAuthor ">Evan M.  Kelly</span>, <span class="hlFld-ContribAuthor ">R. David  Ross</span>, <span class="hlFld-ContribAuthor ">Ernest  Hamel</span>, <span class="hlFld-ContribAuthor ">David J.  Chaplin</span>, <span class="hlFld-ContribAuthor ">Mary L.  Trawick</span>, <span class="hlFld-ContribAuthor ">Kevin G.  Pinney</span>. </span><span class="cited-content_cbyCitation_article-title">Bioreductively activatable prodrug conjugates of phenstatin designed to target tumor hypoxia. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (3)
                                     , 636-641. <a href="https://doi.org/10.1016/j.bmcl.2016.11.093" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.11.093</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.11.093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.11.093%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DBioreductively%252Bactivatable%252Bprodrug%252Bconjugates%252Bof%252Bphenstatin%252Bdesigned%252Bto%252Btarget%252Btumor%252Bhypoxia%26aulast%3DWinn%26aufirst%3DBlake%2BA.%26date%3D2017%26volume%3D27%26issue%3D3%26spage%3D636%26epage%3D641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zaki S.  Seddigi</span>, <span class="hlFld-ContribAuthor ">M. Shaheer  Malik</span>, <span class="hlFld-ContribAuthor ">A Prasanth  Saraswati</span>, <span class="hlFld-ContribAuthor ">Saleh A.  Ahmed</span>, <span class="hlFld-ContribAuthor ">Ahmed O.  Babalghith</span>, <span class="hlFld-ContribAuthor ">Hawazen A.  Lamfon</span>, <span class="hlFld-ContribAuthor ">Ahmed  Kamal</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in combretastatin based derivatives and prodrugs as antimitotic agents. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2017,</strong> <em>8 </em>
                                    (8)
                                     , 1592-1603. <a href="https://doi.org/10.1039/C7MD00227K" title="DOI URL">https://doi.org/10.1039/C7MD00227K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7MD00227K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7MD00227K%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DRecent%252Badvances%252Bin%252Bcombretastatin%252Bbased%252Bderivatives%252Band%252Bprodrugs%252Bas%252Bantimitotic%252Bagents%26aulast%3DSeddigi%26aufirst%3DZaki%2BS.%26date%3D2017%26date%3D2017%26volume%3D8%26issue%3D8%26spage%3D1592%26epage%3D1603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Souvik  Banerjee</span>, <span class="hlFld-ContribAuthor ">Dong-Jin  Hwang</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Duane  Miller</span>. </span><span class="cited-content_cbyCitation_article-title">Current Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/Angiogenesis. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2016,</strong> <em>21 </em>
                                    (11)
                                     , 1468. <a href="https://doi.org/10.3390/molecules21111468" title="DOI URL">https://doi.org/10.3390/molecules21111468</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules21111468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules21111468%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DCurrent%252BAdvances%252Bof%252BTubulin%252BInhibitors%252Bin%252BNanoparticle%252BDrug%252BDelivery%252Band%252BVascular%252BDisruption%25252FAngiogenesis%26aulast%3DBanerjee%26aufirst%3DSouvik%26date%3D2016%26date%3D2016%26volume%3D21%26issue%3D11%26spage%3D1468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic representation of the effects of VDA treatment on tumor vascularization. (a) In the normal vasculature, blood vessels are organized hierarchically and the basement membrane and pericytes provide structure and stability to the vessels. (b) Intratumoral vessels are chaotic and often lack pericytes and a proper basement membrane. Reduced blood flow renders the tumor center hypoxic, and tumor cells can invade the unstable and leaky vessels. VDA treatment results in disruption of the cytoskeleton and reduced cell–cell junctions, further increasing vascular leakage. This triggers a cascade of events, resulting in a reduction of blood flow, vessel occlusion, and necrosis in the tumor center. In the periphery, there is a rim of surviving tumor cells that receive nutritional support from nearby blood vessels, which are less responsive to VDAs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) Classification of VDAs. (b) Incorporation of αβ-tubulin dimers into protofilaments, sheet assembly, and microtubule formation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Examples of natural products binding tubulin at the colchicine site (<b>5</b>, <b>6</b>) and a colchicine derivative tested in clinical trials (<b>7</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Relevant combretastatins and their prodrugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. <i>Cis</i>–<i>trans</i> isomerization of CA-4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. <i>Cis</i>-restricted bridged compounds mimicking CA-4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. 1,1-Diaryl ketone derivatives mimicking CA-4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Other modifications at B-ring on 1,1-diarylketone derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Chalcone derivatives with a combrestastatin-like behavior.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Colchicine-site binders structurally different from CA-4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Structure of αβ-tubulin in complex with taxol (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1JFF">1JFF</a>). Color code for the domain in each monomer: N-terminal in magenta, intermediate domain in orange, and C-terminal domain in green. Taxol (cyan), GDP, and GTP (green) are shown in sticks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Overall structure of the DAMA–colchicine–tubulin complex and detailed insight into the binding mode of DAMA–colchicine. The α subunit is represented in light pink and the β subunit in light cyan. Colchicine is represented in green in sticks, and relevant amino acids at the colchicine site are also represented in sticks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Chemical structures of colchicine site ligands cocrystallized with αβ-tubulin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. (a) Crystal structure of the complex of tubulin with the pyrrolidinedione <b>53</b>. The α subunit of tubulin is represented in light pink and the β subunit in light cyan. (b) View of the binding mode of <b>53</b> represented in sticks (cyan) after a 180° rotation. For comparison, DAMA–colchicine is shown in green sticks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Conformation change of the T7-loop upon colchicine binding. α-Tubulin in the unbounded state is represented in magenta and β-tubulin is represented in blue; the α-tubulin in the colchicine complex is represented in light pink, while β-tubulin is represented in pale cyan.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. (a) The colchicine-binding domain. The α subunit of tubulin is represented in light pink and the β subunit in light cyan. Residues from zone 1 (yellow), zone 2 (green), and zone 3 (violet) are shown in sticks. (b) Superposition of the ligands mimicking the colchicine-binding mode: <b>6</b> (brown), <b>38</b> (light orange), <b>41</b> (white), <b>52</b> (blue), <b>54</b> (light-pink and cyan), <b>57</b> (green), <b>59</b> (pink), and <b>60</b> (yellow). (c) Superposition of ligands mimicking the pyrrolidinedione-binding mode: <b>40</b> (orange), <b>48</b> (marine blue), <b>53</b> (pink), <b>55</b> (light pink), <b>56</b> (light yellow), and <b>58</b> (cyan). For chemical structures of the ligands, see <a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/medium/jm-2016-00463p_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. (a) Superposition of the N-terminal domain of β-subunits of the straight (slate blue) and curved (light cyan) conformations of tubulin. The α-subunit of the straight state is shown in gray, and colchicine is shown in sticks (green). In the straight tubulin (slate blue), the T7-loop occludes the colchicine site when compared to the curved tubulin (light cyan). (b) Curved-to-straight conformational transition of αβ-tubulin upon GTP binding required for microtubule growth. Binding of colchicine (represented by a yellow pentagon) into the αβ-tubulin dimer prevents the conformational transition and suppresses microtubule dynamics.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00463/20161007/images/large/jm-2016-00463p_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00463&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i42">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65187" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65187" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 204 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Siemann, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bibby, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dark, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dicker, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eskens, F. A. L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horsman, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marmé, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P. M.</span><span> </span><span class="NLM_article-title">Differentiation and definition of vascular-targeted therapies</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">416</span><span class="NLM_x">–</span> <span class="NLM_lpage">420</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=15701823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD2MXislWgtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=416-420&author=D.+W.+Siemannauthor=M.+C.+Bibbyauthor=G.+G.+Darkauthor=A.+P.+Dickerauthor=F.+A.+L.+M.+Eskensauthor=M.+R.+Horsmanauthor=D.+Marm%C3%A9author=P.+M.+LoRusso&title=Differentiation+and+definition+of+vascular-targeted+therapies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Differentiation and Definition of Vascular-Targeted Therapies</span></div><div class="casAuthors">Siemann, Dietmar W.; Bibby, Michael C.; Dark, Graham G.; Dicker, Adam P.; Eskens, Ferry A. L. M.; Horsman, Michael R.; Marme, Dieter; LoRusso, Patricia M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2, Pt. 1</span>),
    <span class="NLM_cas:pages">416-420</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The therapeutic potential of targeting the tumor vascular supply is now widely recognized.  Intense research and development activity has resulted in a variety of investigational agents, a no. of which are currently in clin. development.  As these novel agents are quite distinct from the cytotoxic drugs conventionally used in the treatment of solid tumors, it will be particularly important to ensure early differentiation of these vascular-targeted therapies in order to encourage widespread understanding of their potential benefits and application in the clinic.  Two distinct groups of vascular-targeted therapies have evolved: antiangiogenic agents and vascular-disrupting approaches.  These differ in three key respects: their physiol. target, the type or extent of disease that is likely to be susceptible, and the treatment scheduling.  Inhibitors of angiogenesis interfere with new vessel formation and therefore have a preventative action, require chronic administration, and are likely to be of particular benefit in early-stage or asymptomatic metastatic disease.  Vascular-disrupting agents target the established tumor blood vessels, resulting in tumor ischemia and necrosis.  These agents are therefore given acutely, show more immediate effects, and may have particular efficacy against advanced disease.  It is essential that these agents can be readily distinguished from conventional therapies and that an understanding of key differences between the two types of vascular-targeted therapies is fostered.  Here, a simple taxonomy and nomenclature is proposed in anticipation that the therapeutic potential of this novel class can be realized as these approaches advance in clin. settings and a new anticancer strategy becomes available in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIEL4anGTuWbVg90H21EOLACvtfcHk0ljOsgXhkvJcQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXislWgtro%253D&md5=8a037771f2908fb5729425f7bdc9ae10</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSiemann%26aufirst%3DD.%2BW.%26aulast%3DBibby%26aufirst%3DM.%2BC.%26aulast%3DDark%26aufirst%3DG.%2BG.%26aulast%3DDicker%26aufirst%3DA.%2BP.%26aulast%3DEskens%26aufirst%3DF.%2BA.%2BL.%2BM.%26aulast%3DHorsman%26aufirst%3DM.%2BR.%26aulast%3DMarm%25C3%25A9%26aufirst%3DD.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26atitle%3DDifferentiation%2520and%2520definition%2520of%2520vascular-targeted%2520therapies%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D416%26epage%3D420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Tozer, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanthou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baguley, B. C.</span><span> </span><span class="NLM_article-title">Disrupting tumour blood vessels</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">423</span><span class="NLM_x">–</span> <span class="NLM_lpage">435</span><span class="refDoi"> DOI: 10.1038/nrc1628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1038%2Fnrc1628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=15928673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Gmsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=423-435&author=G.+M.+Tozerauthor=C.+Kanthouauthor=B.+C.+Baguley&title=Disrupting+tumour+blood+vessels&doi=10.1038%2Fnrc1628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Disrupting tumor blood vessels</span></div><div class="casAuthors">Tozer, Gillian M.; Kanthou, Chryso; Baguley, Bruce C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">423-435</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Low-mol.-wt. vascular-disrupting agents (VDAs) cause a pronounced shutdown in blood flow to solid tumors, resulting in extensive tumor-cell necrosis, while they leave the blood flow in normal tissues relatively intact.  The largest group of VDAs is the tubulin-binding combretastatins, several of which are now being tested in clin. trials.  DMXAA (5,6-dimethylxanthenone-4-acetic acid) - one of a structurally distinct group of drugs - is also being tested in clin. trials.  A full understanding of the action of these and other VDAs will provide insights into mechanisms that control tumor blood flow and will be the basis for the development of new therapeutic drugs for targeting the established tumor vasculature for therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjdnxmo6H1JrVg90H21EOLACvtfcHk0lgDoPrrsQrTpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Gmsr0%253D&md5=869e9f19ba4b9b82b166b39f089e003b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc1628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1628%26sid%3Dliteratum%253Aachs%26aulast%3DTozer%26aufirst%3DG.%2BM.%26aulast%3DKanthou%26aufirst%3DC.%26aulast%3DBaguley%26aufirst%3DB.%2BC.%26atitle%3DDisrupting%2520tumour%2520blood%2520vessels%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D423%26epage%3D435%26doi%3D10.1038%2Fnrc1628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Kanthou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozer, G. M.</span><span> </span><span class="NLM_article-title">Selective destruction of the tumour vasculature by targeting the endothelial cytoskeleton</span> <span class="citation_source-journal">Drug Discovery Today: Ther. Strategies</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">237</span><span class="NLM_x">–</span> <span class="NLM_lpage">243</span><span class="refDoi"> DOI: 10.1016/j.ddstr.2008.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.ddstr.2008.03.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=237-243&author=C.+Kanthouauthor=G.+M.+Tozer&title=Selective+destruction+of+the+tumour+vasculature+by+targeting+the+endothelial+cytoskeleton&doi=10.1016%2Fj.ddstr.2008.03.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.ddstr.2008.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddstr.2008.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DKanthou%26aufirst%3DC.%26aulast%3DTozer%26aufirst%3DG.%2BM.%26atitle%3DSelective%2520destruction%2520of%2520the%2520tumour%2520vasculature%2520by%2520targeting%2520the%2520endothelial%2520cytoskeleton%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Ther.%2520Strategies%26date%3D2007%26volume%3D4%26spage%3D237%26epage%3D243%26doi%3D10.1016%2Fj.ddstr.2008.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Potente, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerhardt, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmeliet, P.</span><span> </span><span class="NLM_article-title">Basic and therapeutic aspects of angiogenesis</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">873</span><span class="NLM_x">–</span> <span class="NLM_lpage">887</span><span class="refDoi"> DOI: 10.1016/j.cell.2011.08.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.cell.2011.08.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=21925313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtF2ht7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2011&pages=873-887&author=M.+Potenteauthor=H.+Gerhardtauthor=P.+Carmeliet&title=Basic+and+therapeutic+aspects+of+angiogenesis&doi=10.1016%2Fj.cell.2011.08.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Basic and Therapeutic Aspects of Angiogenesis</span></div><div class="casAuthors">Potente, Michael; Gerhardt, Holger; Carmeliet, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">873-887</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Blood vessels form extensive networks that nurture all tissues in the body.  Abnormal vessel growth and function are hallmarks of cancer and ischemic and inflammatory diseases, and they contribute to disease progression.  Therapeutic approaches to block vascular supply have reached the clinic, but limited efficacy and resistance pose unresolved challenges.  Recent insights establish how endothelial cells communicate with each other and with their environment to form a branched vascular network.  The emerging principles of vascular growth provide exciting new perspectives, the translation of which might overcome the current limitations of pro- and antiangiogenic medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYIoNjjHU-iLVg90H21EOLACvtfcHk0lgDoPrrsQrTpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtF2ht7fL&md5=60cb7dbf953d3c9c1c6fc50584c9e53a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.08.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.08.039%26sid%3Dliteratum%253Aachs%26aulast%3DPotente%26aufirst%3DM.%26aulast%3DGerhardt%26aufirst%3DH.%26aulast%3DCarmeliet%26aufirst%3DP.%26atitle%3DBasic%2520and%2520therapeutic%2520aspects%2520of%2520angiogenesis%26jtitle%3DCell%26date%3D2011%26volume%3D146%26spage%3D873%26epage%3D887%26doi%3D10.1016%2Fj.cell.2011.08.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Carmeliet, P.</span><span> </span><span class="NLM_article-title">Angiogenesis in life, disease and medicine</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">438</span><span class="NLM_x">, </span> <span class="NLM_fpage">932</span><span class="NLM_x">–</span> <span class="NLM_lpage">936</span><span class="refDoi"> DOI: 10.1038/nature04478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1038%2Fnature04478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=16355210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSksrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=438&publication_year=2005&pages=932-936&author=P.+Carmeliet&title=Angiogenesis+in+life%2C+disease+and+medicine&doi=10.1038%2Fnature04478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis in life, disease and medicine</span></div><div class="casAuthors">Carmeliet, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">438</span>
        (<span class="NLM_cas:issue">7070</span>),
    <span class="NLM_cas:pages">932-936</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The growth of blood vessels (a process known as angiogenesis) is essential for organ growth and repair.  An imbalance in this process contributes to numerous malignant, inflammatory, ischemic, infectious and immune disorders.  Recently, the first anti-angiogenic agents have been approved for the treatment of cancer and blindness.  Angiogenesis research will probably change the face of medicine in the next decades, with more than 500 million people worldwide predicted to benefit from pro- or anti-angiogenesis treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor5NqkaUGRfrVg90H21EOLACvtfcHk0lgDoPrrsQrTpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSksrjF&md5=e196d7203fa60d5ecd9182fa023cd30e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnature04478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04478%26sid%3Dliteratum%253Aachs%26aulast%3DCarmeliet%26aufirst%3DP.%26atitle%3DAngiogenesis%2520in%2520life%252C%2520disease%2520and%2520medicine%26jtitle%3DNature%26date%3D2005%26volume%3D438%26spage%3D932%26epage%3D936%26doi%3D10.1038%2Fnature04478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">El-Kenawi, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Remessy, A. B.</span><span> </span><span class="NLM_article-title">Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">170</span><span class="NLM_x">, </span> <span class="NLM_fpage">712</span><span class="NLM_x">–</span> <span class="NLM_lpage">729</span><span class="refDoi"> DOI: 10.1111/bph.12344</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1111%2Fbph.12344" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=23962094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFOgs7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2013&pages=712-729&author=A.+E.+El-Kenawiauthor=A.+B.+El-Remessy&title=Angiogenesis+inhibitors+in+cancer+therapy%3A+mechanistic+perspective+on+classification+and+treatment+rationales&doi=10.1111%2Fbph.12344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales</span></div><div class="casAuthors">El-Kenawi, Asmaa E.; El-Remessy, Azza B.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">712-729</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Angiogenesis, a process of new blood vessel formation, is a prerequisite for tumor growth to supply the proliferating tumor with oxygen and nutrients.  The angiogenic process may contribute to tumor progression, invasion and metastasis, and is generally accepted as an indicator of tumor prognosis.  Therefore, targeting tumor angiogenesis has become of high clin. relevance.  The current review aimed to highlight mechanistic details of anti-angiogenic therapies and how they relate to classification and treatment rationales.  Angiogenesis inhibitors are classified into either direct inhibitors that target endothelial cells in the growing vasculature or indirect inhibitors that prevent the expression or block the activity of angiogenesis inducers.  The latter class extends to include targeted therapy against oncogenes, conventional chemotherapeutic agents and drugs targeting other cells of the tumor micro-environment.  Angiogenesis inhibitors may be used as either monotherapy or in combination with other anticancer drugs.  In this context, many preclin. and clin. studies revealed higher therapeutic effectiveness of the combined treatments compared with individual treatments.  The proper understanding of synergistic treatment modalities of angiogenesis inhibitors as well as their wide range of cellular targets could provide effective tools for future therapies of many types of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou_Tt3ysAIULVg90H21EOLACvtfcHk0lirdrJQ2nG5qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFOgs7fO&md5=660db903fa77cbd241f0f9687fdfde89</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1111%2Fbph.12344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12344%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Kenawi%26aufirst%3DA.%2BE.%26aulast%3DEl-Remessy%26aufirst%3DA.%2BB.%26atitle%3DAngiogenesis%2520inhibitors%2520in%2520cancer%2520therapy%253A%2520mechanistic%2520perspective%2520on%2520classification%2520and%2520treatment%2520rationales%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D170%26spage%3D712%26epage%3D729%26doi%3D10.1111%2Fbph.12344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Vasudev, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, A. R.</span><span> </span><span class="NLM_article-title">Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions</span> <span class="citation_source-journal">Angiogenesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">471</span><span class="NLM_x">–</span> <span class="NLM_lpage">494</span><span class="refDoi"> DOI: 10.1007/s10456-014-9420-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1007%2Fs10456-014-9420-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=24482243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsVGrtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2014&pages=471-494&author=N.+S.+Vasudevauthor=A.+R.+Reynolds&title=Anti-angiogenic+therapy+for+cancer%3A+current+progress%2C+unresolved+questions+and+future+directions&doi=10.1007%2Fs10456-014-9420-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions</span></div><div class="casAuthors">Vasudev, Naveen S.; Reynolds, Andrew R.</div><div class="citationInfo"><span class="NLM_cas:title">Angiogenesis</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">471-494</span>CODEN:
                <span class="NLM_cas:coden">AGIOFT</span>;
        ISSN:<span class="NLM_cas:issn">0969-6970</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Tumors require a vascular supply to grow and can achieve this via the expression of pro-angiogenic growth factors, including members of the vascular endothelial growth factor (VEGF) family of ligands.  Since one or more of the VEGF ligand family is overexpressed in most solid cancers, there was great optimism that inhibition of the VEGF pathway would represent an effective anti-angiogenic therapy for most tumor types.  Encouragingly, VEGF pathway targeted drugs such as bevacizumab, sunitinib and aflibercept have shown activity in certain settings.  However, inhibition of VEGF signalling is not effective in all cancers, prompting the need to further understand how the vasculature can be effectively targeted in tumors.  Here we present a succinct review of the progress with VEGF-targeted therapy and the unresolved questions that exist in the field: including its use in different disease stages (metastatic, adjuvant, neoadjuvant), interactions with chemotherapy, duration and scheduling of therapy, potential predictive biomarkers and proposed mechanisms of resistance, including paradoxical effects such as enhanced tumor aggressiveness.  In terms of future directions, we discuss the need to delineate further the complexities of tumor vascularization if we are to develop more effective and personalized anti-angiogenic therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7sZyCdaihyrVg90H21EOLACvtfcHk0lirdrJQ2nG5qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsVGrtrk%253D&md5=ee472c1380b302319febb605695c8ba9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs10456-014-9420-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10456-014-9420-y%26sid%3Dliteratum%253Aachs%26aulast%3DVasudev%26aufirst%3DN.%2BS.%26aulast%3DReynolds%26aufirst%3DA.%2BR.%26atitle%3DAnti-angiogenic%2520therapy%2520for%2520cancer%253A%2520current%2520progress%252C%2520unresolved%2520questions%2520and%2520future%2520directions%26jtitle%3DAngiogenesis%26date%3D2014%26volume%3D17%26spage%3D471%26epage%3D494%26doi%3D10.1007%2Fs10456-014-9420-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Siemann, D. W.</span><span> </span><span class="NLM_article-title">The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents</span> <span class="citation_source-journal">Cancer Treat. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">63</span><span class="NLM_x">–</span> <span class="NLM_lpage">74</span><span class="refDoi"> DOI: 10.1016/j.ctrv.2010.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.ctrv.2010.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=20570444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFajs7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2011&pages=63-74&author=D.+W.+Siemann&title=The+unique+characteristics+of+tumor+vasculature+and+preclinical+evidence+for+its+selective+disruption+by+tumor-vascular+disrupting+agents&doi=10.1016%2Fj.ctrv.2010.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents</span></div><div class="casAuthors">Siemann, Dietmar W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-74</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The vasculature of solid tumors is fundamentally different from that of normal vasculature and offers a unique target for anti-cancer therapy.  Direct vascular-targeting with Tumor-Vascular Disrupting Agents (Tumor-VDAs) is distinctly different from anti-angiogenic strategies, and offers a complementary approach to std. therapies.  Tumor-VDAs therefore have significant potential when combined with chemotherapy, radiotherapy, and angiogenesis-inhibiting agents.  Preclin. studies with the different Tumor-VDA classes have demonstrated key tumor-selective anti-vascular and anti-tumor effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKL8nIIVWtVbVg90H21EOLACvtfcHk0lirdrJQ2nG5qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFajs7vI&md5=85fe2cb36db459ad473bf53bbcae60af</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2010.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2010.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DSiemann%26aufirst%3DD.%2BW.%26atitle%3DThe%2520unique%2520characteristics%2520of%2520tumor%2520vasculature%2520and%2520preclinical%2520evidence%2520for%2520its%2520selective%2520disruption%2520by%2520tumor-vascular%2520disrupting%2520agents%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2011%26volume%3D37%26spage%3D63%26epage%3D74%26doi%3D10.1016%2Fj.ctrv.2010.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Siemann, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horsman, M. R.</span><span> </span><span class="NLM_article-title">Modulation of the tumor vasculature and oxygenation to improve therapy</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">153</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span><span class="refDoi"> DOI: 10.1016/j.pharmthera.2015.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.pharmthera.2015.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=26073310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWgu7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=2015&pages=107-124&author=D.+W.+Siemannauthor=M.+R.+Horsman&title=Modulation+of+the+tumor+vasculature+and+oxygenation+to+improve+therapy&doi=10.1016%2Fj.pharmthera.2015.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of the tumor vasculature and oxygenation to improve therapy</span></div><div class="casAuthors">Siemann, Dietmar W.; Horsman, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">153</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">107-124</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The tumor microenvironment is increasingly recognized as a major factor influencing the success of therapeutic treatments and has become a key focus for cancer research.  The progressive growth of a tumor results in an inability of normal tissue blood vessels to oxygenate and provide sufficient nutritional support to tumor cells.  As a consequence the expanding neoplastic cell population initiates its own vascular network which is both structurally and functionally abnormal.  This aberrant vasculature impacts all aspects of the tumor microenvironment including the cells, extracellular matrix, and extracellular mols. which together are essential for the initiation, progression and spread of tumor cells.  The phys. conditions that arise are imposing and manifold, and include elevated interstitial pressure, localized extracellular acidity, and regions of oxygen and nutrient deprivation.  No less important are the functional consequences experienced by the tumor cells residing in such environments: adaptation to hypoxia, cell quiescence, modulation of transporters and crit. signaling mols., immune escape, and enhanced metastatic potential.  Together these factors lead to therapeutic barriers that create a significant hindrance to the control of cancers by conventional anticancer therapies.  However, the aberrant nature of the tumor microenvironments also offers unique therapeutic opportunities.  Particularly interventions that seek to improve tumor physiol. and alleviate tumor hypoxia will selectively impair the neoplastic cell populations residing in these environments.  Ultimately, by combining such therapeutic strategies with conventional anticancer treatments it may be possible to bring cancer growth, invasion, and metastasis to a halt.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7Wh0bMP_sC7Vg90H21EOLACvtfcHk0ljH7IghsBDexQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWgu7jO&md5=7237bedb6225d6e3cab430b62cdc9121</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2015.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2015.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DSiemann%26aufirst%3DD.%2BW.%26aulast%3DHorsman%26aufirst%3DM.%2BR.%26atitle%3DModulation%2520of%2520the%2520tumor%2520vasculature%2520and%2520oxygenation%2520to%2520improve%2520therapy%26jtitle%3DPharmacol.%2520Ther.%26date%3D2015%26volume%3D153%26spage%3D107%26epage%3D124%26doi%3D10.1016%2Fj.pharmthera.2015.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Kanthou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozer, G. M.</span><span> </span><span class="NLM_article-title">Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies</span> <span class="citation_source-journal">Int. J. Exp. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">284</span><span class="NLM_x">–</span> <span class="NLM_lpage">294</span><span class="refDoi"> DOI: 10.1111/j.1365-2613.2009.00651.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1111%2Fj.1365-2613.2009.00651.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=19563611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotV2isr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2009&pages=284-294&author=C.+Kanthouauthor=G.+M.+Tozer&title=Microtubule+depolymerizing+vascular+disrupting+agents%3A+novel+therapeutic+agents+for+oncology+and+other+pathologies&doi=10.1111%2Fj.1365-2613.2009.00651.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies</span></div><div class="casAuthors">Kanthou, Chryso; Tozer, Gillian M.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Experimental Pathology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">284-294</span>CODEN:
                <span class="NLM_cas:coden">IJEPEI</span>;
        ISSN:<span class="NLM_cas:issn">0959-9673</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Vascular disrupting agents (VDAs) are a relatively new group of "vascular targeting" agents that exhibit selective activity against established tumor vascular networks, causing severe interruption of tumor blood flow and necrosis to the tumor mass.  Microtubule depolymg. agents form by far the largest group of small mol. wt. VDAs many of which, including lead compd. disodium combretastatin A-4 3-O-phosphate (CA-4-P), are under clin. development for cancer.  Although distinct from the angiogenesis inhibitors, VDAs can also interfere with angiogenesis and therefore constitute a potential group of novel drugs for the treatment of pathol. conditions characterized by excessive angiogenesis, in addn. to cancer.  The endothelial cytoskeleton is the primary cellular target of this family of drugs, and some progress in understanding the mol. and signalling mechanisms assocd. with their endothelial disrupting activity has been made in the last few years.  Susceptibility of tumor vessels to VDA damage is ascribed to their immature pericyte-defective nature, although the exact mol. mechanisms involved have not been clearly defined.  Despite causing profound damage to tumors, VDAs fail to halt tumor growth unless used together with conventional treatments.  This failure is attributed to resistance mechanisms, primarily assocd. with cells that remain viable within the tumor rim, and enhanced angiogenesis.  The focus is now to understand mechanisms of susceptibility and resistance to identify novel mol. targets and develop strategies that are more effective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmpN7il32X0rVg90H21EOLACvtfcHk0ljH7IghsBDexQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotV2isr4%253D&md5=42b728813bf9c53bbc6d32d262639d15</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2613.2009.00651.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2613.2009.00651.x%26sid%3Dliteratum%253Aachs%26aulast%3DKanthou%26aufirst%3DC.%26aulast%3DTozer%26aufirst%3DG.%2BM.%26atitle%3DMicrotubule%2520depolymerizing%2520vascular%2520disrupting%2520agents%253A%2520novel%2520therapeutic%2520agents%2520for%2520oncology%2520and%2520other%2520pathologies%26jtitle%3DInt.%2520J.%2520Exp.%2520Pathol.%26date%3D2009%26volume%3D90%26spage%3D284%26epage%3D294%26doi%3D10.1111%2Fj.1365-2613.2009.00651.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Thorpe, P. E.</span><span> </span><span class="NLM_article-title">Vascular targeting agents as cancer therapeutics</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">415</span><span class="NLM_x">–</span> <span class="NLM_lpage">427</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-0642-03</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1158%2F1078-0432.CCR-0642-03" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=14760060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A280%3ADC%252BD2c%252FntFWntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=415-427&author=P.+E.+Thorpe&title=Vascular+targeting+agents+as+cancer+therapeutics&doi=10.1158%2F1078-0432.CCR-0642-03"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular targeting agents as cancer therapeutics</span></div><div class="casAuthors">Thorpe Philip E</div><div class="citationInfo"><span class="NLM_cas:title">Clinical cancer research : an official journal of the American Association for Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">415-27</span>
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    </div><div class="casAbstract">Vascular targeting agents (VTAs) for the treatment of cancer are designed to cause a rapid and selective shutdown of the blood vessels of tumors.  Unlike antiangiogenic drugs that inhibit the formation of new vessels, VTAs occlude the pre-existing blood vessels of tumors to cause tumor cell death from ischemia and extensive hemorrhagic necrosis.  Tumor selectivity is conferred by differences in the pathophysiology of tumor versus normal tissue vessels (e.g., increased proliferation and fragility, and up-regulated proteins).  VTAs can kill indirectly the tumor cells that are resistant to conventional antiproliferative cancer therapies, i.e., cells in areas distant from blood vessels where drug penetration is poor, and hypoxia can lead to radiation and drug resistance.  VTAs are expected to show the greatest therapeutic benefit as part of combined modality regimens.  Preclinical studies have shown VTA-induced enhancement of the effects of conventional chemotherapeutic agents, radiation, hyperthermia, radioimmunotherapy, and antiangiogenic agents.  There are broadly two types of VTAs, small molecules and ligand-based, which are grouped together, because they both cause acute vascular shutdown in tumors leading to massive necrosis.  The small molecules include the microtubulin destabilizing drugs, combretastatin A-4 disodium phosphate, ZD6126, AVE8062, and Oxi 4503, and the flavonoid, DMXAA.  Ligand-based VTAs use antibodies, peptides, or growth factors that bind selectively to tumor versus normal vessels to target tumors with agents that occlude blood vessels.  The ligand-based VTAs include fusion proteins (e.g., vascular endothelial growth factor linked to the plant toxin gelonin), immunotoxins (e.g., monoclonal antibodies to endoglin conjugated to ricin A), antibodies linked to cytokines, liposomally encapsulated drugs, and gene therapy approaches.  Combretastatin A-4 disodium phosphate, ZD6126, AVE8062, and DMXAA are undergoing clinical evaluation.  Phase I monotherapy studies have shown that the agents are tolerated with some demonstration of single agent efficacy.  Because efficacy is expected when the agents are used with conventional chemotherapeutic drugs or radiation, the results of Phase II combination studies are eagerly awaited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRGxP3zCqIkxEewzGPswiWOfW6udTcc2eavw56xoYtmP7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c%252FntFWntg%253D%253D&md5=7fa217c143bb3950071a3c7de76ceafd</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-0642-03&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-0642-03%26sid%3Dliteratum%253Aachs%26aulast%3DThorpe%26aufirst%3DP.%2BE.%26atitle%3DVascular%2520targeting%2520agents%2520as%2520cancer%2520therapeutics%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D415%26epage%3D427%26doi%3D10.1158%2F1078-0432.CCR-0642-03" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Gaya, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G. J. S.</span><span> </span><span class="NLM_article-title">Vascular disrupting agents: a new class of drug in cancer therapy</span> <span class="citation_source-journal">Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">277</span><span class="NLM_x">–</span> <span class="NLM_lpage">290</span><span class="refDoi"> DOI: 10.1016/j.clon.2004.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.clon.2004.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=15997924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A280%3ADC%252BD2Mzks1Wmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2005&pages=277-290&author=A.+M.+Gayaauthor=G.+J.+S.+Rustin&title=Vascular+disrupting+agents%3A+a+new+class+of+drug+in+cancer+therapy&doi=10.1016%2Fj.clon.2004.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular disrupting agents: a new class of drug in cancer therapy</span></div><div class="casAuthors">Gaya A M; Rustin G J S</div><div class="citationInfo"><span class="NLM_cas:title">Clinical oncology (Royal College of Radiologists (Great Britain))</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">277-90</span>
        ISSN:<span class="NLM_cas:issn">0936-6555</span>.
    </div><div class="casAbstract">AIMS:  To provide a comprehensive overview of the current state of development of a novel class of anti-cancer drugs, the vascular disrupting agents (VDAs), previously known as vascular targeting agents (VTAs).  MATERIALS AND METHODS:  A comprehensive review, analysis and commentary of the published medical literature on VDAs was performed.  RESULTS:  Tumour vascular targeting therapy exploits known differences between normal and tumour blood vessels.  VDAs target the preexisting vessels of tumours (cf anti-angiogenics), and cause vascular shutdown leading to tumour cell death and rapid haemorrhagic necrosis within hours.  It is becoming clear that VDAs have overlapping activity with anti-angiogenic drugs, which prevent the formation of new blood vessels.  There are two types of VDA.  First, biological or ligand-directed VDAs use antibodies, peptides or growth factors to target toxins or pro-coagulants to the tumour endothelium.  In contrast, small molecule VDAs work either as tubulin-binding agents or through induction of local cytokine production.  VDAs can kill tumour cells resistant to conventional chemotherapy and radiotherapy, and work best on cells in the poorly perfused hypoxic core of tumours, leaving a viable rim of well-perfused tumour tissue at the periphery, which rapidly regrows.  Consequently, responses of tumours to VDAs given as single agents have been poor; however, combination therapy with cytotoxic chemotherapy, external-beam radiotherapy, and radioimmunotherapy, which target the peripheral tumour cells, has produced some excellent responses in animal tumours.  VDAs are generally well tolerated with different side-effect profiles to current oncological therapies.  Dynamic magnetic resonance imaging is most frequently used to obtain a pharmacodynamic end point to determine whether the VDA is acting on its intended target.  CONCLUSIONS:  VDAs are a promising new class of drug, which offer the attractive possibility of inducing responses in all tumour types with combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTnWiE5fGCD_Jw7prLlxLOzfW6udTcc2eY0OmUPyYqeULntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mzks1Wmuw%253D%253D&md5=c4caf3ef1f6bd785bf1e74cbf0f05080</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.clon.2004.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clon.2004.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DGaya%26aufirst%3DA.%2BM.%26aulast%3DRustin%26aufirst%3DG.%2BJ.%2BS.%26atitle%3DVascular%2520disrupting%2520agents%253A%2520a%2520new%2520class%2520of%2520drug%2520in%2520cancer%2520therapy%26jtitle%3DClin.%2520Oncol.%26date%3D2005%26volume%3D17%26spage%3D277%26epage%3D290%26doi%3D10.1016%2Fj.clon.2004.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Lara, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douillard, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Pawel, J. v.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeage, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albert, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Losonczy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reck, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heo, D.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scagliotti, G.</span><span> </span><span class="NLM_article-title">Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">2965</span><span class="NLM_x">–</span> <span class="NLM_lpage">2971</span><span class="refDoi"> DOI: 10.1200/JCO.2011.35.0660</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1200%2FJCO.2011.35.0660" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=21709202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCqtLbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=2965-2971&author=P.+N.+Laraauthor=J.+Y.+Douillardauthor=K.+Nakagawaauthor=J.+v.+von+Pawelauthor=M.+J.+McKeageauthor=I.+Albertauthor=G.+Losonczyauthor=M.+Reckauthor=D.-S.+Heoauthor=X.+Fanauthor=A.+Fandiauthor=G.+Scagliotti&title=Randomized+phase+III+placebo-controlled+trial+of+carboplatin+and+paclitaxel+with+or+without+the+vascular+disrupting+agent+vadimezan+%28ASA404%29+in+advanced+non-small-cell+lung+cancer&doi=10.1200%2FJCO.2011.35.0660"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer</span></div><div class="casAuthors">Lara, Primo N., Jr.; Douillard, Jean-Yves; Nakagawa, Kazuhiko; von Pawel, Joachim; McKeage, Mark J.; Albert, Istvan; Losonczy, Gyorgy; Reck, Martin; Heo, Dae-Seog; Fan, Xiaolin; Fandi, Abderrahim; Scagliotti, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2965-2971</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: This phase III trial was conducted to test whether the novel vascular disrupting agent ASA404 (vadimezan), when combined with first-line platinum-based chemotherapy, improves survival in patients with advanced non-small-cell lung cancer (NSCLC) vs. chemotherapy alone.  Patients and Methods: Patients with advanced stage IIIB or IV NSCLC, stratified by sex and tumor histol., were randomly assigned 1:1 to paclitaxel (200 mg/m2) and carboplatin (area under the curve, 6.0) with or without ASA404 (1,800 mg m2), given i.v. once every 3 wk for six cycles followed by maintenance ASA404 or placebo.  Primary end point was overall survival (OS); secondary end points included overall response rate (ORR) and progression-free survival (PFS).  Results: One thousand two hundred ninety-nine patients were randomly assigned.  The trial was stopped for futility at interim anal.  At final anal., there was no difference in OS seen between ASA404 (n = 649) and placebo (n = 650) arms: median OS was 13.4 and 12.7 mo resp. (hazard ratio [HR], 1.01; 95% CI, 0.85 to 1.19; P = .535).  Similarly, no OS difference was seen in the histol. (squamous or nonsquamous) and sex (male or female) strata.  Median PFS was 5.5 mo in both arms (HR, 1.04; P = .727), while ORR was 25% in both arms (P = 1.0).  Overall rate of adverse events (AEs) was comparable between the ASA404 and placebo arms.  Grade 4 neutropenia (27% v 19%) and infusion site pain (10% v 0.5%) were reported more frequently in the ASA404 arm.  Conclusion: The addn. of ASA404 to carboplatin and paclitaxel, although generally well tolerated, failed to improve frontline efficacy in advanced NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiAainXGdqJbVg90H21EOLACvtfcHk0lgK5WUMoFH7Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCqtLbO&md5=c9a9400016724941dad3b9104f9d546f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.35.0660&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.35.0660%26sid%3Dliteratum%253Aachs%26aulast%3DLara%26aufirst%3DP.%2BN.%26aulast%3DDouillard%26aufirst%3DJ.%2BY.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3Dvon%2BPawel%26aufirst%3DJ.%2Bv.%26aulast%3DMcKeage%26aufirst%3DM.%2BJ.%26aulast%3DAlbert%26aufirst%3DI.%26aulast%3DLosonczy%26aufirst%3DG.%26aulast%3DReck%26aufirst%3DM.%26aulast%3DHeo%26aufirst%3DD.-S.%26aulast%3DFan%26aufirst%3DX.%26aulast%3DFandi%26aufirst%3DA.%26aulast%3DScagliotti%26aufirst%3DG.%26atitle%3DRandomized%2520phase%2520III%2520placebo-controlled%2520trial%2520of%2520carboplatin%2520and%2520paclitaxel%2520with%2520or%2520without%2520the%2520vascular%2520disrupting%2520agent%2520vadimezan%2520%2528ASA404%2529%2520in%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D2965%26epage%3D2971%26doi%3D10.1200%2FJCO.2011.35.0660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">LoRusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boerner, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunsberger, S.</span><span> </span><span class="NLM_article-title">Clinical development of vascular disrupting agents: what lessons can we learn from ASA404?</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">2952</span><span class="NLM_x">–</span> <span class="NLM_lpage">2955</span><span class="refDoi"> DOI: 10.1200/JCO.2011.36.1311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1200%2FJCO.2011.36.1311" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=21709201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A280%3ADC%252BC3MjhvF2jtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=2952-2955&author=P.+M.+LoRussoauthor=S.+A.+Boernerauthor=S.+Hunsberger&title=Clinical+development+of+vascular+disrupting+agents%3A+what+lessons+can+we+learn+from+ASA404%3F&doi=10.1200%2FJCO.2011.36.1311"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical development of vascular disrupting agents: what lessons can we learn from ASA404?</span></div><div class="casAuthors">Lorusso Patricia M; Boerner Scott A; Hunsberger Sally</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2952-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcScRNi03td6tynGiHuhFGv8fW6udTcc2eZmpw_ly30uY7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MjhvF2jtA%253D%253D&md5=e5e8407390c050c3ca9915ab6849df77</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.36.1311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.36.1311%26sid%3Dliteratum%253Aachs%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DBoerner%26aufirst%3DS.%2BA.%26aulast%3DHunsberger%26aufirst%3DS.%26atitle%3DClinical%2520development%2520of%2520vascular%2520disrupting%2520agents%253A%2520what%2520lessons%2520can%2520we%2520learn%2520from%2520ASA404%253F%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D2952%26epage%3D2955%26doi%3D10.1200%2FJCO.2011.36.1311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Kretzschmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fürst, R.</span><span> </span><span class="NLM_article-title">Plant-derived vascular disrupting agents: compounds, actions, and clinical trials</span> <span class="citation_source-journal">Phytochem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span><span class="refDoi"> DOI: 10.1007/s11101-013-9304-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1007%2Fs11101-013-9304-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislCht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=191-206&author=V.+Kretzschmannauthor=R.+F%C3%BCrst&title=Plant-derived+vascular+disrupting+agents%3A+compounds%2C+actions%2C+and+clinical+trials&doi=10.1007%2Fs11101-013-9304-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Plant-derived vascular disrupting agents: compounds, actions, and clinical trials</span></div><div class="casAuthors">Kretzschmann, Verena K.; Fuerst, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Phytochemistry Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">191-206</span>CODEN:
                <span class="NLM_cas:coden">PRHEBS</span>;
        ISSN:<span class="NLM_cas:issn">1568-7767</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The tumor vasculature of solid tumors offers unique characteristics compared to the normal vasculature and, therefore, represents an attractive target in anti-cancer therapy.  Besides the classic anti-angiogenic agents, which inhibit tumor neovascularization, a novel promising class of anti-tumor drugs has emerged in the last years, the vascular-disrupting agents (VDAs).  In contrast to angiogenesis inhibitors, VDAs act on already established tumor blood vessels of large solid tumors and induce a vascular shutdown by targeting tumor endothelial cells.  This results in extensive necrotic tumor cell death.  The sources of VDAs are quite divers, however, the plant-derived compds. represent the largest and most prominent class.  Plant-derived VDAs have undergone extensive preclin. investigations and are now tested in several advanced clin. trials.  In this review we summarize preclin. data, including drug-target relationships as well as functional in vitro and in vivo assays, discuss their mol. way of action, and update the clin. status of the most prominent plant-derived VDAs: FAA/DMXAA, CA-4-P, OXi4503, AVE8062, and ZD6126.  All these data emphasize the value of secondary plant metabolites and their (semi-)synthetic derivs. for current drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro7gqZKoAc2bVg90H21EOLACvtfcHk0lieWBVSX7EE1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislCht7o%253D&md5=e5563128a501c8c462ad9b5545365fad</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs11101-013-9304-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11101-013-9304-6%26sid%3Dliteratum%253Aachs%26aulast%3DKretzschmann%26aufirst%3DV.%26aulast%3DF%25C3%25BCrst%26aufirst%3DR.%26atitle%3DPlant-derived%2520vascular%2520disrupting%2520agents%253A%2520compounds%252C%2520actions%252C%2520and%2520clinical%2520trials%26jtitle%3DPhytochem.%2520Rev.%26date%3D2014%26volume%3D13%26spage%3D191%26epage%3D206%26doi%3D10.1007%2Fs11101-013-9304-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Risinger, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span> </span><span class="NLM_article-title">Microtubule dynamics as a target in oncology</span> <span class="citation_source-journal">Cancer Treat. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">–</span> <span class="NLM_lpage">261</span><span class="refDoi"> DOI: 10.1016/j.ctrv.2008.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.ctrv.2008.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=19117686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVantrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2009&pages=255-261&author=A.+L.+Risingerauthor=F.+J.+Gilesauthor=S.+L.+Mooberry&title=Microtubule+dynamics+as+a+target+in+oncology&doi=10.1016%2Fj.ctrv.2008.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule dynamics as a target in oncology</span></div><div class="casAuthors">Risinger, April L.; Giles, Francis J.; Mooberry, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">255-261</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: Drugs that affect microtubule dynamics, including the taxanes and vinca alkaloids, have been a mainstay in the treatment of leukemias and solid tumors for decades.  New, more effective microtubule-targeting agents continue to enter into clin. trials and some, including the epothilone ixapebilone, have been approved for use.  In contrast, several other drugs of this class with promising preclin. data were later shown to be ineffective or intolerable in animal models or clin. trials.  In this review, we discuss the mol. mechanisms as well as preclin. and clin. results for a variety of microtubule-targeting agents in various stages of development.  We also offer a frank discussion of which microtubule-targeting agents are amenable to further development based on their availability, efficacy and toxic profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh2wR_5ls3DLVg90H21EOLACvtfcHk0lixl1G76uuvbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVantrg%253D&md5=2d18cb599b5c35f1e0bc0292c183826f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2008.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2008.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DRisinger%26aufirst%3DA.%2BL.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26atitle%3DMicrotubule%2520dynamics%2520as%2520a%2520target%2520in%2520oncology%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2009%26volume%3D35%26spage%3D255%26epage%3D261%26doi%3D10.1016%2Fj.ctrv.2008.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Shelanski, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, E. W.</span><span> </span><span class="NLM_article-title">Properties of the protein subunit of central-pair and outer-doublet microtubules of sea urchin flagella</span> <span class="citation_source-journal">J. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1968</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">304</span><span class="NLM_x">–</span> <span class="NLM_lpage">315</span><span class="refDoi"> DOI: 10.1083/jcb.38.2.304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1083%2Fjcb.38.2.304" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1968&pages=304-315&author=M.+L.+Shelanskiauthor=E.+W.+Taylor&title=Properties+of+the+protein+subunit+of+central-pair+and+outer-doublet+microtubules+of+sea+urchin+flagella&doi=10.1083%2Fjcb.38.2.304"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1083%2Fjcb.38.2.304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.38.2.304%26sid%3Dliteratum%253Aachs%26aulast%3DShelanski%26aufirst%3DM.%2BL.%26aulast%3DTaylor%26aufirst%3DE.%2BW.%26atitle%3DProperties%2520of%2520the%2520protein%2520subunit%2520of%2520central-pair%2520and%2520outer-doublet%2520microtubules%2520of%2520sea%2520urchin%2520flagella%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D1968%26volume%3D38%26spage%3D304%26epage%3D315%26doi%3D10.1083%2Fjcb.38.2.304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Ravelli, R. B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gigant, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curmi, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jourdain, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachkar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sobel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knossow, M.</span><span> </span><span class="NLM_article-title">Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">428</span><span class="NLM_x">, </span> <span class="NLM_fpage">198</span><span class="NLM_x">–</span> <span class="NLM_lpage">202</span><span class="refDoi"> DOI: 10.1038/nature02393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1038%2Fnature02393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=15014504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvFCls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=428&publication_year=2004&pages=198-202&author=R.+B.+G.+Ravelliauthor=B.+Gigantauthor=P.+A.+Curmiauthor=I.+Jourdainauthor=S.+Lachkarauthor=A.+Sobelauthor=M.+Knossow&title=Insight+into+tubulin+regulation+from+a+complex+with+colchicine+and+a+stathmin-like+domain&doi=10.1038%2Fnature02393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain</span></div><div class="casAuthors">Ravelli, Raimond B. G.; Gigant, Benoit; Curmi, Patrick A.; Jourdain, Isabelle; Lachkar, Sylvie; Sobel, Andre; Knossow, Marcel</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">428</span>
        (<span class="NLM_cas:issue">6979</span>),
    <span class="NLM_cas:pages">198-202</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Microtubules are cytoskeletal polymers of tubulin involved in many cellular functions.  Their dynamic instability is controlled by numerous compds. and proteins, including colchicine and stathmin family proteins.  The way in which microtubule instability is regulated at the mol. level has remained elusive, mainly because of the lack of appropriate structural data.  Here, the authors present the structure, at 3.5 Å resoln., of tubulin in complex with colchicine (I) and with the stathmin-like domain (SLD) of RB3.  It showed the interaction of RB3-SLD with 2 tubulin heterodimers in a curved complex capped by the SLD N-terminal domain, which prevented the incorporation of the complexed tubulin into microtubules.  A comparison with the structure of tubulin in protofilaments showed changes in the subunits of tubulin as it switched from its straight conformation to a curved one.  These changes correlated with the loss of lateral contacts and provided a rationale for the rapid microtubule depolymn. characteristic of dynamic instability.  Moreover, the tubulin-I complex shed light on the mechanism of I activity; it was shown that I binds at a location where it prevents curved tubulin from adopting a straight structure, which inhibits assembly.  Thus, the results establish a relation between the onset and speed of microtubule disassembly and the changes in tubulin subunits when tubulin switches from its straight to its curved conformation.  The results further provide a mol. description of the interaction of RB3-SLD and I with tubulin, and may be useful for the development of novel therapeutic I analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx2vePjtf347Vg90H21EOLACvtfcHk0lixl1G76uuvbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvFCls7g%253D&md5=9fbb1edfc64239638a3c2eac879bffe9</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnature02393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature02393%26sid%3Dliteratum%253Aachs%26aulast%3DRavelli%26aufirst%3DR.%2BB.%2BG.%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DCurmi%26aufirst%3DP.%2BA.%26aulast%3DJourdain%26aufirst%3DI.%26aulast%3DLachkar%26aufirst%3DS.%26aulast%3DSobel%26aufirst%3DA.%26aulast%3DKnossow%26aufirst%3DM.%26atitle%3DInsight%2520into%2520tubulin%2520regulation%2520from%2520a%2520complex%2520with%2520colchicine%2520and%2520a%2520stathmin-like%2520domain%26jtitle%3DNature%26date%3D2004%26volume%3D428%26spage%3D198%26epage%3D202%26doi%3D10.1038%2Fnature02393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Bhattacharyya, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panda, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerjee, M.</span><span> </span><span class="NLM_article-title">Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">155</span><span class="NLM_x">–</span> <span class="NLM_lpage">183</span><span class="refDoi"> DOI: 10.1002/med.20097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1002%2Fmed.20097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=17464966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvVSjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=155-183&author=B.+Bhattacharyyaauthor=D.+Pandaauthor=S.+Guptaauthor=M.+Banerjee&title=Anti-mitotic+activity+of+colchicine+and+the+structural+basis+for+its+interaction+with+tubulin&doi=10.1002%2Fmed.20097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin</span></div><div class="casAuthors">Bhattacharyya, Bhabatarak; Panda, Dulal; Gupta, Suvroma; Banerjee, Mithu</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">155-183</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">In this review, an attempt has been made to throw light on the mechanism of action of colchicine and its different analogs as anti-cancer agents.  Colchicine interacts with tubulin and perturbs the assembly dynamics of microtubules.  Though its use has been limited because of its toxicity, colchicine can still be used as a lead compd. for the generation of potent anti-cancer drugs.  Colchicine binds to tubulin in a poorly reversible manner with high activation energy.  The binding interaction is favored entropically.  In contrast, binding of its simple analogs AC or DAAC is enthalpically favored and commences with comparatively low activation energy.  Colchicine-tubulin interaction, which is normally pH dependent, has been found to be independent of pH in the presence of microtubule-assocd. proteins, salts or upon cleavage of carboxy termini of tubulin.  Biphasic kinetics of colchicines-tubulin interaction has been explained in light of the variation in the residues around the drug-binding site on β-tubulin.  Using the crystal structure of the tubulin-DAMAcolchicine complex, a detailed discussion on the pharmacophore concept that explains the variation of affinity for different colchicine site inhibitors (CSI) has been discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9F4KA4GVMr7Vg90H21EOLACvtfcHk0ljbYd-EUQZv6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvVSjsA%253D%253D&md5=720f26c98a40dd91634dbe558d982e98</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fmed.20097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20097%26sid%3Dliteratum%253Aachs%26aulast%3DBhattacharyya%26aufirst%3DB.%26aulast%3DPanda%26aufirst%3DD.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DBanerjee%26aufirst%3DM.%26atitle%3DAnti-mitotic%2520activity%2520of%2520colchicine%2520and%2520the%2520structural%2520basis%2520for%2520its%2520interaction%2520with%2520tubulin%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2008%26volume%3D28%26spage%3D155%26epage%3D183%26doi%3D10.1002%2Fmed.20097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Leung, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hui, L. L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraus, V. B.</span><span> </span><span class="NLM_article-title">Colchicine-Update on mechanisms of action and therapeutic uses</span> <span class="citation_source-journal">Semin. Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">350</span><span class="refDoi"> DOI: 10.1016/j.semarthrit.2015.06.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.semarthrit.2015.06.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=26228647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Gru73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2015&pages=341-350&author=Y.+Y.+Leungauthor=L.+L.+Y.+Huiauthor=V.+B.+Kraus&title=Colchicine-Update+on+mechanisms+of+action+and+therapeutic+uses&doi=10.1016%2Fj.semarthrit.2015.06.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Colchicine-Update on mechanisms of action and therapeutic uses</span></div><div class="casAuthors">Leung, Ying Ying; Hui, Laura Li Yao; Kraus, Virginia B.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Arthritis and Rheumatism</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">341-350</span>CODEN:
                <span class="NLM_cas:coden">SAHRBF</span>;
        ISSN:<span class="NLM_cas:issn">0049-0172</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">To review the literature and provide an update on the mechanisms of action and therapeutic uses of oral colchicine in arthritis and inflammatory conditions.  We performed PubMed database searches through June 2014 for relevant studies in the English literature published since the last update of colchicine in 2008.  Searches encompassed colchicine mechanisms of action and clin. applications in medical conditions.  A total of 381 articles were reviewed.  The primary mechanism of action of colchicine is tubulin disruption.  This leads to subsequent down regulation of multiple inflammatory pathways and modulation of innate immunity.  Newly described mechanisms include various inhibitory effects on macrophages including the inhibition of the NACHT-LRRPYD-contg. protein 3 (NALP3) inflammasome, inhibition of pore formation activated by purinergic receptors P2X7 and P2X2, and stimulation of dendritic cell maturation and antigen presentation.  Colchicine also has anti-fibrotic activities and various effects on endothelial function.  The therapeutic use of colchicine has extended beyond gouty arthritis and familial Mediterranean fever, to osteoarthritis, pericarditis, and atherosclerosis.  Further understanding of the mechanisms of action underlying the therapeutic efficacy of colchicine will lead to its potential use in a variety of conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVZcLsYpoWE7Vg90H21EOLACvtfcHk0ljbYd-EUQZv6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Gru73L&md5=963522f41dcdd97e15fee9c2bc22bd9b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.semarthrit.2015.06.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semarthrit.2015.06.013%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DY.%2BY.%26aulast%3DHui%26aufirst%3DL.%2BL.%2BY.%26aulast%3DKraus%26aufirst%3DV.%2BB.%26atitle%3DColchicine-Update%2520on%2520mechanisms%2520of%2520action%2520and%2520therapeutic%2520uses%26jtitle%3DSemin.%2520Arthritis%2520Rheum.%26date%3D2015%26volume%3D45%26spage%3D341%26epage%3D350%26doi%3D10.1016%2Fj.semarthrit.2015.06.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cragg, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S. B.</span><span> </span><span class="NLM_article-title">Antineoplastic agents 122. Constituents of <i>Combretum caffrum</i></span> <span class="citation_source-journal">J. Nat. Prod.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">386</span><span class="NLM_x">–</span> <span class="NLM_lpage">391</span><span class="refDoi"> DOI: 10.1021/np50051a008</span> </span><div class="citationLinks">[<a href="/doi/10.1021/np50051a008" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1987&pages=386-391&author=G.+R.+Pettitauthor=G.+M.+Craggauthor=S.+B.+Singh&title=Antineoplastic+agents+122.+Constituents+of+Combretum+caffrum&doi=10.1021%2Fnp50051a008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fnp50051a008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnp50051a008%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DCragg%26aufirst%3DG.%2BM.%26aulast%3DSingh%26aufirst%3DS.%2BB.%26atitle%3DAntineoplastic%2520agents%2520122.%2520Constituents%2520of%2520Combretum%2520caffrum%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D1987%26volume%3D50%26spage%3D386%26epage%3D391%26doi%3D10.1021%2Fnp50051a008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Temple, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narayanan, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyd, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rener, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bansal, N.</span><span> </span><span class="NLM_article-title">Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs</span> <span class="citation_source-journal">Anti-Cancer Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">299</span><span class="NLM_x">–</span> <span class="NLM_lpage">309</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=7786396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADyaK2MXms1Wktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1995&pages=299-309&author=G.+R.+Pettitauthor=C.+J.+Templeauthor=V.+L.+Narayananauthor=R.+Varmaauthor=M.+J.+Simpsonauthor=M.+R.+Boydauthor=G.+A.+Renerauthor=N.+Bansal&title=Antineoplastic+agents+322.+Synthesis+of+combretastatin+A-4+prodrugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Antineoplastic agents. 322. Synthesis of combretastatin A-4 prodrugs</span></div><div class="casAuthors">Pettit, George R.; Temple, Carroll, Jr.; Narayanan, Ven L.; Varma, Ravi; Simpson, Michael J.; Boyd, Michael R.; Rener, Gregory A.; Bansal, Namita</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drug Design</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">299-309</span>CODEN:
                <span class="NLM_cas:coden">ACDDEA</span>;
        ISSN:<span class="NLM_cas:issn">0266-9536</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Combretastatin A-4 (I, R = H), the principal cancer cell growth-inhibitory constituent of the Zulu medicinal plant (Combretum caffrum, has been undergoing preclin. development.  However, the very limited water soly. of this phenol has complicated drug formation.  Hence, derivs. of the combretastatin A-4 3'-phenol group were prepd. for evaluation as possible water-sol. prodrugs.  As obsd. for combretastatin A-4, the sodium salt (I, R = Na), potassium salt (I, R = K), and hemisuccinic acid ester (I, R = COCH2CH2CO2H) derivs. were essentially insol. in water.  Indeed, these substances regenerated combretastatin A-4 upon reaction with water.  A series of other simple derivs., e.g. I [R = COCH(NH2)CH2CH2CO2H], proved unsatisfactory in terms of water soly. or stability, or both.  The most sol. derivs. evaluated included the ammonium [I, R = P(O)(OH)ONH4], and potassium [I, R = P(O)(OK)2] and sodium [I, R = P(O)(ONa)2] phosphate salts, where the latter two proved most stable and suitable.  Both the potassium and sodium phosphate derivs. of combretastatin A-4 were also found to exhibit the requisite biol. properties necessary for a useful prodrug.  The sodium phosphate salt was selected for drug formulation and further pre-clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCWV9UApN5crVg90H21EOLACvtfcHk0lhMIO0pQ7CMfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXms1Wktbs%253D&md5=0a16b2b4db491916a9a742c7af69669a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DTemple%26aufirst%3DC.%2BJ.%26aulast%3DNarayanan%26aufirst%3DV.%2BL.%26aulast%3DVarma%26aufirst%3DR.%26aulast%3DSimpson%26aufirst%3DM.%2BJ.%26aulast%3DBoyd%26aufirst%3DM.%2BR.%26aulast%3DRener%26aufirst%3DG.%2BA.%26aulast%3DBansal%26aufirst%3DN.%26atitle%3DAntineoplastic%2520agents%2520322.%2520Synthesis%2520of%2520combretastatin%2520A-4%2520prodrugs%26jtitle%3DAnti-Cancer%2520Drug%2520Des.%26date%3D1995%26volume%3D10%26spage%3D299%26epage%3D309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Lin, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span> </span><span class="NLM_article-title">Antimitotic natural products combretastatin A-4 and combretastatin A-2: Studies on the mechanism of their inhibition of the binding of colchicine to tubulin</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">6984</span><span class="NLM_x">–</span> <span class="NLM_lpage">6991</span><span class="refDoi"> DOI: 10.1021/bi00443a031</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00443a031" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADyaL1MXkvV2ru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1989&pages=6984-6991&author=C.+M.+Linauthor=H.+H.+Hoauthor=G.+R.+Pettitauthor=E.+Hamel&title=Antimitotic+natural+products+combretastatin+A-4+and+combretastatin+A-2%3A+Studies+on+the+mechanism+of+their+inhibition+of+the+binding+of+colchicine+to+tubulin&doi=10.1021%2Fbi00443a031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Antimitotic natural products combretastatin A-4 and combretastatin A-2:  studies on the mechanism of their inhibition of the binding of colchicine to tubulin</span></div><div class="casAuthors">Lin, Chii M.; Ho, Holly H.; Pettit, George R.; Hamel, Ernest</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6984-91</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">The mechanism of the binding of combretastatin A-4 (CS-A4) and combretastatin A-2 (CS-A2), isolated from Combretum caffrum, to tubulin was examd. indirectly by evaluating their effects on the binding of radiolabeled colchicine to the protein.  There was rapid binding of both compds. to tubulin even at 0° (binding was complete at the earliest times examd.), in contrast to the relatively slow and temp.-dependent binding of colchicine.  Although the binding of the C. caffrum compds. to tubulin was quite tight, permitting ready isolation of near-stoichiometric amts. of drug-tubulin complex even in the absence of free drug, both CS-A4 and CS-A2 dissocd. rapidly from tubulin in the presence of high concns. of radiolabeled colchicine.  Apparent rate consts. for drug dissocn. from tubulin at 37° were 3.2 × 10-3/s for CS-A4, 4.8 × 10-3/s for CS-A2, and 2.9 × 10-5/s for colchicine (half-lives of 3.6, 2.4, and 405 min, resp.).  Thus, the effectiveness of the C. caffrum compds. as antimitotic agents appears to derive primarily from the rapidity of their binding to tubulin.  A new model for the colchicine binding site on tubulin is proposed which envisages A-ring and C-ring subsites in homologous locations on the 2 tubulin subunits, with Ph rings binding as well as or better than the tropolone ring of colchicine in the C-ring subsite.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBVM6YQr13WbVg90H21EOLACvtfcHk0lhMIO0pQ7CMfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXkvV2ru78%253D&md5=4fc9bd899f65be38961729d7c51a6b16</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fbi00443a031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00443a031%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DC.%2BM.%26aulast%3DHo%26aufirst%3DH.%2BH.%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DHamel%26aufirst%3DE.%26atitle%3DAntimitotic%2520natural%2520products%2520combretastatin%2520A-4%2520and%2520combretastatin%2520A-2%253A%2520Studies%2520on%2520the%2520mechanism%2520of%2520their%2520inhibition%2520of%2520the%2520binding%2520of%2520colchicine%2520to%2520tubulin%26jtitle%3DBiochemistry%26date%3D1989%26volume%3D28%26spage%3D6984%26epage%3D6991%26doi%3D10.1021%2Fbi00443a031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Dark, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prise, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozer, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span> </span><span class="NLM_article-title">Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1829</span><span class="NLM_x">–</span> <span class="NLM_lpage">1834</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=9157969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADyaK2sXjtlGnsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=1829-1834&author=G.+G.+Darkauthor=S.+A.+Hillauthor=V.+E.+Priseauthor=G.+M.+Tozerauthor=G.+R.+Pettitauthor=D.+J.+Chaplin&title=Combretastatin+A-4%2C+an+agent+that+displays+potent+and+selective+toxicity+toward+tumor+vasculature"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature</span></div><div class="casAuthors">Dark, Graham G.; Hill, Sally A.; Prise, Vivien E.; Tozer, Gillian M.; Pettit, George R.; Chaplin, Dai J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1829-1834</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Selective induction of vascular damage within tumors represents an emerging approach to cancer treatment.  Histol. studies have shown that several tubulin-binding agents can induce vascular damage within tumors but only at doses approximating the max. tolerated dose, which has limited their clin. applicability.  In this study, we show that the combretastatin A-4 prodrug induces vascular shutdown within tumors at doses less than one-tenth of the max. tolerated dose.  In vitro studies indicate that a short drug exposure results in profound long-term antiproliferative/cytotoxic effects against proliferating endothelial cells but not cells that are quiescent prior to and during drug exposure.  Vascular shutdown, within exptl. and human breast cancer models in vivo following systemic drug administration, was demonstrated with a redn. in functional vascular vol. of 93% at 6 h following drug administration and persisted over the next 12 h, with corresponding histol. consistent with hemorrhagic necrosis resulting from vascular damage.  The actions against tumor vasculature and the broad therapeutic window demonstrate the clin. potential of these drugs and warrant further study to elucidate the mechanisms responsible for the antivascular effects of combretastatin A-4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEdUvgSGIqp7Vg90H21EOLACvtfcHk0lhMIO0pQ7CMfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjtlGnsbk%253D&md5=889e82f6a746aef44c2a28b77135e61f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDark%26aufirst%3DG.%2BG.%26aulast%3DHill%26aufirst%3DS.%2BA.%26aulast%3DPrise%26aufirst%3DV.%2BE.%26aulast%3DTozer%26aufirst%3DG.%2BM.%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26atitle%3DCombretastatin%2520A-4%252C%2520an%2520agent%2520that%2520displays%2520potent%2520and%2520selective%2520toxicity%2520toward%2520tumor%2520vasculature%26jtitle%3DCancer%2520Res.%26date%3D1997%26volume%3D57%26spage%3D1829%26epage%3D1834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Greene, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meegan, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zisterer, D. M.</span><span> </span><span class="NLM_article-title">Combretastatins: more than just vascular targeting agents?</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">355</span><span class="NLM_x">, </span> <span class="NLM_fpage">212</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span><span class="refDoi"> DOI: 10.1124/jpet.115.226225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1124%2Fjpet.115.226225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=26354991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslantLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2015&pages=212-227&author=L.+M.+Greeneauthor=M.+J.+Meeganauthor=D.+M.+Zisterer&title=Combretastatins%3A+more+than+just+vascular+targeting+agents%3F&doi=10.1124%2Fjpet.115.226225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatins: more than just vascular targeting agents?</span></div><div class="casAuthors">Greene, Lisa M.; Meegan, Mary J.; Zisterer, Daniela M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">212-227</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Several prodrugs of the naturally occurring combretastatins have undergone extensive clin. evaluation as vascular targeting agents (VTAs).  Their increased selectivity toward endothelial cells together with their innate ability to rapidly induce vascular shutdown and inhibit tumor growth at doses up to 10-fold less than the max. tolerated dose led to the clin. evaluation of combretastatins as VTAs.  Tubulin is well established as the mol. target of the combretastatins and the vast majority of its synthetic derivs.  Furthermore, tubulin is a highly validated mol. target of many direct anticancer agents routinely used as front-line chemotherapeutics.  The unique vascular targeting properties of the combretastatins have somewhat overshadowed their development as direct anticancer agents and the delineation of the various cell death pathways and anticancer properties assocd. with such chemotherapeutics.  Moreover, the ongoing clin. trial of OXi4503 (combretastatin-A1 diphosphate) together with preliminary preclin. evaluation for the treatment of refractory acute myelogenous leukemia has successfully highlighted both the indirect and direct anticancer properties of combretastatins.  In this review, we discuss the development of the combretastatins from nature to the clinic.  The various mechanisms underlying combretastatin-induced cell cycle arrest, mitotic catastrophe, cell death, and survival are also reviewed in an attempt to further enhance the clin. prospects of this unique class of VTAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonKpiV5x3vPLVg90H21EOLACvtfcHk0lhE1YFYCPGWQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslantLY%253D&md5=7e965d3cd51715cec3f84fde9cd6e88e</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.226225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.226225%26sid%3Dliteratum%253Aachs%26aulast%3DGreene%26aufirst%3DL.%2BM.%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26aulast%3DZisterer%26aufirst%3DD.%2BM.%26atitle%3DCombretastatins%253A%2520more%2520than%2520just%2520vascular%2520targeting%2520agents%253F%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D355%26spage%3D212%26epage%3D227%26doi%3D10.1124%2Fjpet.115.226225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Mita, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sargsyan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mita, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spear, M.</span><span> </span><span class="NLM_article-title">Vascular-disrupting agents in oncology</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">317</span><span class="NLM_x">–</span> <span class="NLM_lpage">328</span><span class="refDoi"> DOI: 10.1517/13543784.2013.759557</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1517%2F13543784.2013.759557" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=23316880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1GhtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2013&pages=317-328&author=M.+M.+Mitaauthor=L.+Sargsyanauthor=A.+C.+Mitaauthor=M.+Spear&title=Vascular-disrupting+agents+in+oncology&doi=10.1517%2F13543784.2013.759557"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular-disrupting agents in oncology</span></div><div class="casAuthors">Mita, Monica M.; Sargsyan, Liza; Mita, Alain C.; Spear, Matt</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">317-328</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Vascular-disrupting agents (VDAs) are a new class of oncol. drugs, which specifically target established tumor neovasculature and have a relatively low toxicity profile.  VDAs generally have non-overlapping side effects when concomitantly used with conventional cytotoxics.  Several members of the VDA class have recently progressed through mid-to-late stages of clin. trials.Areas covered: We examd. recent publications on preclin. findings and Phase I/II/III clin. trial data on mechanisms of actions, toxicities, and optimal use of VDA class drugs.  It is becoming apparent that VDAs should be used in combination with other classes of cytotoxic agents for the optimization of their effect in treating various cancers.  In this article we describe doses, timing of delivery, and sequence of combined therapy.  We also address the combined mechanisms of actions of VDAs and conventional cytotoxic medications.Expert opinion: Vascular-disrupting agents represent a new class of promising anticancer agents, which exhibit synergistic and/or additive effects in combination with many conventional cytotoxics.  Pharmacol. evaluation of the optimal combinations of VDAs with agents of other classes and drug interactions need to be continued.  Further clin. and preclin. studies are required for distinguishing cancer patients' subpopulations that would most benefit from VDAs, identifying tumor biomarkers predictive of response as well as reliable and reproducible imaging and/or biol. assays indicative of pharmacodynamic effects, and establishing clin. algorithms for treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBLi8h_Pg11rVg90H21EOLACvtfcHk0lhE1YFYCPGWQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1GhtL8%253D&md5=fcb6a91e3b281192cceaa55c681127a0</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1517%2F13543784.2013.759557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2013.759557%26sid%3Dliteratum%253Aachs%26aulast%3DMita%26aufirst%3DM.%2BM.%26aulast%3DSargsyan%26aufirst%3DL.%26aulast%3DMita%26aufirst%3DA.%2BC.%26aulast%3DSpear%26aufirst%3DM.%26atitle%3DVascular-disrupting%2520agents%2520in%2520oncology%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2013%26volume%3D22%26spage%3D317%26epage%3D328%26doi%3D10.1517%2F13543784.2013.759557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Porcu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bortolozzi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basso, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viola, G.</span><span> </span><span class="NLM_article-title">Recent advances in vascular disrupting agents in cancer therapy</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1485</span><span class="NLM_x">–</span> <span class="NLM_lpage">1498</span><span class="refDoi"> DOI: 10.4155/fmc.14.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.4155%2Ffmc.14.104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=25365233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGltrjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=1485-1498&author=E.+Porcuauthor=R.+Bortolozziauthor=G.+Bassoauthor=G.+Viola&title=Recent+advances+in+vascular+disrupting+agents+in+cancer+therapy&doi=10.4155%2Ffmc.14.104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in vascular disrupting agents in cancer therapy</span></div><div class="casAuthors">Porcu, Elena; Bortolozzi, Roberta; Basso, Giuseppe; Viola, Giampietro</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1485-1498</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Vascular disrupting agents (VDAs) are an important class of compds. that exhibit selective activity against pre-existing tumor vasculature, causing rapid shutdown of the tumor blood flow and consequent necrosis of the tumor mass.  The VDAs can be divided into flavonoid compds., which are related to flavone acetic acid, and tubulin-binding agents.  Tubulin-binding agents represent the largest group of VDAs and are characterized by different chem. structures, although most of them are derivs. of the lead compd. combretastatin (CA-4).  They demonstrated clin. activity, although recent findings have established that they have insufficient activity as single agents.  Several resistance mechanisms occur, such as the resistance of the tumor rim cells, while promising results have been described in combination with other chemotherapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG_xRqLIL1wrVg90H21EOLACvtfcHk0lhE1YFYCPGWQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGltrjN&md5=daf2387ad5729d02e889bf0301dac807</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.104%26sid%3Dliteratum%253Aachs%26aulast%3DPorcu%26aufirst%3DE.%26aulast%3DBortolozzi%26aufirst%3DR.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DViola%26aufirst%3DG.%26atitle%3DRecent%2520advances%2520in%2520vascular%2520disrupting%2520agents%2520in%2520cancer%2520therapy%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D1485%26epage%3D1498%26doi%3D10.4155%2Ffmc.14.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Ji, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z. P.</span><span> </span><span class="NLM_article-title">Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1348</span><span class="NLM_x">–</span> <span class="NLM_lpage">1360</span><span class="refDoi"> DOI: 10.2174/0929867322666150114163732</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.2174%2F0929867322666150114163732" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=25620094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1amurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=1348-1360&author=Y.+T.+Jiauthor=Y.+N.+Liuauthor=Z.+P.+Liu&title=Tubulin+colchicine+binding+site+inhibitors+as+vascular+disrupting+agents+in+clinical+developments&doi=10.2174%2F0929867322666150114163732"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments</span></div><div class="casAuthors">Ji, Ya-Ting; Liu, Yan-Na; Liu, Zhao-Peng</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1348-1360</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Tumor vasculature is an important target in cancer treatment.  Two distinct vasculartargeting therapeutic strategies are applied to attack cancer cells indirectly.  The antiangiogenic approach intervenes in the neovascularization processes and blocks the formation of new blood vessels, while th e antivascular approach targets the established tumor blood vessels, making vascular shutdown and resulting in rapid haemorrhagic necrosis and tumor cell death.  A no. of compds. with diverse structural scaffolds have been designed to target tumor vasculature and they are called vascular disrupting agents (VDAs).  The biol. or ligand-directed VDAs utilize antibodies, peptides or growth factors to deliver toxins or pro-coagulants or proapoptotic affectors to tumor-related blood vessels, while the small-mol. VDAs selectively target tumor blood vessels and have little effects on the normal endothelium.  Among the small-mol. VDAs, the tubulin colchicine binding site inhibitors have been extensively studied and many of them have entered the clin. trials, including CA-4P, CA-1P, AVE8062, OXi4503, CKD-516, BNC105P, ABT-751, CYT- 997, ZD6126, NPI-2358, MN-029 and EPC2407.  This review makes a summary of the small-mol. VDAs in clin. developments and highlights some potential VDA leads or candidates for the treatment of tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-aHECQeEv7LVg90H21EOLACvtfcHk0liu7wJ1iWIy5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1amurg%253D&md5=65300d3649e348a5c3c66fbc2dac4f07</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2174%2F0929867322666150114163732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867322666150114163732%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DY.%2BT.%26aulast%3DLiu%26aufirst%3DY.%2BN.%26aulast%3DLiu%26aufirst%3DZ.%2BP.%26atitle%3DTubulin%2520colchicine%2520binding%2520site%2520inhibitors%2520as%2520vascular%2520disrupting%2520agents%2520in%2520clinical%2520developments%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2015%26volume%3D22%26spage%3D1348%26epage%3D1360%26doi%3D10.2174%2F0929867322666150114163732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Barbier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsvetkov, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breuzard, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devred, F.</span><span> </span><span class="NLM_article-title">Deciphering the molecular mechanisms of anti-tubulin plant derived drugs</span> <span class="citation_source-journal">Phytochem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span><span class="NLM_x">–</span> <span class="NLM_lpage">169</span><span class="refDoi"> DOI: 10.1007/s11101-013-9302-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1007%2Fs11101-013-9302-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislCksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=157-169&author=P.+Barbierauthor=P.+O.+Tsvetkovauthor=G.+Breuzardauthor=F.+Devred&title=Deciphering+the+molecular+mechanisms+of+anti-tubulin+plant+derived+drugs&doi=10.1007%2Fs11101-013-9302-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Deciphering the molecular mechanisms of anti-tubulin plant derived drugs</span></div><div class="casAuthors">Barbier, P.; Tsvetkov, P. O.; Breuzard, G.; Devred, F.</div><div class="citationInfo"><span class="NLM_cas:title">Phytochemistry Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">157-169</span>CODEN:
                <span class="NLM_cas:coden">PRHEBS</span>;
        ISSN:<span class="NLM_cas:issn">1568-7767</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Even though commercialized anticancer drugs are now produced by pharmaceutical companies, most of them were originally obtained from natural sources, and more particularly from plants.  Indeed, many structurally diverse compds. isolated from plants or marine flora have been purified and synthesized for their anticancer bioactivity.  Among these, several mols. belong to the class of anticancer drugs which target the microtubule cytoskeleton, either by stabilizing it or destabilizing it.  To characterize the activity of these drugs and to understand in which physiol. context they are more likely to be used as therapeutic agents, it is necessary to fully det. their interaction with tubulin.  Understanding the mol. basis of their effects on microtubule cytoskeleton is an important step in designing analogs with greater pharmacol. activity and with fewer side effects.  In addn., knowing the mol. mechanism of action of each drug that is already used in chemotherapy protocols will also help to find strategies to circumvent resistance.  By taking examples of known anti-tubulin plant derived drugs, we show how identification of microtubule targeting agents and further characterization of their activity can be achieved combining biophys. and biochem. approaches.  We also illustrate how continuing in depth study of mols. with already known primary mechanisms of action can lead to the discovery of new targets or biomarkers which can open new perspectives in anticancer strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi3RE25Y1WjLVg90H21EOLACvtfcHk0liu7wJ1iWIy5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislCksb0%253D&md5=080159383138e7ed1f86783ed272d360</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2Fs11101-013-9302-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11101-013-9302-8%26sid%3Dliteratum%253Aachs%26aulast%3DBarbier%26aufirst%3DP.%26aulast%3DTsvetkov%26aufirst%3DP.%2BO.%26aulast%3DBreuzard%26aufirst%3DG.%26aulast%3DDevred%26aufirst%3DF.%26atitle%3DDeciphering%2520the%2520molecular%2520mechanisms%2520of%2520anti-tubulin%2520plant%2520derived%2520drugs%26jtitle%3DPhytochem.%2520Rev.%26date%3D2014%26volume%3D13%26spage%3D157%26epage%3D169%26doi%3D10.1007%2Fs11101-013-9302-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Tsvetkov, P. O.; Barbier, P.; Breuzard, G.; Peyrot, V.; Devred, F.</span><span> </span><span class="NLM_article-title">Microtubule-associated proteins and tubulin interaction by isothermal titration calorimetry</span>. In  <span class="citation_source-book">Methods in Cell Biology</span>; <span class="NLM_contrib-group">John, J. C.; Leslie, W.</span>, Eds.; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">115</span>, pp  <span class="NLM_fpage">283</span><span class="NLM_x">–</span> <span class="NLM_lpage">302</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2FB978-0-12-407757-7.00018-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=283-302&author=P.+O.+Tsvetkov&author=P.+Barbier&author=G.+Breuzard&author=V.+Peyrot&author=F.+Devredauthor=J.+C.+John&author=W.+Leslie&title=Methods+in+Cell+Biology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-407757-7.00018-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-407757-7.00018-9%26sid%3Dliteratum%253Aachs%26aulast%3DTsvetkov%26aufirst%3DP.%2BO.%26atitle%3DMicrotubule-associated%2520proteins%2520and%2520tubulin%2520interaction%2520by%2520isothermal%2520titration%2520calorimetry%26btitle%3DMethods%2520in%2520Cell%2520Biology%26aulast%3DJohn%26aufirst%3DJ.%2BC.%26pub%3DAcademic%2520Press%26date%3D2013%26volume%3D115%26spage%3D283%26epage%3D302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Fortin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacroix, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Côté, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreau, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petitclerc, É.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">C.-Gaudreault, R.</span><span> </span><span class="NLM_article-title">Quick and simple detection technique to assess the binding of antimicrotubule agents to the colchicine-binding site</span> <span class="citation_source-journal">Biol. Proced. Online</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">117</span><span class="refDoi"> DOI: 10.1007/s12575-010-9029-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1007%2Fs12575-010-9029-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=21406120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFCqtrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=113-117&author=S.+Fortinauthor=J.+Lacroixauthor=M.+F.+C%C3%B4t%C3%A9author=E.+Moreauauthor=%C3%89.+Petitclercauthor=R.+C.-Gaudreault&title=Quick+and+simple+detection+technique+to+assess+the+binding+of+antimicrotubule+agents+to+the+colchicine-binding+site&doi=10.1007%2Fs12575-010-9029-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Quick and Simple Detection Technique to Assess the Binding of Antimicrotubule Agents to the Colchicine-Binding Site</span></div><div class="casAuthors">Fortin, Sebastien; Lacroix, Jacques; Cote, Marie-France; Moreau, Emmanuel; Petitclerc, Eric; C.-Gaudreault, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Biological Procedures Online</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">113-117</span>CODEN:
                <span class="NLM_cas:coden">BLPOF8</span>;
        ISSN:<span class="NLM_cas:issn">1480-9222</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Development of antimitotic binding to the colchicine-binding site for the treatment of cancer is rapidly expanding.  Numerous antimicrotubule agents are prepd. every year, and the detn. of their binding affinity to tubulin requires the use of purified tubulins and radiolabeled ligands.  Such a procedure is costly and time-consuming and therefore is limited to the most promising candidates.  Here, we report a quick and inexpensive method that requires only usual lab. resources to assess the binding of antimicrotubules to colchicine-binding site.  The method is based on the ability of N,N'-ethylene-bis(iodoacetamide) (EBI) to crosslink in living cells the cysteine residues at position 239 and 354 of β-tubulin, residues which are involved in the colchicine-binding site.  The β-tubulin adduct formed by EBI is easily detectable by Western blot as a second immunoreacting band of β-tubulin that migrates faster than β-tubulin.  The occupancy of colchicine-binding site by pertinent antimitotics inhibits the formation of the EBI: β-tubulin adduct, resulting in an assay that allows the screening of new mols. targeting this binding site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLYer3i2rYW7Vg90H21EOLACvtfcHk0liu7wJ1iWIy5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFCqtrnF&md5=e7650e076d02b8605a7be32d57a0ff4c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1007%2Fs12575-010-9029-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12575-010-9029-5%26sid%3Dliteratum%253Aachs%26aulast%3DFortin%26aufirst%3DS.%26aulast%3DLacroix%26aufirst%3DJ.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DM.%2BF.%26aulast%3DMoreau%26aufirst%3DE.%26aulast%3DPetitclerc%26aufirst%3D%25C3%2589.%26aulast%3DC.-Gaudreault%26aufirst%3DR.%26atitle%3DQuick%2520and%2520simple%2520detection%2520technique%2520to%2520assess%2520the%2520binding%2520of%2520antimicrotubule%2520agents%2520to%2520the%2520colchicine-binding%2520site%26jtitle%3DBiol.%2520Proced.%2520Online%26date%3D2010%26volume%3D12%26spage%3D113%26epage%3D117%26doi%3D10.1007%2Fs12575-010-9029-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Canela, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pérez-Pérez, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noppen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sáez-Calvo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Díaz, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camarasa, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liekens, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Priego, E. M.</span><span> </span><span class="NLM_article-title">Novel colchicine-site binders with a cyclohexanedione scaffold identified through a ligand-based virtual screening approach</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">3924</span><span class="NLM_x">–</span> <span class="NLM_lpage">3938</span><span class="refDoi"> DOI: 10.1021/jm401939g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401939g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3924-3938&author=M.+D.+Canelaauthor=M.+J.+P%C3%A9rez-P%C3%A9rezauthor=S.+Noppenauthor=G.+S%C3%A1ez-Calvoauthor=J.+F.+D%C3%ADazauthor=M.+J.+Camarasaauthor=S.+Liekensauthor=E.+M.+Priego&title=Novel+colchicine-site+binders+with+a+cyclohexanedione+scaffold+identified+through+a+ligand-based+virtual+screening+approach&doi=10.1021%2Fjm401939g"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm401939g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401939g%26sid%3Dliteratum%253Aachs%26aulast%3DCanela%26aufirst%3DM.%2BD.%26aulast%3DP%25C3%25A9rez-P%25C3%25A9rez%26aufirst%3DM.%2BJ.%26aulast%3DNoppen%26aufirst%3DS.%26aulast%3DS%25C3%25A1ez-Calvo%26aufirst%3DG.%26aulast%3DD%25C3%25ADaz%26aufirst%3DJ.%2BF.%26aulast%3DCamarasa%26aufirst%3DM.%2BJ.%26aulast%3DLiekens%26aufirst%3DS.%26aulast%3DPriego%26aufirst%3DE.%2BM.%26atitle%3DNovel%2520colchicine-site%2520binders%2520with%2520a%2520cyclohexanedione%2520scaffold%2520identified%2520through%2520a%2520ligand-based%2520virtual%2520screening%2520approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3924%26epage%3D3938%26doi%3D10.1021%2Fjm401939g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Canela, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bueno, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noppen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sáez Calvo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estévez Gallego, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Díaz, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camarasa, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liekens, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pérez-Pérez, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Priego, E. M.</span><span> </span><span class="NLM_article-title">Targeting the colchicine site in tubulin through cyclohexanedione derivatives</span> <span class="citation_source-journal">RSC Adv.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">19492</span><span class="NLM_x">–</span> <span class="NLM_lpage">19506</span><span class="refDoi"> DOI: 10.1039/C5RA26807A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1039%2FC5RA26807A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC28Xit1agu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=19492-19506&author=M.+D.+Canelaauthor=O.+Buenoauthor=S.+Noppenauthor=G.+S%C3%A1ez+Calvoauthor=J.+Est%C3%A9vez+Gallegoauthor=J.+F.+D%C3%ADazauthor=M.+J.+Camarasaauthor=S.+Liekensauthor=M.+J.+P%C3%A9rez-P%C3%A9rezauthor=E.+M.+Priego&title=Targeting+the+colchicine+site+in+tubulin+through+cyclohexanedione+derivatives&doi=10.1039%2FC5RA26807A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the colchicine site in tubulin through cyclohexanedione derivatives</span></div><div class="casAuthors">Canela, Maria-Dolores; Bueno, Oskia; Noppen, Sam; Saez Calvo, Gonzalo; Estevez Gallego, Juan; Diaz, J. F.; Camarasa, Maria-Jose; Liekens, Sandra; Perez-Perez, Maria-Jesus; Priego, Eva-Maria</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">19492-19506</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Cyclohexanedione derivs. represent a new family of colchicine-site binders that were identified through a ligand-based virtual screening approach.  Structural modifications have now been performed at both distal sites of our identified hit [2-(1-((2-methoxyphenyl)amino)ethylidene)-5-phenylcyclohexane-1,3-dione (4)] in order to improve tubulin binding affinity, anti-proliferative activity and/or aq. soly.  The results obtained indicate that the 2-methoxyphenyl ring, the fragment located closer to the αβ-tubulin interface according to docking studies, is the one that allows structural variation in order to improve the Ka value against tubulin (as in compd. 20a with a Ka = 1.3 × 107 M-1, analogous to colchicine) or to improve aq. soly., as in compd. 22c, being more than 10 times more sol. than the previous hit 4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIQ-6dxS59JbVg90H21EOLACvtfcHk0lieXbrBNJC4Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xit1agu7g%253D&md5=1d876707537340ad41d68132fd00e0dd</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1039%2FC5RA26807A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5RA26807A%26sid%3Dliteratum%253Aachs%26aulast%3DCanela%26aufirst%3DM.%2BD.%26aulast%3DBueno%26aufirst%3DO.%26aulast%3DNoppen%26aufirst%3DS.%26aulast%3DS%25C3%25A1ez%2BCalvo%26aufirst%3DG.%26aulast%3DEst%25C3%25A9vez%2BGallego%26aufirst%3DJ.%26aulast%3DD%25C3%25ADaz%26aufirst%3DJ.%2BF.%26aulast%3DCamarasa%26aufirst%3DM.%2BJ.%26aulast%3DLiekens%26aufirst%3DS.%26aulast%3DP%25C3%25A9rez-P%25C3%25A9rez%26aufirst%3DM.%2BJ.%26aulast%3DPriego%26aufirst%3DE.%2BM.%26atitle%3DTargeting%2520the%2520colchicine%2520site%2520in%2520tubulin%2520through%2520cyclohexanedione%2520derivatives%26jtitle%3DRSC%2520Adv.%26date%3D2016%26volume%3D6%26spage%3D19492%26epage%3D19506%26doi%3D10.1039%2FC5RA26807A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Hadimani, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonough, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghatak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strecker, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sriram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirali, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garner, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trawick, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinney, K. G.</span><span> </span><span class="NLM_article-title">Synthesis of a 2-aryl-3-aroyl indole salt (OXi8007) resembling Combretastatin A-4 with application as a vascular disrupting agent</span> <span class="citation_source-journal">J. Nat. Prod.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">1668</span><span class="NLM_x">–</span> <span class="NLM_lpage">1678</span><span class="refDoi"> DOI: 10.1021/np400374w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/np400374w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVWkur%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2013&pages=1668-1678&author=M.+B.+Hadimaniauthor=M.+T.+MacDonoughauthor=A.+Ghatakauthor=T.+E.+Streckerauthor=R.+Lopezauthor=M.+Sriramauthor=B.+L.+Nguyenauthor=J.+J.+Hallauthor=R.+J.+Kesslerauthor=A.+R.+Shiraliauthor=L.+Liuauthor=C.+M.+Garnerauthor=G.+R.+Pettitauthor=E.+Hamelauthor=D.+J.+Chaplinauthor=R.+P.+Masonauthor=M.+L.+Trawickauthor=K.+G.+Pinney&title=Synthesis+of+a+2-aryl-3-aroyl+indole+salt+%28OXi8007%29+resembling+Combretastatin+A-4+with+application+as+a+vascular+disrupting+agent&doi=10.1021%2Fnp400374w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of a 2-Aryl-3-aroyl Indole Salt (OXi8007) Resembling Combretastatin A-4 with Application as a Vascular Disrupting Agent</span></div><div class="casAuthors">Hadimani, Mallinath B.; MacDonough, Matthew T.; Ghatak, Anjan; Strecker, Tracy E.; Lopez, Ramona; Sriram, Madhavi; Nguyen, Benson L.; Hall, John J.; Kessler, Raymond J.; Shirali, Anupama R.; Liu, Li; Garner, Charles M.; Pettit, George R.; Hamel, Ernest; Chaplin, David J.; Mason, Ralph P.; Trawick, Mary Lynn; Pinney, Kevin G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Natural Products</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1668-1678</span>CODEN:
                <span class="NLM_cas:coden">JNPRDF</span>;
        ISSN:<span class="NLM_cas:issn">0163-3864</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society-American Society of Pharmacognosy</span>)
        </div><div class="casAbstract">The natural products colchicine and combretastatin A-4 are potent inhibitors of tubulin assembly, and they have inspired the design and synthesis of a large no. of small-mol., potential anticancer agents.  The indole-based mol. scaffold is prominent among these SAR modifications, leading to a rapidly increasing no. of agents.  The water-sol. phosphate prodrug I [R = P(O)(O-Na+)2] (OXi8007) (II) of 2-aryl-3-aroylindole-based phenol I (R = H) (OXi8006) (III) was prepd. by chem. synthesis and found to be strongly cytotoxic against selected human cancer cell lines (GI50 = 36 nM against DU-145 cells, for example).  The free phenol, III (OXi8006), was a strong inhibitor (IC50 = 1.1 μM) of tubulin assembly.  The corresponding phosphate prodrug II (OXi8007) also demonstrated pronounced interference with tumor vasculature in a preliminary in vivo study utilizing a SCID mouse model bearing an orthotopic PC-3 (prostate) tumor as imaged by color Doppler ultrasound.  The combination of these results provides evidence that the indole-based phosphate prodrug II (OXi8007) functions as a vascular disrupting agent that may prove useful for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBPuuWz4Lp4LVg90H21EOLACvtfcHk0lgBG-o4ToB-_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVWkur%252FN&md5=d17de0d4667b5565c5715a956549c456</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fnp400374w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnp400374w%26sid%3Dliteratum%253Aachs%26aulast%3DHadimani%26aufirst%3DM.%2BB.%26aulast%3DMacDonough%26aufirst%3DM.%2BT.%26aulast%3DGhatak%26aufirst%3DA.%26aulast%3DStrecker%26aufirst%3DT.%2BE.%26aulast%3DLopez%26aufirst%3DR.%26aulast%3DSriram%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DB.%2BL.%26aulast%3DHall%26aufirst%3DJ.%2BJ.%26aulast%3DKessler%26aufirst%3DR.%2BJ.%26aulast%3DShirali%26aufirst%3DA.%2BR.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DGarner%26aufirst%3DC.%2BM.%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DMason%26aufirst%3DR.%2BP.%26aulast%3DTrawick%26aufirst%3DM.%2BL.%26aulast%3DPinney%26aufirst%3DK.%2BG.%26atitle%3DSynthesis%2520of%2520a%25202-aryl-3-aroyl%2520indole%2520salt%2520%2528OXi8007%2529%2520resembling%2520Combretastatin%2520A-4%2520with%2520application%2520as%2520a%2520vascular%2520disrupting%2520agent%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2013%26volume%3D76%26spage%3D1668%26epage%3D1678%26doi%3D10.1021%2Fnp400374w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Tron, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirali, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorba, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pagliai, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busacca, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genazzani, A. A.</span><span> </span><span class="NLM_article-title">Medicinal chemistry of combretastatin A4: present and future directions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">3033</span><span class="NLM_x">–</span> <span class="NLM_lpage">3044</span><span class="refDoi"> DOI: 10.1021/jm0512903</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0512903" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvFyjuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=3033-3044&author=G.+C.+Tronauthor=T.+Piraliauthor=G.+Sorbaauthor=F.+Pagliaiauthor=S.+Busaccaauthor=A.+A.+Genazzani&title=Medicinal+chemistry+of+combretastatin+A4%3A+present+and+future+directions&doi=10.1021%2Fjm0512903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of combretastatin A4: Present and future directions</span></div><div class="casAuthors">Tron, Gian Cesare; Pirali, Tracey; Sorba, Giovanni; Pagliai, Francesca; Busacca, Sara; Genazzani, Armando A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3033-3044</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with refs.  A review on the medicinal chem. of combretastatin A4 (CA-4), a compd. with antitumor properties.  The mechanism of action of CA-4, including its ability to inhibit tubulin polymn., is discussed, along with selected analogs of CA-4 modified on the arom. rings A and B, substituted Ph rings, heterocycling rings, non-substituted arom. rings, modifications on the double bond, and analogs where the olefinic group is replaced by a ring.  Some issues related to the pharmacol. of CA-4 and future directions in research are considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGNHvpiUH4mbVg90H21EOLACvtfcHk0lgBG-o4ToB-_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvFyjuro%253D&md5=be023d8f1f059f952308bb06196459da</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm0512903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0512903%26sid%3Dliteratum%253Aachs%26aulast%3DTron%26aufirst%3DG.%2BC.%26aulast%3DPirali%26aufirst%3DT.%26aulast%3DSorba%26aufirst%3DG.%26aulast%3DPagliai%26aufirst%3DF.%26aulast%3DBusacca%26aufirst%3DS.%26aulast%3DGenazzani%26aufirst%3DA.%2BA.%26atitle%3DMedicinal%2520chemistry%2520of%2520combretastatin%2520A4%253A%2520present%2520and%2520future%2520directions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D3033%26epage%3D3044%26doi%3D10.1021%2Fjm0512903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, D. D.</span><span> </span><span class="NLM_article-title">An overview of tubulin inhibitors that interact with the colchicine binding site</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">2943</span><span class="NLM_x">–</span> <span class="NLM_lpage">2971</span><span class="refDoi"> DOI: 10.1007/s11095-012-0828-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1007%2Fs11095-012-0828-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=22814904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOis7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2012&pages=2943-2971&author=Y.+Luauthor=J.+Chenauthor=M.+Xiaoauthor=W.+Liauthor=D.+D.+Miller&title=An+overview+of+tubulin+inhibitors+that+interact+with+the+colchicine+binding+site&doi=10.1007%2Fs11095-012-0828-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site</span></div><div class="casAuthors">Lu, Yan; Chen, Jianjun; Xiao, Min; Li, Wei; Miller, Duane D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2943-2971</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Tubulin dynamics is a promising target for new chemotherapeutic agents.  The colchicine binding site is one of the most important pockets for potential tubulin polymn. destabilizers.  Colchicine binding site inhibitors (CBSI) exert their biol. effects by inhibiting tubulin assembly and suppressing microtubule formation.  A large no. of mols. interacting with the colchicine binding site have been designed and synthesized with significant structural diversity.  CBSIs have been modified as to chem. structure as well as pharmacokinetic properties, and tested in order to find a highly potent, low toxicity agent for treatment of cancers.  CBSIs are believed to act by a common mechanism via binding to the colchicine site on tubulin.  The present review is a synopsis of compds. that have been reported in the past decade that have provided an increase in our understanding of the actions of CBSIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFrFQVgeCbBbVg90H21EOLACvtfcHk0lgBG-o4ToB-_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOis7vN&md5=dfe42e8eb1f0ff22b256641aaa8c17ab</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1007%2Fs11095-012-0828-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-012-0828-z%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26atitle%3DAn%2520overview%2520of%2520tubulin%2520inhibitors%2520that%2520interact%2520with%2520the%2520colchicine%2520binding%2520site%26jtitle%3DPharm.%2520Res.%26date%3D2012%26volume%3D29%26spage%3D2943%26epage%3D2971%26doi%3D10.1007%2Fs11095-012-0828-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Shan, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, Y.</span><span> </span><span class="NLM_article-title">Developments of combretastatin A-4 derivatives as anticancer agents</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">523</span><span class="NLM_x">–</span> <span class="NLM_lpage">538</span><span class="refDoi"> DOI: 10.2174/092986711794480221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.2174%2F092986711794480221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=21143124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsl2lt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=523-538&author=Y.+S.+Shanauthor=J.+Zhangauthor=Z.+Liuauthor=M.+Wangauthor=Y.+Dong&title=Developments+of+combretastatin+A-4+derivatives+as+anticancer+agents&doi=10.2174%2F092986711794480221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Developments of combretastatin A-4 derivatives as anticancer agents</span></div><div class="casAuthors">Shan, Y.; Zhang, J.; Liu, Z.; Wang, M.; Dong, Y.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">523-538</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Tubulin protein is one of several members of a small family of globular proteins.  It offers a potential target for anticancer drug design and development.  Combretastatin A-4 (CA-4) is a potent anticancer and antiangiogenesis natural substance isolated from Combretum caffrum.  Modifications on the Ca-4 structure have led to a great no. of novel CA-4 derivs. as potent tubulin inhibitors and high cytotoxic anticancer agents is becoming an interesting field, leading to a breakthrough in the treatment of cancer.  In this review, the recent developments of novel CA-4 derivs. via the modifications on the A- and B-ring and the double bond as anticancer agents are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUzBhk-7FdB7Vg90H21EOLACvtfcHk0lh17viE15QeUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsl2lt70%253D&md5=81b78f1ee900478f3771ba7e9b7ef1d9</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.2174%2F092986711794480221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711794480221%26sid%3Dliteratum%253Aachs%26aulast%3DShan%26aufirst%3DY.%2BS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DY.%26atitle%3DDevelopments%2520of%2520combretastatin%2520A-4%2520derivatives%2520as%2520anticancer%2520agents%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D523%26epage%3D538%26doi%3D10.2174%2F092986711794480221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Marrelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conforti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Statti, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cachet, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tillequin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menichini, F.</span><span> </span><span class="NLM_article-title">Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: An overview of new derivatives of natural combretastatin A-4</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3035</span><span class="NLM_x">–</span> <span class="NLM_lpage">3081</span><span class="refDoi"> DOI: 10.2174/092986711796391642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.2174%2F092986711796391642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=21651481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsl2ru7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=3035-3081&author=M.+Marrelliauthor=F.+Confortiauthor=G.+A.+Stattiauthor=X.+Cachetauthor=S.+Michelauthor=F.+Tillequinauthor=F.+Menichini&title=Biological+potential+and+structure-activity+relationships+of+most+recently+developed+vascular+disrupting+agents%3A+An+overview+of+new+derivatives+of+natural+combretastatin+A-4&doi=10.2174%2F092986711796391642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: an overview of new derivatives of natural combretastatin A-4</span></div><div class="casAuthors">Marrelli, M.; Conforti, F.; Statti, G. A.; Cachet, X.; Michel, S.; Tillequin, F.; Menichini, F.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3035-3081</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Tumor blood vessels are an important emerging target for anti-cancer therapy.  The antimitotic agent combretastatin A-4 (CA-4), a cis-stilbene natural product isolated from the South African tree Combretum caffrum Kuntze, is the lead compd. of a new class of anti-cancer drugs that target tumor vasculature.  CA-4 inhibits tubulin polymn. by interacting at the colchicine binding site on tubulin.  This alters the morphol. of endothelial cells and causes vascular shutdown and regression of tumor vasculature.  Some tubulin-binding vascular-disrupting agents (VDAs) are currently in clin. trials for cancer therapy.  As a consequence of the potential favorable applications of these compds., several analogs projected to induce rapid and selective vascular shutdown in tumors have been synthesized during the last few years.  Many of these mols. have already been tested for their effects on tubulin polymn. as well as for their antiproliferative activity and other biol. properties, and possible mechanisms of action have been investigated.  The aim of the present review is to offer an overview of most recently developed combretastatin derivs., focusing on biol. effects exerted by these compds.  The published data about new analogs are presented and compared, and a detailed investigation of structure-activity relationships is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrl-P26R4lDYbVg90H21EOLACvtfcHk0lh17viE15QeUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsl2ru7k%253D&md5=de9cc466fef8e21d30ded33457377545</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.2174%2F092986711796391642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711796391642%26sid%3Dliteratum%253Aachs%26aulast%3DMarrelli%26aufirst%3DM.%26aulast%3DConforti%26aufirst%3DF.%26aulast%3DStatti%26aufirst%3DG.%2BA.%26aulast%3DCachet%26aufirst%3DX.%26aulast%3DMichel%26aufirst%3DS.%26aulast%3DTillequin%26aufirst%3DF.%26aulast%3DMenichini%26aufirst%3DF.%26atitle%3DBiological%2520potential%2520and%2520structure-activity%2520relationships%2520of%2520most%2520recently%2520developed%2520vascular%2520disrupting%2520agents%253A%2520An%2520overview%2520of%2520new%2520derivatives%2520of%2520natural%2520combretastatin%2520A-4%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D3035%26epage%3D3081%26doi%3D10.2174%2F092986711796391642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Patil, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patil, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rane, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patil, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bari, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patil, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naphade, S. S.</span><span> </span><span class="NLM_article-title">Recent advancement in discovery and development of natural product combretastatin-inspired anticancer agents</span> <span class="citation_source-journal">Anti-Cancer Agents Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">955</span><span class="NLM_x">–</span> <span class="NLM_lpage">969</span><span class="refDoi"> DOI: 10.2174/1871520615666150526141259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.2174%2F1871520615666150526141259" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=955-969&author=P.+O.+Patilauthor=A.+G.+Patilauthor=R.+A.+Raneauthor=P.+C.+Patilauthor=P.+K.+Deshmukhauthor=S.+B.+Bariauthor=D.+A.+Patilauthor=S.+S.+Naphade&title=Recent+advancement+in+discovery+and+development+of+natural+product+combretastatin-inspired+anticancer+agents&doi=10.2174%2F1871520615666150526141259"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.2174%2F1871520615666150526141259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520615666150526141259%26sid%3Dliteratum%253Aachs%26aulast%3DPatil%26aufirst%3DP.%2BO.%26aulast%3DPatil%26aufirst%3DA.%2BG.%26aulast%3DRane%26aufirst%3DR.%2BA.%26aulast%3DPatil%26aufirst%3DP.%2BC.%26aulast%3DDeshmukh%26aufirst%3DP.%2BK.%26aulast%3DBari%26aufirst%3DS.%2BB.%26aulast%3DPatil%26aufirst%3DD.%2BA.%26aulast%3DNaphade%26aufirst%3DS.%2BS.%26atitle%3DRecent%2520advancement%2520in%2520discovery%2520and%2520development%2520of%2520natural%2520product%2520combretastatin-inspired%2520anticancer%2520agents%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2015%26volume%3D15%26spage%3D955%26epage%3D969%26doi%3D10.2174%2F1871520615666150526141259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Rajak, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar Dewangan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar Jain, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veerasamy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chander Sharma, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixit, A.</span><span> </span><span class="NLM_article-title">Design of combretastatin A-4 analogs as tubulin targeted vascular disrupting agent with special emphasis on their cis-restricted isomers</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1923</span><span class="NLM_x">–</span> <span class="NLM_lpage">1955</span><span class="refDoi"> DOI: 10.2174/1381612811319100013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.2174%2F1381612811319100013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=23237054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1Gntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1923-1955&author=H.+Rajakauthor=P.+Kumar+Dewanganauthor=V.+Patelauthor=D.+Kumar+Jainauthor=A.+Singhauthor=R.+Veerasamyauthor=P.+Chander+Sharmaauthor=A.+Dixit&title=Design+of+combretastatin+A-4+analogs+as+tubulin+targeted+vascular+disrupting+agent+with+special+emphasis+on+their+cis-restricted+isomers&doi=10.2174%2F1381612811319100013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Design of combretastatin A-4 analogs as tubulin targeted vascular disrupting agent with special emphasis on their cis-restricted isomers</span></div><div class="casAuthors">Rajak, Harish; Dewangan, Pramod Kumar; Patel, Vijay; Jain, Deepak Kumar; Singh, Avineesh; Veerasamy, Ravichandran; Sharma, Prabodh Chander; Dixit, Anshuman</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1923-1955</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Tubulin protein is a highly imperative and feasible goal for anticancer drug discovery.  Hundreds of naturally occurring, semi synthetic and synthetic antitubulin agents have been reported till now.  Among these, Combretastatin A - 4 (CA - 4) is effective antimitotic agent possessing potent cytotoxicity against a panel of cancer cells, including multi-drug resistant cancer cell lines.  The inadequate water soly. and inactivation of these analogs during storage limit their use as clin. anticancer agents.  To overcome these short-comings, numerous water sol. amino analogs, amino acid deriv., phosphate prodrug (CA - 4P) and cis-locked CA - 4 have been developed with distinctive attributes of antitubulin and antivascular properties in a wide variety of preclin. tumor models.  Subsequently, several heterocycle based cis restricted CA - 4 analogs are being reported for antitumor activity against collection of cancer cell lines.  This review recapitulates the rational design, structure activity relationship, pharmacokinetic and pharmacodynamic profile of synthesized cis restricted CA - 4 analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVkQxS7xaDPLVg90H21EOLACvtfcHk0lg2Iiek-9OKoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1Gntr4%253D&md5=4aaa3f776e46ef2c0e4b18e8a163dee2</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.2174%2F1381612811319100013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612811319100013%26sid%3Dliteratum%253Aachs%26aulast%3DRajak%26aufirst%3DH.%26aulast%3DKumar%2BDewangan%26aufirst%3DP.%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DKumar%2BJain%26aufirst%3DD.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DVeerasamy%26aufirst%3DR.%26aulast%3DChander%2BSharma%26aufirst%3DP.%26aulast%3DDixit%26aufirst%3DA.%26atitle%3DDesign%2520of%2520combretastatin%2520A-4%2520analogs%2520as%2520tubulin%2520targeted%2520vascular%2520disrupting%2520agent%2520with%2520special%2520emphasis%2520on%2520their%2520cis-restricted%2520isomers%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2013%26volume%3D19%26spage%3D1923%26epage%3D1955%26doi%3D10.2174%2F1381612811319100013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Kaur, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bariwal, J.</span><span> </span><span class="NLM_article-title">Recent developments in tubulin polymerization inhibitors: An overview</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2014.09.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.ejmech.2014.09.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=25240869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFOltbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2014&pages=89-124&author=R.+Kaurauthor=G.+Kaurauthor=R.+K.+Gillauthor=R.+Soniauthor=J.+Bariwal&title=Recent+developments+in+tubulin+polymerization+inhibitors%3A+An+overview&doi=10.1016%2Fj.ejmech.2014.09.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in tubulin polymerization inhibitors: An overview</span></div><div class="casAuthors">Kaur, Ramandeep; Kaur, Gurneet; Gill, Rupinder Kaur; Soni, Richard; Bariwal, Jitender</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89-124</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Microtubules are protein biopolymers formed through polymn. of heterodimers of α- and β-tubulins.  Disruption of microtubules can induce cell cycle arrest in G2-M phase and formation of abnormal mitotic spindles.  Their importance in mitosis and cell division makes microtubules an attractive target for anticancer drug discovery.  A no. of naturally occurring compds. such as paclitaxel, epothilones, vinblastine, combretastatin, and colchicines exert their effect by changing dynamics of tubulin such as polymn. and depolymn.  During past few years, rapid development of the novel tubulin polymn. inhibitors has been witnessed.  Diverse classes of chem. compds. from the natural as well as from the synthetic origin have been extensively studied.  This review highlights the various classes of synthetically derived chem. compds. those have been reported in last few years as potential tubulin polymn. inhibitors.  A brief synthetic methodol. to access these compds. has been highlighted along with the brief SAR studies.  We strongly believe that this review will provide a platform to the synthetic chemists and biologists to design and synthesize new and potent compds. to inhibit the tubulin polymn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV6nQysY8nvbVg90H21EOLACvtfcHk0lg2Iiek-9OKoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFOltbzE&md5=2ffd2f9bb073a7830f4aae7c29f070d9</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.09.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.09.051%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DR.%26aulast%3DKaur%26aufirst%3DG.%26aulast%3DGill%26aufirst%3DR.%2BK.%26aulast%3DSoni%26aufirst%3DR.%26aulast%3DBariwal%26aufirst%3DJ.%26atitle%3DRecent%2520developments%2520in%2520tubulin%2520polymerization%2520inhibitors%253A%2520An%2520overview%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D87%26spage%3D89%26epage%3D124%26doi%3D10.1016%2Fj.ejmech.2014.09.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Álvarez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medarde, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peláez, R.</span><span> </span><span class="NLM_article-title">New ligands of the tubulin colchicine site based on X-ray structures</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2231</span><span class="NLM_x">–</span> <span class="NLM_lpage">2252</span><span class="refDoi"> DOI: 10.2174/1568026614666141130092637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.2174%2F1568026614666141130092637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=25434358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVSru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=2231-2252&author=R.+%C3%81lvarezauthor=M.+Medardeauthor=R.+Pel%C3%A1ez&title=New+ligands+of+the+tubulin+colchicine+site+based+on+X-ray+structures&doi=10.2174%2F1568026614666141130092637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">New Ligands of the Tubulin Colchicine Site Based on X-Ray Structures</span></div><div class="casAuthors">Alvarez, Raquel; Medarde, Manuel; Pelaez, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2231-2252</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Colchicine site ligands have proved to be potent inhibitors of tubulin polymn., which leads them not only to display cytotoxic effects but also vascular disrupting effects on tumor neovasculature.  In recent years, many compds. have been designed, synthesized and evaluated in order to improve the potency, stability and physicochem. properties of these agents with the aim of developing an agent that could reach the clin. assay level.  Here we analyze the eleven X-ray structures of tubulin in complex with ligands at the colchicine site by dividing it into four different zones of interaction, we review the new compds. that have appeared in the literature since 2008 and that were designed based on any of these X-ray structures and, finally, we describe our latest results in the design of new potent antimitotic indole derivs. that have confirmed the flexibility of one of the zones described for the colchicine site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB6HvmgggtxbVg90H21EOLACvtfcHk0lgobyqDYNIhJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVSru78%253D&md5=a7a289b0e6b986e59c8e0f875d4ae51e</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.2174%2F1568026614666141130092637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026614666141130092637%26sid%3Dliteratum%253Aachs%26aulast%3D%25C3%2581lvarez%26aufirst%3DR.%26aulast%3DMedarde%26aufirst%3DM.%26aulast%3DPel%25C3%25A1ez%26aufirst%3DR.%26atitle%3DNew%2520ligands%2520of%2520the%2520tubulin%2520colchicine%2520site%2520based%2520on%2520X-ray%2520structures%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2014%26volume%3D14%26spage%3D2231%26epage%3D2252%26doi%3D10.2174%2F1568026614666141130092637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Massarotti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coluccia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvestri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorba, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brancale, A.</span><span> </span><span class="NLM_article-title">The tubulin colchicine domain: a molecular modeling perspective</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">33</span><span class="NLM_x">–</span> <span class="NLM_lpage">42</span><span class="refDoi"> DOI: 10.1002/cmdc.201100361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1002%2Fcmdc.201100361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=21990124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht12qt7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=33-42&author=A.+Massarottiauthor=A.+Colucciaauthor=R.+Silvestriauthor=G.+Sorbaauthor=A.+Brancale&title=The+tubulin+colchicine+domain%3A+a+molecular+modeling+perspective&doi=10.1002%2Fcmdc.201100361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">The Tubulin Colchicine Domain: a Molecular Modeling Perspective</span></div><div class="casAuthors">Massarotti, Alberto; Coluccia, Antonio; Silvestri, Romano; Sorba, Giovanni; Brancale, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-42</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Computational approaches have been increasingly applied to drug design over the past three decades and have already provided some useful results in the discovery of anticancer drugs.  Given the increased availability of crystal structures in recent years, a growing no. of mol. modeling studies on tubulin have been reported.  Herein we present a brief overview of the role played by computational methods in anti-tubulin research, specifically in the context of colchicine binding agent research.  An overview of current structures is reported, along with a brief discussion on the issues assocd. with the various tubulin isotypes.  Finally, a summary of the most recent and relevant results is presented, highlighting the challenges and opportunities faced by researchers in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpomkM8Gy2eS7Vg90H21EOLACvtfcHk0lgobyqDYNIhJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht12qt7zO&md5=84b4f8c78b635c2b7df31bbd1e4a89de</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201100361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201100361%26sid%3Dliteratum%253Aachs%26aulast%3DMassarotti%26aufirst%3DA.%26aulast%3DColuccia%26aufirst%3DA.%26aulast%3DSilvestri%26aufirst%3DR.%26aulast%3DSorba%26aufirst%3DG.%26aulast%3DBrancale%26aufirst%3DA.%26atitle%3DThe%2520tubulin%2520colchicine%2520domain%253A%2520a%2520molecular%2520modeling%2520perspective%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D33%26epage%3D42%26doi%3D10.1002%2Fcmdc.201100361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Hartley, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fest, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dakshanamurthy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frantz, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span> </span><span class="NLM_article-title">Polygamain, a new microtubule depolymerizing agent that occupies a unique pharmacophore in the colchicine site</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">431</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span><span class="refDoi"> DOI: 10.1124/mol.111.075838</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1124%2Fmol.111.075838" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2012&pages=431-439&author=R.+M.+Hartleyauthor=J.+Pengauthor=G.+A.+Festauthor=S.+Dakshanamurthyauthor=D.+E.+Frantzauthor=M.+L.+Brownauthor=S.+L.+Mooberry&title=Polygamain%2C+a+new+microtubule+depolymerizing+agent+that+occupies+a+unique+pharmacophore+in+the+colchicine+site&doi=10.1124%2Fmol.111.075838"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1124%2Fmol.111.075838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.111.075838%26sid%3Dliteratum%253Aachs%26aulast%3DHartley%26aufirst%3DR.%2BM.%26aulast%3DPeng%26aufirst%3DJ.%26aulast%3DFest%26aufirst%3DG.%2BA.%26aulast%3DDakshanamurthy%26aufirst%3DS.%26aulast%3DFrantz%26aufirst%3DD.%2BE.%26aulast%3DBrown%26aufirst%3DM.%2BL.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26atitle%3DPolygamain%252C%2520a%2520new%2520microtubule%2520depolymerizing%2520agent%2520that%2520occupies%2520a%2520unique%2520pharmacophore%2520in%2520the%2520colchicine%2520site%26jtitle%3DMol.%2520Pharmacol.%26date%3D2012%26volume%3D81%26spage%3D431%26epage%3D439%26doi%3D10.1124%2Fmol.111.075838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Jordan, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, L.</span><span> </span><span class="NLM_article-title">Microtubules as target for anticancer drugs</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">253</span><span class="NLM_x">–</span> <span class="NLM_lpage">265</span><span class="refDoi"> DOI: 10.1038/nrc1317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1038%2Fnrc1317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=15057285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=253-265&author=M.+A.+Jordanauthor=L.+Wilson&title=Microtubules+as+target+for+anticancer+drugs&doi=10.1038%2Fnrc1317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubules as a target for anticancer drugs</span></div><div class="casAuthors">Jordan, Mary Ann; Wilson, Leslie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">253-265</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Highly dynamic mitotic-spindle microtubules are among the most successful targets for anticancer therapy.  Microtubule-targeted drugs, including paclitaxel and Vinca alkaloids, were previously considered to work primarily by increasing or decreasing the cellular microtubule mass.  Although these effects might have a role in their chemotherapeutic actions, we now know that at lower concns., microtubule-targeted drugs can suppress microtubule dynamics without changing microtubule mass; this action leads to mitotic block and apoptosis.  In addn. to the expanding array of chem. diverse antimitotic agents, some microtubule-targeted drugs can act as vascular-targeting agents, rapidly depolymg. microtubules of newly formed vasculature to shut down the blood supply to tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRJbrFnzwqjbVg90H21EOLACvtfcHk0lhx0e22M79uVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D&md5=bbbf212e03ffe6763098fc41f21a8158</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnrc1317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1317%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DM.%2BA.%26aulast%3DWilson%26aufirst%3DL.%26atitle%3DMicrotubules%2520as%2520target%2520for%2520anticancer%2520drugs%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D253%26epage%3D265%26doi%3D10.1038%2Fnrc1317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyd, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettit, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogan, F.</span><span> </span><span class="NLM_article-title">Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1666</span><span class="NLM_x">–</span> <span class="NLM_lpage">1672</span><span class="refDoi"> DOI: 10.1021/jm00010a011</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00010a011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=1666-1672&author=G.+R.+Pettitauthor=S.+B.+Singhauthor=M.+R.+Boydauthor=E.+Hamelauthor=R.+K.+Pettitauthor=J.+M.+Schmidtauthor=F.+Hogan&title=Antineoplastic+agents.+291.+Isolation+and+synthesis+of+combretastatins+A-4%2C+A-5%2C+and+A-6&doi=10.1021%2Fjm00010a011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm00010a011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00010a011%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DSingh%26aufirst%3DS.%2BB.%26aulast%3DBoyd%26aufirst%3DM.%2BR.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DPettit%26aufirst%3DR.%2BK.%26aulast%3DSchmidt%26aufirst%3DJ.%2BM.%26aulast%3DHogan%26aufirst%3DF.%26atitle%3DAntineoplastic%2520agents.%2520291.%2520Isolation%2520and%2520synthesis%2520of%2520combretastatins%2520A-4%252C%2520A-5%252C%2520and%2520A-6%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D1666%26epage%3D1672%26doi%3D10.1021%2Fjm00010a011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhodes, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herald, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratford, M. R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettit, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapuis, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliva, D.</span><span> </span><span class="NLM_article-title">Antineoplastic agents 393. Synthesis of the trans-isomer of combretastatin A-4 prodrug</span> <span class="citation_source-journal">Anti-Cancer Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">981</span><span class="NLM_x">–</span> <span class="NLM_lpage">993</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1998&pages=981-993&author=G.+R.+Pettitauthor=M.+R.+Rhodesauthor=D.+L.+Heraldauthor=D.+J.+Chaplinauthor=M.+R.+L.+Stratfordauthor=E.+Hamelauthor=R.+K.+Pettitauthor=J.+C.+Chapuisauthor=D.+Oliva&title=Antineoplastic+agents+393.+Synthesis+of+the+trans-isomer+of+combretastatin+A-4+prodrug"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DRhodes%26aufirst%3DM.%2BR.%26aulast%3DHerald%26aufirst%3DD.%2BL.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DStratford%26aufirst%3DM.%2BR.%2BL.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DPettit%26aufirst%3DR.%2BK.%26aulast%3DChapuis%26aufirst%3DJ.%2BC.%26aulast%3DOliva%26aufirst%3DD.%26atitle%3DAntineoplastic%2520agents%2520393.%2520Synthesis%2520of%2520the%2520trans-isomer%2520of%2520combretastatin%2520A-4%2520prodrug%26jtitle%3DAnti-Cancer%2520Drug%2520Des.%26date%3D1998%26volume%3D13%26spage%3D981%26epage%3D993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippert, J. W.</span><span> </span><span class="NLM_article-title">Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs</span> <span class="citation_source-journal">Anti-Cancer Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">216</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2000&pages=203-216&author=G.+R.+Pettitauthor=J.+W.+Lippert&title=Antineoplastic+agents+429.+Syntheses+of+the+combretastatin+A-1+and+combretastatin+B-1+prodrugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DLippert%26aufirst%3DJ.%2BW.%26atitle%3DAntineoplastic%2520agents%2520429.%2520Syntheses%2520of%2520the%2520combretastatin%2520A-1%2520and%2520combretastatin%2520B-1%2520prodrugs%26jtitle%3DAnti-Cancer%2520Drug%2520Des.%26date%3D2000%26volume%3D15%26spage%3D203%26epage%3D216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Ohsumi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morinaga, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nihei, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohishi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suga, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuji, T.</span><span> </span><span class="NLM_article-title">Novel combretastatin analogues effective against murine solid tumors: Design and structure–activity relationships</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">3022</span><span class="NLM_x">–</span> <span class="NLM_lpage">3032</span><span class="refDoi"> DOI: 10.1021/jm980101w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm980101w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=3022-3032&author=K.+Ohsumiauthor=R.+Nakagawaauthor=Y.+Fukudaauthor=T.+Hatanakaauthor=Y.+Morinagaauthor=Y.+Niheiauthor=K.+Ohishiauthor=Y.+Sugaauthor=Y.+Akiyamaauthor=T.+Tsuji&title=Novel+combretastatin+analogues+effective+against+murine+solid+tumors%3A+Design+and+structure%E2%80%93activity+relationships&doi=10.1021%2Fjm980101w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm980101w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm980101w%26sid%3Dliteratum%253Aachs%26aulast%3DOhsumi%26aufirst%3DK.%26aulast%3DNakagawa%26aufirst%3DR.%26aulast%3DFukuda%26aufirst%3DY.%26aulast%3DHatanaka%26aufirst%3DT.%26aulast%3DMorinaga%26aufirst%3DY.%26aulast%3DNihei%26aufirst%3DY.%26aulast%3DOhishi%26aufirst%3DK.%26aulast%3DSuga%26aufirst%3DY.%26aulast%3DAkiyama%26aufirst%3DY.%26aulast%3DTsuji%26aufirst%3DT.%26atitle%3DNovel%2520combretastatin%2520analogues%2520effective%2520against%2520murine%2520solid%2520tumors%253A%2520Design%2520and%2520structure%25E2%2580%2593activity%2520relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D3022%26epage%3D3032%26doi%3D10.1021%2Fjm980101w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Folkes, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christlieb, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madej, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratford, M. R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardman, P.</span><span> </span><span class="NLM_article-title">Oxidative metabolism of combretastatin A-1 produces quinone intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1885</span><span class="NLM_x">–</span> <span class="NLM_lpage">1894</span><span class="refDoi"> DOI: 10.1021/tx7002195</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx7002195" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=1885-1894&author=L.+K.+Folkesauthor=M.+Christliebauthor=E.+Madejauthor=M.+R.+L.+Stratfordauthor=P.+Wardman&title=Oxidative+metabolism+of+combretastatin+A-1+produces+quinone+intermediates+with+the+potential+to+bind+to+nucleophiles+and+to+enhance+oxidative+stress+via+free+radicals&doi=10.1021%2Ftx7002195"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Ftx7002195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx7002195%26sid%3Dliteratum%253Aachs%26aulast%3DFolkes%26aufirst%3DL.%2BK.%26aulast%3DChristlieb%26aufirst%3DM.%26aulast%3DMadej%26aufirst%3DE.%26aulast%3DStratford%26aufirst%3DM.%2BR.%2BL.%26aulast%3DWardman%26aufirst%3DP.%26atitle%3DOxidative%2520metabolism%2520of%2520combretastatin%2520A-1%2520produces%2520quinone%2520intermediates%2520with%2520the%2520potential%2520to%2520bind%2520to%2520nucleophiles%2520and%2520to%2520enhance%2520oxidative%2520stress%2520via%2520free%2520radicals%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2007%26volume%3D20%26spage%3D1885%26epage%3D1894%26doi%3D10.1021%2Ftx7002195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Ohsumi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nihei, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suga, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morinaga, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuji, T.</span><span> </span><span class="NLM_article-title">Syntheses and antitumor activity of cis-restricted combretastatins: 5-Membered heterocyclic analogues</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">3153</span><span class="NLM_x">–</span> <span class="NLM_lpage">3158</span><span class="refDoi"> DOI: 10.1016/S0960-894X(98)00579-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2FS0960-894X%2898%2900579-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=3153-3158&author=K.+Ohsumiauthor=T.+Hatanakaauthor=K.+Fujitaauthor=R.+Nakagawaauthor=Y.+Fukudaauthor=Y.+Niheiauthor=Y.+Sugaauthor=Y.+Morinagaauthor=Y.+Akiyamaauthor=T.+Tsuji&title=Syntheses+and+antitumor+activity+of+cis-restricted+combretastatins%3A+5-Membered+heterocyclic+analogues&doi=10.1016%2FS0960-894X%2898%2900579-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2898%2900579-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252898%252900579-4%26sid%3Dliteratum%253Aachs%26aulast%3DOhsumi%26aufirst%3DK.%26aulast%3DHatanaka%26aufirst%3DT.%26aulast%3DFujita%26aufirst%3DK.%26aulast%3DNakagawa%26aufirst%3DR.%26aulast%3DFukuda%26aufirst%3DY.%26aulast%3DNihei%26aufirst%3DY.%26aulast%3DSuga%26aufirst%3DY.%26aulast%3DMorinaga%26aufirst%3DY.%26aulast%3DAkiyama%26aufirst%3DY.%26aulast%3DTsuji%26aufirst%3DT.%26atitle%3DSyntheses%2520and%2520antitumor%2520activity%2520of%2520cis-restricted%2520combretastatins%253A%25205-Membered%2520heterocyclic%2520analogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1998%26volume%3D8%26spage%3D3153%26epage%3D3158%26doi%3D10.1016%2FS0960-894X%2898%2900579-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Romagnoli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baraldi, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brancale, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricci, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bortolozzi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basso, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viola, G.</span><span> </span><span class="NLM_article-title">Convergent synthesis and biological evaluation of 2-amino-4-(3′,4′,5′-trimethoxyphenyl)-5-aryl thiazoles as microtubule targeting agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">5144</span><span class="NLM_x">–</span> <span class="NLM_lpage">5153</span><span class="refDoi"> DOI: 10.1021/jm200392p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200392p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVaksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=5144-5153&author=R.+Romagnoliauthor=P.+G.+Baraldiauthor=A.+Brancaleauthor=A.+Ricciauthor=E.+Hamelauthor=R.+Bortolozziauthor=G.+Bassoauthor=G.+Viola&title=Convergent+synthesis+and+biological+evaluation+of+2-amino-4-%283%E2%80%B2%2C4%E2%80%B2%2C5%E2%80%B2-trimethoxyphenyl%29-5-aryl+thiazoles+as+microtubule+targeting+agents&doi=10.1021%2Fjm200392p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Convergent Synthesis and Biological Evaluation of 2-Amino-4-(3',4',5'-trimethoxyphenyl)-5-aryl Thiazoles as Microtubule Targeting Agents</span></div><div class="casAuthors">Romagnoli, Romeo; Baraldi, Pier Giovanni; Brancale, Andrea; Ricci, Antonio; Hamel, Ernest; Bortolozzi, Roberta; Basso, Giuseppe; Viola, Giampietro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5144-5153</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Combretastatin A-4, a potent tubulin polymn. inhibitor, caused us to synthesize a novel series of 2-amino-4-(3',4',5'-trimethoxyphenyl)-5-aryl thiazoles with the goal of evaluating the effects of substituents on the Ph at the 5-position of the thiazole skeleton on biol. activities.  An ethoxy group at the para-position produced the most active compd. in the series, with IC50 values of 0.03-0.9 nM against five of seven cancer cell lines.  The most active compds. retained full activity in multidrug resistant cancer cells and acted through the colchicine site of tubulin.  Treated cells were arrested in the G2/M phase of the cell cycle, with cell death proceeding through an apoptotic pathway that was only partially caspase-dependent.  Preliminary results suggest that, in addn. to cell death by apoptosis, cells were also killed via mitotic catastrophe as an alternative cell death mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphsFMgTMUUn7Vg90H21EOLACvtfcHk0lh2TM5kZ-b29A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVaksL0%253D&md5=9bd8f076b8c49a3894cda6c47d8cabb0</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm200392p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200392p%26sid%3Dliteratum%253Aachs%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DBrancale%26aufirst%3DA.%26aulast%3DRicci%26aufirst%3DA.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DBortolozzi%26aufirst%3DR.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DViola%26aufirst%3DG.%26atitle%3DConvergent%2520synthesis%2520and%2520biological%2520evaluation%2520of%25202-amino-4-%25283%25E2%2580%25B2%252C4%25E2%2580%25B2%252C5%25E2%2580%25B2-trimethoxyphenyl%2529-5-aryl%2520thiazoles%2520as%2520microtubule%2520targeting%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D5144%26epage%3D5153%26doi%3D10.1021%2Fjm200392p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barr, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCroskey, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannick, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gherke, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Credo, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hui, Y.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zielinski-Mozng, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sham, H. L.</span><span> </span><span class="NLM_article-title">Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure–activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">1697</span><span class="NLM_x">–</span> <span class="NLM_lpage">1711</span><span class="refDoi"> DOI: 10.1021/jm010523x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm010523x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=1697-1711&author=L.+Wangauthor=K.+W.+Woodsauthor=Q.+Liauthor=K.+J.+Barrauthor=R.+W.+McCroskeyauthor=S.+M.+Hannickauthor=L.+Gherkeauthor=R.+B.+Credoauthor=Y.-H.+Huiauthor=K.+Marshauthor=R.+Warnerauthor=J.+Y.+Leeauthor=N.+Zielinski-Mozngauthor=D.+Frostauthor=S.+H.+Rosenbergauthor=H.+L.+Sham&title=Potent%2C+orally+active+heterocycle-based+combretastatin+A-4+analogues%3A+synthesis%2C+structure%E2%80%93activity+relationship%2C+pharmacokinetics%2C+and+in+vivo+antitumor+activity+evaluation&doi=10.1021%2Fjm010523x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fjm010523x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010523x%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWoods%26aufirst%3DK.%2BW.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DBarr%26aufirst%3DK.%2BJ.%26aulast%3DMcCroskey%26aufirst%3DR.%2BW.%26aulast%3DHannick%26aufirst%3DS.%2BM.%26aulast%3DGherke%26aufirst%3DL.%26aulast%3DCredo%26aufirst%3DR.%2BB.%26aulast%3DHui%26aufirst%3DY.-H.%26aulast%3DMarsh%26aufirst%3DK.%26aulast%3DWarner%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DZielinski-Mozng%26aufirst%3DN.%26aulast%3DFrost%26aufirst%3DD.%26aulast%3DRosenberg%26aufirst%3DS.%2BH.%26aulast%3DSham%26aufirst%3DH.%2BL.%26atitle%3DPotent%252C%2520orally%2520active%2520heterocycle-based%2520combretastatin%2520A-4%2520analogues%253A%2520synthesis%252C%2520structure%25E2%2580%2593activity%2520relationship%252C%2520pharmacokinetics%252C%2520and%2520in%2520vivo%2520antitumor%2520activity%2520evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D1697%26epage%3D1711%26doi%3D10.1021%2Fjm010523x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keenan, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arora, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welsh, W. J.</span><span> </span><span class="NLM_article-title">Highly potent triazole-based tubulin polymerization inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">749</span><span class="NLM_x">–</span> <span class="NLM_lpage">754</span><span class="refDoi"> DOI: 10.1021/jm061142s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061142s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=749-754&author=Q.+Zhangauthor=Y.+Pengauthor=X.+I.+Wangauthor=S.+M.+Keenanauthor=S.+Aroraauthor=W.+J.+Welsh&title=Highly+potent+triazole-based+tubulin+polymerization+inhibitors&doi=10.1021%2Fjm061142s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjm061142s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061142s%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%2BI.%26aulast%3DKeenan%26aufirst%3DS.%2BM.%26aulast%3DArora%26aufirst%3DS.%26aulast%3DWelsh%26aufirst%3DW.%2BJ.%26atitle%3DHighly%2520potent%2520triazole-based%2520tubulin%2520polymerization%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D749%26epage%3D754%26doi%3D10.1021%2Fjm061142s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Arora, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keenan, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andaya, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welsh, W. J.</span><span> </span><span class="NLM_article-title">Novel microtubule polymerization inhibitor with potent antiproliferative and antitumor activity</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">1910</span><span class="NLM_x">–</span> <span class="NLM_lpage">1915</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-0877</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1158%2F0008-5472.CAN-08-0877" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=1910-1915&author=S.+Aroraauthor=X.+I.+Wangauthor=S.+M.+Keenanauthor=C.+Andayaauthor=Q.+Zhangauthor=Y.+Pengauthor=W.+J.+Welsh&title=Novel+microtubule+polymerization+inhibitor+with+potent+antiproliferative+and+antitumor+activity&doi=10.1158%2F0008-5472.CAN-08-0877"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-0877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-0877%26sid%3Dliteratum%253Aachs%26aulast%3DArora%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%2BI.%26aulast%3DKeenan%26aufirst%3DS.%2BM.%26aulast%3DAndaya%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DWelsh%26aufirst%3DW.%2BJ.%26atitle%3DNovel%2520microtubule%2520polymerization%2520inhibitor%2520with%2520potent%2520antiproliferative%2520and%2520antitumor%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D1910%26epage%3D1915%26doi%3D10.1158%2F0008-5472.CAN-08-0877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasilevich, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuselier, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hocart, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coy, D. H.</span><span> </span><span class="NLM_article-title">Examination of the 1,4-disubstituted azetidinone ring system as a template for combretastatin A-4 conformationally restricted analogue design</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2041</span><span class="NLM_x">–</span> <span class="NLM_lpage">2046</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2004.02.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.bmcl.2004.02.050" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=2041-2046&author=L.+Sunauthor=N.+I.+Vasilevichauthor=J.+A.+Fuselierauthor=S.+J.+Hocartauthor=D.+H.+Coy&title=Examination+of+the+1%2C4-disubstituted+azetidinone+ring+system+as+a+template+for+combretastatin+A-4+conformationally+restricted+analogue+design&doi=10.1016%2Fj.bmcl.2004.02.050"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.02.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.02.050%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DVasilevich%26aufirst%3DN.%2BI.%26aulast%3DFuselier%26aufirst%3DJ.%2BA.%26aulast%3DHocart%26aufirst%3DS.%2BJ.%26aulast%3DCoy%26aufirst%3DD.%2BH.%26atitle%3DExamination%2520of%2520the%25201%252C4-disubstituted%2520azetidinone%2520ring%2520system%2520as%2520a%2520template%2520for%2520combretastatin%2520A-4%2520conformationally%2520restricted%2520analogue%2520design%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D2041%26epage%3D2046%26doi%3D10.1016%2Fj.bmcl.2004.02.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">O’Boyle, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergin, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathwani, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCabe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lloyd, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zisterer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meegan, M. J.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8569</span><span class="NLM_x">–</span> <span class="NLM_lpage">8584</span><span class="refDoi"> DOI: 10.1021/jm101115u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101115u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8569-8584&author=N.+M.+O%E2%80%99Boyleauthor=M.+Carrauthor=L.+M.+Greeneauthor=O.+Berginauthor=S.+M.+Nathwaniauthor=T.+McCabeauthor=D.+G.+Lloydauthor=D.+M.+Zistererauthor=M.+J.+Meegan&title=Synthesis+and+evaluation+of+azetidinone+analogues+of+combretastatin+A-4+as+tubulin+targeting+agents&doi=10.1021%2Fjm101115u"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fjm101115u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101115u%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DN.%2BM.%26aulast%3DCarr%26aufirst%3DM.%26aulast%3DGreene%26aufirst%3DL.%2BM.%26aulast%3DBergin%26aufirst%3DO.%26aulast%3DNathwani%26aufirst%3DS.%2BM.%26aulast%3DMcCabe%26aufirst%3DT.%26aulast%3DLloyd%26aufirst%3DD.%2BG.%26aulast%3DZisterer%26aufirst%3DD.%2BM.%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520azetidinone%2520analogues%2520of%2520combretastatin%2520A-4%2520as%2520tubulin%2520targeting%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8569%26epage%3D8584%26doi%3D10.1021%2Fjm101115u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Greene, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathwani, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollock, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malebari, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCabe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Twamley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zisterer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meegan, M. J.</span><span> </span><span class="NLM_article-title">Synthesis and biochemical evaluation of 3-phenoxy-1,4-diarylazetidin-2-ones as tubulin-targeting antitumor agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">90</span><span class="NLM_x">–</span> <span class="NLM_lpage">113</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01086</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01086" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=90-113&author=T.+F.+Greeneauthor=S.+Wangauthor=L.+M.+Greeneauthor=S.+M.+Nathwaniauthor=J.+K.+Pollockauthor=A.+M.+Malebariauthor=T.+McCabeauthor=B.+Twamleyauthor=N.+M.+O%E2%80%99Boyleauthor=D.+M.+Zistererauthor=M.+J.+Meegan&title=Synthesis+and+biochemical+evaluation+of+3-phenoxy-1%2C4-diarylazetidin-2-ones+as+tubulin-targeting+antitumor+agents&doi=10.1021%2Facs.jmedchem.5b01086"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01086%26sid%3Dliteratum%253Aachs%26aulast%3DGreene%26aufirst%3DT.%2BF.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DGreene%26aufirst%3DL.%2BM.%26aulast%3DNathwani%26aufirst%3DS.%2BM.%26aulast%3DPollock%26aufirst%3DJ.%2BK.%26aulast%3DMalebari%26aufirst%3DA.%2BM.%26aulast%3DMcCabe%26aufirst%3DT.%26aulast%3DTwamley%26aufirst%3DB.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DN.%2BM.%26aulast%3DZisterer%26aufirst%3DD.%2BM.%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26atitle%3DSynthesis%2520and%2520biochemical%2520evaluation%2520of%25203-phenoxy-1%252C4-diarylazetidin-2-ones%2520as%2520tubulin-targeting%2520antitumor%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D90%26epage%3D113%26doi%3D10.1021%2Facs.jmedchem.5b01086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span> </span><span class="NLM_article-title">Quantum chemistry calculation-aided structural optimization of combretastatin A-4-like tubulin polymerization inhibitors: improved stability and biological activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">2538</span><span class="NLM_x">–</span> <span class="NLM_lpage">2546</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00118</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00118" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2538-2546&author=J.+Jiangauthor=C.+Zhengauthor=K.+Zhuauthor=J.+Liuauthor=N.+Sunauthor=C.+Wangauthor=H.+Jiangauthor=J.+Zhuauthor=C.+Luoauthor=Y.+Zhou&title=Quantum+chemistry+calculation-aided+structural+optimization+of+combretastatin+A-4-like+tubulin+polymerization+inhibitors%3A+improved+stability+and+biological+activity&doi=10.1021%2Facs.jmedchem.5b00118"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00118%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DY.%26atitle%3DQuantum%2520chemistry%2520calculation-aided%2520structural%2520optimization%2520of%2520combretastatin%2520A-4-like%2520tubulin%2520polymerization%2520inhibitors%253A%2520improved%2520stability%2520and%2520biological%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2538%26epage%3D2546%26doi%3D10.1021%2Facs.jmedchem.5b00118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toki, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herald, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verdier-Pinard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyd, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettit, R. K.</span><span> </span><span class="NLM_article-title">Antineoplastic agents. 379. Synthesis of phenstatin phosphate1a</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1688</span><span class="NLM_x">–</span> <span class="NLM_lpage">1695</span><span class="refDoi"> DOI: 10.1021/jm970644q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm970644q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=1688-1695&author=G.+R.+Pettitauthor=B.+Tokiauthor=D.+L.+Heraldauthor=P.+Verdier-Pinardauthor=M.+R.+Boydauthor=E.+Hamelauthor=R.+K.+Pettit&title=Antineoplastic+agents.+379.+Synthesis+of+phenstatin+phosphate1a&doi=10.1021%2Fjm970644q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fjm970644q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm970644q%26sid%3Dliteratum%253Aachs%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DToki%26aufirst%3DB.%26aulast%3DHerald%26aufirst%3DD.%2BL.%26aulast%3DVerdier-Pinard%26aufirst%3DP.%26aulast%3DBoyd%26aufirst%3DM.%2BR.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DPettit%26aufirst%3DR.%2BK.%26atitle%3DAntineoplastic%2520agents.%2520379.%2520Synthesis%2520of%2520phenstatin%2520phosphate1a%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D1688%26epage%3D1695%26doi%3D10.1021%2Fjm970644q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H.-m.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moon, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. J.</span><span> </span><span class="NLM_article-title">Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">6337</span><span class="NLM_x">–</span> <span class="NLM_lpage">6354</span><span class="refDoi"> DOI: 10.1021/jm1002414</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1002414" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVaqsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6337-6354&author=J.+Leeauthor=S.+J.+Kimauthor=H.+Choiauthor=Y.+H.+Kimauthor=I.+T.+Limauthor=H.-m.+Yangauthor=C.+S.+Leeauthor=H.+R.+Kangauthor=S.+K.+Ahnauthor=S.+K.+Moonauthor=D.-H.+Kimauthor=S.+Leeauthor=N.+S.+Choiauthor=K.+J.+Lee&title=Identification+of+CKD-516%3A+a+potent+tubulin+polymerization+inhibitor+with+marked+antitumor+activity+against+murine+and+human+solid+tumors&doi=10.1021%2Fjm1002414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of CKD-516: A Potent Tubulin Polymerization Inhibitor with Marked Antitumor Activity against Murine and Human Solid Tumors</span></div><div class="casAuthors">Lee, Jaekwang; Kim, Soo Jin; Choi, Hojin; Kim, Young Hoon; Lim, In Taek; Yang, Hyun-mo; Lee, Chang Sik; Kang, Hee Ryong; Ahn, Soon Kil; Moon, Seung Kee; Kim, Dal-Hyun; Lee, Sungsook; Choi, Nam Song; Lee, Kyung Joo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6337-6354</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tubulin polymn. inhibitors had emerged as one of promising anticancer therapeutics because of their dual mechanism of action, i.e. apoptosis by cell-cycle arrest and VDA, vascular disrupting agent.  VDAs are believed to be more efficient, less toxic, and several of them are currently undergoing clin. trials.  To identify novel tubulin inhibitors that possess potent cytotoxicity and strong inhibition of tubulin polymn. as well as potent in vivo antitumor efficacy, we have utilized benzophenone scaffold.  Complete SAR anal. of newly synthesized analogs that were prepd. by incorporation of small heterocycles (C2, C4, and C5 position) into B-ring along with the evaluation of their in vitro cytotoxicity, tubulin polymn. inhibition, and in vivo antitumor activity allowed us to identify I [R = H] (II)(S516).  Compd. II was found to have potent cytotoxicity against several cancer cells including P-gp overexpressing MDR pos. cell line (HCT15).  It also induced cell cycle arrest at G2/M phase, which is assocd. with strong inhibition of tubulin polymn.  Its in vivo efficacy was improved by prepg. its (L)-valine prodrug, I [ R = (S)- COCH(i-Pr)NH2·HCl] (CKD-516), which together with greatly improved aq. soly. has shown marked antitumor efficacy against both murine tumors (CT26 and 3LL) and human xenografts (HCT116 and HCT15) in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGre7093jjHolLVg90H21EOLACvtfcHk0ljbusC1TOXFMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVaqsbs%253D&md5=17d60d54b31b7b75bbf6d2b41bfe6975</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm1002414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1002414%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BJ.%26aulast%3DChoi%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DLim%26aufirst%3DI.%2BT.%26aulast%3DYang%26aufirst%3DH.-m.%26aulast%3DLee%26aufirst%3DC.%2BS.%26aulast%3DKang%26aufirst%3DH.%2BR.%26aulast%3DAhn%26aufirst%3DS.%2BK.%26aulast%3DMoon%26aufirst%3DS.%2BK.%26aulast%3DKim%26aufirst%3DD.-H.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DChoi%26aufirst%3DN.%2BS.%26aulast%3DLee%26aufirst%3DK.%2BJ.%26atitle%3DIdentification%2520of%2520CKD-516%253A%2520a%2520potent%2520tubulin%2520polymerization%2520inhibitor%2520with%2520marked%2520antitumor%2520activity%2520against%2520murine%2520and%2520human%2520solid%2520tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6337%26epage%3D6354%26doi%3D10.1021%2Fjm1002414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Oh, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y. J.</span><span> </span><span class="NLM_article-title">Phase I study of CKD-516, a novel vascular disrupting agent, in patients with advanced solid tumors</span> <span class="citation_source-journal">Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">36</span><span class="refDoi"> DOI: 10.4143/crt.2014.258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.4143%2Fcrt.2014.258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=25715767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A280%3ADC%252BC2MroslKnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2016&pages=28-36&author=D.+Y.+Ohauthor=T.+M.+Kimauthor=S.+W.+Hanauthor=D.+Y.+Shinauthor=Y.+G.+Leeauthor=K.+W.+Leeauthor=J.+H.+Kimauthor=T.+Y.+Kimauthor=I.+J.+Jangauthor=J.+S.+Leeauthor=Y.+J.+Bang&title=Phase+I+study+of+CKD-516%2C+a+novel+vascular+disrupting+agent%2C+in+patients+with+advanced+solid+tumors&doi=10.4143%2Fcrt.2014.258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Oh Do-Youn; Kim Tae-Min; Han Sae-Won; Kim Tae-You; Bang Yung-Jue; Shin Dong-Yeop; Lee Yun Gyoo; Lee Keun-Wook; Kim Jee Hyun; Lee Jong-Seok; Jang In-Jin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer research and treatment : official journal of Korean Cancer Association</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-36</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  CKD-516 is a newly developed vascular disrupting agent.  This phase I dose-escalation study of CKD-516 was conducted to determine maximum-tolerated dose (MTD), safety, pharmacokinetics, and preliminary antitumor efficacy in patients with advanced solid tumors.  MATERIALS AND METHODS:  Patients received CKD-516 intravenously on D1 and D8 every 3 weeks, in a standard 3+3 design.  Safety was evaluated by National Cancer Institute Common Terminology Criteria for Adverse Events ver. 4.02 and response was assessed by Response Evaluation Criteria in Solid Tumor ver. 1.1.  RESULTS:  Twenty-three patients were treated with CKD-516 at seven dosing levels: 1 mg/m(2)/day (n=3), 2 mg/m(2)/day (n=3), 3.3 mg/m(2)/day (n=3), 5 mg/m(2)/day (n=3), 7 mg/m(2)/day (n=3), 9 mg/m(2)/day (n=6), and 12 mg/m(2)/day (n=2).  Mean age was 54 and 56.5% of patients were male.  Two dose-limiting toxicities, which were both grade 3 hypertension, were observed in two patients at 12 mg/m(2)/day.  The MTD was determined as 12 mg/m(2)/day.  Most common adverse events were gastrointestinal adverse events (diarrhea, 34.8% [30.4% grade 1/2, 13.0% grade 3]; nausea, 21.7% [all grade 1/2]; vomiting, 21.7% [all grade 1/2]), myalgia (17.4%, all grade 1/2), and abdominal pain (21.7% [21.7% grade 1/2, 4.3% grade 3]).  The pharmacokinetic study showed the dose-linearity of all dosing levels.  Among 23 patients, six patients (26.1%) showed stable disease.  Median progression-free survival was 39 days (95% confidence interval, 37 to 41 days).  CONCLUSION:  This study demonstrates feasibility of CKD-516, novel vascular disrupting agent, in patients with advanced solid tumor.  MTD of CKD-516 was defined as 12 mg/m(2)/day on D1 and D8 every 3 weeks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQO4HjIonre9q2q3xNe7a7QfW6udTcc2eZwhVBJWidf-Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MroslKnsA%253D%253D&md5=718d6c3621f564ee53d20961432ea061</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.4143%2Fcrt.2014.258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4143%252Fcrt.2014.258%26sid%3Dliteratum%253Aachs%26aulast%3DOh%26aufirst%3DD.%2BY.%26aulast%3DKim%26aufirst%3DT.%2BM.%26aulast%3DHan%26aufirst%3DS.%2BW.%26aulast%3DShin%26aufirst%3DD.%2BY.%26aulast%3DLee%26aufirst%3DY.%2BG.%26aulast%3DLee%26aufirst%3DK.%2BW.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DT.%2BY.%26aulast%3DJang%26aufirst%3DI.%2BJ.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DBang%26aufirst%3DY.%2BJ.%26atitle%3DPhase%2520I%2520study%2520of%2520CKD-516%252C%2520a%2520novel%2520vascular%2520disrupting%2520agent%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Res.%2520Treat.%26date%3D2016%26volume%3D48%26spage%3D28%26epage%3D36%26doi%3D10.4143%2Fcrt.2014.258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Kuo, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liou, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. Y.</span><span> </span><span class="NLM_article-title">BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">4621</span><span class="NLM_x">–</span> <span class="NLM_lpage">4628</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-03-3474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1158%2F0008-5472.CAN-03-3474" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=15231674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltlOrsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=4621-4628&author=C.+C.+Kuoauthor=H.+P.+Hsiehauthor=W.+Y.+Panauthor=C.+P.+Chenauthor=J.+P.+Liouauthor=S.+J.+Leeauthor=Y.+L.+Changauthor=L.+T.+Chenauthor=C.+T.+Chenauthor=J.+Y.+Chang&title=BPR0L075%2C+a+novel+synthetic+indole+compound+with+antimitotic+activity+in+human+cancer+cells%2C+exerts+effective+antitumoral+activity+in+vivo&doi=10.1158%2F0008-5472.CAN-03-3474"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">BPR0L075, a Novel Synthetic Indole Compound with Antimitotic Activity in Human Cancer Cells, Exerts Effective Antitumoral Activity in Vivo</span></div><div class="casAuthors">Kuo, Ching-Chuan; Hsieh, Hsing-Pang; Pan, Wen-Yu; Chen, Ching-Ping; Liou, Jing-Ping; Lee, Shiow-Ju; Chang, Yi-Ling; Chen, Li-Tzong; Chen, Chiung-Tong; Chang, Jang-Yang</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4621-4628</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">BPR0L075 is a novel synthetic compd. discovered through research to identify new microtubule inhibitors.  BPR0L075 inhibits tubulin polymn. through binding to the colchicine-binding site of tubulin.  Cytotoxic activity of BPR0L075 in a variety of human tumor cell lines has been ascertained, with IC50 values in single-digit nanomolar ranges.  As detd. by flow cytometry, human cervical carcinoma KB cells are arrested in G2-M phases in a time-dependent manner before cell death occurs.  Terminal deoxynucleotidyl transferase-mediated nick end labeling assay indicates that cell death proceeds through an apoptotic pathway.  Addnl. studies indicate that the effect of BPR0L075 on cell cycle arrest is assocd. with an increase in cyclin B1 levels and a mobility shift of Cdc2 and Cdc25C.  The changes in Cdc2 and Cdc25C coincide with the appearance of phosphoepitopes recognized by a marker of mitosis, MPM-2.  Furthermore, phosphorylated forms of Bcl-2, perturbed mitochondrial membrane potential, and activation of the caspase-3 cascade may be involved in BPR0L075-induced apoptosis.  Notably, several KB-derived multidrug-resistant cell lines overexpressing P-gp170/MDR and MRP are resistant to vincristine, paclitaxel, and colchicine but not to BPR0L075.  Moreover, BPR0L075 shows potent activity against the growth of xenograft tumors of the gastric carcinoma MKN-45, human cervical carcinoma KB, and KB-derived P-gp170/MDR-overexpressing KB-VIN10 cells at i.v. doses of 50 mg/kg in nude mice.  These findings indicate BPR0L075 is a promising anticancer compd. with antimitotic activity that has potential for management of various malignancies, particularly for patients with drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoSqx6pRirD7Vg90H21EOLACvtfcHk0li_AYek0pwDMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltlOrsbc%253D&md5=c828eca8875e66dc0780c6a61574828b</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-03-3474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-03-3474%26sid%3Dliteratum%253Aachs%26aulast%3DKuo%26aufirst%3DC.%2BC.%26aulast%3DHsieh%26aufirst%3DH.%2BP.%26aulast%3DPan%26aufirst%3DW.%2BY.%26aulast%3DChen%26aufirst%3DC.%2BP.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DChang%26aufirst%3DY.%2BL.%26aulast%3DChen%26aufirst%3DL.%2BT.%26aulast%3DChen%26aufirst%3DC.%2BT.%26aulast%3DChang%26aufirst%3DJ.%2BY.%26atitle%3DBPR0L075%252C%2520a%2520novel%2520synthetic%2520indole%2520compound%2520with%2520antimitotic%2520activity%2520in%2520human%2520cancer%2520cells%252C%2520exerts%2520effective%2520antitumoral%2520activity%2520in%2520vivo%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D4621%26epage%3D4628%26doi%3D10.1158%2F0008-5472.CAN-03-3474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Tung, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coumar, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiao, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liou, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shukla, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H. P.</span><span> </span><span class="NLM_article-title">Scaffold-hopping strategy: synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">3076</span><span class="NLM_x">–</span> <span class="NLM_lpage">3080</span><span class="refDoi"> DOI: 10.1021/jm101027s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101027s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsleksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=3076-3080&author=Y.+S.+Tungauthor=M.+S.+Coumarauthor=Y.+S.+Wuauthor=H.+Y.+Shiaoauthor=J.+Y.+Changauthor=J.+P.+Liouauthor=P.+Shuklaauthor=C.+W.+Changauthor=C.+Y.+Changauthor=C.+C.+Kuoauthor=T.+K.+Yehauthor=C.+Y.+Linauthor=J.+S.+Wuauthor=S.+Y.+Wuauthor=C.+C.+Liaoauthor=H.+P.+Hsieh&title=Scaffold-hopping+strategy%3A+synthesis+and+biological+evaluation+of+5%2C6-fused+bicyclic+heteroaromatics+to+identify+orally+bioavailable+anticancer+agents&doi=10.1021%2Fjm101027s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Scaffold-hopping strategy: synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents</span></div><div class="casAuthors">Tung, Yen-Shih; Coumar, Mohane Selvaraj; Wu, Yu-Shan; Shiao, Hui-Yi; Chang, Jang-Yang; Liou, Jing-Ping; Shukla, Paritosh; Chang, Chun-Wei; Chang, Chi-Yen; Kuo, Ching-Chuan; Yeh, Teng-Kuang; Lin, Chin-Yu; Wu, Jian-Sung; Wu, Su-Ying; Liao, Chun-Chen; Hsieh, Hsing-Pang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3076-3080</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Utilizing scaffold-hopping drug-design strategy, we sought to identify a backup drug candidate for BPR0L075 I, an indole-based anticancer agent.  For this purpose, 5,6-fused bicyclic heteroarom. scaffolds were designed and synthesized through shuffling of the nitrogen from the N-1 position or by insertion of one or two nitrogen atoms into the indole core of I.  Among these, 7-azaindole core II showed potent in vitro anticancer activity and improved oral bioavailability (F = 35%) compared with I (F < 10%).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGjnmU15CEwrVg90H21EOLACvtfcHk0li_AYek0pwDMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsleksbk%253D&md5=0b8adad6e78a680d54de3ba893ed5d62</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fjm101027s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101027s%26sid%3Dliteratum%253Aachs%26aulast%3DTung%26aufirst%3DY.%2BS.%26aulast%3DCoumar%26aufirst%3DM.%2BS.%26aulast%3DWu%26aufirst%3DY.%2BS.%26aulast%3DShiao%26aufirst%3DH.%2BY.%26aulast%3DChang%26aufirst%3DJ.%2BY.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DShukla%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DC.%2BW.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DKuo%26aufirst%3DC.%2BC.%26aulast%3DYeh%26aufirst%3DT.%2BK.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DWu%26aufirst%3DJ.%2BS.%26aulast%3DWu%26aufirst%3DS.%2BY.%26aulast%3DLiao%26aufirst%3DC.%2BC.%26aulast%3DHsieh%26aufirst%3DH.%2BP.%26atitle%3DScaffold-hopping%2520strategy%253A%2520synthesis%2520and%2520biological%2520evaluation%2520of%25205%252C6-fused%2520bicyclic%2520heteroaromatics%2520to%2520identify%2520orally%2520bioavailable%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D3076%26epage%3D3080%26doi%3D10.1021%2Fjm101027s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Flynn, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grobelny, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leske, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavranos, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chalmers, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charman, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kostewicz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shackleford, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morizzi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kremmidiotis, G.</span><span> </span><span class="NLM_article-title">Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6014</span><span class="NLM_x">–</span> <span class="NLM_lpage">6027</span><span class="refDoi"> DOI: 10.1021/jm200454y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200454y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvVWlsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6014-6027&author=B.+L.+Flynnauthor=G.+S.+Gillauthor=D.+W.+Grobelnyauthor=J.+H.+Chaplinauthor=D.+Paulauthor=A.+F.+Leskeauthor=T.+C.+Lavranosauthor=D.+K.+Chalmersauthor=S.+A.+Charmanauthor=E.+Kostewiczauthor=D.+M.+Shacklefordauthor=J.+Morizziauthor=E.+Hamelauthor=M.+K.+Jungauthor=G.+Kremmidiotis&title=Discovery+of+7-hydroxy-6-methoxy-2-methyl-3-%283%2C4%2C5-trimethoxybenzoyl%29benzo%5Bb%5Dfuran+%28BNC105%29%2C+a+tubulin+polymerization+inhibitor+with+potent+antiproliferative+and+tumor+vascular+disrupting+properties&doi=10.1021%2Fjm200454y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 7-Hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a Tubulin Polymerization Inhibitor with Potent Antiproliferative and Tumor Vascular Disrupting Properties</span></div><div class="casAuthors">Flynn, Bernard L.; Gill, Gurmit S.; Grobelny, Damian W.; Chaplin, Jason H.; Paul, Dharam; Leske, Annabell F.; Lavranos, Tina C.; Chalmers, David K.; Charman, Susan A.; Kostewicz, Edmund; Shackleford, David M.; Morizzi, Julia; Hamel, Ernest; Jung, M. Katherine; Kremmidiotis, Gabriel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6014-6027</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Trimethoxybenzoyl benzofurans such as I [R = H, (NaO)2P:O] were prepd. as analogs of combretastatin A4 for use as antitumor agents and tested for their inhibition of tubulin polymn.  Structure-activity relationships were detd. for the inhibition of tubulin polymn. by benzoyl benzofurans; introduction of a conformation bias and addn. of a hydrogen bond donor improved the activities of the compds.  I (R = H) was found by screening for selectivity against cancer cells and activated endothelial cells over quiescent endothelial cells; its activity against nonresistant and resistant human cancer cell lines and pharmacokinetics in rats were detd.  I [R = (NaO)2P:O] has improved soly., improved ability to disrupt tumor vasculature, and improved tumor growth inhibition over both I (R = H) and combretastatin A-4 disodium phosphate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV_WE1ggYIxLVg90H21EOLACvtfcHk0liLt-sjuVrInQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvVWlsb8%253D&md5=7c9a9ea031ebbb02d2c262015ff3df25</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fjm200454y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200454y%26sid%3Dliteratum%253Aachs%26aulast%3DFlynn%26aufirst%3DB.%2BL.%26aulast%3DGill%26aufirst%3DG.%2BS.%26aulast%3DGrobelny%26aufirst%3DD.%2BW.%26aulast%3DChaplin%26aufirst%3DJ.%2BH.%26aulast%3DPaul%26aufirst%3DD.%26aulast%3DLeske%26aufirst%3DA.%2BF.%26aulast%3DLavranos%26aufirst%3DT.%2BC.%26aulast%3DChalmers%26aufirst%3DD.%2BK.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DKostewicz%26aufirst%3DE.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DMorizzi%26aufirst%3DJ.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DJung%26aufirst%3DM.%2BK.%26aulast%3DKremmidiotis%26aufirst%3DG.%26atitle%3DDiscovery%2520of%25207-hydroxy-6-methoxy-2-methyl-3-%25283%252C4%252C5-trimethoxybenzoyl%2529benzo%255Bb%255Dfuran%2520%2528BNC105%2529%252C%2520a%2520tubulin%2520polymerization%2520inhibitor%2520with%2520potent%2520antiproliferative%2520and%2520tumor%2520vascular%2520disrupting%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6014%26epage%3D6027%26doi%3D10.1021%2Fjm200454y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Kremmidiotis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leske, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavranos, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaumont, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasic, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Callaghan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, B.</span><span> </span><span class="NLM_article-title">BNC105: A novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1562</span><span class="NLM_x">–</span> <span class="NLM_lpage">1573</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0815</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1158%2F1535-7163.MCT-09-0815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=20515948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntFGgsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1562-1573&author=G.+Kremmidiotisauthor=A.+F.+Leskeauthor=T.+C.+Lavranosauthor=D.+Beaumontauthor=J.+Gasicauthor=A.+Hallauthor=M.+O%E2%80%99Callaghanauthor=C.+A.+Matthewsauthor=B.+Flynn&title=BNC105%3A+A+novel+tubulin+polymerization+inhibitor+that+selectively+disrupts+tumor+vasculature+and+displays+single-agent+antitumor+efficacy&doi=10.1158%2F1535-7163.MCT-09-0815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">BNC105: A Novel Tubulin Polymerization Inhibitor That Selectively Disrupts Tumor Vasculature and Displays Single-Agent Antitumor Efficacy</span></div><div class="casAuthors">Kremmidiotis, Gabriel; Leske, Annabell F.; Lavranos, Tina C.; Beaumont, Donna; Gasic, Jelena; Hall, Allison; O'Callaghan, Michael; Matthews, Clayton A.; Flynn, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1562-1573</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Vascular disruption agents (VDA) cause occlusion of tumor vasculature, resulting in hypoxia-driven tumor cell necrosis.  Tumor vascular disruption is a therapeutic strategy of great potential; however, VDAs currently under development display a narrow therapeutic margin, with cardiovascular toxicity posing a dose-limiting obstacle.  Discovery of new VDAs, which display a wider therapeutic margin, may allow attainment of improved clin. outcomes.  To identify such compds., we used an in vitro selectivity screening approach that exploits the fact that tumor endothelial cells are in a const. state of activation and angiogenesis and do not undergo senescence.  Our effort yielded the compd. BNC105.  This compd. acts as a tubulin polymn. inhibitor and displays 80-fold higher potency against endothelial cells that are actively proliferating or are engaged in the formation of in vitro capillaries compared with nonproliferating endothelial cells or endothelium found in stable capillaries.  This selectivity was not obsd. with CA4, a VDA currently under evaluation in phase III clin. trials.  BNC105 is more potent and offers a wider therapeutic window.  CA4 produces 90% vascular disruption at its no obsd. adverse event level (NOAEL), whereas BNC105 causes 95% vascular disruption at 1/8th of its NOAEL.  Tissue distribution anal. of BNC105 in tumor-bearing mice showed that while the drug is cleared from all tissues 24 h after administration, it is still present at high concns. within the solid tumor mass.  Furthermore, BNC105 treatment causes tumor regressions with complete tumor clearance in 20% of treated animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLcKlwS1G0NrVg90H21EOLACvtfcHk0liLt-sjuVrInQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntFGgsLk%253D&md5=94a9f916319585f07bd4b8467b1b5a89</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0815%26sid%3Dliteratum%253Aachs%26aulast%3DKremmidiotis%26aufirst%3DG.%26aulast%3DLeske%26aufirst%3DA.%2BF.%26aulast%3DLavranos%26aufirst%3DT.%2BC.%26aulast%3DBeaumont%26aufirst%3DD.%26aulast%3DGasic%26aufirst%3DJ.%26aulast%3DHall%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Callaghan%26aufirst%3DM.%26aulast%3DMatthews%26aufirst%3DC.%2BA.%26aulast%3DFlynn%26aufirst%3DB.%26atitle%3DBNC105%253A%2520A%2520novel%2520tubulin%2520polymerization%2520inhibitor%2520that%2520selectively%2520disrupts%2520tumor%2520vasculature%2520and%2520displays%2520single-agent%2520antitumor%2520efficacy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D1562%26epage%3D1573%26doi%3D10.1158%2F1535-7163.MCT-09-0815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Nien, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liou, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. Y.</span><span> </span><span class="NLM_article-title">5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2309</span><span class="NLM_x">–</span> <span class="NLM_lpage">2313</span><span class="refDoi"> DOI: 10.1021/jm900685y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900685y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvFKhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2309-2313&author=C.+Y.+Nienauthor=Y.+C.+Chenauthor=C.+C.+Kuoauthor=H.+P.+Hsiehauthor=C.+Y.+Changauthor=J.+S.+Wuauthor=S.+Y.+Wuauthor=J.+P.+Liouauthor=J.+Y.+Chang&title=5-Amino-2-aroylquinolines+as+highly+potent+tubulin+polymerization+inhibitors&doi=10.1021%2Fjm900685y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">5-Amino-2-Aroylquinolines as Highly Potent Tubulin Polymerization Inhibitors</span></div><div class="casAuthors">Nien, Chih-Ying; Chen, Yun-Ching; Kuo, Ching-Chuan; Hsieh, Hsing-Pang; Chang, Chi-Yen; Wu, Jian-Sung; Wu, Su-Ying; Liou, Jing-Ping; Chang, Jang-Yang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2309-2313</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of aroylquinoline derivs. were synthesized and evaluated for anticancer activity. 5-Amino-6-methoxy-2-aroylquinoline 15(I) showed more potent antiproliferative activity (IC50 values ranging from 0.2 to 0.4 nM) as compared to 1a (II) (combretastatin A-4) (IC50 = 1.9-835 nM) against various human cancer cell lines and a MDR-resistant cancer cell line.  Compd. 15 (IC50 = 1.6 μM) exhibited more potent inhibition of tubulin polymn. than 1a (IC50 = 2.1 μM) and showed strong binding property to the colchicine binding site of microtubules.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq735xVDh1uqLVg90H21EOLACvtfcHk0lgblrjeD3WmDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvFKhs7s%253D&md5=fb47dc7b2c00383517cfbbeb8cc274c8</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Fjm900685y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900685y%26sid%3Dliteratum%253Aachs%26aulast%3DNien%26aufirst%3DC.%2BY.%26aulast%3DChen%26aufirst%3DY.%2BC.%26aulast%3DKuo%26aufirst%3DC.%2BC.%26aulast%3DHsieh%26aufirst%3DH.%2BP.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DWu%26aufirst%3DJ.%2BS.%26aulast%3DWu%26aufirst%3DS.%2BY.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DChang%26aufirst%3DJ.%2BY.%26atitle%3D5-Amino-2-aroylquinolines%2520as%2520highly%2520potent%2520tubulin%2520polymerization%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2309%26epage%3D2313%26doi%3D10.1021%2Fjm900685y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Wen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span> </span><span class="NLM_article-title">3-(3,4,5-Trimethoxyphenylselenyl)-1H-indoles and their selenoxides as combretastatin A-4 analogs: Microwave-assisted synthesis and biological evaluation</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">184</span><span class="NLM_x">–</span> <span class="NLM_lpage">194</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2014.11.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.ejmech.2014.11.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=25461319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGisL7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2015&pages=184-194&author=Z.+Wenauthor=J.+Xuauthor=Z.+Wangauthor=H.+Qiauthor=Q.+Xuauthor=Z.+Baiauthor=Q.+Zhangauthor=K.+Baoauthor=Y.+Wuauthor=W.+Zhang&title=3-%283%2C4%2C5-Trimethoxyphenylselenyl%29-1H-indoles+and+their+selenoxides+as+combretastatin+A-4+analogs%3A+Microwave-assisted+synthesis+and+biological+evaluation&doi=10.1016%2Fj.ejmech.2014.11.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">3-(3,4,5-Trimethoxyphenylselenyl)-1H-indoles and their selenoxides as combretastatin A-4 analogs: Microwave-assisted synthesis and biological evaluation</span></div><div class="casAuthors">Wen, Zhiyong; Xu, Jingwen; Wang, Zhiwei; Qi, Huan; Xu, Qile; Bai, Zhaoshi; Zhang, Qian; Bao, Kai; Wu, Yingling; Zhang, Weige</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">184-194</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 3-(3,4,5-trimethoxyphenylselenyl)-1H-indoles and their selenoxides were designed as a new class of combretastatin A-4 (CA-4) analogs.  The B ring and the cis double bond of CA-4 were replaced by an indole moiety and selenium atom, resp.  A facile and efficient microwave-assisted synthesis of 3-arylselenylindoles was developed to prep. the target compds., which were then evaluated for antiproliferative activity against three human cancer cell lines using an MTT assay.  Most of these compds. exhibited significant antiproliferative activity, with some showing nanomolar IC50 values.  Tubulin polymn. and immunostaining expts. revealed that I potently inhibited tubulin polymn. and disrupted tubulin microtubule dynamics in a similar manner to CA-4.  Docking studies demonstrated that I adopts an orientation similar to that of CA-4 at the colchicine binding site on tubulin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY8hKuwuW35LVg90H21EOLACvtfcHk0lgblrjeD3WmDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGisL7N&md5=d38286bbc411759251da9eac04d1f76b</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.11.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.11.024%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DQi%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DBai%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DBao%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DW.%26atitle%3D3-%25283%252C4%252C5-Trimethoxyphenylselenyl%2529-1H-indoles%2520and%2520their%2520selenoxides%2520as%2520combretastatin%2520A-4%2520analogs%253A%2520Microwave-assisted%2520synthesis%2520and%2520biological%2520evaluation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D90%26spage%3D184%26epage%3D194%26doi%3D10.1016%2Fj.ejmech.2014.11.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Romagnoli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baraldi, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvador, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prencipe, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Cara, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiaffino Ortega, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brancale, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castagliuolo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitola, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ronca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bortolozzi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porcù, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basso, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viola, G.</span><span> </span><span class="NLM_article-title">Design, synthesis, in vitro, and in vivo anticancer and antiangiogenic activity of novel 3-arylaminobenzofuran derivatives targeting the colchicine site on tubulin</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3209</span><span class="NLM_x">–</span> <span class="NLM_lpage">3222</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00155</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00155" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksl2gtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3209-3222&author=R.+Romagnoliauthor=P.+G.+Baraldiauthor=M.+K.+Salvadorauthor=F.+Prencipeauthor=C.+Lopez-Caraauthor=S.+Schiaffino+Ortegaauthor=A.+Brancaleauthor=E.+Hamelauthor=I.+Castagliuoloauthor=S.+Mitolaauthor=R.+Roncaauthor=R.+Bortolozziauthor=E.+Porc%C3%B9author=G.+Bassoauthor=G.+Viola&title=Design%2C+synthesis%2C+in+vitro%2C+and+in+vivo+anticancer+and+antiangiogenic+activity+of+novel+3-arylaminobenzofuran+derivatives+targeting+the+colchicine+site+on+tubulin&doi=10.1021%2Facs.jmedchem.5b00155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, in Vitro, and in Vivo Anticancer and Antiangiogenic Activity of Novel 3-Arylaminobenzofuran Derivatives Targeting the Colchicine Site on Tubulin</span></div><div class="casAuthors">Romagnoli, Romeo; Baraldi, Pier Giovanni; Salvador, Maria Kimatrai; Prencipe, Filippo; Lopez-Cara, Carlota; Schiaffino Ortega, Santiago; Brancale, Andrea; Hamel, Ernest; Castagliuolo, Ignazio; Mitola, Stefania; Ronca, Roberto; Bortolozzi, Roberta; Porcu, Elena; Basso, Giuseppe; Viola, Giampietro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3209-3222</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">(Trimethoxyphenylamino)benzofurancarboxylates I (R, R1, R2 = H, MeO; R3 = H, MeO, EtO; R4 = Me, Et) were prepd. as potential antitumor agents; the growth inhibition of the compds. in human cancer cell lines was detd.  The toxicity of I (R = H; R1 = MeO; R2 = R3 = H; R4 = Me) and I (R = R1 = H; R2 = MeO; R3 = H; R4 = Me) to human noncancer cells was detd.  I (R = R1 = H; R2 = MeO; R3 = H; R4 = Me) inhibited cancer cell growth at concs. of 0.3-27 nM and had in vivo antitumor activity in a murine model comparable to the activity obtained with combretastatin A-4 phosphate.  I (R = R1 = H; R2 = MeO; R3 = H; R4 = Me, Et) inhibited tubulin polymn. and bound to the colchicine binding site of tubulin.  I (R = R1 = H; R2 = MeO; R3 = H; R4 = Me, Et) induced apoptosis through the mitochondrial pathway, inducing activation of caspases 3 and 9 and downregulating the antiapoptotic proteins Bcl-2 and Mcl-1.  I (R = R1 = H; R2 = MeO; R3 = H; R4 = Me) inhibited angiogenesis in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMDBCGQx4elbVg90H21EOLACvtfcHk0lijtrTp9h-rhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksl2gtrs%253D&md5=1219975a7865db5d56a784eab8c0dd66</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00155%26sid%3Dliteratum%253Aachs%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DSalvador%26aufirst%3DM.%2BK.%26aulast%3DPrencipe%26aufirst%3DF.%26aulast%3DLopez-Cara%26aufirst%3DC.%26aulast%3DSchiaffino%2BOrtega%26aufirst%3DS.%26aulast%3DBrancale%26aufirst%3DA.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DCastagliuolo%26aufirst%3DI.%26aulast%3DMitola%26aufirst%3DS.%26aulast%3DRonca%26aufirst%3DR.%26aulast%3DBortolozzi%26aufirst%3DR.%26aulast%3DPorc%25C3%25B9%26aufirst%3DE.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DViola%26aufirst%3DG.%26atitle%3DDesign%252C%2520synthesis%252C%2520in%2520vitro%252C%2520and%2520in%2520vivo%2520anticancer%2520and%2520antiangiogenic%2520activity%2520of%2520novel%25203-arylaminobenzofuran%2520derivatives%2520targeting%2520the%2520colchicine%2520site%2520on%2520tubulin%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3209%26epage%3D3222%26doi%3D10.1021%2Facs.jmedchem.5b00155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">La Regina, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coluccia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Famiglini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelliccia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Passacantilli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzoccoli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggieri, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verrico, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miele, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nalli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfonsi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Marcotullio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricci, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soriani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caraglia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Da Pozzo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brancale, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marinelli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novellino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vultaggio, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varasi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercurio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigogno, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dondio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavia, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvestri, R.</span><span> </span><span class="NLM_article-title">New indole tubulin assembly inhibitors cause stable arrest of mitotic progression, enhanced stimulation of natural killer cell cytotoxic activity, and repression of Hedgehog-dependent cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">5789</span><span class="NLM_x">–</span> <span class="NLM_lpage">5807</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00310</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00310" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5789-5807&author=G.+La+Reginaauthor=R.+Baiauthor=A.+Colucciaauthor=V.+Famigliniauthor=S.+Pellicciaauthor=S.+Passacantilliauthor=C.+Mazzoccoliauthor=V.+Ruggieriauthor=A.+Verricoauthor=A.+Mieleauthor=L.+Montiauthor=M.+Nalliauthor=R.+Alfonsiauthor=L.+Di+Marcotullioauthor=A.+Gulinoauthor=B.+Ricciauthor=A.+Sorianiauthor=A.+Santoniauthor=M.+Caragliaauthor=S.+Portoauthor=E.+Da+Pozzoauthor=C.+Martiniauthor=A.+Brancaleauthor=L.+Marinelliauthor=E.+Novellinoauthor=S.+Vultaggioauthor=M.+Varasiauthor=C.+Mercurioauthor=C.+Bigognoauthor=G.+Dondioauthor=E.+Hamelauthor=P.+Laviaauthor=R.+Silvestri&title=New+indole+tubulin+assembly+inhibitors+cause+stable+arrest+of+mitotic+progression%2C+enhanced+stimulation+of+natural+killer+cell+cytotoxic+activity%2C+and+repression+of+Hedgehog-dependent+cancer&doi=10.1021%2Facs.jmedchem.5b00310"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00310%26sid%3Dliteratum%253Aachs%26aulast%3DLa%2BRegina%26aufirst%3DG.%26aulast%3DBai%26aufirst%3DR.%26aulast%3DColuccia%26aufirst%3DA.%26aulast%3DFamiglini%26aufirst%3DV.%26aulast%3DPelliccia%26aufirst%3DS.%26aulast%3DPassacantilli%26aufirst%3DS.%26aulast%3DMazzoccoli%26aufirst%3DC.%26aulast%3DRuggieri%26aufirst%3DV.%26aulast%3DVerrico%26aufirst%3DA.%26aulast%3DMiele%26aufirst%3DA.%26aulast%3DMonti%26aufirst%3DL.%26aulast%3DNalli%26aufirst%3DM.%26aulast%3DAlfonsi%26aufirst%3DR.%26aulast%3DDi%2BMarcotullio%26aufirst%3DL.%26aulast%3DGulino%26aufirst%3DA.%26aulast%3DRicci%26aufirst%3DB.%26aulast%3DSoriani%26aufirst%3DA.%26aulast%3DSantoni%26aufirst%3DA.%26aulast%3DCaraglia%26aufirst%3DM.%26aulast%3DPorto%26aufirst%3DS.%26aulast%3DDa%2BPozzo%26aufirst%3DE.%26aulast%3DMartini%26aufirst%3DC.%26aulast%3DBrancale%26aufirst%3DA.%26aulast%3DMarinelli%26aufirst%3DL.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DVultaggio%26aufirst%3DS.%26aulast%3DVarasi%26aufirst%3DM.%26aulast%3DMercurio%26aufirst%3DC.%26aulast%3DBigogno%26aufirst%3DC.%26aulast%3DDondio%26aufirst%3DG.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DLavia%26aufirst%3DP.%26aulast%3DSilvestri%26aufirst%3DR.%26atitle%3DNew%2520indole%2520tubulin%2520assembly%2520inhibitors%2520cause%2520stable%2520arrest%2520of%2520mitotic%2520progression%252C%2520enhanced%2520stimulation%2520of%2520natural%2520killer%2520cell%2520cytotoxic%2520activity%252C%2520and%2520repression%2520of%2520Hedgehog-dependent%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5789%26epage%3D5807%26doi%3D10.1021%2Facs.jmedchem.5b00310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Álvarez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puebla, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Díaz, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bento, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Navas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de la Iglesia-Vicente, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mollinedo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreu, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medarde, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peláez, R.</span><span> </span><span class="NLM_article-title">Endowing indole-based tubulin inhibitors with an anchor for derivatization: highly potent 3-substituted indolephenstatins and indoleisocombretastatins</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">2813</span><span class="NLM_x">–</span> <span class="NLM_lpage">2827</span><span class="refDoi"> DOI: 10.1021/jm3015603</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3015603" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2813-2827&author=R.+%C3%81lvarezauthor=P.+Pueblaauthor=J.+F.+D%C3%ADazauthor=A.+C.+Bentoauthor=R.+Garc%C3%ADa-Navasauthor=J.+de+la+Iglesia-Vicenteauthor=F.+Mollinedoauthor=J.+M.+Andreuauthor=M.+Medardeauthor=R.+Pel%C3%A1ez&title=Endowing+indole-based+tubulin+inhibitors+with+an+anchor+for+derivatization%3A+highly+potent+3-substituted+indolephenstatins+and+indoleisocombretastatins&doi=10.1021%2Fjm3015603"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Fjm3015603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3015603%26sid%3Dliteratum%253Aachs%26aulast%3D%25C3%2581lvarez%26aufirst%3DR.%26aulast%3DPuebla%26aufirst%3DP.%26aulast%3DD%25C3%25ADaz%26aufirst%3DJ.%2BF.%26aulast%3DBento%26aufirst%3DA.%2BC.%26aulast%3DGarc%25C3%25ADa-Navas%26aufirst%3DR.%26aulast%3Dde%2Bla%2BIglesia-Vicente%26aufirst%3DJ.%26aulast%3DMollinedo%26aufirst%3DF.%26aulast%3DAndreu%26aufirst%3DJ.%2BM.%26aulast%3DMedarde%26aufirst%3DM.%26aulast%3DPel%25C3%25A1ez%26aufirst%3DR.%26atitle%3DEndowing%2520indole-based%2520tubulin%2520inhibitors%2520with%2520an%2520anchor%2520for%2520derivatization%253A%2520highly%2520potent%25203-substituted%2520indolephenstatins%2520and%2520indoleisocombretastatins%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2813%26epage%3D2827%26doi%3D10.1021%2Fjm3015603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohler, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalton, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, D. D.</span><span> </span><span class="NLM_article-title">Design, synthesis, and SAR studies of 4-substituted methoxylbenzoyl-aryl- thiazoles analogues as potent and orally bioavailable anticancer agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4678</span><span class="NLM_x">–</span> <span class="NLM_lpage">4693</span><span class="refDoi"> DOI: 10.1021/jm2003427</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2003427" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4678-4693&author=Y.+Luauthor=C.+M.+Liauthor=Z.+Wangauthor=J.+Chenauthor=M.+L.+Mohlerauthor=W.+Liauthor=J.+T.+Daltonauthor=D.+D.+Miller&title=Design%2C+synthesis%2C+and+SAR+studies+of+4-substituted+methoxylbenzoyl-aryl-+thiazoles+analogues+as+potent+and+orally+bioavailable+anticancer+agents&doi=10.1021%2Fjm2003427"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Fjm2003427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2003427%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DC.%2BM.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMohler%26aufirst%3DM.%2BL.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520SAR%2520studies%2520of%25204-substituted%2520methoxylbenzoyl-aryl-%2520thiazoles%2520analogues%2520as%2520potent%2520and%2520orally%2520bioavailable%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4678%26epage%3D4693%26doi%3D10.1021%2Fjm2003427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">La Regina, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coluccia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Famiglini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelliccia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Passacantilli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzoccoli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggieri, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sisinni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolognesi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rensen, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miele, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nalli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfonsi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Marcotullio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brancale, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novellino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dondio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vultaggio, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varasi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercurio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavia, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvestri, R.</span><span> </span><span class="NLM_article-title">New pyrrole derivatives with potent tubulin polymerization inhibiting activity as anticancer agents including Hedgehog-dependent cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">6531</span><span class="NLM_x">–</span> <span class="NLM_lpage">6552</span><span class="refDoi"> DOI: 10.1021/jm500561a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500561a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6531-6552&author=G.+La+Reginaauthor=R.+Baiauthor=A.+Colucciaauthor=V.+Famigliniauthor=S.+Pellicciaauthor=S.+Passacantilliauthor=C.+Mazzoccoliauthor=V.+Ruggieriauthor=L.+Sisinniauthor=A.+Bolognesiauthor=W.+M.+Rensenauthor=A.+Mieleauthor=M.+Nalliauthor=R.+Alfonsiauthor=L.+Di+Marcotullioauthor=A.+Gulinoauthor=A.+Brancaleauthor=E.+Novellinoauthor=G.+Dondioauthor=S.+Vultaggioauthor=M.+Varasiauthor=C.+Mercurioauthor=E.+Hamelauthor=P.+Laviaauthor=R.+Silvestri&title=New+pyrrole+derivatives+with+potent+tubulin+polymerization+inhibiting+activity+as+anticancer+agents+including+Hedgehog-dependent+cancer&doi=10.1021%2Fjm500561a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Fjm500561a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500561a%26sid%3Dliteratum%253Aachs%26aulast%3DLa%2BRegina%26aufirst%3DG.%26aulast%3DBai%26aufirst%3DR.%26aulast%3DColuccia%26aufirst%3DA.%26aulast%3DFamiglini%26aufirst%3DV.%26aulast%3DPelliccia%26aufirst%3DS.%26aulast%3DPassacantilli%26aufirst%3DS.%26aulast%3DMazzoccoli%26aufirst%3DC.%26aulast%3DRuggieri%26aufirst%3DV.%26aulast%3DSisinni%26aufirst%3DL.%26aulast%3DBolognesi%26aufirst%3DA.%26aulast%3DRensen%26aufirst%3DW.%2BM.%26aulast%3DMiele%26aufirst%3DA.%26aulast%3DNalli%26aufirst%3DM.%26aulast%3DAlfonsi%26aufirst%3DR.%26aulast%3DDi%2BMarcotullio%26aufirst%3DL.%26aulast%3DGulino%26aufirst%3DA.%26aulast%3DBrancale%26aufirst%3DA.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DDondio%26aufirst%3DG.%26aulast%3DVultaggio%26aufirst%3DS.%26aulast%3DVarasi%26aufirst%3DM.%26aulast%3DMercurio%26aufirst%3DC.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DLavia%26aufirst%3DP.%26aulast%3DSilvestri%26aufirst%3DR.%26atitle%3DNew%2520pyrrole%2520derivatives%2520with%2520potent%2520tubulin%2520polymerization%2520inhibiting%2520activity%2520as%2520anticancer%2520agents%2520including%2520Hedgehog-dependent%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6531%26epage%3D6552%26doi%3D10.1021%2Fjm500561a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Romagnoli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baraldi, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvador, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prencipe, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertolasi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cancellieri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brancale, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castagliuolo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Consolaro, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porcù, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basso, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viola, G.</span><span> </span><span class="NLM_article-title">Synthesis, antimitotic and antivascular activity of 1-(3′,4′,5′-trimethoxybenzoyl)-3-arylamino-5-amino-1,2,4-triazoles</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">6795</span><span class="NLM_x">–</span> <span class="NLM_lpage">6808</span><span class="refDoi"> DOI: 10.1021/jm5008193</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5008193" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6795-6808&author=R.+Romagnoliauthor=P.+G.+Baraldiauthor=M.+K.+Salvadorauthor=F.+Prencipeauthor=V.+Bertolasiauthor=M.+Cancellieriauthor=A.+Brancaleauthor=E.+Hamelauthor=I.+Castagliuoloauthor=F.+Consolaroauthor=E.+Porc%C3%B9author=G.+Bassoauthor=G.+Viola&title=Synthesis%2C+antimitotic+and+antivascular+activity+of+1-%283%E2%80%B2%2C4%E2%80%B2%2C5%E2%80%B2-trimethoxybenzoyl%29-3-arylamino-5-amino-1%2C2%2C4-triazoles&doi=10.1021%2Fjm5008193"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Fjm5008193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5008193%26sid%3Dliteratum%253Aachs%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DSalvador%26aufirst%3DM.%2BK.%26aulast%3DPrencipe%26aufirst%3DF.%26aulast%3DBertolasi%26aufirst%3DV.%26aulast%3DCancellieri%26aufirst%3DM.%26aulast%3DBrancale%26aufirst%3DA.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DCastagliuolo%26aufirst%3DI.%26aulast%3DConsolaro%26aufirst%3DF.%26aulast%3DPorc%25C3%25B9%26aufirst%3DE.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DViola%26aufirst%3DG.%26atitle%3DSynthesis%252C%2520antimitotic%2520and%2520antivascular%2520activity%2520of%25201-%25283%25E2%2580%25B2%252C4%25E2%2580%25B2%252C5%25E2%2580%25B2-trimethoxybenzoyl%2529-3-arylamino-5-amino-1%252C2%252C4-triazoles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6795%26epage%3D6808%26doi%3D10.1021%2Fjm5008193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">León-González, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acero, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muñoz-Mingarro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navarro, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martín-Cordero, C.</span><span> </span><span class="NLM_article-title">Chalcones as promising lead compounds on cancer therapy</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3407</span><span class="NLM_x">–</span> <span class="NLM_lpage">3425</span><span class="refDoi"> DOI: 10.2174/0929867322666150729114829</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.2174%2F0929867322666150729114829" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=26219392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslGitbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=3407-3425&author=A.+J.+Le%C3%B3n-Gonz%C3%A1lezauthor=N.+Aceroauthor=D.+Mu%C3%B1oz-Mingarroauthor=I.+Navarroauthor=C.+Mart%C3%ADn-Cordero&title=Chalcones+as+promising+lead+compounds+on+cancer+therapy&doi=10.2174%2F0929867322666150729114829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Chalcones as Promising Lead Compounds on Cancer Therapy</span></div><div class="casAuthors">Leon-Gonzalez, Antonio J.; Acero, Nuria; Munoz-Mingarro, Dolores; Navarro, Inmaculada; Martin-Cordero, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">3407-3425</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Chalcones constitute a group of phenolic compds. that command an increasing interest on cancer research.  Natural chalcones are widespread through the plant kingdom.  The most abundant and investigated chalcones are isoliquiritigenin, flavokawain and xanthohumol, which are present in the Fabaceae, Piperaceae, Cannabaceae, and Moraceae families.  These chalcones have been shown to be promising lead antitumor-chemopreventive drugs by three different activities: antioxidants, cytotoxic and apoptosis inducers.  In the recent years, SAR (structure-activity relationship) has contributed towards the improvement of anticancer properties of chalcones by substituting aryl rings and introducing heterocyclic moieties.  This review summarizes the anticancer activities shown by natural chalcones and the SAR and describes how different chem. moiety modifications could lead them to be therapeutically useful in the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLg8VAf9Rj7bVg90H21EOLACvtfcHk0lgz0pduXxxpEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslGitbbK&md5=667ae49e0b8bcf0d8c3423cd3ad24303</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.2174%2F0929867322666150729114829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867322666150729114829%26sid%3Dliteratum%253Aachs%26aulast%3DLe%25C3%25B3n-Gonz%25C3%25A1lez%26aufirst%3DA.%2BJ.%26aulast%3DAcero%26aufirst%3DN.%26aulast%3DMu%25C3%25B1oz-Mingarro%26aufirst%3DD.%26aulast%3DNavarro%26aufirst%3DI.%26aulast%3DMart%25C3%25ADn-Cordero%26aufirst%3DC.%26atitle%3DChalcones%2520as%2520promising%2520lead%2520compounds%2520on%2520cancer%2520therapy%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2015%26volume%3D22%26spage%3D3407%26epage%3D3425%26doi%3D10.2174%2F0929867322666150729114829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Ducki, S.</span><span> </span><span class="NLM_article-title">Antimitotic chalcones and related compounds as inhibitors of tubulin assembly</span> <span class="citation_source-journal">Anti-Cancer Agents Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">336</span><span class="NLM_x">–</span> <span class="NLM_lpage">347</span><span class="refDoi"> DOI: 10.2174/1871520610909030336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.2174%2F1871520610909030336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=19275525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks1Cgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=336-347&author=S.+Ducki&title=Antimitotic+chalcones+and+related+compounds+as+inhibitors+of+tubulin+assembly&doi=10.2174%2F1871520610909030336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Antimitotic chalcones and related compounds as inhibitors of tubulin assembly</span></div><div class="casAuthors">Ducki, Sylvie</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">336-347</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of chalcones as antimitotic agents has led to the design of other analogs able to interact with tubulin and inhibit its assembly into microtubules.  This activity has also been assocd. with their anti-vascular activity.  This review focuses on the development of chalcones and related analogs as antimitotic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4udbevzeoA7Vg90H21EOLACvtfcHk0li5UL6k7k1qIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks1Cgu7c%253D&md5=de9d119eedd2f60dc9f3f9783b3d6495</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.2174%2F1871520610909030336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520610909030336%26sid%3Dliteratum%253Aachs%26aulast%3DDucki%26aufirst%3DS.%26atitle%3DAntimitotic%2520chalcones%2520and%2520related%2520compounds%2520as%2520inhibitors%2520of%2520tubulin%2520assembly%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D336%26epage%3D347%26doi%3D10.2174%2F1871520610909030336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Ducki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rennison, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabert, J. F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGown, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, N. J.</span><span> </span><span class="NLM_article-title">Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: Synthesis and biological evaluation of antivascular activity</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">7698</span><span class="NLM_x">–</span> <span class="NLM_lpage">7710</span><span class="refDoi"> DOI: 10.1016/j.bmc.2009.09.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.bmc.2009.09.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=19837593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCrsLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=7698-7710&author=S.+Duckiauthor=D.+Rennisonauthor=M.+Wooauthor=A.+Kendallauthor=J.+F.+D.+Chabertauthor=A.+T.+McGownauthor=N.+J.+Lawrence&title=Combretastatin-like+chalcones+as+inhibitors+of+microtubule+polymerization.+Part+1%3A+Synthesis+and+biological+evaluation+of+antivascular+activity&doi=10.1016%2Fj.bmc.2009.09.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: Synthesis and biological evaluation of antivascular activity</span></div><div class="casAuthors">Ducki, Sylvie; Rennison, David; Woo, Meiko; Kendall, Alexander; Fournier Dit Chabert, Jeremie; McGown, Alan T.; Lawrence, Nicholas J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7698-7710</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The α-Me chalcone SD400 is a potent inhibitor of tubulin assembly and possesses potent anticancer activity.  Various chalcone analogs were synthesized and evaluated for their cell growth inhibitory properties against the K562 human chronic myelogenous leukemia cell line (SD400, IC50 0.21 nM; combretastatin A4 CA4, IC50 2.0 nM).  Cell cycle anal. by flow cytometry indicated that these agents are antimitotic (SD400, 83% of the cells are in G2/M phase; CA4 90%).  They inhibit tubulin assembly at low concn. (SD400, IC50 0.46 μM; CA4, 0.10 μM) and compete with [3H]colchicine for binding to tubulin (8% [3H]colchicine remained bound to tubulin after competition with SD400 or CA4).  Upon treatment with SD400, remarkable cell shape changes were elicited in HUVEC cells, consistent with vasculature damaging activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo372LoP6iI8rVg90H21EOLACvtfcHk0li5UL6k7k1qIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCrsLbE&md5=486602f554293d500f9794150be4c31f</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2009.09.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2009.09.039%26sid%3Dliteratum%253Aachs%26aulast%3DDucki%26aufirst%3DS.%26aulast%3DRennison%26aufirst%3DD.%26aulast%3DWoo%26aufirst%3DM.%26aulast%3DKendall%26aufirst%3DA.%26aulast%3DChabert%26aufirst%3DJ.%2BF.%2BD.%26aulast%3DMcGown%26aufirst%3DA.%2BT.%26aulast%3DLawrence%26aufirst%3DN.%2BJ.%26atitle%3DCombretastatin-like%2520chalcones%2520as%2520inhibitors%2520of%2520microtubule%2520polymerization.%2520Part%25201%253A%2520Synthesis%2520and%2520biological%2520evaluation%2520of%2520antivascular%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D7698%26epage%3D7710%26doi%3D10.1016%2Fj.bmc.2009.09.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Zhu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yue, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shang, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bu, X.</span><span> </span><span class="NLM_article-title">Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">6364</span><span class="NLM_x">–</span> <span class="NLM_lpage">6382</span><span class="refDoi"> DOI: 10.1021/jm500024v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500024v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6364-6382&author=C.+Zhuauthor=Y.+Zuoauthor=R.+Wangauthor=B.+Liangauthor=X.+Yueauthor=G.+Wenauthor=N.+Shangauthor=L.+Huangauthor=Y.+Chenauthor=J.+Duauthor=X.+Bu&title=Discovery+of+potent+cytotoxic+ortho-aryl+chalcones+as+new+scaffold+targeting+tubulin+and+mitosis+with+affinity-based+fluorescence&doi=10.1021%2Fjm500024v"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fjm500024v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500024v%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DZuo%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DLiang%26aufirst%3DB.%26aulast%3DYue%26aufirst%3DX.%26aulast%3DWen%26aufirst%3DG.%26aulast%3DShang%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DBu%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520potent%2520cytotoxic%2520ortho-aryl%2520chalcones%2520as%2520new%2520scaffold%2520targeting%2520tubulin%2520and%2520mitosis%2520with%2520affinity-based%2520fluorescence%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6364%26epage%3D6382%26doi%3D10.1021%2Fjm500024v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Martel-Frachet, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keramidas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nurisso, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeBonis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rome, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coll, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boumendjel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skoufias, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ronot, X.</span><span> </span><span class="NLM_article-title">IPP51, a chalcone acting as a microtubule inhibitor with in vivo antitumor activity against bladder carcinoma</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">14669</span><span class="NLM_x">–</span> <span class="NLM_lpage">14686</span><span class="refDoi"> DOI: 10.18632/oncotarget.4144</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.18632%2Foncotarget.4144" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=14669-14686&author=V.+Martel-Frachetauthor=M.+Keramidasauthor=A.+Nurissoauthor=S.+DeBonisauthor=C.+Romeauthor=J.+L.+Collauthor=A.+Boumendjelauthor=D.+A.+Skoufiasauthor=X.+Ronot&title=IPP51%2C+a+chalcone+acting+as+a+microtubule+inhibitor+with+in+vivo+antitumor+activity+against+bladder+carcinoma&doi=10.18632%2Foncotarget.4144"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.4144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.4144%26sid%3Dliteratum%253Aachs%26aulast%3DMartel-Frachet%26aufirst%3DV.%26aulast%3DKeramidas%26aufirst%3DM.%26aulast%3DNurisso%26aufirst%3DA.%26aulast%3DDeBonis%26aufirst%3DS.%26aulast%3DRome%26aufirst%3DC.%26aulast%3DColl%26aufirst%3DJ.%2BL.%26aulast%3DBoumendjel%26aufirst%3DA.%26aulast%3DSkoufias%26aufirst%3DD.%2BA.%26aulast%3DRonot%26aufirst%3DX.%26atitle%3DIPP51%252C%2520a%2520chalcone%2520acting%2520as%2520a%2520microtubule%2520inhibitor%2520with%2520in%2520vivo%2520antitumor%2520activity%2520against%2520bladder%2520carcinoma%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D14669%26epage%3D14686%26doi%3D10.18632%2Foncotarget.4144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Zheng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mottamal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeMelle, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFerrin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, G.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel pyridine-bridged analogues of combretastatin-A4 as anticancer agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">3369</span><span class="NLM_x">–</span> <span class="NLM_lpage">3381</span><span class="refDoi"> DOI: 10.1021/jm500002k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500002k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVCrsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3369-3381&author=S.+Zhengauthor=Q.+Zhongauthor=M.+Mottamalauthor=Q.+Zhangauthor=C.+Zhangauthor=E.+LeMelleauthor=H.+McFerrinauthor=G.+Wang&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+pyridine-bridged+analogues+of+combretastatin-A4+as+anticancer+agents&doi=10.1021%2Fjm500002k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Novel Pyridine-Bridged Analogues of Combretastatin-A4 as Anticancer Agents</span></div><div class="casAuthors">Zheng, Shilong; Zhong, Qiu; Mottamal, Madhusoodanan; Zhang, Qiang; Zhang, Changde; LeMelle, Elise; McFerrin, Harris; Wang, Guangdi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3369-3381</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel pyridine-bridged analogs of combretastatin-A4 (CA-4) were designed and synthesized.  As expected, the 4-atom linker configuration retained little cytotoxicities.  Activities of the analogs with 3-atom linker varied widely depending on the Ph ring substitutions, and the 3-atom linker contg. nitrogen represents the more favorable linker structure.  Among them, three analogs (4h, 4s, and 4t; I - III, resp.) potently inhibited cell survival and growth, arrested cell cycle, and blocked angiogenesis and vasculature formation in vivo in ways comparable to CA-4.  The superposition of 4h and 4s in the colchicine-binding pocket of tubulin shows the binding posture of CA-4, 4h, and 4s are similar, as confirmed by the competitive binding assay where the ability of the ligands to replace tubulin-bound colchicine was measured.  The binding data are consistent with the obsd. biol. activities in antiproliferation and suppression of angiogenesis but are not predictive of their antitubulin polymn. activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe8RTj0wT9RLVg90H21EOLACvtfcHk0lgSr8gdfNo8IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVCrsLc%253D&md5=818f0a1793ce803a0b48e827004aa1e5</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fjm500002k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500002k%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DZhong%26aufirst%3DQ.%26aulast%3DMottamal%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLeMelle%26aufirst%3DE.%26aulast%3DMcFerrin%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DG.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520pyridine-bridged%2520analogues%2520of%2520combretastatin-A4%2520as%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3369%26epage%3D3381%26doi%3D10.1021%2Fjm500002k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Yoshimatsu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshino, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koyanagi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitoh, K.</span><span> </span><span class="NLM_article-title">Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">3208</span><span class="NLM_x">–</span> <span class="NLM_lpage">3213</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=9242451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADyaK2sXkvFKqs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=3208-3213&author=K.+Yoshimatsuauthor=A.+Yamaguchiauthor=H.+Yoshinoauthor=N.+Koyanagiauthor=K.+Kitoh&title=Mechanism+of+action+of+E7010%2C+an+orally+active+sulfonamide+antitumor+agent%3A+inhibition+of+mitosis+by+binding+to+the+colchicine+site+of+tubulin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin</span></div><div class="casAuthors">Yoshimatsu, Kentaro; Yamaguchi, Atsumi; Yoshino, Hiroshi; Koyanagi, Nozomu; Kitoh, Kyosuke</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3208-3213</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">E7010 (N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide), an orally active sulfonamide antitumor agent that is currently in a Phase I clin. trial, showed rather consistent growth-inhibitory activities against a panel of 26 human tumor cell lines (IC50 = 0.06-0.8 μg/mL), in contrast to vincristine (VCR; IC50 = 0.0002-0.04 μg/mL), 5-fluorouracil (IC50 = 0.2-30 -μg/mL), Adriamycin (IC50 = 0.002-0.7 μg/mL), mitomycin C (IC50 = 0.007-3 μg/mL), 1-β-D-arabionfuranoxylcytosine (IC50 = 0.005 to >30 μg/mL), camptothecin (IC50 = 0.002-0.4 μg/mL), and cisplatin (IC50 = 0.5-20 μg/mL).  It caused a dose-dependent increase in the percentage or mitotic cells in parallel with a decrease in cell proliferation, like VCR.  It also showed a dose-dependent inhibition of tubulin polymn., which correlated well with the cell growth-inhibitory activity.  14C-labeled E7010 bound to purified tubulin, and this binding was inhibited by colchicine but not by VCR.  However, its binding properties were different from those of colchicine, as well as those of VCR.  E7010 was active against two kind of VCR-resistant P388 cell lines, one of which showed multidrug resistance due to the overexpression of P-glycoprotein (resistant to Taxol), and the other did not show multidrug resistance (sensitive to Taxol).  Furthermore, four E7010-resistant P388 cell lines showed no cross-resistance to VCR, a different pattern of resistance to podophyllotoxin, and collateral sensitivity to Taxol.  Therefore, E7010 is a novel tubulin-binding agent that has a wider antitumor spectrum than VCR and has different properties from those of VCR or Taxol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVpxr7g_T5H7Vg90H21EOLACvtfcHk0lgSr8gdfNo8IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkvFKqs7Y%253D&md5=8e3c1d8dd4d82dad09ee5e930d58b6c6</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYoshimatsu%26aufirst%3DK.%26aulast%3DYamaguchi%26aufirst%3DA.%26aulast%3DYoshino%26aufirst%3DH.%26aulast%3DKoyanagi%26aufirst%3DN.%26aulast%3DKitoh%26aufirst%3DK.%26atitle%3DMechanism%2520of%2520action%2520of%2520E7010%252C%2520an%2520orally%2520active%2520sulfonamide%2520antitumor%2520agent%253A%2520inhibition%2520of%2520mitosis%2520by%2520binding%2520to%2520the%2520colchicine%2520site%2520of%2520tubulin%26jtitle%3DCancer%2520Res.%26date%3D1997%26volume%3D57%26spage%3D3208%26epage%3D3213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Hande, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berlin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meek, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothenberg, M. L.</span><span> </span><span class="NLM_article-title">The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2834</span><span class="NLM_x">–</span> <span class="NLM_lpage">2840</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-05-2159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1158%2F1078-0432.CCR-05-2159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=16675578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD28Xltlamt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=2834-2840&author=K.+R.+Handeauthor=A.+Hageyauthor=J.+Berlinauthor=Y.+Caiauthor=K.+Meekauthor=H.+Kobayashiauthor=A.+C.+Lockhartauthor=D.+Medinaauthor=J.+Sosmanauthor=G.+B.+Gordonauthor=M.+L.+Rothenberg&title=The+pharmacokinetics+and+safety+of+ABT-751%2C+a+novel%2C+orally+bioavailable+sulfonamide+antimitotic+agent%3A+results+of+a+phase+1+study&doi=10.1158%2F1078-0432.CCR-05-2159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study</span></div><div class="casAuthors">Hande, Kenneth R.; Hagey, Anne; Berlin, Jordan; Cai, Yingna; Meek, Kysa; Kobayashi, Hiro; Lockhart, A. Craig; Medina, Diane; Sosman, Jeffrey; Gordon, Gary B.; Rothenberg, Mace L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2834-2840</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Microtubules play a crit. role in many cellular functions, including cell division and mitosis.  ABT-751 is a novel sulfonamide antimitotic that binds to the colchicine site on β-tubulin that leads to a block in the cell cycle at the G2M phase, resulting in cellular apoptosis.  ABT-751 was investigated in this phase 1 trial designed to assess its max. tolerated dose (MTD), dose-limiting toxicity (DLT), tolerability, and pharmacokinetics.  Exptl. Design: ABT-751 was administered on a daily (q.d.) or twice daily (b.i.d.) oral schedule for 7 days every 3 wk to 39 patients with refractory solid tumors.  Toxicity was monitored weekly.  Plasma and urine ABT-751 and metabolite pharmacokinetics were detd.  Results: The MTD for the q.d. schedule was 250 mg/d.  DLTs during cycle 1 were abdominal pain, constipation, and fatigue.  The MTD on the b.i.d. schedule was 150 mg.  Cycle 1 of therapy with the 175 mg b.i.d. schedule was tolerated without DLT.  However, six of seven patients reported grade 3 toxicity (ileus, constipation, abdominal pain, or fatigue), which occurred in cycle 2 or 3.  ABT-751 was absorbed after oral administration with an overall mean Tmax of about 2 h.  The pharmacokinetics of ABT-751 were dose-proportional and time-independent.  There was minimal accumulation of ABT-751 after multiple q.d. and b.i.d. doses.  Efficacious concns., as detd. from preclin. models (0.5-1.5 μg/mL), were achieved in all subjects.  ABT-751 metab. occurred primarily by glucuronidation and sulfation.  No complete or partial tumor responses were noted, but one patient had a minor response, and four patients had stable disease lasting at least 6 mo.  Conclusions: The MTD and recommended phase 2 doses for ABT-751 were 250 mg q.d. and 150 mg b.i.d. on a 7-day schedule given every 3 wk, due to subsequent cycle toxicities at 175 mg b.i.d. dosing.  Toxicities were abdominal pain, constipation, and neuropathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBiv6KDudi_7Vg90H21EOLACvtfcHk0lgSr8gdfNo8IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xltlamt70%253D&md5=26b14f0577a4531cd93a7245044fa286</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-2159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-2159%26sid%3Dliteratum%253Aachs%26aulast%3DHande%26aufirst%3DK.%2BR.%26aulast%3DHagey%26aufirst%3DA.%26aulast%3DBerlin%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DY.%26aulast%3DMeek%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DH.%26aulast%3DLockhart%26aufirst%3DA.%2BC.%26aulast%3DMedina%26aufirst%3DD.%26aulast%3DSosman%26aufirst%3DJ.%26aulast%3DGordon%26aufirst%3DG.%2BB.%26aulast%3DRothenberg%26aufirst%3DM.%2BL.%26atitle%3DThe%2520pharmacokinetics%2520and%2520safety%2520of%2520ABT-751%252C%2520a%2520novel%252C%2520orally%2520bioavailable%2520sulfonamide%2520antimitotic%2520agent%253A%2520results%2520of%2520a%2520phase%25201%2520study%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D2834%26epage%3D2840%26doi%3D10.1158%2F1078-0432.CCR-05-2159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Dorléans, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gigant, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravelli, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mailliet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikol, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knossow, M.</span><span> </span><span class="NLM_article-title">Variations in the colchicine-binding domain provide insight into the structural switch of tubulin</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">13775</span><span class="NLM_x">–</span> <span class="NLM_lpage">13779</span><span class="refDoi"> DOI: 10.1073/pnas.0904223106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1073%2Fpnas.0904223106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=19666559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFWksLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=13775-13779&author=A.+Dorl%C3%A9ansauthor=B.+Gigantauthor=R.+B.+Ravelliauthor=P.+Maillietauthor=V.+Mikolauthor=M.+Knossow&title=Variations+in+the+colchicine-binding+domain+provide+insight+into+the+structural+switch+of+tubulin&doi=10.1073%2Fpnas.0904223106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Variations in the colchicine-binding domain provide insight into the structural switch of tubulin</span></div><div class="casAuthors">Dorleans, Audrey; Gigant, Benoit; Ravelli, Raimond B. G.; Mailliet, Patrick; Mikol, Vincent; Knossow, Marcel</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">13775-13779, S13775/1-S13775/8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Structural changes occur in the αβ-tubulin heterodimer during the microtubule assembly/disassembly cycle.  Their most prominent feature is a transition from a straight, microtubular structure to a curved structure.  There is a broad range of small mol. compds. that disturbs the microtubule cycle, a class of which targets the colchicine-binding site and prevents microtubule assembly.  This class includes compds. with very different chem. structures, and it is presently unknown whether they prevent tubulin polymn. by the same mechanism.  To address this issue, we have detd. the structures of tubulin complexed with a set of such ligands and show that they interfere with several of the movements of tubulin subunit structural elements upon its transition from curved to straight.  We also detd. the structure of tubulin unliganded at the colchicine site; this reveals that a β-tubulin loop (termed T7) flips into this site.  As with colchicine site ligands, this prevents a helix which is at the interface with α-tubulin from stacking onto a β-tubulin P sheet as in straight protofilaments.  Whereas in the presence of these ligands the interference with microtubule assembly gets frozen, by flipping in and out, the β-subunit T7 loop participates in a reversible way in the resistance to straightening that opposes microtubule assembly.  Our results suggest that it thereby contributes to microtubule dynamic instability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDDUQBAmYNvbVg90H21EOLACvtfcHk0lgUoDCqMGJiSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFWksLrO&md5=6d18732f78ac484b9db09ad1ec52aa5c</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0904223106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0904223106%26sid%3Dliteratum%253Aachs%26aulast%3DDorl%25C3%25A9ans%26aufirst%3DA.%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DRavelli%26aufirst%3DR.%2BB.%26aulast%3DMailliet%26aufirst%3DP.%26aulast%3DMikol%26aufirst%3DV.%26aulast%3DKnossow%26aufirst%3DM.%26atitle%3DVariations%2520in%2520the%2520colchicine-binding%2520domain%2520provide%2520insight%2520into%2520the%2520structural%2520switch%2520of%2520tubulin%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26spage%3D13775%26epage%3D13779%26doi%3D10.1073%2Fpnas.0904223106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Chang, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liou, J. P.</span><span> </span><span class="NLM_article-title">7-Aroyl-aminoindoline-1-sulfonamides as a novel class of potent antitubulin agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6656</span><span class="NLM_x">–</span> <span class="NLM_lpage">6659</span><span class="refDoi"> DOI: 10.1021/jm061076u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061076u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6656-6659&author=J.+Y.+Changauthor=H.+P.+Hsiehauthor=C.+Y.+Changauthor=K.+S.+Hsuauthor=Y.+F.+Chiangauthor=C.+M.+Chenauthor=C.+C.+Kuoauthor=J.+P.+Liou&title=7-Aroyl-aminoindoline-1-sulfonamides+as+a+novel+class+of+potent+antitubulin+agents&doi=10.1021%2Fjm061076u"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1021%2Fjm061076u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061076u%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DJ.%2BY.%26aulast%3DHsieh%26aufirst%3DH.%2BP.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DHsu%26aufirst%3DK.%2BS.%26aulast%3DChiang%26aufirst%3DY.%2BF.%26aulast%3DChen%26aufirst%3DC.%2BM.%26aulast%3DKuo%26aufirst%3DC.%2BC.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26atitle%3D7-Aroyl-aminoindoline-1-sulfonamides%2520as%2520a%2520novel%2520class%2520of%2520potent%2520antitubulin%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6656%26epage%3D6659%26doi%3D10.1021%2Fjm061076u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Nicholson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lloyd, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palladino, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiso, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuteboom, S. T. C.</span><span> </span><span class="NLM_article-title">NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">31</span><span class="refDoi"> DOI: 10.1097/01.cad.0000182745.01612.8a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1097%2F01.cad.0000182745.01612.8a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=16317287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A280%3ADC%252BD2MnjsFCqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=25-31&author=B.+Nicholsonauthor=G.+K.+Lloydauthor=B.+R.+Millerauthor=M.+A.+Palladinoauthor=Y.+Kisoauthor=Y.+Hayashiauthor=S.+T.+C.+Neuteboom&title=NPI-2358+is+a+tubulin-depolymerizing+agent%3A+in-vitro+evidence+for+activity+as+a+tumor+vascular-disrupting+agent&doi=10.1097%2F01.cad.0000182745.01612.8a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent</span></div><div class="casAuthors">Nicholson Benjamin; Lloyd G Kenneth; Miller Brian R; Palladino Michael A; Kiso Yoshiaki; Hayashi Yoshio; Neuteboom Saskia T C</div><div class="citationInfo"><span class="NLM_cas:title">Anti-cancer drugs</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-31</span>
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    </div><div class="casAbstract">The diketopiperazine NPI-2358 is a synthetic analog of NPI-2350, a natural product isolated from Aspergillus sp., which depolymerizes microtubules in A549 human lung carcinoma cells.  Although structurally different from the colchicine-binding site agents reported to date, NPI-2358 binds to the colchicine-binding site of tubulin.  NPI-2358 has potent in-vitro anti-tumor activity against various human tumor cell lines and maintains activity against tumor cell lines with various multidrug-resistant (MDR) profiles.  In addition, when evaluated in proliferating human umbilical vein endothelial cells (HUVECs), concentrations as low as 10 nmol/l NPI-2358 induced tubulin depolymerization within 30 min.  Furthermore, NPI-2358 dose dependently increases HUVEC monolayer permeability--an in-vitro model of tumor vascular collapse.  NPI-2358 was compared with three tubulin-depolymerizing agents with vascular-disrupting activity: colchicine, vincristine and combretastatin A-4 (CA4).  Results showed that the activity of NPI-2358 in HUVECs was more potent than either colchicine or vincristine; the profile of CA4 approached that of NPI-2358.  Altogether, our data show that NPI-2358 is a potent anti-tumor agent which is active in MDR tumor cell lines, and is able to rapidly induce tubulin depolymerization and monolayer permeability in HUVECs.  These data warrant further evaluation of NPI-2358 as a vascular-disrupting agent in vivo.  Currently, NPI-2358 is in preclinical development for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ6ysYjEuHQMxcr74wzj5o5fW6udTcc2eZRkaBiVtxR6Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MnjsFCqug%253D%253D&md5=c8f8e21db08175e196ea0d673fc0322b</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1097%2F01.cad.0000182745.01612.8a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.cad.0000182745.01612.8a%26sid%3Dliteratum%253Aachs%26aulast%3DNicholson%26aufirst%3DB.%26aulast%3DLloyd%26aufirst%3DG.%2BK.%26aulast%3DMiller%26aufirst%3DB.%2BR.%26aulast%3DPalladino%26aufirst%3DM.%2BA.%26aulast%3DKiso%26aufirst%3DY.%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DNeuteboom%26aufirst%3DS.%2BT.%2BC.%26atitle%3DNPI-2358%2520is%2520a%2520tubulin-depolymerizing%2520agent%253A%2520in-vitro%2520evidence%2520for%2520activity%2520as%2520a%2520tumor%2520vascular-disrupting%2520agent%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2006%26volume%3D17%26spage%3D25%26epage%3D31%26doi%3D10.1097%2F01.cad.0000182745.01612.8a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Yamazaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sumikura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hidaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasui, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiso, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakushiji, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, Y.</span><span> </span><span class="NLM_article-title">Anti-microtubule ‘plinabulin’ chemical probe KPU-244-B3 labeled both α- and β-tubulin</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3169</span><span class="NLM_x">–</span> <span class="NLM_lpage">3174</span><span class="refDoi"> DOI: 10.1016/j.bmc.2010.03.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.bmc.2010.03.037" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=3169-3174&author=Y.+Yamazakiauthor=M.+Sumikuraauthor=K.+Hidakaauthor=H.+Yasuiauthor=Y.+Kisoauthor=F.+Yakushijiauthor=Y.+Hayashi&title=Anti-microtubule+%E2%80%98plinabulin%E2%80%99+chemical+probe+KPU-244-B3+labeled+both+%CE%B1-+and+%CE%B2-tubulin&doi=10.1016%2Fj.bmc.2010.03.037"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.03.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.03.037%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DY.%26aulast%3DSumikura%26aufirst%3DM.%26aulast%3DHidaka%26aufirst%3DK.%26aulast%3DYasui%26aufirst%3DH.%26aulast%3DKiso%26aufirst%3DY.%26aulast%3DYakushiji%26aufirst%3DF.%26aulast%3DHayashi%26aufirst%3DY.%26atitle%3DAnti-microtubule%2520%25E2%2580%2598plinabulin%25E2%2580%2599%2520chemical%2520probe%2520KPU-244-B3%2520labeled%2520both%2520%25CE%25B1-%2520and%2520%25CE%25B2-tubulin%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D3169%26epage%3D3174%26doi%3D10.1016%2Fj.bmc.2010.03.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Yamazaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kido, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hidaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasui, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiso, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakushiji, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, Y.</span><span> </span><span class="NLM_article-title">Tubulin photoaffinity labeling study with a plinabulin chemical probe possessing a biotin tag at the oxazole</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">595</span><span class="NLM_x">–</span> <span class="NLM_lpage">602</span><span class="refDoi"> DOI: 10.1016/j.bmc.2010.10.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.bmc.2010.10.055" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=595-602&author=Y.+Yamazakiauthor=Y.+Kidoauthor=K.+Hidakaauthor=H.+Yasuiauthor=Y.+Kisoauthor=F.+Yakushijiauthor=Y.+Hayashi&title=Tubulin+photoaffinity+labeling+study+with+a+plinabulin+chemical+probe+possessing+a+biotin+tag+at+the+oxazole&doi=10.1016%2Fj.bmc.2010.10.055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.10.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.10.055%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DY.%26aulast%3DKido%26aufirst%3DY.%26aulast%3DHidaka%26aufirst%3DK.%26aulast%3DYasui%26aufirst%3DH.%26aulast%3DKiso%26aufirst%3DY.%26aulast%3DYakushiji%26aufirst%3DF.%26aulast%3DHayashi%26aufirst%3DY.%26atitle%3DTubulin%2520photoaffinity%2520labeling%2520study%2520with%2520a%2520plinabulin%2520chemical%2520probe%2520possessing%2520a%2520biotin%2520tag%2520at%2520the%2520oxazole%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D595%26epage%3D602%26doi%3D10.1016%2Fj.bmc.2010.10.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gigant, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span> </span><span class="NLM_article-title">Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery</span> <span class="citation_source-journal">FEBS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">102</span><span class="NLM_x">–</span> <span class="NLM_lpage">111</span><span class="refDoi"> DOI: 10.1111/febs.13555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1111%2Ffebs.13555" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=26462166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKktrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2016&pages=102-111&author=Y.+Wangauthor=H.+Zhangauthor=B.+Gigantauthor=Y.+Yuauthor=Y.+Wuauthor=X.+Chenauthor=Q.+Laiauthor=Z.+Yangauthor=Q.+Chenauthor=J.+Yang&title=Structures+of+a+diverse+set+of+colchicine+binding+site+inhibitors+in+complex+with+tubulin+provide+a+rationale+for+drug+discovery&doi=10.1111%2Ffebs.13555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery</span></div><div class="casAuthors">Wang, Yuxi; Zhang, Hang; Gigant, Benoit; Yu, Yamei; Wu, Yangping; Chen, Xiangzheng; Lai, Qinhuai; Yang, Zhaoya; Chen, Qiang; Yang, Jinliang</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-111</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Microtubules are dynamic assemblies of αβ-tubulin heterodimers and have been recognized as highly attractive targets for cancer chemotherapy.  A broad range of agents bind to tubulin and interfere with microtubule assembly.  Despite having a long history of characterization, colchicine binding site inhibitors (CBSIs) have not yet reached the com. phase as anti-cancer drugs to date.  We detd. the structures of tubulin complexed with a set of structurally diverse CBSIs (lexibulin, nocodazole, plinabulin and tivantinib), among which nocodazole and tivantinib are both binary-function inhibitors targeting cancer-related kinases and microtubules simultaneously.  High resoln. structures revealed the detailed interactions between these ligands and tubulin.  Our results showed that the binding modes of the CBSIs were different from previous docking models, highlighting the importance of crystal structure information in structure-based drug design.  A real structure-based pharmacophore was proposed to rationalize key common interactions of the CBSIs at the colchicine domain.  Our studies provide a solid structural basis for developing new anti-cancer agents for the colchicine binding site.  Database : The at. coordinates and structure factors for tubulin complexed with lexibulin, nocodazole, plinabulin and tivantinib have been deposited in the Protein Data Bank under accession codes , , and , resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSIAVSS_EsIbVg90H21EOLACvtfcHk0ljdtXVeKnK77A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKktrzP&md5=d5a17d9a3ac54d8eda44d0543ffa5fbd</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1111%2Ffebs.13555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Ffebs.13555%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLai%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DStructures%2520of%2520a%2520diverse%2520set%2520of%2520colchicine%2520binding%2520site%2520inhibitors%2520in%2520complex%2520with%2520tubulin%2520provide%2520a%2520rationale%2520for%2520drug%2520discovery%26jtitle%3DFEBS%2520J.%26date%3D2016%26volume%3D283%26spage%3D102%26epage%3D111%26doi%3D10.1111%2Ffebs.13555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Yamazaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deyanat-Yazdi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potts, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitagawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orikasa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiso, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasui, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akamatsu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chinen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Usui, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinozaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakushiji, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuteboom, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palladino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanoh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lloyd, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, Y.</span><span> </span><span class="NLM_article-title">Synthesis and structure–activity relationship study of antimicrotubule agents phenylahistin derivatives with a didehydropiperazine-2,5-dione structure</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1056</span><span class="NLM_x">–</span> <span class="NLM_lpage">1071</span><span class="refDoi"> DOI: 10.1021/jm2009088</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2009088" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1056-1071&author=Y.+Yamazakiauthor=K.+Tanakaauthor=B.+Nicholsonauthor=G.+Deyanat-Yazdiauthor=B.+Pottsauthor=T.+Yoshidaauthor=A.+Odaauthor=T.+Kitagawaauthor=S.+Orikasaauthor=Y.+Kisoauthor=H.+Yasuiauthor=M.+Akamatsuauthor=T.+Chinenauthor=T.+Usuiauthor=Y.+Shinozakiauthor=F.+Yakushijiauthor=B.+R.+Millerauthor=S.+Neuteboomauthor=M.+Palladinoauthor=K.+Kanohauthor=G.+K.+Lloydauthor=Y.+Hayashi&title=Synthesis+and+structure%E2%80%93activity+relationship+study+of+antimicrotubule+agents+phenylahistin+derivatives+with+a+didehydropiperazine-2%2C5-dione+structure&doi=10.1021%2Fjm2009088"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Fjm2009088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2009088%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DK.%26aulast%3DNicholson%26aufirst%3DB.%26aulast%3DDeyanat-Yazdi%26aufirst%3DG.%26aulast%3DPotts%26aufirst%3DB.%26aulast%3DYoshida%26aufirst%3DT.%26aulast%3DOda%26aufirst%3DA.%26aulast%3DKitagawa%26aufirst%3DT.%26aulast%3DOrikasa%26aufirst%3DS.%26aulast%3DKiso%26aufirst%3DY.%26aulast%3DYasui%26aufirst%3DH.%26aulast%3DAkamatsu%26aufirst%3DM.%26aulast%3DChinen%26aufirst%3DT.%26aulast%3DUsui%26aufirst%3DT.%26aulast%3DShinozaki%26aufirst%3DY.%26aulast%3DYakushiji%26aufirst%3DF.%26aulast%3DMiller%26aufirst%3DB.%2BR.%26aulast%3DNeuteboom%26aufirst%3DS.%26aulast%3DPalladino%26aufirst%3DM.%26aulast%3DKanoh%26aufirst%3DK.%26aulast%3DLloyd%26aufirst%3DG.%2BK.%26aulast%3DHayashi%26aufirst%3DY.%26atitle%3DSynthesis%2520and%2520structure%25E2%2580%2593activity%2520relationship%2520study%2520of%2520antimicrotubule%2520agents%2520phenylahistin%2520derivatives%2520with%2520a%2520didehydropiperazine-2%252C5-dione%2520structure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1056%26epage%3D1071%26doi%3D10.1021%2Fjm2009088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Reddy, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, C.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, U.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coumar, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liou, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H.-P.</span><span> </span><span class="NLM_article-title">Synthesis and structure–activity relationships of 2-amino-1-aroylnaphthalene and 2-hydroxy-1-aroylnaphthalenes as potent antitubulin agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">8163</span><span class="NLM_x">–</span> <span class="NLM_lpage">8167</span><span class="refDoi"> DOI: 10.1021/jm8008635</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8008635" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=8163-8167&author=G.+R.+Reddyauthor=C.-C.+Kuoauthor=U.-K.+Tanauthor=M.+S.+Coumarauthor=C.-Y.+Changauthor=Y.-K.+Chiangauthor=M.-J.+Laiauthor=J.-Y.+Yehauthor=S.-Y.+Wuauthor=J.-Y.+Changauthor=J.-P.+Liouauthor=H.-P.+Hsieh&title=Synthesis+and+structure%E2%80%93activity+relationships+of+2-amino-1-aroylnaphthalene+and+2-hydroxy-1-aroylnaphthalenes+as+potent+antitubulin+agents&doi=10.1021%2Fjm8008635"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Fjm8008635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8008635%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DG.%2BR.%26aulast%3DKuo%26aufirst%3DC.-C.%26aulast%3DTan%26aufirst%3DU.-K.%26aulast%3DCoumar%26aufirst%3DM.%2BS.%26aulast%3DChang%26aufirst%3DC.-Y.%26aulast%3DChiang%26aufirst%3DY.-K.%26aulast%3DLai%26aufirst%3DM.-J.%26aulast%3DYeh%26aufirst%3DJ.-Y.%26aulast%3DWu%26aufirst%3DS.-Y.%26aulast%3DChang%26aufirst%3DJ.-Y.%26aulast%3DLiou%26aufirst%3DJ.-P.%26aulast%3DHsieh%26aufirst%3DH.-P.%26atitle%3DSynthesis%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%25202-amino-1-aroylnaphthalene%2520and%25202-hydroxy-1-aroylnaphthalenes%2520as%2520potent%2520antitubulin%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D8163%26epage%3D8167%26doi%3D10.1021%2Fjm8008635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Burns, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harte, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joffe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sikanyika, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tranberg, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charman, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shackleford, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilks, A. F.</span><span> </span><span class="NLM_article-title">Discovery of CYT997: a structurally novel orally active microtubule targeting agent</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4639</span><span class="NLM_x">–</span> <span class="NLM_lpage">4642</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.06.079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.bmcl.2009.06.079" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4639-4642&author=C.+J.+Burnsauthor=M.+F.+Harteauthor=X.+Buauthor=E.+Fantinoauthor=M.+Joffeauthor=H.+Sikanyikaauthor=S.+Suauthor=C.+E.+Tranbergauthor=N.+Wilsonauthor=S.+A.+Charmanauthor=D.+M.+Shacklefordauthor=A.+F.+Wilks&title=Discovery+of+CYT997%3A+a+structurally+novel+orally+active+microtubule+targeting+agent&doi=10.1016%2Fj.bmcl.2009.06.079"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.06.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.06.079%26sid%3Dliteratum%253Aachs%26aulast%3DBurns%26aufirst%3DC.%2BJ.%26aulast%3DHarte%26aufirst%3DM.%2BF.%26aulast%3DBu%26aufirst%3DX.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DJoffe%26aufirst%3DM.%26aulast%3DSikanyika%26aufirst%3DH.%26aulast%3DSu%26aufirst%3DS.%26aulast%3DTranberg%26aufirst%3DC.%2BE.%26aulast%3DWilson%26aufirst%3DN.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26atitle%3DDiscovery%2520of%2520CYT997%253A%2520a%2520structurally%2520novel%2520orally%2520active%2520microtubule%2520targeting%2520agent%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4639%26epage%3D4642%26doi%3D10.1016%2Fj.bmcl.2009.06.079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Burns, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harte, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bukczynska, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frazzetto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joffe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruszelnicki, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dilley, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charman, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shackleford, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fida, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malcontenti-Wilson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilks, A. F.</span><span> </span><span class="NLM_article-title">CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">3036</span><span class="NLM_x">–</span> <span class="NLM_lpage">3045</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1158%2F1535-7163.MCT-09-0076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=19887548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlyrt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=3036-3045&author=C.+J.+Burnsauthor=E.+Fantinoauthor=I.+D.+Phillipsauthor=S.+Suauthor=M.+F.+Harteauthor=P.+E.+Bukczynskaauthor=M.+Frazzettoauthor=M.+Joffeauthor=I.+Kruszelnickiauthor=B.+Wangauthor=Y.+Wangauthor=N.+Wilsonauthor=R.+J.+Dilleyauthor=S.+S.+Wanauthor=S.+A.+Charmanauthor=D.+M.+Shacklefordauthor=R.+Fidaauthor=C.+Malcontenti-Wilsonauthor=A.+F.+Wilks&title=CYT997%3A+a+novel+orally+active+tubulin+polymerization+inhibitor+with+potent+cytotoxic+and+vascular+disrupting+activity+in+vitro+and+in+vivo&doi=10.1158%2F1535-7163.MCT-09-0076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo</span></div><div class="casAuthors">Burns, Christopher J.; Fantino, Emmanuelle; Phillips, Ian D.; Su, Stephen; Harte, Michael F.; Bukczynska, Patricia E.; Frazzetto, Mark; Joffe, Max; Kruszelnicki, Irma; Wang, Bing; Wang, Yue; Wilson, Neil; Dilley, Rodney J.; Wan, Soo S.; Charman, Susan A.; Shackleford, David M.; Fida, Rosa; Malcontenti-Wilson, Cathy; Wilks, Andrew F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3036-3045</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">CYT997 is a wholly synthetic compd. that possesses highly potent cytotoxic activity in vitro through inhibition of microtubule polymn.  CYT997 blocks the cell cycle at the G2-M boundary, and Western blot anal. indicates an increase in phosphorylated Bcl-2, along with increased expression of cyclin B1.  Caspase-3 activation is also obsd. in cells treated with CYT997 along with the generation of poly(ADP-ribose) polymerase.  The compd. possesses favorable pharmacokinetic properties, is orally bioavailable, and is efficacious per os in a range of in vivo cancer models, including some refractory to paclitaxel treatment.  CYT997 exhibits vascular disrupting activity as measured in vitro by effects on the permeability of human umbilical vein endothelial cell monolayers, and in vivo by effects on tumor blood flow.  CYT997 possesses a useful combination of pharmacol. and pharmacokinetic properties and has considerable potential as a novel anticancer agent. [Mol Cancer Ther 2009;8(11):3036-45].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr09YoJx33QQ7Vg90H21EOLACvtfcHk0lgEg1oY4i3KIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlyrt7%252FM&md5=76f883c9aa6a5bbde05b11c0e3f42fd0</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0076%26sid%3Dliteratum%253Aachs%26aulast%3DBurns%26aufirst%3DC.%2BJ.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DPhillips%26aufirst%3DI.%2BD.%26aulast%3DSu%26aufirst%3DS.%26aulast%3DHarte%26aufirst%3DM.%2BF.%26aulast%3DBukczynska%26aufirst%3DP.%2BE.%26aulast%3DFrazzetto%26aufirst%3DM.%26aulast%3DJoffe%26aufirst%3DM.%26aulast%3DKruszelnicki%26aufirst%3DI.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWilson%26aufirst%3DN.%26aulast%3DDilley%26aufirst%3DR.%2BJ.%26aulast%3DWan%26aufirst%3DS.%2BS.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DFida%26aufirst%3DR.%26aulast%3DMalcontenti-Wilson%26aufirst%3DC.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26atitle%3DCYT997%253A%2520a%2520novel%2520orally%2520active%2520tubulin%2520polymerization%2520inhibitor%2520with%2520potent%2520cytotoxic%2520and%2520vascular%2520disrupting%2520activity%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D3036%26epage%3D3045%26doi%3D10.1158%2F1535-7163.MCT-09-0076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Bacher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emig, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanhoefer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shandra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klenner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckers, T.</span><span> </span><span class="NLM_article-title">D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">392</span><span class="NLM_x">–</span> <span class="NLM_lpage">399</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=392-399&author=G.+Bacherauthor=B.+Nickelauthor=P.+Emigauthor=U.+Vanhoeferauthor=S.+Seeberauthor=A.+Shandraauthor=T.+Klennerauthor=T.+Beckers&title=D-24851%2C+a+novel+synthetic+microtubule+inhibitor%2C+exerts+curative+antitumoral+activity+in+vivo%2C+shows+efficacy+toward+multidrug-resistant+tumor+cells%2C+and+lacks+neurotoxicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBacher%26aufirst%3DG.%26aulast%3DNickel%26aufirst%3DB.%26aulast%3DEmig%26aufirst%3DP.%26aulast%3DVanhoefer%26aufirst%3DU.%26aulast%3DSeeber%26aufirst%3DS.%26aulast%3DShandra%26aufirst%3DA.%26aulast%3DKlenner%26aufirst%3DT.%26aulast%3DBeckers%26aufirst%3DT.%26atitle%3DD-24851%252C%2520a%2520novel%2520synthetic%2520microtubule%2520inhibitor%252C%2520exerts%2520curative%2520antitumoral%2520activity%2520in%2520vivo%252C%2520shows%2520efficacy%2520toward%2520multidrug-resistant%2520tumor%2520cells%252C%2520and%2520lacks%2520neurotoxicity%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D392%26epage%3D399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group">Oostendorp, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witteveen, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vainchtein, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schot, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nol, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosing, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beijnen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voest, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellens, J. H. M.</span><span> </span><span class="NLM_article-title">Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">163</span><span class="NLM_x">–</span> <span class="NLM_lpage">170</span><span class="refDoi"> DOI: 10.1007/s10637-009-9244-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1007%2Fs10637-009-9244-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=163-170&author=R.+L.+Oostendorpauthor=P.+O.+Witteveenauthor=B.+Schwartzauthor=L.+D.+Vainchteinauthor=M.+Schotauthor=A.+Nolauthor=H.+Rosingauthor=J.+H.+Beijnenauthor=E.+E.+Voestauthor=J.+H.+M.+Schellens&title=Dose-finding+and+pharmacokinetic+study+of+orally+administered+indibulin+%28D-24851%29+to+patients+with+advanced+solid+tumors&doi=10.1007%2Fs10637-009-9244-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1007%2Fs10637-009-9244-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-009-9244-6%26sid%3Dliteratum%253Aachs%26aulast%3DOostendorp%26aufirst%3DR.%2BL.%26aulast%3DWitteveen%26aufirst%3DP.%2BO.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DVainchtein%26aufirst%3DL.%2BD.%26aulast%3DSchot%26aufirst%3DM.%26aulast%3DNol%26aufirst%3DA.%26aulast%3DRosing%26aufirst%3DH.%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3DVoest%26aufirst%3DE.%2BE.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%2BM.%26atitle%3DDose-finding%2520and%2520pharmacokinetic%2520study%2520of%2520orally%2520administered%2520indibulin%2520%2528D-24851%2529%2520to%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2010%26volume%3D28%26spage%3D163%26epage%3D170%26doi%3D10.1007%2Fs10637-009-9244-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">Colley, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muthana, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danson, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brett, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coole, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tulasi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockey, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dossetter, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffen, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, M. J.</span><span> </span><span class="NLM_article-title">An orally bioavailable, indole-3-glyoxylamide based series of tubulin polymerization inhibitors showing tumor growth inhibition in a mouse xenograft model of head and neck cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">9309</span><span class="NLM_x">–</span> <span class="NLM_lpage">9333</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01312</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01312" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9309-9333&author=H.+E.+Colleyauthor=M.+Muthanaauthor=S.+J.+Dansonauthor=L.+V.+Jacksonauthor=M.+L.+Brettauthor=J.+Harrisonauthor=S.+F.+Cooleauthor=D.+P.+Masonauthor=L.+R.+Jenningsauthor=M.+Wongauthor=V.+Tulasiauthor=D.+Normanauthor=P.+M.+Lockeyauthor=L.+Williamsauthor=A.+G.+Dossetterauthor=E.+J.+Griffenauthor=M.+J.+Thompson&title=An+orally+bioavailable%2C+indole-3-glyoxylamide+based+series+of+tubulin+polymerization+inhibitors+showing+tumor+growth+inhibition+in+a+mouse+xenograft+model+of+head+and+neck+cancer&doi=10.1021%2Facs.jmedchem.5b01312"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01312%26sid%3Dliteratum%253Aachs%26aulast%3DColley%26aufirst%3DH.%2BE.%26aulast%3DMuthana%26aufirst%3DM.%26aulast%3DDanson%26aufirst%3DS.%2BJ.%26aulast%3DJackson%26aufirst%3DL.%2BV.%26aulast%3DBrett%26aufirst%3DM.%2BL.%26aulast%3DHarrison%26aufirst%3DJ.%26aulast%3DCoole%26aufirst%3DS.%2BF.%26aulast%3DMason%26aufirst%3DD.%2BP.%26aulast%3DJennings%26aufirst%3DL.%2BR.%26aulast%3DWong%26aufirst%3DM.%26aulast%3DTulasi%26aufirst%3DV.%26aulast%3DNorman%26aufirst%3DD.%26aulast%3DLockey%26aufirst%3DP.%2BM.%26aulast%3DWilliams%26aufirst%3DL.%26aulast%3DDossetter%26aufirst%3DA.%2BG.%26aulast%3DGriffen%26aufirst%3DE.%2BJ.%26aulast%3DThompson%26aufirst%3DM.%2BJ.%26atitle%3DAn%2520orally%2520bioavailable%252C%2520indole-3-glyoxylamide%2520based%2520series%2520of%2520tubulin%2520polymerization%2520inhibitors%2520showing%2520tumor%2520growth%2520inhibition%2520in%2520a%2520mouse%2520xenograft%2520model%2520of%2520head%2520and%2520neck%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9309%26epage%3D9333%26doi%3D10.1021%2Facs.jmedchem.5b01312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group">Ricart, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooney, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarantopoulos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brell, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruby, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munsey, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zambito, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolcher, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remick, S. C.</span><span> </span><span class="NLM_article-title">A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">959</span><span class="NLM_x">–</span> <span class="NLM_lpage">970</span><span class="refDoi"> DOI: 10.1007/s00280-011-1565-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1007%2Fs00280-011-1565-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=21305290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1eiu7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2011&pages=959-970&author=A.+D.+Ricartauthor=E.+A.+Ashtonauthor=M.+M.+Cooneyauthor=J.+Sarantopoulosauthor=J.+M.+Brellauthor=M.+A.+Feldmanauthor=K.+E.+Rubyauthor=K.+Matsudaauthor=M.+S.+Munseyauthor=G.+Medinaauthor=A.+Zambitoauthor=A.+W.+Tolcherauthor=S.+C.+Remick&title=A+phase+I+study+of+MN-029+%28denibulin%29%2C+a+novel+vascular-disrupting+agent%2C+in+patients+with+advanced+solid+tumors&doi=10.1007%2Fs00280-011-1565-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors</span></div><div class="casAuthors">Ricart, Alejandro D.; Ashton, Edward A.; Cooney, Matthew M.; Sarantopoulos, John; Brell, Joanna M.; Feldman, Maria A.; Ruby, Kale E.; Matsuda, Kazuko; Munsey, Mark S.; Medina, Gerardo; Zambito, Angela; Tolcher, Anthony W.; Remick, Scot C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">959-970</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose MN-029 (denibulin HCl) is a novel vascular-disrupting agent that reversibly inhibits microtubule assembly, resulting in disruption of the cytoskeleton of tumor vascular endothelial cells.  This study detd. the safety, pharmacokinetics, and acute anti-vascular effects of MN-029.  Methods Patients were treated with escalating doses of MN-029 (4.0-225 mg/m2) administered IV at 3-wk intervals.  This first-in-human study followed an accelerated titrn. design, with intra-patient dose escalation.  Plasma samples were assayed to det. PK parameters.  DCE-MRI scans were acquired at baseline and at 6-8 h post-dose.  Results Thirty-four patients received 151 infusions of MN-029.  The most common toxicities of MN-029 included nausea and vomiting (which appeared to be dose related), diarrhea, fatigue, headache, and anorexia.  No clin. significant myelotoxicity, stomatitis or alopecia was obsd.  There was no evidence of cumulative toxicity in patients receiving multiple courses of therapy.  The cohort at 180 mg/m2 was expanded to six patients due to a reversible episode of acute coronary ischemia, without sequelae and with preservation of myocardial function.  Two dose-limiting toxicities occurred at 225 mg/m2, a transient ischemic attack and grade 3 transaminitis, thus ending dose escalation.  Pharmacokinetic data indicated dose-related increases in C max and AUC values, although substantial inter-subject variability was obsd.  No objective responses were noted; however, five patients had stable disease ≥6 mo.  A significant linear correlation was found between redn. in K trans and exposure to MN-029.  Conclusions MN-029 was generally well tolerated and showed decrease in tumor vascular parameters.  The max. tolerated dose was 180 mg/m2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxgyxrtbsON7Vg90H21EOLACvtfcHk0lhjU_UiAGRM-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1eiu7%252FL&md5=53ffe56de2b460a865da4c36d57a7ed1</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1007%2Fs00280-011-1565-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-011-1565-4%26sid%3Dliteratum%253Aachs%26aulast%3DRicart%26aufirst%3DA.%2BD.%26aulast%3DAshton%26aufirst%3DE.%2BA.%26aulast%3DCooney%26aufirst%3DM.%2BM.%26aulast%3DSarantopoulos%26aufirst%3DJ.%26aulast%3DBrell%26aufirst%3DJ.%2BM.%26aulast%3DFeldman%26aufirst%3DM.%2BA.%26aulast%3DRuby%26aufirst%3DK.%2BE.%26aulast%3DMatsuda%26aufirst%3DK.%26aulast%3DMunsey%26aufirst%3DM.%2BS.%26aulast%3DMedina%26aufirst%3DG.%26aulast%3DZambito%26aufirst%3DA.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DRemick%26aufirst%3DS.%2BC.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520MN-029%2520%2528denibulin%2529%252C%2520a%2520novel%2520vascular-disrupting%2520agent%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2011%26volume%3D68%26spage%3D959%26epage%3D970%26doi%3D10.1007%2Fs00280-011-1565-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group">Kasibhatla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baichwal, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, S. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skvortsova, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skvortsov, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">English, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirisoma, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drewe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pervin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, R. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pleiman, C. M.</span><span> </span><span class="NLM_article-title">MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">5865</span><span class="NLM_x">–</span> <span class="NLM_lpage">5871</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-0127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1158%2F0008-5472.CAN-07-0127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=17575155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsFCqtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=5865-5871&author=S.+Kasibhatlaauthor=V.+Baichwalauthor=S.+X.+Caiauthor=B.+Rothauthor=I.+Skvortsovaauthor=S.+Skvortsovauthor=P.+Lukasauthor=N.+M.+Englishauthor=N.+Sirisomaauthor=J.+Dreweauthor=A.+Pervinauthor=B.+Tsengauthor=R.+O.+Carlsonauthor=C.+M.+Pleiman&title=MPC-6827%3A+a+small-molecule+inhibitor+of+microtubule+formation+that+is+not+a+substrate+for+multidrug+resistance+pumps&doi=10.1158%2F0008-5472.CAN-07-0127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">MPC-6827: A small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps</span></div><div class="casAuthors">Kasibhatla, Shailaja; Baichwal, Vijay; Cai, Sui Xiong; Roth, Bruce; Skvortsova, Ira; Skvortsov, Sergej; Lukas, Peter; English, Nicole M.; Sirisoma, Nilantha; Drewe, John; Pervin, Azra; Tseng, Ben; Carlson, Robert O.; Pleiman, Christopher M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5865-5871</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A novel series of 4-arylaminoquinazolines were identified from a cell-based screening assay as potent apoptosis inducers.  Through structure-activity relationship studies, MPC-6827 and its close structural analog, MPI-0441138, were discovered as proapoptotic mols. and mitotic inhibitors with potencies at low nanomolar concns. in multiple tumor cell lines.  Photoaffinity and radiolabeled analogs of MPC-6827 were found to bind a 55-kDa protein, and this binding was competed by MPC-6827, paclitaxel, and colchicine, but not vinblastine.  MPC-6827 effectively inhibited the polymn. of tubulin in vitro, competed with colchicine binding, and disrupted the formation of microtubules in a variety of tumor cell lines, which together showed the mol. target as tubulin.  Treatment of MCF-7 breast carcinoma or Jurkat leukemia cells with MPC-6827 led to pronounced G2-M cell cycle arrest followed by apoptosis.  Apoptosis, as detd. by terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling assay, was preceded by loss of mitochondrial membrane potential, cytochrome c translocation from mitochondria to nuclei, activation of caspase-3, and cleavage of poly(ADP-ribose) polymerase.  MPC-6827 was equipotent in an in vitro growth inhibition assay in several cancer cell lines regardless of the expression levels of the multidrug resistance ABC transporters MDR-1 (Pgp-1), MRP-1, and BCRP-1.  In B16-F1 allografts and in OVCAR-3, MIAPaCa-2, MCF-7, HT-29, MDA-MB-435, and MX-1 xenografts, statistically significant tumor growth inhibition was obsd. with MPC-6827.  These studies show that MPC-6827 is a microtubule-disrupting agent with potent and broad-spectrum in vitro and in vivo cytotoxic activities and, therefore, MPC-6827 is a promising candidate for development as a novel therapeutic for multiple cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqo-qab7pG6E7Vg90H21EOLACvtfcHk0lhqz2o8ocCObg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsFCqtrg%253D&md5=3ce57c281fdc663115a794ac7e91f177</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-0127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-0127%26sid%3Dliteratum%253Aachs%26aulast%3DKasibhatla%26aufirst%3DS.%26aulast%3DBaichwal%26aufirst%3DV.%26aulast%3DCai%26aufirst%3DS.%2BX.%26aulast%3DRoth%26aufirst%3DB.%26aulast%3DSkvortsova%26aufirst%3DI.%26aulast%3DSkvortsov%26aufirst%3DS.%26aulast%3DLukas%26aufirst%3DP.%26aulast%3DEnglish%26aufirst%3DN.%2BM.%26aulast%3DSirisoma%26aufirst%3DN.%26aulast%3DDrewe%26aufirst%3DJ.%26aulast%3DPervin%26aufirst%3DA.%26aulast%3DTseng%26aufirst%3DB.%26aulast%3DCarlson%26aufirst%3DR.%2BO.%26aulast%3DPleiman%26aufirst%3DC.%2BM.%26atitle%3DMPC-6827%253A%2520a%2520small-molecule%2520inhibitor%2520of%2520microtubule%2520formation%2520that%2520is%2520not%2520a%2520substrate%2520for%2520multidrug%2520resistance%2520pumps%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D5865%26epage%3D5871%26doi%3D10.1158%2F0008-5472.CAN-07-0127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group">Sirisoma, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pervin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willardsen, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mather, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pleiman, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasibhatla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drewe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, S. X.</span><span> </span><span class="NLM_article-title">Discovery of N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine, a potent apoptosis inducer and efficacious anticancer agent with high blood brain barrier penetration</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">2341</span><span class="NLM_x">–</span> <span class="NLM_lpage">2351</span><span class="refDoi"> DOI: 10.1021/jm801315b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801315b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtlensL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2341-2351&author=N.+Sirisomaauthor=A.+Pervinauthor=H.+Zhangauthor=S.+Jiangauthor=J.+A.+Willardsenauthor=M.+B.+Andersonauthor=G.+Matherauthor=C.+M.+Pleimanauthor=S.+Kasibhatlaauthor=B.+Tsengauthor=J.+Dreweauthor=S.+X.+Cai&title=Discovery+of+N-%284-methoxyphenyl%29-N%2C2-dimethylquinazolin-4-amine%2C+a+potent+apoptosis+inducer+and+efficacious+anticancer+agent+with+high+blood+brain+barrier+penetration&doi=10.1021%2Fjm801315b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-(4-Methoxyphenyl)-N,2-dimethylquinazolin-4-amine, a Potent Apoptosis Inducer and Efficacious Anticancer Agent with High Blood Brain Barrier Penetration</span></div><div class="casAuthors">Sirisoma, Nilantha; Pervin, Azra; Zhang, Hong; Jiang, Songchun; Willardsen, J. Adam; Anderson, Mark B.; Mather, Gary; Pleiman, Christopher M.; Kasibhatla, Shailaja; Tseng, Ben; Drewe, John; Cai, Sui Xiong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2341-2351</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">As a continuation of our structure-activity relationship (SAR) studies on 4-anilinoquinazolines as potent apoptosis inducers and to identify anticancer development candidates, we explored the replacement of the 2-Cl group in our lead compd. 2-chloro-N-(4-methoxyphenyl)-N-methylquinazolin-4-amine (I) (, EP128265, MPI-0441138) by other functional groups.  This SAR study and lead optimization resulted in the identification of N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine ( (II), EP128495, MPC-6827) as an anticancer clin. candidate.  Compd.(I) was found to be a potent apoptosis inducer with EC50 of 2 nM in our cell-based apoptosis induction assay.  It also has excellent blood brain barrier penetration, and is highly efficacious in human MX-1 breast and other mouse xenograft cancer models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkdiJFWdOwYrVg90H21EOLACvtfcHk0lhqz2o8ocCObg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtlensL0%253D&md5=811ef9a923d386a43d7f0d010f996566</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Fjm801315b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801315b%26sid%3Dliteratum%253Aachs%26aulast%3DSirisoma%26aufirst%3DN.%26aulast%3DPervin%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DWillardsen%26aufirst%3DJ.%2BA.%26aulast%3DAnderson%26aufirst%3DM.%2BB.%26aulast%3DMather%26aufirst%3DG.%26aulast%3DPleiman%26aufirst%3DC.%2BM.%26aulast%3DKasibhatla%26aufirst%3DS.%26aulast%3DTseng%26aufirst%3DB.%26aulast%3DDrewe%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DS.%2BX.%26atitle%3DDiscovery%2520of%2520N-%25284-methoxyphenyl%2529-N%252C2-dimethylquinazolin-4-amine%252C%2520a%2520potent%2520apoptosis%2520inducer%2520and%2520efficacious%2520anticancer%2520agent%2520with%2520high%2520blood%2520brain%2520barrier%2520penetration%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2341%26epage%3D2351%26doi%3D10.1021%2Fjm801315b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group">Canela, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liekens, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camarasa, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Priego, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pérez-Pérez, M. J.</span><span> </span><span class="NLM_article-title">Synthesis and antiproliferative activity of 6-phenylaminopurines</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">421</span><span class="NLM_x">–</span> <span class="NLM_lpage">428</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2014.09.093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.ejmech.2014.09.093" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2014&pages=421-428&author=M.+D.+Canelaauthor=S.+Liekensauthor=M.+J.+Camarasaauthor=E.+M.+Priegoauthor=M.+J.+P%C3%A9rez-P%C3%A9rez&title=Synthesis+and+antiproliferative+activity+of+6-phenylaminopurines&doi=10.1016%2Fj.ejmech.2014.09.093"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.09.093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.09.093%26sid%3Dliteratum%253Aachs%26aulast%3DCanela%26aufirst%3DM.%2BD.%26aulast%3DLiekens%26aufirst%3DS.%26aulast%3DCamarasa%26aufirst%3DM.%2BJ.%26aulast%3DPriego%26aufirst%3DE.%2BM.%26aulast%3DP%25C3%25A9rez-P%25C3%25A9rez%26aufirst%3DM.%2BJ.%26atitle%3DSynthesis%2520and%2520antiproliferative%2520activity%2520of%25206-phenylaminopurines%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D87%26spage%3D421%26epage%3D428%26doi%3D10.1016%2Fj.ejmech.2014.09.093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghavan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risinger, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span> </span><span class="NLM_article-title">Synthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistance</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8116</span><span class="NLM_x">–</span> <span class="NLM_lpage">8128</span><span class="refDoi"> DOI: 10.1021/jm101010n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101010n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8116-8128&author=A.+Gangjeeauthor=Y.+Zhaoauthor=L.+Linauthor=S.+Raghavanauthor=E.+G.+Robertsauthor=A.+L.+Risingerauthor=E.+Hamelauthor=S.+L.+Mooberry&title=Synthesis+and+discovery+of+water-soluble+microtubule+targeting+agents+that+bind+to+the+colchicine+site+on+tubulin+and+circumvent+Pgp+mediated+resistance&doi=10.1021%2Fjm101010n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Fjm101010n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101010n%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DRaghavan%26aufirst%3DS.%26aulast%3DRoberts%26aufirst%3DE.%2BG.%26aulast%3DRisinger%26aufirst%3DA.%2BL.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26atitle%3DSynthesis%2520and%2520discovery%2520of%2520water-soluble%2520microtubule%2520targeting%2520agents%2520that%2520bind%2520to%2520the%2520colchicine%2520site%2520on%2520tubulin%2520and%2520circumvent%2520Pgp%2520mediated%2520resistance%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8116%26epage%3D8128%26doi%3D10.1021%2Fjm101010n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghavan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihnat, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorpe, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Disch, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey-Downs, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dybdal-Hargreaves, N. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohena, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gangjee, A.</span><span> </span><span class="NLM_article-title">The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2, 3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3753</span><span class="NLM_x">–</span> <span class="NLM_lpage">3772</span><span class="refDoi"> DOI: 10.1016/j.bmc.2014.04.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.bmc.2014.04.049" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=3753-3772&author=X.+Zhangauthor=S.+Raghavanauthor=M.+Ihnatauthor=J.+E.+Thorpeauthor=B.+C.+Dischauthor=A.+Bastianauthor=L.+C.+Bailey-Downsauthor=N.+F.+Dybdal-Hargreavesauthor=C.+C.+Rohenaauthor=E.+Hamelauthor=S.+L.+Mooberryauthor=A.+Gangjee&title=The+design+and+discovery+of+water+soluble+4-substituted-2%2C6-dimethylfuro%5B2%2C+3-d%5Dpyrimidines+as+multitargeted+receptor+tyrosine+kinase+inhibitors+and+microtubule+targeting+antitumor+agents&doi=10.1016%2Fj.bmc.2014.04.049"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.04.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.04.049%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DRaghavan%26aufirst%3DS.%26aulast%3DIhnat%26aufirst%3DM.%26aulast%3DThorpe%26aufirst%3DJ.%2BE.%26aulast%3DDisch%26aufirst%3DB.%2BC.%26aulast%3DBastian%26aufirst%3DA.%26aulast%3DBailey-Downs%26aufirst%3DL.%2BC.%26aulast%3DDybdal-Hargreaves%26aufirst%3DN.%2BF.%26aulast%3DRohena%26aufirst%3DC.%2BC.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26aulast%3DGangjee%26aufirst%3DA.%26atitle%3DThe%2520design%2520and%2520discovery%2520of%2520water%2520soluble%25204-substituted-2%252C6-dimethylfuro%255B2%252C%25203-d%255Dpyrimidines%2520as%2520multitargeted%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520and%2520microtubule%2520targeting%2520antitumor%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D3753%26epage%3D3772%26doi%3D10.1016%2Fj.bmc.2014.04.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">D’Amato, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span> </span><span class="NLM_article-title">2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">3964</span><span class="NLM_x">–</span> <span class="NLM_lpage">3968</span><span class="refDoi"> DOI: 10.1073/pnas.91.9.3964</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1073%2Fpnas.91.9.3964" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=3964-3968&author=R.+J.+D%E2%80%99Amatoauthor=C.+M.+Linauthor=E.+Flynnauthor=J.+Folkmanauthor=E.+Hamel&title=2-Methoxyestradiol%2C+an+endogenous+mammalian+metabolite%2C+inhibits+tubulin+polymerization+by+interacting+at+the+colchicine+site&doi=10.1073%2Fpnas.91.9.3964"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.9.3964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.9.3964%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Amato%26aufirst%3DR.%2BJ.%26aulast%3DLin%26aufirst%3DC.%2BM.%26aulast%3DFlynn%26aufirst%3DE.%26aulast%3DFolkman%26aufirst%3DJ.%26aulast%3DHamel%26aufirst%3DE.%26atitle%3D2-Methoxyestradiol%252C%2520an%2520endogenous%2520mammalian%2520metabolite%252C%2520inhibits%2520tubulin%2520polymerization%2520by%2520interacting%2520at%2520the%2520colchicine%2520site%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1994%26volume%3D91%26spage%3D3964%26epage%3D3968%26doi%3D10.1073%2Fpnas.91.9.3964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">Leese, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leblond, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Fiore, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Simone, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supuran, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Purohit, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potter, B. V. L.</span><span> </span><span class="NLM_article-title">2-Substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">7683</span><span class="NLM_x">–</span> <span class="NLM_lpage">7696</span><span class="refDoi"> DOI: 10.1021/jm060705x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060705x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=7683-7696&author=M.+P.+Leeseauthor=B.+Leblondauthor=A.+Smithauthor=S.+P.+Newmanauthor=A.+Di+Fioreauthor=G.+De+Simoneauthor=C.+T.+Supuranauthor=A.+Purohitauthor=M.+J.+Reedauthor=B.+V.+L.+Potter&title=2-Substituted+estradiol+bis-sulfamates%2C+multitargeted+antitumor+agents%3A+synthesis%2C+in+vitro+SAR%2C+protein+crystallography%2C+and+in+vivo+activity&doi=10.1021%2Fjm060705x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Fjm060705x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060705x%26sid%3Dliteratum%253Aachs%26aulast%3DLeese%26aufirst%3DM.%2BP.%26aulast%3DLeblond%26aufirst%3DB.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DNewman%26aufirst%3DS.%2BP.%26aulast%3DDi%2BFiore%26aufirst%3DA.%26aulast%3DDe%2BSimone%26aufirst%3DG.%26aulast%3DSupuran%26aufirst%3DC.%2BT.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DReed%26aufirst%3DM.%2BJ.%26aulast%3DPotter%26aufirst%3DB.%2BV.%2BL.%26atitle%3D2-Substituted%2520estradiol%2520bis-sulfamates%252C%2520multitargeted%2520antitumor%2520agents%253A%2520synthesis%252C%2520in%2520vitro%2520SAR%252C%2520protein%2520crystallography%252C%2520and%2520in%2520vivo%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D7683%26epage%3D7696%26doi%3D10.1021%2Fjm060705x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group">Stengel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leese, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potter, B. V. L</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Purohit, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, P. A.</span><span> </span><span class="NLM_article-title">The in vitro and in vivo activity of the microtubule disruptor STX140 is mediated by HIF-1 alpha and CAIX expression</span> <span class="citation_source-journal">Anticancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">5249</span><span class="NLM_x">–</span> <span class="NLM_lpage">5262</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=26408684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlt1arur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=5249-5262&author=C.+Stengelauthor=S.+P.+Newmanauthor=M.+P.+Leeseauthor=M.+P.+Thomasauthor=B.+V.+L+Potterauthor=M.+J.+Reedauthor=A.+Purohitauthor=P.+A.+Foster&title=The+in+vitro+and+in+vivo+activity+of+the+microtubule+disruptor+STX140+is+mediated+by+HIF-1+alpha+and+CAIX+expression"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">The In Vitro and In Vivo activity of the microtubule disruptor STX140 is mediated by Hif-1 Alpha and CAIX expression</span></div><div class="casAuthors">Stengel, Chloe; Newman, Simon P.; Leese, Mathew P.; Thomas, Mark p.; Potter, Barry V. l.; Reed, Michael j.; Purohit, Atul; Foster, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5249-5262</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">Tumor neo-angiogenesis is regulated, in part, by the hypoxia-inducible gene HIFI.  Evidence suggests HIFI assocs. with polymd. microtubules and traffics to the nucleus.  This study investigated the role of HIFI in mediating the antitumor activity of two steroid-based sulfamate ester microtubule disruptors, STX140 and STX243, in vitro and in vivo.  The effects of STX140, STX243 and the parental compd. 2-tnethoxyestradiol (STX66) can HIF 1α and H1F2α protein expression were assessed in vitro in MCF-7 and MDA-MB-231 cells cultured under hypoxia.  More pertinently, their effects were examd. on HIFI-regulated genes in vivo in mice bearing MCF-7 or MDA-MB-231 tumors.  The level of mRNA expression of vascular endothelial growth factor (VEGF), glucose transporter 1 (GLUTI), phosphoglycerate kinase (PGK), ATP-binding cassette sub family B member I (ABCB1) and carbonic anhydrase IX (CAIX) was quantified by Real-time Polymerase Chain Reaction (RT-PCR).  Despite inhibiting nuclear HIFI a protein accumulation under hypoxia in vitro, STX140 and STX243 did not significantly regulate the expression of four out of five HIF lα -regulated genes in vitro and in vivo.  Only CAIX mRNA expression was down-regulated both in vitro and in vivo.  Immunoblor anal. showed that STX140 and STX243 reduced CAIX protein expression in vitro.  These compds. had no effect on H1F2a translocation.  The potential for inhibition of CAIX by STX140 and STX243 was examd. by docking the ligands to the active site in comparison with a known sulfwnate-based inhibitor.  Microtubule disruption and antitumor activity of STX140 and STX243 is most likely HIFI-independent and may, at least in part, be mediated by inhibition of CAIX expression and activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_YLkURrop_LVg90H21EOLACvtfcHk0li5e6MHJ1D5IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlt1arur4%253D&md5=c7a07b09751f132c2e43a8ff0c058c68</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStengel%26aufirst%3DC.%26aulast%3DNewman%26aufirst%3DS.%2BP.%26aulast%3DLeese%26aufirst%3DM.%2BP.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DPotter%26aufirst%3DB.%2BV.%2BL%26aulast%3DReed%26aufirst%3DM.%2BJ.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DFoster%26aufirst%3DP.%2BA.%26atitle%3DThe%2520in%2520vitro%2520and%2520in%2520vivo%2520activity%2520of%2520the%2520microtubule%2520disruptor%2520STX140%2520is%2520mediated%2520by%2520HIF-1%2520alpha%2520and%2520CAIX%2520expression%26jtitle%3DAnticancer%2520Res.%26date%3D2015%26volume%3D35%26spage%3D5249%26epage%3D5262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group">Leese, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jourdan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dohle, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimberley, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrandis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potter, B. V. L.</span><span> </span><span class="NLM_article-title">Steroidomimetic tetrahydroisoquinolines for the design of new microtubule disruptors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span><span class="refDoi"> DOI: 10.1021/ml200232c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200232c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=5-9&author=M.+P.+Leeseauthor=F.+Jourdanauthor=W.+Dohleauthor=M.+R.+Kimberleyauthor=M.+P.+Thomasauthor=R.+Baiauthor=E.+Hamelauthor=E.+Ferrandisauthor=B.+V.+L.+Potter&title=Steroidomimetic+tetrahydroisoquinolines+for+the+design+of+new+microtubule+disruptors&doi=10.1021%2Fml200232c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Fml200232c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200232c%26sid%3Dliteratum%253Aachs%26aulast%3DLeese%26aufirst%3DM.%2BP.%26aulast%3DJourdan%26aufirst%3DF.%26aulast%3DDohle%26aufirst%3DW.%26aulast%3DKimberley%26aufirst%3DM.%2BR.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DBai%26aufirst%3DR.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DFerrandis%26aufirst%3DE.%26aulast%3DPotter%26aufirst%3DB.%2BV.%2BL.%26atitle%3DSteroidomimetic%2520tetrahydroisoquinolines%2520for%2520the%2520design%2520of%2520new%2520microtubule%2520disruptors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D5%26epage%3D9%26doi%3D10.1021%2Fml200232c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group">Pasquier, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinnappan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munoz, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kavallaris, M.</span><span> </span><span class="NLM_article-title">ENMD-1198, a new analogue of 2-methoxyestradiol, displays both antiangiogenic and vascular-disrupting properties</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1408</span><span class="NLM_x">–</span> <span class="NLM_lpage">1418</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0894</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1158%2F1535-7163.MCT-09-0894" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=20442304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlslektLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1408-1418&author=E.+Pasquierauthor=S.+Sinnappanauthor=M.+A.+Munozauthor=M.+Kavallaris&title=ENMD-1198%2C+a+new+analogue+of+2-methoxyestradiol%2C+displays+both+antiangiogenic+and+vascular-disrupting+properties&doi=10.1158%2F1535-7163.MCT-09-0894"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">ENMD-1198, a New Analogue of 2-Methoxyestradiol, Displays Both Antiangiogenic and Vascular-Disrupting Properties</span></div><div class="casAuthors">Pasquier, Eddy; Sinnappan, Snega; Munoz, Marcia A.; Kavallaris, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1408-1418</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The formation of a new vascular network by angiogenesis is a key driver in tumor growth and metastasis, making this an attractive therapeutic target.  Different strategies are being developed to either prevent tumor angiogenesis or disrupt the tumor vasculature already in place.  In this in vitro study, we investigated the antivascular properties of ENMD-1198, a new anticancer drug currently in clin. trials.  ENMD-1198 is a new analog of 2-methoxyestradiol, a microtubule-targeting agent that has shown promising results in the treatment of multiple myeloma and hormone-refractory prostate cancer.  Using both bone marrow-derived and dermal microvascular endothelial cell lines, we analyzed the effect of ENMD-1198 on the different functions of endothelial cells involved in angiogenesis.  In both cell lines, ENMD-1198 was more potent than 2-methoxyestradiol at inhibiting endothelial cell proliferation, motility, migration, and morphogenesis.  In addn., ENMD-1198 induced a significant decrease in vascular endothelial growth factor receptor-2 protein expression in endothelial cells.  Furthermore, videomicroscopy expts. showed that ENMD-1198 was able to completely disrupt preformed vascular structures within 2 h.  This vascular-disrupting activity was assocd. with extensive depolymn. of the microtubule network and accumulation of actin stress fibers and large focal adhesions in vascular endothelial cells.  Collectively, our results show that this new compd. displays potent antivascular properties, and this study provides important insights into the mechanism of action of this promising new anticancer drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3pqJlCJsshrVg90H21EOLACvtfcHk0lhBFk0ld5PlVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlslektLc%253D&md5=a0582514ec05fc4a03b3cea635d2df17</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0894%26sid%3Dliteratum%253Aachs%26aulast%3DPasquier%26aufirst%3DE.%26aulast%3DSinnappan%26aufirst%3DS.%26aulast%3DMunoz%26aufirst%3DM.%2BA.%26aulast%3DKavallaris%26aufirst%3DM.%26atitle%3DENMD-1198%252C%2520a%2520new%2520analogue%2520of%25202-methoxyestradiol%252C%2520displays%2520both%2520antiangiogenic%2520and%2520vascular-disrupting%2520properties%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D1408%26epage%3D1418%26doi%3D10.1158%2F1535-7163.MCT-09-0894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group">Nogales, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downing, K. H.</span><span> </span><span class="NLM_article-title">Structure of the αβ tubulin dimer by electron crystallography</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">391</span><span class="NLM_x">, </span> <span class="NLM_fpage">199</span><span class="NLM_x">–</span> <span class="NLM_lpage">203</span><span class="refDoi"> DOI: 10.1038/34465</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1038%2F34465" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=9428769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADyaK1cXmt1Kisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=391&publication_year=1998&pages=199-203&author=E.+Nogalesauthor=S.+G.+Wolfauthor=K.+H.+Downing&title=Structure+of+the+%CE%B1%CE%B2+tubulin+dimer+by+electron+crystallography&doi=10.1038%2F34465"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the αβ tubulin dimer by electron crystallography</span></div><div class="casAuthors">Nogales, Eva; Wolf, Sharon G.; Downing, Kenneth H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">391</span>
        (<span class="NLM_cas:issue">6663</span>),
    <span class="NLM_cas:pages">199-203</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">The αβ tubulin heterodimer is the structural subunit of microtubules, which are cytoskeletal elements that are essential for intracellular transport and cell division in all eukaryotes.  Each tubulin monomer binds a guanine nucleotide, which is nonexchangeable when it is bound in the α subunit, or N site, and exchangeable when bound in the β subunit, or E site.  The α- and β-tubulins share 40% amino-acid sequence identity, both exist in several isotype forms, and both undergo a variety of post-translational modifications.  Limited sequence homol. has been found with the proteins FtsZ and Misato, which are involved in cell division in bacteria and Drosophila, resp.  Here, the authors present an at. model of the αβ tubulin dimer fitted to a 3.7-Å d. map obtained by electron crystallog. of zinc-induced tubulin sheets.  The structures of α- and β-tubulin are basically identical: each monomer is formed by a core of two β-sheets surrounded by α-helixes.  The monomer structure is very compact, but can be divided into three functional domains: the amino-terminal domain contg. the nucleotide-binding region, an intermediate domain contg. the Taxol-binding site, and the carboxy-terminal domain, which probably constitutes the binding surface for motor proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKgcRV89nSo7Vg90H21EOLACvtfcHk0lg8UPEUHF_y_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmt1Kisw%253D%253D&md5=6aa8d1a79a039f4f1ee7e665a6b4039d</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1038%2F34465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F34465%26sid%3Dliteratum%253Aachs%26aulast%3DNogales%26aufirst%3DE.%26aulast%3DWolf%26aufirst%3DS.%2BG.%26aulast%3DDowning%26aufirst%3DK.%2BH.%26atitle%3DStructure%2520of%2520the%2520%25CE%25B1%25CE%25B2%2520tubulin%2520dimer%2520by%2520electron%2520crystallography%26jtitle%3DNature%26date%3D1998%26volume%3D391%26spage%3D199%26epage%3D203%26doi%3D10.1038%2F34465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group">Löwe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downing, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nogales, E.</span><span> </span><span class="NLM_article-title">Refined structure of α,β-tubulin at 3.5 Å resolution</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">313</span><span class="NLM_x">, </span> <span class="NLM_fpage">1045</span><span class="NLM_x">–</span> <span class="NLM_lpage">1057</span><span class="refDoi"> DOI: 10.1006/jmbi.2001.5077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1006%2Fjmbi.2001.5077" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2001&pages=1045-1057&author=J.+L%C3%B6weauthor=H.+Liauthor=K.+H.+Downingauthor=E.+Nogales&title=Refined+structure+of+%CE%B1%2C%CE%B2-tubulin+at+3.5+%C3%85+resolution&doi=10.1006%2Fjmbi.2001.5077"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.2001.5077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.2001.5077%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6we%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DDowning%26aufirst%3DK.%2BH.%26aulast%3DNogales%26aufirst%3DE.%26atitle%3DRefined%2520structure%2520of%2520%25CE%25B1%252C%25CE%25B2-tubulin%2520at%25203.5%2520%25C3%2585%2520resolution%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2001%26volume%3D313%26spage%3D1045%26epage%3D1057%26doi%3D10.1006%2Fjmbi.2001.5077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Janke, C.</span><span> </span><span class="NLM_article-title">The tubulin code Molecular components, readout mechanisms, and functions</span> <span class="citation_source-journal">J. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">206</span><span class="NLM_x">, </span> <span class="NLM_fpage">461</span><span class="NLM_x">–</span> <span class="NLM_lpage">472</span><span class="refDoi"> DOI: 10.1083/jcb.201406055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1083%2Fjcb.201406055" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=206&publication_year=2014&pages=461-472&author=C.+Janke&title=The+tubulin+code+Molecular+components%2C+readout+mechanisms%2C+and+functions&doi=10.1083%2Fjcb.201406055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1083%2Fjcb.201406055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.201406055%26sid%3Dliteratum%253Aachs%26aulast%3DJanke%26aufirst%3DC.%26atitle%3DThe%2520tubulin%2520code%2520Molecular%2520components%252C%2520readout%2520mechanisms%252C%2520and%2520functions%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2014%26volume%3D206%26spage%3D461%26epage%3D472%26doi%3D10.1083%2Fjcb.201406055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Gigant, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curmi, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Barbey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charbaut, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachkar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebeau, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siavoshian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sobel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knossow, M.</span><span> </span><span class="NLM_article-title">The 4 Å X-Ray structure of a tubulin:stathmin-like domain complex</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">–</span> <span class="NLM_lpage">816</span><span class="refDoi"> DOI: 10.1016/S0092-8674(00)00069-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2FS0092-8674%2800%2900069-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2000&pages=809-816&author=B.+Gigantauthor=P.+A.+Curmiauthor=C.+Martin-Barbeyauthor=E.+Charbautauthor=S.+Lachkarauthor=L.+Lebeauauthor=S.+Siavoshianauthor=A.+Sobelauthor=M.+Knossow&title=The+4+%C3%85+X-Ray+structure+of+a+tubulin%3Astathmin-like+domain+complex&doi=10.1016%2FS0092-8674%2800%2900069-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2900069-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252900069-6%26sid%3Dliteratum%253Aachs%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DCurmi%26aufirst%3DP.%2BA.%26aulast%3DMartin-Barbey%26aufirst%3DC.%26aulast%3DCharbaut%26aufirst%3DE.%26aulast%3DLachkar%26aufirst%3DS.%26aulast%3DLebeau%26aufirst%3DL.%26aulast%3DSiavoshian%26aufirst%3DS.%26aulast%3DSobel%26aufirst%3DA.%26aulast%3DKnossow%26aufirst%3DM.%26atitle%3DThe%25204%2520%25C3%2585%2520X-Ray%2520structure%2520of%2520a%2520tubulin%253Astathmin-like%2520domain%2520complex%26jtitle%3DCell%26date%3D2000%26volume%3D102%26spage%3D809%26epage%3D816%26doi%3D10.1016%2FS0092-8674%2800%2900069-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group">Barbier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorléans, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devred, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanz, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allegro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfonso, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knossow, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peyrot, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreu, J. M.</span><span> </span><span class="NLM_article-title">Stathmin and interfacial microtubule inhibitors recognize a naturally curved conformation of tubulin dimers</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">285</span><span class="NLM_x">, </span> <span class="NLM_fpage">31672</span><span class="NLM_x">–</span> <span class="NLM_lpage">31681</span><span class="refDoi"> DOI: 10.1074/jbc.M110.141929</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1074%2Fjbc.M110.141929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=20675373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1aqt7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2010&pages=31672-31681&author=P.+Barbierauthor=A.+Dorl%C3%A9ansauthor=F.+Devredauthor=L.+Sanzauthor=D.+Allegroauthor=C.+Alfonsoauthor=M.+Knossowauthor=V.+Peyrotauthor=J.+M.+Andreu&title=Stathmin+and+interfacial+microtubule+inhibitors+recognize+a+naturally+curved+conformation+of+tubulin+dimers&doi=10.1074%2Fjbc.M110.141929"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Stathmin and Interfacial Microtubule Inhibitors Recognize a Naturally Curved Conformation of Tubulin Dimers</span></div><div class="casAuthors">Barbier, Pascale; Dorleans, Audrey; Devred, Francois; Sanz, Laura; Allegro, Diane; Alfonso, Carlos; Knossow, Marcel; Peyrot, Vincent; Andreu, Jose M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">31672-31681</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Tubulin is able to switch between a straight microtubule-like structure and a curved structure in complex with the stathmin-like domain (SLD) of the RB3 protein (T2RB3).  GTP hydrolysis following microtubule assembly induces protofilament curvature and disassembly.  The conformation of the labile αβ-tubulin heterodimers is unknown.  One important question is whether free GDP-tubulin dimers are straightened by GTP binding or whether GTP-tubulin is also curved and switches into a straight conformation upon assembly.  We have obtained insight into the bending flexibility of tubulin by analyzing the interplay of tubulin-stathmin assocn. with the binding of several small mol. inhibitors to the colchicine domain at the tubulin intradimer interface, combining structural and biochem. approaches.  The crystal structures of T2RB3 complexes with the chiral R and S isomers of ethyl-5-amino-2-methyl-1,2-dihydro-3-phenylpyrido[3,4-b]pyrazin-7-yl-carbamate, show that their binding site overlaps with colchicine ring A and that both complexes have the same curvature as unliganded T2RB3.  The binding of these ligands is incompatible with a straight tubulin structure in microtubules.  Anal. ultracentrifugation and binding measurements show that tubulin-stathmin assocns. (T2RB3, T2Stath) and binding of ligands (R, S, TN-16, or the colchicine analog MTC) are thermodynamically independent from one another, irresp. of tubulin being bound to GTP or GDP.  The fact that the interfacial ligands bind equally well to tubulin dimers or stathmin complexes supports a bent conformation of the free tubulin dimers.  It is tempting to speculate that stathmin evolved to recognize curved structures in unassembled and disassembling tubulin, thus regulating microtubule assembly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ08-xYl4OcbVg90H21EOLACvtfcHk0lg8UPEUHF_y_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1aqt7%252FP&md5=d889f62c22d8c6fcefb9dd8ab7d21e0e</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110.141929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110.141929%26sid%3Dliteratum%253Aachs%26aulast%3DBarbier%26aufirst%3DP.%26aulast%3DDorl%25C3%25A9ans%26aufirst%3DA.%26aulast%3DDevred%26aufirst%3DF.%26aulast%3DSanz%26aufirst%3DL.%26aulast%3DAllegro%26aufirst%3DD.%26aulast%3DAlfonso%26aufirst%3DC.%26aulast%3DKnossow%26aufirst%3DM.%26aulast%3DPeyrot%26aufirst%3DV.%26aulast%3DAndreu%26aufirst%3DJ.%2BM.%26atitle%3DStathmin%2520and%2520interfacial%2520microtubule%2520inhibitors%2520recognize%2520a%2520naturally%2520curved%2520conformation%2520of%2520tubulin%2520dimers%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2010%26volume%3D285%26spage%3D31672%26epage%3D31681%26doi%3D10.1074%2Fjbc.M110.141929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">Arce, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barra, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caputto, R.</span><span> </span><span class="NLM_article-title">Incorporation of L-tyrosine, L-phenylalanine and L-3,4-dihydroxyphenylalanine as single units into rat-brain tubulin</span> <span class="citation_source-journal">Eur. J. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1975</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">145</span><span class="NLM_x">–</span> <span class="NLM_lpage">149</span><span class="refDoi"> DOI: 10.1111/j.1432-1033.1975.tb02435.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1111%2Fj.1432-1033.1975.tb02435.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1204603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADyaE28XhtlKitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1975&pages=145-149&author=C.+A.+Arceauthor=J.+A.+Rodriguezauthor=H.+S.+Barraauthor=R.+Caputto&title=Incorporation+of+L-tyrosine%2C+L-phenylalanine+and+L-3%2C4-dihydroxyphenylalanine+as+single+units+into+rat-brain+tubulin&doi=10.1111%2Fj.1432-1033.1975.tb02435.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Incorporation of L-tyrosine, L-phenylalanine, and L-3,4-dihydroxyphenylalanine as single units into rat brain tubulin</span></div><div class="casAuthors">Arce, Carlos A.; Rodriguez, Julio A.; Barra, Hector S.; Caputto, Ranwel</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">145-9</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    </div><div class="casAbstract">The product of the incorporation of tyrosine-14C as single unit into a protein of the sol. fraction of rat brain homogenate was purified by following a procedure used to purify tubulin.  Na dodecyl sulfate-polyacrylamide gel electrophoresis of the purified material showed a single protein band contg. all the radioactivity and accounting for 10.2% of the total protein of the supernatant fraction.  The incorporated tyrosine was found in the α-subunit of tubulin.  Protein labeled with colchicine-3H and tyrosine-14C was pptd. with vinblastine sulfate and the radioactivity of 3H and that of 14C were quant. recovered in the ppt. (98%).  Na dodecyl sulfate-polyacrylamide gel electrophoresis of the vinblastine ppt. showed that the 14C radioactivity moved with the tubulin band.  Results obtained in expts. with phenylalanine and 3,4-dihydroxyphenylalanine were identical to those obtained for tyrosine.  About 30% of tubulin from rat brain supernatant fraction could incorporate tyrosine as single unit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVas0MpjDTO7Vg90H21EOLACvtfcHk0ljYLthC-A0-2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28XhtlKitA%253D%253D&md5=9f81b33a07940656529a268934cb1c7d</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1111%2Fj.1432-1033.1975.tb02435.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1432-1033.1975.tb02435.x%26sid%3Dliteratum%253Aachs%26aulast%3DArce%26aufirst%3DC.%2BA.%26aulast%3DRodriguez%26aufirst%3DJ.%2BA.%26aulast%3DBarra%26aufirst%3DH.%2BS.%26aulast%3DCaputto%26aufirst%3DR.%26atitle%3DIncorporation%2520of%2520L-tyrosine%252C%2520L-phenylalanine%2520and%2520L-3%252C4-dihydroxyphenylalanine%2520as%2520single%2520units%2520into%2520rat-brain%2520tubulin%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1975%26volume%3D59%26spage%3D145%26epage%3D149%26doi%3D10.1111%2Fj.1432-1033.1975.tb02435.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group">Prota, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magiera, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuijpers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bargsten, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frey, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wieser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaussi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoogenraad, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kammerer, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janke, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmetz, M. O.</span><span> </span><span class="NLM_article-title">Structural basis of tubulin tyrosination by tubulin tyrosine ligase</span> <span class="citation_source-journal">J. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">200</span><span class="NLM_x">, </span> <span class="NLM_fpage">259</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span><span class="refDoi"> DOI: 10.1083/jcb.201211017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1083%2Fjcb.201211017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=23358242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitFemsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=200&publication_year=2013&pages=259-270&author=A.+E.+Protaauthor=M.+M.+Magieraauthor=M.+Kuijpersauthor=K.+Bargstenauthor=D.+Freyauthor=M.+Wieserauthor=R.+Jaussiauthor=C.+C.+Hoogenraadauthor=R.+A.+Kammererauthor=C.+Jankeauthor=M.+O.+Steinmetz&title=Structural+basis+of+tubulin+tyrosination+by+tubulin+tyrosine+ligase&doi=10.1083%2Fjcb.201211017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of tubulin tyrosination by tubulin tyrosine ligase</span></div><div class="casAuthors">Prota, Andrea E.; Magiera, Maria M.; Kuijpers, Marijn; Bargsten, Katja; Frey, Daniel; Wieser, Mara; Jaussi, Rolf; Hoogenraad, Casper C.; Kammerer, Richard A.; Janke, Carsten; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">200</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">259-270</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Tubulin tyrosine ligase (TTL) catalyzes the post-translational retyrosination of detyrosinated α-tubulin.  Despite the indispensable role of TTL in cell and organism development, its mol. mechanism of action is poorly understood.  By solving crystal structures of TTL in complex with tubulin, we here demonstrate that TTL binds to the α and β subunits of tubulin and recognizes the curved conformation of the dimer.  Biochem. and cellular assays revealed that specific tubulin dimer recognition controls the activity of the enzyme, and as a consequence, neuronal development.  The TTL-tubulin structure further illustrates how the enzyme binds the functionally crucial C-terminal tail sequence of α-tubulin and how this interaction catalyzes the tyrosination reaction.  It also reveals how TTL discriminates between α- and β-tubulin, and between different post-translationally modified forms of α-tubulin.  Together, our data suggest that TTL has specifically evolved to recognize and modify tubulin, thus highlighting a fundamental role of the evolutionary conserved tubulin tyrosination cycle in regulating the microtubule cytoskeleton.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC0GnzXPTwGrVg90H21EOLACvtfcHk0ljYLthC-A0-2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitFemsb8%253D&md5=fac60a4c8cefab58a1a8df0d2eaea949</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1083%2Fjcb.201211017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.201211017%26sid%3Dliteratum%253Aachs%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DMagiera%26aufirst%3DM.%2BM.%26aulast%3DKuijpers%26aufirst%3DM.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DFrey%26aufirst%3DD.%26aulast%3DWieser%26aufirst%3DM.%26aulast%3DJaussi%26aufirst%3DR.%26aulast%3DHoogenraad%26aufirst%3DC.%2BC.%26aulast%3DKammerer%26aufirst%3DR.%2BA.%26aulast%3DJanke%26aufirst%3DC.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DStructural%2520basis%2520of%2520tubulin%2520tyrosination%2520by%2520tubulin%2520tyrosine%2520ligase%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2013%26volume%3D200%26spage%3D259%26epage%3D270%26doi%3D10.1083%2Fjcb.201211017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group">Prota, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bargsten, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zurwerra, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Field, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altmann, K.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmetz, M. O.</span><span> </span><span class="NLM_article-title">Molecular mechanism of action of microtubule-stabilizing anticancer agents</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">339</span><span class="NLM_x">, </span> <span class="NLM_fpage">587</span><span class="NLM_x">–</span> <span class="NLM_lpage">590</span><span class="refDoi"> DOI: 10.1126/science.1230582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1126%2Fscience.1230582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=23287720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFGrsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2013&pages=587-590&author=A.+E.+Protaauthor=K.+Bargstenauthor=D.+Zurwerraauthor=J.+J.+Fieldauthor=J.+F.+Diazauthor=K.-H.+Altmannauthor=M.+O.+Steinmetz&title=Molecular+mechanism+of+action+of+microtubule-stabilizing+anticancer+agents&doi=10.1126%2Fscience.1230582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Mechanism of Action of Microtubule-Stabilizing Anticancer Agents</span></div><div class="casAuthors">Prota, Andrea E.; Bargsten, Katja; Zurwerra, Didier; Field, Jessica J.; Diaz, Jose Fernando; Altmann, Karl-Heinz; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">6119</span>),
    <span class="NLM_cas:pages">587-590</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Microtubule-stabilizing agents (MSAs) are efficacious chemotherapeutic drugs widely used for the treatment of cancer.  Despite the importance of MSAs for medical applications and basic research, their mol. mechanisms of action on tubulin and microtubules remain elusive.  We detd. high-resoln. crystal structures of αβ-tubulin in complex with two unrelated MSAs, zampanolide and epothilone A.  Both compds. were bound to the taxane pocket of β-tubulin and used their resp. side chains to induce structuring of the M-loop into a short helix.  Because the M-loop establishes lateral tubulin contacts in microtubules, these findings explain how taxane-site MSAs promote microtubule assembly and stability.  Further, our results offer fundamental structural insights into the control mechanisms of microtubule dynamics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_p8NfCWTU-rVg90H21EOLACvtfcHk0ljYLthC-A0-2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFGrsrw%253D&md5=b253c015f75f5eac4857d01e34d65f54</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1126%2Fscience.1230582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1230582%26sid%3Dliteratum%253Aachs%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DZurwerra%26aufirst%3DD.%26aulast%3DField%26aufirst%3DJ.%2BJ.%26aulast%3DDiaz%26aufirst%3DJ.%2BF.%26aulast%3DAltmann%26aufirst%3DK.-H.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DMolecular%2520mechanism%2520of%2520action%2520of%2520microtubule-stabilizing%2520anticancer%2520agents%26jtitle%3DScience%26date%3D2013%26volume%3D339%26spage%3D587%26epage%3D590%26doi%3D10.1126%2Fscience.1230582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group">Prota, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danel, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bargsten, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buey, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pohlmann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinelt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmetz, M. O.</span><span> </span><span class="NLM_article-title">The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">426</span><span class="NLM_x">, </span> <span class="NLM_fpage">1848</span><span class="NLM_x">–</span> <span class="NLM_lpage">1860</span><span class="refDoi"> DOI: 10.1016/j.jmb.2014.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.jmb.2014.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=24530796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlSrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=426&publication_year=2014&pages=1848-1860&author=A.+E.+Protaauthor=F.+Danelauthor=F.+Bachmannauthor=K.+Bargstenauthor=R.+M.+Bueyauthor=J.+Pohlmannauthor=S.+Reineltauthor=H.+Laneauthor=M.+O.+Steinmetz&title=The+novel+microtubule-destabilizing+drug+BAL27862+binds+to+the+colchicine+site+of+tubulin+with+distinct+effects+on+microtubule+organization&doi=10.1016%2Fj.jmb.2014.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">The Novel Microtubule-Destabilizing Drug BAL27862 Binds to the Colchicine Site of Tubulin with Distinct Effects on Microtubule Organization</span></div><div class="casAuthors">Prota, Andrea E.; Danel, Franck; Bachmann, Felix; Bargsten, Katja; Buey, Ruben M.; Pohlmann, Jens; Reinelt, Stefan; Lane, Heidi; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">426</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1848-1860</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Microtubule-targeting agents are widely used for the treatment of cancer and as tool compds. to study the microtubule cytoskeleton.  BAL27862 is a novel microtubule-destabilizing drug that is currently undergoing phase I clin. evaluation as the prodrug BAL101553.  The drug is a potent inhibitor of tumor cell growth and shows a promising activity profile in a panel of human cancer models resistant to clin. relevant microtubule-targeting agents.  Here, we evaluated the mol. mechanism of the tubulin-BAL27862 interaction using a combination of cell biol., biochem. and structural biol. methods.  Tubulin-binding assays revealed that BAL27862 potently inhibited tubulin assembly at 37 °C with an IC50 of 1.4 μM and bound to unassembled tubulin with a stoichiometry of 1 mol/mol tubulin and a dissocn. const. of 244 ± 30 nM.  BAL27862 bound to tubulin independently of vinblastine, without the formation of tubulin oligomers.  The kinetics of BAL27862 binding to tubulin were distinct from those of colchicine, with evidence of competition between BAL27862 and colchicine for binding.  Detn. of the tubulin-BAL27862 structure by X-ray crystallog. demonstrated that BAL27862 binds to the same site as colchicine at the intradimer interface.  Comparison of crystal structures of tubulin-BAL27862 and tubulin-colchicine complexes shows that the binding mode of BAL27862 to tubulin is similar to that of colchicine.  However, comparative analyses of the effects of BAL27862 and colchicine on the microtubule mitotic spindle and in tubulin protease-protection expts. suggest different outcomes of tubulin binding.  Taken together, our data define BAL27862 as a potent, colchicine site-binding, microtubule-destabilizing agent with distinct effects on microtubule organization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIsVCA_6rcHLVg90H21EOLACvtfcHk0ljePGY_GCPjfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlSrtrs%253D&md5=147ddbbfe5b90157cb8b2e04e1791668</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2014.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2014.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DDanel%26aufirst%3DF.%26aulast%3DBachmann%26aufirst%3DF.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DBuey%26aufirst%3DR.%2BM.%26aulast%3DPohlmann%26aufirst%3DJ.%26aulast%3DReinelt%26aufirst%3DS.%26aulast%3DLane%26aufirst%3DH.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DThe%2520novel%2520microtubule-destabilizing%2520drug%2520BAL27862%2520binds%2520to%2520the%2520colchicine%2520site%2520of%2520tubulin%2520with%2520distinct%2520effects%2520on%2520microtubule%2520organization%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2014%26volume%3D426%26spage%3D1848%26epage%3D1860%26doi%3D10.1016%2Fj.jmb.2014.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group">Prota, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bargsten, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuevas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liniger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuhaus, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreu, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altmann, K.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmetz, M. O.</span><span> </span><span class="NLM_article-title">A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">13817</span><span class="NLM_x">–</span> <span class="NLM_lpage">13821</span><span class="refDoi"> DOI: 10.1073/pnas.1408124111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1073%2Fpnas.1408124111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=25114240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCju7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=13817-13821&author=A.+E.+Protaauthor=K.+Bargstenauthor=J.+F.+Diazauthor=M.+Marshauthor=C.+Cuevasauthor=M.+Linigerauthor=C.+Neuhausauthor=J.+M.+Andreuauthor=K.-H.+Altmannauthor=M.+O.+Steinmetz&title=A+new+tubulin-binding+site+and+pharmacophore+for+microtubule-destabilizing+anticancer+drugs&doi=10.1073%2Fpnas.1408124111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs</span></div><div class="casAuthors">Prota, Andrea E.; Bargsten, Katja; Diaz, J. Fernando; Marsh, May; Cuevas, Carmen; Liniger, Marc; Neuhaus, Christian; Andreu, Jose M.; Altmann, Karl-Heinz; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">13817-13821</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The recent success of antibody-drug conjugates (ADCs) in the treatment of cancer has led to a revived interest in microtubule-destabilizing agents.  Here, we detd. the high-resoln. crystal structure of the complex between tubulin and maytansine, which is part of an ADC that is approved by the US Food and Drug Administration (FDA) for the treatment of advanced breast cancer.  We found that the drug binds to a site on β-tubulin that is distinct from the vinca domain and that blocks the formation of longitudinal tubulin interactions in microtubules.  We also solved crystal structures of tubulin in complex with both a variant of rhizoxin and the phase 1 drug PM060184.  Consistent with biochem. and mutagenesis data, we found that the two compds. bound to the same site as maytansine and that the structures revealed a common pharmacophore for the three ligands.  Our results delineate a distinct mol. mechanism of action for the inhibition of microtubule assembly by clin. relevant agents.  They further provide a structural basis for the rational design of potent microtubule-destabilizing agents, thus opening opportunities for the development of next-generation ADCs for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX4icqk698gLVg90H21EOLACvtfcHk0lj8-eI_YBir8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCju7vM&md5=798cae320e427ff76c2099387d9e6ba4</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1408124111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1408124111%26sid%3Dliteratum%253Aachs%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DDiaz%26aufirst%3DJ.%2BF.%26aulast%3DMarsh%26aufirst%3DM.%26aulast%3DCuevas%26aufirst%3DC.%26aulast%3DLiniger%26aufirst%3DM.%26aulast%3DNeuhaus%26aufirst%3DC.%26aulast%3DAndreu%26aufirst%3DJ.%2BM.%26aulast%3DAltmann%26aufirst%3DK.-H.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DA%2520new%2520tubulin-binding%2520site%2520and%2520pharmacophore%2520for%2520microtubule-destabilizing%2520anticancer%2520drugs%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D13817%26epage%3D13821%26doi%3D10.1073%2Fpnas.1408124111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group">McNamara, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senese, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeates, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torres, J. Z.</span><span> </span><span class="NLM_article-title">Structures of potent anticancer compounds bound to tubulin</span> <span class="citation_source-journal">Protein Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1164</span><span class="NLM_x">–</span> <span class="NLM_lpage">1172</span><span class="refDoi"> DOI: 10.1002/pro.2704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1002%2Fpro.2704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=25970265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2MXovV2ksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=1164-1172&author=D.+E.+McNamaraauthor=S.+Seneseauthor=T.+O.+Yeatesauthor=J.+Z.+Torres&title=Structures+of+potent+anticancer+compounds+bound+to+tubulin&doi=10.1002%2Fpro.2704"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of potent anticancer compounds bound to tubulin</span></div><div class="casAuthors">McNamara, Dan E.; Senese, Silvia; Yeates, Todd O.; Torres, Jorge Z.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1164-1172</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Small mols. that bind to tubulin exert powerful effects on cell division and apoptosis (programmed cell death).  Cell-based high-throughput screening combined with chemo/bioinformatic and biochem. analyses recently revealed a novel compd. MI-181 as a potent mitotic inhibitor with heightened activity towards melanomas.  MI-181 causes tubulin depolymn., activates the spindle assembly checkpoint arresting cells in mitosis, and induces apoptotic cell death.  C2 is an unrelated compd. previously shown to have lethal effects on microtubules in tumorigenic cell lines.  We report 2.60 Å and 3.75 Å resoln. structures of MI-181 and C2, resp., bound to a ternary complex of αβ-tubulin, the tubulin-binding protein stathmin, and tubulin tyrosine ligase.  In the first of these structures, our crystallog. results reveal a unique binding mode for MI-181 extending unusually deep into the well-studied colchicine-binding site on β-tubulin.  In the second structure the C2 compd. occupies the colchicine-binding site on β-tubulin with two chem. moieties recapitulating contacts made by colchicine, in combination with another system of at. contacts.  These insights reveal the source of the obsd. effects of MI-181 and C2 on microtubules, mitosis, and cultured cancer cell lines.  The structural details of the interaction between tubulin and the described compds. may guide the development of improved deriv. compds. as therapeutic candidates or mol. probes to study cancer cell division.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUeszHaBRf07Vg90H21EOLACvtfcHk0lj8-eI_YBir8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXovV2ksbs%253D&md5=7a37db0aa66e0d2281bcf8f6c8140825</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1002%2Fpro.2704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.2704%26sid%3Dliteratum%253Aachs%26aulast%3DMcNamara%26aufirst%3DD.%2BE.%26aulast%3DSenese%26aufirst%3DS.%26aulast%3DYeates%26aufirst%3DT.%2BO.%26aulast%3DTorres%26aufirst%3DJ.%2BZ.%26atitle%3DStructures%2520of%2520potent%2520anticancer%2520compounds%2520bound%2520to%2520tubulin%26jtitle%3DProtein%2520Sci.%26date%3D2015%26volume%3D24%26spage%3D1164%26epage%3D1172%26doi%3D10.1002%2Fpro.2704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group">Deng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuaqui, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span> </span><span class="NLM_article-title">Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein–ligand binding interactions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">337</span><span class="NLM_x">–</span> <span class="NLM_lpage">344</span><span class="refDoi"> DOI: 10.1021/jm030331x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030331x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1yrsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=337-344&author=Z.+Dengauthor=C.+Chuaquiauthor=J.+Singh&title=Structural+interaction+fingerprint+%28SIFt%29%3A+a+novel+method+for+analyzing+three-dimensional+protein%E2%80%93ligand+binding+interactions&doi=10.1021%2Fjm030331x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Interaction Fingerprint (SIFt): A Novel Method for Analyzing Three-Dimensional Protein-Ligand Binding Interactions</span></div><div class="casAuthors">Deng, Zhan; Chuaqui, Claudio; Singh, Juswinder</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">337-344</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Representing and understanding the three-dimensional (3D) structural information of protein-ligand complexes is a crit. step in the rational drug discovery process.  Traditional anal. methods are proving inadequate and inefficient in dealing with the massive amt. of structural information being generated from x-ray crystallog., NMR, and in silico approaches such as structure-based docking expts.  Here, we present SIFt (structural interaction fingerprint), a novel method for representing and analyzing 3D protein-ligand binding interactions.  Key to this approach is the generation of an interaction fingerprint that translates 3D structural binding information from a protein-ligand complex into a one-dimensional binary string.  Each fingerprint represents the "structural interaction profile" of the complex that can be used to organize, analyze, and visualize the rich amt. of information encoded in ligand-receptor complexes and also to assist database mining.  We have applied SIFt to tackle three common tasks in structure-based drug design.  The first involved the anal. and organization of a typical set of results generated from a docking study.  Using SIFt, docking poses with similar binding modes were identified, clustered, and subsequently compared with conventional scoring function information.  A second application of SIFt was to analyze ∼90 known x-ray crystal structures of protein kinase-inhibitor complexes obtained from the Protein Databank.  Using SIFt, we were able to organize the structures and reveal striking similarities and diversity between their small mol. binding interactions.  Finally, we have shown how SIFt can be used as an effective mol. filter during the virtual chem. library screening process to select mols. with desirable binding mode(s) and/or desirable interaction patterns with the protein target.  In summary, SIFt shows promise to fully leverage the wealth of information being generated in rational drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkjji1ni0HHbVg90H21EOLACvtfcHk0liCA4Q-d1ceeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1yrsrs%253D&md5=a652b70184155c107202cbe3bc74596a</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1021%2Fjm030331x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030331x%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DZ.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DSingh%26aufirst%3DJ.%26atitle%3DStructural%2520interaction%2520fingerprint%2520%2528SIFt%2529%253A%2520a%2520novel%2520method%2520for%2520analyzing%2520three-dimensional%2520protein%25E2%2580%2593ligand%2520binding%2520interactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D337%26epage%3D344%26doi%3D10.1021%2Fjm030331x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group">Pecqueur, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duellberg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plueckthun, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surrey, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gigant, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knossow, M.</span><span> </span><span class="NLM_article-title">A designed ankyrin repeat protein selected to bind to tubulin caps the microtubule plus end</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">12011</span><span class="NLM_x">–</span> <span class="NLM_lpage">12016</span><span class="refDoi"> DOI: 10.1073/pnas.1204129109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1073%2Fpnas.1204129109" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=12011-12016&author=L.+Pecqueurauthor=C.+Duellbergauthor=B.+Dreierauthor=Q.+Jiangauthor=C.+Wangauthor=A.+Plueckthunauthor=T.+Surreyauthor=B.+Gigantauthor=M.+Knossow&title=A+designed+ankyrin+repeat+protein+selected+to+bind+to+tubulin+caps+the+microtubule+plus+end&doi=10.1073%2Fpnas.1204129109"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1204129109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1204129109%26sid%3Dliteratum%253Aachs%26aulast%3DPecqueur%26aufirst%3DL.%26aulast%3DDuellberg%26aufirst%3DC.%26aulast%3DDreier%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DPlueckthun%26aufirst%3DA.%26aulast%3DSurrey%26aufirst%3DT.%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DKnossow%26aufirst%3DM.%26atitle%3DA%2520designed%2520ankyrin%2520repeat%2520protein%2520selected%2520to%2520bind%2520to%2520tubulin%2520caps%2520the%2520microtubule%2520plus%2520end%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D12011%26epage%3D12016%26doi%3D10.1073%2Fpnas.1204129109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group">Ayaz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huddleston, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brautigam, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, L. M.</span><span> </span><span class="NLM_article-title">A TOG:alpha beta-tubulin complex structure reveals conformation-based mechanisms for a microtubule polymerase</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">337</span><span class="NLM_x">, </span> <span class="NLM_fpage">857</span><span class="NLM_x">–</span> <span class="NLM_lpage">860</span><span class="refDoi"> DOI: 10.1126/science.1221698</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1126%2Fscience.1221698" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=337&publication_year=2012&pages=857-860&author=P.+Ayazauthor=X.+Yeauthor=P.+Huddlestonauthor=C.+A.+Brautigamauthor=L.+M.+Rice&title=A+TOG%3Aalpha+beta-tubulin+complex+structure+reveals+conformation-based+mechanisms+for+a+microtubule+polymerase&doi=10.1126%2Fscience.1221698"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1126%2Fscience.1221698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1221698%26sid%3Dliteratum%253Aachs%26aulast%3DAyaz%26aufirst%3DP.%26aulast%3DYe%26aufirst%3DX.%26aulast%3DHuddleston%26aufirst%3DP.%26aulast%3DBrautigam%26aufirst%3DC.%2BA.%26aulast%3DRice%26aufirst%3DL.%2BM.%26atitle%3DA%2520TOG%253Aalpha%2520beta-tubulin%2520complex%2520structure%2520reveals%2520conformation-based%2520mechanisms%2520for%2520a%2520microtubule%2520polymerase%26jtitle%3DScience%26date%3D2012%26volume%3D337%26spage%3D857%26epage%3D860%26doi%3D10.1126%2Fscience.1221698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group">Skoufias, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, L.</span><span> </span><span class="NLM_article-title">Mechanism of inhibition of microtubule polymerization by colchicine - inhibitory potencies of unliganded colchicine and tubulin colchicine complexes</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">738</span><span class="NLM_x">–</span> <span class="NLM_lpage">746</span><span class="refDoi"> DOI: 10.1021/bi00118a015</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00118a015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1992&pages=738-746&author=D.+A.+Skoufiasauthor=L.+Wilson&title=Mechanism+of+inhibition+of+microtubule+polymerization+by+colchicine+-+inhibitory+potencies+of+unliganded+colchicine+and+tubulin+colchicine+complexes&doi=10.1021%2Fbi00118a015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1021%2Fbi00118a015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00118a015%26sid%3Dliteratum%253Aachs%26aulast%3DSkoufias%26aufirst%3DD.%2BA.%26aulast%3DWilson%26aufirst%3DL.%26atitle%3DMechanism%2520of%2520inhibition%2520of%2520microtubule%2520polymerization%2520by%2520colchicine%2520-%2520inhibitory%2520potencies%2520of%2520unliganded%2520colchicine%2520and%2520tubulin%2520colchicine%2520complexes%26jtitle%3DBiochemistry%26date%3D1992%26volume%3D31%26spage%3D738%26epage%3D746%26doi%3D10.1021%2Fbi00118a015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group">Akhmanova, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmetz, M. O.</span><span> </span><span class="NLM_article-title">Control of microtubule organization and dynamics: two ends in the limelight</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">711</span><span class="NLM_x">–</span> <span class="NLM_lpage">726</span><span class="refDoi"> DOI: 10.1038/nrm4084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1038%2Fnrm4084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=26562752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVOgt7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=711-726&author=A.+Akhmanovaauthor=M.+O.+Steinmetz&title=Control+of+microtubule+organization+and+dynamics%3A+two+ends+in+the+limelight&doi=10.1038%2Fnrm4084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Control of microtubule organization and dynamics: two ends in the limelight</span></div><div class="casAuthors">Akhmanova, Anna; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">711-726</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Microtubules have fundamental roles in many essential biol. processes, including cell division and intracellular transport.  They assemble and disassemble from their two ends, denoted the plus end and the minus end.  Significant advances have been made in our understanding of microtubule plus-end-tracking proteins (+TIPs) such as end-binding protein 1 (EB1), XMAP215, selected kinesins and dynein.  By contrast, information on microtubule minus-end-targeting proteins (-TIPs), such as the calmodulin-regulated spectrin-assocd. proteins (CAMSAPs) and Patronin, has only recently started to emerge.  Here, we review our current knowledge of factors, including microtubule-targeting agents, that assoc. with microtubule ends to control the dynamics and function of microtubules during the cell cycle and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps4xzvh0o6PbVg90H21EOLACvtfcHk0lhGvIP1VwgTCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVOgt7%252FI&md5=7c941bcce8d5d51aef6a8deb140356d3</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1038%2Fnrm4084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm4084%26sid%3Dliteratum%253Aachs%26aulast%3DAkhmanova%26aufirst%3DA.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DControl%2520of%2520microtubule%2520organization%2520and%2520dynamics%253A%2520two%2520ends%2520in%2520the%2520limelight%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2015%26volume%3D16%26spage%3D711%26epage%3D726%26doi%3D10.1038%2Fnrm4084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group">O’Boyle, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keely, N. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cotter, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zisterer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meegan, M. J.</span><span> </span><span class="NLM_article-title">Synthesis and biochemical activities of antiproliferative amino acid and phosphate derivatives of microtubule-disrupting β-lactam combretastatins</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">705</span><span class="NLM_x">–</span> <span class="NLM_lpage">721</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2013.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.ejmech.2013.01.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2013&pages=705-721&author=N.+M.+O%E2%80%99Boyleauthor=L.+M.+Greeneauthor=N.+O.+Keelyauthor=S.+Wangauthor=T.+S.+Cotterauthor=D.+M.+Zistererauthor=M.+J.+Meegan&title=Synthesis+and+biochemical+activities+of+antiproliferative+amino+acid+and+phosphate+derivatives+of+microtubule-disrupting+%CE%B2-lactam+combretastatins&doi=10.1016%2Fj.ejmech.2013.01.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DN.%2BM.%26aulast%3DGreene%26aufirst%3DL.%2BM.%26aulast%3DKeely%26aufirst%3DN.%2BO.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DCotter%26aufirst%3DT.%2BS.%26aulast%3DZisterer%26aufirst%3DD.%2BM.%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26atitle%3DSynthesis%2520and%2520biochemical%2520activities%2520of%2520antiproliferative%2520amino%2520acid%2520and%2520phosphate%2520derivatives%2520of%2520microtubule-disrupting%2520%25CE%25B2-lactam%2520combretastatins%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D62%26spage%3D705%26epage%3D721%26doi%3D10.1016%2Fj.ejmech.2013.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group">Aprile, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaninetti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Del Grosso, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genazzani, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosa, G.</span><span> </span><span class="NLM_article-title">Metabolic fate of combretastatin A-1: LC-DAD-MS/MS investigation and biological evaluation of its reactive metabolites</span> <span class="citation_source-journal">J. Pharm. Biomed. Anal.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">78–79</span><span class="NLM_x">, </span> <span class="NLM_fpage">233</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span><span class="refDoi"> DOI: 10.1016/j.jpba.2013.02.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.jpba.2013.02.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=23501444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVGisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78%E2%80%9379&publication_year=2013&pages=233-242&author=S.+Aprileauthor=R.+Zaninettiauthor=E.+Del+Grossoauthor=A.+A.+Genazzaniauthor=G.+Grosa&title=Metabolic+fate+of+combretastatin+A-1%3A+LC-DAD-MS%2FMS+investigation+and+biological+evaluation+of+its+reactive+metabolites&doi=10.1016%2Fj.jpba.2013.02.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic fate of combretastatin A-1: LC-DAD-MS/MS investigation and biological evaluation of its reactive metabolites</span></div><div class="casAuthors">Aprile, Silvio; Zaninetti, Roberta; Del Grosso, Erika; Genazzani, Armando A.; Grosa, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical and Biomedical Analysis</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">78-79</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">233-242</span>CODEN:
                <span class="NLM_cas:coden">JPBADA</span>;
        ISSN:<span class="NLM_cas:issn">0731-7085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Combretastatin A-1, an antineoplastic agent characterized by a remarkable cytotoxicity and a strong antitubulinic activity, is currently under investigation in phase I clin. trials.  Yet a comprehensive metabolic study of CA-1 in human and animal models has so far not been reported in the literature.  We have therefore investigated, through LC-UV and LC-MS anal. the in vitro/in vivo metab. of CA-1, have synthesized its reactive quinone metabolite Q1, and have evaluated its cytotoxic and antitubulinic activities.  In vitro CA-1 metab. was studied in rat and human liver microsomes in the presence of the nucleophilic trapping agent GSH were performed while urine samples of the CA-1-treated rats were analyzed to establish the in vivo metabolic pathways.  The metabolite Q1, that was synthesized in good yield using a polymer supported oxidant, displayed a significant cytotoxicity but was devoid of significant antitubulinic activity.  Finally the chem. interaction of Q1 and the other combretastatin quinone metabolites with sulfydryl groups of tubulin was measured by Ellman's method: the results suggested the haptenization of the tubulin through the formation of a covalent bond.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbAvvJUDy4CbVg90H21EOLACvtfcHk0lhGvIP1VwgTCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVGisr8%253D&md5=1feeb591fc4b43b87a70d094f29c8a30</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.jpba.2013.02.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpba.2013.02.030%26sid%3Dliteratum%253Aachs%26aulast%3DAprile%26aufirst%3DS.%26aulast%3DZaninetti%26aufirst%3DR.%26aulast%3DDel%2BGrosso%26aufirst%3DE.%26aulast%3DGenazzani%26aufirst%3DA.%2BA.%26aulast%3DGrosa%26aufirst%3DG.%26atitle%3DMetabolic%2520fate%2520of%2520combretastatin%2520A-1%253A%2520LC-DAD-MS%252FMS%2520investigation%2520and%2520biological%2520evaluation%2520of%2520its%2520reactive%2520metabolites%26jtitle%3DJ.%2520Pharm.%2520Biomed.%2520Anal.%26date%3D2013%26volume%3D78%25E2%2580%259379%26spage%3D233%26epage%3D242%26doi%3D10.1016%2Fj.jpba.2013.02.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group">Rautio, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumpulainen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heimbach, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliyai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarvinen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savolainen, J.</span><span> </span><span class="NLM_article-title">Prodrugs: design and clinical applications</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span><span class="refDoi"> DOI: 10.1038/nrd2468</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1038%2Fnrd2468" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=18219308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFOrs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=255-270&author=J.+Rautioauthor=H.+Kumpulainenauthor=T.+Heimbachauthor=R.+Oliyaiauthor=D.+Ohauthor=T.+Jarvinenauthor=J.+Savolainen&title=Prodrugs%3A+design+and+clinical+applications&doi=10.1038%2Fnrd2468"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs: design and clinical applications</span></div><div class="casAuthors">Rautio, Jarkko; Kumpulainen, Hanna; Heimbach, Tycho; Oliyai, Reza; Oh, Dooman; Jaervinen, Tomi; Savolainen, Jouko</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">255-270</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Prodrugs are bioreversible derivs. of drug mols. that undergo an enzymic and/or chem. transformation in vivo to release the active parent drug, which can then exert the desired pharmacol. effect.  In both drug discovery and development, prodrugs have become an established tool for improving physicochem., biopharmaceutical or pharmacokinetic properties of pharmacol. active agents.  About 5-7% of drugs approved worldwide can be classified as prodrugs, and the implementation of a prodrug approach in the early stages of drug discovery is a growing trend.  To illustrate the applicability of the prodrug strategy, this article describes the most common functional groups that are amenable to prodrug design, and highlights examples of prodrugs that are either launched or are undergoing human trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxnlEXYMLCVbVg90H21EOLACvtfcHk0liZ-goetLVRZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFOrs7w%253D&md5=481a088ad2ee4da062779b5b28a33cbb</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1038%2Fnrd2468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2468%26sid%3Dliteratum%253Aachs%26aulast%3DRautio%26aufirst%3DJ.%26aulast%3DKumpulainen%26aufirst%3DH.%26aulast%3DHeimbach%26aufirst%3DT.%26aulast%3DOliyai%26aufirst%3DR.%26aulast%3DOh%26aufirst%3DD.%26aulast%3DJarvinen%26aufirst%3DT.%26aulast%3DSavolainen%26aufirst%3DJ.%26atitle%3DProdrugs%253A%2520design%2520and%2520clinical%2520applications%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D255%26epage%3D270%26doi%3D10.1038%2Fnrd2468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group">Eskens, F. A. L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tresca, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tosi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Doorn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontaine, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van der Gaast, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veyrat-Follet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oprea, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hospitel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dieras, V.</span><span> </span><span class="NLM_article-title">A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">2170</span><span class="NLM_x">–</span> <span class="NLM_lpage">2177</span><span class="refDoi"> DOI: 10.1038/bjc.2014.137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1038%2Fbjc.2014.137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=24714750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtFSqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2014&pages=2170-2177&author=F.+A.+L.+M.+Eskensauthor=P.+Trescaauthor=D.+Tosiauthor=L.+Van+Doornauthor=H.+Fontaineauthor=A.+Van+der+Gaastauthor=C.+Veyrat-Folletauthor=C.+Opreaauthor=M.+Hospitelauthor=V.+Dieras&title=A+phase+I+pharmacokinetic+study+of+the+vascular+disrupting+agent+ombrabulin+%28AVE8062%29+and+docetaxel+in+advanced+solid+tumours&doi=10.1038%2Fbjc.2014.137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours</span></div><div class="casAuthors">Eskens, F. A. L. M.; Tresca, P.; Tosi, D.; Van Doorn, L.; Fontaine, H.; Van der Gaast, A.; Veyrat-Follet, C.; Oprea, C.; Hospitel, M.; Dieras, V.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2170-2177</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: The vascular disrupting agent ombrabulin shows synergy with docetaxel in vivo.  Recommended phase II doses were detd. in a dose escalation study in advanced solid tumors.  Methods: Ombrabulin (30-min infusion, day 1) followed by docetaxel (1-h infusion, day 2) every 3 wk was explored.  Ombrabulin was escalated from 11.5 to 42 mg m-2 with 75 mg m-2 docetaxel, then from 30 to 35 mg m-2 with 100 mg m-2 docetaxel.  Recommended phase II dose cohorts were expanded.  Results: Fifty-eight patients were treated.  Recommended phase II doses were 35 mg m-2 ombrabulin with 75 mg m-2 docetaxel (35/75 mg m-2; 13 patients) and 30 mg m-2 ombrabulin with 100 mg m-2 docetaxel (30/100 mg m-2; 16 patients).  Dose-limiting toxicities were grade 3 fatigue (two patients; 42/75, 35/100), grade 3 neutropaenic infection (25/75), grade 3 headache (42/75), grade 4 febrile neutropaenia (30/100), and grade 3 thrombosis (35/100).  Toxicities were consistent with each agent; mild nausea/vomiting, asthaenia/fatigue, alopecia, and anemia were common, as were neutropaenia and leukopaenia.  Diarrhoea, nail disorders and neurol. symptoms were frequent at 100 mg m-2 docetaxel.  Pharmacokinetic analyses did not show any relevant drug interactions.  Ten patients had partial responses (seven at 30 mg m-2 ombrabulin), eight lasting >3 mo.  Conclusions: Sequential administration of ombrabulin with 75 or 100 mg m-2 docetaxel every 3 wk is feasible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDxQcFD-TwWLVg90H21EOLACvtfcHk0liZ-goetLVRZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtFSqurg%253D&md5=e95bf24299e4bb43e89b19509d305f69</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2014.137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2014.137%26sid%3Dliteratum%253Aachs%26aulast%3DEskens%26aufirst%3DF.%2BA.%2BL.%2BM.%26aulast%3DTresca%26aufirst%3DP.%26aulast%3DTosi%26aufirst%3DD.%26aulast%3DVan%2BDoorn%26aufirst%3DL.%26aulast%3DFontaine%26aufirst%3DH.%26aulast%3DVan%2Bder%2BGaast%26aufirst%3DA.%26aulast%3DVeyrat-Follet%26aufirst%3DC.%26aulast%3DOprea%26aufirst%3DC.%26aulast%3DHospitel%26aufirst%3DM.%26aulast%3DDieras%26aufirst%3DV.%26atitle%3DA%2520phase%2520I%2520pharmacokinetic%2520study%2520of%2520the%2520vascular%2520disrupting%2520agent%2520ombrabulin%2520%2528AVE8062%2529%2520and%2520docetaxel%2520in%2520advanced%2520solid%2520tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2014%26volume%3D110%26spage%3D2170%26epage%3D2177%26doi%3D10.1038%2Fbjc.2014.137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group">Nkepang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajaputra, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awuah, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">You, Y.</span><span> </span><span class="NLM_article-title">Folate receptor-mediated enhanced and specific delivery of far-red light-activatable prodrugs of combretastatin A-4 to FR-positive tumor</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">2175</span><span class="NLM_x">–</span> <span class="NLM_lpage">2188</span><span class="refDoi"> DOI: 10.1021/bc500376j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc500376j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVWlt7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=2175-2188&author=G.+Nkepangauthor=M.+Bioauthor=P.+Rajaputraauthor=S.+G.+Awuahauthor=Y.+You&title=Folate+receptor-mediated+enhanced+and+specific+delivery+of+far-red+light-activatable+prodrugs+of+combretastatin+A-4+to+FR-positive+tumor&doi=10.1021%2Fbc500376j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Folate Receptor-Mediated Enhanced and Specific Delivery of Far-Red Light-Activatable Prodrugs of Combretastatin A-4 to FR-Positive Tumor</span></div><div class="casAuthors">Nkepang, Gregory; Bio, Moses; Rajaputra, Pallavi; Awuah, Samuel G.; You, Youngjae</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2175-2188</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We examd. the concept of a novel prodrug strategy in which anticancer drug can be locally released by visible/near IR light, taking advantage of the photodynamic process and photo-unclick chem.  Our most recently formulated prodrug of combretastatin A-4, Pc-(L-CA4)2, showed multifunctionality for fluorescence imaging, light-activated drug release, and the combined effects of PDT and local chemotherapy.  In this formulation, L is a singlet oxygen cleavable linker.  Here, we advanced this multifunctional prodrug by adding a tumor-targeting group, folic acid (FA).  We designed and prepd. four FA-conjugated prodrugs 1-4 (CA4-L-Pc-PEGn-FA: n = 0, 2, 18, ∼45) and one non-FA-conjugated prodrug 5 (CA4-L-Pc-PEG18-boc).  Prodrugs 3 and 4 had a longer PEG spacer and showed higher hydrophilicity, enhanced uptake to colon 26 cells via FR-mediated mechanisms, and more specific localization to SC colon 26 tumors in Balb/c mice than prodrugs 1 and 2.  Prodrug 4 also showed higher and more specific uptake to tumors, resulting in selective tumor damage and more effective antitumor efficacy than non-FA-conjugated prodrug 5.  FR-mediated targeting seemed to be an effective strategy to spare normal tissues surrounding tumors in the illuminated area during treatment with this prodrug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJfkU0m3ozN7Vg90H21EOLACvtfcHk0lgQmNUVHrEXOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVWlt7vJ&md5=7b8c839db1b6a44873d3bb734a9b8405</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1021%2Fbc500376j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc500376j%26sid%3Dliteratum%253Aachs%26aulast%3DNkepang%26aufirst%3DG.%26aulast%3DBio%26aufirst%3DM.%26aulast%3DRajaputra%26aufirst%3DP.%26aulast%3DAwuah%26aufirst%3DS.%2BG.%26aulast%3DYou%26aufirst%3DY.%26atitle%3DFolate%2520receptor-mediated%2520enhanced%2520and%2520specific%2520delivery%2520of%2520far-red%2520light-activatable%2520prodrugs%2520of%2520combretastatin%2520A-4%2520to%2520FR-positive%2520tumor%26jtitle%3DBioconjugate%2520Chem.%26date%3D2014%26volume%3D25%26spage%3D2175%26epage%3D2188%26doi%3D10.1021%2Fbc500376j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group">Yang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ying, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span> </span><span class="NLM_article-title">Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature</span> <span class="citation_source-journal">Nanomedicine</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">92</span><span class="refDoi"> DOI: 10.1016/j.nano.2011.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.nano.2011.05.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=81-92&author=T.+Yangauthor=Y.+Wangauthor=Z.+Liauthor=W.+Daiauthor=J.+Yinauthor=L.+Liangauthor=X.+Yingauthor=S.+Zhouauthor=J.+Wangauthor=X.+Zhangauthor=Q.+Zhang&title=Targeted+delivery+of+a+combination+therapy+consisting+of+combretastatin+A4+and+low-dose+doxorubicin+against+tumor+neovasculature&doi=10.1016%2Fj.nano.2011.05.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.nano.2011.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nano.2011.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DDai%26aufirst%3DW.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DYing%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DQ.%26atitle%3DTargeted%2520delivery%2520of%2520a%2520combination%2520therapy%2520consisting%2520of%2520combretastatin%2520A4%2520and%2520low-dose%2520doxorubicin%2520against%2520tumor%2520neovasculature%26jtitle%3DNanomedicine%26date%3D2012%26volume%3D8%26spage%3D81%26epage%3D92%26doi%3D10.1016%2Fj.nano.2011.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bian, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span> </span><span class="NLM_article-title">Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: In vitro and in vivo studies</span> <span class="citation_source-journal">Eur. J. Pharm. Biopharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">467</span><span class="NLM_x">–</span> <span class="NLM_lpage">473</span><span class="refDoi"> DOI: 10.1016/j.ejpb.2010.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.ejpb.2010.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=20064608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivFGrsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2010&pages=467-473&author=Y.+Zhangauthor=J.+Wangauthor=D.+Bianauthor=X.+Zhangauthor=Q.+Zhang&title=Targeted+delivery+of+RGD-modified+liposomes+encapsulating+both+combretastatin+A-4+and+doxorubicin+for+tumor+therapy%3A+In+vitro+and+in+vivo+studies&doi=10.1016%2Fj.ejpb.2010.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: In vitro and in vivo studies</span></div><div class="casAuthors">Zhang, Yi-fei; Wang, Jian-cheng; Bian, Dong-yan; Zhang, Xuan; Zhang, Qiang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutics and Biopharmaceutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">467-473</span>CODEN:
                <span class="NLM_cas:coden">EJPBEL</span>;
        ISSN:<span class="NLM_cas:issn">0939-6411</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Arg-Gly-Asp (RGD) modified doxorubicin-loaded liposomes could improve anticancer effect, and vascular disrupting agents (VDAs) could induce a rapid and selective shutdown of the blood vessels of tumors.  We propose that RGD-modified liposomes for co-encapsulation and sequential release of vascular disrupting agent combretastatin A-4 (CA-4) and cytotoxic agent doxorubicin (Dox) could enhance tumor inhibition responses.  In this study, we encapsulated Dox and CA-4 in RGD-modified liposomes.  The release rate of Dox was proved to be much slower than that of CA-4 in vitro.  Flow cytometry and laser confocal scanning microscopy clearly showed that RGD-modification promoted intracellular uptake of liposomal drugs by B16/B16F10 melanoma tumor cells and human umbilical vein endothelial cells (HUVECs).  Cytotoxicity assay showed that the IC50 of RGD-modified liposomes was lower than that of the corresponding unmodified liposomes.  Therapeutic benefits were examd. on B16F10 melanoma tumors s.c. growing in C57BL/6 mice.  In vivo study demonstrated that RGD-modified liposomes exhibited the most pronounced tumor regression effect when both CA-4 and Dox were co-encapsulated.  These results suggest that the targeted drug delivery system for co-encapsulation of vascular disrupting agents and anticancer agents may be a promising strategy for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf0bsFcQy_prVg90H21EOLACvtfcHk0lgQmNUVHrEXOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivFGrsb0%253D&md5=376e51f67b9f121c8999516f53a709f0</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2Fj.ejpb.2010.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejpb.2010.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DBian%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DQ.%26atitle%3DTargeted%2520delivery%2520of%2520RGD-modified%2520liposomes%2520encapsulating%2520both%2520combretastatin%2520A-4%2520and%2520doxorubicin%2520for%2520tumor%2520therapy%253A%2520In%2520vitro%2520and%2520in%2520vivo%2520studies%26jtitle%3DEur.%2520J.%2520Pharm.%2520Biopharm.%26date%3D2010%26volume%3D74%26spage%3D467%26epage%3D473%26doi%3D10.1016%2Fj.ejpb.2010.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group">Zhang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span> </span><span class="NLM_article-title">Multifunctional dendrimer/combretastatin A4 inclusion complexes enable in vitro targeted cancer therapy</span> <span class="citation_source-journal">Int. J. Nanomed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2337</span><span class="NLM_x">–</span> <span class="NLM_lpage">2349</span><span class="refDoi"> DOI: 10.2147/IJN.S24705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.2147%2FIJN.S24705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=22072871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Sjs77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=2337-2349&author=M.+Zhangauthor=R.+Guoauthor=Y.+Wangauthor=X.+Caoauthor=M.+Shenauthor=X.+Shi&title=Multifunctional+dendrimer%2Fcombretastatin+A4+inclusion+complexes+enable+in+vitro+targeted+cancer+therapy&doi=10.2147%2FIJN.S24705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Multifunctional dendrimer/combretastatin A4 inclusion complexes enable in vitro targeted cancer therapy</span></div><div class="casAuthors">Zhang, Mengen; Guo, Rui; Wang, Yin; Cao, Xueyan; Shen, Mingwu; Shi, Xiangyang</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Nanomedicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2337-2349</span>CODEN:
                <span class="NLM_cas:coden">IJNNHQ</span>;
        ISSN:<span class="NLM_cas:issn">1178-2013</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: We report here a unique approach to using multifunctional dendrimer/combretastatin A4 (CA4) inclusion complexes for targeted cancer therapeutics.  Methods: Amine-terminated generation 5 polyamidoamine dendrimers were first partially acetylated to neutralize a significant portion of the terminal amines, and then the remaining dendrimer terminal amines were sequentially modified with fluorescein isothiocyanate as an imaging agent and folic acid as a targeting ligand.  The multifunctional dendrimers formed (G5.NHAc-FI-FA) were utilized to encapsulate the anticancer drug, CA4, for targeted delivery into cancer cells overexpressing folic acid receptors.  Results: The inclusion complexes of G5.NHAc-FI-FA/CA4 formed were stable and are able to significantly improve the water soly. of CA4 from 11.8 to 240 μg/mL.  In vitro release studies showed that the multifunctional dendrimers complexed with CA4 could be released in a sustained manner.  Both 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide colorimetric assay and morphol. cell observation showed that the inhibitory effect of the G5.NHAc-FI-FA/CA4 complexes was similar to that of free CA4 at the same selected drug concn.  More importantly, the complexes were able to target selectively and display specific therapeutic efficacy to cancer cells overexpressing high-affinity folic acid receptors.  Conclusion: Multifunctional dendrimers may serve as a valuable carrier to form stable inclusion complexes with various hydrophobic anticancer drugs with improved water soly., for targeting chemotherapy to different types of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnbxiWphITV7Vg90H21EOLACvtfcHk0lhC3m4NF6mMLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Sjs77E&md5=e0c8be71e76e2ae08e1a797e9e810cb9</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.2147%2FIJN.S24705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S24705%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DGuo%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DShen%26aufirst%3DM.%26aulast%3DShi%26aufirst%3DX.%26atitle%3DMultifunctional%2520dendrimer%252Fcombretastatin%2520A4%2520inclusion%2520complexes%2520enable%2520in%2520vitro%2520targeted%2520cancer%2520therapy%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2011%26volume%3D6%26spage%3D2337%26epage%3D2349%26doi%3D10.2147%2FIJN.S24705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, N.</span><span> </span><span class="NLM_article-title">pH-sensitive pullulan-based nanoparticle carrier of methotrexate and combretastatin A4 for the combination therapy against hepatocellular carcinoma</span> <span class="citation_source-journal">Biomaterials</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">7181</span><span class="NLM_x">–</span> <span class="NLM_lpage">7190</span><span class="refDoi"> DOI: 10.1016/j.biomaterials.2013.05.081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.biomaterials.2013.05.081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=23791500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvFCjsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=7181-7190&author=Y.+Wangauthor=H.+Chenauthor=Y.+Liuauthor=J.+Wuauthor=P.+Zhouauthor=Y.+Wangauthor=R.+Liauthor=X.+Yangauthor=N.+Zhang&title=pH-sensitive+pullulan-based+nanoparticle+carrier+of+methotrexate+and+combretastatin+A4+for+the+combination+therapy+against+hepatocellular+carcinoma&doi=10.1016%2Fj.biomaterials.2013.05.081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">pH-sensitive pullulan-based nanoparticle carrier of methotrexate and combretastatin A4 for the combination therapy against hepatocellular carcinoma</span></div><div class="casAuthors">Wang, Yinsong; Chen, Hongli; Liu, Yuanyuan; Wu, Jing; Zhou, Ping; Wang, Yan; Li, Rongshan; Yang, Xiaoying; Zhang, Ning</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">7181-7190</span>CODEN:
                <span class="NLM_cas:coden">BIMADU</span>;
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">This study designs a pH-sensitive nanoparticle carrier of methotrexate (MTX) and combretastatin A4 (CA4) based on pullulan for the combination therapy against hepatocellular carcinoma (HCC).  Briefly, N-urocanyl pullulan (URPA) with the degree of substitution (DS) of 5.2% was synthesized and then conjugated with MTX to form MTX-URPA, in which MTX content was 17.8%.  MTX-URPA nanoparticles prepd. by the dialysis method had spherical shape and the mean size of 187.1 nm, and showed high affinity for HepG2 cells.  CA4 was successfully loaded into MTX-URPA nanoparticles and exhibited pH-sensitive in vitro release property.  After i.v. injection to PLC/PRF/5-bearing nude mice, CA4 loaded MTX-URPA (CA4/MTX-URPA) nanoparticles achieved the enhanced antitumor and anti-angiogenic effects, the prolonged circulation time in blood, and the increased distributions both in the liver and the tumor.  In conclusion, this drug carrier system has significant liver-targeting property and exhibits advantages for the combination therapy against hepatocellular carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9ZeO6rAlDJLVg90H21EOLACvtfcHk0lhC3m4NF6mMLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvFCjsL4%253D&md5=251ad018ee1fa4fbc6438a53a611b9c7</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2013.05.081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2013.05.081%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DN.%26atitle%3DpH-sensitive%2520pullulan-based%2520nanoparticle%2520carrier%2520of%2520methotrexate%2520and%2520combretastatin%2520A4%2520for%2520the%2520combination%2520therapy%2520against%2520hepatocellular%2520carcinoma%26jtitle%3DBiomaterials%26date%3D2013%26volume%3D34%26spage%3D7181%26epage%3D7190%26doi%3D10.1016%2Fj.biomaterials.2013.05.081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group">Sengupta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eavarone, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capila, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiziltepe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasisekharan, R.</span><span> </span><span class="NLM_article-title">Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">436</span><span class="NLM_x">, </span> <span class="NLM_fpage">568</span><span class="NLM_x">–</span> <span class="NLM_lpage">572</span><span class="refDoi"> DOI: 10.1038/nature03794</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1038%2Fnature03794" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=16049491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmsFCgs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=436&publication_year=2005&pages=568-572&author=S.+Senguptaauthor=D.+Eavaroneauthor=I.+Capilaauthor=G.+Zhaoauthor=N.+Watsonauthor=T.+Kiziltepeauthor=R.+Sasisekharan&title=Temporal+targeting+of+tumour+cells+and+neovasculature+with+a+nanoscale+delivery+system&doi=10.1038%2Fnature03794"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Temporal targeting of tumor cells and neovasculature with a nanoscale delivery system</span></div><div class="casAuthors">Sengupta, Shiladitya; Eavarone, David; Capila, Ishan; Zhao, Ganlin; Watson, Nicki; Kiziltepe, Tanyel; Sasisekharan, Ram</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">436</span>
        (<span class="NLM_cas:issue">7050</span>),
    <span class="NLM_cas:pages">568-572</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In the continuing search for effective treatments for cancer, the emerging model is the combination of traditional chemotherapy with anti-angiogenesis agents that inhibit blood vessel growth.  However, the implementation of this strategy has faced two major obstacles.  First, the long-term shutdown of tumor blood vessels by the anti-angiogenesis agent can prevent the tumor from receiving a therapeutic concn. of the chemotherapy agent.  Second, inhibiting blood supply drives the intra-tumoral accumulation of hypoxia-inducible factor-1α (HIF1-α); overexpression of HIF1-α is correlated with increased tumor invasiveness and resistance to chemotherapy.  Here we report the disease-driven engineering of a drug delivery system, a 'nanocell', which overcomes these barriers unique to solid tumors.  The nanocell comprises a nuclear nanoparticle within an extranuclear pegylated-lipid envelope, and is preferentially taken up by the tumor.  The nanocell enables a temporal release of two drugs: the outer envelope first releases an anti-angiogenesis agent, causing a vascular shutdown; the inner nanoparticle, which is trapped inside the tumor, then releases a chemotherapy agent.  This focal release within a tumor results in improved therapeutic index with reduced toxicity.  The technol. can be extended to addnl. agents, so as to target multiple signalling pathways or distinct tumor compartments, enabling the model of an 'integrative' approach in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0HlLud2V1hLVg90H21EOLACvtfcHk0lhC3m4NF6mMLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmsFCgs70%253D&md5=9a29315c805eca28d022832368f1b5c9</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1038%2Fnature03794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03794%26sid%3Dliteratum%253Aachs%26aulast%3DSengupta%26aufirst%3DS.%26aulast%3DEavarone%26aufirst%3DD.%26aulast%3DCapila%26aufirst%3DI.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DWatson%26aufirst%3DN.%26aulast%3DKiziltepe%26aufirst%3DT.%26aulast%3DSasisekharan%26aufirst%3DR.%26atitle%3DTemporal%2520targeting%2520of%2520tumour%2520cells%2520and%2520neovasculature%2520with%2520a%2520nanoscale%2520delivery%2520system%26jtitle%3DNature%26date%3D2005%26volume%3D436%26spage%3D568%26epage%3D572%26doi%3D10.1038%2Fnature03794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group">Poojari, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srivastava, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panda, D.</span><span> </span><span class="NLM_article-title">A chimeric cetuximab-functionalized corona as a potent delivery system for microtubule-destabilizing nanocomplexes to hepatocellular carcinoma cells: a focus on EGFR and tubulin intracellular dynamics</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">3908</span><span class="NLM_x">–</span> <span class="NLM_lpage">3923</span><span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.5b00337</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.5b00337" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2iu77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=3908-3923&author=R.+Poojariauthor=S.+Kiniauthor=R.+Srivastavaauthor=D.+Panda&title=A+chimeric+cetuximab-functionalized+corona+as+a+potent+delivery+system+for+microtubule-destabilizing+nanocomplexes+to+hepatocellular+carcinoma+cells%3A+a+focus+on+EGFR+and+tubulin+intracellular+dynamics&doi=10.1021%2Facs.molpharmaceut.5b00337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">A Chimeric Cetuximab-Functionalized Corona as a Potent Delivery System for Microtubule-Destabilizing Nanocomplexes to Hepatocellular Carcinoma Cells: A Focus on EGFR and Tubulin Intracellular Dynamics</span></div><div class="casAuthors">Poojari, Radhika; Kini, Sudarshan; Srivastava, Rohit; Panda, Dulal</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3908-3923</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this s tudy, we have developed microtubule destabilizing agents combretastatin A4 (CA4) or 2-methoxyestradiol (2ME) encapsulated poly(D,L-lactide-co-glycolide)-b-poly(ethylene glycol) (PLGA-b-PEG) nanocomplexes for targeted delivery to human hepatocellular carcinoma (HCC) cells.  An epidermal growth factor receptor (EGFR) is known to be overexpressed in HCC cells.  Therefore, the targeting moiety cetuximab (Cet), an anti-EGFR chimeric monoclonal antibody, is functionalized on the surface of these diblock copolymeric coronas.  Cetuximab is assocd. with the extracellular domain of the EGFR; therefore, the uptake of the cetuximab conjugated nanocomplexes occurred efficiently in EGFR overexpressing HCC cells indicating potent internalization of the complex.  The cetuximab targeted-PLGA-b-PEG nanocomplexes encapsulating CA4 or 2ME strongly inhibited phospho-EGFR expression, depolymd. microtubules, produced spindle abnormalities, stalled mitosis, and induced apoptosis in Huh7 cells compared to the free drugs, CA4 or 2ME.  Further, the combinatorial strategy of targeted nanocomplexes, Cet-PLGA-b-PEG-CA4 NP and Cet-PLGA-b-PEG-2ME NP, significantly reduced the migration of Huh7 cells, and markedly enhanced the anticancer effects of the microtubule-targeted drugs in Huh7 cells compared to the free drugs, CA4 or 2ME.  The results indicated that EGFR receptor-mediated internalization via cetuximab facilitated enhanced uptake of the nanocomplexes leading to potent anticancer efficacy in Huh7 cells.  Cetuximab-functionalized PLGA-b-PEG nanocomplexes possess a strong potential for the targeted delivery of CA4 or 2ME in EGFR overexpressed HCC cells, and the strategy may be useful for selectively targeting microtubules in these cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8ckb30rnN4rVg90H21EOLACvtfcHk0lgdKSkwe4jgwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2iu77P&md5=b8812064316746378a193d1640cb8119</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.5b00337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.5b00337%26sid%3Dliteratum%253Aachs%26aulast%3DPoojari%26aufirst%3DR.%26aulast%3DKini%26aufirst%3DS.%26aulast%3DSrivastava%26aufirst%3DR.%26aulast%3DPanda%26aufirst%3DD.%26atitle%3DA%2520chimeric%2520cetuximab-functionalized%2520corona%2520as%2520a%2520potent%2520delivery%2520system%2520for%2520microtubule-destabilizing%2520nanocomplexes%2520to%2520hepatocellular%2520carcinoma%2520cells%253A%2520a%2520focus%2520on%2520EGFR%2520and%2520tubulin%2520intracellular%2520dynamics%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2015%26volume%3D12%26spage%3D3908%26epage%3D3923%26doi%3D10.1021%2Facs.molpharmaceut.5b00337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group">Song, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span> </span><span class="NLM_article-title">Coadministration of vascular disrupting agents and nanomedicines to eradicate tumors from peripheral and central regions</span> <span class="citation_source-journal">Small</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">3755</span><span class="NLM_x">–</span> <span class="NLM_lpage">3761</span><span class="refDoi"> DOI: 10.1002/smll.201500324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1002%2Fsmll.201500324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=25919954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnt1WhsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=3755-3761&author=W.+Songauthor=Z.+Tangauthor=D.+Zhangauthor=H.+Yuauthor=X.+Chen&title=Coadministration+of+vascular+disrupting+agents+and+nanomedicines+to+eradicate+tumors+from+peripheral+and+central+regions&doi=10.1002%2Fsmll.201500324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Coadministration of Vascular Disrupting Agents and Nanomedicines to Eradicate Tumors from Peripheral and Central Regions</span></div><div class="casAuthors">Song, Wantong; Tang, Zhaohui; Zhang, Dawei; Yu, Haiyang; Chen, Xuesi</div><div class="citationInfo"><span class="NLM_cas:title">Small</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">3755-3761</span>CODEN:
                <span class="NLM_cas:coden">SMALBC</span>;
        ISSN:<span class="NLM_cas:issn">1613-6810</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">We developed a strategy for coadministering CDDP-NPs plus free small-mol. VDAs in order to improve treatment ef cacy within the central region of solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS8QuLnh2Ov7Vg90H21EOLACvtfcHk0lgdKSkwe4jgwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnt1WhsLk%253D&md5=6cf76235b5e4eeb7ebf83e12146ae4c7</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1002%2Fsmll.201500324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsmll.201500324%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DW.%26aulast%3DTang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DCoadministration%2520of%2520vascular%2520disrupting%2520agents%2520and%2520nanomedicines%2520to%2520eradicate%2520tumors%2520from%2520peripheral%2520and%2520central%2520regions%26jtitle%3DSmall%26date%3D2015%26volume%3D11%26spage%3D3755%26epage%3D3761%26doi%3D10.1002%2Fsmll.201500324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group">Al-Abd, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aljehani, Z. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazzaz, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fakhri, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jabbad, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alahdal, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torchilin, V. P.</span><span> </span><span class="NLM_article-title">Pharmacokinetic strategies to improve drug penetration and entrapment within solid tumors</span> <span class="citation_source-journal">J. Controlled Release</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">219</span><span class="NLM_x">, </span> <span class="NLM_fpage">269</span><span class="NLM_x">–</span> <span class="NLM_lpage">277</span><span class="refDoi"> DOI: 10.1016/j.jconrel.2015.08.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.jconrel.2015.08.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=26342660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVygtbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=219&publication_year=2015&pages=269-277&author=A.+M.+Al-Abdauthor=Z.+K.+Aljehaniauthor=R.+W.+Gazzazauthor=S.+H.+Fakhriauthor=A.+H.+Jabbadauthor=A.+M.+Alahdalauthor=V.+P.+Torchilin&title=Pharmacokinetic+strategies+to+improve+drug+penetration+and+entrapment+within+solid+tumors&doi=10.1016%2Fj.jconrel.2015.08.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic strategies to improve drug penetration and entrapment within solid tumors</span></div><div class="casAuthors">Al-Abd, Ahmed M.; Aljehani, Zekra K.; Gazzaz, Rana W.; Fakhri, Sarah H.; Jabbad, Aisha H.; Alahdal, Abdulrahman M.; Torchilin, Vladimir P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">219</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">269-277</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Despite the discovery of a large no. of anticancer agents, cancer still remains among the leading causes of death since the middle of the twentieth century.  Solid tumors possess a high degree of genetic instability and emergence of treatment resistance.  Tumor resistance has emerged for almost all approved anticancer drugs and will most probably emerge for newly discovered anticancer agents as well.  The use of pharmacokinetic approaches to increase anticancer drug concns. within the solid tumor compartment and prolong its entrapment might diminish the possibility of resistance emergence at the mol. pharmacodynamic level and might even reverse tumor resistance.  Several novel treatment modalities such as metronomic therapy, angiogenesis inhibitors, vascular disrupting agents and tumor priming have been introduced to improve solid tumor treatment outcomes.  In the current review we will discuss the pharmacokinetic aspect of these treatment modalities in addn. to other older treatment modalities, such as extracellular matrix dissolving agents, extracellular matrix synthesis inhibitors, chemoembolization and cellular efflux pump inhibition.  Many of these strategies showed variable degrees of success/failure; however, reallocating these modalities based on their influence on the intratumoral pharmacokinetics might improve their understanding and treatment outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrf-2BeX0FbBbVg90H21EOLACvtfcHk0lg3O4Jx93Ookw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVygtbjI&md5=c43a87fc1e85c63268b2d71d691b074d</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2015.08.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2015.08.055%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Abd%26aufirst%3DA.%2BM.%26aulast%3DAljehani%26aufirst%3DZ.%2BK.%26aulast%3DGazzaz%26aufirst%3DR.%2BW.%26aulast%3DFakhri%26aufirst%3DS.%2BH.%26aulast%3DJabbad%26aufirst%3DA.%2BH.%26aulast%3DAlahdal%26aufirst%3DA.%2BM.%26aulast%3DTorchilin%26aufirst%3DV.%2BP.%26atitle%3DPharmacokinetic%2520strategies%2520to%2520improve%2520drug%2520penetration%2520and%2520entrapment%2520within%2520solid%2520tumors%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2015%26volume%3D219%26spage%3D269%26epage%3D277%26doi%3D10.1016%2Fj.jconrel.2015.08.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group">Tozer, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prise, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilso, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cemazar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewhirst, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barber, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vojnovic, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span> </span><span class="NLM_article-title">Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: Intravital microscopy and measurement of vascular permeability</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">6413</span><span class="NLM_x">–</span> <span class="NLM_lpage">6422</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=6413-6422&author=G.+M.+Tozerauthor=V.+E.+Priseauthor=J.+Wilsoauthor=M.+Cemazarauthor=S.+Shanauthor=M.+W.+Dewhirstauthor=P.+R.+Barberauthor=B.+Vojnovicauthor=D.+J.+Chaplin&title=Mechanisms+associated+with+tumor+vascular+shut-down+induced+by+combretastatin+A-4+phosphate%3A+Intravital+microscopy+and+measurement+of+vascular+permeability"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTozer%26aufirst%3DG.%2BM.%26aulast%3DPrise%26aufirst%3DV.%2BE.%26aulast%3DWilso%26aufirst%3DJ.%26aulast%3DCemazar%26aufirst%3DM.%26aulast%3DShan%26aufirst%3DS.%26aulast%3DDewhirst%26aufirst%3DM.%2BW.%26aulast%3DBarber%26aufirst%3DP.%2BR.%26aulast%3DVojnovic%26aufirst%3DB.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26atitle%3DMechanisms%2520associated%2520with%2520tumor%2520vascular%2520shut-down%2520induced%2520by%2520combretastatin%2520A-4%2520phosphate%253A%2520Intravital%2520microscopy%2520and%2520measurement%2520of%2520vascular%2520permeability%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D6413%26epage%3D6422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group">McPhail, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, S. P.</span><span> </span><span class="NLM_article-title">Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging</span> <span class="citation_source-journal">Int. J. Radiat. Oncol., Biol., Phys.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">1238</span><span class="NLM_x">–</span> <span class="NLM_lpage">1245</span><span class="refDoi"> DOI: 10.1016/j.ijrobp.2007.08.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.ijrobp.2007.08.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=17967313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1aktbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2007&pages=1238-1245&author=L.+D.+McPhailauthor=J.+R.+Griffithsauthor=S.+P.+Robinson&title=Assessment+of+tumor+response+to+the+vascular+disrupting+agents+5%2C6-dimethylxanthenone-4-acetic+acid+or+combretastatin-A4-phosphate+by+intrinsic+susceptibility+magnetic+resonance+imaging&doi=10.1016%2Fj.ijrobp.2007.08.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of Tumor Response to the Vascular Disrupting Agents 5,6-Dimethylxanthenone-4-Acetic Acid or Combretastatin-A4-Phosphate by Intrinsic Susceptibility Magnetic Resonance Imaging</span></div><div class="casAuthors">McPhail, Lesley D.; Griffiths, John R.; Robinson, Simon P.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Radiation Oncology, Biology, Physics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1238-1245</span>CODEN:
                <span class="NLM_cas:coden">IOBPD3</span>;
        ISSN:<span class="NLM_cas:issn">0360-3016</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Purpose: To investigate the use of the transverse magnetic resonance imaging (MRI) relaxation rate R2* (s-1) as a biomarker of tumor vascular response to monitor vascular disrupting agent (VDA) therapy.  Methods and Materials: Multigradient echo MRI was used to quantify R2* in rat GH3 prolactinomas.  R2 is a sensitive index of deoxyHb in the blood and can therefore be used to give an index of tissue oxygenation.  Tumor R2* was measured before and up to 35 min after treatment, and 24 h after treatment with either 350 mg/kg 5,6-dimethylxanthenone-4-acetic acid (DMXAA) or 100 mg/kg combretastatin-A4-phosphate (CA4P).  After acquisition of the MRI data, functional tumor blood vessels remaining after VDA treatment were quantified using fluorescence microscopy of the perfusion marker Hoechst 33342.  Results: DMXAA induced a transient, significant (p < 0.05) increase in tumor R2* 7 min after treatment, whereas CA4P induced no significant changes in tumor R2* over the first 35 min.  Twenty-four hours after treatment, some DMXAA-treated tumors demonstrated a decrease in R2*, but overall, redn. in R2* was not significant for this cohort.  Tumors treated with CA4P showed a significant (p < 0.05) redn. in R2* 24 h after treatment.  The degree of Hoechst 33342 uptake was assocd. with the degree of R2* redn. at 24 h for both agents.  Conclusions: The redn. in tumor R2 * or deoxyHb levels 24 h after VDA treatment was a result of reduced blood vol. caused by prolonged vascular collapse.  Our results suggest that DMXAA was less effective than CA4P in this rat tumor model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrWzZPX3W1nbVg90H21EOLACvtfcHk0lg3O4Jx93Ookw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1aktbzF&md5=c6aa34ca0a42a80193caab54d66bbd48</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.ijrobp.2007.08.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijrobp.2007.08.025%26sid%3Dliteratum%253Aachs%26aulast%3DMcPhail%26aufirst%3DL.%2BD.%26aulast%3DGriffiths%26aufirst%3DJ.%2BR.%26aulast%3DRobinson%26aufirst%3DS.%2BP.%26atitle%3DAssessment%2520of%2520tumor%2520response%2520to%2520the%2520vascular%2520disrupting%2520agents%25205%252C6-dimethylxanthenone-4-acetic%2520acid%2520or%2520combretastatin-A4-phosphate%2520by%2520intrinsic%2520susceptibility%2520magnetic%2520resonance%2520imaging%26jtitle%3DInt.%2520J.%2520Radiat.%2520Oncol.%252C%2520Biol.%252C%2520Phys.%26date%3D2007%26volume%3D69%26spage%3D1238%26epage%3D1245%26doi%3D10.1016%2Fj.ijrobp.2007.08.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horsman, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedersen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stødkilde-Jørgensen, H.</span><span> </span><span class="NLM_article-title">The effect of combretastatin A4 disodium phosphate and 5,6- dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours</span> <span class="citation_source-journal">Acta Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1071</span><span class="NLM_x">–</span> <span class="NLM_lpage">1076</span><span class="refDoi"> DOI: 10.1080/02841860701769750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1080%2F02841860701769750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=18770061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOrur%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=1071-1076&author=G.+Chenauthor=M.+R.+Horsmanauthor=M.+Pedersenauthor=Q.+Pangauthor=H.+St%C3%B8dkilde-J%C3%B8rgensen&title=The+effect+of+combretastatin+A4+disodium+phosphate+and+5%2C6-+dimethylxanthenone-4-acetic+acid+on+water+diffusion+and+blood+perfusion+in+tumours&doi=10.1080%2F02841860701769750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of combretastatin A4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours</span></div><div class="casAuthors">Chen, Gang; Horsman, Michael R.; Pedersen, Michael; Pang, Qi; Stodkilde-jorgensen, Hans</div><div class="citationInfo"><span class="NLM_cas:title">Acta Oncologica</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1071-1076</span>CODEN:
                <span class="NLM_cas:coden">ACTOEL</span>;
        ISSN:<span class="NLM_cas:issn">0284-186X</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Purpose: To evaluate the effect of the vascular disrupting drugs combretastatin A-4 disodium phosphate (CA4DP) and 5,6-dimethylxanthenone-4-acetic acid (DMXAA) on the intra/extracellular vol. fraction of water and blood perfusion in tumors using MRI.  Methods and Materials: Mice with C3H mammary carcinomas underwent repeated MRI T2-weighted imaging, water-diffusion and perfusion measurements before and up to 6-h following CA4DP and DMXAA treatment.  Results: CA4DP treatment caused an increase in water diffusion in those tumor areas that presented the lowest blood perfusion, however this appeared only after five hours.  The blood perfusion in highly perfused tumor regions decreased immediately after administration of CA4DP.  DMXAA treatment caused an early decrease in water diffusion in the low-perfused tumor segments and followed by a subsequent decrease in the remaining part of the tumor.  The blood perfusion decreased early in all parts of the tumor.  Conclusion: The effect of CA4DP and DMXAA on tumor blood flow was comparable.  The redn. in regional blood flow caused by CA4DP in the whole tumor segment occurred early, however, changes in ADC after DMXAA appeared more extended and earlier than after CA4DP treatment, esp. in tumor areas already suffering from a low blood perfusion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqso2Qfo2FQrLVg90H21EOLACvtfcHk0lhv3nXdYiJAiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOrur%252FO&md5=8a198c9a1d3d95a9be566507d5073903</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1080%2F02841860701769750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F02841860701769750%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DG.%26aulast%3DHorsman%26aufirst%3DM.%2BR.%26aulast%3DPedersen%26aufirst%3DM.%26aulast%3DPang%26aufirst%3DQ.%26aulast%3DSt%25C3%25B8dkilde-J%25C3%25B8rgensen%26aufirst%3DH.%26atitle%3DThe%2520effect%2520of%2520combretastatin%2520A4%2520disodium%2520phosphate%2520and%25205%252C6-%2520dimethylxanthenone-4-acetic%2520acid%2520on%2520water%2520diffusion%2520and%2520blood%2520perfusion%2520in%2520tumours%26jtitle%3DActa%2520Oncol.%26date%3D2008%26volume%3D47%26spage%3D1071%26epage%3D1076%26doi%3D10.1080%2F02841860701769750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group">Zhao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antich, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, R. P.</span><span> </span><span class="NLM_article-title">Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging and confirmed by MRI</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2445</span><span class="NLM_x">–</span> <span class="NLM_lpage">2451</span><span class="refDoi"> DOI: 10.1096/fj.07-103713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1096%2Ffj.07-103713" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=2445-2451&author=D.+Zhaoauthor=E.+Richerauthor=P.+P.+Antichauthor=R.+P.+Mason&title=Antivascular+effects+of+combretastatin+A4+phosphate+in+breast+cancer+xenograft+assessed+using+dynamic+bioluminescence+imaging+and+confirmed+by+MRI&doi=10.1096%2Ffj.07-103713"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1096%2Ffj.07-103713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.07-103713%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DD.%26aulast%3DRicher%26aufirst%3DE.%26aulast%3DAntich%26aufirst%3DP.%2BP.%26aulast%3DMason%26aufirst%3DR.%2BP.%26atitle%3DAntivascular%2520effects%2520of%2520combretastatin%2520A4%2520phosphate%2520in%2520breast%2520cancer%2520xenograft%2520assessed%2520using%2520dynamic%2520bioluminescence%2520imaging%2520and%2520confirmed%2520by%2520MRI%26jtitle%3DFASEB%2520J.%26date%3D2008%26volume%3D22%26spage%3D2445%26epage%3D2451%26doi%3D10.1096%2Ffj.07-103713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group">Nielsen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentzen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedersen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tramm, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rijken, P. F. J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bussink, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horsman, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ostergaard, L.</span><span> </span><span class="NLM_article-title">Combretastatin A-4 phosphate affects tumor vessel volume and size distribution as assessed using MRI-based vessel size imaging</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">6469</span><span class="NLM_x">–</span> <span class="NLM_lpage">6477</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-2014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1158%2F1078-0432.CCR-12-2014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=23071260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslKgurjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=6469-6477&author=T.+Nielsenauthor=L.+Bentzenauthor=M.+Pedersenauthor=T.+Trammauthor=P.+F.+J.+W.+Rijkenauthor=J.+Bussinkauthor=M.+R.+Horsmanauthor=L.+Ostergaard&title=Combretastatin+A-4+phosphate+affects+tumor+vessel+volume+and+size+distribution+as+assessed+using+MRI-based+vessel+size+imaging&doi=10.1158%2F1078-0432.CCR-12-2014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatin A-4 Phosphate Affects Tumor Vessel Volume and Size Distribution as Assessed Using MRI-Based Vessel Size Imaging</span></div><div class="casAuthors">Nielsen, Thomas; Bentzen, Lise; Pedersen, Michael; Tramm, Trine; Rijken, Paul F. J. W.; Bussink, Johan; Horsman, Michael R.; Ostergaard, Leif</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6469-6477</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Combretastatin A-4 disodium phosphate (CA4P) is a promising vascular disrupting agent (VDA) in clin. trials.  As CA4P acts on dividing endothelial cells, we hypothesize that CA4P affects vessels of certain sizes.  The aim of this study was to evaluate the effect of CA4P by the MRI-based vessel size imaging (VSI).  Exptl. Design: C3H mammary carcinomas were grown to 200 mm3 in the right rear foot of female CDF1 mice.  A control group of mice received no treatment, and a treatment group had CA4P administered i.p. at a dose of 250 mg/kg.  VSI was conducted on a 3 T MR scanner to est. the tumor blood vol. (ζ0) and mean vessel radius (R).  Vascularization was also estd. histol. by endothelial and Hoechst 33342 staining.  Results: ζ0 and R showed different spatial heterogeneity.  Tumor median and quartile values of ζ0 were all significantly reduced by about 35% in the CA4P-treated group as compared with the control group, and the median and upper quartile of R were significantly increased.  Histograms of ζ0 and R showed a general decrease in ζ0 following treatment, and values of R in a certain range (≈20-30 μm) were decreased in the treatment group.  The drug-induced change in ζ0 was in agreement with histol. and our previous dynamic contrast enhanced MRI (DCE-MRI) data.  Conclusions: Tumor blood vol. and mean vessel radius showed a clear response following treatment with CA4P.  VSI may prove valuable in estn. of tumor angiogenesis and prediction of response to VDAs.  Clin Cancer Res; 18(23); 6469-77. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMyMKTh5kSQ7Vg90H21EOLACvtfcHk0liRHxmkzy5XDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslKgurjE&md5=1394edb3198d2e601903c171f6f379c0</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-2014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-2014%26sid%3Dliteratum%253Aachs%26aulast%3DNielsen%26aufirst%3DT.%26aulast%3DBentzen%26aufirst%3DL.%26aulast%3DPedersen%26aufirst%3DM.%26aulast%3DTramm%26aufirst%3DT.%26aulast%3DRijken%26aufirst%3DP.%2BF.%2BJ.%2BW.%26aulast%3DBussink%26aufirst%3DJ.%26aulast%3DHorsman%26aufirst%3DM.%2BR.%26aulast%3DOstergaard%26aufirst%3DL.%26atitle%3DCombretastatin%2520A-4%2520phosphate%2520affects%2520tumor%2520vessel%2520volume%2520and%2520size%2520distribution%2520as%2520assessed%2520using%2520MRI-based%2520vessel%2520size%2520imaging%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D6469%26epage%3D6477%26doi%3D10.1158%2F1078-0432.CCR-12-2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group">Horsman, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murata, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breidahl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, F. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maxwell, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stødkiled-Jørgensen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overgaard, J.</span><span> </span><span class="NLM_article-title">Combretastatins novel vascular targeting drugs for improving anti-cancer therapy: Combretastatins and conventional therapy</span> <span class="citation_source-journal">Adv. Exp. Med. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">476</span><span class="NLM_x">, </span> <span class="NLM_fpage">311</span><span class="NLM_x">–</span> <span class="NLM_lpage">323</span><span class="refDoi"> DOI: 10.1007/978-1-4615-4221-6_26</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1007%2F978-1-4615-4221-6_26" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=476&publication_year=2000&pages=311-323&author=M.+R.+Horsmanauthor=R.+Murataauthor=T.+Breidahlauthor=F.+U.+Nielsenauthor=R.+J.+Maxwellauthor=H.+St%C3%B8dkiled-J%C3%B8rgensenauthor=J.+Overgaard&title=Combretastatins+novel+vascular+targeting+drugs+for+improving+anti-cancer+therapy%3A+Combretastatins+and+conventional+therapy&doi=10.1007%2F978-1-4615-4221-6_26"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1007%2F978-1-4615-4221-6_26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4615-4221-6_26%26sid%3Dliteratum%253Aachs%26aulast%3DHorsman%26aufirst%3DM.%2BR.%26aulast%3DMurata%26aufirst%3DR.%26aulast%3DBreidahl%26aufirst%3DT.%26aulast%3DNielsen%26aufirst%3DF.%2BU.%26aulast%3DMaxwell%26aufirst%3DR.%2BJ.%26aulast%3DSt%25C3%25B8dkiled-J%25C3%25B8rgensen%26aufirst%3DH.%26aulast%3DOvergaard%26aufirst%3DJ.%26atitle%3DCombretastatins%2520novel%2520vascular%2520targeting%2520drugs%2520for%2520improving%2520anti-cancer%2520therapy%253A%2520Combretastatins%2520and%2520conventional%2520therapy%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2000%26volume%3D476%26spage%3D311%26epage%3D323%26doi%3D10.1007%2F978-1-4615-4221-6_26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group">Lunt, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akerman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyes-Aldasoro, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozer, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanthou, C.</span><span> </span><span class="NLM_article-title">Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">1979</span><span class="NLM_x">–</span> <span class="NLM_lpage">1989</span><span class="refDoi"> DOI: 10.1002/ijc.25848</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1002%2Fijc.25848" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=21154772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVKlsrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2011&pages=1979-1989&author=S.+J.+Luntauthor=S.+Akermanauthor=S.+A.+Hillauthor=M.+Fisherauthor=V.+J.+Wrightauthor=C.+C.+Reyes-Aldasoroauthor=G.+M.+Tozerauthor=C.+Kanthou&title=Vascular+effects+dominate+solid+tumor+response+to+treatment+with+combretastatin+A-4-phosphate&doi=10.1002%2Fijc.25848"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate</span></div><div class="casAuthors">Lunt, Sarah Jane; Akerman, Simon; Hill, Sally A.; Fisher, Matthew; Wright, Victoria J.; Reyes-Aldasoro, Constantino C.; Tozer, Gillian M.; Kanthou, Chryso</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1979-1989</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Vascular-targeted therapeutics are increasingly used in the clinic.  However, less is known about the direct response of tumor cells to these agents.  We have developed a combretastatin-A-4-phosphate (CA4P) resistant variant of SW1222 human colorectal carcinoma cells to examine the relative importance of vascular vs. tumor cell targeting in the ultimate treatment response.  SW1222Res cells were generated through exposure of wild-type cells (SW1222WT) to increasing CA4P concns. in vitro.  Increased resistance was confirmed through analyses of cell viability, apoptosis and multidrug-resistance (MDR) protein expression.  In vivo, comparative studies examd. tumor cell necrosis, apoptosis, vessel morphol. and functional vascular end-points following treatment with CA4P (single 100 mg/kg dose).  Tumor response to repeated CA4P dosing (50 mg/kg/day, 5 days/wk for 2 wk) was examd. through growth measurement, and ultimate tumor cell survival was studied by ex vivo clonogenic assay.  In vitro, SW1222Res cells showed reduced CA4P sensitivity, enhanced MDR protein expression and a reduced apoptotic index.  In vivo, CA4P induced significantly lower apoptotic cell death in SW1222Res vs. SW1222WT tumors indicating maintenance of resistance characteristics.  However, CA4P-induced tumor necrosis was equiv. in both lines.  Similarly, rapid CA4P-mediated vessel disruption and blood flow shut-down were obsd. in both lines.  Cell surviving fraction was comparable in the two tumor types following single dose CA4P and SW1222Res tumors were at least as sensitive as SW1222WT tumors to repeated dosing.  Despite tumor cell resistance to CA4P, SW1222Res response in vivo was not impaired, strongly supporting the view that vascular damage dominates the therapeutic response to this agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXfeiOzwb1brVg90H21EOLACvtfcHk0liRHxmkzy5XDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVKlsrvI&md5=155f50bc021c9117845b47f4b63268b8</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1002%2Fijc.25848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.25848%26sid%3Dliteratum%253Aachs%26aulast%3DLunt%26aufirst%3DS.%2BJ.%26aulast%3DAkerman%26aufirst%3DS.%26aulast%3DHill%26aufirst%3DS.%2BA.%26aulast%3DFisher%26aufirst%3DM.%26aulast%3DWright%26aufirst%3DV.%2BJ.%26aulast%3DReyes-Aldasoro%26aufirst%3DC.%2BC.%26aulast%3DTozer%26aufirst%3DG.%2BM.%26aulast%3DKanthou%26aufirst%3DC.%26atitle%3DVascular%2520effects%2520dominate%2520solid%2520tumor%2520response%2520to%2520treatment%2520with%2520combretastatin%2520A-4-phosphate%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2011%26volume%3D129%26spage%3D1979%26epage%3D1989%26doi%3D10.1002%2Fijc.25848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group">Ley, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horsman, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kristjansen, P. E. G.</span><span> </span><span class="NLM_article-title">Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure</span> <span class="citation_source-journal">Neoplasia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">108</span><span class="NLM_x">–</span> <span class="NLM_lpage">112</span><span class="refDoi"> DOI: 10.1593/neo.06733</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1593%2Fneo.06733" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2007&pages=108-112&author=C.+D.+Leyauthor=M.+R.+Horsmanauthor=P.+E.+G.+Kristjansen&title=Early+effects+of+combretastatin-A4+disodium+phosphate+on+tumor+perfusion+and+interstitial+fluid+pressure&doi=10.1593%2Fneo.06733"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1593%2Fneo.06733&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Fneo.06733%26sid%3Dliteratum%253Aachs%26aulast%3DLey%26aufirst%3DC.%2BD.%26aulast%3DHorsman%26aufirst%3DM.%2BR.%26aulast%3DKristjansen%26aufirst%3DP.%2BE.%2BG.%26atitle%3DEarly%2520effects%2520of%2520combretastatin-A4%2520disodium%2520phosphate%2520on%2520tumor%2520perfusion%2520and%2520interstitial%2520fluid%2520pressure%26jtitle%3DNeoplasia%26date%3D2007%26volume%3D9%26spage%3D108%26epage%3D112%26doi%3D10.1593%2Fneo.06733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group">Williams, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukherjee, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyes-Aldasoro, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akerman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanthou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozer, G. M.</span><span> </span><span class="NLM_article-title">An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">171</span><span class="NLM_x">, </span> <span class="NLM_fpage">4902</span><span class="NLM_x">–</span> <span class="NLM_lpage">4913</span><span class="refDoi"> DOI: 10.1111/bph.12817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1111%2Fbph.12817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=24930520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVSjsLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2014&pages=4902-4913&author=L.+J.+Williamsauthor=D.+Mukherjeeauthor=M.+Fisherauthor=C.+C.+Reyes-Aldasoroauthor=S.+Akermanauthor=C.+Kanthouauthor=G.+M.+Tozer&title=An+in+vivo+role+for+Rho+kinase+activation+in+the+tumour+vascular+disrupting+activity+of+combretastatin+A-4+3-O-phosphate&doi=10.1111%2Fbph.12817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate</span></div><div class="casAuthors">Williams, L. J.; Mukherjee, D.; Fisher, M.; Reyes-Aldasoro, C. C.; Akerman, S.; Kanthou, C.; Tozer, G. M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4902-4913</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Combretastatin A-4 3-O-phosphate (CA4P) is in clin. trial as a tumor vascular disrupting agent (VDA) but the cause of blood flow disruption is unclear.  We tested the hypothesis that activation of Rho/Rho kinase (ROCK) is fundamental to the effects of this drug in vivo.  Mouse models of human colorectal carcinoma (SW1222 and LS174T) were used.  Effects of the ROCK inhibitor, Y27632, alone or in combination with CA4P, on ROCK activity, vascular function, necrosis and immune cell infiltration in solid tumors were detd.  Mean arterial BP (MABP) was measured to monitor systemic interactions and the vasodilator, hydralazine, was used to control for the hypotensive effects of Y27632.  Y27632 caused a rapid drop in blood flow in SW1222 tumors, with recovery by around 3 h, which was paralleled by MABP changes.  Y27632 pretreatment reduced CA4P-induced ROCK activation and partially blocked CA4P-induced tumor vascular effects, in both tumor types.  Y27632 also partially inhibited CA4P-induced tumor necrosis and was assocd. with reduced immune cell infiltration in SW1222 tumors.  Hydralazine caused a similar hypotensive effect as Y27632 but had no protective effect against CA4P treatment.  These results demonstrate that ROCK activity is crit. for full manifestation of the vascular activity of CA4P in vivo, providing the evidence for pharmacol. intervention to enhance the anti-tumor efficacy of CA4P and related VDAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb3sOB9jdFIrVg90H21EOLACvtfcHk0liYwe5jD8l9mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVSjsLbF&md5=044a7f085749c5ca6d8f3eac8438375d</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1111%2Fbph.12817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12817%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DL.%2BJ.%26aulast%3DMukherjee%26aufirst%3DD.%26aulast%3DFisher%26aufirst%3DM.%26aulast%3DReyes-Aldasoro%26aufirst%3DC.%2BC.%26aulast%3DAkerman%26aufirst%3DS.%26aulast%3DKanthou%26aufirst%3DC.%26aulast%3DTozer%26aufirst%3DG.%2BM.%26atitle%3DAn%2520in%2520vivo%2520role%2520for%2520Rho%2520kinase%2520activation%2520in%2520the%2520tumour%2520vascular%2520disrupting%2520activity%2520of%2520combretastatin%2520A-4%25203-O-phosphate%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D171%26spage%3D4902%26epage%3D4913%26doi%3D10.1111%2Fbph.12817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group">Vincent, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kermani, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shido, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bompais-Vincent, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohlen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">May, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafii, S.</span><span> </span><span class="NLM_article-title">Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">2992</span><span class="NLM_x">–</span> <span class="NLM_lpage">3006</span><span class="refDoi"> DOI: 10.1172/JCI24586</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1172%2FJCI24586" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=16224539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtF2kt73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2005&pages=2992-3006&author=L.+Vincentauthor=P.+Kermaniauthor=L.+M.+Youngauthor=J.+Chengauthor=F.+Zhangauthor=K.+Shidoauthor=G.+Lamauthor=H.+Bompais-Vincentauthor=Z.+Zhuauthor=D.+J.+Hicklinauthor=P.+Bohlenauthor=D.+J.+Chaplinauthor=C.+Mayauthor=S.+Rafii&title=Combretastatin+A4+phosphate+induces+rapid+regression+of+tumor+neovessels+and+growth+through+interference+with+vascular+endothelial-cadherin+signaling&doi=10.1172%2FJCI24586"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling</span></div><div class="casAuthors">Vincent, Loic; Kermani, Pouneh; Young, Lauren M.; Cheng, Joseph; Zhang, Fan; Shido, Koji; Lam, George; Bompais-Vincent, Heidi; Zhu, Zhenping; Hicklin, Daniel J.; Bohlen, Peter; Chaplin, David J.; May, Chad; Rafii, Shahin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2992-3006</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">The mol. and cellular pathways that support the maintenance and stability of tumor neovessels are not well defined.  The efficacy of microtubule-disrupting agents, such as combretastatin A4 phosphate (CA4P), in inducing rapid regression of specific subsets of tumor neovessels has opened up new avenues of research to identify factors that support tumor neoangiogenesis.  Herein, we show that CA4P selectively targeted endothelial cells, but not smooth muscle cells, and induced regression of unstable nascent tumor neovessels by rapidly disrupting the mol. engagement of the endothelial cell-specific junctional mol. vascular endothelial-cadherin (VE-cadherin) in vitro and in vivo in mice.  CA4P increases endothelial cell permeability, while inhibiting endothelial cell migration and capillary tube formation predominantly through disruption of VE-cadherin/β-catenin/Akt signaling pathway, thereby leading to rapid vascular collapse and tumor necrosis.  Remarkably, stabilization of VE-cadherin signaling in endothelial cells with adenovirus E4 gene or ensheathment with smooth muscle cells confers resistance to CA4P.  CA4P synergizes with low and nontoxic doses of neutralizing mAbs to VE-cadherin by blocking assembly of neovessels, thereby inhibiting tumor growth.  These data suggest that the microtubule-targeting agent CA4P selectively induces regression of unstable tumor neovessels, in part through disruption of VE-cadherin signaling.  Combined treatment with anti-VE-cadherin agents in conjunction with microtubule-disrupting agents provides a novel synergistic strategy to selectively disrupt assembly and induce regression of nascent tumor neovessels, with minimal toxicity and without affecting normal stabilized vasculature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKFBiwt81RFbVg90H21EOLACvtfcHk0liYwe5jD8l9mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtF2kt73M&md5=b36f1e2a344823daaacccd7925b4b4ce</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1172%2FJCI24586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI24586%26sid%3Dliteratum%253Aachs%26aulast%3DVincent%26aufirst%3DL.%26aulast%3DKermani%26aufirst%3DP.%26aulast%3DYoung%26aufirst%3DL.%2BM.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DShido%26aufirst%3DK.%26aulast%3DLam%26aufirst%3DG.%26aulast%3DBompais-Vincent%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DBohlen%26aufirst%3DP.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DMay%26aufirst%3DC.%26aulast%3DRafii%26aufirst%3DS.%26atitle%3DCombretastatin%2520A4%2520phosphate%2520induces%2520rapid%2520regression%2520of%2520tumor%2520neovessels%2520and%2520growth%2520through%2520interference%2520with%2520vascular%2520endothelial-cadherin%2520signaling%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2005%26volume%3D115%26spage%3D2992%26epage%3D3006%26doi%3D10.1172%2FJCI24586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group">Hussain, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steimle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoppeler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egginton, S.</span><span> </span><span class="NLM_article-title">The vascular-disrupting agent combretastatin impairs splitting and sprouting forms of physiological angiogenesis</span> <span class="citation_source-journal">Microcirculation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">296</span><span class="NLM_x">–</span> <span class="NLM_lpage">305</span><span class="refDoi"> DOI: 10.1111/j.1549-8719.2012.00160.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1111%2Fj.1549-8719.2012.00160.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=296-305&author=A.+Hussainauthor=M.+Steimleauthor=H.+Hoppelerauthor=O.+Baumauthor=S.+Egginton&title=The+vascular-disrupting+agent+combretastatin+impairs+splitting+and+sprouting+forms+of+physiological+angiogenesis&doi=10.1111%2Fj.1549-8719.2012.00160.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1111%2Fj.1549-8719.2012.00160.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1549-8719.2012.00160.x%26sid%3Dliteratum%253Aachs%26aulast%3DHussain%26aufirst%3DA.%26aulast%3DSteimle%26aufirst%3DM.%26aulast%3DHoppeler%26aufirst%3DH.%26aulast%3DBaum%26aufirst%3DO.%26aulast%3DEgginton%26aufirst%3DS.%26atitle%3DThe%2520vascular-disrupting%2520agent%2520combretastatin%2520impairs%2520splitting%2520and%2520sprouting%2520forms%2520of%2520physiological%2520angiogenesis%26jtitle%3DMicrocirculation%26date%3D2012%26volume%3D19%26spage%3D296%26epage%3D305%26doi%3D10.1111%2Fj.1549-8719.2012.00160.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group">Jiang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span> </span><span class="NLM_article-title">Deoxypodophyllotoxin exerts both anti-angiogenic and vascular disrupting effects</span> <span class="citation_source-journal">Int. J. Biochem. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">1710</span><span class="NLM_x">–</span> <span class="NLM_lpage">1719</span><span class="refDoi"> DOI: 10.1016/j.biocel.2013.04.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.biocel.2013.04.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=23702033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFaktLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2013&pages=1710-1719&author=Z.+Jiangauthor=M.+Wuauthor=J.+Miaoauthor=H.+Duanauthor=S.+Zhangauthor=M.+Chenauthor=L.+Sunauthor=Y.+Wangauthor=X.+Zhangauthor=X.+Zhuauthor=L.+Zhang&title=Deoxypodophyllotoxin+exerts+both+anti-angiogenic+and+vascular+disrupting+effects&doi=10.1016%2Fj.biocel.2013.04.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Deoxypodophyllotoxin exerts both anti-angiogenic and vascular disrupting effects</span></div><div class="casAuthors">Jiang, Zhenzhou; Wu, Meijuan; Miao, Jingshan; Duan, Huaqin; Zhang, Shuang; Chen, Mi; Sun, Lixin; Wang, Yurong; Zhang, Xueji; Zhu, Xiong; Zhang, Luyong</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1710-1719</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A functioning vascular supply is essential for solid tumor growth and metastases, which means that blood vessels are an ideal target for antitumor drug discovery.  Targeting tumor vasculature involves two main approaches, anti-angiogenesis and vascular disruption.  The anti-angiogenic and vascular disrupting activities of deoxypodophyllotoxin (DPT), a natural microtubule destabilizer, were examd. with several in vitro, ex vivo and/or in vivo models.  First, we demonstrated that DPT significantly inhibits the proliferation, migration and tube formation of endothelial cells and inhibits angiogenesis in rat aortic ring and chick chorioallantoic membrane assays.  In further studies, DPT induced cytoskeleton reorganization in endothelial cells, which likely contributed to the anti-angiogenic effect at non-cytotoxic concns.  DPT treatment at higher concns. for longer time induced the cell cycle arrest, which may contributes to its anti-proliferation effect and anti-angiogenic activity.  And DPT dramatically inducted the expression of cyclin B1 and p21 (WAF1/CIP1).  Meanwhile, DPT disrupted capillary-like networks in vitro and newly formed vessels from rat aortic rings.  Endothelial cell contraction assocd. with an increase in F-actin via the Rho/Rho kinase pathway likely contributed to the vascular disrupting activity.  Taken together, our results provided the initial evidence that DPT exerts potent anti-angiogenic and vascular disrupting effects.  This study also provides important insight into the mechanism of action of promising new anticancer drugs with both anti-angiogenic and vascular disrupting activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWcp6tQaGNWrVg90H21EOLACvtfcHk0lhyDWlcamLDEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFaktLfJ&md5=c5a4c8b11434b89318286dcae35bd3ce</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1016%2Fj.biocel.2013.04.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biocel.2013.04.030%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DMiao%26aufirst%3DJ.%26aulast%3DDuan%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DDeoxypodophyllotoxin%2520exerts%2520both%2520anti-angiogenic%2520and%2520vascular%2520disrupting%2520effects%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2013%26volume%3D45%26spage%3D1710%26epage%3D1719%26doi%3D10.1016%2Fj.biocel.2013.04.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group">Ahmed, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Eijk, L. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouma-ter Steege, J. C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Der Schaft, D. W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Esch, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joosten-Achjanie, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landuyt, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffioen, A. W.</span><span> </span><span class="NLM_article-title">Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">20</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span><span class="refDoi"> DOI: 10.1002/ijc.11010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1002%2Fijc.11010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=12672025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtVWrsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2003&pages=20-25&author=B.+Ahmedauthor=L.+I.+Van+Eijkauthor=J.+C.+A.+Bouma-ter+Steegeauthor=D.+W.+J.+Van+Der+Schaftauthor=A.+M.+Van+Eschauthor=S.+R.+Joosten-Achjanieauthor=P.+Lambinauthor=W.+Landuytauthor=A.+W.+Griffioen&title=Vascular+targeting+effect+of+combretastatin+A-4+phosphate+dominates+the+inherent+angiogenesis+inhibitory+activity&doi=10.1002%2Fijc.11010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity</span></div><div class="casAuthors">Ahmed, Bisan; van Eijk, Loes I.; Bouma-ter Steege, Jessica C. A.; van der Schaft, Daisy W. J.; van Esch, Anita M.; Joosten-Achjanie, Susan R.; Lambin, Philippe; Landuyt, Willy; Griffioen, Arjan W.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-25</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The current research aimed to define hypothesis-based anti-angiogenic properties of the vascular targeting agent combretastatin A-4 phosphate (combreAp).  The in vitro wound assay indicated that combreAp potently inhibited migration of endothelial cells (EC).  A significant inhibition of migration could already be measured after 2 h of treatment.  In a three-dimensional (3D) tube formation assay, combreAp inhibited sprout formation at concns. that did not inhibit the proliferation of EC.  At sub-ng concns. the half-maximal response was reached.  Interestingly, although combreAp is considered a vascular targeting agent, the human tumor cell lines tested were found to be 20-30 times more sensitive for combreAp than the human umbilical vein endothelial cells (HUVEC).  A similar response difference between rat EC and RI rat rhabdomyosarcoma tumor cells was obsd.  The growth inhibition in EC was only in part mediated by induction of apoptosis.  The growth delay results obtained with the in vivo rodent tumor models involving repeat dosing of combreAp can partly be explained by anti-angiogenic activity of the compd.  The results obtained with the various in vitro and in vivo assays substantiate an anti-angiogenic profile of combreAp, largely at the level of EC migration.  This mechanism may operate to a different extent in different tumor types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeVFxAZLthCbVg90H21EOLACvtfcHk0lhyDWlcamLDEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtVWrsr4%253D&md5=fa5c45dc32672fe33b7dd33398398d10</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1002%2Fijc.11010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.11010%26sid%3Dliteratum%253Aachs%26aulast%3DAhmed%26aufirst%3DB.%26aulast%3DVan%2BEijk%26aufirst%3DL.%2BI.%26aulast%3DBouma-ter%2BSteege%26aufirst%3DJ.%2BC.%2BA.%26aulast%3DVan%2BDer%2BSchaft%26aufirst%3DD.%2BW.%2BJ.%26aulast%3DVan%2BEsch%26aufirst%3DA.%2BM.%26aulast%3DJoosten-Achjanie%26aufirst%3DS.%2BR.%26aulast%3DLambin%26aufirst%3DP.%26aulast%3DLanduyt%26aufirst%3DW.%26aulast%3DGriffioen%26aufirst%3DA.%2BW.%26atitle%3DVascular%2520targeting%2520effect%2520of%2520combretastatin%2520A-4%2520phosphate%2520dominates%2520the%2520inherent%2520angiogenesis%2520inhibitory%2520activity%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2003%26volume%3D105%26spage%3D20%26epage%3D25%26doi%3D10.1002%2Fijc.11010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group">Porcù, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viola, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bortolozzi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persano, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitola, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ronca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Presta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romagnoli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baraldi, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basso, G.</span><span> </span><span class="NLM_article-title">TR-644 a novel potent tubulin binding agent induces impairment of endothelial cells function and inhibits angiogenesis</span> <span class="citation_source-journal">Angiogenesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">647</span><span class="NLM_x">–</span> <span class="NLM_lpage">662</span><span class="refDoi"> DOI: 10.1007/s10456-013-9343-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1007%2Fs10456-013-9343-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=23456551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXps1yksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2013&pages=647-662&author=E.+Porc%C3%B9author=G.+Violaauthor=R.+Bortolozziauthor=L.+Persanoauthor=S.+Mitolaauthor=R.+Roncaauthor=M.+Prestaauthor=R.+Romagnoliauthor=P.+G.+Baraldiauthor=G.+Basso&title=TR-644+a+novel+potent+tubulin+binding+agent+induces+impairment+of+endothelial+cells+function+and+inhibits+angiogenesis&doi=10.1007%2Fs10456-013-9343-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">TR-644 a novel potent tubulin binding agent induces impairment of endothelial cells function and inhibits angiogenesis</span></div><div class="casAuthors">Porcu, Elena; Viola, Giampietro; Bortolozzi, Roberta; Persano, Luca; Mitola, Stefania; Ronca, Roberto; Presta, Marco; Romagnoli, Romeo; Baraldi, Pier Giovanni; Basso, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Angiogenesis</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">647-662</span>CODEN:
                <span class="NLM_cas:coden">AGIOFT</span>;
        ISSN:<span class="NLM_cas:issn">0969-6970</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">TR-644 is a novel combretastatin A-4 (CA-4) analog endowed with potent microtubule depolymg. activity superior to that of the lead compd. and it also has high affinity to colchicines binding site of tubulin.  We tested TR-644 anti-angiogenic effects in human umbilical endothelial cells (HUVEC).  It showed no significant effects on the growth of HUVEC cells at concns. below 1,000 nM, but at much lower concns. (10-100 nM) it induced inhibition of capillary tube formation, inhibition of endothelial cell migration and affected endothelial cell morphol. as demonstrated by the disruption of the microtubule network.  TR-644 also increased permeability of HUVEC cells in a time dependent manner.  The mol. mechanism for the anti-vascular activity of TR-644 was investigated in detail.  TR-644 caused G2/M arrest in endothelial cells and this effect correlated with downregulation of the expression of Cdc25C and Cdc2Tyr15.  Moreover TR-644 inhibited VEGF-induced phosphorylation of VE-cadherin but did not prevent the VEGF-induced phosphorylation of FAK.  In chick chorioallantoic membrane in vivo assay, TR-644 (0.1-1.0 pmol/egg) efficiently counteracted the strong angiogenic response induced by FGF.  Also CA-4, used as ref. compd., caused an antagonistic effect, but in contrast, it induced per se, a remarkable angiogenic response probably due to an inflammatory reaction in the site of treatment.  In a mice allogenic tumor model, immunohistochem. staining of tumors with anti-CD31 antibody showed that TR-644 significantly reduced the no. of vessel, after 24 h from the administration of a single dose (30 mg/Kg).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjdcGwvsKlwbVg90H21EOLACvtfcHk0lh86z_7S3gFHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXps1yksbk%253D&md5=701845b28683c4a73edd13455485c742</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1007%2Fs10456-013-9343-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10456-013-9343-z%26sid%3Dliteratum%253Aachs%26aulast%3DPorc%25C3%25B9%26aufirst%3DE.%26aulast%3DViola%26aufirst%3DG.%26aulast%3DBortolozzi%26aufirst%3DR.%26aulast%3DPersano%26aufirst%3DL.%26aulast%3DMitola%26aufirst%3DS.%26aulast%3DRonca%26aufirst%3DR.%26aulast%3DPresta%26aufirst%3DM.%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DBasso%26aufirst%3DG.%26atitle%3DTR-644%2520a%2520novel%2520potent%2520tubulin%2520binding%2520agent%2520induces%2520impairment%2520of%2520endothelial%2520cells%2520function%2520and%2520inhibits%2520angiogenesis%26jtitle%3DAngiogenesis%26date%3D2013%26volume%3D16%26spage%3D647%26epage%3D662%26doi%3D10.1007%2Fs10456-013-9343-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group">Samarin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rehm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waschke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goppelt-Struebe, M.</span><span> </span><span class="NLM_article-title">Up-regulation of connective tissue growth factor in endothelial cells by the microtubule-destabilizing agent combretastatin A-4</span> <span class="citation_source-journal">Mol. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">180</span><span class="NLM_x">–</span> <span class="NLM_lpage">188</span><span class="refDoi"> DOI: 10.1158/1541-7786.MCR-08-0292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1158%2F1541-7786.MCR-08-0292" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=19208742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitlWgsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=180-188&author=J.+Samarinauthor=M.+Rehmauthor=B.+Kruegerauthor=J.+Waschkeauthor=M.+Goppelt-Struebe&title=Up-regulation+of+connective+tissue+growth+factor+in+endothelial+cells+by+the+microtubule-destabilizing+agent+combretastatin+A-4&doi=10.1158%2F1541-7786.MCR-08-0292"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Up-Regulation of Connective Tissue Growth Factor in Endothelial Cells by the Microtubule-Destabilizing Agent Combretastatin A-4</span></div><div class="casAuthors">Samarin, Jana; Rehm, Margot; Krueger, Bettina; Waschke, Jens; Goppelt-Struebe, Margarete</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">180-188</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Incubation of microvascular endothelial cells with combretastatin A-4 phosphate (CA-4P), a microtubule-destabilizing compd. that preferentially targets tumor vessels, altered cell morphol. and induced scattering of Golgi stacks.  Concomitantly, CA-4P up-regulated connective tissue growth factor (CTGF/CCN2), a pleiotropic factor with antiangiogenic properties.  In contrast to the effects of other microtubule-targeting agents such as colchicine or nocodazole, up-regulation of CTGF was only detectable in sparse cells, which were not embedded in a cell monolayer.  Furthermore, CA-4P induced CTGF expression in endothelial cells, forming tube-like structures on basement membrane gels.  Up-regulation of CTGF by CA-4P was dependent on Rho kinase signaling and was increased when p42/44 mitogen-activated protein kinase was inhibited.  Addnl., FoxO transcription factors were identified as potent regulators of CTGF expression in endothelial cells.  Activation of FoxO transcription factors by inhibition of phosphatidylinositol 3-kinase/AKT signaling resulted in a synergistic increase in CA-4P-mediated CTGF induction.  CA-4P-mediated expression of CTGF was thus potentiated by the inhibition of kinase pathways, which are targets of novel antineoplastic drugs.  Up-regulation of CTGF by low concns. of CA-4P may thus occur in newly formed tumor vessels and contribute to the microvessel destabilization and antiangiogenic effects of CA-4P obsd. in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5clL-00SGILVg90H21EOLACvtfcHk0lh86z_7S3gFHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitlWgsb8%253D&md5=4095a38d90ccae5cdf980a22415e72d8</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-08-0292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-08-0292%26sid%3Dliteratum%253Aachs%26aulast%3DSamarin%26aufirst%3DJ.%26aulast%3DRehm%26aufirst%3DM.%26aulast%3DKrueger%26aufirst%3DB.%26aulast%3DWaschke%26aufirst%3DJ.%26aulast%3DGoppelt-Struebe%26aufirst%3DM.%26atitle%3DUp-regulation%2520of%2520connective%2520tissue%2520growth%2520factor%2520in%2520endothelial%2520cells%2520by%2520the%2520microtubule-destabilizing%2520agent%2520combretastatin%2520A-4%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2009%26volume%3D7%26spage%3D180%26epage%3D188%26doi%3D10.1158%2F1541-7786.MCR-08-0292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group">Alotaibi, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asnake, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durrant, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simoni, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baruchello, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gewirtz, D. A.</span><span> </span><span class="NLM_article-title">Stilbene 5c, a microtubule poison with vascular disrupting properties that induces multiple modes of growth arrest and cell death</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">1688</span><span class="NLM_x">–</span> <span class="NLM_lpage">1698</span><span class="refDoi"> DOI: 10.1016/j.bcp.2013.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.bcp.2013.10.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2013&pages=1688-1698&author=M.+R.+Alotaibiauthor=B.+Asnakeauthor=X.+Diauthor=M.+J.+Beckmanauthor=D.+Durrantauthor=D.+Simoniauthor=R.+Baruchelloauthor=R.+M.+Leeauthor=E.+L.+Schwartzauthor=D.+A.+Gewirtz&title=Stilbene+5c%2C+a+microtubule+poison+with+vascular+disrupting+properties+that+induces+multiple+modes+of+growth+arrest+and+cell+death&doi=10.1016%2Fj.bcp.2013.10.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2013.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2013.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DAlotaibi%26aufirst%3DM.%2BR.%26aulast%3DAsnake%26aufirst%3DB.%26aulast%3DDi%26aufirst%3DX.%26aulast%3DBeckman%26aufirst%3DM.%2BJ.%26aulast%3DDurrant%26aufirst%3DD.%26aulast%3DSimoni%26aufirst%3DD.%26aulast%3DBaruchello%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DR.%2BM.%26aulast%3DSchwartz%26aufirst%3DE.%2BL.%26aulast%3DGewirtz%26aufirst%3DD.%2BA.%26atitle%3DStilbene%25205c%252C%2520a%2520microtubule%2520poison%2520with%2520vascular%2520disrupting%2520properties%2520that%2520induces%2520multiple%2520modes%2520of%2520growth%2520arrest%2520and%2520cell%2520death%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2013%26volume%3D86%26spage%3D1688%26epage%3D1698%26doi%3D10.1016%2Fj.bcp.2013.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group">Shen, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shee, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y. W.</span><span> </span><span class="NLM_article-title">Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">160</span><span class="NLM_x">, </span> <span class="NLM_fpage">2008</span><span class="NLM_x">–</span> <span class="NLM_lpage">2027</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.00861.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1111%2Fj.1476-5381.2010.00861.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=20649598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Kjur3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2010&pages=2008-2027&author=C.+H.+Shenauthor=J.+J.+Sheeauthor=J.+Y.+Wuauthor=Y.+W.+Linauthor=J.+D.+Wuauthor=Y.+W.+Liu&title=Combretastatin+A-4+inhibits+cell+growth+and+metastasis+in+bladder+cancer+cells+and+retards+tumour+growth+in+a+murine+orthotopic+bladder+tumour+model&doi=10.1111%2Fj.1476-5381.2010.00861.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model</span></div><div class="casAuthors">Shen, Cheng-Huang; Shee, Jia-Jen; Wu, Jin-Yi; Lin, Yi-Wen; Wu, Jiann-Der; Liu, Yi-Wen</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2008-2027</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Bladder cancer is a highly recurrent cancer after intravesical therapy, so new drugs are needed to treat this cancer.  Hence, we investigated the anti-cancer activity of combretastatin A-4 (CA-4), an anti-tubulin agent, in human bladder cancer cells and in a murine orthotopic bladder tumor model.  Cytotoxicity of CA-4 was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, propidium iodide (PI) staining assay and clonogenic survival assay.  In vivo microtubule assembly assay, cell cycle analyses, Western blot and cell migration assay were used to study the mechanism of CA-4.  The effect of intravesical CA-4 therapy on the development of tumors was studied in the murine orthotopic bladder tumor model.  CA-4 inhibited microtubule polymn. in vivo.  Cytotoxic IC50 values of CA-4 in human bladder cancer cells were below 4 nM.  Analyses of cell-cycle distribution showed CA-4 obviously induced G2-M phase arrest with sub-G1 formation.  The analyses of apoptosis showed that CA-4 induced caspase-3 activation and decreased BubR1 and Bub3 in cancer cells.  In addn. to apoptosis, CA-4 was also found to induce the formation of multinucleated cells.  CA-4 had a significantly reduced cell migration in vitro.  Importantly, the in vivo study revealed that intravesical CA-4 therapy retarded the development of murine bladder tumors.  These data demonstrate that CA-4 kills bladder cancer cells by inducing apoptosis and mitotic catastrophe.  It inhibited cell migration in vitro and tumor growth in vivo.  Hence, CA-4 intravesical therapy could provide another strategy for treating superficial bladder cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2ISb0EU1aD7Vg90H21EOLACvtfcHk0lj-HUh9jhBCXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Kjur3K&md5=e65336da5df600b9c02b8f26b7649f23</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00861.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00861.x%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DC.%2BH.%26aulast%3DShee%26aufirst%3DJ.%2BJ.%26aulast%3DWu%26aufirst%3DJ.%2BY.%26aulast%3DLin%26aufirst%3DY.%2BW.%26aulast%3DWu%26aufirst%3DJ.%2BD.%26aulast%3DLiu%26aufirst%3DY.%2BW.%26atitle%3DCombretastatin%2520A-4%2520inhibits%2520cell%2520growth%2520and%2520metastasis%2520in%2520bladder%2520cancer%2520cells%2520and%2520retards%2520tumour%2520growth%2520in%2520a%2520murine%2520orthotopic%2520bladder%2520tumour%2520model%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D160%26spage%3D2008%26epage%3D2027%26doi%3D10.1111%2Fj.1476-5381.2010.00861.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group">Kanthou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greco, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratford, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benzakour, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozer, G.</span><span> </span><span class="NLM_article-title">The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">165</span><span class="NLM_x">, </span> <span class="NLM_fpage">1401</span><span class="NLM_x">–</span> <span class="NLM_lpage">1411</span><span class="refDoi"> DOI: 10.1016/S0002-9440(10)63398-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2FS0002-9440%2810%2963398-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=15466404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptFSlsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2004&pages=1401-1411&author=C.+Kanthouauthor=O.+Grecoauthor=A.+Stratfordauthor=I.+Cookauthor=R.+Knightauthor=O.+Benzakourauthor=G.+Tozer&title=The+tubulin-binding+agent+combretastatin+A-4-phosphate+arrests+endothelial+cells+in+mitosis+and+induces+mitotic+cell+death&doi=10.1016%2FS0002-9440%2810%2963398-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death</span></div><div class="casAuthors">Kanthou, Chryso; Greco, Olga; Stratford, Anna; Cook, Ian; Knight, Richard; Benzakour, Omar; Tozer, Gillian</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1401-1411</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">The tubulin-binding agent combretastatin A-4-phosphate (CA-4-P), rapidly disrupts the vascular network of tumors leading to secondary tumor cell death.  In vitro, CA-4-P destabilizes microtubules and causes endothelial cell death.  In this study we analyze the mechanisms by which CA-4-P induces the death of proliferating endothelial cells, we demonstrate that at ≥7.5 nmol/L, CA-4-P damages mitotic spindles, arrests cells at metaphase, and leads to the death of mitotic veils with characteristic G2/M DNA content.  Mitotic arrest was assocd. with elevated levels of cyclin B1 protein and p34cdc2 activity.  Inhibition of P34odc2 activity by purvalanol A caused mitotic arrested cells to rapidly exit mitosis, suggesting that sustained p34cdc2 activity was responsible for metaphase arrest.  Pharmacol. prevention of entry into mitosis protected cells from undergoing cell death, further establishing the link between mitosis and cell death induction by CA-4-P.  CA-4-P-mediated cell death shared characteristics of apoptosis but was independent of caspase activation suggesting the involvement of a noncaspase pathway(s).  These data suggest that induction of apoptosis in endothelial cells by CA-4-P is assocd. with prolonged mitotic arrest.  Therefore, by activating cell death pathways, CA-4-P, in addn. to being an effective and vascular agent, tray also interfere with regrowth of blood vessels in the tumor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGog1b4gtWsXSLVg90H21EOLACvtfcHk0lj-HUh9jhBCXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptFSlsr4%253D&md5=5419cef021fb851390f47a5048c63072</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2963398-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252963398-6%26sid%3Dliteratum%253Aachs%26aulast%3DKanthou%26aufirst%3DC.%26aulast%3DGreco%26aufirst%3DO.%26aulast%3DStratford%26aufirst%3DA.%26aulast%3DCook%26aufirst%3DI.%26aulast%3DKnight%26aufirst%3DR.%26aulast%3DBenzakour%26aufirst%3DO.%26aulast%3DTozer%26aufirst%3DG.%26atitle%3DThe%2520tubulin-binding%2520agent%2520combretastatin%2520A-4-phosphate%2520arrests%2520endothelial%2520cells%2520in%2520mitosis%2520and%2520induces%2520mitotic%2520cell%2520death%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2004%26volume%3D165%26spage%3D1401%26epage%3D1411%26doi%3D10.1016%2FS0002-9440%2810%2963398-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group">Nabha, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammad, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dandashi, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coupaye-Gerard, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aboukameel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Katib, A. M.</span><span> </span><span class="NLM_article-title">Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2735</span><span class="NLM_x">–</span> <span class="NLM_lpage">2741</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=12171907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD38XmvVahtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=2735-2741&author=S.+M.+Nabhaauthor=R.+M.+Mohammadauthor=M.+H.+Dandashiauthor=B.+Coupaye-Gerardauthor=A.+Aboukameelauthor=G.+R.+Pettitauthor=A.+M.+Al-Katib&title=Combretastatin-A4+prodrug+induces+mitotic+catastrophe+in+chronic+lymphocytic+leukemia+cell+line+independent+of+caspase+activation+and+poly%28ADP-ribose%29+polymerase+cleavage"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage</span></div><div class="casAuthors">Nabha, Sanaa M.; Mohammad, Ramzi M.; Dandashi, Mahmoud H.; Coupaye-Gerard, Brigitte; Aboukameel, Amro; Pettit, George R.; Al-Katib, Ayad M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2735-2741</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The authors have previously reported that combretastatin-A4 prodrug (CA4P), an antitubulin/antiangiogenic agent isolated from the South African willow tree Combretum caffrum, induced cell death primarily through mitotic catastrophe in a panel of human B-lymphoid tumors.  In this study, the authors investigated the mol. aspects of the mitotic catastrophe and whether or not it shares the same pathways of apoptosis.  For this the authors studied the effect of CA4P on selected markers of apoptosis [caspases 9 and 3, poly(ADP-ribose) polymerase (PARP), bcl-2, and bax] and G2-M protein regulators (p53, MDM2, 14-3-3.vsigma., GADD45, cdc2, cdc25, chk1, wee1, p21, and cyclin B1).  The chronic lymphocytic leukemia cell line WSU-CLL was used for this purpose.  Western blot anal. showed that 24 h of CA4P (5 nM) exposure induces caspase 9 activation and PARP cleavage.  However, the addn. of Z-Val-Ala-Asp-fluoromethylketone (a general caspase inhibitor) or Z-Leu-Glu(OMe)-His-Asp(OMe)-CH2F (a caspase 9 inhibitor) before CA4P treatment did not block cell death.  No change in bcl-2 or bax protein expression was obsd.  Exposure of WSU-CLL cells to 4 and 5 nM CA4P was assocd. with overprodn. of total p53 and no dramatic change in MDM2, 14-3-3.vsigma., GADD45, the cyclin-dependent kinase cdc2, its inhibitory phosphorylation, the cdc2-inhibitory kinase (wee1), chk1, or cdc25 hyperphosphorylation.  The overaccumulation of p21 and cyclin B1 protein was obvious at 24 h.  Furthermore, CA4P treatment showed an increase in the expression of a marker of mitosis (mitotic protein monoclonal-2 antibody) and an overaccumulation of the cyclin B in the nucleus.  The authors' findings suggest that CA4P induces mitotic catastrophe and arrest of WSU-CLL cells mostly in the M phase independent of p53 and independent of chk1 and cdc2 phosphorylation pathways.  Apoptosis is a 2ndary mechanism of death in a small proportion of cells through activation of caspase 9 and PARP cleavage.  The 2 mechanisms of cell death, i.e., mitotic catastrophe and apoptosis, are independent of each other in the authors' model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIOrpvUlDuxLVg90H21EOLACvtfcHk0lj-HUh9jhBCXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmvVahtL4%253D&md5=523b6c765d14abae0aaae2994e78c8e4</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNabha%26aufirst%3DS.%2BM.%26aulast%3DMohammad%26aufirst%3DR.%2BM.%26aulast%3DDandashi%26aufirst%3DM.%2BH.%26aulast%3DCoupaye-Gerard%26aufirst%3DB.%26aulast%3DAboukameel%26aufirst%3DA.%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DAl-Katib%26aufirst%3DA.%2BM.%26atitle%3DCombretastatin-A4%2520prodrug%2520induces%2520mitotic%2520catastrophe%2520in%2520chronic%2520lymphocytic%2520leukemia%2520cell%2520line%2520independent%2520of%2520caspase%2520activation%2520and%2520poly%2528ADP-ribose%2529%2520polymerase%2520cleavage%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2002%26volume%3D8%26spage%3D2735%26epage%3D2741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group">Vitale, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galluzzi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castedo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroemer, G.</span><span> </span><span class="NLM_article-title">Mitotic catastrophe: a mechanism for avoiding genomic instability</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">392</span><span class="refDoi"> DOI: 10.1038/nrm3115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1038%2Fnrm3115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=21527953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVSjs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=385-392&author=I.+Vitaleauthor=L.+Galluzziauthor=M.+Castedoauthor=G.+Kroemer&title=Mitotic+catastrophe%3A+a+mechanism+for+avoiding+genomic+instability&doi=10.1038%2Fnrm3115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Mitotic catastrophe: a mechanism for avoiding genomic instability</span></div><div class="casAuthors">Vitale, Ilio; Galluzzi, Lorenzo; Castedo, Maria; Kroemer, Guido</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">385-392</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The improper distribution of chromosomes during mitosis compromises cellular functions and can reduce cellular fitness or contribute to malignant transformation.  As a countermeasure, higher eukaryotes have developed strategies for eliminating mitosis-incompetent cells, one of which is mitotic catastrophe.  Mitotic catastrophe is driven by a complex and poorly understood signalling cascade but, from a functional perspective, it can be defined as an oncosuppressive mechanism that precedes (and is distinct from) apoptosis, necrosis or senescence.  Accordingly, the disruption of mitotic catastrophe ppts. tumorigenesis and cancer progression, and its induction constitutes a therapeutic endpoint.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_SWBPBcc957Vg90H21EOLACvtfcHk0lg0_yfnSwdGKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVSjs7o%253D&md5=1af21f749fca1bf75d526c38a75df61b</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1038%2Fnrm3115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3115%26sid%3Dliteratum%253Aachs%26aulast%3DVitale%26aufirst%3DI.%26aulast%3DGalluzzi%26aufirst%3DL.%26aulast%3DCastedo%26aufirst%3DM.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DMitotic%2520catastrophe%253A%2520a%2520mechanism%2520for%2520avoiding%2520genomic%2520instability%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2011%26volume%3D12%26spage%3D385%26epage%3D392%26doi%3D10.1038%2Fnrm3115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group">Nabha, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wall, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammad, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettit, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Katib, A. M.</span><span> </span><span class="NLM_article-title">Effects of Combretastatin A-4 prodrug against a panel of malignant human B-lymphoid cell lines</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">392</span><span class="refDoi"> DOI: 10.1097/00001813-200006000-00009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1097%2F00001813-200006000-00009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2000&pages=385-392&author=S.+M.+Nabhaauthor=N.+R.+Wallauthor=R.+M.+Mohammadauthor=G.+R.+Pettitauthor=A.+M.+Al-Katib&title=Effects+of+Combretastatin+A-4+prodrug+against+a+panel+of+malignant+human+B-lymphoid+cell+lines&doi=10.1097%2F00001813-200006000-00009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1097%2F00001813-200006000-00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00001813-200006000-00009%26sid%3Dliteratum%253Aachs%26aulast%3DNabha%26aufirst%3DS.%2BM.%26aulast%3DWall%26aufirst%3DN.%2BR.%26aulast%3DMohammad%26aufirst%3DR.%2BM.%26aulast%3DPettit%26aufirst%3DG.%2BR.%26aulast%3DAl-Katib%26aufirst%3DA.%2BM.%26atitle%3DEffects%2520of%2520Combretastatin%2520A-4%2520prodrug%2520against%2520a%2520panel%2520of%2520malignant%2520human%2520B-lymphoid%2520cell%2520lines%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2000%26volume%3D11%26spage%3D385%26epage%3D392%26doi%3D10.1097%2F00001813-200006000-00009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group">Cenciarelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanzarella, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitale, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pisano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crateri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meschini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arancia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antoccia, A.</span><span> </span><span class="NLM_article-title">The tubulin-depolymerising agent combretastatin-4 induces ectopic aster assembly and mitotic catastrophe in lung cancer cells H460</span> <span class="citation_source-journal">Apoptosis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">659</span><span class="NLM_x">–</span> <span class="NLM_lpage">669</span><span class="refDoi"> DOI: 10.1007/s10495-008-0200-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1007%2Fs10495-008-0200-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=659-669&author=C.+Cenciarelliauthor=C.+Tanzarellaauthor=I.+Vitaleauthor=C.+Pisanoauthor=P.+Crateriauthor=S.+Meschiniauthor=G.+Aranciaauthor=A.+Antoccia&title=The+tubulin-depolymerising+agent+combretastatin-4+induces+ectopic+aster+assembly+and+mitotic+catastrophe+in+lung+cancer+cells+H460&doi=10.1007%2Fs10495-008-0200-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1007%2Fs10495-008-0200-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10495-008-0200-2%26sid%3Dliteratum%253Aachs%26aulast%3DCenciarelli%26aufirst%3DC.%26aulast%3DTanzarella%26aufirst%3DC.%26aulast%3DVitale%26aufirst%3DI.%26aulast%3DPisano%26aufirst%3DC.%26aulast%3DCrateri%26aufirst%3DP.%26aulast%3DMeschini%26aufirst%3DS.%26aulast%3DArancia%26aufirst%3DG.%26aulast%3DAntoccia%26aufirst%3DA.%26atitle%3DThe%2520tubulin-depolymerising%2520agent%2520combretastatin-4%2520induces%2520ectopic%2520aster%2520assembly%2520and%2520mitotic%2520catastrophe%2520in%2520lung%2520cancer%2520cells%2520H460%26jtitle%3DApoptosis%26date%3D2008%26volume%3D13%26spage%3D659%26epage%3D669%26doi%3D10.1007%2Fs10495-008-0200-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group">Vitale, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antoccia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cenciarelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crateri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meschini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arancia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pisano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanzarella, C.</span><span> </span><span class="NLM_article-title">Combretastatin CA-4 and combretastatin derivative induce mitotic catastrophe dependent on spindle checkpoint and caspase-3 activation in non-small cell lung cancer cells</span> <span class="citation_source-journal">Apoptosis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">155</span><span class="NLM_x">–</span> <span class="NLM_lpage">166</span><span class="refDoi"> DOI: 10.1007/s10495-006-0491-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1007%2Fs10495-006-0491-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=155-166&author=I.+Vitaleauthor=A.+Antocciaauthor=C.+Cenciarelliauthor=P.+Crateriauthor=S.+Meschiniauthor=G.+Aranciaauthor=C.+Pisanoauthor=C.+Tanzarella&title=Combretastatin+CA-4+and+combretastatin+derivative+induce+mitotic+catastrophe+dependent+on+spindle+checkpoint+and+caspase-3+activation+in+non-small+cell+lung+cancer+cells&doi=10.1007%2Fs10495-006-0491-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1007%2Fs10495-006-0491-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10495-006-0491-0%26sid%3Dliteratum%253Aachs%26aulast%3DVitale%26aufirst%3DI.%26aulast%3DAntoccia%26aufirst%3DA.%26aulast%3DCenciarelli%26aufirst%3DC.%26aulast%3DCrateri%26aufirst%3DP.%26aulast%3DMeschini%26aufirst%3DS.%26aulast%3DArancia%26aufirst%3DG.%26aulast%3DPisano%26aufirst%3DC.%26aulast%3DTanzarella%26aufirst%3DC.%26atitle%3DCombretastatin%2520CA-4%2520and%2520combretastatin%2520derivative%2520induce%2520mitotic%2520catastrophe%2520dependent%2520on%2520spindle%2520checkpoint%2520and%2520caspase-3%2520activation%2520in%2520non-small%2520cell%2520lung%2520cancer%2520cells%26jtitle%3DApoptosis%26date%3D2007%26volume%3D12%26spage%3D155%26epage%3D166%26doi%3D10.1007%2Fs10495-006-0491-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group">O’Boyle, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keely, N. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knox, A. J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCabe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lloyd, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zisterer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meegan, M. J.</span><span> </span><span class="NLM_article-title">Synthesis, biochemical and molecular modelling studies of antiproliferative azetidinones causing microtubule disruption and mitotic catastrophe</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">4595</span><span class="NLM_x">–</span> <span class="NLM_lpage">4607</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2011.07.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.ejmech.2011.07.039" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=4595-4607&author=N.+M.+O%E2%80%99Boyleauthor=M.+Carrauthor=L.+M.+Greeneauthor=N.+O.+Keelyauthor=A.+J.+S.+Knoxauthor=T.+McCabeauthor=D.+G.+Lloydauthor=D.+M.+Zistererauthor=M.+J.+Meegan&title=Synthesis%2C+biochemical+and+molecular+modelling+studies+of+antiproliferative+azetidinones+causing+microtubule+disruption+and+mitotic+catastrophe&doi=10.1016%2Fj.ejmech.2011.07.039"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2011.07.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2011.07.039%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DN.%2BM.%26aulast%3DCarr%26aufirst%3DM.%26aulast%3DGreene%26aufirst%3DL.%2BM.%26aulast%3DKeely%26aufirst%3DN.%2BO.%26aulast%3DKnox%26aufirst%3DA.%2BJ.%2BS.%26aulast%3DMcCabe%26aufirst%3DT.%26aulast%3DLloyd%26aufirst%3DD.%2BG.%26aulast%3DZisterer%26aufirst%3DD.%2BM.%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26atitle%3DSynthesis%252C%2520biochemical%2520and%2520molecular%2520modelling%2520studies%2520of%2520antiproliferative%2520azetidinones%2520causing%2520microtubule%2520disruption%2520and%2520mitotic%2520catastrophe%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2011%26volume%3D46%26spage%3D4595%26epage%3D4607%26doi%3D10.1016%2Fj.ejmech.2011.07.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group">Green, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llambi, F.</span><span> </span><span class="NLM_article-title">Cell death signaling</span> <span class="citation_source-journal">Cold Spring Harbor Perspect. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">a006080</span><span class="refDoi"> DOI: 10.1101/cshperspect.a006080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1101%2Fcshperspect.a006080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=26626938" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=a006080&author=D.+R.+Greenauthor=F.+Llambi&title=Cell+death+signaling&doi=10.1101%2Fcshperspect.a006080"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a006080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a006080%26sid%3Dliteratum%253Aachs%26aulast%3DGreen%26aufirst%3DD.%2BR.%26aulast%3DLlambi%26aufirst%3DF.%26atitle%3DCell%2520death%2520signaling%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Biol.%26date%3D2015%26volume%3D7%26spage%3Da006080%26doi%3D10.1101%2Fcshperspect.a006080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group">Iyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenthal, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulares, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smulson, M. E.</span><span> </span><span class="NLM_article-title">Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4510</span><span class="NLM_x">–</span> <span class="NLM_lpage">4514</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=4510-4514&author=S.+Iyerauthor=D.+J.+Chaplinauthor=D.+S.+Rosenthalauthor=A.+H.+Boularesauthor=L.+Y.+Liauthor=M.+E.+Smulson&title=Induction+of+apoptosis+in+proliferating+human+endothelial+cells+by+the+tumor-specific+antiangiogenesis+agent+combretastatin+A-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIyer%26aufirst%3DS.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DRosenthal%26aufirst%3DD.%2BS.%26aulast%3DBoulares%26aufirst%3DA.%2BH.%26aulast%3DLi%26aufirst%3DL.%2BY.%26aulast%3DSmulson%26aufirst%3DM.%2BE.%26atitle%3DInduction%2520of%2520apoptosis%2520in%2520proliferating%2520human%2520endothelial%2520cells%2520by%2520the%2520tumor-specific%2520antiangiogenesis%2520agent%2520combretastatin%2520A-4%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26spage%3D4510%26epage%3D4514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group">Petit, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karajannis, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooper, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shido, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steller, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafii, S.</span><span> </span><span class="NLM_article-title">The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">1951</span><span class="NLM_x">–</span> <span class="NLM_lpage">1961</span><span class="refDoi"> DOI: 10.1182/blood-2007-05-089219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1182%2Fblood-2007-05-089219" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=1951-1961&author=I.+Petitauthor=M.+A.+Karajannisauthor=L.+Vincentauthor=L.+Youngauthor=J.+Butlerauthor=A.+T.+Hooperauthor=K.+Shidoauthor=H.+Stellerauthor=D.+J.+Chaplinauthor=E.+Feldmanauthor=S.+Rafii&title=The+microtubule-targeting+agent+CA4P+regresses+leukemic+xenografts+by+disrupting+interaction+with+vascular+cells+and+mitochondrial-dependent+cell+death&doi=10.1182%2Fblood-2007-05-089219"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-05-089219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-05-089219%26sid%3Dliteratum%253Aachs%26aulast%3DPetit%26aufirst%3DI.%26aulast%3DKarajannis%26aufirst%3DM.%2BA.%26aulast%3DVincent%26aufirst%3DL.%26aulast%3DYoung%26aufirst%3DL.%26aulast%3DButler%26aufirst%3DJ.%26aulast%3DHooper%26aufirst%3DA.%2BT.%26aulast%3DShido%26aufirst%3DK.%26aulast%3DSteller%26aufirst%3DH.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DFeldman%26aufirst%3DE.%26aulast%3DRafii%26aufirst%3DS.%26atitle%3DThe%2520microtubule-targeting%2520agent%2520CA4P%2520regresses%2520leukemic%2520xenografts%2520by%2520disrupting%2520interaction%2520with%2520vascular%2520cells%2520and%2520mitochondrial-dependent%2520cell%2520death%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D1951%26epage%3D1961%26doi%3D10.1182%2Fblood-2007-05-089219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group">Mendez, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Policarpi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cenciarelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanzarella, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antoccia, A.</span><span> </span><span class="NLM_article-title">Role of Bim in apoptosis induced in H460 lung tumor cells by the spindle poison combretastatin-A4</span> <span class="citation_source-journal">Apoptosis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">940</span><span class="NLM_x">–</span> <span class="NLM_lpage">949</span><span class="refDoi"> DOI: 10.1007/s10495-011-0619-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1007%2Fs10495-011-0619-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=21671007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVSlu7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=940-949&author=G.+Mendezauthor=C.+Policarpiauthor=C.+Cenciarelliauthor=C.+Tanzarellaauthor=A.+Antoccia&title=Role+of+Bim+in+apoptosis+induced+in+H460+lung+tumor+cells+by+the+spindle+poison+combretastatin-A4&doi=10.1007%2Fs10495-011-0619-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Bim in apoptosis induced in H460 lung tumor cells by the spindle poison Combretastatin-A4</span></div><div class="casAuthors">Mendez, G.; Policarpi, C.; Cenciarelli, C.; Tanzarella, C.; Antoccia, A.</div><div class="citationInfo"><span class="NLM_cas:title">Apoptosis</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">940-949</span>CODEN:
                <span class="NLM_cas:coden">APOPFN</span>;
        ISSN:<span class="NLM_cas:issn">1360-8185</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The BH3-only Bcl-2 subfamily member Bim is a well known apoptosis promoting protein.  However, the mechanisms upstream of mitochondrion membrane permeability by which Bim is involved in apoptosis have been poorly investigated, particularly in response to agents capable of interfering with the cytoskeleton architecture and arresting cells in mitosis.  Based on the observation that Bim is sequestered on the microtubule-array by interaction with the light chain of dynein, we have investigated upon depolymn., whether Bim could be involved in the commitment of apoptosis.  With this purpose H460 Non Small Lung Cancer Cells (NSLC) were treated with the microtubule damaging agent combretastatin-A4 (CA-4) (7.5 nM; 8-48 h), and various parameters were investigated.  Upon treatment, cells arrested in mitosis and died through a caspase-3-dependent mitotic catastrophe.  Transient knock down of Bim drastically reduced apoptosis, indicating that this protein was involved in cell death as induced by microtubules disorganisation.  In response to increasing conditions of microtubules depolymn., we found that the protein level of Bim was strongly upregulated in a time-dependent manner at transcriptional level.  Furthermore, Bim was released from microtubule-assocd. components.  Bim was translocated to mitochondria, even in a condition of protein synthesis inhibition, where it showed a markedly increased interaction with Bcl-2.  In turn, the fraction of Bax bound to Bcl-2 decreases in response to treatment, thereby indicating that Bim possibly promotes Bax release from the pro-survival protein Bcl-2.  Overall, we demonstrated that Bim is required for the CA-4-induced cell death in the H460 lung cancer cell line via activation of the mitochondrial signalling pathway.  Defining the contribution of Bim to the mechanism of apoptosis may offer some different clues in view of developing new strategies for chemotherapy with CA-4, underlining the relevance of the cytoskeleton integrity in the apoptotic response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFAXUMi6LRGLVg90H21EOLACvtfcHk0liKqlfxByNJDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVSlu7bF&md5=f2c8e59481098e10b8939421d59170b9</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1007%2Fs10495-011-0619-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10495-011-0619-8%26sid%3Dliteratum%253Aachs%26aulast%3DMendez%26aufirst%3DG.%26aulast%3DPolicarpi%26aufirst%3DC.%26aulast%3DCenciarelli%26aufirst%3DC.%26aulast%3DTanzarella%26aufirst%3DC.%26aulast%3DAntoccia%26aufirst%3DA.%26atitle%3DRole%2520of%2520Bim%2520in%2520apoptosis%2520induced%2520in%2520H460%2520lung%2520tumor%2520cells%2520by%2520the%2520spindle%2520poison%2520combretastatin-A4%26jtitle%3DApoptosis%26date%3D2011%26volume%3D16%26spage%3D940%26epage%3D949%26doi%3D10.1007%2Fs10495-011-0619-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group">Méndez-Callejas, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leone, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanzarella, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antoccia, A.</span><span> </span><span class="NLM_article-title">Combretastatin A-4 induces p53 mitochondrial-relocalisation independent-apoptosis in non-small lung cancer cells</span> <span class="citation_source-journal">Cell Biol. Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">296</span><span class="NLM_x">–</span> <span class="NLM_lpage">308</span><span class="refDoi"> DOI: 10.1002/cbin.10199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1002%2Fcbin.10199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=24155061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFajuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2014&pages=296-308&author=G.+M.+M%C3%A9ndez-Callejasauthor=S.+Leoneauthor=C.+Tanzarellaauthor=A.+Antoccia&title=Combretastatin+A-4+induces+p53+mitochondrial-relocalisation+independent-apoptosis+in+non-small+lung+cancer+cells&doi=10.1002%2Fcbin.10199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatin A-4 induces p53 mitochondrial-relocalisation independent-apoptosis in non-small lung cancer cells</span></div><div class="casAuthors">Mendez-Callejas, Gina Marcela; Leone, Stefano; Tanzarella, Caterina; Antoccia, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Cell Biology International</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">296-308</span>CODEN:
                <span class="NLM_cas:coden">CBIIEV</span>;
        ISSN:<span class="NLM_cas:issn">1065-6995</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Combretastatin A-4 (CA-4) is one of the most effective agents used in chemotherapy.  Nevertheless, the contribution of p53 and Bim proteins in the CA-4-induced apoptosis in non-small lung cancer cells (NSCLC) remains unresolved, specifically on involving of p53 in the mitochondrial pathway activation by a transcription-independent mechanism.  In this context, the p53-null H1299 and wt-p53 H460 NSCLC cells, in the absence and presence of pifithrin-μ (PFTμ), an inhibitor of p53 mitochondrial-translocation, were treated with CA-4 and different cellular endpoints were analyzed.  In contrast to previous observations in H460 cells, CA-4 failed in the activation of an apoptotic response in H1299 cells, thus indicating an involvement of p53 in the cell death induced by the drug.  We found that CA-4 led to p53 cellular re-localisation in H460 cells; in particular, p53 was released from the microtubular network and accumulated at mitochondria where it interacts with Bim protein and other proteins of the Bcl-2 (B-cell leukemia-2) family, leading to cytochrome c release, alteration in the mitochondrial membrane polarisation, cell cycle arrest at the G2/M-phase, and cell death.  Interestingly, the cytosolic and the mitochondrial accumulation of protein Bim was strictly dependent on p53 status.  The extent of cell death was not reduced in H460 after combined treatment of PFTμ with CA-4.  Overall, the data support a model of CA-4-induced apoptosis in NSCLC, for which the expression of p53 protein is essential, but its mitochondrial function, linked to p53-transcription independent apoptosis pathway, is negligible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqso_tnnoRArLVg90H21EOLACvtfcHk0libii4oiL_PgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFajuro%253D&md5=b1ea8bc6519a362a56b9ebe25ce8c164</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1002%2Fcbin.10199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbin.10199%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25A9ndez-Callejas%26aufirst%3DG.%2BM.%26aulast%3DLeone%26aufirst%3DS.%26aulast%3DTanzarella%26aufirst%3DC.%26aulast%3DAntoccia%26aufirst%3DA.%26atitle%3DCombretastatin%2520A-4%2520induces%2520p53%2520mitochondrial-relocalisation%2520independent-apoptosis%2520in%2520non-small%2520lung%2520cancer%2520cells%26jtitle%3DCell%2520Biol.%2520Int.%26date%3D2014%26volume%3D38%26spage%3D296%26epage%3D308%26doi%3D10.1002%2Fcbin.10199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group">Mahal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmad, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sethi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Resch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ficner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkar, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schobert, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biersack, B.</span><span> </span><span class="NLM_article-title">Role of JNK and NF-κB in mediating the effect of combretastatin A-4 and brimamin on endothelial and carcinoma cells</span> <span class="citation_source-journal">Cell. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">478</span><span class="refDoi"> DOI: 10.1007/s13402-015-0243-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1007%2Fs13402-015-0243-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFagtbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2015&pages=463-478&author=K.+Mahalauthor=A.+Ahmadauthor=S.+Sethiauthor=M.+Reschauthor=R.+Ficnerauthor=F.+H.+Sarkarauthor=R.+Schobertauthor=B.+Biersack&title=Role+of+JNK+and+NF-%CE%BAB+in+mediating+the+effect+of+combretastatin+A-4+and+brimamin+on+endothelial+and+carcinoma+cells&doi=10.1007%2Fs13402-015-0243-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Role of JNK and NF-κB in mediating the effect of combretastatin A-4 and brimamin on endothelial and carcinoma cells</span></div><div class="casAuthors">Mahal, Katharina; Ahmad, Aamir; Sethi, Seema; Resch, Marcus; Ficner, Ralf; Sarkar, Fazlul H.; Schobert, Rainer; Biersack, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">463-478</span>CODEN:
                <span class="NLM_cas:coden">COENGH</span>;
        ISSN:<span class="NLM_cas:issn">2211-3436</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: The 4,5-diarylimidazole brimamin is an analog of the natural vascular-disrupting agent combretastatin A-4 (CA-4) with improved water soly., tolerance by animals and efficacy in multidrug-resistant tumors.  Here, we aimed at identifying the major mechanisms underlying the in vitro and in vivo actions of brimamin on endothelial and carcinoma cells, including vascularization.  Methods: The contribution of specific signaling kinases to the effects of brimamin on cytoskeleton organization and the viability and differentiation of endothelial cells was assessed by MTT and tube formation assays in the presence or absence of specific kinase inhibitors.  Changes in DNA affinity and expression of NF-κB in endothelial and carcinoma-derived cells and their solid tumors (xenografts) treated with brimamin were ascertained by electrophoretic mobility shift assays and Western blotting.  The anti-vascular effect of brimamin in solid tumors was verified by CD31 immunostaining.  Results: We found that brimamin can inhibit tubulin polymn. and cause a reorganization of F-actin in Ea.hy926 endothelial cells.  Its inhibitory effect on tube formation was found to depend on functional Rho kinase and JNK.  JNK inhibition was found to suppress the induction of endothelial cell apoptosis by brimamin.  In CA-4-refractory human BxPC-3 pancreas carcinoma-derived and triple-neg. MDA-MB-231 breast carcinoma-derived cells brimamin was found to inhibit growth and to induce apoptosis at low nanomolar concns. by blocking NF-κB activation in a dose-dependent manner.  Brimamin was also found to reduce the in vivo growth rate and vascularization of MDA-MB-231 xenografts in mice.  Residual tumor cells of these treated xenografts showed a relatively low expression of the p65 subunit of NF-κB.  Conclusions: Our data indicate that cellular JNK and Rho kinase activities are crucial for the cytotoxic and cytoskeleton reorganizing effects of brimamin on endothelial cells.  In addn., we found that in resistant carcinoma cells and xenografts brimamin can induce down-regulation of anti-apoptotic NF-κB expression and signaling.  Its chem. properties and efficacy against clin. relevant cancer entities make brimamin a promising candidate vascular-disrupting agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGv3M16a_pYLVg90H21EOLACvtfcHk0libii4oiL_PgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFagtbnE&md5=598a584b17aaed4ab396258af920ca60</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1007%2Fs13402-015-0243-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13402-015-0243-7%26sid%3Dliteratum%253Aachs%26aulast%3DMahal%26aufirst%3DK.%26aulast%3DAhmad%26aufirst%3DA.%26aulast%3DSethi%26aufirst%3DS.%26aulast%3DResch%26aufirst%3DM.%26aulast%3DFicner%26aufirst%3DR.%26aulast%3DSarkar%26aufirst%3DF.%2BH.%26aulast%3DSchobert%26aufirst%3DR.%26aulast%3DBiersack%26aufirst%3DB.%26atitle%3DRole%2520of%2520JNK%2520and%2520NF-%25CE%25BAB%2520in%2520mediating%2520the%2520effect%2520of%2520combretastatin%2520A-4%2520and%2520brimamin%2520on%2520endothelial%2520and%2520carcinoma%2520cells%26jtitle%3DCell.%2520Oncol.%26date%3D2015%26volume%3D38%26spage%3D463%26epage%3D478%26doi%3D10.1007%2Fs13402-015-0243-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group">Lin, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiou, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uen, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liou, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chi, C. W.</span><span> </span><span class="NLM_article-title">Combretastatin A4-induced differential cytotoxicity and reduced metastatic ability by inhibition of AKT function in human gastric cancer cells</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">323</span><span class="NLM_x">, </span> <span class="NLM_fpage">365</span><span class="NLM_x">–</span> <span class="NLM_lpage">373</span><span class="refDoi"> DOI: 10.1124/jpet.107.124966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1124%2Fjpet.107.124966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=17646428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFahsb%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2007&pages=365-373&author=H.+L.+Linauthor=S.+H.+Chiouauthor=C.+W.+Wuauthor=W.+B.+Linauthor=L.+H.+Chenauthor=Y.+P.+Yangauthor=M.+L.+Tsaiauthor=Y.+H.+Uenauthor=J.+P.+Liouauthor=C.+W.+Chi&title=Combretastatin+A4-induced+differential+cytotoxicity+and+reduced+metastatic+ability+by+inhibition+of+AKT+function+in+human+gastric+cancer+cells&doi=10.1124%2Fjpet.107.124966"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatin A4-induced differential cytotoxicity and reduced metastatic ability by inhibition of AKT function in human gastric cancer cells</span></div><div class="casAuthors">Lin, Heng-Liang; Chiou, Shih-Hwa; Wu, Chew-Wun; Lin, Wen-Bin; Chen, Li-Hsin; Yang, Yi-Ping; Tsai, Ming-Long; Uen, Yih-Huei; Liou, Jing-Ping; Chi, Chin-Wen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">365-373</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Combretastatin A4 (CA4) is a drug that targets tumor vasculature to inhibit angiogenesis.  Whether CA4 has a direct effect on gastric cancer is not known.  We herein investigated the effect of CA4 on growth and metastasis of gastric cancer cells at clin. achievable concn. and explored the assocd. antitumor mechanisms.  Nine human gastric cancer cell lines, including two metastatic gastric cancer cell lines (AGS-GFPM1/2), constitutively expressing green fluorescence protein (GFP) were used.  These metastatic AGS-GFPM1/2 cells expressed a higher level of phosphorylated serine 473 on AKT (p-AKT).  Our results showed that CA4 (0.02-20 μM) has significant in vitro effects on reducing cell attachment, migration, invasiveness, as well as cell G2/M disturbance on p-AKT-pos. gastric cancer cells.  In addn., a phosphoinositide 3-kinase inhibitor, LY294002 [2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride], a specific AKT inhibitor, and 0.2 to 20 μM CA4 displayed a similar response profile on p-AKT-pos. cells, suggesting that CA4-induced effect was mediated by inhibition of the PI3 kinase/AKT pathway.  The results from in vivo GFP monitoring system indicated that CA4 phosphate (CA4-P; 200 mg/kg) significantly inhibited the s.c. and intra-abdominal growth of xenotransplanted AGS-GFPM2 cells in nude mice.  Furthermore, CA4-P treatment showed a remarkable ability to inhibit gastric tumor metastasis as well as attenuate p-AKT expression.  In conclusion, our study is the first to find that CA4 inhibited AKT activity in human gastric cancer cells.  The decreased AKT activity correlated well with the CA4 antitumor growth response and decrease of metastasis.  Further investigation on drugs targeting the PI3 kinase-AKT pathway may provide a new approach for the treatment of human gastric cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9B2XNKJAQPrVg90H21EOLACvtfcHk0lj6evGetk1o3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFahsb%252FP&md5=ca153b2393c7fbb7eece677e2e2937bb</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.124966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.124966%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DH.%2BL.%26aulast%3DChiou%26aufirst%3DS.%2BH.%26aulast%3DWu%26aufirst%3DC.%2BW.%26aulast%3DLin%26aufirst%3DW.%2BB.%26aulast%3DChen%26aufirst%3DL.%2BH.%26aulast%3DYang%26aufirst%3DY.%2BP.%26aulast%3DTsai%26aufirst%3DM.%2BL.%26aulast%3DUen%26aufirst%3DY.%2BH.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DChi%26aufirst%3DC.%2BW.%26atitle%3DCombretastatin%2520A4-induced%2520differential%2520cytotoxicity%2520and%2520reduced%2520metastatic%2520ability%2520by%2520inhibition%2520of%2520AKT%2520function%2520in%2520human%2520gastric%2520cancer%2520cells%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D323%26spage%3D365%26epage%3D373%26doi%3D10.1124%2Fjpet.107.124966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group">Pollock, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verma, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meegan, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zisterer, D. M.</span><span> </span><span class="NLM_article-title">Combretastatin (CA)-4 and its novel analogue CA-432 impair T-cell migration through the Rho/ROCK signalling pathway</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">544</span><span class="NLM_x">–</span> <span class="NLM_lpage">557</span><span class="refDoi"> DOI: 10.1016/j.bcp.2014.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.bcp.2014.10.002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2014&pages=544-557&author=J.+K.+Pollockauthor=N.+K.+Vermaauthor=N.+M.+O%E2%80%99Boyleauthor=M.+Carrauthor=M.+J.+Meeganauthor=D.+M.+Zisterer&title=Combretastatin+%28CA%29-4+and+its+novel+analogue+CA-432+impair+T-cell+migration+through+the+Rho%2FROCK+signalling+pathway&doi=10.1016%2Fj.bcp.2014.10.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2014.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2014.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DPollock%26aufirst%3DJ.%2BK.%26aulast%3DVerma%26aufirst%3DN.%2BK.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DN.%2BM.%26aulast%3DCarr%26aufirst%3DM.%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26aulast%3DZisterer%26aufirst%3DD.%2BM.%26atitle%3DCombretastatin%2520%2528CA%2529-4%2520and%2520its%2520novel%2520analogue%2520CA-432%2520impair%2520T-cell%2520migration%2520through%2520the%2520Rho%252FROCK%2520signalling%2520pathway%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2014%26volume%3D92%26spage%3D544%26epage%3D557%26doi%3D10.1016%2Fj.bcp.2014.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group">Hori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubota, K.</span><span> </span><span class="NLM_article-title">A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">1604</span><span class="NLM_x">–</span> <span class="NLM_lpage">1614</span><span class="refDoi"> DOI: 10.1038/sj.bjc.6600296</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1038%2Fsj.bjc.6600296" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=12085211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvVaitbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2002&pages=1604-1614&author=K.+Horiauthor=S.+Saitoauthor=K.+Kubota&title=A+novel+combretastatin+A-4+derivative%2C+AC7700%2C+strongly+stanches+tumour+blood+flow+and+inhibits+growth+of+tumours+developing+in+various+tissues+and+organs&doi=10.1038%2Fsj.bjc.6600296"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs</span></div><div class="casAuthors">Hori, K.; Saito, S.; Kubota, K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1604-1614</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In a previous study, the authors used s.c. LY80 tumors (a subline of Yoshida sarcoma), Sato lung carcinoma, and methylcholanthrene-induced primary tumors, to demonstrate that a novel water-sol. combretastatin A-4 deriv., AC7700, abruptly and irreversibly stopped tumor blood flow.  As a result of this interrupted supply of nutrients, extensive necrosis was induced within the tumor.  In the present study, the authors investigated whether AC7700 acts in the same way against solid tumors growing in the liver, stomach, kidney, muscle, and lymph nodes.  Tumor blood flow and the change in tumor blood flow induced by AC7700 were measured by the hydrogen clearance method.  In a model of cancer chemotherapy against metastases, LY80 cells (2×106) were injected into the lateral tail vein, and AC7700 at 10 mg kg-1 was injected i.v. 5 times at intervals of 2 days, starting on day 7 after tumor cell injection.  The no. and size of tumors were compared with those in the control group.  The change in tumor blood flow and the therapeutic effect of AC7700 on microtumors were obsd. directly by Sato lung carcinoma implanted in a rat transparent chamber.  AC7700 caused a marked decrease in the tumor blood flow of all LY80 tumors developing in various tissues and organs and growth of all tumors including lymph node metastases and microtumors was inhibited.  In every tumor, tumor blood flow began to decrease immediately after AC7700 administration and reached a min. at approx. 30 min after injection.  In many tumor capillaries, blood flow completely stopped within 3 min after AC7700 administration.  These results demonstrate that AC7700 is effective for tumors growing in various tissues and organs and for metastases.  The authors conclude that tumor blood flow stanching induced by AC7700 may become an effective therapeutic strategy for all cancers, including refractory cancers because the therapeutic effect is independent of tumor site and specific type of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO13kBP3gkhLVg90H21EOLACvtfcHk0liCqbxmWAmwIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvVaitbc%253D&md5=ece92f90ba2de5ad260829429e4699fc</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6600296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6600296%26sid%3Dliteratum%253Aachs%26aulast%3DHori%26aufirst%3DK.%26aulast%3DSaito%26aufirst%3DS.%26aulast%3DKubota%26aufirst%3DK.%26atitle%3DA%2520novel%2520combretastatin%2520A-4%2520derivative%252C%2520AC7700%252C%2520strongly%2520stanches%2520tumour%2520blood%2520flow%2520and%2520inhibits%2520growth%2520of%2520tumours%2520developing%2520in%2520various%2520tissues%2520and%2520organs%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2002%26volume%3D86%26spage%3D1604%26epage%3D1614%26doi%3D10.1038%2Fsj.bjc.6600296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group">Ridley, A. J.</span><span> </span><span class="NLM_article-title">Rho GTPase signalling in cell migration</span> <span class="citation_source-journal">Curr. Opin. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">112</span><span class="refDoi"> DOI: 10.1016/j.ceb.2015.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.ceb.2015.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=26363959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVentr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=103-112&author=A.+J.+Ridley&title=Rho+GTPase+signalling+in+cell+migration&doi=10.1016%2Fj.ceb.2015.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Rho GTPase signalling in cell migration</span></div><div class="casAuthors">Ridley, Anne J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103-112</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Cells migrate in multiple different ways depending on their environment, which includes the extracellular matrix compn., interactions with other cells, and chem. stimuli.  For all types of cell migration, Rho GTPases play a central role, although the relative contribution of each Rho GTPase depends on the environment and cell type.  Here, I review recent advances in our understanding of how Rho GTPases contribute to different types of migration, comparing lamellipodium-driven vs. bleb-driven migration modes.  I also describe how cells migrate across the endothelium.  In addn. to Rho, Rac and Cdc42, which are well known to regulate migration, I discuss the roles of other less-well characterized members of the Rho family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9u3iM9PoTD7Vg90H21EOLACvtfcHk0liCqbxmWAmwIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVentr3K&md5=12f9e17652641d59d3d8566b039733c4</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2015.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2015.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DRidley%26aufirst%3DA.%2BJ.%26atitle%3DRho%2520GTPase%2520signalling%2520in%2520cell%2520migration%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2015%26volume%3D36%26spage%3D103%26epage%3D112%26doi%3D10.1016%2Fj.ceb.2015.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group">Kanthou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozer, G. M.</span><span> </span><span class="NLM_article-title">The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">2060</span><span class="NLM_x">–</span> <span class="NLM_lpage">2069</span><span class="refDoi"> DOI: 10.1182/blood.V99.6.2060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1182%2Fblood.V99.6.2060" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=2060-2069&author=C.+Kanthouauthor=G.+M.+Tozer&title=The+tumor+vascular+targeting+agent+combretastatin+A-4-phosphate+induces+reorganization+of+the+actin+cytoskeleton+and+early+membrane+blebbing+in+human+endothelial+cells&doi=10.1182%2Fblood.V99.6.2060"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1182%2Fblood.V99.6.2060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V99.6.2060%26sid%3Dliteratum%253Aachs%26aulast%3DKanthou%26aufirst%3DC.%26aulast%3DTozer%26aufirst%3DG.%2BM.%26atitle%3DThe%2520tumor%2520vascular%2520targeting%2520agent%2520combretastatin%2520A-4-phosphate%2520induces%2520reorganization%2520of%2520the%2520actin%2520cytoskeleton%2520and%2520early%2520membrane%2520blebbing%2520in%2520human%2520endothelial%2520cells%26jtitle%3DBlood%26date%3D2002%26volume%3D99%26spage%3D2060%26epage%3D2069%26doi%3D10.1182%2Fblood.V99.6.2060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span> </span><span class="NLM_article-title">Deoxypodophyllotoxin suppresses tumor vasculature in HUVECs by promoting cytoskeleton remodeling through LKB1-AMPK dependent Rho A activation</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">29497</span><span class="NLM_x">–</span> <span class="NLM_lpage">29512</span><span class="refDoi"> DOI: 10.18632/oncotarget.4985</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.18632%2Foncotarget.4985" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=29497-29512&author=Y.+Wangauthor=B.+Wangauthor=M.+Guerramauthor=L.+Sunauthor=W.+Shiauthor=C.+Tianauthor=X.+Zhuauthor=Z.+Jiangauthor=L.+Zhang&title=Deoxypodophyllotoxin+suppresses+tumor+vasculature+in+HUVECs+by+promoting+cytoskeleton+remodeling+through+LKB1-AMPK+dependent+Rho+A+activation&doi=10.18632%2Foncotarget.4985"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.4985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.4985%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DGuerram%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DW.%26aulast%3DTian%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DDeoxypodophyllotoxin%2520suppresses%2520tumor%2520vasculature%2520in%2520HUVECs%2520by%2520promoting%2520cytoskeleton%2520remodeling%2520through%2520LKB1-AMPK%2520dependent%2520Rho%2520A%2520activation%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D29497%26epage%3D29512%26doi%3D10.18632%2Foncotarget.4985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group">Hori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akita, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sumiyoshi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taki, Y.</span><span> </span><span class="NLM_article-title">Prevention of cancer recurrence in tumor margins by stopping microcirculation in the tumor and tumor-host interface</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">1196</span><span class="NLM_x">–</span> <span class="NLM_lpage">1204</span><span class="refDoi"> DOI: 10.1111/cas.12477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1111%2Fcas.12477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=24981848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFymu7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2014&pages=1196-1204&author=K.+Horiauthor=H.+Akitaauthor=H.+Nonakaauthor=A.+Sumiyoshiauthor=Y.+Taki&title=Prevention+of+cancer+recurrence+in+tumor+margins+by+stopping+microcirculation+in+the+tumor+and+tumor-host+interface&doi=10.1111%2Fcas.12477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of cancer recurrence in tumor margins by stopping microcirculation in the tumor and tumor-host interface</span></div><div class="casAuthors">Hori, Katsuyoshi; Akita, Hirotoshi; Nonaka, Hiroi; Sumiyoshi, Akira; Taki, Yasuyuki</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1196-1204</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Combretastatins interrupt blood flow of solid tumor vascular networks and lead to necrosis by blocking nutrients.  However, tumors recover from tumor blood flow interruption-induced damage and develop viable rims.  To investigate why cancer recurs and its prevention, we used a combretastatin deriv., Cderiv (=AC7700), and analyzed changes in tumor-host interface (T-HI) vessels, which were closest to cancer cells in the tumor margin after tumor vessel disruption, and the microenvironment surrounding them.  Treatment with Cderiv (10 mg/kg) interrupted tumor blood flow in all regions of LY80 (a variant of Yoshida sarcoma) tumor, but not T-HI vessel blood flow.  The same Cderiv dose given 72 h after 5 Gy irradn. stopped T-HI vessel blood flow and prevented cancer recurrence.  Treatment in the reverse order, however, did not affect T-HI vessel blood flow.  The greatest difference between the two treatments was the occurrence of gradual T-HI edema with the former.  Severe T-HI edema compressed T-HI blood vessels, so that circulation stopped.  Thus, the distance between a tumor margin and its nearest functioning host vessel became much larger, and the tumor marginal region became a microenvironment that lacked a nutritional supply.  Cancer cells in tumor margins received nutrients through two circulation routes: tumor vessels and T-HI vessels.  Our starvation methods, which involved treatment with Cderiv 72 h after 5 Gy irradn., blocked both circulation routes and may have great potential as a clin. strategy to prevent cancer recurrence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYut25JtLfEbVg90H21EOLACvtfcHk0lgUu1TzjzgA6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFymu7zI&md5=df5115837beea89bd44316f173755cbc</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1111%2Fcas.12477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.12477%26sid%3Dliteratum%253Aachs%26aulast%3DHori%26aufirst%3DK.%26aulast%3DAkita%26aufirst%3DH.%26aulast%3DNonaka%26aufirst%3DH.%26aulast%3DSumiyoshi%26aufirst%3DA.%26aulast%3DTaki%26aufirst%3DY.%26atitle%3DPrevention%2520of%2520cancer%2520recurrence%2520in%2520tumor%2520margins%2520by%2520stopping%2520microcirculation%2520in%2520the%2520tumor%2520and%2520tumor-host%2520interface%26jtitle%3DCancer%2520Sci.%26date%3D2014%26volume%3D105%26spage%3D1196%26epage%3D1204%26doi%3D10.1111%2Fcas.12477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group">Yao, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ni, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span> </span><span class="NLM_article-title">Combretastatin A4 phosphate treatment induces vasculogenic mimicry formation of W256 breast carcinoma tumor in vitro and in vivo</span> <span class="citation_source-journal">Tumor Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">8499</span><span class="NLM_x">–</span> <span class="NLM_lpage">8510</span><span class="refDoi"> DOI: 10.1007/s13277-015-3508-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1007%2Fs13277-015-3508-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=26026583" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsVynsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=8499-8510&author=N.+Yaoauthor=K.+Renauthor=C.+Jiangauthor=M.+Gaoauthor=D.+Huangauthor=X.+Luauthor=B.+Louauthor=F.+Pengauthor=A.+Yangauthor=X.+Wangauthor=Y.+Niauthor=J.+Zhang&title=Combretastatin+A4+phosphate+treatment+induces+vasculogenic+mimicry+formation+of+W256+breast+carcinoma+tumor+in+vitro+and+in+vivo&doi=10.1007%2Fs13277-015-3508-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatin A4 phosphate treatment induces vasculogenic mimicry formation of W256 breast carcinoma tumor in vitro and in vivo</span></div><div class="casAuthors">Yao, Nan; Ren, Ke; Jiang, Cuihua; Gao, Meng; Huang, Dejian; Lu, Xiao; Lou, Bin; Peng, Fei; Yang, Aizhen; Wang, Xiaoning; Ni, Yicheng; Zhang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Tumor Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">8499-8510</span>CODEN:
                <span class="NLM_cas:coden">TUMBEA</span>;
        ISSN:<span class="NLM_cas:issn">1010-4283</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The purpose of this study was to investigate the effect of combretastatin A4 phosphate (CA4P) on vasculogenic mimicry (VM) channel formation in vitro and in vivo after a single-dose treatment and the underlying mechanism involved in supporting VM.  In vitro model of three-dimensional cultures was used to test the effect of CA4P on the tube formation of Walker 256 cells.  Western blot anal. was conducted to assess the expression of hypoxia-inducible factor (HIF)-1α and VM-assocd. markers.  W256 tumor-bearing rat model was established to demonstrate the effect of CA4P on VM formation and tumor hypoxia by double staining and a hypoxic marker pimonidazole.  Anti-tumor efficacy of CA4P treatment was evaluated by tumor growth curve.  Under hypoxic conditions for 48 h in vitro, W256 cells formed VM network assocd. with increased expression of VM markers.  Pretreatment with CA4P did not influence the amt. of VM in 3-D culture as well as the expression of these key mols.  In vivo, W256 tumors showed marked intratumoral hypoxia after CA4P treatment, accompanied by increased VM formation.  CA4P exhibited only a delay in tumor growth within 2 days but rapid tumor regrowth afterward.  VM d. was pos. related to tumor vol. and tumor wt. at day 8.  CA4P causes hypoxia which induces VM formation in W256 tumors through HIF-1α/EphA2/PI3K/matrix metalloproteinase (MMP) signaling pathway, resulting in the consequent regrowth of the damaged tumor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzjp_ytrU0WrVg90H21EOLACvtfcHk0lgUu1TzjzgA6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsVynsLs%253D&md5=b885509f7094abad46daa1b8af3736a7</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1007%2Fs13277-015-3508-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13277-015-3508-x%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DN.%26aulast%3DRen%26aufirst%3DK.%26aulast%3DJiang%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DD.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DLou%26aufirst%3DB.%26aulast%3DPeng%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DNi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DCombretastatin%2520A4%2520phosphate%2520treatment%2520induces%2520vasculogenic%2520mimicry%2520formation%2520of%2520W256%2520breast%2520carcinoma%2520tumor%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DTumor%2520Biol.%26date%3D2015%26volume%3D36%26spage%3D8499%26epage%3D8510%26doi%3D10.1007%2Fs13277-015-3508-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group">El-Emir, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxer, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrie, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boden, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dearling, J. L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Begent, R. H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedley, R. B.</span><span> </span><span class="NLM_article-title">Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">799</span><span class="NLM_x">–</span> <span class="NLM_lpage">806</span><span class="refDoi"> DOI: 10.1016/j.ejca.2005.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.ejca.2005.01.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2005&pages=799-806&author=E.+El-Emirauthor=G.+M.+Boxerauthor=I.+A.+Petrieauthor=R.+W.+Bodenauthor=J.+L.+J.+Dearlingauthor=R.+H.+J.+Begentauthor=R.+B.+Pedley&title=Tumour+parameters+affected+by+combretastatin+A-4+phosphate+therapy+in+a+human+colorectal+xenograft+model+in+nude+mice&doi=10.1016%2Fj.ejca.2005.01.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2005.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2005.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Emir%26aufirst%3DE.%26aulast%3DBoxer%26aufirst%3DG.%2BM.%26aulast%3DPetrie%26aufirst%3DI.%2BA.%26aulast%3DBoden%26aufirst%3DR.%2BW.%26aulast%3DDearling%26aufirst%3DJ.%2BL.%2BJ.%26aulast%3DBegent%26aufirst%3DR.%2BH.%2BJ.%26aulast%3DPedley%26aufirst%3DR.%2BB.%26atitle%3DTumour%2520parameters%2520affected%2520by%2520combretastatin%2520A-4%2520phosphate%2520therapy%2520in%2520a%2520human%2520colorectal%2520xenograft%2520model%2520in%2520nude%2520mice%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2005%26volume%3D41%26spage%3D799%26epage%3D806%26doi%3D10.1016%2Fj.ejca.2005.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group">Dachs, G. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steele, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coralli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanthou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunningham, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozer, G. M.</span><span> </span><span class="NLM_article-title">Anti-vascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression</span> <span class="citation_source-journal">BMC Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">280</span><span class="refDoi"> DOI: 10.1186/1471-2407-6-280</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1186%2F1471-2407-6-280" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=280&author=G.+U.+Dachsauthor=A.+J.+Steeleauthor=C.+Coralliauthor=C.+Kanthouauthor=A.+C.+Brooksauthor=S.+P.+Gunninghamauthor=M.+J.+Currieauthor=A.+I.+Watsonauthor=B.+A.+Robinsonauthor=G.+M.+Tozer&title=Anti-vascular+agent+Combretastatin+A-4-P+modulates+hypoxia+inducible+factor-1+and+gene+expression&doi=10.1186%2F1471-2407-6-280"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-6-280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-6-280%26sid%3Dliteratum%253Aachs%26aulast%3DDachs%26aufirst%3DG.%2BU.%26aulast%3DSteele%26aufirst%3DA.%2BJ.%26aulast%3DCoralli%26aufirst%3DC.%26aulast%3DKanthou%26aufirst%3DC.%26aulast%3DBrooks%26aufirst%3DA.%2BC.%26aulast%3DGunningham%26aufirst%3DS.%2BP.%26aulast%3DCurrie%26aufirst%3DM.%2BJ.%26aulast%3DWatson%26aufirst%3DA.%2BI.%26aulast%3DRobinson%26aufirst%3DB.%2BA.%26aulast%3DTozer%26aufirst%3DG.%2BM.%26atitle%3DAnti-vascular%2520agent%2520Combretastatin%2520A-4-P%2520modulates%2520hypoxia%2520inducible%2520factor-1%2520and%2520gene%2520expression%26jtitle%3DBMC%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D280%26doi%3D10.1186%2F1471-2407-6-280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group">Peichev, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naiyer, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pereira, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oz, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, M. A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafii, S.</span><span> </span><span class="NLM_article-title">Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">952</span><span class="NLM_x">–</span> <span class="NLM_lpage">958</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2000&pages=952-958&author=M.+Peichevauthor=A.+J.+Naiyerauthor=D.+Pereiraauthor=Z.+Zhuauthor=W.+J.+Laneauthor=M.+Williamsauthor=M.+C.+Ozauthor=D.+J.+Hicklinauthor=L.+Witteauthor=M.+A.+S.+Mooreauthor=S.+Rafii&title=Expression+of+VEGFR-2+and+AC133+by+circulating+human+CD34%2B+cells+identifies+a+population+of+functional+endothelial+precursors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeichev%26aufirst%3DM.%26aulast%3DNaiyer%26aufirst%3DA.%2BJ.%26aulast%3DPereira%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DLane%26aufirst%3DW.%2BJ.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DOz%26aufirst%3DM.%2BC.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DWitte%26aufirst%3DL.%26aulast%3DMoore%26aufirst%3DM.%2BA.%2BS.%26aulast%3DRafii%26aufirst%3DS.%26atitle%3DExpression%2520of%2520VEGFR-2%2520and%2520AC133%2520by%2520circulating%2520human%2520CD34%252B%2520cells%2520identifies%2520a%2520population%2520of%2520functional%2520endothelial%2520precursors%26jtitle%3DBlood%26date%3D2000%26volume%3D95%26spage%3D952%26epage%3D958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group">Nolan, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciarrocchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellick, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaggi, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bambino, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heikamp, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDevitt, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheinberg, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benezra, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mittal, V.</span><span> </span><span class="NLM_article-title">Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1546</span><span class="NLM_x">–</span> <span class="NLM_lpage">1558</span><span class="refDoi"> DOI: 10.1101/gad.436307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1101%2Fgad.436307" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=1546-1558&author=D.+J.+Nolanauthor=A.+Ciarrocchiauthor=A.+S.+Mellickauthor=J.+S.+Jaggiauthor=K.+Bambinoauthor=S.+Guptaauthor=E.+Heikampauthor=M.+R.+McDevittauthor=D.+A.+Scheinbergauthor=R.+Benezraauthor=V.+Mittal&title=Bone+marrow-derived+endothelial+progenitor+cells+are+a+major+determinant+of+nascent+tumor+neovascularization&doi=10.1101%2Fgad.436307"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1101%2Fgad.436307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.436307%26sid%3Dliteratum%253Aachs%26aulast%3DNolan%26aufirst%3DD.%2BJ.%26aulast%3DCiarrocchi%26aufirst%3DA.%26aulast%3DMellick%26aufirst%3DA.%2BS.%26aulast%3DJaggi%26aufirst%3DJ.%2BS.%26aulast%3DBambino%26aufirst%3DK.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DHeikamp%26aufirst%3DE.%26aulast%3DMcDevitt%26aufirst%3DM.%2BR.%26aulast%3DScheinberg%26aufirst%3DD.%2BA.%26aulast%3DBenezra%26aufirst%3DR.%26aulast%3DMittal%26aufirst%3DV.%26atitle%3DBone%2520marrow-derived%2520endothelial%2520progenitor%2520cells%2520are%2520a%2520major%2520determinant%2520of%2520nascent%2520tumor%2520neovascularization%26jtitle%3DGenes%2520Dev.%26date%3D2007%26volume%3D21%26spage%3D1546%26epage%3D1558%26doi%3D10.1101%2Fgad.436307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group">Ceradini, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulkarni, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callaghan, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tepper, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastidas, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleinman, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capla, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galiano, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurtner, G. C.</span><span> </span><span class="NLM_article-title">Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">858</span><span class="NLM_x">–</span> <span class="NLM_lpage">864</span><span class="refDoi"> DOI: 10.1038/nm1075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1038%2Fnm1075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=15235597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtFWrtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=858-864&author=D.+J.+Ceradiniauthor=A.+R.+Kulkarniauthor=M.+J.+Callaghanauthor=O.+M.+Tepperauthor=N.+Bastidasauthor=M.+E.+Kleinmanauthor=J.+M.+Caplaauthor=R.+D.+Galianoauthor=J.+P.+Levineauthor=G.+C.+Gurtner&title=Progenitor+cell+trafficking+is+regulated+by+hypoxic+gradients+through+HIF-1+induction+of+SDF-1&doi=10.1038%2Fnm1075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1</span></div><div class="casAuthors">Ceradini, Daniel J.; Kulkarni, Anita R.; Callaghan, Matthew J.; Tepper, Oren M.; Bastidas, Nicholas; Kleinman, Mark E.; Capla, Jennifer M.; Galiano, Robert D.; Levine, Jamie P.; Gurtner, Geoffrey C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">858-864</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The trafficking of circulating stem and progenitor cells to areas of tissue damage is poorly understood.  The chemokine stromal cell-derived factor-1 (SDF-1 or CXCL12) mediates homing of stem cells to bone marrow by binding to CXCR4 on circulating cells.  SDF-1 and CXCR4 are expressed in complementary patterns during embryonic organogenesis and guide primordial stem cells to sites of rapid vascular expansion.  However, the regulation of SDF-1 and its physiol. role in peripheral tissue repair remain incompletely understood.  Here the authors show that SDF-1 gene expression is regulated by the transcription factor hypoxia-inducible factor-1 (HIF-1) in endothelial cells, resulting in selective in vivo expression of SDF-1 in ischemic tissue in direct proportion to reduced oxygen tension.  HIF-1-induced SDF-1 expression increases the adhesion, migration and homing of circulating CXCR4-pos. progenitor cells to ischemic tissue.  Blockade of SDF-1 in ischemic tissue or CXCR4 on circulating cells prevents progenitor cell recruitment to sites of injury.  Discrete regions of hypoxia in the bone marrow compartment also show increased SDF-1 expression and progenitor cell tropism.  These data show that the recruitment of CXCR4-pos. progenitor cells to regenerating tissues is mediated by hypoxic gradients via HIF-1-induced expression of SDF-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrV1Q85cyOcb7Vg90H21EOLACvtfcHk0liR09zMk6Cqyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtFWrtr0%253D&md5=6d0bef060be512c348fd2e453b6e19df</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1038%2Fnm1075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1075%26sid%3Dliteratum%253Aachs%26aulast%3DCeradini%26aufirst%3DD.%2BJ.%26aulast%3DKulkarni%26aufirst%3DA.%2BR.%26aulast%3DCallaghan%26aufirst%3DM.%2BJ.%26aulast%3DTepper%26aufirst%3DO.%2BM.%26aulast%3DBastidas%26aufirst%3DN.%26aulast%3DKleinman%26aufirst%3DM.%2BE.%26aulast%3DCapla%26aufirst%3DJ.%2BM.%26aulast%3DGaliano%26aufirst%3DR.%2BD.%26aulast%3DLevine%26aufirst%3DJ.%2BP.%26aulast%3DGurtner%26aufirst%3DG.%2BC.%26atitle%3DProgenitor%2520cell%2520trafficking%2520is%2520regulated%2520by%2520hypoxic%2520gradients%2520through%2520HIF-1%2520induction%2520of%2520SDF-1%26jtitle%3DNat.%2520Med.%26date%3D2004%26volume%3D10%26spage%3D858%26epage%3D864%26doi%3D10.1038%2Fnm1075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group">Moschetta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mishima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahin, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glavey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roccaro, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghobrial, I. M.</span><span> </span><span class="NLM_article-title">Role of endothelial progenitor cells in cancer progression</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">1846</span><span class="NLM_x">, </span> <span class="NLM_fpage">26</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span><span class="refDoi"> DOI: 10.1016/j.bbcan.2014.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.bbcan.2014.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=24709008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1OqsrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1846&publication_year=2014&pages=26-39&author=M.+Moschettaauthor=Y.+Mishimaauthor=I.+Sahinauthor=S.+Manierauthor=S.+Glaveyauthor=A.+Vaccaauthor=A.+M.+Roccaroauthor=I.+M.+Ghobrial&title=Role+of+endothelial+progenitor+cells+in+cancer+progression&doi=10.1016%2Fj.bbcan.2014.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Role of endothelial progenitor cells in cancer progression</span></div><div class="casAuthors">Moschetta, Michele; Mishima, Yuji; Sahin, Ilyas; Manier, Salomon; Glavey, Siobhan; Vacca, Angelo; Roccaro, Aldo M.; Ghobrial, Irene M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Reviews on Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1846</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26-39</span>CODEN:
                <span class="NLM_cas:coden">BBACEU</span>;
        ISSN:<span class="NLM_cas:issn">0304-419X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Tumor-assocd. neovasculature is a crit. therapeutic target; however, despite significant progress made in the clin. efficacy of anti-vessel drugs, the effect of these agents remains transient: over time, most patients develop resistance, which inevitably leads to tumor progression.  To develop more effective treatments, it is imperative that we better understand the mechanisms involved in tumor vessel formation, how they participate to the tumor progression and metastasis, and the best way to target them.  Several mechanisms contribute to the formation of tumor-assocd. vasculature: i) neoangiogenesis; ii) vascular co-option; iii) mosaicism; iv) vasculogenic mimicry, and v) postnatal vasculogenesis.  These mechanisms can also play a role in the development of resistance to anti-angiogenic drugs, and could serve as targets for designing new anti-vascular mols. to treat solid as well as hematol. malignancies.  Bone marrow-derived endothelial progenitor cell (EPC)-mediated vasculogenesis represents an important new target, esp. at the early stage of tumor growth (when EPCs are crit. for promoting the "angiogenic switch"), and during metastasis, when EPCs promote the transition from micro- to macro-metastases.  In hematol. malignancies, the EPC population could be related to the neoplastic clone, and both may share a common ontogeny.  Thus, characterization of tumor-assocd. EPCs in blood cancers may provide clues for more specific anti-vascular therapy that has both direct and indirect anti-tumor effects.  Here, we review the role of vasculogenesis, mediated by bone marrow-derived EPCs, in the progression of cancer, with a particular focus on the role of these cells in promoting progression of hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSltj3sCnUQrVg90H21EOLACvtfcHk0liR09zMk6Cqyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1OqsrzK&md5=f7441312b188aee8838d30b7cef3818f</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1016%2Fj.bbcan.2014.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbcan.2014.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DMoschetta%26aufirst%3DM.%26aulast%3DMishima%26aufirst%3DY.%26aulast%3DSahin%26aufirst%3DI.%26aulast%3DManier%26aufirst%3DS.%26aulast%3DGlavey%26aufirst%3DS.%26aulast%3DVacca%26aufirst%3DA.%26aulast%3DRoccaro%26aufirst%3DA.%2BM.%26aulast%3DGhobrial%26aufirst%3DI.%2BM.%26atitle%3DRole%2520of%2520endothelial%2520progenitor%2520cells%2520in%2520cancer%2520progression%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Rev.%2520Cancer%26date%3D2014%26volume%3D1846%26spage%3D26%26epage%3D39%26doi%3D10.1016%2Fj.bbcan.2014.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group">Shaked, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woloszynek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daenen, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Man, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arbeit, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voest, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smythe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertolini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Link, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerbel, R. S.</span><span> </span><span class="NLM_article-title">Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">7524</span><span class="NLM_x">–</span> <span class="NLM_lpage">7528</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-0381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1158%2F0008-5472.CAN-09-0381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=19738066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Skt7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=7524-7528&author=Y.+Shakedauthor=T.+Tangauthor=J.+Woloszynekauthor=L.+G.+Daenenauthor=S.+Manauthor=P.+Xuauthor=S.+R.+Caiauthor=J.+M.+Arbeitauthor=E.+E.+Voestauthor=D.+J.+Chaplinauthor=J.+Smytheauthor=A.+Harrisauthor=P.+Nathanauthor=I.+Judsonauthor=G.+Rustinauthor=F.+Bertoliniauthor=D.+C.+Linkauthor=R.+S.+Kerbel&title=Contribution+of+granulocyte+colony-stimulating+factor+to+the+acute+mobilization+of+endothelial+precursor+cells+by+vascular+disrupting+agents&doi=10.1158%2F0008-5472.CAN-09-0381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Contribution of Granulocyte Colony-Stimulating Factor to the Acute Mobilization of Endothelial Precursor Cells by Vascular Disrupting Agents</span></div><div class="casAuthors">Shaked, Yuval; Tang, Terence; Woloszynek, Jill; Daenen, Laura G.; Man, Shan; Xu, Ping; Cai, Shi-Rong; Arbeit, Jeffrey M.; Voest, Emile E.; Chaplin, David J.; Smythe, Jon; Harris, Adrian; Nathan, Paul; Judson, Ian; Rustin, Gordon; Bertolini, Francesco; Link, Daniel C.; Kerbel, Robert S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7524-7528</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Vascular disrupting agents (VDA) cause acute shutdown of abnormal established tumor vasculature, followed by massive intratumoral hypoxia and necrosis.  However, a viable rim of tumor tissue invariably remains from which tumor regrowth rapidly resumes.  We have recently shown that an acute systemic mobilization and homing of bone marrow-derived circulating endothelial precursor (CEP) cells could promote tumor regrowth following treatment with either a VDA or certain chemotherapy drugs.  The mol. mediators of this systemic reactive host process are unknown.  Here, we show that following treatment of mice with OXi-4503, a second-generation potent prodrug deriv. of combretastatin-A4 phosphate, rapid increases in circulating plasma vascular endothelial growth factor, stromal derived factor-1 (SDF-1), and granulocyte colony-stimulating factor (G-CSF) levels are detected.  With the aim of detg. whether G-CSF is involved in VDA-induced CEP mobilization, mutant G-CSF-R-/- mice were treated with OXi-4503.  We found that as opposed to wild-type controls, G-CSF-R-/- mice failed to mobilize CEPs or show induction of SDF-1 plasma levels.  Furthermore, Lewis lung carcinomas grown in such mice treated with OXi-4503 showed greater levels of necrosis compared with tumors treated in wild-type mice.  Evidence for rapid elevations in circulating plasma G-CSF, vascular endothelial growth factor, and SDF-1 were also obsd. in patients with VDA (combretastatin-A4 phosphate)-treated cancer.  These results highlight the possible effect of drug-induced G-CSF on tumor regrowth following certain cytotoxic drug therapies, in this case using a VDA, and hence G-CSF as a possible therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2jpuiF1WWrLVg90H21EOLACvtfcHk0lizIfCJaqA-Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Skt7rI&md5=d84f9c870de167454b3251c751d948f9</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-0381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-0381%26sid%3Dliteratum%253Aachs%26aulast%3DShaked%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DT.%26aulast%3DWoloszynek%26aufirst%3DJ.%26aulast%3DDaenen%26aufirst%3DL.%2BG.%26aulast%3DMan%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DP.%26aulast%3DCai%26aufirst%3DS.%2BR.%26aulast%3DArbeit%26aufirst%3DJ.%2BM.%26aulast%3DVoest%26aufirst%3DE.%2BE.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DSmythe%26aufirst%3DJ.%26aulast%3DHarris%26aufirst%3DA.%26aulast%3DNathan%26aufirst%3DP.%26aulast%3DJudson%26aufirst%3DI.%26aulast%3DRustin%26aufirst%3DG.%26aulast%3DBertolini%26aufirst%3DF.%26aulast%3DLink%26aufirst%3DD.%2BC.%26aulast%3DKerbel%26aufirst%3DR.%2BS.%26atitle%3DContribution%2520of%2520granulocyte%2520colony-stimulating%2520factor%2520to%2520the%2520acute%2520mobilization%2520of%2520endothelial%2520precursor%2520cells%2520by%2520vascular%2520disrupting%2520agents%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D7524%26epage%3D7528%26doi%3D10.1158%2F0008-5472.CAN-09-0381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group">Shaked, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciarrocchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Man, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benezra, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerbel, R. S.</span><span> </span><span class="NLM_article-title">Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">313</span><span class="NLM_x">, </span> <span class="NLM_fpage">1785</span><span class="NLM_x">–</span> <span class="NLM_lpage">1787</span><span class="refDoi"> DOI: 10.1126/science.1127592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1126%2Fscience.1127592" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=16990548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD28Xpsl2qs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2006&pages=1785-1787&author=Y.+Shakedauthor=A.+Ciarrocchiauthor=M.+Francoauthor=C.+R.+Leeauthor=S.+Manauthor=A.+M.+Cheungauthor=D.+J.+Hicklinauthor=D.+Chaplinauthor=F.+S.+Fosterauthor=R.+Benezraauthor=R.+S.+Kerbel&title=Therapy-induced+acute+recruitment+of+circulating+endothelial+progenitor+cells+to+tumors&doi=10.1126%2Fscience.1127592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors</span></div><div class="casAuthors">Shaked, Yuval; Ciarrocchi, Alessia; Franco, Marcela; Lee, Christina R.; Man, Shan; Cheung, Alison M.; Hicklin, Daniel J.; Chaplin, David; Stuart Foster, F.; Benezra, Robert; Kerbel, Robert S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">313</span>
        (<span class="NLM_cas:issue">5794</span>),
    <span class="NLM_cas:pages">1785-1787</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The contribution of bone marrow-derived circulating endothelial progenitor cells (CEPs) to tumor angiogenesis has been controversial, primarily because of their low nos. in blood vessels of untreated tumors.  We show that treatment of tumor-bearing mice with vascular disrupting agents (VDAs) leads to an acute mobilization of CEPs, which home to the viable tumor rim that characteristically remains after such therapy.  Disruption of this CEP spike by antiangiogenic drugs or by genetic manipulation resulted in marked redns. in tumor rim size and blood flow as well as enhanced VDA antitumor activity.  These findings also provide a mechanistic rationale for the enhanced efficacy of VDAs when combined with antiangiogenic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt4x1ShGytGbVg90H21EOLACvtfcHk0lizIfCJaqA-Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xpsl2qs74%253D&md5=b0cd350a081f69bd889a250e1a704c17</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1126%2Fscience.1127592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1127592%26sid%3Dliteratum%253Aachs%26aulast%3DShaked%26aufirst%3DY.%26aulast%3DCiarrocchi%26aufirst%3DA.%26aulast%3DFranco%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DC.%2BR.%26aulast%3DMan%26aufirst%3DS.%26aulast%3DCheung%26aufirst%3DA.%2BM.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DChaplin%26aufirst%3DD.%26aulast%3DFoster%26aufirst%3DF.%2BS.%26aulast%3DBenezra%26aufirst%3DR.%26aulast%3DKerbel%26aufirst%3DR.%2BS.%26atitle%3DTherapy-induced%2520acute%2520recruitment%2520of%2520circulating%2520endothelial%2520progenitor%2520cells%2520to%2520tumors%26jtitle%3DScience%26date%3D2006%26volume%3D313%26spage%3D1785%26epage%3D1787%26doi%3D10.1126%2Fscience.1127592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group">Lewis, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Palma, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naldini, L.</span><span> </span><span class="NLM_article-title">Tie2-expressing monocytes and tumor angiogenesis: Regulation by hypoxia and angiopoietin-2</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">8429</span><span class="NLM_x">–</span> <span class="NLM_lpage">8432</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-1684</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1158%2F0008-5472.CAN-07-1684" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=8429-8432&author=C.+E.+Lewisauthor=M.+De+Palmaauthor=L.+Naldini&title=Tie2-expressing+monocytes+and+tumor+angiogenesis%3A+Regulation+by+hypoxia+and+angiopoietin-2&doi=10.1158%2F0008-5472.CAN-07-1684"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-1684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-1684%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DC.%2BE.%26aulast%3DDe%2BPalma%26aufirst%3DM.%26aulast%3DNaldini%26aufirst%3DL.%26atitle%3DTie2-expressing%2520monocytes%2520and%2520tumor%2520angiogenesis%253A%2520Regulation%2520by%2520hypoxia%2520and%2520angiopoietin-2%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D8429%26epage%3D8432%26doi%3D10.1158%2F0008-5472.CAN-07-1684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group">Welford, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biziato, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coffelt, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nucera, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pucci, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Serio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naldini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Palma, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozer, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C. E.</span><span> </span><span class="NLM_article-title">TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">1969</span><span class="NLM_x">–</span> <span class="NLM_lpage">1973</span><span class="refDoi"> DOI: 10.1172/JCI44562</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1172%2FJCI44562" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=21490397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvFKntLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2011&pages=1969-1973&author=A.+F.+Welfordauthor=D.+Biziatoauthor=S.+B.+Coffeltauthor=S.+Nuceraauthor=M.+Fisherauthor=F.+Pucciauthor=C.+Di+Serioauthor=L.+Naldiniauthor=M.+De+Palmaauthor=G.+M.+Tozerauthor=C.+E.+Lewis&title=TIE2-expressing+macrophages+limit+the+therapeutic+efficacy+of+the+vascular-disrupting+agent+combretastatin+A4+phosphate+in+mice&doi=10.1172%2FJCI44562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice</span></div><div class="casAuthors">Welford, Abigail F.; Biziato, Daniela; Coffelt, Seth B.; Nucera, Silvia; Fisher, Matthew; Pucci, Ferdinando; Di Serio, Clelia; Naldini, Luigi; De Palma, Michele; Tozer, Gillian M.; Lewis, Claire E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1969-1973</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Vascular-disrupting agents (VDAs) such as combretastatin A4 phosphate (CA4P) selectively disrupt blood vessels in tumors and induce tumor necrosis.  However, tumors rapidly repopulate after treatment with such compds.  Here, we show that CA4P-induced vessel narrowing, hypoxia, and hemorrhagic necrosis in murine mammary tumors were accompanied by elevated tumor levels of the chemokine CXCL12 and infiltration by proangiogenic TIE2-expressing macrophages (TEMs).  Inhibiting TEM recruitment to CA4P-treated tumors either by interfering pharmacol. with the CXCL12/CXCR4 axis or by genetically depleting TEMs in tumor-bearing mice markedly increased the efficacy of CA4P treatment.  These data suggest that TEMs limit VDA-induced tumor injury and represent a potential target for improving the clin. efficacy of VDA-based therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocb26kJmJmKrVg90H21EOLACvtfcHk0ljYDL28F7A-Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvFKntLY%253D&md5=d54a510e428639e16fd9e6c94ecfd181</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1172%2FJCI44562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI44562%26sid%3Dliteratum%253Aachs%26aulast%3DWelford%26aufirst%3DA.%2BF.%26aulast%3DBiziato%26aufirst%3DD.%26aulast%3DCoffelt%26aufirst%3DS.%2BB.%26aulast%3DNucera%26aufirst%3DS.%26aulast%3DFisher%26aufirst%3DM.%26aulast%3DPucci%26aufirst%3DF.%26aulast%3DDi%2BSerio%26aufirst%3DC.%26aulast%3DNaldini%26aufirst%3DL.%26aulast%3DDe%2BPalma%26aufirst%3DM.%26aulast%3DTozer%26aufirst%3DG.%2BM.%26aulast%3DLewis%26aufirst%3DC.%2BE.%26atitle%3DTIE2-expressing%2520macrophages%2520limit%2520the%2520therapeutic%2520efficacy%2520of%2520the%2520vascular-disrupting%2520agent%2520combretastatin%2520A4%2520phosphate%2520in%2520mice%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2011%26volume%3D121%26spage%3D1969%26epage%3D1973%26doi%3D10.1172%2FJCI44562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group">Parkins, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holder, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozer, G. M.</span><span> </span><span class="NLM_article-title">Determinants of anti-vascular action by combretastatin A-4 phosphate: Role of nitric oxide</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">811</span><span class="NLM_x">–</span> <span class="NLM_lpage">816</span><span class="refDoi"> DOI: 10.1054/bjoc.2000.1361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1054%2Fbjoc.2000.1361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10952787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntFOhsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2000&pages=811-816&author=C.+S.+Parkinsauthor=A.+L.+Holderauthor=S.+A.+Hillauthor=D.+J.+Chaplinauthor=G.+M.+Tozer&title=Determinants+of+anti-vascular+action+by+combretastatin+A-4+phosphate%3A+Role+of+nitric+oxide&doi=10.1054%2Fbjoc.2000.1361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide</span></div><div class="casAuthors">Parkins, C. S.; Holder, A. L.; Hill, S. A.; Chaplin, D. J.; Tozer, G. M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">811-816</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Harcourt Publishers Ltd.</span>)
        </div><div class="casAbstract">The anti-vascular action of the tubulin binding agent combretastatin A-4 phosphate (CA-4-P) has been quantified in two types of murine tumor, the breast adenocarcinoma CaNT and the round cell sarcoma SaS.  The functional vascular vol., assessed using a fluorescent carbocyanine dye, was significantly reduced at 18 h after CA-4-P treatment in both tumor types, although the degree of redn. was very different in the two tumors.  The SaS tumor, which has a higher nitric oxide synthase (NOS) activity than the CaNT tumor, showed ∼10-fold greater resistance to vascular damage by CA-4-P.  This is consistent with our previous findings, which showed that NO exerts a protective action against this drug.  Simultaneous administration of CA-4-P with a NOS inhibitor, Nω-nitro-L-arginine (L-NNA), resulted in enhanced vascular damage and cytotoxicity in both tumor types.  Administration of diethylamine NO, an NO donor, conferred protection against the vascular damaging effects.  Following treatment with CA-4-P, neutrophil infiltration into the tumors, measured by myeloperoxidase (MPO) activity, was significantly increased.  Levels of MPO activity also correlated with the levels of vascular injury and cytotoxicity measured in both tumor types.  Neutrophilic MPO generates free radicals and may therefore contribute to the vascular damage assocd. with CA-4-P treatment.  MPO activity was significantly increased in the presence of L-NNA, suggesting that the protective effect of NO against CA-4-P-induced vascular injury may be, at least partially, mediated by limiting neutrophil infiltration.  The data are consistent with the hypothesis that neutrophil action contributes to vascular injury by CA-4-P and that NO generation acts to protect the tumor vasculature against CA4-P-induced injury.  The protective effect of NO is probably assocd. with an anti-neutrophil action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqibguGCtOqGLVg90H21EOLACvtfcHk0ljYDL28F7A-Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntFOhsL0%253D&md5=9eb82cbaff18333d42eaef00087491d9</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1054%2Fbjoc.2000.1361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1054%252Fbjoc.2000.1361%26sid%3Dliteratum%253Aachs%26aulast%3DParkins%26aufirst%3DC.%2BS.%26aulast%3DHolder%26aufirst%3DA.%2BL.%26aulast%3DHill%26aufirst%3DS.%2BA.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DTozer%26aufirst%3DG.%2BM.%26atitle%3DDeterminants%2520of%2520anti-vascular%2520action%2520by%2520combretastatin%2520A-4%2520phosphate%253A%2520Role%2520of%2520nitric%2520oxide%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2000%26volume%3D83%26spage%3D811%26epage%3D816%26doi%3D10.1054%2Fbjoc.2000.1361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group">Bohn, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittenborn, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brems-Eskildsen, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertelsen, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stødkilde-Jørgensen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Møller, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horsman, M. R.</span><span> </span><span class="NLM_article-title">A combretastatin-mediated decrease in neutrophil concentration in peripheral blood and the impact on the anti-tumor activity of this drug in two different murine tumor models</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">e110091</span><span class="refDoi"> DOI: 10.1371/journal.pone.0110091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1371%2Fjournal.pone.0110091" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e110091&author=A.+B.+Bohnauthor=T.+Wittenbornauthor=A.+S.+Brems-Eskildsenauthor=T.+Laurbergauthor=L.+B.+Bertelsenauthor=T.+Nielsenauthor=H.+St%C3%B8dkilde-J%C3%B8rgensenauthor=B.+K.+M%C3%B8llerauthor=M.+R.+Horsman&title=A+combretastatin-mediated+decrease+in+neutrophil+concentration+in+peripheral+blood+and+the+impact+on+the+anti-tumor+activity+of+this+drug+in+two+different+murine+tumor+models&doi=10.1371%2Fjournal.pone.0110091"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0110091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0110091%26sid%3Dliteratum%253Aachs%26aulast%3DBohn%26aufirst%3DA.%2BB.%26aulast%3DWittenborn%26aufirst%3DT.%26aulast%3DBrems-Eskildsen%26aufirst%3DA.%2BS.%26aulast%3DLaurberg%26aufirst%3DT.%26aulast%3DBertelsen%26aufirst%3DL.%2BB.%26aulast%3DNielsen%26aufirst%3DT.%26aulast%3DSt%25C3%25B8dkilde-J%25C3%25B8rgensen%26aufirst%3DH.%26aulast%3DM%25C3%25B8ller%26aufirst%3DB.%2BK.%26aulast%3DHorsman%26aufirst%3DM.%2BR.%26atitle%3DA%2520combretastatin-mediated%2520decrease%2520in%2520neutrophil%2520concentration%2520in%2520peripheral%2520blood%2520and%2520the%2520impact%2520on%2520the%2520anti-tumor%2520activity%2520of%2520this%2520drug%2520in%2520two%2520different%2520murine%2520tumor%2520models%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De110091%26doi%3D10.1371%2Fjournal.pone.0110091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group">Greene, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolan, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meegan, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zisterer, D. M.</span><span> </span><span class="NLM_article-title">The vascular targeting agent Combretastatin-A4 directly induces autophagy in adenocarcinoma-derived colon cancer cells</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">612</span><span class="NLM_x">–</span> <span class="NLM_lpage">624</span><span class="refDoi"> DOI: 10.1016/j.bcp.2012.06.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.bcp.2012.06.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2012&pages=612-624&author=L.+M.+Greeneauthor=N.+M.+O%E2%80%99Boyleauthor=D.+P.+Nolanauthor=M.+J.+Meeganauthor=D.+M.+Zisterer&title=The+vascular+targeting+agent+Combretastatin-A4+directly+induces+autophagy+in+adenocarcinoma-derived+colon+cancer+cells&doi=10.1016%2Fj.bcp.2012.06.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2012.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2012.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DGreene%26aufirst%3DL.%2BM.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DN.%2BM.%26aulast%3DNolan%26aufirst%3DD.%2BP.%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26aulast%3DZisterer%26aufirst%3DD.%2BM.%26atitle%3DThe%2520vascular%2520targeting%2520agent%2520Combretastatin-A4%2520directly%2520induces%2520autophagy%2520in%2520adenocarcinoma-derived%2520colon%2520cancer%2520cells%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2012%26volume%3D84%26spage%3D612%26epage%3D624%26doi%3D10.1016%2Fj.bcp.2012.06.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Q.</span><span> </span><span class="NLM_article-title">Autophagy blockade sensitizes the anticancer activity of CA-4 via JNK-Bcl-2 pathway</span> <span class="citation_source-journal">Toxicol. Appl. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">274</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">327</span><span class="refDoi"> DOI: 10.1016/j.taap.2013.11.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.taap.2013.11.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=24321340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksFemsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=2014&pages=319-327&author=Y.+Liauthor=P.+Luoauthor=J.+Wangauthor=J.+Daiauthor=X.+Yangauthor=H.+Wuauthor=B.+Yangauthor=Q.+He&title=Autophagy+blockade+sensitizes+the+anticancer+activity+of+CA-4+via+JNK-Bcl-2+pathway&doi=10.1016%2Fj.taap.2013.11.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Autophagy blockade sensitizes the anticancer activity of CA-4 via JNK-Bcl-2 pathway</span></div><div class="casAuthors">Li, Yangling; Luo, Peihua; Wang, Jincheng; Dai, Jiabin; Yang, Xiaochun; Wu, Honghai; Yang, Bo; He, Qiaojun</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">274</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">319-327</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Combretastatin A-4 (CA-4) has already entered clin. trials of solid tumors over ten years.  However, the limited anticancer activity and dose-dependent toxicity restrict its clin. application.  Here, we offered convincing evidence that CA-4 induced autophagy in various cancer cells, which was demonstrated by acridine orange staining of intracellular acidic vesicles, the degrdn. of p62, the conversion of LC3-I to LC3-II and GFP-LC3 punctate fluorescence.  Interestingly, CA-4-mediated apoptotic cell death was further potentiated by pretreatment with autophagy inhibitors (3-methyladenine and bafilomycin A1) or small interfering RNAs against the autophagic genes (Atg5 and Beclin 1).  The enhanced anticancer activity of CA-4 and 3-MA was further confirmed in the SGC-7901 xenograft tumor model.  These findings suggested that CA-4-elicited autophagic response played a protective role that impeded the eventual cell death while autophagy inhibition was expected to improve chemotherapeutic efficacy of CA-4.  Meanwhile, CA-4 treatment led to phosphorylation/activation of JNK and JNK-dependent phosphorylation of Bcl-2.  Importantly, JNK inhibitor or JNK siRNA inhibited autophagy but promoted CA-4-induced apoptosis, indicating a key requirement of JNK-Bcl-2 pathway in the activation of autophagy by CA-4.  We also identified that pretreatment of Bcl-2 inhibitor (ABT-737) could significantly enhance anticancer activity of CA-4 due to inhibition of autophagy.  Taken together, our data suggested that the JNK-Bcl-2 pathway was considered as the crit. regulator of CA-4-induced protective autophagy and a potential drug target for chemotherapeutic combination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHZSB2u4cjH7Vg90H21EOLACvtfcHk0li3Z-fW5-nz0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksFemsw%253D%253D&md5=4d0cdca9cef0bc9c58135d244940a4b6</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2013.11.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2013.11.018%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DQ.%26atitle%3DAutophagy%2520blockade%2520sensitizes%2520the%2520anticancer%2520activity%2520of%2520CA-4%2520via%2520JNK-Bcl-2%2520pathway%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2014%26volume%3D274%26spage%3D319%26epage%3D327%26doi%3D10.1016%2Fj.taap.2013.11.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group">Clémenson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jouannot, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merino-Trigo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin-Carrez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deutsch, E.</span><span> </span><span class="NLM_article-title">The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">–</span> <span class="NLM_lpage">284</span><span class="refDoi"> DOI: 10.1007/s10637-012-9852-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1007%2Fs10637-012-9852-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=273-284&author=C.+Cl%C3%A9mensonauthor=E.+Jouannotauthor=A.+Merino-Trigoauthor=C.+Rubin-Carrezauthor=E.+Deutsch&title=The+vascular+disrupting+agent+ombrabulin+%28AVE8062%29+enhances+the+efficacy+of+standard+therapies+in+head+and+neck+squamous+cell+carcinoma+xenograft+models&doi=10.1007%2Fs10637-012-9852-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1007%2Fs10637-012-9852-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-012-9852-4%26sid%3Dliteratum%253Aachs%26aulast%3DCl%25C3%25A9menson%26aufirst%3DC.%26aulast%3DJouannot%26aufirst%3DE.%26aulast%3DMerino-Trigo%26aufirst%3DA.%26aulast%3DRubin-Carrez%26aufirst%3DC.%26aulast%3DDeutsch%26aufirst%3DE.%26atitle%3DThe%2520vascular%2520disrupting%2520agent%2520ombrabulin%2520%2528AVE8062%2529%2520enhances%2520the%2520efficacy%2520of%2520standard%2520therapies%2520in%2520head%2520and%2520neck%2520squamous%2520cell%2520carcinoma%2520xenograft%2520models%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2013%26volume%3D31%26spage%3D273%26epage%3D284%26doi%3D10.1007%2Fs10637-012-9852-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group">Martinelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonezzi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riccardi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frapolli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zucchetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taraboletti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giavazzi, R.</span><span> </span><span class="NLM_article-title">Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">888</span><span class="NLM_x">–</span> <span class="NLM_lpage">894</span><span class="refDoi"> DOI: 10.1038/sj.bjc.6603969</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1038%2Fsj.bjc.6603969" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=17848949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSnurbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2007&pages=888-894&author=M.+Martinelliauthor=K.+Bonezziauthor=E.+Riccardiauthor=E.+Kuhnauthor=R.+Frapolliauthor=M.+Zucchettiauthor=A.+J.+Ryanauthor=G.+Tarabolettiauthor=R.+Giavazzi&title=Sequence+dependent+antitumour+efficacy+of+the+vascular+disrupting+agent+ZD6126+in+combination+with+paclitaxel&doi=10.1038%2Fsj.bjc.6603969"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel</span></div><div class="casAuthors">Martinelli, M.; Bonezzi, K.; Riccardi, E.; Kuhn, E.; Frapolli, R.; Zucchetti, M.; Ryan, A. J.; Taraboletti, G.; Giavazzi, R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">888-894</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. success of small-mol. vascular disrupting agents (VDAs) depends on their combination with conventional therapies.  Scheduling and sequencing remain key issues in the design of VDA-chemotherapy combination treatments.  This study examd. the antitumor activity of ZD6126, a microtubule destabilizing VDA, in combination with paclitaxel (PTX), a microtubule-stabilizing cytotoxic drug, and the influence of schedule and sequence on the efficacy of the combination.  Nude mice bearing MDA-MB-435 xenografts received weekly cycles of ZD6126 (200 mg kg-1 i.p.) administered at different times before or after PTX (10, 20, and 40 mg kg-1 i.v.).  ZD6126 given 2 or 24 h after PTX showed no significant benefit, a result that was attributed to a protective effect of PTX against ZD6126-induced vascular damage and tumor necrosis, a hallmark of VDA activity.  Paclitaxel counteracting activity was reduced by distancing drug administrations, and ZD6126 given 72 h after PTX potentiated the VDA's antitumor activity.  Schedules with ZD6126 given before PTX improved therapeutic activity, which was paralleled by a VDA-induced increase in cell proliferation in the viable tumor tissue.  Paclitaxel given 72 h after ZD6126 yielded the best response (50% tumors regressing).  A single treatment with ZD6126 followed by weekly administration of PTX was sufficient to achieve a similar response (57% remissions).  These findings show that schedule, sequence and timing are crucial in detg. the antitumor efficacy of PTX in combination with ZD6126.  Induction of tumor necrosis and increased proliferation in the remaining viable tumor tissue could be exploited as readouts to optimize schedules and maximize therapeutic efficacy.  Published online 11 Sept. 2007.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGru-Vn3DW8o37Vg90H21EOLACvtfcHk0li3Z-fW5-nz0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSnurbP&md5=b2ee948386407ba60e97a7aea52c5cf9</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6603969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6603969%26sid%3Dliteratum%253Aachs%26aulast%3DMartinelli%26aufirst%3DM.%26aulast%3DBonezzi%26aufirst%3DK.%26aulast%3DRiccardi%26aufirst%3DE.%26aulast%3DKuhn%26aufirst%3DE.%26aulast%3DFrapolli%26aufirst%3DR.%26aulast%3DZucchetti%26aufirst%3DM.%26aulast%3DRyan%26aufirst%3DA.%2BJ.%26aulast%3DTaraboletti%26aufirst%3DG.%26aulast%3DGiavazzi%26aufirst%3DR.%26atitle%3DSequence%2520dependent%2520antitumour%2520efficacy%2520of%2520the%2520vascular%2520disrupting%2520agent%2520ZD6126%2520in%2520combination%2520with%2520paclitaxel%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2007%26volume%3D97%26spage%3D888%26epage%3D894%26doi%3D10.1038%2Fsj.bjc.6603969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group">Wu, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurung, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, C. H.</span><span> </span><span class="NLM_article-title">Mechanisms of tumor resistance to small-molecule vascular disrupting agents: Treatment and rationale of combination therapy</span> <span class="citation_source-journal">J. Formosan Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">115</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span><span class="refDoi"> DOI: 10.1016/j.jfma.2012.09.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.jfma.2012.09.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=23473523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1GksbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2013&pages=115-124&author=X.+Y.+Wuauthor=W.+Maauthor=K.+Gurungauthor=C.+H.+Guo&title=Mechanisms+of+tumor+resistance+to+small-molecule+vascular+disrupting+agents%3A+Treatment+and+rationale+of+combination+therapy&doi=10.1016%2Fj.jfma.2012.09.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of tumor resistance to small-molecule vascular disrupting agents: Treatment and rationale of combination therapy</span></div><div class="casAuthors">Wu, Xue-Yuan; Ma, Wei; Gurung, Kiran; Guo, Chi-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Formosan Medical Association</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">115-124</span>CODEN:
                <span class="NLM_cas:coden">JFASEO</span>;
        ISSN:<span class="NLM_cas:issn">0929-6646</span>.
    
            (<span class="NLM_cas:orgname">Elsevier (Singapore) Pte Ltd.</span>)
        </div><div class="casAbstract">A review.  Small-mol. vascular disrupting agents (VDAs) target the established tumor blood vessels, resulting in rapidly and selectively widespread ischemia and necrosis of central tumor; meanwhile, blood flow in normal tissues is relatively unaffected.  Although VDAs therapy is considered an important option for treatment, its use is still limited.  The tumor cells at the periphery are less sensitive to vascular shutdown than those at the center, and subsequently avoid a nutrient-deprived environment.  This phenomenon is referred to as tumor resistance to VDAs treatment.  The viable periphery rim of tumor cells contributes to tumor regeneration, metastasis, and ongoing progression.  However, there is no systematic review of the plausible mechanisms of repopulation of the viable tumor cells following VDAs therapy.  The purpose of this review is to provide insights into mechanisms of tumor surviving small-mol. VDAs therapy, and the synergetic treatment to the remaining viable tumor cells at the periphery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXeMYvM5f5krVg90H21EOLACvtfcHk0lgDiD1tYq-p1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1GksbbP&md5=9c85a37cb31674fd5a48a78b4f205b32</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1016%2Fj.jfma.2012.09.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jfma.2012.09.017%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DX.%2BY.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DGurung%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DC.%2BH.%26atitle%3DMechanisms%2520of%2520tumor%2520resistance%2520to%2520small-molecule%2520vascular%2520disrupting%2520agents%253A%2520Treatment%2520and%2520rationale%2520of%2520combination%2520therapy%26jtitle%3DJ.%2520Formosan%2520Med.%2520Assoc.%26date%3D2013%26volume%3D112%26spage%3D115%26epage%3D124%26doi%3D10.1016%2Fj.jfma.2012.09.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group">Nathan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zweifel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padhani, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smythe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stirling, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G. J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I.</span><span> </span><span class="NLM_article-title">Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3428</span><span class="NLM_x">–</span> <span class="NLM_lpage">3439</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-3376</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1158%2F1078-0432.CCR-11-3376" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=22645052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1Oks70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=3428-3439&author=P.+Nathanauthor=M.+Zweifelauthor=A.+R.+Padhaniauthor=D.+M.+Kohauthor=M.+Ngauthor=D.+J.+Collinsauthor=A.+Harrisauthor=C.+Cardenauthor=J.+Smytheauthor=N.+Fisherauthor=N.+J.+Taylorauthor=J.+J.+Stirlingauthor=S.+P.+Luauthor=M.+O.+Leachauthor=G.+J.+S.+Rustinauthor=I.+Judson&title=Phase+I+trial+of+combretastatin+A4+phosphate+%28CA4P%29+in+combination+with+bevacizumab+in+patients+with+advanced+cancer&doi=10.1158%2F1078-0432.CCR-11-3376"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer</span></div><div class="casAuthors">Nathan, Paul; Zweifel, Martin; Padhani, Anwar R.; Koh, Dow-Mu; Ng, Matthew; Collins, David J.; Harris, Adrian; Carden, Craig; Smythe, Jon; Fisher, Nita; Taylor, N. Jane; Stirling, J. James; Lu, Shiao-Ping; Leach, Martin O.; Rustin, Gordon J. S.; Judson, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3428-3439</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The vascular disrupting agent (VDA) combretastatin A4 phosphate (CA4P) induces significant tumor necrosis as a single agent.  Preclin. models have shown that the addn. of an anti-VEGF antibody to a VDA attenuates the revascularization of the surviving tumor rim and thus significantly increases antitumor activity.  Exptl. Design: Patients with advanced solid malignancies received CA4P at 45, 54, or 63 mg/m2 on day 1, day 8, and then every 14 days.  Bevacizumab 10 mg/kg was given on day 8 and at subsequent cycles four hours after CA4P.  Functional imaging with dynamic contrast enhanced-MRI (DCE-MRI) was conducted at baseline, after CA4P alone, and after cycle 1 CA4P + bevacizumab.  Results: A total of 63 mg/m2 CA4P + 10 mg/kg bevacizumab q14 is the recommended phase II dose.  A total of 15 patients were enrolled.  Dose-limiting toxicities were grade III asymptomatic atrial fibrillation and grade IV liver hemorrhage in a patient with a history of hemorrhage.  Most common toxicities were hypertension, headache, lymphopenia, pruritus, and pyrexia.  Asymptomatic electrocardiog. changes were seen in five patients.  Nine of 14 patients experienced disease stabilization.  A patient with ovarian cancer had a CA125 response lasting for more than a year.  DCE-MRI showed statistically significant redns. in tumor perfusion/vascular permeability, which reversed after CA4P alone but which were sustained following bevacizumab.  Circulating CD34+ and CD133+ bone marrow progenitors increased following CA4P as did VEGF and granulocyte colony-stimulating factor levels.  Conclusions: CA4P in combination with bevacizumab appears safe and well tolerated in this dosing schedule.  CA4P induced profound vascular changes, which were maintained by the presence of bevacizumab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDhWR6xfmKNbVg90H21EOLACvtfcHk0lgDiD1tYq-p1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1Oks70%253D&md5=b7d93331d8ad4e6d21fff0ddf35fe461</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-3376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-3376%26sid%3Dliteratum%253Aachs%26aulast%3DNathan%26aufirst%3DP.%26aulast%3DZweifel%26aufirst%3DM.%26aulast%3DPadhani%26aufirst%3DA.%2BR.%26aulast%3DKoh%26aufirst%3DD.%2BM.%26aulast%3DNg%26aufirst%3DM.%26aulast%3DCollins%26aufirst%3DD.%2BJ.%26aulast%3DHarris%26aufirst%3DA.%26aulast%3DCarden%26aufirst%3DC.%26aulast%3DSmythe%26aufirst%3DJ.%26aulast%3DFisher%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DN.%2BJ.%26aulast%3DStirling%26aufirst%3DJ.%2BJ.%26aulast%3DLu%26aufirst%3DS.%2BP.%26aulast%3DLeach%26aufirst%3DM.%2BO.%26aulast%3DRustin%26aufirst%3DG.%2BJ.%2BS.%26aulast%3DJudson%26aufirst%3DI.%26atitle%3DPhase%2520I%2520trial%2520of%2520combretastatin%2520A4%2520phosphate%2520%2528CA4P%2529%2520in%2520combination%2520with%2520bevacizumab%2520in%2520patients%2520with%2520advanced%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D3428%26epage%3D3439%26doi%3D10.1158%2F1078-0432.CCR-11-3376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group">Moens, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goveia, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stapor, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantelmo, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmeliet, P.</span><span> </span><span class="NLM_article-title">The multifaceted activity of VEGF in angiogenesis - Implications for therapy responses</span> <span class="citation_source-journal">Cytokine Growth Factor Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">473</span><span class="NLM_x">–</span> <span class="NLM_lpage">482</span><span class="refDoi"> DOI: 10.1016/j.cytogfr.2014.07.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.cytogfr.2014.07.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=25169850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVKnurvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=473-482&author=S.+Moensauthor=J.+Goveiaauthor=P.+C.+Staporauthor=A.+R.+Cantelmoauthor=P.+Carmeliet&title=The+multifaceted+activity+of+VEGF+in+angiogenesis+-+Implications+for+therapy+responses&doi=10.1016%2Fj.cytogfr.2014.07.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">The multifaceted activity of VEGF in angiogenesis - Implications for therapy responses</span></div><div class="casAuthors">Moens, Stijn; Goveia, Jermaine; Stapor, Peter C.; Cantelmo, Anna Rita; Carmeliet, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">473-482</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Vascular endothelial growth factor (VEGF) is a key growth factor driving angiogenesis (i.e. the formation of new blood vessels) in health and disease.  Pharmacol. blockade of VEGF signaling to inhibit tumor angiogenesis is clin. approved but the survival benefit is limited as patients invariably acquire resistance.  This is partially mediated by the intrinsic flexibility of tumor cells to adapt to VEGF-blockade.  However, it has become clear that tumor stromal cells also contribute to the resistance.  Originally, VEGF was thought to specifically target endothelial cells (ECs) but it is now clear that many stromal cells also respond to VEGF signaling, making anti-VEGF therapy more complex than initially anticipated.  A more comprehensive understanding of the complex responses of stromal cells to VEGF-blockade might inform the design of improved anti-angiogenic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOhBOfmgezwbVg90H21EOLACvtfcHk0lgDiD1tYq-p1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVKnurvE&md5=8823c2f4eee6593d96db325032cb823c</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2014.07.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2014.07.009%26sid%3Dliteratum%253Aachs%26aulast%3DMoens%26aufirst%3DS.%26aulast%3DGoveia%26aufirst%3DJ.%26aulast%3DStapor%26aufirst%3DP.%2BC.%26aulast%3DCantelmo%26aufirst%3DA.%2BR.%26aulast%3DCarmeliet%26aufirst%3DP.%26atitle%3DThe%2520multifaceted%2520activity%2520of%2520VEGF%2520in%2520angiogenesis%2520-%2520Implications%2520for%2520therapy%2520responses%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2014%26volume%3D25%26spage%3D473%26epage%3D482%26doi%3D10.1016%2Fj.cytogfr.2014.07.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group">Lambrechts, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Haas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmeliet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherer, S. J.</span><span> </span><span class="NLM_article-title">Markers of response for the antiangiogenic agent bevacizumab</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1219</span><span class="NLM_x">–</span> <span class="NLM_lpage">1230</span><span class="refDoi"> DOI: 10.1200/JCO.2012.46.2762</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1200%2FJCO.2012.46.2762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=23401453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVyhu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=1219-1230&author=D.+Lambrechtsauthor=H.+J.+Lenzauthor=S.+De+Haasauthor=P.+Carmelietauthor=S.+J.+Scherer&title=Markers+of+response+for+the+antiangiogenic+agent+bevacizumab&doi=10.1200%2FJCO.2012.46.2762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Markers of response for the antiangiogenic agent bevacizumab</span></div><div class="casAuthors">Lambrechts, Diether; Lenz, Heinz-Josef; de Haas, Sanne; Carmeliet, Peter; Scherer, Stefan J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1219-1230</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Bevacizumab is the first antiangiogenic therapy proven to slow metastatic disease progression in patients with cancer.  Although it has changed clin. practice, some patients do not respond or gradually develop resistance, resulting in rather modest gains in terms of overall survival.  A major challenge is to develop robust biomarkers that can guide selection of patients for whom bevacizumab therapy is most beneficial.  Here, we discuss recent progress in finding such markers, including the first results from randomized phase III clin. trials evaluating the efficacy of bevacizumab in combination with comprehensive biomarker analyses.  In particular, these studies suggest that circulating levels of short vascular endothelial growth factor A (VEGF-A) isoforms, expression of neuropilin-1 and VEGF receptor 1 in tumors or plasma, and genetic variants in VEGFA or its receptors are strong biomarker candidates.  The current challenge is to expand this first set of markers and to validate it and implement it into clin. practice.  A first prospective biomarker study known as MERiDiAN, which will treat patients stratified for circulating levels of short VEGF-A isoforms with bevacizumab and paclitaxel, is planned and will hopefully provide us with new directions on how to treat patients more efficiently.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpEt-mPtftaLVg90H21EOLACvtfcHk0lgV1KOwu-98XA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVyhu74%253D&md5=5d7841b2cd2ff58ac32116c972432dbe</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.46.2762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.46.2762%26sid%3Dliteratum%253Aachs%26aulast%3DLambrechts%26aufirst%3DD.%26aulast%3DLenz%26aufirst%3DH.%2BJ.%26aulast%3DDe%2BHaas%26aufirst%3DS.%26aulast%3DCarmeliet%26aufirst%3DP.%26aulast%3DScherer%26aufirst%3DS.%2BJ.%26atitle%3DMarkers%2520of%2520response%2520for%2520the%2520antiangiogenic%2520agent%2520bevacizumab%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D1219%26epage%3D1230%26doi%3D10.1200%2FJCO.2012.46.2762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group">Zweifel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayson, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ledermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shreeves, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balkissoon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G. J. S.</span><span> </span><span class="NLM_article-title">Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2036</span><span class="NLM_x">–</span> <span class="NLM_lpage">2041</span><span class="refDoi"> DOI: 10.1093/annonc/mdq708</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1093%2Fannonc%2Fmdq708" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=21273348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A280%3ADC%252BC3MjpvVSrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=2036-2041&author=M.+Zweifelauthor=G.+C.+Jaysonauthor=N.+S.+Reedauthor=R.+Osborneauthor=B.+Hassanauthor=J.+Ledermannauthor=G.+Shreevesauthor=L.+Poupardauthor=S.+P.+Luauthor=J.+Balkissoonauthor=D.+J.+Chaplinauthor=G.+J.+S.+Rustin&title=Phase+II+trial+of+combretastatin+A4+phosphate%2C+carboplatin%2C+and+paclitaxel+in+patients+with+platinum-resistant+ovarian+cancer&doi=10.1093%2Fannonc%2Fmdq708"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer</span></div><div class="casAuthors">Zweifel M; Jayson G C; Reed N S; Osborne R; Hassan B; Ledermann J; Shreeves G; Poupard L; Lu S-P; Balkissoon J; Chaplin D J; Rustin G J S</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2036-41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  A previous dose-escalation trial of the vascular disrupting agent combretastatin A4 phosphate (CA4P) given before carboplatin, paclitaxel, or both showed responses in 7 of 18 patients with relapsed ovarian cancer.  PATIENTS AND METHODS:  Patients with ovarian cancer that had relapsed and who could start trial therapy within 6 months of their last platinum chemotherapy were given CA4P 63 mg/m(2) minimum 18 h before paclitaxel 175 mg/m(2) and carboplatin AUC (area under the concentration curve) 5, repeated every 3 weeks.  RESULTS:  Five of the first 18 patients' disease responded, so the study was extended and closed after 44 patients were recruited.  Grade ≥2 toxic effects were neutropenia in 75% and thrombocytopenia in 9% of patients (weekly blood counts), tumour pain, fatigue, and neuropathy, with one patient with rapidly reversible ataxia.  Hypertension (23% of patients) was controlled by glyceryl trinitrate or prophylactic amlodipine.  The response rate by RECIST was 13.5% and by Gynecologic Cancer InterGroup CA 125 criteria 34%.  CONCLUSIONS:  The addition of CA4P to paclitaxel and carboplatin is well tolerated and appears to produce a higher response rate in this patient population than if the chemotherapy was given without CA4P.  A planned randomised trial will test this hypothesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTKPQKWSYY7Sqe0F5ixvZgXfW6udTcc2eaE8UHObb7V-7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MjpvVSrsQ%253D%253D&md5=6b960ad4dcccdbbc67ffa9398e85d2be</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdq708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdq708%26sid%3Dliteratum%253Aachs%26aulast%3DZweifel%26aufirst%3DM.%26aulast%3DJayson%26aufirst%3DG.%2BC.%26aulast%3DReed%26aufirst%3DN.%2BS.%26aulast%3DOsborne%26aufirst%3DR.%26aulast%3DHassan%26aufirst%3DB.%26aulast%3DLedermann%26aufirst%3DJ.%26aulast%3DShreeves%26aufirst%3DG.%26aulast%3DPoupard%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DS.%2BP.%26aulast%3DBalkissoon%26aufirst%3DJ.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DRustin%26aufirst%3DG.%2BJ.%2BS.%26atitle%3DPhase%2520II%2520trial%2520of%2520combretastatin%2520A4%2520phosphate%252C%2520carboplatin%252C%2520and%2520paclitaxel%2520in%2520patients%2520with%2520platinum-resistant%2520ovarian%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2011%26volume%3D22%26spage%3D2036%26epage%3D2041%26doi%3D10.1093%2Fannonc%2Fmdq708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group">Sosa, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balkissoon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langecker, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elisei, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarzab, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bal, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gramza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ondrey, F.</span><span> </span><span class="NLM_article-title">Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer</span> <span class="citation_source-journal">Surgery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">152</span><span class="NLM_x">, </span> <span class="NLM_fpage">1078</span><span class="NLM_x">–</span> <span class="NLM_lpage">1087</span><span class="refDoi"> DOI: 10.1016/j.surg.2012.08.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.surg.2012.08.036" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2012&pages=1078-1087&author=J.+A.+Sosaauthor=J.+Balkissoonauthor=S.+P.+Luauthor=P.+Langeckerauthor=R.+Eliseiauthor=B.+Jarzabauthor=C.+S.+Balauthor=S.+Marurauthor=A.+Gramzaauthor=F.+Ondrey&title=Thyroidectomy+followed+by+fosbretabulin+%28CA4P%29+combination+regimen+appears+to+suggest+improvement+in+patient+survival+in+anaplastic+thyroid+cancer&doi=10.1016%2Fj.surg.2012.08.036"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1016%2Fj.surg.2012.08.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.surg.2012.08.036%26sid%3Dliteratum%253Aachs%26aulast%3DSosa%26aufirst%3DJ.%2BA.%26aulast%3DBalkissoon%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DS.%2BP.%26aulast%3DLangecker%26aufirst%3DP.%26aulast%3DElisei%26aufirst%3DR.%26aulast%3DJarzab%26aufirst%3DB.%26aulast%3DBal%26aufirst%3DC.%2BS.%26aulast%3DMarur%26aufirst%3DS.%26aulast%3DGramza%26aufirst%3DA.%26aulast%3DOndrey%26aufirst%3DF.%26atitle%3DThyroidectomy%2520followed%2520by%2520fosbretabulin%2520%2528CA4P%2529%2520combination%2520regimen%2520appears%2520to%2520suggest%2520improvement%2520in%2520patient%2520survival%2520in%2520anaplastic%2520thyroid%2520cancer%26jtitle%3DSurgery%26date%3D2012%26volume%3D152%26spage%3D1078%26epage%3D1087%26doi%3D10.1016%2Fj.surg.2012.08.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group">von Pawel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorbounova, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reck, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowalski, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allard, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chadjaa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennouna, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grossi, F.</span><span> </span><span class="NLM_article-title">DISRUPT: A randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer</span> <span class="citation_source-journal">Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">224</span><span class="NLM_x">–</span> <span class="NLM_lpage">229</span><span class="refDoi"> DOI: 10.1016/j.lungcan.2014.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.lungcan.2014.05.013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2014&pages=224-229&author=J.+von+Pawelauthor=V.+Gorbounovaauthor=M.+Reckauthor=D.+M.+Kowalskiauthor=A.+Allardauthor=M.+Chadjaaauthor=A.+Reyauthor=J.+Bennounaauthor=F.+Grossi&title=DISRUPT%3A+A+randomised+phase+2+trial+of+ombrabulin+%28AVE8062%29+plus+a+taxane-platinum+regimen+as+first-line+therapy+for+metastatic+non-small+cell+lung+cancer&doi=10.1016%2Fj.lungcan.2014.05.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2014.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2014.05.013%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BPawel%26aufirst%3DJ.%26aulast%3DGorbounova%26aufirst%3DV.%26aulast%3DReck%26aufirst%3DM.%26aulast%3DKowalski%26aufirst%3DD.%2BM.%26aulast%3DAllard%26aufirst%3DA.%26aulast%3DChadjaa%26aufirst%3DM.%26aulast%3DRey%26aufirst%3DA.%26aulast%3DBennouna%26aufirst%3DJ.%26aulast%3DGrossi%26aufirst%3DF.%26atitle%3DDISRUPT%253A%2520A%2520randomised%2520phase%25202%2520trial%2520of%2520ombrabulin%2520%2528AVE8062%2529%2520plus%2520a%2520taxane-platinum%2520regimen%2520as%2520first-line%2520therapy%2520for%2520metastatic%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DLung%2520Cancer%26date%3D2014%26volume%3D85%26spage%3D224%26epage%3D229%26doi%3D10.1016%2Fj.lungcan.2014.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group">Siemann, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lepler, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rojiani, A. M.</span><span> </span><span class="NLM_article-title">Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span><span class="refDoi"> DOI: 10.1002/ijc.10316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1002%2Fijc.10316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=11948484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD38XivVCgsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=1-6&author=D.+W.+Siemannauthor=E.+Mercerauthor=S.+Leplerauthor=A.+M.+Rojiani&title=Vascular+targeting+agents+enhance+chemotherapeutic+agent+activities+in+solid+tumor+therapy&doi=10.1002%2Fijc.10316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy</span></div><div class="casAuthors">Siemann, Dietmar W.; Mercer, Emma; Lepler, Sharon; Rojiani, Amyn M.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The utility of combining the vascular targeting agents 5,6-dimethyl-xanthenone-4 acetic acid (DMXAA) and combretastatin A-4 disodium phosphate (CA4DP) with the anticancer drugs cisplatin and cyclophosphamide (CP) was evaluated in exptl. rodent (KHT sarcoma), human breast (SKBR3) and ovarian (OW-1) tumor models.  Doses of the vascular targeting agents that led to rapid vascular shutdown and subsequent extensive central tumor necrosis were identified.  Histol. evaluation showed morphol. damage of tumor cells within a few hours after treatment, followed by extensive hemorrhagic necrosis and dose-dependent neoplastic cell death as a result of prolonged ischemia.  Whereas these effects were induced by a range of CA4DP doses (10-150 mg/kg), the dose response to DMXAA was extremely steep; doses ≤ 15 mg/kg were ineffective and doses ≥ 20 mg/kg were toxic.  DMXAA also enhanced the tumor cell killing of cisplatin, but doses > 15 mg/kg were required.  In contrast, CA4DP increased cisplatin-induced tumor cell killing at all doses studied.  This enhancement of cisplatin efficacy was dependent on the sequence and interval between the agents.  The greatest effects were achieved when the vascular targeting agents were administered 1-3 h after cisplatin.  When CA4DP (100 mg/kg) or DMXAA (17.5 mg/kg) were administered 1 h after a range of doses of cisplatin or CP, the tumor cell kill was 10-500-fold greater than that seen with chemotherapy alone.  In addn., the inclusion of the antivascular agents did not increase bone marrow stem cell toxicity assocd. with these anticancer drugs, thus giving rise to a therapeutic gain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_DC9QCS350rVg90H21EOLACvtfcHk0lh3igckGxd6Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivVCgsr4%253D&md5=746a75652465a9bf12f9b1a7d694ff98</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1002%2Fijc.10316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.10316%26sid%3Dliteratum%253Aachs%26aulast%3DSiemann%26aufirst%3DD.%2BW.%26aulast%3DMercer%26aufirst%3DE.%26aulast%3DLepler%26aufirst%3DS.%26aulast%3DRojiani%26aufirst%3DA.%2BM.%26atitle%3DVascular%2520targeting%2520agents%2520enhance%2520chemotherapeutic%2520agent%2520activities%2520in%2520solid%2520tumor%2520therapy%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2002%26volume%3D99%26spage%3D1%26epage%3D6%26doi%3D10.1002%2Fijc.10316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group">Bilenker, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallagher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevenson, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaughn, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giantonio, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span> </span><span class="NLM_article-title">Phase I trial of combretastatin A-4 phosphate with carboplatin</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1527</span><span class="NLM_x">–</span> <span class="NLM_lpage">1533</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-04-1434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1158%2F1078-0432.CCR-04-1434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=15746056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhvVSrsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=1527-1533&author=J.+H.+Bilenkerauthor=K.+T.+Flahertyauthor=M.+Rosenauthor=L.+Davisauthor=M.+Gallagherauthor=J.+P.+Stevensonauthor=W.+Sunauthor=D.+Vaughnauthor=B.+Giantonioauthor=R.+Zimmerauthor=M.+Schnallauthor=P.+J.+O%E2%80%99Dwyer&title=Phase+I+trial+of+combretastatin+A-4+phosphate+with+carboplatin&doi=10.1158%2F1078-0432.CCR-04-1434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I trial of combretastatin A-4 phosphate with carboplatin</span></div><div class="casAuthors">Bilenker, Joshua H.; Flaherty, Keith T.; Rosen, Mark; Davis, Lisa; Gallagher, Maryann; Stevenson, James P.; Sun, Weijing; Vaughn, David; Giantonio, Bruce; Zimmer, Ross; Schnall, Mitchell; O'Dwyer, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1527-1533</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Preclin. evidence of synergy led to a phase I trial employing combretastatin A-4 phosphate (CA4P), a novel tubulin-binding antivascular drug, in combination with carboplatin.  Based on preclin. scheduling studies, patients were treated on day 1 of a 21-day cycle.  Carboplatin was given as a 30-min i.v. infusion and CA4P was given 60 min later as a 10-min infusion.  Sixteen patients with solid tumors received 40 cycles of therapy at CA4P doses of 27 and 36 mg/m2 together with carboplatin at area under the concn.-time curve (AUC) values of 4 and 5 mg min/mL.  The dose-limiting toxicity of thrombocytopenia halted the dose escalation phase of the study.  Four patients were treated at an amended dose level of CA4P of 36 mg/m2 and carboplatin AUC of 4 mg min/mL although grade 3 neutropenia and thrombocytopenia were still obsd.  Three lines of evidence are adduced to suggest that a pharmacokinetic interaction between the drugs results in greater thrombocytopenia than anticipated: the carboplatin exposure (as AUC) was greater than predicted; the platelet nadirs were lower than predicted; and the deviation of the carboplatin exposure from predicted was proportional to the AUC of CA4, the active metabolite of CA4P.  Patient benefit included six patients with stable disease lasting at least four cycles.  This study of CA4P and carboplatin given in combination showed dose-limiting thrombocytopenia.  Pharmacokinetic/pharmacodynamic modeling permitted the inference that altered carboplatin pharmacokinetics caused the increment in platelet toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaLdRoEnkhG7Vg90H21EOLACvtfcHk0lh3igckGxd6Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhvVSrsbc%253D&md5=3f49677885a550ccfef2e25faaa4cf53</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-1434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-1434%26sid%3Dliteratum%253Aachs%26aulast%3DBilenker%26aufirst%3DJ.%2BH.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DRosen%26aufirst%3DM.%26aulast%3DDavis%26aufirst%3DL.%26aulast%3DGallagher%26aufirst%3DM.%26aulast%3DStevenson%26aufirst%3DJ.%2BP.%26aulast%3DSun%26aufirst%3DW.%26aulast%3DVaughn%26aufirst%3DD.%26aulast%3DGiantonio%26aufirst%3DB.%26aulast%3DZimmer%26aufirst%3DR.%26aulast%3DSchnall%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26atitle%3DPhase%2520I%2520trial%2520of%2520combretastatin%2520A-4%2520phosphate%2520with%2520carboplatin%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D1527%26epage%3D1533%26doi%3D10.1158%2F1078-0432.CCR-04-1434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group">Brouhard, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, L. M.</span><span> </span><span class="NLM_article-title">The contribution of αβ-tubulin curvature to microtubule dynamics</span> <span class="citation_source-journal">J. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">207</span><span class="NLM_x">, </span> <span class="NLM_fpage">323</span><span class="NLM_x">–</span> <span class="NLM_lpage">334</span><span class="refDoi"> DOI: 10.1083/jcb.201407095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1083%2Fjcb.201407095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=25385183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGhs7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=207&publication_year=2014&pages=323-334&author=G.+J.+Brouhardauthor=L.+M.+Rice&title=The+contribution+of+%CE%B1%CE%B2-tubulin+curvature+to+microtubule+dynamics&doi=10.1083%2Fjcb.201407095"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">The contribution of αβ-tubulin curvature to microtubule dynamics</span></div><div class="casAuthors">Brouhard, Gary J.; Rice, Luke M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">207</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">323-334</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">A review.  Microtubules are dynamic polymers of αβ-tubulin that form diverse cellular structures, such as the mitotic spindle for cell division, the backbone of neurons, and axonemes.  To control the architecture of microtubule networks, microtubule-assocd. proteins (MAPs) and motor proteins regulate microtubule growth, shrinkage, and the transitions between these states.  Recent evidence shows that many MAPs exert their effects by selectively binding to distinct conformations of polymd. or unpolymd. αβ-tubulin.  The ability of αβ-tubulin to adopt distinct conformations contributes to the intrinsic polymn. dynamics of microtubules.  αβ-Tubulin conformation is a fundamental property that MAPs monitor and control to build proper microtubule networks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGyoU-iIkFELVg90H21EOLACvtfcHk0lh3igckGxd6Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGhs7jE&md5=5ff241f0a021843f7678daec3f7476f1</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1083%2Fjcb.201407095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.201407095%26sid%3Dliteratum%253Aachs%26aulast%3DBrouhard%26aufirst%3DG.%2BJ.%26aulast%3DRice%26aufirst%3DL.%2BM.%26atitle%3DThe%2520contribution%2520of%2520%25CE%25B1%25CE%25B2-tubulin%2520curvature%2520to%2520microtubule%2520dynamics%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2014%26volume%3D207%26spage%3D323%26epage%3D334%26doi%3D10.1083%2Fjcb.201407095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group">Tozer, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prise, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locke, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vojnovic, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratford, M. R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dennis, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span> </span><span class="NLM_article-title">Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1626</span><span class="NLM_x">–</span> <span class="NLM_lpage">1634</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=1626-1634&author=G.+M.+Tozerauthor=V.+E.+Priseauthor=J.+Wilsonauthor=R.+J.+Lockeauthor=B.+Vojnovicauthor=M.+R.+L.+Stratfordauthor=M.+F.+Dennisauthor=D.+J.+Chaplin&title=Combretastatin+A-4+phosphate+as+a+tumor+vascular-targeting+agent%3A+Early+effects+in+tumors+and+normal+tissues"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTozer%26aufirst%3DG.%2BM.%26aulast%3DPrise%26aufirst%3DV.%2BE.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DLocke%26aufirst%3DR.%2BJ.%26aulast%3DVojnovic%26aufirst%3DB.%26aulast%3DStratford%26aufirst%3DM.%2BR.%2BL.%26aulast%3DDennis%26aufirst%3DM.%2BF.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26atitle%3DCombretastatin%2520A-4%2520phosphate%2520as%2520a%2520tumor%2520vascular-targeting%2520agent%253A%2520Early%2520effects%2520in%2520tumors%2520and%2520normal%2520tissues%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D1626%26epage%3D1634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group">Kim, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukushima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saw, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kataoka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DoHeo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishikawa, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uemura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, G.</span><span> </span><span class="NLM_article-title">Vascular RhoJ is an effective and selective target for tumor angiogenesis and vascular disruption</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">102</span><span class="NLM_x">–</span> <span class="NLM_lpage">117</span><span class="refDoi"> DOI: 10.1016/j.ccr.2013.12.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.ccr.2013.12.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=24434213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFWgs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=102-117&author=C.+Kimauthor=H.+Yangauthor=Y.+Fukushimaauthor=P.+Sawauthor=J.+Leeauthor=J.+S.+Parkauthor=I.+Parkauthor=J.+Jungauthor=H.+Kataokaauthor=D.+Leeauthor=W.+DoHeoauthor=I.+Kimauthor=S.+Jonauthor=R.+H.+Adamsauthor=S.+I.+Nishikawaauthor=A.+Uemuraauthor=G.+Koh&title=Vascular+RhoJ+is+an+effective+and+selective+target+for+tumor+angiogenesis+and+vascular+disruption&doi=10.1016%2Fj.ccr.2013.12.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular RhoJ Is an Effective and Selective Target for Tumor Angiogenesis and Vascular Disruption</span></div><div class="casAuthors">Kim, Chan; Yang, Hanseul; Fukushima, Yoko; Saw, Phei Er; Lee, Junyeop; Park, Jin-Sung; Park, Intae; Jung, Jinmyung; Kataoka, Hiroshi; Lee, Doheon; Do Heo, Won; Kim, Injune; Jon, Sangyong; Adams, Ralf H.; Nishikawa, Shin-ichi; Uemura, Akiyoshi; Koh, Gou Young</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-117</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Current antiangiogenic therapy is limited by its cytostatic nature and systemic side effects.  To address these limitations, we have unveiled the role of RhoJ, an endothelial-enriched Rho GTPase, during tumor progression.  RhoJ blockade provides a double assault on tumor vessels by both inhibiting tumor angiogenesis and disrupting the preformed tumor vessels through the activation of the RhoA-ROCK (Rho kinase) signaling pathway in tumor endothelial cells, consequently resulting in a functional failure of tumor vasculatures.  Moreover, enhanced anticancer effects were obsd. when RhoJ blockade was employed in concert with a cytotoxic chemotherapeutic agent, angiogenesis-inhibiting agent, or vascular-disrupting agent.  These results identify RhoJ blockade as a selective and effective therapeutic strategy for targeting tumor vasculature with minimal side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbBDBnLIA7PbVg90H21EOLACvtfcHk0lj6MLY3t9cLdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFWgs70%253D&md5=6d3ce24689b3db48d588f12a521ef136</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2013.12.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2013.12.010%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DFukushima%26aufirst%3DY.%26aulast%3DSaw%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DJ.%2BS.%26aulast%3DPark%26aufirst%3DI.%26aulast%3DJung%26aufirst%3DJ.%26aulast%3DKataoka%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DDoHeo%26aufirst%3DW.%26aulast%3DKim%26aufirst%3DI.%26aulast%3DJon%26aufirst%3DS.%26aulast%3DAdams%26aufirst%3DR.%2BH.%26aulast%3DNishikawa%26aufirst%3DS.%2BI.%26aulast%3DUemura%26aufirst%3DA.%26aulast%3DKoh%26aufirst%3DG.%26atitle%3DVascular%2520RhoJ%2520is%2520an%2520effective%2520and%2520selective%2520target%2520for%2520tumor%2520angiogenesis%2520and%2520vascular%2520disruption%26jtitle%3DCancer%2520Cell%26date%3D2014%26volume%3D25%26spage%3D102%26epage%3D117%26doi%3D10.1016%2Fj.ccr.2013.12.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group">Quan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, L.</span><span> </span><span class="NLM_article-title">p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">1730</span><span class="NLM_x">–</span> <span class="NLM_lpage">1737</span><span class="refDoi"> DOI: 10.1002/ijc.23262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1002%2Fijc.23262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=18074350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BD1cXksFeitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2008&pages=1730-1737&author=H.+Quanauthor=Y.+Xuauthor=L.+Lou&title=p38+MAPK%2C+but+not+ERK1%2F2%2C+is+critically+involved+in+the+cytotoxicity+of+the+novel+vascular+disrupting+agent+combretastatin+A4&doi=10.1002%2Fijc.23262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4</span></div><div class="casAuthors">Quan, Haitian; Xu, Yongping; Lou, Liguang</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1730-1737</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Combretastatin A4 (CA4) is a novel vascular disrupting agent that has promising clin. efficacy because of its ability to inhibit microtubule assembly and subsequently disrupt tumor blood flow.  In this study, we demonstrate that mitogen-activated protein kinases (MAPKs) are critically involved in the cytotoxicity of CA4.  CA4 stimulates both extracellular signal-regulated kinases (ERK1/2) and p38 MAPK in the BEL-7402 hepatocellular carcinoma cell line in a time- and dose-dependent manner.  This stimulation is a result of CA4-induced microtubule disassembly, which is a reversible process.  Reversibility of microtubule disassembly is evidenced by the ability of disassembled microtubules to reassemble just a few hours after CA4 treatment.  P38 MAPK, but not ERK1/2, contributes to this microtubule reassembly following CA4 exposure, and only inhibition of p38 MAPK, but not ERK1/2, synergistically enhances CA4-induced G2/M cell cycle arrest.  Consistent with this, p38 MAPK inhibitors such as SB203580 and SB202190 also synergistically enhance the cytotoxicity of CA4 in cells where p38 MAPK is activated by CA4.  This enhancement appears to be specific for CA4 because the cytotoxicity of other microtubule-targeted agents such as paclitaxel, vinorelbine and colchicine was not affected by p38 MAPK inhibitors.  These data indicate that p38 MAPK is a potential anticancer target and that the combination of CA4 with p38 MAPK inhibitors may be a novel and promising strategy for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGkvgxgmXwtrVg90H21EOLACvtfcHk0lj6MLY3t9cLdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXksFeitrw%253D&md5=69e7503d5e46f544daba821bf1105190</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1002%2Fijc.23262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.23262%26sid%3Dliteratum%253Aachs%26aulast%3DQuan%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DLou%26aufirst%3DL.%26atitle%3Dp38%2520MAPK%252C%2520but%2520not%2520ERK1%252F2%252C%2520is%2520critically%2520involved%2520in%2520the%2520cytotoxicity%2520of%2520the%2520novel%2520vascular%2520disrupting%2520agent%2520combretastatin%2520A4%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2008%26volume%3D122%26spage%3D1730%26epage%3D1737%26doi%3D10.1002%2Fijc.23262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group">Kwon, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatia, S. N.</span><span> </span><span class="NLM_article-title">Smart nanosystems: Bio-inspired technologies that interact with the host environment</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">14460</span><span class="NLM_x">–</span> <span class="NLM_lpage">14466</span><span class="refDoi"> DOI: 10.1073/pnas.1508522112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1073%2Fpnas.1508522112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=14460-14466&author=E.+J.+Kwonauthor=J.+H.+Loauthor=S.+N.+Bhatia&title=Smart+nanosystems%3A+Bio-inspired+technologies+that+interact+with+the+host+environment&doi=10.1073%2Fpnas.1508522112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1508522112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1508522112%26sid%3Dliteratum%253Aachs%26aulast%3DKwon%26aufirst%3DE.%2BJ.%26aulast%3DLo%26aufirst%3DJ.%2BH.%26aulast%3DBhatia%26aufirst%3DS.%2BN.%26atitle%3DSmart%2520nanosystems%253A%2520Bio-inspired%2520technologies%2520that%2520interact%2520with%2520the%2520host%2520environment%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D14460%26epage%3D14466%26doi%3D10.1073%2Fpnas.1508522112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group">Lin, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatia, S. N.</span><span> </span><span class="NLM_article-title">Drug-induced amplification of nanoparticle targeting to tumors</span> <span class="citation_source-journal">Nano Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">550</span><span class="NLM_x">–</span> <span class="NLM_lpage">559</span><span class="refDoi"> DOI: 10.1016/j.nantod.2014.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=10.1016%2Fj.nantod.2014.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=29731806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyrtrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=550-559&author=K.+Y.+Linauthor=E.+J.+Kwonauthor=J.+H.+Loauthor=S.+N.+Bhatia&title=Drug-induced+amplification+of+nanoparticle+targeting+to+tumors&doi=10.1016%2Fj.nantod.2014.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced amplification of nanoparticle targeting to tumors</span></div><div class="casAuthors">Lin, Kevin Y.; Kwon, Ester J.; Lo, Justin H.; Bhatia, Sangeeta N.</div><div class="citationInfo"><span class="NLM_cas:title">Nano Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">550-559</span>CODEN:
                <span class="NLM_cas:coden">NTAOCG</span>;
        ISSN:<span class="NLM_cas:issn">1748-0132</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Nanomedicines have the potential to significantly impact cancer therapy by improving drug efficacy and decreasing off-target effects, yet our ability to efficiently home nanoparticles to disease sites remains limited.  One frequently overlooked constraint of current active targeting schemes is the relative dearth of targetable antigens within tumors, which restricts the amt. of cargo that can be delivered in a tumor-specific manner.  To address this limitation, we exploit tumor-specific responses to drugs to construct a cooperative targeting system where a small mol. therapeutic modulates the disease microenvironment to amplify nanoparticle recruitment in vivo.  We first administer a vascular disrupting agent, ombrabulin, which selectively affects tumors and leads to locally elevated presentation of the stress-related protein, p32.  This increase in p32 levels provides more binding sites for circulating p32-targeted nanoparticles, enhancing their delivery of diagnostic or therapeutic cargos to tumors.  We show that this cooperative targeting system recruits over five times higher doses of nanoparticles to tumors and decreases tumor burden when compared with non-cooperative controls.  These results suggest that using nanomedicine in conjunction with drugs that enhance the presentation of target antigens in the tumor environment may be an effective strategy for improving the diagnosis and treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQdjHn60fTfrVg90H21EOLACvtfcHk0lhlZNFEF7hCGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyrtrjM&md5=b13791ae4dc7c03050eb72f5ee93f6ed</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1016%2Fj.nantod.2014.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nantod.2014.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DK.%2BY.%26aulast%3DKwon%26aufirst%3DE.%2BJ.%26aulast%3DLo%26aufirst%3DJ.%2BH.%26aulast%3DBhatia%26aufirst%3DS.%2BN.%26atitle%3DDrug-induced%2520amplification%2520of%2520nanoparticle%2520targeting%2520to%2520tumors%26jtitle%3DNano%2520Today%26date%3D2014%26volume%3D9%26spage%3D550%26epage%3D559%26doi%3D10.1016%2Fj.nantod.2014.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1JFF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1JFF','PDB','1JFF'); return false;">PDB: 1JFF</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1SA0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1SA0','PDB','1SA0'); return false;">PDB: 1SA0</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1SA1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1SA1','PDB','1SA1'); return false;">PDB: 1SA1</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3HKB" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3HKB','PDB','3HKB'); return false;">PDB: 3HKB</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3HKC" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3HKC','PDB','3HKC'); return false;">PDB: 3HKC</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3HKD" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3HKD','PDB','3HKD'); return false;">PDB: 3HKD</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3HKE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3HKE','PDB','3HKE'); return false;">PDB: 3HKE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3N2G" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3N2G','PDB','3N2G'); return false;">PDB: 3N2G</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3N2K" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3N2K','PDB','3N2K'); return false;">PDB: 3N2K</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O2A" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O2A','PDB','4O2A'); return false;">PDB: 4O2A</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O2B" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O2B','PDB','4O2B'); return false;">PDB: 4O2B</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4YJ2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4YJ2','PDB','4YJ2'); return false;">PDB: 4YJ2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4YJ3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4YJ3','PDB','4YJ3'); return false;">PDB: 4YJ3</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CA0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CA0','PDB','5CA0'); return false;">PDB: 5CA0</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CA1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CA1','PDB','5CA1'); return false;">PDB: 5CA1</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5C8Y" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5C8Y','PDB','5C8Y'); return false;">PDB: 5C8Y</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CB4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CB4','PDB','5CB4'); return false;">PDB: 5CB4</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00463%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-19" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00463" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799f3d99a7e3ddd","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
